


2023 Veterinary Mycoplasmas Research Report



Funded by
the European Union

This work was funded by UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee [grant numbers 10055666 and 10058793]

2023 Veterinary Mycoplasmas Research Report

Compiled, written & edited by

Drs Daniel Ackerman, Laura Roden & Lucy Robinson



Commissioned by



and the



Contents

Commissioning Body	1
The STAR-IDAZ International Research Consortium	1
The Agricultural Research Service, United States Department of Agriculture.....	1
Purpose of the Report	3
About the Authors	4
Executive Summary	5
Literature Review and Research Updates by Subject Area	17
Report approach.....	18
Introduction	19
Mycoplasma mycoides subsp. mycoides.....	21
Mycoplasma bovis	47
Other mycoplasmas affecting cattle	87
Mycoplasmas affecting small ruminants.....	96
Mycoplasmas affecting swine	132
Mycoplasmas affecting poultry	178
Conclusions	214
Acknowledgements.....	216
References	217
Appendices	317
Abbreviations	317
Details of searches.....	321
Financial Support.....	322
Conflict of Interest Statement.....	322
Additional Resources.....	323

Commissioning Body

This report was commissioned by the STAR-IDAZ International Research Consortium in collaboration with the Agricultural Research Service (ARS) of the United States Department of Agriculture (USDA). USDA-ARS funded the sections on contagious bovine pleuropneumonia (CBPP) and *Mycoplasma bovis*, and STAR-IDAZ IRC funded the remaining sections.

The STAR-IDAZ International Research Consortium

The STAR-IDAZ International Research Consortium (IRC) is a global initiative aiming to coordinate research programmes at the international level and to contribute to the development of new and improved animal health strategies for priority diseases/infections/issues. The partners, research funders and programme owners together form the Executive Committee which is supported by the Scientific Committee of 16 experts and an EU-funded Secretariat, SIRCAH2 (Support for the International Research on Animal Health), which is funded by Horizon Europe (Grant Agreement number 101082377) and UK Research and Innovation (UKRI) under the UK Government's Horizon Europe funding guarantee (Grant numbers 10055666 and 10058793).

Target deliverables of the STAR-IDAZ IRC include candidate vaccines, diagnostics, therapeutics, other animal health products and procedures, and key scientific information/tools to support risk analysis and disease control. To achieve these goals, the IRC partners agree to coordinate/align their research programmes to address identified research needs relating to the priority topics and to share results. Research gaps identified by expert Working Groups are organised into research roadmaps for the development of candidate vaccines, diagnostics, therapeutics and disease control strategies, providing a structure to plot identified research gaps and focus future investment (Entrican et al., 2021).

The Agricultural Research Service, United States Department of Agriculture

The Agricultural Research Service (ARS) is the principal in-house research agency of the United States Department of Agriculture (USDA) and aims to extend the nation's scientific knowledge with research projects in agriculture, human nutrition, food safety, natural resources, and the environment. ARS supports more than 2,000 scientists organised into approximately 660 permanent research projects at over 90 locations across the country and five laboratories overseas.

ARS conducts innovative research to find solutions to problems of high national priority that impact the American people daily. ARS often undertakes high-risk research endeavours to make significant breakthroughs in important problem areas, including biodefence initiatives to detect, prevent, and mitigate the impact of especially dangerous infectious diseases that pose a threat to animals and public health.

Purpose of the Report

Mycoplasma species are responsible for several clinically important diseases of large and small ruminants, swine, and poultry, as well as affecting significant populations of related wildlife, some of which are becoming endangered or already under threat of extinction. Increasing our knowledge of these varied and challenging pathogens and their interactions with their equally diverse host species, is important for understanding the diseases they cause and so for enhancing our ability to control them with effective policies, therapeutics, and vaccines. This in turn is critical for food and economic security in many countries. These efforts should be focused on areas with the greatest potential for future advances, and this then requires regular updates of what is known and unknown in these fields of study.

The purpose of this report is to present and summarise some of the most important research published on these mycoplasmas over the past 8-10 years, covering their fundamental biology; diagnosis of infected herds and animals; pathogenesis and determinants of virulence; immunology and critical host-pathogen interactions; epidemiology and geographic spread; and control, including biosecurity, antimicrobials, and vaccine development.

The findings of this report are intended to be used to support future detailed gap analyses that will also incorporate expert opinion and review of current research and control measures, alongside knowledge of on-the-ground countermeasures (both in use and under development) and their efficacy. Importantly, this literature review does not attempt to rank the knowledge gaps identified, and this will therefore form a key part of future analyses.

About the Authors



Dr Daniel Ackerman

Dr Daniel Ackerman completed his Ph.D. in biological sciences and his subsequent post-doctoral studies at Carnegie Mellon University, Pittsburgh, USA. Since then, he has developed advanced communication and editing skills, joining Insight Editing London in 2020. Daniel has assisted with the publication of diverse research articles during his time with IEL, rapidly building his reputation for writing and editing excellence across fields. He also recently authored the STAR-IDAZ 2022 African Swine Fever Virus Research Review and co-authored the 2021 Animal Influenza Research Review.

Dr Laura Roden obtained her Ph.D. in Plant Sciences from the University of Cambridge, UK, and completed post-doctoral research at the University of Arizona, Tucson, Arizona and the University of Warwick, Coventry, UK, before establishing her own lab at the University of Cape Town, in South Africa. Alongside her academic work at Coventry University, UK, she holds an honorary post in the Department of Human Biology at the University of Cape Town. Laura joined Insight Editing London in 2022, bringing her talent for research review and grant writing to diverse fields and disciplines.



Dr Laura Roden



Dr Lucy Robinson

Dr Lucy Robinson gained her D.Phil. in veterinary immunology from the University of Oxford, UK, and continued her post-doctoral research into exotic infections at the Singapore Immunology Network. Lucy founded Insight Editing London in 2009 and has since successfully assisted with the publication of hundreds of articles and the construction of successful grant applications across diverse scientific fields. She recently directed the writing of, and co-authored, the Animal Influenza Research Review 2021, as well as editing the African Swine Fever Virus Research Review 2022.

Executive Summary

This report combines a comprehensive literature review with input from leading scientists across the field (for details of contributors, see [here](#)) to describe the significant progress made in research into mycoplasmas affecting veterinary species of interest, between 1st January 2012/2015 and May 10th 2023. Herein we provide a literature-based update and summary of notable research, that allows for the identification of some of the areas in which future research and research funding could be targeted for maximum impact and minimum duplication of effort. The priority research areas presented within this report are intended to be used as a tool to supplement future in-depth gap analyses that include additional factors and local/regional considerations.

Despite substantial research efforts and notable advances in knowledge, veterinary mycoplasmas continue to cause a suite of diseases that represents a major global threat to food security and animal welfare; this is most keenly felt by small producers in low-resource settings, who have a real and immediate sense of economic loss and food (in)security upon the onset of illness within their herd. While the mycoplasmas discussed within this report, and their corresponding host species, are diverse, common themes emerge from the literature review that warrant attention across the field:

- the need for standardisation of challenge models for *in vivo* pathogenesis, immunology and vaccine efficacy studies
- the value of genome sequencing, when coupled with analysis of the proteome, secretome and metabolome, to link genetic traits with *in vivo* pathogenesis
- the importance of inexpensive and accurate pen-side (requiring minimal laboratory equipment) diagnostics as the foundation of effective surveillance, epidemiology, and control programmes
- communication with primary stakeholders to ensure translation of research findings into effective practices in the field
- the risks of *in vitro* research in cell lines not mimicking the responses to infection in primary cells or *in vivo*
- the need to phase out immunological/pathogenesis studies of mycoplasmas affecting large animals conducted in inappropriate small animal models; for example, the data so far do not indicate that rabbits can model the immune recognition of pigs, nor that mice can replicate the responses to mycoplasma of cattle, and we therefore cannot rely on data generated in these systems

- exploitation of advances in technology and tissue culture – e.g., bovine lung organoids, and “lung-on-chip” approaches – could prove productive across the field
- similarly, the use of next-generation immunological techniques, such as single-cell RNA-seq, would give an unprecedented level of insight and generate data on which to base targeted studies with the potential to rapidly advance knowledge
- high-density, high-animal-stress farming and transport practices significantly lower the disease resistance of animals and may adversely affect their responses to vaccines, thereby favouring disease-transmission. The move to more sustainable farming practices is not only environmentally indicated but could also significantly reduce the animal disease burden in modern agriculture.

Alongside these repeating themes, a summary of *Mycoplasma* species-specific findings is reported below.

Mycoplasma mycoides subsp. mycoides (Mmm)

The continuing spread of contagious bovine pleuropneumonia (CBPP) represents a real and immediate threat to livestock keepers in sub-Saharan Africa, alongside the risk of the disease spreading to other countries. The worsening of the situation reflects a lack of effective and coordinated disease surveillance, containment, and mitigation strategies, which in turn is underpinned by an incomplete knowledge of the basic biology, pathogenesis, and immunology of *Mmm*. Since 2012, research into these areas has begun to present new opportunities for improved diagnostics, vaccines, and other mitigation measures, with the prospect of better control of CBPP within endemic regions. However, the translation of these findings into real-world benefits will require prioritisation of CBPP by national governments and international bodies: the potential gains from effective CBPP control are huge, not only to individual farmers within these regions, but also to global food security and for increased international trade, while the consequences of continued neglect of this disease are similarly profound.

Epidemiological data show that CBPP continues to spread within sub-Saharan Africa, with some reports suggesting that *Mmm* may also be circulating in parts of southeast Asia, as well as in Pakistan (and likely, northern India). The situation is almost certainly worse than these reports suggest, given the lack of access to diagnostic tools and the absence of comprehensive surveillance strategies in many regions. At present, the diagnosis of CBPP tends to be achieved at the herd level, but advances

are being made: both highly-sensitive loop-mediated isothermal amplification (LAMP) assay kits and ELISA-based lateral-flow devices have been tested and represent a promising way forwards for specific and rapid point-of-care diagnosis.

Efforts to advance understanding of the biology of *Mmm* have been notably advanced by genome sequencing, which has begun to reveal virulence factors of this species that might later be targeted in attempts at rational attenuation to generate improved vaccine strains. Further proteomic study of the pathogen *in vitro*, ideally using the improved primary cell/tissue culture methods reported herein, will advance this field further. In the living host, our understanding of the interactions between *Mmm* and the immune system is far from complete: a general consensus has emerged on the importance of TNF- α and neutrophils in the initial stages of infection, but we do not yet understand how antibodies act to either enhance or reduce symptoms of disease. Moreover, T cells seem important for the formation of immunological memory yet completely dispensable for protection from acute infection, and many questions remain as to how these data fit together. Across *in vivo* studies of immunology and pathology, the success of collaborations between field-study centres in affected regions, and distant laboratories with additional expertise and analytical capabilities, stands out: in the absence of funding to equip local research institutes to carry out high-impact cutting-edge research, this approach should be encouraged. Alongside, solid data reveal the importance of moving away from intra-tracheal challenge for all large-animal studies of CBPP: this should be applied as a matter of urgency, at the risk of rendering future research less-than-valuable when generated in this system.

The need for a standardised challenge method reflects a broader need within the field for standardisation of research approaches, most notably for vaccine research, to enable comparison of studies and the accumulation of knowledge. Current vaccines do somewhat reduce average disease severity and can be used as part of effective control programmes; yet the situation “on the ground” remains dire, with modelling data seeming to suggest that, given the shortfalls in their efficacy, immunisation with the current vaccines is worse than not vaccinating at all. While research continues towards an ideal vaccine, given the dearth of funding and the urgency of the situation, the most rapid path to improved control might well be best supported by prioritising the further testing, optimisation, and commercialisation of existing lead candidates. A vaccine that was even slightly more effective than current options, but better tolerated, and – importantly – more easily, cheaply, and reliably produced, would represent a major step forward for CBPP control.

An improved vaccine would need to be applied as part of a similarly improved vaccination campaign, aiming for at least 80% coverage. The prevalence and relative severity of post-vaccinal reactions to commercial CBPP vaccines has made the development of current and future vaccination programmes extremely challenging: farmers simply do not want to vaccinate their animals, and compliance is accordingly low. A worrying sequela is increased use of antimicrobial drugs, which is a global concern in terms of the emergence of resistant strains and possible masking of symptoms, allowing for further spread of disease. Therefore, recent research into the factors affecting farmers' decision-making around CBPP diagnosis and control has generated important insight that should be placed at the heart of future policymaking around this disease to ensure that future efforts to control CBPP achieve greater success than those of the past.

Mycoplasma bovis

Mycoplasma bovis (*M. bovis*) is one of the most pathogenic members of the *Mycoplasma* genus and pervades cattle farming globally, as well as infecting wild American bison and pronghorn. Since 2012, *M. bovis* has colonised Finland, which was previously a rare disease-free stronghold, reflecting its overall apparently increasing prevalence around the world. Alongside this organism's role in the bovine respiratory disease (BRD) complex, *M. bovis* also commonly causes mastitis and arthritis, which are poorly responsive to antimicrobial drug treatment. In the absence of an effective vaccine, most countries attempt to limit the spread of the pathogen by slaughtering all infected animals; though recent studies suggest that an infected case isolation approach could be as good or better, this has yet to be assessed in the field.

Since 2012, molecular typing has begun to shed light on the evolution and population structure of *M. bovis* isolates from the field, as well as identifying genomic factors involved in transmission. Complete genome sequencing has also advanced our knowledge of strain-specific pathogenic factors, and is now affordable enough to be used for contact tracing and identification of the source of outbreaks in developed countries; while the relative scarcity of material and human resources, and access to specialised laboratory space, preclude the translation of this benefit to low- and middle-income countries.

While some hoped that genome sequencing would have also opened the door to prediction of the phenotype and tissue specificity of different *M. bovis* isolates, this is not yet the case; similarly, genomic/molecular/pathogenicity studies have yet to reveal the basis for the transition from

asymptomatic colonisation to pathogenic infection, as often seen in respiratory infections with *M. bovis*, leading some to suggest that it is (yet undefined) host- or co-infection- derived factors that drive this process. It has, however, become clear that there are important differences in genome and pathogenicity between isolates infecting cattle and those from bison. Newfound abilities to generate targeted *M. bovis* mutants should facilitate a more thorough understanding of these processes and differences in the coming years and help to close the gap between our knowledge of the genetics, proteomics and *in vivo* biology of this pathogen.

The quest for accurate, affordable, and easy-to-use *M. bovis* diagnostics has progressed significantly since 2012. Multiplex PCR assays have now achieved 100% specificity and more than 90% sensitivity, representing a good option for those working in high-resource settings, while LAMP-based protocols may also be accurate and are somewhat more affordable to use. Although historically less sensitive than DNA-based approaches, recent advances hint at the prospect of highly sensitive serology-based lateral-flow devices that show promise under laboratory conditions but require further testing in the field.

Many of the recent studies into the pathogenesis and molecular immunology of *M. bovis* infection have been conducted *in vitro* using immortalised cell lines, or in some cases primary or *ex vivo*-derived cells. Much work lies ahead to validate their potential significance *in vivo* in order to identify those candidates that might be amenable to the generation of rationally attenuated mutants and/or as novel drug targets. Meanwhile, advances in our knowledge of the immune response to *M. bovis* infection of cattle have suggested key features of a protective adaptive immune response that could be targeted in vaccine design: several studies together provide evidence that Th17/Th2 is a hallmark of more severe and/or persistent infection with *M. bovis*, while features of Th1 immunity appear to be linked to protection (at least following vaccination).

Whether or not individual animal's varying susceptibility to *M. bovis*/BRD relates to T cell polarisation, or rather to innate immune traits, remains to be seen. Little work has been done in this area, yet interesting data suggest that such work could be highly productive: for example, the discovery that innate immune loci could be involved in resistance to *M. bovis*, coupled with advances in our knowledge of potentially important molecules such as the NK lysins, which show clear anti-mycoplasmal activity *in vitro*.

Alongside the potential for breeding in increased *M. bovis*/BRD resistance, the first live-attenuated commercial vaccine against *M. bovis* “Protivity™” was launched by Zoetis in 2022, and offers hope of improved control, if its field efficacy aligns with that documented under controlled conditions. One potential issue is how such a vaccine might interfere with diagnostic testing; therefore, a more promising approach might be the further development of the reported attenuated *Mannheimia haemolytica*-vectored *M. bovis* vaccine expressing the cross-strain-conserved Elongation factor Tu and heat-shock protein-70. At the same time, preliminary data suggest that plant-derived antimicrobial agents, such as carvacrol, could also help in the fight against *M. bovis* disease in the near future.

Other mycoplasmas affecting cattle

Cattle are one of the most important livestock animals worldwide and are a keystone of food security and socioeconomic development in many countries. Pathogens that impact their health and productivity are therefore critical targets for veterinary researchers, and advances in our understanding of and ability to control cattle diseases can have an outsized effect on global welfare if put into practice. Numerous mycoplasmas are considered pathogens of cattle and are regularly isolated from cattle tissues, but our knowledge of their biology and prevalence is generally quite limited. As mycoplasmas regularly occur in co-infections with other mycoplasmas, other bacterial species, or viral pathogens, distinguishing the contributions of these individual pathogens to disease can be exceedingly difficult.

Mycoplasma bovis is often detected in bovine genital regions and is usually associated with reproductive disorders, but it has also been detected in the respiratory tract of diseased cows. The pathogenicity of *M. bovis* is thought to vary from strain-to-strain, and few in-depth studies have been conducted on its molecular properties or epidemiology. The past eight years have seen the publication of new genome sequences from *M. bovis* isolates and the development of multiplex diagnostics that can distinguish this bacterium from other commonly isolated pathogens (e.g., *M. bovis* in respiratory swabs and *Ureaplasma diversum* in vaginal swabs). However, many questions about the mechanisms by which *M. bovis* may (or may not) cause reproductive and/or respiratory dysfunction remain to be answered.

While *M. bovis* dominates the research field of bovine respiratory mycoplasmas, more minor players including *M. dispar* and *M. bovirhinis* have been addressed in a number of studies released since 2015. Several genome sequences and some accompanying annotation studies have been published, and the

prevalence of *M. dispar* has been reported in surveys of bovine respiratory disease (BRD) complex-associated pathogens in Europe. The sensitivity of *M. dispar* isolates to specific antimicrobials has also been studied, which is particularly important as the prevalence of drug-resistant mycoplasmas continues to rise.

The third class of bovine mycoplasmas addressed in this section is the haemotropic mycoplasmas (haemoplasmas), primarily *M. wenyonii*. *M. wenyonii* has been associated with severe anaemia in cattle, and the likely role of arthropod vectors in spreading this pathogen raise additional uncertainties in its epidemiology. The bovine haemoplasmas have seen increasing research attention since 2015, including the development of new diagnostic assays for their detection in blood samples. The prevalence of these pathogens has been investigated in countries across the world and has generally been found to be worryingly high. As our knowledge of the basic biology and pathogenicity of bovine haemoplasmas continues to increase, it will be particularly important to apply these findings to the establishment of new surveillance programmes to ensure that the spread of haemoplasmas can be tracked and, eventually, controlled.

Mycoplasmas affecting small ruminants

Pathogenic mycoplasmas of small ruminants reduce the welfare and productivity of sheep and goats, and the frequency of co-infections between these mycoplasmas and other bacterial or viral pathogens complicates the epidemiological picture in these animal populations. Mycoplasma-associated diseases such as contagious agalactia and contagious caprine pleuropneumonia (CCPP) remain poorly controlled in many areas of the world, and a lack of resources for epidemiological studies and surveillance make it difficult to track the spread of these pathogens. Meanwhile, vaccines against mycoplasmas of small ruminants are often unavailable, unaffordable, or inadequately effective; this promotes the overuse of antimicrobials to treat disease and restore animal productivity, which in turn contributes to the rising trend of antimicrobial resistance among mycoplasmas. Since 2015, many studies have begun to fill essential gaps in our understanding of and ability to control these mycoplasmas, including *in vitro* biological studies, *in vivo* investigations of host-pathogen interactions, and diagnostic and vaccine development.

One of the most important mycoplasmal pathogens of small ruminants is *Mycoplasma ovipneumoniae* (*M. ovipneumoniae*), which is endemic in small ruminant populations worldwide and causes acute and chronic pneumonia associated with significant productivity losses. Transmission of this pathogen from

chronically infected ewes to their new-born lambs complicates disease surveillance and control efforts, particularly in wild populations (e.g., bighorn sheep) that experience more severe *M. ovipneumoniae*-associated pneumonia that can substantially impact their population size. Since 2015, many updated estimates of *M. ovipneumoniae* prevalence (in individual countries or regions within countries) have been published, though a lack of standardisation makes it difficult to objectively compare these data between studies. The epidemiology of *M. ovipneumoniae* within American bighorn sheep herds has been studied in particular detail, including transmission patterns, risk factors and control measure within these especially vulnerable populations. Meanwhile, comparative studies of host-pathogen interactions between small ruminant species or domestic sheep breeds have identified transcriptional patterns that may be associated with differences in the immune response to *M. ovipneumoniae* (and subsequent differences in disease severity and mortality), and new putative virulence factors and vaccine targets have been identified by *in vitro* proteomic and immunogenicity studies. New diagnostic assays have also been developed to promote the surveillance and control of *M. ovipneumoniae*, and several studies were conducted on the susceptibility of circulating *M. ovipneumoniae* strains to widely used antimicrobials.

Mycoplasma agalactiae (*M. agalactiae*), the causative agent of contagious agalactia, is another pathogen of particular importance in small ruminants. Significant progress has recently been made in our understanding of this pathogen via many avenues including transcriptomic profiling of gene expression in infected cells, molecular studies of the *M. agalactiae* surface lipoprotein genes and their functions during infection, and *in vivo* studies of the interactions between *M. agalactiae* and the ovine immune system. Studies of *M. agalactiae* regional prevalence and potential avenues of transmission are beginning to expand our ability to monitor and control this pathogen, and research is ongoing into the generation of improved vaccines to replace current versions with limited protective efficacy.

Many papers have also been published since 2015 on the causative agents of CCPP, primarily *Mycoplasma capricolum* subspecies *capripneumoniae* (*Mccp*). Several complete genomes of *Mccp* isolates have been reported, alongside advancements in multilocus molecular typing strategies that allow higher-resolution investigations of the pathogen's evolutionary history and transmission patterns. The prevalence of *Mccp* has also been measured in many countries across Africa, the Middle East, and occasionally Europe and Asia, though as mentioned above, poor standardisation limits the comparability of these findings. *In vivo* studies of experimentally infected goats have identified some new avenues for the study of host-*Mccp* interactions and the generation of protective immunity, and the genetic mechanisms underlying the development of antimicrobial resistance by this pathogen

have been explored. Similar studies have been conducted on *Mycoplasma mycoides* subspecies *capri* (*Mmc*), a pathogen associated with contagious agalactia and CCPP, including developments in phylogenetics and the identification of new putative virulence factors that provide important avenues for the future development of control measures against this pathogen.

Mycoplasmas affecting swine

Mycoplasma infections of the swine respiratory tract reduce welfare and productivity in domestic pigs across the world, and limitations in our ability to monitor and control these diseases introduce substantial uncertainty into pig farming networks. The most prominent pathogenic mycoplasma affecting swine is *Mycoplasma hyopneumoniae* (*Mhp*), the primary causative agent of swine enzootic pneumonia. Infection with *Mhp* alone has been associated with lost productivity (e.g., lower average daily weight gain), but the primary threat from this pathogen comes from co-infections – *Mhp* is very commonly observed alongside other major swine respiratory pathogens such as porcine reproductive and respiratory syndrome virus (PRRSV) and swine influenza A virus (sIAV), with complicated synergistic effects that can aggravate the severity of clinical signs in co-infected animals.

The eight years have seen numerous advances in our understanding of the biology of *Mhp* and its interactions with host cells. Multilocus molecular typing strategies based on just three genes (*adh*, *rpoB* and *tpiA*) have been found to provide high-resolution discrimination between even closely related strains of *Mhp*, simplifying phylogenetic analyses and facilitating a large number of studies into the evolutionary history and transmission networks of this pathogen. *In vitro* and *ex vivo* studies of the *Mhp* proteome and its interactions with host proteins have identified new putative virulence factors and immune evasion-associated proteins that appear to play critical roles in the *Mhp* infection pathway and represent promising targets for the development of new therapeutics and vaccines. Some of these results have been validated *in vivo*, but many findings remain to be tested in experimentally infected animals. Standardisation of these *in vivo* studies will be an important goal: as the route of inoculation is likely to affect pathogenesis and immunity, physiological challenge models should be developed (where lacking), validated and standardised for use in studies of pathogenesis, immunology and vaccine efficacy. Similarly, the use of immortalised cell lines should be discouraged, as should the use of rabbits for vaccine trials: evidence is emerging that they recognise different epitopes.

Meanwhile, studies of swine enzootic pneumonia management and control have continued apace. Many studies have been published on *Mhp* prevalence in endemic areas of Asia, Europe, and the Americas, though very few of these studies have focused on Africa, and *Mhp* epidemiology within this continent remains an important research gap. The risk factors associated with *Mhp* introduction and transmission within domestic pig herds and wild boar populations have been investigated in a variety of geographical settings. Alongside, new diagnostics have been developed, including multiplex assays for discriminating *Mhp* from other swine respiratory pathogens and isothermal assays for improved pen-side performance.

New serodiagnostics for *Mhp* have been reported to discriminate infected from vaccinated animals, which is particularly important as our repertoire of vaccines against *Mhp* continues to grow. Foster gold, the new trivalent *Mhp* vaccine, seems highly effective under a range of field conditions, yet the potential benefits of long-term use have yet to be revealed. If and when other novel vaccines are developed, it will be important to compare these vaccines against Foster gold to ensure the selection of optimal vaccine strains in the field. Meanwhile, needle-free vaccination does not impact the efficacy of the commercially available vaccines and should therefore be more widely adopted for reasons of animal welfare, administrator safety and reduction in the substantial issue of sharps waste generation from veterinary vaccination programmes.

Alongside this progress, many advances have recently been reported in the study of other swine respiratory mycoplasmas – namely *M. flocculare* (*Mfl*), *M. hyorhinis* (*Mhr*), and *M. hyosynoviae* (*Mhs*) – and of the pathogenic swine haemoplasmas – *Mycoplasma suis* (*M. suis*) and the newly identified *Candidatus* *Mycoplasma haemosuis* (*C. M. haemosuis*). Studies of the proteomes and secretomes of these less-pathogenic respiratory mycoplasmas have identified some of the likely determinants of the comparatively greater virulence seen in *Mhp*, and surveillance programmes have begun to generate critical data on the poorly understood epidemiology of swine haemoplasmas (at least, in Europe and the Americas). Further research will be needed to expand our knowledge of the haemoplasmas in Asia and Africa.

Mycoplasmas affecting poultry

The most important pathogenic mycoplasmas of poultry, *Mycoplasma gallisepticum* (*M. gal*) and *Mycoplasma synoviae* (*M. syn*), cause acute or chronic respiratory disease and associated productivity loss in domestic chickens and turkeys worldwide. Domestic chickens are by far the most numerous

livestock animal on the planet, and mycoplasmal infections place a proportionately large economic burden on livestock production networks. As with veterinary mycoplasmas in other livestock species, *M. gal* and *M. syn* infections often occur in combination with other bacterial and viral pathogens of poultry, potentially increasing pathogenicity and negatively impacting the host immune response. This combined with the highly transmissible nature of these pathogens promotes complicated and difficult-to-predict epidemiological patterns, but the current lack of sufficient disease surveillance and control programmes in many countries limits the resources available for pathogen tracking, outbreak prediction, and the establishment of biosecurity measures across much of the globe. In light of these critical needs, this section of the research review will cover the many important strides that have been made over the past decade in clarifying the biology, epidemiology and control of *M. gal* and *M. syn*.

M. gal has been considered a major poultry pathogen for decades, and papers published since 2015 have added substantially to a large existing repertoire of studies. Advances have been reported in the typing and classification of *M. gal* isolates to support phylogenetic, evolutionary and epidemiological studies, while large- and small-scale functional studies of this pathogen's proteome have identified new putative virulence factors involved in cell adhesion, leucocyte chemoattraction, host cell apoptosis and other critical host-cell interactions. *In vitro* models have allowed detailed characterisation of the many proinflammatory responses triggered by *M. gal* infection (e.g., in innate immune signalling pathways, proinflammatory microRNA production and cytokine regulation), though many of these findings remain to be validated *in vivo*. Alongside, new developments in diagnostics are facilitating a slow but apparently steady increase in the coverage of surveillance studies, though the transmission patterns of *M. gal* remain poorly understood in many endemic areas (particularly in low- and middle-income countries). Testing of wild birds for *M. gal* is also generally limited, though many studies have been conducted over the past eight years in the house finch (*Haemorrhous mexicanus*) populations of the USA.

Meanwhile, although numerous commercial vaccines against *M. gal* have been available for decades, but their efficacy in controlling disease is limited by inconsistent protective efficacy and the frequency of chronic *M. gal* infections. Studies published since 2015 have begun to address these issues by further characterising existing vaccines and/or developing new vaccines with improved clinical properties.

Many of the limitations on our knowledge of *M. gal* (many uncharacterised gene products, insufficient surveillance in endemic areas, etc.) apply also to *M. syn*. *M. syn* was previously considered of less

clinical importance compared to *M. gal*, and our research knowledgebase concerning this pathogen was correspondingly limited. However, an increase over the past 15 years in *M. syn*-associated synovitis and weakened eggshells in infected poultry has spurred a massive increase in the number of papers addressing it. The development of multilocus molecular typing protocols has allowed higher resolution phylogenetic characterisation than was previously possible with traditional *vlhA* gene sequencing, and studies of the host transcriptional and proteomic responses to *M. syn* infection have begun to clarify the molecular mechanisms of synovitis and immune dysregulation associated with this pathogen – though the host immune response to *M. syn* and its corresponding immune evasion strategies remain poorly understood. Meanwhile, the prevalence of *M. syn* among domestic poultry has been reported for the first time in some countries, and studies of its transmission have identified vertical transmission as a potentially important factor in *M. syn* epidemiology. *M. syn* has also been the focus of several recent studies on antimicrobial susceptibility, critical for tracking the development of drug resistance.

Literature Review and Research

Updates by Subject Area

Report approach

The primary literature review was conducted using the applied life sciences CAB Abstracts database (www.cabdirect.org) with search terms specific to the species, pathogens, and date range of interest, starting on 1st January of the earliest year, until 8th May of 2023. For a full list of the search terms used, please see [here](#). This approach yielded a total of 3,492 papers across the species of interest. Papers were subsequently excluded from further consideration if they were not published in English or not relevant to the topic. The remaining papers were then manually screened for relevance to the scope of this report, finally leaving 2,157 papers for assessment for inclusion. These papers were allocated to the following topic areas as shown in [Table 1](#).

<i>Mycoplasma</i> species/ Research category	<i>Mycoplasma mycoides</i> subsp. <i>mycoides</i> (2012-2023)	<i>Mycoplasma bovis</i> (2012-2023)	Other mycoplasmas affecting cattle (2015 – 2023)	Mycoplasmas affecting swine (2015-2023)	Mycoplasmas affecting small ruminants (2015-2023)	Mycoplasmas affecting poultry (2015-2023)
Biology of the pathogen	10	33	9	34	29	43
Diagnosis	19	89	18	59	41	68
Pathogenesis	11	59	11	85	59	98
Immunology	7	50	1	39	16	21
Geographic distribution and epidemiology	94	124	48	133	175	160
Prevention and control	48	95	4	163	64	140
Total	189	450	91	513	384	530

Table 1: Veterinary mycoplasmas peer-reviewed publications, sub-divided by topic area.

These studies formed the main structure of the report and were supplemented by 24 recently published studies retrieved from the [PubMed](#) database on May 10th 2023. Additional literature searches were performed during writing to provide appropriate citation for all material and, where needed, useful background. Studies were selected for inclusion based on the authors' impressions of their potential impact within the field and their quality and novelty. More recent studies were given priority within the report. In total, 1,446 studies, reports and resources are referenced herein.

Introduction

The veterinary mycoplasmas comprise a large group of species and subspecies with widely varying clinical significance and host/tissue tropisms. The most pathogenic of these organisms can cause severe diseases, spanning respiratory disease, mastitis, arthritis, conjunctivitis, and reproductive disorders in economically important livestock (primarily chickens, cattle, swine, sheep and goats). Mycoplasma-associated diseases of livestock incur substantial losses through reduced productivity (e.g., lower average daily weight gain, reduced milk or egg production, etc.), direct mortality, treatment and control costs, and in some cases, culling of infected animals. These costs are felt in livestock herds and flocks worldwide; while some pathogenic veterinary mycoplasmas are endemic on in limited geographical ranges, many are present across the globe and are therefore very difficult to control, let alone eradicate. Meanwhile, the widespread overuse of antimicrobials to treat mycoplasma-associated livestock diseases continues to promote the development of antimicrobial resistance in mycoplasmas and other bacterial species.

The study of many veterinary mycoplasmas is, in general, a challenging process. Most of these organisms are difficult to culture, making their isolation and *in vitro* characterisation more difficult compared to other, less fastidious bacteria and subsequently reducing disease detection and surveillance (reviewed in (Dudek et al., 2020)). *In vivo*, several clinically important veterinary mycoplasmas also cause chronic infections and can have synergistic effects with co-infecting bacterial or viral pathogens, complicating analyses of pathogenicity, host-pathogen interactions, and epidemiology. Therefore, while the first veterinary mycoplasma was isolated in 1898 (Nocard et al., 1898), the identification and classification of these organisms remains an active field of research. New potentially pathogenic mycoplasmas have been identified over the past decade (Herndon et al., 2021; Stadler et al., 2020), and even the phylogenetic classification of veterinary mycoplasmas has been the subject of continual updates and some disagreement (Balish et al., 2019; Gupta et al., 2019, 2018; Gupta and Oren, 2020; Thiaucourt et al., 2011). Many gene products of pathogenic mycoplasmas also remain uncharacterised, and significant gaps remain in our understanding of host-pathogen interactions in these diseases. Vaccines are available for many of the most economically important veterinary mycoplasmas, but disease control programmes are often stymied by limited protective efficacy and/or vaccine availability in endemic regions.

These limitations call for a combined research and policy framework that prioritises key questions concerning veterinary mycoplasmas, their host species, and their interactions. Coordination of these efforts is critical, as all areas of veterinary mycoplasma research can have important ramifications for

disease surveillance and control. The past decade has seen significant progress in our understanding of the biology and epidemiology of veterinary mycoplasmas, alongside the development of promising new diagnostic techniques, control methods, and vaccine candidates. This report provides updates on key advances in our understanding of and ability to control the most important veterinary mycoplasmas, aiming to establish the avenues of future investigation that will most effectively promote disease management and loss reduction in domestic livestock.

Mycoplasma mycoides subsp. mycoides

Introduction

Contagious bovine pleuropneumonia (CBPP) is a notifiable respiratory disease of cattle and water buffalo that is caused by infection with *Mycoplasma mycoides subsp. mycoides* (*Mmm*). Thought to have been documented in Europe as early as the mid-1500s, this is not a new disease; however, increased trade also increased the spread of CBPP, leading to reports of infection across the USA, Africa, Asia and Australia in the early-to-mid 19th century (Dupuy et al., 2012). Since then, CBPP has been well-controlled in many regions due to effective monitoring programmes, strict stamping-out policies, movement restrictions, and in some cases, the use of vaccination: the last documented case in Europe was in 1999, and China, the USA, Australia and India are also now officially CBPP-free (for a full list and map of CBPP-free countries, see (WOAH, 2022a)). However, the disease persists in Asia and remains endemic in sub-Saharan Africa (with the exception of South Africa), with an estimated (in 2006) total annual loss of 40 million GBP (47 million USD) across 12 countries (Tambi et al., 2006). This impact is keenly felt at the local level, where a more recent study in Kenya showed that CBPP could cause a family keeping cattle to lose more than twice its annual income, due to vaccination, post-vaccine reactions, treatment costs, morbidity and mortality (Kairu-Wanyoike et al., 2017).

The continuing spread of *Mmm* and its associated economic losses make CBPP the greatest infectious threat to African cattle since the formal elimination of rinderpest in 2011 (USDA, 2017), but the disease surveillance, containment, and mitigation strategies necessary to eventually eliminate CBPP are currently lacking (Jores et al., 2020). Over the past decade, research into the biology of *Mmm* has opened many new avenues, including the development of diagnostics, vaccines, and other control measures, that may substantially boost our ability to control CBPP within endemic regions and prevent its spread to other regions. Effective application of these new data and methods, however, will require greater prioritisation of CBPP by government policymakers. Previous programmes for CBPP control in Africa have mainly relied on international funding due to declining animal health budgets in Africa (reviewed in (Tambi et al., 2006)), and their eventual discontinuation has left CBPP largely uncontrolled within much of its endemic zone (reviewed in (Alhaji et al., 2020)). As a result, the threat CBPP poses to the security and livelihood of millions of cattle owners in Africa must not be underestimated, nor should the benefits (in food security, international trade, etc.) of adequately controlling this disease (Alhaji et al., 2020).

In this section, we will describe some of the most compelling research on *Mmm* and CBPP that has been conducted between 2012 and early 2023. These findings cover the basic biology and molecular mechanisms of *Mmm*, its pathogenesis and immune evasion in host animals, the epidemiology and control of CBPP and other fields crucial for understanding this disease and limiting the damage it causes. We then close by listing the remaining gaps/future research priorities that we believe will be most important for expanding these fields.

Literature review

Biology of the pathogen

Mmm, the causative agent of CBPP, was the first mycoplasma to be isolated in culture, with its identification in 1898 confirming prior knowledge of the contagious nature of CBPP (Nocard et al., 1898; Saraya, 2016). Within genus *Mycoplasma*, *Mmm* is included in the “*Mycoplasma mycoides* cluster” alongside several other pathogenic subspecies responsible for clinically significant infections of livestock (Pettersson et al., 1996). Like all mycoplasmas, *Mmm* is an obligate parasite and is among the smallest known free-living organisms, with a minimum diameter of only 300 nm (Maniloff and Morowitz, 1972) and a 1,211 kb genome (Westberg et al., 2004). Mycoplasmas also lack a cell wall, rendering them pleomorphic and naturally resistant to beta-lactams and other antibiotics that target components of cell wall synthesis (Mitchell et al., 2012).

Molecular typing and genome sequencing

Mmm has low sequence diversity compared to other members of the *Mycoplasma mycoides* cluster, which has been attributed to its relatively recent emergence (Dupuy et al., 2012; Fischer et al., 2012). Notably, however, *Mmm* appears to exhibit higher diversity in Africa relative to historical isolates from pre-eradication Europe, suggesting the presence of understudied evolutionary pathways (Dupuy et al., 2012). Studies of genome sequences from new *Mmm* isolates are important for tracking these pathways and monitoring the geographical spread of the pathogen within its enzootic zone. Prior to 2015, GenBank lacked *Mmm* genome sequences representing virulent circulating strains from Africa (Fischer et al., 2015). Newer studies have begun to address this, and the ongoing development and proliferation of sophisticated next-generation sequencing techniques has facilitated the analysis of numerous *Mmm* genomes over the past decade. These include the Australian strain Gladysdale (Wise

et al., 2012), the Italian strain 57/13 (Orsini et al., 2015) and the sequencing and microscopic analysis of the African challenge strains Afadé and B237 that provided new insights into the bacteria's evolutionary history – these two strains exhibited protrusions similar to the attachment organelle of *Mycoplasma pneumoniae*, but their genomes lacked homologs of the cytoadhesion proteins used by *M. pneumoniae* to create this structure, suggesting the presence of an alternative adhesion pathway (Fischer et al., 2015). Other recently published African *Mmm* genome sequences include the vaccine strain T1/44 (Gourgues et al., 2016) and the Nigerian strains APF9 and AP108 (Di Federico et al., 2019). The sequencing and analysis of *Mmm* genomes will continue to be an important aspect of their characterisation, laying the foundation for in-depth structural and functional studies of the proteins involved in *Mmm* biology and its similarities and differences relative to other mycoplasmas.

Proteomics and gene characterisation

The outer surface of *Mmm*, being the pathogen's point of contact with target cells, is a natural target for such studies of its functionality and fundamental molecular biology. Characterisation of the surface proteome of nine European and African *Mmm* strains identified 44 lipoproteins or cytoplasmic membrane-associated proteins expressed by all the strains, comprising a “core *in vitro* surface membrane-associated proteome” of promising targets for vaccine/diagnostic development and future studies of host-pathogen interactions (Krasteva et al., 2014). The authors of this study note, however, that there may be significant differences between the *in vitro* and *in vivo* surface proteomes of *Mmm*, and they reported relatively low agreement between their 44 identified core surface proteins and previous studies of the *in vivo* serological response to purified *Mmm* antigens (Krasteva et al., 2014). This research group subsequently conducted a more extensive study specifically on the high-pathogenicity African field strain N6 and the low-pathogenicity vaccine strain KH3J, aiming to define new targets in both the surface and intracellular proteomes for targeted studies of individual proteins; they ultimately identified ~31% of the predicted proteome, including 145 previously unreported proteins (Krasteva et al., 2015). Such studies provide valuable roadmaps for further research into *Mmm* proteomic functionality, host-pathogen interactions, and the determinants of pathogenicity.

Alongside large-scale proteomics research, smaller-scale in-depth studies have continued to clarify previously unknown capabilities and functional pathways with important consequences for understanding CBPP and developing effective control strategies. Following the observation that *Mmm* strain Afadé produces two types of colony on solid medium – an “opaque” variant that produces a capsule and a “translucent” capsule-less variant that secretes cell-free exopolysaccharides (Bertin et

al., 2013; Gaurivaud et al., 2004) – these modes were shown to facilitate different bacterial functions *in vitro* and *in vivo*, with the absence of a capsule reducing serum resistance but increasing adherence and antimicrobial resistance (Gaurivaud et al., 2014). The stress-induced switch between these forms was therefore hypothesised to be an adaptive response to different microenvironments, allowing the pathogen to modulate its virulence during the different stages of CBPP (Gaurivaud et al., 2014). These authors later examined the exopolysaccharide secretion by the strain Afadé translucent variant in greater detail, finding that despite their tiny size, the *Mmm* cells secreted extracellular vesicles of highly variable size during culture (Gaurivaud et al., 2018). Analysis of these vesicles' membrane-associated proteins revealed several that had previously been linked to pathogenicity and host-pathogen interaction, suggesting that this secretion pathway may play an active role in *Mmm* infectivity (Gaurivaud et al., 2018).

These studies indicate the broad range of research questions and experimental techniques that have been applied to the study of *Mmm* over the past decade. Even after 125 years of research into the causative agent of CBPP, many aspects of its molecular biology remain only partially understood, and further acquisition of complete genome sequences in conjunction with large- and small-scale proteomics studies will be required to complete the picture of *Mmm*'s core functionality.

Diagnosis

CBPP diagnosis is a crucial part of disease surveillance and control. Pathological findings in suspected cases of disease can provide a presumptive diagnosis (Di Provvio et al., 2018), but laboratory testing is then required to confirm the presence of *Mmm* from nasal swabs or discharges (live animals) or from pleural fluid or tissue samples (necropsy), with polymerase chain reaction (PCR) considered the method of choice for molecular validation of a CBPP diagnosis (reviewed in (Francis et al., 2015a)). World Organisation for Animal Health (WOAH)-recommended serological tests (e.g., competitive ELISA and immunoblotting tests) are also suitable for herd-level diagnosis (reviewed in (Di Teodoro et al., 2020)).

DNA diagnostics

Although highly sensitive, laboratory-based PCR and real-time PCR assays require skilled personnel and laboratory equipment, making them inherently unsuitable for pen-side use. This is a particular

problem in the remote rural areas that comprise much of the CBPP-endemic region of Africa, where access to laboratory services is often severely limited (Vudriko et al., 2021). These restrictions have encouraged the development of isothermal amplification assays that do not require a thermocycler, making them far easier to deploy under field conditions. A new photometric loop-mediated isothermal amplification (LAMP) assay kit was reported to allow detection of *Mmm* DNA directly from crude fluid samples, requiring only a battery-powered mobile device to run the assay (Mair et al., 2013). The sensitivity of LAMP assays for CBPP diagnosis has been compared favourably against serology and even PCR (Enyaru et al., 2012), encouraging further development of isothermal tests for field applications.

Serological diagnostics

Serological assays are generally less sensitive compared to molecular amplification techniques – importantly, no single serological test can reliably detect all CBPP-infected animals, and multiple tests must therefore be applied in parallel to achieve maximum sensitivity (Marobela-Raborokgwe et al., 2003; Sidibé et al., 2012). However, these assays are generally faster and simpler and are thus much more amenable to pen-side diagnostic applications. In Nigeria, a comparison of the dot blot and complement fixation diagnostic tests reported that the dot blot could serve as a reliable, affordable means of presumptively confirming CBPP in slaughtered cattle with lung lesions (Egwu et al., 2012). The latex agglutination test has also been used for on-farm diagnosis in Nigeria (Okaiyeto et al., 2013), though its sensitivity and specificity have been compared unfavourably against the complement fixation test (Odongo et al., 2013). ELISAs have been used for CBPP diagnosis for many years (Le Goff and Thiaucourt, 1998), and Heller *et al.* developed a cocktail ELISA with diagnostic sensitivity and specificity comparable to WOAHP-recommended assays – transferring this assay onto a commercially produced lateral flow test platform allowed it to be used for rapid proof-of-concept field diagnosis (Heller et al., 2016).

Sampling strategies and other developments

Training local personnel in the use of diagnostic techniques is necessary for expanding the range of CBPP surveillance and promoting appropriate sample collection and analysis. In Botswana, annual proficiency testing begun in 2010 has dramatically increased CBPP diagnostic skill among participating laboratories (Modise et al., 2018), and a dedicated smartphone app (*VetAfrica-Ethiopia*) was piloted

in Ethiopia to assist student practitioners in diagnosing CBPP and other livestock diseases (Beyene et al., 2017).

Pathogenesis

The respiratory disease caused by *Mmm* infection is characterised by severe bronchopneumonia and pleural effusion in the acute/sub-acute stages, which develops to include the emergence of pulmonary sequestra in chronically infected cattle (reviewed in (Di Teodoro et al., 2020)). Following inhalation of aerosolised pathogen from nearby infected animals, cattle may take anywhere between three weeks and six months to manifest the disease; once they do, CBPP is associated with high morbidity and a variable mortality rate of up to 90% in a naïve and unvaccinated population (reviewed in (Di Teodoro et al., 2020)).

Advances in knowledge of CBPP pathogenesis are hard-won due to the lack of a small animal experimental model and a relative dearth of physiologically relevant *in vitro/ex vivo* tissue culture systems (DISCONTTOOLS, 2016a). Some progress has been made in understanding the pathogenesis of *Mmm*, but many questions remain. Large animal experiments are costly to conduct and are often carried out in resource-limited settings, restricting the range and type of analyses that can be performed. Collaborations with other laboratories have proven productive, and the emergence of validated *ex vivo/in vitro* model systems to investigate the interaction of *Mmm* with host cells represent important steps forward.

In vivo studies

CBPP is most commonly induced in cattle by intratracheal instillation of *Mmm*. However, studies have now highlighted the impact of route of experimental challenge, demonstrating that endo-tracheal infection does not fully replicate the features of CBPP seen in animals infected naturally or by contact with experimentally infected cattle (Lutta et al., 2017; Scacchia et al., 2011). These findings are critically important for the planning of experiments seeking to understand host-pathogen interactions, and researchers should aim to avoid the endo-tracheal challenge model wherever possible. Contact challenge is of course more costly and has the major limitation that you cannot be certain of the point of infection; yet, aerosol challenge methods are successfully used to model other bovine diseases, and

there is encouraging evidence that this approach could be similarly standardised and applied to CBPP (Sacchini et al., 2020).

As CBPP becomes established, cattle typically develop pleural effusion from which *Mmm* can also be isolated. The first proteomic characterisation of both the fluid and the mycoplasma within it has yielded interesting insights: firstly, this study detected expression of almost all *Mmm* proteins involved in glycerol import, which culminates in H₂O₂ production, in the pleural effusion, as well as of enzymes involved in synthesis of the potential virulence factor, capsule polysaccharide; from the host side, alongside acute-phase-response- and inflammation-related proteins, the authors detected molecules involved in antigen processing, ubiquitination, and proteasome degradation (Weldearegay et al., 2016). It would be of great interest to compare the *in vivo* proteome generated in this study to the various *in vitro* datasets of *Mmm* protein expression, to assess the extent to which the *in vitro* data are able to inform on the infection of the natural host.

Meanwhile, Li & Wang *et al.* studied the changes associated with host tropism and virulence in *Mmm*, reporting their adaptation of pathogenic strain BEN-1 to rabbits over the course of continuous passaging for 468 generations (during which the bacterium lost immunogenicity in cattle but gained virulence in rabbits). Analysis of strains that emerged during this process revealed a total of 59 specific *Mmm* genes that were involved in host adaptation to rabbits or virulence or immunogenicity in cattle (Yuan Li et al., 2016).

In vitro studies

Di Teodoro *et al.* reported significant progress in the development of a physiologically relevant tissue culture system in which to study *Mmm* pathogenesis: they showed that bovine respiratory tissue explants can be successfully used to study some aspects of early pathogenesis during CBPP, while noting that further improvements to the model will be required to dissect the local immune response (Di Teodoro et al., 2018a). Their findings led them to suggest that *Mmm* may not be the only relevant source of tissue-damaging H₂O₂ during infection; alongside, activated immune cells were also found to produce H₂O₂ (Di Teodoro et al., 2018a), which indicates the need for further immunological studies of this phenomenon.

Recent work also investigated the use of precision-cut bovine lung slices as an *in vitro* model for understanding the pathogenesis of CBPP. By comparing the *in vitro*-infected lung slices with lung

sections from experimentally infected cattle, the authors concluded that the model was able to recapitulate key features of the disease, including destruction of lung tissue at high doses of *Mmm* (Weldearegay et al., 2019). Comparing these *ex vivo*-infected lung slices with lung slices generated from naturally infected cattle would allow us to more fully understand the applicability of this model.

Additional insights into the early stages of host invasion have come from the application of new tools to meet the challenge. Aye *et al.* utilised flow cytometry to measure the adherence of eight distinct strains of *Mmm* to a range of primary cell types from adult cattle and from foetal lung; the results confirmed the preference of the pathogen for adult lung epithelial cells, consistent with the presence of a specific (yet unidentified) receptor that is lacking or expressed at lower levels on other cell types and in the lungs of foetal cows (Aye et al., 2015). The same group went on to exploit a panel of anti-*Mmm* monoclonal antibodies that inhibited the pathogen's binding to bovine lung epithelial cells, identifying capsular polysaccharide and 2-oxoacid dehydrogenase acyltransferase as important targets used by *Mmm* for cell adhesion (Aye et al., 2018). These studies also provided important insights into the humoral immune response to *Mmm* and are discussed in this context in the [Adaptive immunity](#) section.

Despite earlier work showing that some strains of *Mmm* are able to form biofilms on agar which significantly increases their resistance to peroxide, detergent and heat (McAuliffe et al., 2008), and may contribute to pathogenesis, we did not find any studies following up on this phenomenon.

Immunology

CBPP can occur as acute, sub-acute and chronic forms, each with their own distinct pathological features, which are likely mirrored in the host's immune response. Moreover, responses to reinfection are likely to be different: accordingly, unpicking the complexity of the bovine immune response to the various facets of CBPP is an ongoing challenge.

Over the past ten years, progress has been made in understanding the role of T cells in primary infections and reinfections in cattle, and in starting to dissect the interaction of *Mmm* with cells of the innate immune system. Of note, researchers have also uncovered key pieces of information that will support further progress: previously, Scacchia *et al.* showed that significant immunological differences existed between individual animals infected experimentally by either contact exposure or

endotracheal intubation (Scacchia et al., 2011), and some subsequent studies have taken this into account; alongside, the work of Rodrigues *et al.* using whole blood transcriptome analysis showed that local reactions in the lung cannot be inferred from blood samples (Rodrigues et al., 2015), unlike for *Mycobacterium bovis* infection (Rhodes et al., 2000). These studies strongly caution against inference between experimental/natural infection, and extrapolation from findings made in other respiratory pathogens.

Although there remain many hurdles before we have a complete understanding of the immunology of *Mmm* infection, work in this area must be considered a high priority for future research: full understanding of the interaction of the pathogen with the host immune system is a pre-requisite for rational vaccine design and/or the development of novel therapeutics. In turn, gaining this understanding will require comprehensive, accurate and rigorously conducted immunological studies, using the latest tools available and considering the insights into improved experimental design that have been reported in recent years.

Immunogenetics

While it has long been known that CBPP susceptibility varies markedly according to breed (Masiga, 1972), age (Masiga and Windsor, 1978) and immune status of the host, to our knowledge, there have not been any research reports over the past decade concerning the identification of the host factors underpinning resistance or susceptibility to *Mmm* infection.

Innate immunity

Mmm most often enters a host via the airways; therefore, alveolar macrophages are likely to be the first line of defence. While an early study showed that bovine alveolar macrophages incubated *ex vivo* with *Mmm* produced pro-inflammatory TNF- α and nitrogen monoxide (Jungi et al., 1996), later work revealed that monocyte-derived macrophages incubated *in vitro* with the *Mmm* exopolysaccharide galactan produced anti-inflammatory IL-10, and not TNF- α or IL-12p40 (Totté et al., 2015). The authors of the latter study suggested that galactan may thus moderate the inflammation caused by *Mmm*, which could contribute to immune escape; alternatively, this difference could reflect the different cell types and culture conditions used in the two studies. A more recent study, reported in preprint form, showed that bovine monocyte-derived macrophages did secrete TNF- α during incubation with high (500-1000) MOIs of *Mmm in vitro*, but not at a lower (100) MOI: the authors suggested that, as the

higher MOIs were associated with phagocytosis-independent uptake of *Mmm* by macrophages, this could indicate a role for autophagy in TNF- α production by these cells (Totté et al., 2022). The authors also excluded a role for host complement in either blocking *Mmm* adhesion to macrophages or increasing its uptake, while neutralising antibodies increased both uptake and killing of the mycoplasma (Totté et al., 2022). Given the earlier differences between studies using alveolar macrophages and monocyte-derived macrophages, further work is needed to determine the extent to which the *in vitro*-derived cells recapitulate features of primary bovine lung macrophages.

Although the conclusions of the *in vitro* studies are yet to be fully resolved, there is convincing *in vivo* evidence for an important role of TNF- α in CBPP. As discussed in more detail below, Sacchini *et al.* found that high levels of TNF- α in the serum correlated with more severe disease in cattle experimentally infected by intra-tracheal intubation (Sacchini et al., 2012). Furthermore, Sterner-Kock *et al.* experimentally infected a group of *Bos indicus* cattle with *Mmm* and analysed immune cell numbers and the frequency of TNF- α -, IL-1 β - and IL-17A-producing cells in their lung tissue at 30 days post-infection (dpi) (Sterner-Kock et al., 2016). They found that CBPP lesions exhibited higher levels of all three tested cytokines compared to lung regions from uninfected controls (Sterner-Kock et al., 2016). Taken together, it seems that TNF- α is consistently induced both locally, at the primary infection site in the lung, and systemically, where higher levels of the cytokine may contribute to, or be a consequence of, pathology.

Neutrophils and lymphocytes are both present within the interstitial space of the CBPP-affected lungs of cattle experimentally infected by intubation at 30 dpi, as are macrophages that contain *Mmm* antigen (Sterner-Kock et al., 2016). Neutrophils may be particularly important in this regard, as a recent study showed that *Mmm* can adhere to, and significantly increase the production of reactive oxygen species (ROS) by bovine polymorphonuclear cells *ex vivo* (Di Teodoro et al., 2018b); this could exacerbate the cell and tissue damage caused by ROS during CBPP (reviewed in (Pilo et al., 2007)). Moreover, bovine neutrophils incubated with *Mmm ex vivo* expressed high levels of IL-1 β , IL-8 and COX-2 and 5-LOX, as well as rapidly inducing iNOS, in the first minutes and hours after exposure to the mycoplasma (Di Federico et al., 2020).

Adaptive immunity

Both humoral and T cell-mediated responses are thought to be important in determining protection/recovery from, or susceptibility to, *Mmm* infection, but studies have historically reported

somewhat contradictory results: while early work linked CD4⁺ T cells and levels of IFN- γ produced by PBMCs *ex vivo* with protection during primary infection (Dedieu et al., 2005a), subsequent studies did not fully support either the correlation between IFN- γ production *ex vivo* and disease severity (Jores et al., 2008) or the idea of a major role for CD4⁺ T cells in protection from acute disease (Sacchini et al., 2012, 2011). Moreover, a comparison of TNF- α , IFN- γ , IL-4 and IL-10 levels in samples of plasma from experimentally infected cattle that were either depleted of CD4⁺ T cells from 6 dpi or not, did not reveal any consistent differences in these cytokines between the two groups (Sacchini et al., 2012). The authors did uncover a possible correlation between high levels of TNF- α and more severe disease in the three most-affected animals, and they also noted the general absence of IL-4 in infected animals, a peak in IL-10 at 1-2 weeks post-infection and a peak in IFN- γ at 3 weeks post-infection (which was significantly higher in the absence of CD4⁺ T cells) (Sacchini et al., 2012). Early T cell depletion did not affect levels of IgG2 or IgM antibodies in plasma, but it did lead to lower levels of IgG1 and IgA later in infection; meanwhile, when animals with severe or mild disease were compared, there was a strong statistical association between high IgG1 in the first two weeks post-infection (and to a lesser extent high IgG2 and IgA) and severe CBPP in the four animals affected (Sacchini et al., 2012). Taken together, these studies show that the absence of CD4⁺ T cells after the first week of infection has little impact on the levels of the cytokines measured, but the levels of antibodies that may be associated with worse disease are higher in the presence of CD4⁺ T cells. The validation of these results under more field-like conditions would be a useful goal for future studies, assessing the impact of T cell depletion at the point of infection and measuring the concentrations of a broader range of cytokines/immune mediators/cell populations in the blood and lungs of infected animals.

While the role of CD4⁺ T cells during the acute phase of primary infection seems to be at best dispensable, and at worst pathogenic, there is some evidence of their importance in establishing the immune memory that is associated with recovery from CBPP and perhaps from reinfection. Early work by Dedieu *et al.* suggested that IFN- γ -secreting memory T cells in the lymph nodes were important for protection of recovered animals (Dedieu et al., 2006); this was supported by Totté *et al.* who examined the cells from lymph nodes draining the lungs of cattle during or after experimental infection with *Mmm* and found evidence of strong recall proliferation of memory CD4⁺ T cells, accompanied by Th1 cytokine production and T cell-dependent memory B cell proliferation in recovered animals (Totté et al., 2008). These studies highlight the potential differences between the responses detected in blood and those in the draining lymph nodes, urging caution in generalising the conclusions based on one to the situation in the other.

Alongside, several studies have also advanced our knowledge of the role of B cells during CBPP. At 30 dpi, Sterner-Kock *et al.* found that the pulmonary lymph nodes of *Mmm*-infected animals exhibited follicular hyperplasia and had activated germinal centres, while uninfected controls did not (Sterner-Kock *et al.*, 2016). However, an earlier study suggested that high antibody titres during infection might rather more be linked to immunopathology (particularly vasculitis) than to recovery (Schieck *et al.*, 2014), supporting previous work showing the potential negative role of post-vaccination immune complexes in CBPP (Mulongo *et al.*, 2015). Subunit vaccine studies have also generated considerable insights into potentially protective versus pathogenic *Mmm* antigens (see [Vaccines](#) section).

Despite the possible immunopathology induced by antibodies during acute infection, understanding the neutralising antibody response is an important step towards the design of effective vaccines against CBPP. Building on their previous work dissecting the specificity of the adherence mechanisms used by *Mmm* to attach to bovine lung epithelial cells (Aye *et al.*, 2015), Aye *et al.* went on to screen a panel of 80 murine monoclonal antibodies specific for *Mmm* and identified 13 clones able to significantly – but not completely – inhibit binding to primary bovine lung epithelial cells, of which one also directly inhibited the growth of the mycoplasma in culture (Aye *et al.*, 2018). This same clone had previously been reported to bind an *Mmm* capsular polysaccharide (Schieck *et al.*, 2016), and Aye *et al.* went on to define the specificity of several others: most notably, they found that three of the clones recognised 2-oxoacid dehydrogenase acyltransferase, which is part of the pyruvate dehydrogenase (PDH) complex that is important for the survival of *Mmm* (Aye *et al.*, 2018). Early studies showed that this protein is immunogenic in experimentally infected cattle (Jores *et al.*, 2009), but more work is needed to understand its functional role *in vivo* and whether targeting this antigen could represent a rational step forwards for vaccine design.

The importance of testing the effect of antibodies specific for *Mmm* antigens is also highly relevant if exacerbation of disease by vaccine-induced immunity is to be avoided. Following earlier work by Hübschle *et al.* that showed the potential of immunising cattle with *Mmm* lipoprotein Q (LppQ) to exacerbate disease (Hübschle *et al.*, 2003), Mulongo *et al.* conducted another study aiming to refine and extend our understanding of this phenomenon (Mulongo *et al.*, 2015). The authors found that immunising cattle three times with LppQ in Freund's adjuvant elicited levels of antibodies that were associated with the development of kidney lesions that appeared to be caused by immune complexes in over 70% of animals challenged with *Mmm* (Mulongo *et al.*, 2015). This is particularly interesting given that anti-LppQ antibodies are present in cattle after natural or experimental infection with *Mmm*

(Abdo et al., 2000), leading to the question of whether antibody responses to this lipoprotein contribute to immunopathology in naturally infected animals.

Lastly, Sterner-Kock *et al.* also reported that IL-17 is present in CBBP lung lesions of experimentally infected cattle at 30 dpi (Sterner-Kock et al., 2016). As studies in mice and humans (reviewed in (Luo et al., 2021)) show that this cytokine can be associated with the pathology of mycoplasma respiratory infections, this finding warrants further investigation.

Despite earlier work showing the potential of the local IgA response to contribute to protection, no work has been done on this.

Maternal immunity

There have not been any notable advances published in this area since 2012.

Immune evasion

Given that animals may recover from, succumb to or become carriers of *Mmm*, it is reasonable to speculate that the pathogen has evolved mechanisms to prevent effective clearance in every case. While these mechanisms are far from completely elucidated, some progress has been made.

Firstly, there is evidence from early *ex vivo/in vitro* studies that *Mmm* can induce apoptosis (Dedieu et al., 2005b) or unresponsiveness (Dedieu and Balcer-Rodrigues, 2006) in bovine leucocytes. In support of this, a more recent study found further evidence of systemic immunosuppression in the blood of contact-infected cattle. Rodrigues *et al.* conducted a comprehensive time-course analysis of global gene expression in whole blood samples from cattle before, during and after acute infection with *Mmm*, finding evidence of widespread downregulation of gene expression, most notably affecting cell-to-cell signalling and cellular functions pathways (Rodrigues et al., 2015). However, the authors noted that this picture does not seem to represent local events in the inflamed lung.

Geographic distribution and epidemiology

Mmm spreads between animals via aerosols, and transmission therefore usually requires close contact between infected and susceptible animals (DISCONTTOOLS, 2016a). Lacking a cell wall, *Mmm* is susceptible to many disinfectant methods (e.g., commercial cleaners, heat and high or low pH) – its environmental survival is also short (≤ 2 weeks), restricting its routes of transmission relative to hardier pathogens (WOAH, 2020). Transmission via bodily fluids and indirect transmission (from contaminated surfaces or fomites) appears to be mostly negligible (reviewed in (Di Teodoro et al., 2020)). Long-range transmission is rare but possible under favourable climatic conditions (DISCONTTOOLS, 2016a; WOAH, 2023a) and has been reported in past outbreaks (Giovannini et al., 2000), though illegal movement of cattle remains a far more common cause of international transmission events. The significance of transmission from chronically infected animals, which harbour *Mmm* in pulmonary sequestra, is also not completely understood, though it is thought unlikely to play a major role in CBPP spread and maintenance (EFSA Panel on AHAW et al., 2022a).

Despite these limitations, *Mmm* is highly contagious via direct transmission within and between cattle herds, facilitating high prevalence and subsequent mortality in endemic areas. CBPP currently remains endemic in sub-Saharan Africa, where it is considered one of the most economically important diseases of livestock in the region, and outbreaks in the 20th century demonstrated the ability of *Mmm* to spread rapidly to other continents if left unchecked (Alhaji et al., 2020; Di Teodoro et al., 2020; WOAH, 2023a).

Global situation

The Americas

There have not been any notable findings published in this area since 2012.

Europe

There have not been any notable findings published in this area since 2012.

Africa

CBPP is widely prevalent across a wide swathe of western, central and eastern Africa. The WOAH Global Framework for the Progressive Control of Transboundary Animal Diseases (GF-TADs) reports that the area of spread and the incidence of outbreaks appear to be increasing, with the latest

reported outbreaks occurring in the Gambia, Niger and Namibia (Mbiri et al., 2020; WOA, 2023b). Lack of access to vaccines and other veterinary resources allows CBPP to spread rapidly in many regions of Africa, and Zambia and Namibia are currently the only WOA members with endorsed official CBPP control programmes (WOA, 2023a). Seroprevalence and abattoir surveillance studies also continue to report high levels of disease burden across this region (Abusara and Abdelgadir, 2014; N’Goran, 2020; Noah et al., 2015; Séry et al., 2015; Yansambou et al., 2018; Zerbo et al., 2021), though methodological challenges in low-income countries (e.g., in sampling design, sample transport and accuracy of diagnostic tests) must be considered when assessing the accuracy of reported data (Lewerin et al., 2018). Endemic CBPP has been described as a “disregarded” disease where insufficient data and lack of surveillance lead to disinterest from donors and researchers, leading in turn to lack of surveillance and reliable data-gathering (Roger et al., 2017). The current status of CBPP control in Africa is further discussed in the [Control](#) section below.

In Nigeria, CBPP causes losses of >2 billion USD annually (FAO, 2004) and reported seroprevalence is generally high, with animal-level estimates ranging from approximately 10% to 56% in different states (Ankeli et al., 2017; Anyika et al., 2021; Jamilu et al., 2018; Olorunshola et al., 2020; Suleiman et al., 2015a). Reported CBPP seroprevalence is also highly variable Ethiopia (reviewed in (Abdela and Yune, 2017)), which houses the largest livestock population on the continent (Endalew and Wakene, 2021; Mekuriaw and Harris-Coble, 2021), and the disease appears to be particularly concentrated in the lowland regions where many mobile pastoral cattle herds are kept (Mamo et al., 2018). Numerous analyses have been conducted on the risk factors associated with seroprevalence, but these studies rarely assess the same parameters and often reach different conclusions regarding the significance of factors including cattle age, breed and body condition (Daniel et al., 2016; Kassaye and Molla, 2012; Mamo et al., 2018; Minda et al., 2017; Negash and Dubie, 2021).

Asia, the Middle East and Oceania

CBPP epidemiology in Asia appears to have changed little over the past decade. The outlook from the continent’s most populous nations is positive: China remains CBPP-free after eliminating the disease in the 1980s (reviewed in (Jores et al., 2020; Xin et al., 2012)), and India has also maintained its CBPP-free status (EFSA Panel on AHAW et al., 2022a). Elsewhere in Asia, the situation is more complicated. Many countries do not report to the WOA (Xin et al., 2012) and/or lack surveillance programmes against CBPP (EFSA Panel on AHAW et al., 2022a; WOA, 2020). A recent study reported increasing CBPP seroprevalence in northeast Malaysia, but the causative *Mmm* was unable to be isolated (Zarina et al., 2016).

Surveillance is similarly limited in the Middle East, and little research has been conducted there to investigate CBPP epidemiology. Afghanistan is one of the few countries in the region where a large-scale study of CBPP prevalence has been performed, finding no evidence that it is present there (Bahir et al., 2017). In Pakistan, a recent series of clinical and seroprevalence studies reported the presence of CBPP in several districts of Punjab province, near the border with India (Anjum et al., 2020, 2019b, 2019a), but official notifications were not made to the WOA (EFSA Panel on AHAW et al., 2022a).

Surveillance, transmission and risk factors

The predominance of rural, mobile livestock farming systems in many endemic regions of Africa limits the applicability of standard surveillance methods and epidemiological studies, which often rely on regular, standardised data collection from statistically significant population sizes. As with other endemic livestock diseases of Africa, participatory epidemiology has proven a valuable tool for collecting qualitative data on local knowledge, disease prevalence and control measures among smallholders in Africa, who are disproportionately affected by CBPP (Attoh-Kotoku et al., 2018; Baluka et al., 2014; Chenais and Fischer, 2018; Onono et al., 2014). Many such studies have been conducted over the past decade in the endemic countries of Africa including Nigeria (Alhaji and Babalobi, 2016; Geidam et al., 2013; Jamilu et al., 2015), Ethiopia (Bahiru and Assefa, 2020), Kenya (Illes et al., 2022, 2019; Kairu-Wanyoike et al., 2013; Waithanji et al., 2019b), and Uganda (Baluka et al., 2013). These studies have identified numerous sociocultural risk factors influencing *Mmm* transmission, including borrowing/loaning of cattle, sharing of water sources, response to droughts and the extensive management system widely practiced among pastoral cattle herds.

Nigeria is home to a large percentage of Africa's cattle population. Infected animals in that country are regularly sent to abattoirs for slaughter (Nwankwo et al., 2019; Sada et al., 2021), and these infections often go undetected. Investigations of working conditions and management in Nigerian slaughterhouses have found a lack of water and electricity, non-existent hygiene, insufficient inspection of animals and indiscriminate disposal of hazardous animal waste combining to produce a dire outlook for the spread of CBPP within Nigeria's meat production system (Bello et al., 2015; Njoga et al., 2023). Nigeria has continued to conduct mass vaccination campaigns against CBPP using the T1/44 vaccine, but frequent shortages and lack of funding severely limit their efficacy (Majekodunmi et al., 2018).

Vaccination is also often met by strong resistance from pastoral communities. More than 80% of Nigerian cattle are thought to be kept by such communities (Suleiman et al., 2015b), where they play a vital role in food security and income generation. Many pastoralists appreciate the dangers presented by CBPP (Majekodunmi et al., 2018), but this is not universal (Nuvey et al., 2023) and cooperation with vaccination campaigns remains very low overall (Alhaji et al., 2020; Billy et al., 2015; Sada et al., 2015). Importantly, vaccine prices are often unaffordable for pastoral farmers, and veterinary services are inaccessible by many communities; these factors encourage the use of ethnoveterinary practices for CBPP control, ranging from the feeding of medicinal plants to the topical application of kerosene or spent engine oil (Alhaji and Babalobi, 2015; Basheir et al., 2012; Soladoye et al., 2016; Waithanji et al., 2019a).

Wildlife

There have not been any notable findings published in this area since 2012.

Control of the disease

The mainstays of an effective CBPP prevention and control programme are vaccination, treatment, movement restrictions and culling of infected animals (the latter two relying on effective surveillance and diagnosis). However, an opinion article published by Jores *et al.* in 2013 noted that, alongside the shortfalls of the currently available vaccines, the WOAHA-recommended diagnostic assays had limited sensitivity in defining the disease status of individual animals, while movement control and destruction of infected animals was impractical in the absence of public support and in the face of mobile production systems, limited veterinary services and little-to-no financial compensation for the loss of the animals (Jores et al., 2013). Perhaps unsurprisingly, data from the WOAHA revealed a marked lack of progress in CBPP control in the decade between 2010 and 2020 (Jores et al., 2020).

Given the obstacles to establishing an effective CBPP control programme, standard “field practice” relies more heavily on the somewhat controversial use of antimicrobial drugs such as tetracyclines, macrolides or quinolones. Studies have shown their potentially beneficial effects at the herd (reviewed in (Rweyemamu et al., 2000)), and individual (Muuka et al., 2019; Otina et al., 2022) levels, while in parallel there are concerns that this practice increases antimicrobial resistance risk, sequestra

formation and the number of carriers and may mask clinical signs of disease (FAO, 2004; Niang et al., 2010).

More effective control of CBPP will require action at the international, national, and local levels to overcome these obstacles; the development of improved vaccines remains probably the most important step in increasing the efficacy of control strategies in endemic regions, and some progress towards this aim has been made. Modelling studies have already indicated key parameters for improved vaccines and diagnostic tests (Ssematimba et al., 2015), and may help pave the way towards rational design of next-generation tools in the fight against *Mmm*.

Policy

As noted in the [Epidemiology](#) section above, the effective control of CBPP in Africa is hampered by a multitude of inter-related challenges, including under-funded veterinary services leading to poor or no surveillance, low sensitivity diagnostic testing, sub-optimal vaccines and vaccination regimens and a lack of enforcement of control programmes (reviewed in (Alhaji et al., 2020)). Multiple studies have attempted to dissect and propose solutions to these various challenges.

In the many areas lacking centrally organised and funded control programmes, the task of CBPP management most often falls to individual farmers; therefore, understanding the factors motivating or dissuading them from various control measures is an important area of research. Through structured interviews with Nigerian Fulani pastoral herdsman, Suleiman *et al.* identified the importance of information from trusted sources (the local veterinarian or other herdsman who had controlled the disease) and good access to affordable veterinary services (Suleiman et al., 2018). In the Narok region of Kenya, education of pastoralist farmers on CBPP control measures was also identified as a priority, as was a strategy to reduce post-vaccine adverse reactions, which were stated as a major factor in pastoralists' decisions not to revaccinate; alongside, farmers expressed a strong preference for vaccinating at specific times of year and together with vaccines against other diseases (Kairu-Wanyoike et al., 2014). Together, these studies highlight the importance of a strong veterinary infrastructure; private sector involvement may help, as shown in parts of Zambia (Muuka et al., 2013), and is recommended by the WOAHA as a means of delivering high-quality government-subsidised veterinary services and training for CBPP control (Onono et al., 2017). Alongside, the implementation of an animal identification system would be a relatively low-cost intervention that could markedly assist efforts to control CBPP (Muuka et al., 2012)

Therapeutics

Mmm is susceptible to several types of antimicrobial drug, among which oxytetracycline (Muuka et al., 2019, 2017), gamithromycin and tulathromycin (Muuka et al., 2019) have all been shown to significantly reduce disease severity; in a recent study, tulathromycin treatment also led to *Mmm* clearance in 90% of animals (Muuka et al., 2019). Several studies highlighted the importance of the pharmacodynamic properties of antimicrobials in determining their efficacy against *Mmm*, arguing for the preferential use of drugs with a longer half-life, such as tulathromycin (Mitchell et al., 2013a, 2013b, 2012). These studies evidence a potential role for careful and regulated use of new-generation macrolides – specifically tulathromycin – in the management of CBPP; however, at present the unregulated use of antimicrobial drugs for CBPP risks the emergence of resistant strains and cannot be recommended. Moreover, the suboptimal use of antimicrobials that lessen disease severity but allow residual *Mmm* to survive may also decrease detection of the disease at slaughter, thereby inadvertently contributing to the spread of CBPP.

Alongside the testing of macrolides for CBPP, several studies have reported trials of other synthetic or natural compounds, aiming to assess their use against *Mmm*. Plant-derived traditional remedies are easily available, low-cost, and readily accepted by local communities: proper assessment of their anti-mycoplasma activity is therefore warranted. Following their previous *in vitro* screening study that identified preliminary signs of anti-mycoplasma activity in crude extracts from five traditional medicinal plants used in Kenya (Kama-Kama et al., 2016), Kama-Kama *et al.* went on to test the anti-*Mmm* properties of eight potentially bioactive compounds isolated from *Solanum aculeastrum* and *Piliostigma thonningii* (Kama-Kama et al., 2017). They found that the individual compounds exhibited little or no growth-inhibiting activity against *Mmm in vitro* under the test conditions. This difference with the previous findings could be due to the extraction procedure, or the bioactive compounds present in the crude extract may have worked in concert to induce the previously reported anti-mycoplasma effects. Safety and efficacy studies of these extracts in the field would provide relevant data on their potential as anti-CBPP agents.

Vaccines

Currently available CBPP vaccines are based on the egg passage-attenuated *Mmm* T1/44 strain, either with or without further passage to induce streptomycin resistance (the T1-SR strain) (See also **Error! R**

reference source not found.) These vaccines rapidly induce detectable antibody responses in ~66-75% of cattle after a single immunisation, but levels drop quickly: a large study in the Gambia found that just one third of animals tested positive for anti-*Mmm* antibodies after three months (and 15% has been positive before the immunisation) (Secka et al., 2015). Another study in Kenya showed that 60% of vaccinated cattle that were challenged by intubation developed lesions, compared to 90% of unvaccinated animals, though the lesions were less severe after vaccination (Nkando et al., 2012).

As well as short duration of immunity and incomplete protection from disease, the attenuation of the vaccine strain is not robust; a degree of virulence remains including the retained ability to produce cytotoxic H₂O₂, which is likely to be the cause of the common and relatively severe vaccine site reactions (Mulongo et al., 2013a). These vaccines also require cold-chain storage after reconstitution, which is often problematic. Therefore, an improved vaccine should ideally be safe, extend the duration and extent of protection to around 18 months post-immunisation (Ssematimba et al., 2015), be protective after a single immunisation, be affordable within the means of the current socioeconomic status in CBPP-endemic areas and not require cold-chain storage.

While the field engages with the development of more effective vaccines, it is important to note that, even with the shortcomings of the conventional vaccine, annual herd immunisation was deemed an effective control measure by the WOA (WOAH, 2018) and was a mainstay of the successful CBPP eradication campaign in Australia in the 1960s (Newton and Norris, 2000), as well as in China with a locally made vaccine in the 1950s (Xin et al., 2012). That said, the situation in Africa is socioeconomically and politically very different, and mathematical modelling somewhat disagrees with the WOA's conclusion that annual vaccination as it stands will be effective in controlling the disease in sub-Saharan Africa (Ssematimba et al., 2015). Coverage is a key factor in any model vaccine, with a critical minimum of 80% for eradication to be considered possible; yet many African countries are unable to achieve even half this level with the current CBPP vaccines (reviewed in (Dudek et al., 2021)). Therefore, the success of any novel vaccine, or an improved conventional vaccine, will similarly depend on increased vaccine uptake and coverage, as well as complimentary control measures.

Current vaccines

As noted above, studies of the current commercially available vaccines confirm the limited protection, post-vaccinal adverse reactions and short duration of immunity that are elicited (DISCONTTOOLS, 2016a; Mwirigi et al., 2016a; Nkando et al., 2012). Attempts to increase the efficacy of the conventional vaccine have been mixed: Nkando *et al.* tested the hypothesis that the immunogenicity

of the current vaccine could be improved by modifying the medium used to grow the vaccine strain, but these authors observed that previous findings of increased viability in the laboratory (March et al., 2002) did not extend to increased protection from challenge in cattle experimentally infected by intubation (Nkando et al., 2012).

Other research has asked whether the current immunogenicity can be retained, but the safety profile improved, by using inactivated *Mmm* in place of the attenuated T1/44 strain. Mwirigi *et al.* compared conventional T1/44 vaccine with heat- or formalin-inactivated *Mmm* strain Afadé, combined with complete or incomplete Freund's adjuvant, respectively, finding that three immunisations with the inactivated vaccines elicited worse or comparable levels of protection compared to a single immunisation with the conventional vaccine (Mwirigi et al., 2016a). Therefore, while the inactivated vaccine route might yet offer important advantages, further study is needed to define the optimal composition of the vaccine, the immunisation regimen, and the duration of protection.

Alternative strategies for vaccine improvement might emerge from a more complete understanding of the immune response to T1/44. Totte *et al.* combined data from groups of cattle at different research sites that had been immunised with the same dose of T1/44 once, T1-SR twice a month apart, or T1/44 three times at annual intervals, and compared their T cell responses to *Mmm* with those of naïve unvaccinated animals (Totte et al., 2013). They found that measurable *Mmm*-specific CD4⁺ T cell proliferation and IFN- γ production only occurred in the animals that had been vaccinated three times, and also detected CD4⁺ T cell-dependent proliferation of non-CD4⁺ T cells (which were not identified in this study) and the presence of both T effector and central memory cells within the proliferating compartment (Totte et al., 2013). These data are important, given the association between the emergence of *Mmm*-specific CD4⁺ T cells and recovery from CBPP (Dedieu et al., 2006; Totté et al., 2008).

Novel vaccines

Various strategies have been trialled in mice and in cattle to assess potential novel vaccine candidates.

Inactivated vaccines

There have not been any notable advances published in this area since 2012.

Live-attenuated vaccines

There have not been any notable advances published in this area since 2012.

Subunit vaccines

Studies of the adaptive immune response during CBPP (see [Adaptive immunity](#)) reveal the presence of protective as well as pathogenic responses to *Mmm*, both of which are likely to be stimulated by immunisation with the live-attenuated organism. Therefore, alongside the general advantages offered by subunit vaccines (safe, inexpensive, and quick to manufacture), here there is the key potential to focus immunity on those antigens most relevant for protection, while avoiding those linked with immunopathology. The challenge remaining is to identify the optimal antigen or combination of antigens, as well as defining the optimal adjuvant to shape the immune response and ensure sufficient immunogenicity.

Trials of subunit vaccines against CBPP have met with mixed success. Mulongo *et al.* hypothesised that antibodies targeting l- α -glycerol-3-phosphate oxidase (GlpO), which mediates the oxidation of glycerol-3-phosphate and so the generation of tissue-damaging H₂O₂ by *Mmm* (Pilo *et al.*, 2005), could both protect cattle from infection and also inhibit the activity of GlpO (Mulongo *et al.*, 2013a). However, they found that while three immunisations of recombinant GlpO in incomplete Freund's adjuvant (IFA) did induce specific antibodies in cattle, these antibodies neither inhibited the enzyme's activity *in vitro* nor protected the animals from experimental challenge (Mulongo *et al.*, 2013a). Notably, monoclonal antibodies raised in mice *did* reduce H₂O₂ production by *Mmm* *in vitro* while those produced in the immunised cattle appeared to exacerbate the disease (Mulongo *et al.*, 2013a).

Following the identification of GlpO as an immunopathological antigen, Mulongo *et al.* also conducted subunit vaccination with the N-terminus of LppQ from *Mmm* to confirm its role in inducing immunopathology: indeed, they found that immunised animals suffered worse disease, likely due to the formation of immune complexes that caused glomerulonephritis (Mulongo *et al.*, 2015). Shortly after, Mwirigi *et al.* published their findings on the ability of two immunisations with an adjuvanted mixture of *Mmm* capsule polysaccharide conjugated to ovalbumin to reduce the severity of CBPP by almost two thirds, with antibody titres and protection comparable to that elicited by the commercially available vaccine (Mwirigi *et al.*, 2016b).

Further progress towards identifying antigens for inclusion or exclusion in novel CBPP subunit vaccines was made by a pair of studies that screened a larger number of proteins. Perez-Casal *et al.* used reverse vaccinology to define a set of 66 candidate *Mmm* proteins based on their predicted exposure on the surface of the mycoplasma, their likelihood of being involved in adhesion and their recognition

by serum from infected cattle; they then tested their immunogenicity *in vivo* (Perez-Casal et al., 2015). The authors vaccinated groups of cattle with adjuvanted pools of four or five proteins and confirmed the ability of the candidates to elicit antibody responses that were detected by ELISA; however, the proteins failed to induce detectable levels of recall proliferation in peripheral blood mononuclear cells (PBMCs) restimulated *ex vivo* (Perez-Casal et al., 2015). Building on this work, Nkando *et al.* repeated the vaccination experiment with an additional boost after three weeks, and then challenged the groups with *Mmm* administered intra-tracheally two weeks later (Nkando et al., 2016). Here, the use of the complement-fixation test to detect antibody responses indicated that immunisation with the protein pools induced seroconversion at one-to-two weeks only in a minority of the animals and did not induce any specific antibody responses to the pooled proteins that lasted until the point of challenge. Despite this, animals in two of the vaccine groups exhibited significantly less severe lung lesions, and in one of the groups it was not possible to culture *Mmm* from samples of their lungs or pleural fluid at six weeks post-challenge; alongside, several of the vaccinated groups exhibited worsened immunopathology (Nkando et al., 2016). Taken together, these two studies identified several candidate proteins warranting further investigation as components of a subunit vaccine: MSC_0431 (a prolipoprotein), MSC_0136 (a hypothetical lipoprotein), MSC_0816 (a variable lipoprotein) and MSC_0160 (the translation elongation factor Tu). The proteins in groups showing enhanced immunopathology should also be investigated as potential determinants of pathogenicity.

Vectored vaccines

Building on earlier work identifying *Mmm* LppA as a B cell antigen (Cheng et al., 1996), which is also recognised by CD4⁺ T cells associated with recovery from CBPP (Dedieu et al., 2010), Carozza *et al.* generated a non-replicative human adenovirus 5 (Ad5) vector expressing a truncated form of LppA and used it to immunise mice twice (Carozza et al., 2015). The authors found that the vaccine elicited a strong specific antibody response after a single administration, which was followed by a Th1 type cell-mediated immune response characterised by the production of IFN- γ , TNF- α and IL-10 by splenocytes restimulated *ex vivo* (Carozza et al., 2015). These data are a highly promising basis on which to conduct further studies in cattle, in which the mucosal response and duration of protection could be carefully assessed; further, the incorporation of additional potentially protective antigens identified in subunit vaccine studies could also be trialled to increase efficacy.

Adjuvants

There have not been any notable advances published in this area since 2012.

Conclusions

The studies highlighted here are representative of the current state of research into the biology of *Mmm* and the diagnosis, management and control of CBPP. Over the past decade, substantial strides have been made in these fields, including the sequencing and genomic analysis of new *Mmm* isolates, the identification of potential virulence and immune evasion factors *in vitro* and *in vivo*, an increased focus on epidemiology and surveillance within understudied endemic areas of Africa and the testing of new vaccines to limit the spread of disease in those regions. However, many questions remain unanswered, and much remains to be done to ensure that future efforts to control CBPP find greater success than they have in the past. In particular, the development of control programmes and application of new developments in *Mmm* control and vaccination have been “painfully slow” in Africa, with corresponding consequences for economic and political security (reviewed in (Olorunshola et al., 2017)).

The geographic range of CBPP continues to expand, and the possibility of this pathogen spreading internationally is never negligible. The past decade has seen increased focus on *Mmm* as a pathogen that is capable of threatening cattle populations worldwide if it remains uncontrolled; hopefully, the next decade will continue advancing our understanding of CBPP while applying new disease-monitoring technologies and control measures directly to endemic zones of Africa. Even as more advanced diagnostic and surveillance techniques continue to be developed, international cooperation will be required to ensure that these new resources can be deployed to the remote, resource-limited regions where they are most needed to limit the economic impact of CBPP on vulnerable populations.

Future research priorities

Based on the available literature, expert opinion, and previously published reviews (DISCONTTOOLS, 2016a; Jores et al., 2020), we suggest that the following areas of research into *Mmm* should be considered high priority:

Biology of the pathogen

- *Development of a reproducible and robust cattle challenge model, ideally aerosol-based, utilising a low passage field isolate, cattle over one year of age, and with a defined dose of Mmm; and applicable to low-resource settings*

- *Continuing collection of complete Mmm genome sequences, especially from virulent African strains*

Diagnosis

- *Development and validation of rapid, cost-effective diagnostic assays able to be performed in the field without laboratory equipment*
- *Development of a pen-side test capable of diagnosing both acute and chronic Mmm infections*
- *Increased training (on PCR, ELISA, etc.) for veterinary personnel in low- and middle-income countries*

Pathogenesis

- *Continuing research into the factors underlying the establishment of infection and persistence in chronically infected animals*
- *Verification of surface-localised virulence factors, both in vivo and ex vivo*
- *Generation of Mmm mutants based on attenuated *M. mycoides* subsp. *capri* model and their testing in vivo as live-attenuated vaccine candidates*
- *Extension of current immunological knowledge, both local and systemic, following natural infection or vaccination against Mmm, taking advantage of multi-omics technology to generate valuable insights*
- *Characterisation of the Willem's reaction following vaccination against Mmm to support rational design of vaccines without this drawback*
- *Assessment of the potential role of anti-LppQ antibodies in immunopathology*
- *Understanding of responses of respiratory epithelia to Mmm infection (e.g., cilia loss, necrosis/apoptosis, metaplasia)*
- *Studies to assess the importance of Mmm biofilm formation in the field*

Immunology

- *Standardisation of studies analysing risk factors for CBPP transmission and maintenance, including the incorporation of local sociocultural and/or climatic variables*
- *Characterisation of the local IgA response and its role in protection*
- *Studies to understand the role of maternal immunity in early protection/interference with vaccination*
- *Immunogenetics of resistance/susceptibility to Mmm*

- *Assessing whether blood sampling is useful in understanding T cell responses to Mmm or rather lymph node T cells should be assayed as standard*
- *Identification of pathogenic versus protective antigens/antibodies in cattle*

Epidemiology

- *Increased surveillance for Mmm in Africa, the Middle East and Southeast Asia*
- *Communication and outreach methods for promoting vaccine usage among farmers in endemic rural areas*
- *Effective outreach and financial assistance programmes for farmers in low- and middle-income countries*
- *Potential transmission by chronically infected animals under different farm management systems*

Control

- *Design of an improved vaccine with an excellent safety profile: in the absence of/while awaiting significant advances in knowledge on pathogenicity and immunology of Mmm, existing lead candidates should be prioritised for further testing, optimisation, and commercialisation*
- *Development of an experimental animal model for CBPP disease*
- *Evidence-based requirements for new vaccines to include a duration of immunity of around 18 months, minimal/no induction of vaccine-site reaction, suitability for needle-free or mucosal delivery, DIVA compatibility, and being cheap, safe and easy to produce*
- *Standardisation of vaccine challenge studies towards a protocol that might include: control unvaccinated group, adjuvant-only group, conventional vaccine group, and two-test vaccine groups (one for challenge and another for duration of immunity studies); the challenge should then be conducted by a standardised aerosol method and disease severity/pathogen titre comprehensively assessed.*
- *Standardisation of immunological readouts for vaccine studies to increase value; assays could include specific immunoglobulin titre, specific T cell proliferation including information on T cell phenotype and cytokine production (ideally by multi-colour flow cytometry), and lung IgA response.*

Mycoplasma bovis

Introduction

Mycoplasma bovis (*M. bovis*) is one of the most pathogenic members of the *Mycoplasma* genus (Calcutt et al., 2018; Francoz et al., 2015) and is predominantly a pathogen of cattle, where it can inflict a wide array of clinical manifestations that significantly impact animal welfare and productivity. One of the most important members of the bovine respiratory disease (BRD) complex, *M. bovis* causes chronic pneumonia and polyarthritis syndrome (CPPS) (Kryszak, 2006), and it is a major source of mastitis in dairy cows ((DISCONTTOOLS, 2022); reviewed in (Gelgie et al., 2022)). *M. bovis* can also cause other nonspecific manifestations including arthritis, otitis, meningitis, keratoconjunctivitis, endocarditis and abortion, making it very challenging to positively identify the presence of this pathogen without laboratory diagnostics. There are few commercial vaccines available against *M. bovis* in most of the world, and diseases associated with this pathogen are often poorly responsive to drug treatments because of the natural properties of mycoplasmas and a rising trend in antimicrobial resistance (reviewed in (Lysnyansky and Ayling, 2016)). In addition to cattle, *M. bovis* is capable of infecting buffalo and bison, and infections of sheep, goats, swine, deer, chickens and pigs have also been reported ((Sperspser et al., 2013); reviewed in (Calcutt et al., 2018)).

Altogether, these properties make *M. bovis* an extremely difficult pathogen to control. Originally identified in the United States in 1962, *M. bovis* spread quickly via international animal movements that facilitate direct contact transmission among cattle, and it has now been detected in every major cattle-rearing country (reviewed in (Dudek et al., 2020)). As it is already pervasive across the globe, *M. bovis* is not subject to WOAHA regulations (Dudek et al., 2020), but the consequences of infection are substantial. Because many *M. bovis* infections are chronic and/or subclinical, treatment and productivity costs tend to be higher compared to other pathogens in the BRD complex (reviewed in (Maunsell et al., 2011)). Comprehensive estimates of the total economic burden of *M. bovis* are rare, but older estimates indicate the scale of the problem (Nicholas and Ayling, 2003): total losses due to *M. bovis* were estimated to be at least 144 million euros (~237 million euros adjusted for inflation in 2023) in Europe, while *M. bovis*-associated mastitis alone cost an estimated 108 million USD (~195 million USD adjusted for inflation in 2023). The lack of options for controlling this pathogen make it one of the most important mycoplasmas of livestock today, and substantial economic benefits could be reaped by expanding our ability to detect, contain and treat it.

This section will cover a representative subset of the research conducted on *M. bovis* and its clinical manifestations from 2012-2023, including the molecular biology and epidemiology of this pathogen, its typing and diagnosis, current strategies for control and ongoing research into vaccines and effective antimicrobial treatments.

Literature review

Biology of the pathogen

Like other mycoplasmas, *M. bovis* is a tiny obligate parasite with low genomic G+C content and lacks a cell wall, rendering it inherently resistant to beta-lactams and other cell wall-targeting antibiotics (reviewed in (Ammar et al., 2021)). It is also naturally resistant to several other classes of antimicrobials including polymyxins and sulfonamides, adding to the difficulty of controlling *M. bovis*-associated disease in lieu of a vaccine (reviewed in (Lysnyansky and Ayling, 2016)).

Considering these disadvantages, monitoring and surveillance of *M. bovis* are two of our most powerful tools for limiting the spread of infection. Genomic analyses are an important component of these approaches, allowing researchers to track the spread and evolution of specific *M. bovis* lineages within a region or country. Over the past decade, research into the molecular biology of *M. bovis* has focused primarily on two fields: the typing and/or genome sequencing of new *M. bovis* isolates and the classification of gene functions, many of which remain unknown.

Molecular typing and genome sequencing

Molecular typing is essential for understanding the evolution and population structure of *M. bovis* and the genomic factors involved in its transmissibility, but typing techniques have historically been complicated by subjective interpretation and a lack of standardisation among analysis methods (Pinho et al., 2012; Register et al., 2015). Multilocus variable number tandem repeat (VNTR) analysis (MLVA), which allows a higher degree of comparability by relying on standardised primer sequences and DNA sequencing workflows, has been used to circumvent these issues (Pinho et al., 2012; Spergser et al., 2013). MLVA of *M. bovis* isolates from Israeli cattle identified 35 different VNTR types, some associated with strains originating in Israel and other from strains in cattle imported from Europe and Australia (Amram et al., 2013). A similar study of Hungarian isolates used MLVA to map within-herd

divergence of *M. bovis* strains, where the fine-scale typing of MLVA was ideal for discriminating between closely related strains isolated from single farms (Sulyok et al., 2014b).

At the intermediate scale (i.e., comparing less closely related isolates), multilocus sequence typing (MLST), a similar technique that classifies isolates based on polymorphisms in housekeeping genes rather than on number of tandem repeats (Jenke et al., 2011), is generally considered more suitable for phylogenetic comparisons (Sulyok et al., 2014b). Two MLST methods for *M. bovis* were reported independently in 2015 (Register et al., 2015; Rosales et al., 2015). Rosales *et al.* used their method to identify 35 distinct sequence types (STs) in two main clonal complexes which differentiated most British and German *M. bovis* strains from a more heterogeneous set including European, Asian and Australian isolates (Rosales et al., 2015). The initial report from Register *et al.* was published alongside a corresponding public database for *M. bovis* MLST data ([PubMLST](#)) and used a different set of seven loci to distinguish 32 STs from cattle and North American bison (*Bison bison*) (Register et al., 2015). While this study identified four bison-specific and 28 cattle-specific STs, indicating that genetically distinct *M. bovis* populations are responsible for infections in these respective species, the authors later found four STs that were shared between cattle and bison isolates and one shared between cattle and North American deer (*Odocoileus virginianus* and *hemionus*) isolates (Register et al., 2019). This study also confirmed an earlier report identifying *M. bovis* isolates lacking the *adh-1* typing locus used in their original MLST method (Josi et al., 2018), necessitating a revised version of the PubMLST reference method that incorporated the previously validated *dnaA* locus (Rosales et al., 2015) in place of *adh-1* (Register et al., 2020b). MLST can also be combined with MLVA when both intermediate- and fine-scale typing are required (L. Manso-Silvan et al., 2013). A comparison of *M. bovis* isolates from Canadian cattle and North American bison employed this combination alongside whole-genome sequencing to identify 10 STs, 20 VNTR types and 40 putative virulence genes among these isolates (Menghwar et al., 2021a; Menghwar and Perez-Casal, 2022).

As sequencing and genomics techniques have continued to improve in precision and efficiency, the molecular typing repertoire has diversified as well. Newer developments include core genome MLST (cgMLST), which analyses alleles from hundreds of genes as opposed to the typical seven housekeeping genes used in standard MLST (Menghwar et al., 2022), and core- and whole-genome variations of single-nucleotide variant (SNV) comparison. Kinnear *et al.* recently compared these phylogenetic methods using 129 *M. bovis* isolates from North American cattle, reporting pros and cons to each approach (Kinnear et al., 2021). cgMLST provided a higher genotypic resolution than standard MLST but lacked ease-of-use; whole-genome SNV demonstrated the highest resolution among the

four methods and was able to type all 129 isolates (compared to 101 for cgMLST and cgSNV), but further development will be needed to improve the intuitiveness of this workflow (Kinneer et al., 2021).

These molecular typing techniques can generate phylogenetic data from only partial *M. bovis* genomic sequences, but whole genome sequencing is also necessary to provide the up-to-date reference sequences required for tracking the evolution and transmission of bacterial lineages (Ambroset et al., 2022; Wise et al., 2011). The genome of *M. bovis* is unusual, with numerous highly repetitive regions and low G+C content even in comparison to other mycoplasmas (Bürki et al., 2015; Razin et al., 1998; Zhou et al., 2014). However, the proliferation and continuing simplification of standardised next-generation sequencing techniques has facilitated the collection of many complete *M. bovis* sequences over the past decade, including isolates from Canada (Menghwar et al., 2021b; Register et al., 2020a), France (Ambroset et al., 2022), Belgium (Bokma et al., 2020d), China (Chen et al., 2017a; Shen et al., 2020; Sun et al., 2018), Japan (Morimoto et al., 2019) and Australia (Parker et al., 2016b). In addition to supporting disease surveillance and phylogenetics, complete genome sequences also provide crucial information for subsequent studies of strain-specific pathogenesis and evolution – analysis of the genome sequence of the Chinese Ningxia-1 strain, for instance, identified several suggestive differences from the reference *M. bovis* genome, including variable surface lipoproteins and pathogenicity islands (Sun et al., 2018).

Proteomics and gene characterisation

Genotyping and whole-genome comparison of new *M. bovis* isolates against reference strains provide valuable insights, allowing researchers to associate particular adaptations with specific sites in the genome. However, despite the small size of the *M. bovis* genome, many of its gene products are uncharacterised (Kumar et al., 2020). Genome dynamics and evolutionary adaptations are difficult to map to precise functions. A comparison of the Chinese HB0801 isolate with the established standard PG45 reference strain, for instance, revealed substantial genomic plasticity, including a large chromosomal inversion, a significant reduction in variable surface lipoprotein genes, and numerous smaller insertions and losses within the genome – notably, however, HB0801 and PG45 both exhibited similar pathology in cattle, indicating that these genomic differences had not impacted their virulence (Qi et al., 2012). Prediction of the phenotype of an isolate based on its genotype is an attractive target, but the genetic complexity of *M. bovis* and the myriad interactions between pathogen, host and environmental variables during infection render this a daunting task. In their comparison of four MLST-

and SNV-based genotyping methods, for instance, Kinnear *et al.* reported that none could associate genotypes with phenotypes (Kinnear *et al.*, 2021).

Where such large gaps exist in our understanding of a pathogen's functional components, wide-scale high-throughput methods are important for narrowing the field and identifying genes of particular interest. Sharma *et al.* generated a library of transposon mutants of the PG45 strain, then directly sequenced mutants with insertions in putative membrane nuclease genes (Sharma *et al.*, 2015b). Inactivation of the *mnuA* gene specifically abrogated cellular exo- and endonuclease activity, indicating that MnuA is an important bacterial nuclease involved in the acquisition of nucleotide precursors (Sharma *et al.*, 2015b). This enzyme was also later shown to aid in immune escape by degrading DNA-containing neutrophil extracellular traps (Mitiku *et al.*, 2018) (see also [Immunology](#)).

In a similar high-throughput study, Josi *et al.* generated a library of *M. bovis* strain JF4278 mutants, then applied high-throughput screening and bioinformatics to classify genes as essential vs. non-essential (Josi *et al.*, 2019). Among other findings, this workflow identified a set of non-essential virulence-associated genes, including three factors (the adhesin TrmFO and two previously unknown proteins) associated with a reduced-adhesion phenotype (Josi *et al.*, 2019).

Metabolomics provide complementary data to large-scale genome screening, focusing on the downstream products of functional pathways to identify their unidentified components. Masukagami *et al.* used ¹³C isotope labelling to track *M. bovis* metabolism in culture; these authors uncovered new functional metabolic pathways and assigned likely functions to previously uncharacterised *M. bovis* genes, including a putative *sn*-glycerol-3-phosphate ABC transporter operon, a phosphotransferase system transporter and a multifunctional phosphoribosyltransferase (Masukagami *et al.*, 2019). These findings are also discussed in the [Pathogenesis](#) section below.

Finally, the CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated endonuclease) genome-editing system has recently been applied to *M. bovis* (alongside [Mmm](#) and [M. gallisepticum](#)), with Ipoutcha *et al.* demonstrating proof-of-concept by successfully knocking out the *mnuA* gene in the PG45 strain (Ipoutcha *et al.*, 2022).

Diagnosis

Diagnosis of *M. bovis* is complicated by its various clinical signs (which can easily be confused with those of other bovine pathogens), the presence of subclinical infections, intermittent pathogen shedding and varying test responses observed in animals of different age groups (Penterman et al., 2022; Petersen et al., 2020). Recommendations for high-sensitivity *M. bovis* diagnosis often involve bacteriological culture (accurate, but difficult and time-intensive) and/or the combination of multiple diagnostic tests (which may increase false positive rates) (Manning, 2020). The efficacy of any given test depends on farm-, herd-, and animal-level factors (reviewed in (Parker et al., 2018)), making field validation a vital component of diagnostic development in order to define the conditions under which each test is most effective.

Numerous *M. bovis* diagnostic tests had been published in the research, and some commercialised by 2012, but advancements in sequencing, nucleic acid amplification techniques and serology have been applied over the past decade to produce new or improved tests with higher sensitivity and positive detection rates. Many of these tests have been designed with ease-of-use in mind to facilitate their deployment in remote locations that may lack access to standard veterinary laboratory services. This section will discuss some of these advancements, bearing in mind that combined use of diagnostic tests will continue to be the most effective means of obtaining a definitive *M. bovis* diagnosis.

DNA diagnostics

Isolation and culturing of *M. bovis* is the gold standard for diagnosis, but the slow-growing and fastidious nature of mycoplasmas necessitates the use of highly specialised and time-consuming culture methods (reviewed in (Dudek et al., 2020)), and growth-inhibited or dead bacteria due to antibiotic treatment cannot be detected (Bell et al., 2014). For these reasons, many laboratories use PCR as a fast and accurate alternative for routine diagnosis of *M. bovis* (reviewed in (Parker et al., 2018)), and a recent interlaboratory comparison of different PCR techniques found a high level of reproducibility among methods and labs, supporting a high degree of confidence in PCR data generated under different circumstances (Wisselink et al., 2019). The *uvrC* gene, which encodes a DNA repair protein in *M. bovis*, has long been used as a target for PCR diagnostics because of its conservation among field isolates (Naikare et al., 2015; Rossetti et al., 2010; Subramaniam et al., 1998; Thomas et al., 2004). Notably, however, Register *et al.* reported several *M. bovis* isolates with mutations that caused failure of *uvrC*-targeted PCR, including a single nucleotide polymorphism in a

primer-binding region and a transposase gene insertion within the amplicon (Register et al., 2018a). The *oppD* gene has also been used as a target for molecular diagnosis of *M. bovis*, with associated real-time PCR (qPCR) assays providing high sensitivity and specificity (Loy et al., 2018; Sachse et al., 2010).

As *M. bovis* infections can cause varied and nonspecific phenotypes, multiplex PCR (incorporating multiple primer pairs that amplify distinct target sequences) can be a useful tool for identifying and/or discriminating *M. bovis* against other potential causes of observed clinical signs (Gioia et al., 2016). In 2018, two independent groups reported the development of multiplex qPCR tests for discriminating *M. bovis* from its fellow BRD complex members *Mannheimia haemolytica*, *Histophilus somni* and *Pasteurella multocida* (Loy et al., 2018; Thantrige-Don et al., 2018). Zheng *et al.* developed a multiplex qPCR assay for differentiating *M. bovis* from four other pathogens (three bacterial and one viral) capable of causing bovine pinkeye (Zheng et al., 2019), and a multiplex qPCR targeting the *rpoB* gene of *M. bovis* was shown to distinguish the bacterium from other mycoplasmas and *Acholeplasma laidlawii* in milk samples with 100% and 93% diagnostic specificity and sensitivity, respectively (Chauhan et al., 2021). DNA Diagnostic A/S developed two commercial multiplex qPCR assays – Pneumo4B and 4V – for the detection and quantification of bacterial (including *M. bovis*) and viral members of the BRD complex, reporting high diagnostic performance by both kits (Pansri et al., 2020). The BioMark HD high-throughput qPCR system has also been used as a lower-cost alternative to multiplex PCR, differentiating *M. bovis* from other respiratory and enteric pathogens in pooled faecal and nasal swab samples (Goecke et al., 2021).

Finally, post-PCR high resolution melting curve analysis has been employed in several studies to effectively discriminate *M. bovis*, and even individual *M. bovis* isolates, based on the 16S gene or 16S-23S intergenic spacer region (Ahani Azari et al., 2020; Ajitkumar et al., 2012; Al-Farha et al., 2018b; McDaniel and Derscheid, 2021).

While highly accurate and reproducible, PCR assays typically require laboratory equipment, trained personnel and cold storage, meaning that they often are impossible to conduct in remote, resource-limited regions ((DISCONTTOOLS, 2022); reviewed in (Calcutt et al., 2018)). One common solution is isothermal nucleic acid amplification, which is relatively simple and does not require a thermocycler (reviewed in (Koczula and Gallotta, 2016)), making it ideal for use under field conditions. Conrad *et al.* developed a set of isothermal recombinase polymerase amplification (RPA) assays for multiplex identification of BRD-associated pathogens and detection of antimicrobial resistance genes (Conrad

et al., 2020), while two groups reported their development of *uvrC*-targeting isothermal RPA assays combined with lateral flow strips for greater ease-of-use (R. Li et al., 2021; Zhao et al., 2018).

LAMP is another commonly employed technique for field-capable rapid diagnostic tests, offering performance that is generally equivalent to or slightly greater than RPA, depending on the assay (Howson et al., 2017; Zou et al., 2020). Bai *et al.* developed a *uvrC*-targeting LAMP assay (Bai et al., 2011), and its diagnostic performance was later improved by targeting the *oppD/F* locus and incorporating a loop primer to increase amplification speed (Higa et al., 2016). Meanwhile, a comparison of three LAMP assays targeting the *uvrC*, *gyrB* or 16S rRNA genes of *M. bovis* in milk from mastitic cattle reported the highest sensitivity and specificity from the *uvrC*- and *gyrB*-targeting assays, respectively (Ashraf et al., 2018), and a similar approach combining LAMP with the commercial Loopamp PURE DNA extraction kit achieved comparable performance versus traditional PCR (Itoh et al., 2020). This requirement of a DNA extraction step is an important hurdle for developing pen-side tests aimed at minimising the use of laboratory equipment (Appelt et al., 2019), and continued development of field-useable nucleic acid extraction techniques (and/or amplification diagnostics useable on crude samples) will likely be an important component of future studies.

Serological diagnostics

Serodiagnostics fill a need for rapid, sensitive assays that detect the presence of anti-*M. bovis* antibodies to demonstrate whether a specific cohort or herd has been exposed to this pathogen. For instance, herd-level serodiagnostics can also be particularly effective at identifying herds from which purchasing animals may pose a higher risk of introducing *M. bovis* (Parker et al., 2017a). ELISAs are the most used *M. bovis* serodiagnostic, but their performance is affected by several test- and target-specific factors. Establishing a reliable cut-off value is critical for obtaining optimal sensitivity from diagnostic ELISAs, and this value will vary depending on sample type (Al-Farha et al., 2020). The sample type itself and the stage of infection in tested animals are also important to consider. A recent study of Danish dairy herds reported that milk antibody levels were increased only in mastitic animals, indicating that milk samples can only be used to diagnose animals with *M. bovis* infection presenting with mastitis (Petersen et al., 2018a).

The choice of capture antigen is particularly important for pathogen-specific diagnosis, as many antigens expressed by *M. bovis* are also expressed by other mycoplasmas (reviewed in (Parker et al., 2018)). The variable surface proteins (Vsps) were among the first immunogenic proteins of *M. bovis* to be identified, but their propensity for genetic rearrangements makes them poor targets for

serodiagnostics (Rosengarten and Yogev, 1996). More recent studies have identified immunogenic proteins that are highly conserved and less prone to variation. The *M. bovis* PDHB and P48 proteins have been targeted by indirect and direct ELISAs, respectively, to produce assays with higher positive detection rates relative to comparable commercial kits (Fu et al., 2014b; Sun et al., 2014), and the lipoprotein MbovP579 was later identified as an immunogenic target for highly *M. bovis*-specific serodiagnosis (Khan et al., 2016). Wawegama *et al.* developed an ELISA based on a recombinant fragment of the *M. bovis* membrane lipase MilA, reporting ~94% diagnostic sensitivity and specificity in feedlot cattle under field conditions (Wawegama et al., 2016, 2014). This group observed similar results in later studies that compared the MilA ELISA favourably against commercially available ELISAs (Petersen et al., 2018b; Salgadu et al., 2022a) and in a diagnostic evaluation on bulk tank milk (BTM) samples from Australian dairy herds (Salgadu et al., 2022b).

Several commercial ELISAs for *M. bovis* serodiagnosis are available on the market. Bio-X Diagnostics, for example, produces two commercial ELISAs – the BIO K302 and K260 kits – for detection of antibodies in serum, plasma, and milk samples. Nielsen *et al.* compared the BIO K302 test and PCR in diagnosis from milk samples, reporting that raising the ELISA cut-off value above the manufacturer’s recommendation provided higher sensitivity than PCR (~44% versus 37%) while maintaining near-100% specificity (Nielsen et al., 2015). A later comparison of both Bio-X kits against western blotting in the serodiagnosis of experimentally infected cattle was more negative, reporting high specificity but lower sensitivity for the BIO K302 and K260 kits (47% and 28%, respectively) versus western blotting (74%) (Schibrowski et al., 2018a). More recently, IDVet released their ID Screen indirect ELISA for *M. bovis*, and a field comparison of this test against the BIO K302 kit reported substantially higher sensitivity (though several false positives were also observed) (Petersen et al., 2020). Alongside the above-mentioned interlaboratory trial of PCR reproducibility, a corresponding comparison of serological methods reported high consistency between the ID Screen ELISA and western blotting, which offered higher diagnostic precision and accuracy compared to the BIO K302 (Andersson et al., 2019).

While ELISAs comprise the bulk of *M. bovis* serodiagnostics, other technologies have been also been tested for their performance or ease-of-use compared to this standard technique. Fu *et al.* developed an indirect competitive enzyme-linked aptamer assay (using single-stranded oligonucleotides rather than antibodies as the molecular recognition agent) against the *M. bovis* P48 protein, reporting higher positive detection rates from bovine serum compared to commercial ELISAs (Fu et al., 2014a). The simplicity and cost-effectiveness of lateral flow assays (LFAs) has made them an attractive target for

M. bovis serodiagnostics as well: Shi *et al.* developed an LFA using colloidal carbon test strips to detect *M. bovis* antibodies in serum and reported 100% specificity and >97% diagnostic sensitivity under laboratory conditions (Shi *et al.*, 2020), and pen-side validation could confirm the utility of this simple visual assay under field conditions.

Finally, the detection of *M. bovis* outbreaks in American bison around the turn of the millennium (discussed in more detail in [Epidemiology](#)) required that serodiagnostic tests be validated in this species as well. Unfortunately, ELISAs developed for cattle exhibited low sensitivity in bison, particularly in animals with low-to-moderate infection levels, but replacing the capture antigen with one derived from bison isolates improved assay performance (Register *et al.*, 2013a).

Sampling strategies and other developments

Efforts have been made to improve the throughput of traditional culture methods for *M. bovis* diagnosis. A recent approach predicted the likelihood of *M. bovis* isolation via C_t values obtained from high-throughput qPCR on direct cultures of deep nasopharyngeal swabs, which ruled out 97.3% of *M. bovis*-negative samples without further processing (Andrés-Lasheras *et al.*, 2020).

The development of third-generation sequencing has also opened new avenues for pathogen diagnostics, facilitating the incorporation of whole-genome sequencing into cost-effective and field-deployable tests. A recent study applied taxon-specific basecalling for the Oxford MinION sequencer and single-use long-read nanopore sequencing to the detection of *M. bovis* field strains, reporting results comparable to those obtained from hybrid (short- and long-read sequencing) approaches (Vereecke *et al.*, 2020). This group later developed a workflow for rapid identification of *M. bovis* in bovine bronchoalveolar lavage fluid using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and compared this assay against nanopore sequencing, reporting higher diagnostic sensitivity but lower specificity versus sequencing (Bokma *et al.*, 2021b, 2020c).

Finally, other studies have aimed to identify biomarkers that could indicate the presence of clinical or subclinical *M. bovis* infections in individual animals. The levels of several inflammation-related microRNAs (miRNAs) were reported to increase significantly in the milk of infected Holstein-Friesian and Foğu Anadolu Kırmızısı cows (Özdemir, 2020); however, a later analysis of the miRNA profiles in tissues isolated from *M. bovis*-infected calves indicated that circulating miRNA levels were unsuitable for assessing disease condition and did not correlate with tissue expression levels (Casas *et al.*, 2022).

A recent study using 16S rRNA sequencing and metabolomics reported significant differences in the nasal microbiota of healthy versus diseased cattle, indicating that the prevalence of various bacterial species and serum metabolites may be useful as biomarkers for different infections and co-infections responsible for BRD (Zhang et al., 2022).

Pathogenesis

Typical infections of cattle with *M. bovis* are associated with caseonecrotic pneumonia, mastitis and arthritis; yet, there are reports of many other tissues being affected including the eye, the ear, the brain meninges, the skin, the heart and the reproductive system (reviewed in (Dudek et al., 2020)). Recently identified less-typical presentations in the field include necrotic pharyngitis (Dyer et al., 2013), placentitis associated with abortion (Register et al., 2013b), the formation of caseonecrotic granulomas in cattle (Suwanruengsri et al., 2022) and the detection of transplacentally transmitted *M. bovis* in aborted bovine foetuses (de Oliveira et al., 2022; Kathrin Hermeyer et al., 2012). *M. bovis* has also been isolated from post-surgical seromas arising after caesarean section (Gille et al., 2016) and from calves with toxic epidermal necrolysis (Senturk et al., 2012).

These broad and varied observations from the field raise many important questions around the pathogenesis of *M. bovis* infections. In the past ten years, researchers have attempted to provide answers by examining animals infected in the field or under experimental conditions, conducting studies in experimental models, and generating data from *in vitro* analysis of infected cells.

In vivo and ex vivo studies

M. bovis has become increasingly recognised as a key factor in the BRD complex in both adult cattle (T. E. S. Oliveira et al., 2020) and in calves (Antonis et al., 2022; Pardon et al., 2020), and has been detected in cases of acute (Centeno-Martinez et al., 2022; Oliveira et al., 2021; Timsit et al., 2018; Valeris-Chacin et al., 2022) as well as chronic BRD, where is accepted as a causative agent (Becker et al., 2020; Booker et al., 2008; Mehinagic et al., 2019). However, these findings are complicated by the long-known fact that the upper respiratory tract of young calves is often colonised by *M. bovis* in the absence of clinical disease, which may later develop as the pathogen migrates to the lower respiratory tract or middle ear (reviewed in (Perez-Casal, 2020)). More recent analysis of the bronchoalveolar lavage fluid of healthy calves also detected *M. bovis* in almost two thirds of samples – roughly the

same frequency as in calves with BRD – indicating that migration of the pathogen alone does not always lead to disease (Kudirkiene et al., 2021). A preceding study also detected *M. bovis* in lung tissue of diseased and healthy calves, but in this case, 24 out of the 26 *M. bovis*-positive animals exhibited clear signs of disease (Giovannini et al., 2013). These data raise many questions about how *M. bovis* asymptomatic colonisation progresses to frank disease, and whether the factors driving this change are host-derived, pathogen-derived, or perhaps relate to coinfecting microorganisms or local environmental influences. *M. bovis* isolates from diseased versus healthy calves do not appear to significantly differ genetically (Castillo-Alcala et al., 2012), nor do they produce differing amounts of H₂O₂ when cultured *ex vivo* (Schott et al., 2014). Current experimental *M. bovis* exposure models have yet, to our knowledge, been used to study field-like asymptomatic colonisation, which significantly limits our ability to answer key questions about the progression or otherwise to overt clinical disease.

Several studies have shed light on the colonisation of different host organs by *M. bovis*. Meningitis is a rare but serious complication of infection, but it has long been unclear whether this was most likely to result from spread of *M. bovis* through the blood, lymph, directly through a nearby lesion, or via ascending infection along a peripheral nerve. A recent study revealed that direct spread was most likely, showing that in cattle with meningitis, *M. bovis* had likely first infected the palatine tonsil, next moving into the nearby eustachian tube, from where the pathogen could directly penetrate into the brain (Suwanruengsri et al., 2021). Complementing these findings, an earlier study showed that the most likely route of initial colonisation of the tonsil in calves was the consumption of *M. bovis*-containing milk, and that from the infected tonsil, the mycoplasma was able to colonise both the lower respiratory tract and the middle ear (Maunsell et al., 2012).

Infection of the joints by *M. bovis* can occur as a sequelae lung infection (Gagea et al., 2006), and causes a severe inflammatory response that leads to pain, swelling, synovial hyperplasia and osteolysis (Desrochers and Francoz, 2014). Recent studies have shed light on the molecular processes involved. Devi *et al.* uncovered signs of nitritative injury in the joints of calves that had been experimentally intraarticularly inoculated with *M. bovis*, with evidence of production of iNOS and nitrotyrosine by macrophages that were associated with the necrotic tissue lesions (Devi et al., 2014). More recently, Nishi *et al.* found that *M. bovis* arthritis was associated with a massive increase in the proportion of neutrophils within the synovial fluid, which was accompanied by significantly increased expression of cytokines such as IL-1 β , IL-6, IL-8, IL-17 and IL-22 at the gene (Nishi et al., 2019) and protein (Nishi et al., 2021b) levels; the authors speculated that IL-1 β could promote the bone resorption seen in *M. bovis* arthritis, while IL-6 might drive synovial hyperplasia, and IL-8/IL-17 were likely to attract

neutrophils and leucocytes, respectively. The same group went on to further dissect the interaction with bovine synovial cells by exposing them to *M. bovis ex vivo*, finding that the mycoplasma invaded the cells via clathrin-dependent, caveolin-independent, endocytosis; once inside the synovial cells, *M. bovis* was able to evade killing by antibiotics added to the culture medium (Nishi et al., 2021a).

Increasing our understanding of early events during *in vivo* infections would be greatly enhanced by the development and validation of a cattle infection protocol that reliably induced field-like disease via a natural (or natural-like) inoculation route. When aiming to study *M. bovis* pneumonia, intratracheal (K. Hermeyer et al., 2012; Prysliak et al., 2011) or intranasal (White et al., 2012; Zhang et al., 2014) inoculation has been favoured, but these require large numbers of bacteria to induce clinical disease and the administration route is likely to prove stressful to animals, which could have relevant effects on their susceptibility/disease process (DISCONTTOOLS, 2022). Moreover, earlier studies showed how cattle age/pathogen co-infection status can markedly affect the outcome of these commonly used routes of challenge (Prysliak et al., 2011). Kanci *et al.* reported promising results from a novel aerosol infection method that exposed small groups of calves twice to *M. bovis* in a controlled air-flow chamber and required minimal handling; this method induced disease in all exposed calves with comparable features to *M. bovis* pneumonia reported in the field (Kanci et al., 2017). It would be of interest to establish whether this approach could also replicate asymptomatic colonisation of young animals, which could lead to invaluable insights into the processes determining pathologic progression of *M. bovis* infection.

Cattle are not the only hosts of *M. bovis*, and studies are now showing that bison are highly susceptible to pneumonia and arthritis (Dyer et al., 2008) and to necrotic pharyngitis (Dyer et al., 2013) caused by this pathogen. Register *et al.* showed that isolates of *M. bovis* from cattle and bison are phylogenetically distinct (Register et al., 2015), and also that bison are uniquely vulnerable to *M. bovis* isolates that circulate within this species, while cattle are not (Register et al., 2018b). Earlier work revealed distinct *in vitro* properties of *M. bovis* from bison and cattle, including differences in their abilities to invade lung epithelial or tracheal cell lines, and their interactions with PBMC and alveolar macrophages (Suleman et al., 2016a). Together, these findings point towards important species-specific features of *M. bovis* isolates from bison and cattle, but a fuller picture of the distinct processes or determinants of pathogenicity in each species has yet to emerge.

Finally, it is widely acknowledged that the development of an improved small animal model of *M. bovis* infection would facilitate studies of its pathogenesis and immunology. Towards this aim,

Schneider *et al.* injected the mammary glands of specific-pathogen-free C3H/HeN mice with an *M. bovis* field strain and conducted histopathology and gene expression analysis 24-48 hours later; they found that *M. bovis* injection caused massive neutrophil recruitment and inflammation, accompanied by elevated expression of genes encoding TNF- α , iNOS and I κ B α (Schneider *et al.*, 2022). Alongside, the authors exposed murine mammary epithelial cells to live or UV-inactivated *M. bovis*, showing that NF- κ B activation was stimulated by both: this differs from both (also contradictory) previous studies of NF- κ B activation in bovine mammary epithelial cells (Gondaira *et al.*, 2018; Zbinden *et al.*, 2015), and should therefore be interpreted with caution. Bovine lung organoids may be a better option for understanding the pathogenesis of lung disease caused by *M. bovis*: Archer *et al.* reported preliminary data showing the feasibility of generating such organoids from embryonic lungs (Archer *et al.*, 2021), yet to our knowledge they have yet to be exploited for research into mycoplasma-associated diseases. Similarly, bovine “lung-on-a-chip” technology is beginning to emerge (Lee *et al.*, 2022).

In vitro studies

Embryonic bovine lung (EBL) cells are a commonly used tool for the study of *M. bovis* infections. Recent research described their use to identify changes in gene expression elicited by the pathogen: infected cells expressed significantly lower levels of genes associated with metabolic and immune processes, most notably those in the PI3K-Akt-mTOR signalling pathway, which is involved in nutrient metabolism, compared to control cells (X. Wu *et al.*, 2022). The same group previously showed that application of exogenous recombinant *M. bovis* membrane lipoprotein P48, which may participate in the pathogen’s adhesion to host cells, was sufficient to induce ER-stress-mediated apoptosis, leading them to speculate on a similar role for this protein *in vivo* (Wu *et al.*, 2021).

EBL cells have also been used in *in vitro* studies aiming to identify individual *M. bovis* virulence/adhesion factors. Zhu *et al.* showed that a novel *M. bovis* cytoadhesin, encoded by Mbov_503, was required for efficient cell adhesion and translocation of the mycoplasma across epithelial cell monolayers (X. Zhu *et al.*, 2020). Alongside, Gao *et al.* showed that fructose-1,6-bisphosphate aldolase is also involved in the adhesion of *M. bovis* to EBL cells (Gao *et al.*, 2018), as are methylenetetrahydrofolate-tRNA-(uracil-5-)-methyltransferase (YongPeng *et al.*, 2017) and P27 (X. Chen *et al.*, 2018). On the host side, Zhang *et al.* recently identified annexin A2 expressed on EBL cells as an important partner for *M. bovis* adhesion and invasion in this system (H. Zhang *et al.*, 2022).

Aiming to shed light on the processes underpinning mammary tissue damage in *M. bovis* mastitis, Liu *et al.* exposed bovine mammary epithelial cells (MEC) to large (MOI of 1000) numbers of *M. bovis* from two different field strains, finding that the mycoplasma induced ROS production *in vitro* leading to mitochondria-mediated apoptosis of MEC (Y. Liu *et al.*, 2020). The extent of ROS production and MEC death varied between strains (Y. Liu *et al.*, 2020), but it was not established whether this related to differences in virulence *in vivo*, which is difficult to assess given the influence of multiple other host factors. Also in MEC, Liu *et al.* provided convincing evidence that after invading the cells, *M. bovis* was able to block the autophagic pathway, preventing acidification of the autophagosomes, and allowing its own survival in cells; if the pathway was reactivated by drug treatment, *M. bovis* was killed within MEC (Y. Liu *et al.*, 2021). A follow-up study led the group to conclude that *M. bovis* elicited knock-down of autophagy by promoting phosphorylation of PI3K-Akt-mTOR (Xu *et al.*, 2022). The lower MOI of 30 used in these studies increases confidence in the conclusions, warranting their follow-up *in vivo*.

Efforts to identify novel determinants of *M. bovis* virulence using genomics and targeted mutation have generated interesting data. Rasheed *et al.* conducted a comparative genomics study between a virulent *M. bovis* field strain and several passage-attenuated variants. This approach revealed changes to 11 genes that were deemed likely to relate to virulence: ascorbate-specific phosphotransferase system enzyme IIB and IIA components, enolase, L-lactate dehydrogenase, pyruvate kinase, glycerol, and multiple sugar ATP-binding cassette transporters, ATP binding proteins, NADH dehydrogenase, phosphate acetyltransferase, transketolase, and a variable surface protein (Rasheed *et al.*, 2017). Other researchers have generated modified *M. bovis* strains with mutations affecting specific genes thought to be involved in pathogenesis. For example, Zhao *et al.* generated *M. bovis* lacking full-length NADH oxidase, which allowed the identification of this protein as being involved in the process of attachment to EBL cells, as well as being required for production of H₂O₂ (G. Zhao *et al.*, 2017). Masukagami *et al.* also used this approach to selectively ablate the functions of predicted nutrient transport genes of *M. bovis*, then compared their metabolic profiles; they found evidence of a surprising level of redundancy within the glycerol transport system, among others, and identified different roles for some genes than predicted *in silico* (Masukagami *et al.*, 2019).

In vitro gene mutation and protein expression studies have also yielded interesting insights into the likely functions of *M. bovis* molecules. Adamu *et al.* showed that *M. bovis* P226 (encoded by the *mila* gene) was surface-exposed and had a range of lipid- and glycosaminoglycan-binding properties, including a carboxyl-terminal that bound and hydrolysed ATP (Adamu *et al.*, 2020).

Immunology

The immune response to *M. bovis* is a primary determinant of the onset, severity, duration, and outcome of disease, and it is particularly challenging to study given the multiple manifestations of the infection and the different tissues that can be affected. The presence of asymptomatic infection in animals has yet, to our knowledge, to be purposefully replicated experimentally and is therefore relatively unstudied (though experimental infection studies do occasionally unintentionally generate an asymptomatic state in one or two animals). Individual animals also vary in susceptibility, and so studies seeking the knowledge required for molecular breeding programmes focusing on *M. bovis*/BRD resistance traits should be encouraged. Earlier work suggested several innate immune loci that could be involved (Neibergs et al., 2014; Tizioto et al., 2015), yet the follow-up outcomes of these findings have yet to be reported.

Most immunological studies since 2012 have focused on immune evasion strategies of the pathogen, which broaden and deepen our understanding, even though many have been conducted *in vitro* or *ex vivo*. However, there are also important advances to report in our knowledge of innate and adaptive immune pathways that could feasibly be used to improve the prospect of designing effective treatments and/or better vaccines. Notably, the discovery of bovine lung-specific NK-lysins, which have bactericidal effects that would be difficult for *M. bovis* to escape (Chen et al., 2016; Junfeng Chen et al., 2015; Dassanayake et al., 2018); and the insights gained from considering the results of several studies on the polarisation of the immune response during infection/vaccination and how this might be linked to pathogen clearance, persistence or exacerbation of disease (Behura et al., 2017; Chao et al., 2019; Ohtsuka et al., 2020; Prysliak et al., 2018). The majority of immunological studies since 2012 have focused on immune evasion strategies of the pathogen, which broaden and deepen our understanding, even though many have been conducted *in vitro* or *ex vivo*. However, there are also important advances to report in our knowledge of innate and adaptive immune pathways that could feasibly be used to improve the prospect of designing effective treatments and/or better vaccines. Notably, the discovery of bovine lung-specific NK-lysins, which have bactericidal effects that would be difficult for *M. bovis* to escape (Chen et al., 2016; Junfeng Chen et al., 2015; Dassanayake et al., 2018); and the insights gained from considering the results of several studies on the polarisation of the immune response during infection/vaccination and how this might be linked to pathogen clearance, persistence or exacerbation of disease (Behura et al., 2017; Chao et al., 2019; Ohtsuka et al., 2020; Prysliak et al., 2018).

Immunogenetics

There have not been any published studies in this area since 2012.

Innate immunity

Innate immunity in the respiratory mucosa is likely to be the first line of defence against *M. bovis*. Among the key cell types involved are alveolar macrophages, which are known to be present in, and around, *M. bovis* pneumonia lesions (K. Hermeyer et al., 2012). Monocyte-derived lung macrophages are also likely to form an important part of the immunological network during *M. bovis* infection. A recent study compared the responses of alveolar macrophages and monocyte-derived-macrophages to *M. bovis in vitro*, and found that while the monocyte-derived cells secreted matrix metalloproteinase-12 and secreted phospholipase A2 (which is involved in cell death), the lung alveolar macrophages did not (Baquero et al., 2021). Whether this represents a difference that can be recapitulated *in vivo* and its relevance for the disease pathway are topics for future investigation.

Alongside macrophage functions, the role of Natural Killer (NK) cells in *M. bovis* is starting to be explored. An important antimicrobial mechanism used by NK cells is the production of NK-lysins; peptides that are electrostatically attracted to the membranes of pathogenic microorganisms but not host cells, and can either directly kill some pathogens, or synergise with other immune mechanisms to render them more effective. The genome of cattle contains four NK-lysin-encoding genes, whereas most mammals possess just one; interestingly, *NK2C* is predominantly expressed in the lung (Junfeng Chen et al., 2015). Chen *et al.* also observed marked upregulation of the *NK2C* gene in the lungs of animals challenged with *M. bovis* compared to controls (Chen et al., 2016), while Dassanayake *et al.* documented significant damage to the plasma membrane of *M. bovis* following incubation with recombinant bovine NK2A or NK2C *in vitro* (Dassanayake et al., 2018). Such antimicrobial peptides are an attractive potential therapeutic option, given their innate specificity for microorganisms and the lack of receptor-mediated-binding, making their action hard or impossible to develop resistance to; it is also possible that selective breeding for increased NK-lysin activity/expression could represent a promising strategy for increased antimicrobial resistance, as shown in genetically modified fish (Huang et al., 2018) and beginning to be explored in pigs (Tong et al., 2022).

As well as studies focusing on the lung, there are several reports of insights into the response of mammary cells exposed to *M. bovis*. In one study, *ex vivo* incubation of primary bovine MEC to high concentrations of *M. bovis* induced expression of IL-6, IL-8 and TNF- α at the mRNA level, as well as Toll-like receptors (TLRs) 1, 2, 3, 6 and 9 at the mRNA and protein levels (J. Yang et al., 2022). This confirmed a previous report of the induction of transcription of TNF- α , IL-1 β , IL-6, IL-8, lactoferrin, TLR2, RANTES and serum amyloid A mRNA in MEC exposed to live but not inactivated *M. bovis* (Zbinden et al., 2015). A different study using a bovine MEC cell line and a range of infection levels also found significantly increased expression of IL-1 β , IL-6, TNF- α , TLR2 and TLR4, but in this case, only after exposure to killed and not live *M. bovis* (Rodríguez et al., 2015a). The same group also exposed PBMC to *M. bovis ex vivo*, detecting significantly increased expression of the genes encoding IL-12p40 and IFN- γ at an MOI of 100, and conversely, proliferation of PBMC only at an MOI of 100 or less (Gondaira et al., 2015). Taken together, these studies show that bovine MEC, at least *ex vivo/in vitro*, have the capacity to initiate programmes of immune gene expression in response to *M. bovis*; whether these pathways are initiated in primary cells under physiological/near-physiological levels of exposure to the pathogen will require additional study to resolve.

Adaptive immunity

Studies in this area have predominantly aimed to characterise the adaptive cytokine and cellular responses of immune cells exposed *ex vivo* to *M. bovis*, or within samples from infected animals, and in some cases to correlate their findings with disease severity. A clear picture of protective immunity has yet to emerge, but advances continue to be made.

Concerning the systemic immune response, Chao *et al.* compared the transcriptomes of PBMC from calves nasally inoculated with either virulent or attenuated *M. bovis*, or medium broth alone; this allowed them to identify potentially relevant gene sets that were associated with disease severity (Chao et al., 2019). Calves exhibiting worse gross and lung scores during infection with virulent *M. bovis* expressed higher levels of *ATP5B*, *JAK1*, *RORB*, *SYK*, *IL-17D*, *IL-23R*, *STAT3*, *GSK3B*, *IL-1RL1*, *ACTG1*, *TP53*, *IL-6*, *IL-21R* and *GATA3*; while those with less severe disease expressed higher levels of *INS*, *INSR*, *UBC*, *TNF*, *NFKBIA*, *FOXP3*, *NOS3*, *HSPA8*, *TLR4*, *BIRC3* and *IFNG* (Chao et al., 2019). Lastly, given the prevalence of IL-17-related genes in the former list, the researchers measured the levels of these transcripts in lungs of infected animals, finding that diseased animals expressed significantly higher levels of *IL-17A*, *IL-6*, *IL-21R* and *IL-23R* (Chao et al., 2019). It remains unclear whether these immune signatures are a result of severe disease that drives persistent inflammation with a Th17

component, or whether the immune response of these calves is more permissive to *M. bovis* and results in worse outcomes for the animals.

Further support for the importance of Th-17/IL-17 in the response to *M. bovis* came from Ohtsuka *et al.* who collected blood samples from *M. bovis*-infected calves at the onset of symptoms and either at the end of treatment or at the point of euthanasia, and compared levels of cytokine transcripts between those calves that resolved their symptoms and those that did not (Ohtsuka *et al.*, 2020). They found that lack of resolution of the infection was associated with significantly higher IL-17 levels that were maintained through treatment or until the animal was killed (Ohtsuka *et al.*, 2020). PBMC exposed to *M. bovis ex vivo* similarly increased their expression of IL-17 mRNA, as well as of IL-36A, IL-27, and IFN- γ (Gondaira *et al.*, 2021b). Lastly, an earlier vaccine study aiming to elicit Th-17 responses in fact achieved exacerbation of disease upon challenge, in agreement with the above findings (Prysljak *et al.*, 2018). Taken together, these data provide strong support for further investigation of the role of IL-17 in *M. bovis* infection.

By contrast to Th-17 responses, there is some evidence that Th1 responses are elicited following vaccination with reportedly protective attenuated *M. bovis* strains (Chao *et al.*, 2019) (discussed below, see [Live-attenuated vaccines](#)). Enriching this picture further, a detailed transcriptional study that compared lung and lymph node transcriptomes following challenge with different pathogens involved in BRD uncovered evidence of a primarily Th2 response in *M. bovis*-challenged animals as well as identifying common innate pathways activated during infection with respiratory pathogens (Behura *et al.*, 2017). In summary, the above studies paint a picture of Th17/Th2 immunity being a hallmark of more severe and/or persistent infection with *M. bovis*, while features of Th1 immunity appear more likely to be related to protection (at least following vaccination).

Few studies have reported advances in our understanding of the antibody response to *M. bovis*, though the work of two groups has offered insight into the potential role of complement-fixing antibodies in protection from disease. Zhang *et al.* initially reported that rabbit antibodies recognising *M. bovis* membrane proteins were able to initiate complement-mediated killing of the pathogen *in vitro* (Y. Zhang *et al.*, 2019); and, while some bovine antibodies were able to replicate these *in vitro* results, vaccination against the proteins recognised by complement-fixing antibodies did not enhance protection of cattle from *M. bovis in vivo* (Prysljak *et al.*, 2023).

Maternal immunity

There have not been any notable advances published in this area since 2012.

Immune evasion

M. bovis exhibits multiple means of immune evasion, which are strongly implicated in its ability to persist in the host. Most of the proposed pathways have been primarily evidenced *in vitro*; some of these findings are contradictory while others appear to reflect the *in vivo* situation more clearly. The pathways and processes identified warrant further investigation to enhance our understanding of the pathogenesis of *M. bovis* infection and to inform rational vaccine strategies (DISCONTTOOLS, 2022).

It is clear that during disease caused by *M. bovis*, immunosuppression – or at least immunomodulation – occurs *in vivo* (for example (Dudek et al., 2013)). Various immune-suppressive processes have been evidenced *in vitro*: *M. bovis* has both induced (Bürigi et al., 2018; G. Zhao et al., 2021) and inhibited (Maina et al., 2019; Mulongo et al., 2014) apoptosis of bovine monocytes and macrophages, with the reasons for the discrepancy in findings yet unclear. Alongside, other studies showed that *M. bovis* infection of monocytes reduces their ability to produce IFN- γ and TNF- α but increases production of the immunosuppressive cytokine IL-10 (Mulongo et al., 2014); while earlier work identified the ability of *M. bovis* to infect multiple cell types within bovine blood, reducing PBMC proliferation (van der Merwe et al., 2010). The mechanism of this reduced proliferation might also have been identified: Suleman *et al.* uncovered a potentially important role of the immune-inhibitory programmed death-1 (PD-1)/PD ligand-1 (PD-L1) pathway in this process, showing elevated expression of PD-L1 on macrophages from the lungs of infected animals, coincident with increased expression of PD-1 on both CD4⁺ and CD8⁺ T cells in the blood, which together correlated with low proliferation of PBMC (Suleman et al., 2018). A more recent study has contributed a further strand of knowledge, showing that *M. bovis* shapes the systemic immune environment to favour the emergence of regulatory T cells and the production of TGF β , which inhibited the production of the Th1 cytokines IFN- γ and TNF- α by bovine PBMC *in vitro* (Sajiki et al., 2020).

Recent work has also uncovered a potentially significant role for prostaglandin E2 (PGE2)-driven upregulation of the PD-1/PD-L1 pathway. Goto *et al.* initially correlated increased expression of PD-1 on T cells from *M. bovis*-infected cattle with reduced IFN- γ production by their PBMC *ex vivo*, then showed that blocking PD-1/PD-L1 reinstated IFN- γ production by *M. bovis*-stimulated PBMC (Goto et

al., 2017). The same group went on to show that PGE2 was also induced by incubation of PBMC with *M. bovis ex vivo*, as well as finding elevated levels of PGE2 in the blood of infected cattle, both of which correlated with elevated expression of PD-L1 in each setting (Goto et al., 2020). The authors suggested that *M. bovis*-induced PGE2 production by monocytes could increase expression of PD-L1 on bovine T cells, limiting their ability to produce IFN- γ and promoting mycoplasma survival in the host. Further support for the significance of this pathway came from a study by Gondiera *et al.*, who found elevated expression of PD-1, PD-L1 and other immune-suppression/exhaustion genes in mononuclear cells from the milk of experimentally infected mammary glands (Gondaira et al., 2020).

PGE2 is also known to affect innate immune cells, including neutrophils, in other species; and although it is not yet known whether this pathway is relevant in *M. bovis* infection, it is clear that neutrophils are a main target of immune suppression. Jimbo *et al.* incubated *M. bovis* with bovine neutrophils from healthy cattle *ex vivo* and found that the mycoplasma inhibited the production of nitric oxide, increased production of IL-12 and TNF- α , and promoted neutrophil apoptosis (Jimbo et al., 2017). *M. bovis* also appears able to disarm neutrophil extracellular traps (NETs), which are DNA-based structures that represent potent antimicrobial tools in other settings. Bovine neutrophils did not form detectable NETs after incubation with *M. bovis ex vivo*, and the addition of *M. bovis* led to destruction of existing nets in stimulated neutrophil cultures, most likely due to the action of the *M. bovis* nuclease and/or its inhibition of ROS production (Gondaira et al., 2017). These findings were supported by more recent work showing that live *M. bovis* could escape/prevent the formation of NETs, while killed *M. bovis* could not (Gondaira et al., 2021a), and the study by Mitiku *et al.* that revealed the NET-degrading ability of *M. bovis* major membrane nuclease MnuA (Mitiku et al., 2018).

Lastly, a study by Zhao *et al.* found that *M. bovis*, like other mycoplasmas, encodes at least two surface proteins that are able to bind *M. bovis*-specific IgG *in vitro*: they showed that a recombinant version of MBOVPG45_0375 prevented effective binding of the antibody to the mycoplasmal surface, while in concert, recombinant MBOVPG45_0376 could proteolytically cleave IgG (H. Zhao et al., 2021). The extent to which these proteins are involved in *in vivo* immune evasion requires further investigation.

Geographic distribution and epidemiology

Mycoplasma bovis began spreading across the globe in the mid-20th century, with introductions of the pathogen facilitated by burgeoning international trade networks and a lack of understanding of the

opportunistic nature of *M. bovis* infections (reviewed in (Dudek et al., 2020)). Today, anthropogenic factors (e.g., cattle trading, farm management factors and insufficient biosecurity) continue to play a major role in the long-distance spread of *M. bovis* (Aebi et al., 2015; Yair et al., 2020). Even subclinical *M. bovis* infections have been linked with significant decreases in milk yield and quality (Timonen et al., 2017), and the occurrence of these infections facilitates undetected transmission, with subsequent cases of pneumonia, arthritis, clinical mastitis and other morbidities causing economically significant infections in affected cattle populations (reviewed in (Gelgie et al., 2022)). At present, most of the world's major economies have been exposed to *M. bovis* infections for decades, causing widespread productivity losses within the beef and dairy cattle industries (reviewed in (Nicholas, 2011)).

The past decade saw the introduction of *M. bovis* to two countries that had previously been holdouts. Finland reported its first identification of *M. bovis*-infected cattle at the end of 2012, in the wake of increasing outbreaks in Denmark and introduction to Sweden in 2011 (Arede et al., 2016; Hurri et al., 2022), and the pathogen has subsequently spread among the country's dairy herds (Haapala et al., 2018; Tardy et al., 2020). This made Norway the only remaining Scandinavian country that was considered *M. bovis*-free, though a lack of recent publicly available data has been reported in that country (Tardy et al., 2020). In 2017, an *M. bovis* outbreak was reported in New Zealand, though the pathogen had likely already been present there for years (Jordan et al., 2021). New Zealand implemented an *M. bovis* eradication programme the following year, with outbreak delimitation via network and background surveillance still ongoing (Cowled et al., 2022; Ministry for Primary Industries, 2023).

Global situation

The Americas

M. bovis was first identified in the USA, after its isolation from dairy cattle with mastitis in 1962 (Hale et al., 1962). Today, it remains the most prevalent mycoplasma among American cattle herds, causing substantial production losses alone or in co-infection with other bacterial or viral pathogens (Gioia et al., 2021; Lubbers et al., 2017; Soehnlén et al., 2012). *M. bovis* was also commonly identified in a recent study of Canadian beef feedlot cattle with bronchopneumonia (with or without interstitial pneumonia) or acute interstitial pneumonia (Haydock et al., 2023).

M. bovis is also widespread in South America. In Brazil, a recent analysis of bronchoalveolar lavage fluid samples from dairy calves found *M. bovis* to be the second most common BRD-associated

pathogen complex (after *Pasteurella multocida*) in these animals (V. H. S. Oliveira et al., 2020). Interestingly, an earlier study on nasopharyngeal swab samples from steers on beef cattle feedlots did not detect any *M. bovis* (or indeed *P. multocida*) (Headley et al., 2018). Whether this indicates differences in BRD aetiology between dairy calves and beef steers, or is simply attributable to different sample types or diagnostic techniques, is not clear. Meanwhile, molecular diagnostic surveys of milk samples have indicated that *M. bovis* is also a major cause of bovine clinical mastitis in Brazil (Adorno et al., 2021; Junqueira et al., 2020; Salina et al., 2020), and a survey of Brazilian beef cattle reported that *M. bovis* infections may create a favourable environment in bulls for co-infection with the infertility-associated mollicute *Ureaplasma diversum* (Carli et al., 2022).

Similar findings have been reported in Argentina, where Margineda *et al.* published the first report of *M. bovis*-associated bovine pneumonia and polyarthritis in feedlot calves in 2017 (Margineda et al., 2017). Molecular analysis of samples from Argentinian dairy cattle indicated that *M. bovis* is likely secondary to other mycoplasmas (namely *M. leachii* and *californicum*) as a cause of arthritis and mastitis in these animals (Neder et al., 2022). Argentina currently lacks commercially available vaccines against *M. bovis*, making proactive surveillance and outbreak control critical for preventing unnecessary disease-related production losses (Cantón et al., 2022).

M. bovis has also been detected in milk samples from dairy cattle in Chile (Ulloa et al., 2021), though it was less prevalent than *M. bovis genitalium* (discussed in more detail in [Other mycoplasmas affecting cattle](#)).

Europe

The abolishment of the EU's milk production quotas in 2015 led to a dramatic expansion in dairy farming, which unfortunately also facilitated increased inter-herd transmission of *M. bovis* and other livestock pathogens (McCarthy et al., 2021). The highest-profile development in *M. bovis* epidemiology in Europe over the past decade was its emergence in Finland, and the majority of published studies from the continent report seroprevalence levels in different countries or states. Below is a discussion of studies from representative countries that illustrate general trends in *M. bovis* transmission and occurrence in Europe over the past decade.

The reported seroprevalence of *M. bovis* is particularly high in Spain (Calderón Bernal et al., 2023) and in Poland (Bednarek et al., 2012; Dudek and Bednarek, 2012; Szacawa et al., 2015), where *M. bovis* infections are common on dairy farms and statistically significant correlations have been observed

between the occurrence of *M. bovis* and of its fellow BRD-associated pathogens *Mannheimia haemolytica* and *Histophilus somni* (Lachowicz-Wolak et al., 2022). Clinical infections have also been reported in European bison (*Bison bonasus*) in Poland (Dudek et al., 2015; Krzysiak et al., 2014).

Meanwhile, *M. bovis* infections in Switzerland and Austria primarily caused pneumonia and subclinical mastitis prior to 2007, when severe clinical mastitis cases suddenly increased in both countries (Bürki et al., 2016). An analysis of *M. bovis* strains circulating within Swiss cattle herds found that they were mostly herd-specific, indicating that this spate of outbreaks had not been due to the sudden introduction of any one specific clone of *M. bovis* (Aebi et al., 2012). A subsequent molecular typing study in Switzerland and Austria classified pre- and post-2007 *M. bovis* isolates into separate lineages, with the newer lineage hypothesised to display higher virulence toward mammary gland cells (Bürki et al., 2016).

M. bovis is also highly prevalent among dairy cattle in the Netherlands, with an estimated true prevalence of ~75% (Veldhuis et al., 2022). A recent study of disease dynamics on 20 Dutch dairy farms during early-stage acute clinical outbreaks found that subclinical infections were common and that *M. bovis* transmitted to cattle of all age groups despite separate housing (Penterman et al., 2022).

M. bovis remains widespread in the United Kingdom, where it was the most frequently identified mollicute in an analysis of diagnostic samples received from ruminant farms between 2005-2019 (Deeney et al., 2021), though it is not currently a notifiable pathogen in the country (Ridley and Hateley, 2018). In neighbouring Ireland, a recent seroprevalence study among dairy herds also confirmed continuing endemicity, with herd size and the number of neighbouring farms found to be significant risk factors for herd-level prevalence (McAloon et al., 2022). Herd size was also identified as a particularly important risk factor in Sweden, where *M. bovis* seroprevalence remains generally low but is concentrated in the south of the country (Hurri et al., 2022).

The epidemiology of *M. bovis* is strongly dependent on local and regional variables (e.g., different farming systems, different trade patterns, etc.) that can be very difficult to predict or control. In Belgium, for example, a recent phylogenomic analysis classified circulating *M. bovis* strains into five separate major clusters, with genetic similarities to Israeli, European and American isolates indicating high levels of transmission across international trade networks and among veal, dairy and beef herds (Bokma et al., 2020d). Conversely, an earlier study reported much lower genetic diversity in the Austrian Alps, which saw successive waves of *M. bovis* emergence and re-emergence between 2005-

2009 before a sudden and dramatic increase in outbreaks in 2010-2011 (Spergser et al., 2013). Here, molecular typing indicated that a single *M. bovis* strain had re-emerged in 2009 and subsequently spread throughout the Austrian Alps region; the authors hypothesised that the unique livestock farming practices of the Alps (involving regular transhumance movements and shared mountain pastures) may have supported this epidemiological pattern (Spergser et al., 2013). Similar results emerged from France, where Becker *et al.* analysed the genetic diversity of collected *M. bovis* isolates using MLST and MLVA (see [Biology of the pathogen](#)) supplemented with MALDI-TOF MS to compare their protein expression patterns (Becker et al., 2015). Despite the propensity of *M. bovis* for generating heterogeneous strains, these authors reported a loss in genetic diversity since the 1990s, suggesting the spread of a single clone within France and implicating antimicrobial use in the selection of drug-resistant strains (Becker et al., 2015).

Finally, Fanelli *et al.* conducted a retrospective analysis of the role of *M. bovis* in a string of deadly calf pneumonia outbreaks on Italian dairy farms between 2009-2019, reporting high animal- and herd-level prevalence (~16% and 27%, respectively) and common co-infections with other cattle respiratory pathogens (Fanelli et al., 2021). These authors also observed seasonal morbidity peaks in April and September, positing unknown stress conditions during these periods as a possible cause (Fanelli et al., 2021).

Africa

Few recent studies have addressed the epidemiology of *M. bovis* in Africa beyond small-scale, local-/regional-level analyses, despite the economic impact of BRD across the continent. BRD places a severe burden on cattle farming in Egypt, for instance, and *M. bovis* appears to be particularly widespread, though its exact prevalence in this country has proven difficult to confirm due to inter-study variation and the application of vaccination programmes (Hashem et al., 2022b). The identification of *M. bovis* DIVA (differentiating infected from vaccinated animals) markers and the development of corresponding vaccines would benefit the determination of true prevalence levels (and, thereby, strengthen disease surveillance and control strategies) in Egypt.

Finally, a cross-sectional study of *M. bovis* prevalence in the north-western Sokoto and Kebbi states of Nigeria reported 81% seropositivity among cattle herds (Tambuwal et al., 2017), while only ~20% prevalence was reported in the north-eastern Adamawa state (Francis et al., 2015b).

Asia, the Middle East and Oceania

As in Africa, excepting the recent emergence of *M. bovis* in New Zealand, relatively few studies over the past decade have focused on *M. bovis* epidemiology in Asia, the Middle East and Oceania. However, the reported prevalence of *M. bovis* is very high in Vietnam (Nguyen and Truong, 2015), with lower but still economically significant levels in Japan (Murai and Higuchi, 2019) and China (FuRong et al., 2012).

A few illustrative studies have emerged from the Eastern Mediterranean and the Middle East: in Israel, *M. bovis*-associated cases of mastitis were reported only rarely prior to 2008, when a sudden jump in prevalence led to ongoing annual infections of around nine herds per year in the country (Lysnyansky et al., 2017, 2016; Yair et al., 2020). Seroprevalence studies have also confirmed high levels of circulating *M. bovis* in Afghanistan (Bahir et al., 2017) and Pakistan (Ahmad et al., 2014; Mahmood et al., 2017).

Meanwhile, in Australia, the seroprevalence of *M. bovis* among feeder cattle was reported as 3.5% on feedlot induction and 25.3% six weeks later, indicating a high level of inter-farm transmission in this environment (Schibrowski et al., 2018b). Similar results were observed on Canadian feedlots and in another study of Australian feedlots, altogether suggesting that most *M. bovis* infections occur after feedlot entry rather than before (Barnewall et al., 2022; Castillo-Alcala et al., 2012). Studies of *M. bovis* among live export cattle leaving Australia have also observed a significant increase in prevalence between depot entry and resampling, emphasising the aforementioned role of transport in facilitating disease transmission (Moore et al., 2015, 2014).

Surveillance, transmission, and risk factors

Within herds, *M. bovis* is primarily spread via direct physical contact, through aerosols, and through contaminated milk (Calcutt et al., 2018; Castillo-Alcala et al., 2012; Kanci et al., 2017; Maunsell et al., 2011), and the introduction of subclinically infected replacement animals is a common source of infection in naïve herds ((Hazelton et al., 2018b; Pardon et al., 2020; Woolums et al., 2014); reviewed in (Fox et al., 2005)). Transmission via environmental contamination (e.g., of cattle pens, bedding, etc.) is thought to be negligible because of the generally poor environmental survival of mycoplasmas, but instances of putative indirect transmission have been reported (Justice-Allen et al., 2010; Piccinini et al., 2015), with the formation of a protective biofilm potentially allowing the fragile mycoplasma cells to survive on surfaces for long periods of time. Other, less common, avenues of transmission have

been hypothesised, and recent studies have begun to shed light on these. Following the detection of *M. bovis* in Finland, Haapala *et al.* published the first report of its introduction into a naïve cattle herd via processed semen from an infected bull, raising questions about the antibiotics used to keep these samples contamination-free during transport (Haapala *et al.*, 2018). *M. bovis* DNA has also been identified at low frequency in colostrum, but further studies are needed to determine whether this colostrum is actually infectious (Gille *et al.*, 2020; Timonen *et al.*, 2020).

While research into these understudied means of transmission is ongoing, other studies have focused on direct contact transmission and the factors that affect its occurrence. The conditions of cattle transport, which is extremely common in the farming of most livestock, have been linked to the incidence of BRD in transported animals (reviewed in (Cusack, 2023)) – indeed, *M. bovis* positivity was found to increase ten-fold after travelling in a study of cattle transported from France to Italy, and stocking density and arrival temperature were also significantly correlated with the occurrence of *M. bovis* (Padalino *et al.*, 2021). Several studies have confirmed that *M. bovis* prevalence among transported cattle is significantly higher on arrival (after transport) compared to loading (before transport) (Cirone *et al.*, 2019; Stroebel *et al.*, 2018).

Transport is one unavoidable factor in cattle farming that can substantially impact the risk of *M. bovis* infections – feeding is another. On dairy farms, automatic milk feeders were recently found to increase the risk of *M. bovis* transmission compared to bucket feeding, potentially via the formation of biofilms on shared nipples (Arcangioli *et al.*, 2021). This study's authors also showed that the use of automatic milk feeders was associated with increased consumption of antibiotics, of which *M. bovis* is one of the primary drivers in cattle (Arcangioli *et al.*, 2021; Bokma *et al.*, 2020d). The development of drug resistance is therefore a major concern in the control of this pathogen. A longitudinal study of respiratory pathogens in Canadian beef calves reported high levels of resistance to macrolides including tulathromycin (Nobrega *et al.*, 2021), and a report on antimicrobial resistance in bison isolates also showed decreased susceptibility to tulathromycin (Suleman *et al.*, 2016b). Efforts to reduce antimicrobial use have met resistance from farmers due to concerns that lower treatment levels will lead to higher cattle mortality rates – however, a recent retrospective study of Belgian veal farms was unable to establish a negative correlation between antimicrobial use and mortality in that setting (Bokma *et al.*, 2020a). With drug resistance receiving increasing attention from policymakers and the public over the past decade, further studies of the economic and herd-level effects of reducing antimicrobial use would be useful for establishing, for instance, the level of financial incentive necessary to promote high levels of compliance with drug resistance reduction initiatives.

Wildlife

The trajectory of *M. bovis* in American wildlife highlights the complex epidemiology of this pathogen outside cattle farms. Despite being present in American cattle since at least the 1960s, *M. bovis* was first observed to infect North American bison only decades later, with outbreaks causing up to 30% mortality in affected herds in Canada and the western USA (Register et al., 2021b). However, retrospective analysis of *M. bovis* seropositivity in North American bison revealed that these animals likely harboured subclinical infections since at least the late 1980s, indicating that the later emergence of clinical disease may be attributable to the evolution of new *M. bovis* genotypes (Register et al., 2021b). *M. bovis* is an emerging pathogen of farmed bison particularly in western Canada (Bras et al., 2017a, 2016), where it has been reported as the most common cause of death on bison farms (Epp et al., 2018), but its epidemiology in the broader geographical region remains poorly understood (Register et al., 2021a). Subclinical infections and maintenance of *M. bovis* in the upper respiratory tract appear to be common in bison, making it very difficult to gauge its true prevalence and transmission patterns among bison herds without targeted, active surveillance (Bras et al., 2017b; Register et al., 2021a). Acute *M. bovis* infections have also been identified in American pronghorn (*Antilocapra americana*), with environmental transmission from cattle considered the most likely vector for introduction (M. Johnson et al., 2022; Malmberg et al., 2020).

Control of the disease

Although *M. bovis* is pervasive and not subject to WOA regulations (Dudek et al., 2020), it is one of the most economically burdensome mycoplasmas of livestock today. Effective approaches to its control have been made via government sponsored eradication programmes and voluntary control programmes paid for by the industry and farmers. Key to the control of *M. bovis* is regular surveillance, using accurate testing procedures and methods (Laven, 2019; Pohjanvirta et al., 2021) as asymptomatic carriers are common, and shedding of pathogen is irregular. The testing of individual animals or herds at a single time point is not reliable and it is thus key for accurate measurement of the infection status of herds, that sequential testing is carried out (Vähänikkilä et al., 2019).

To achieve *M. bovis* eradication, the most effective control strategy is to cull animals with Mycoplasma disease due to *M. bovis* as current treatment options do not eliminate the pathogen. It is also noted

that antimicrobial resistance is developing with *M. bovis* from different geographical sources exhibiting high macrolide minimum inhibitory concentrations in many studies (reviewed in (EFSA Panel on AHAW et al., 2021). Coupled with this challenge, no independently validated clinical breakpoints for antimicrobials have been specified for *M. bovis*, making data interpretation and correlation of *in vitro* minimum inhibitory concentrations to *in vivo* efficacy in disease treatment difficult (Jelinski et al., 2020; Klein et al., 2017). Biosecurity measures that include surveillance of clinical symptoms, regular testing of bulk milk, animal trade control and the separation of infected cows remain effective control measures for *M. bovis*.

Policy

Approaches for controlling *M. bovis* range from government-funded control programmes based on surveillance/herd serology and eradication via culling, such as adopted in New Zealand (Jaye et al., 2022; Laven, 2019), to privately funded industry control based on voluntary reporting and control, as in Finland (Autio et al., 2021). Any approach taken relies on adequate and accurate testing, as asymptomatic carriers are common (Pohjanvirta et al., 2021); in the 2017 outbreak in New Zealand, 98% of *M. bovis*-positive test results were from animals with no clinical signs of disease (Laven, 2019). Within dairy herds, the cornerstone of detection of *M. bovis* is via bulk milk testing (Autio et al., 2021; Nicholas et al., 2016), with recent data suggesting that the preservation of *M. bovis* in milk for testing via culture or molecular methods at diagnostic facilities can be best achieved through the addition of a combination of glycine and dimethyl sulphoxide (DMSO) as a cryoprotectant prior for storage at -20°C or -80 °C (Al-Farha et al., 2018a).

The voluntary control programme in Finland has been in place since 2013, and the key elements are observation of clinical signs, nasal swab sampling from calves, testing bulk tank milk and clinical mastitis samples for *M. bovis*, and control of animal trade (Autio et al., 2021). Animal trade control involves the requirement of health certificates when purchasing cattle, where the purchase of cattle is only allowed from farms at the same or a higher level of biosecurity (Autio et al., 2021). Since *M. bovis* is largely untreatable, infection control advice is to cull cows with *M. bovis* mastitis and isolate their calves or prevent nose-to-nose contact with older animals for at least six months. Nicholas *et al.* weighed the pros and cons of culling and proposed an alternative control strategy to test-and-slaughter, based on regular testing, early diagnosis and separation of affected cows (Nicholas et al., 2016). Essentially, their eight recommendations were: weekly testing of bulk tank milk, milking hygiene measures, testing of milk samples from all cows before they enter or re-enter the lactating

herd, rapid segregation and contact monitoring of infected cows, judicious use of antibiotic treatments, and pasteurisation or disposal of waste milk, with culling recommended only when welfare is compromised (Nicholas et al., 2016).

Control

Pasteurising waste milk before feeding to calves is not possible in all situations, and disposal of milk can be undesirable. Beidel *et al.* demonstrated that the addition of dilute formic acid to *M. bovis*-infected raw milk to a final pH of ≤ 4.5 effectively kills the pathogen (Beidel et al., 2016). Similarly, milk acidification using Salstop, a commercially available feed acidification agent, was also effective at eliminating viable *M. bovis* (Parker et al., 2016a). The implementation of this management practice of acidification of waste milk would limit the transmission of *M. bovis* to susceptible calf populations where pasteurisation or UV-irradiation are not available.

The purchase of asymptomatic carrier animals that may harbour *M. bovis* in the airways or mammary glands is a major risk for its introduction into naïve herds; nasopharyngeal swabs or bronchoalveolar lavage sampling of calves for PCR detection, even if no *M. bovis* mastitis has been detected in the herd, has been recommended to manage this route of introduction (Pohjanvirta et al., 2021). Hazelton *et al.* cautioned that herd biosecurity protocols and control programmes should also account for the role of bulls used in breeding across herds in the introduction and spread of Mycoplasma species (Hazelton et al., 2018a). These authors monitored mycoplasma infection status of bulls pre- and post-breeding in four herds using culture and PCR; *M. bovis* was not isolated from any of the 150 bulls pre-breeding, but its seroprevalence increased from 9% pre-breeding to 46% post-breeding with no evidence of clinical disease, indicating that infected bulls could increase the risk of entry of *M. bovis* into other herds or, potentially, transmission within a herd (Hazelton et al., 2018a).

Similarly, Haapala *et al.* reported the introduction of *M. bovis* to two separate, biosecure dairy herds in Finland via artificial insemination from an *M. bovis*-positive bull, and they thus recommended the re-evaluation of antibiotics used in semen extenders or the provision of tested *M. bovis*-free semen for artificial insemination (Haapala et al., 2018). Notably, some of the most common antimicrobials added to semen extenders (e.g., penicillin, gentamicin, streptomycin, tylosin, spectinomycin and lincomycin) are not always effective in controlling mycoplasmas (García-Galán et al., 2020a). Other antimicrobials such as enrofloxacin or doxycycline were shown to efficiently inhibit the growth of *M. bovis* in several *in vitro* studies, but their efficacy had not been assessed in bovine semen. To support

new strategies for reducing the risk of *M. bovis* transmission through artificial insemination, Garcia-Galán *et al.* assessed the viability of *M. bovis* in bull semen diluted in a Tris-citrate-fructose solution after the addition of enrofloxacin, doxycycline or a *Lactobacillus*-based probiotic, reporting that all three were effective at reducing *M. bovis* viability (García-Galán *et al.*, 2020a). Addition of *Lactobacillus* probiotic to cervical mucus *in vitro* also limited mycoplasma viability (A. García-Galán *et al.*, 2020). The authors proposed that this may be due to a reduction in pH, and that the administration of *Lactobacillus*-based probiotics might be used in the future to control *M. bovis* proliferation in the cervico-vaginal tract of cows.

Sanitization of the farm environment and equipment where *M. bovis* is detected is important for biosecurity and preventing the spread of this pathogen. Mycoplasmas lack a cell wall and can be susceptible to osmotic lysis, although the presence of organic material (as expected to be found in agricultural environments) may protect them from lysis. Mahdizadeh *et al.* demonstrated that 0.5% citric acid and 1% sodium hypochlorite were effective disinfectants against *M. bovis* under field conditions in the presence of organic matter, while in the absence of organic material, 0.25% citric acid and 0.04% sodium hypochlorite were sufficient to disinfect against *M. bovis* (Mahdizadeh *et al.*, 2020b).

Therapeutics

Antimicrobials used for the treatment or prevention of BRD usually include broad-spectrum cephalosporins (cefquinome and ceftiofur), extended-spectrum fluoroquinolones (enrofloxacin, danofloxacin, and marbofloxacin), florfenicol, and long-lasting macrolides (tulathromycin, gamithromycin, and tildipirosin). *M. bovis* from different sources has been reported to exhibit high macrolide minimum inhibitory concentrations in many studies ((Bokma *et al.*, 2020b; Jelinski *et al.*, 2020); reviewed in (EFSA Panel on AHAW *et al.*, 2021)), indicating the development of resistance. Reported variabilities in strain susceptibility to antimicrobials may be related to geographical origin, year of isolation, type of livestock production system, clinical presentation, or site of isolation (reviewed in (Lysnyansky and Ayling, 2016)). In response to a mandate from the European Commission to investigate the global situation on resistant animal pathogens, the European Food Safety Authority (EFSA) reviewed studies from Asia, Europe and North America on the antimicrobial sensitivity of *M. bovis*; this analysis found relatively low mean levels of resistance to florfenicol and fluoroquinolones across the continents, whereas resistance to both macrolides and tetracyclines was much more pronounced (EFSA Panel on AHAW *et al.*, 2021). Notably, the assessment of antimicrobial resistance

in *M. bovis* is circumscribed by the lack of approved interpretative criteria and standard procedures for susceptibility testing of mycoplasmas, leading to large uncertainty (EFSA Panel on AHAW et al., 2021).

Sulyok *et al.* determined the minimum inhibitory concentration (MIC) values of 35 *M. bovis* strains sampled in Hungary and reported that the most effective antibiotics tested *in vitro* were fluoroquinolones, though three fluoroquinolone-resistant isolates were identified; they also confirmed the reported increasing MIC values to antibiotics commonly used in the therapy of mycoplasma infections, primarily tetracyclines and macrolides (Sulyok et al., 2014a). The finding of fluoroquinolone-resistant isolates in Hungary and Great Britain (Ayling et al., 2014) is concerning, as many studies have found fluoroquinolones to be the most efficacious in inhibiting *M. bovis* growth and highlight a possible link between antimicrobial treatments and development of resistance in the *M. bovis* population (Barberio et al., 2016; EFSA Panel on AHAW et al., 2021; Heuvelink et al., 2016). Noting that standardised laboratory methods and interpretive criteria for MIC testing of veterinary mycoplasmas are needed, Klein *et al.* made use of a single laboratory to perform all of the antimicrobial resistance tests for 156 *M. bovis* isolates from France, Hungary, Spain, and the UK to ensure consistency in MIC values obtained (Klein et al., 2017). A similar strategy was used in a later study showing a moderate overall MIC₅₀ increase of at most one doubling dilution for enrofloxacin, spiramycin, tylosin, florfenicol and oxytetracycline, and a contrasting reduction in the MIC₉₀ value for oxytetracycline (Klein et al., 2019).

Studies in China and Japan note similar trends: *M. bovis* isolates from bovine respiratory infection outbreaks at beef farms in China were susceptible or had medium sensitivity to ciprofloxacin, enrofloxacin and doxycycline, but were frequently resistant to macrolides (Kong et al., 2016), while in Japan, *M. bovis* isolated from cases of bovine mastitis were sensitive to pirlimycin, danofloxacin and enrofloxacin, but not kanamycin, oxytetracycline, tilmicosin or tylosin (Kawai et al., 2014).

Many studies from around the world have investigated the antimicrobial sensitivity of *M. bovis* isolates from cattle, and these efforts have also recently been extended to isolates from bison. Tetracyclines, fluoroquinolones, and florfenicol failed to inhibit growth of bison isolates from Canada, demonstrating a marked difference from previously reported and laboratory reference cattle isolates (Suleman et al., 2016a). A study of clinical isolates from dead versus healthy cattle in western Canada indicated that those from dead cattle were more likely to be resistant to tulathromycin, gamithromycin, tylosin and enrofloxacin (Jelinski et al., 2020). These authors also noted high levels of antimicrobial resistance to

macrolides in all of the isolates. In a separate study in Alberta, Canada, Anholt *et al.* describe a high frequency of resistance to Category II antimicrobials (high importance to human health—neomycin, tylosin, tulathromycin, tilmicosin, and clindamycin), with extreme multidrug resistance in 30.5% of *M. bovis* isolates (Anholt *et al.*, 2017). The differences between cattle and bison *M. bovis* isolates' antimicrobial sensitivity may be due to differences in management and paraphylaxis in the herds.

Understanding the evolution of *M. bovis* in susceptibility to the main classes of antimicrobials used to treat BRDs is useful and informative for future management strategies. A comparison of strains isolated 30 years apart (1978-1979 and 2010-2012) was carried out to assess the prevalence of acquired resistances on a national level in France (Gautier-Bouchardon *et al.*, 2014). Only *M. bovis* isolated from BRD in young cattle were selected. Resistance to eight antimicrobials was shown to have been acquired over the 30-year period by all the strains, with particularly substantial increases in MIC₅₀ values for tylosin, tilmicosin, tulathromycin and spectinomycin. The authors note that the first-line treatments currently recommended for BRDs in France target only *Pasteurellaceae*, which may promote mycoplasmosis and lead to chronic disease (Gautier-Bouchardon *et al.*, 2014). A similar study of antimicrobial susceptibility profiles of *M. bovis* isolates collected from 1978 to 2009 in Ontario, Canada, was carried out to evaluate changes in MIC (Cai *et al.*, 2019). Significant differences in MIC values across time were observed for chlortetracycline, oxytetracycline, tilmicosin, tylosin, clindamycin, tulathromycin, spectinomycin, danofloxacin, and gentamycin (Cai *et al.*, 2019).

To use antimicrobial agents prudently and specifically in the treatment of *M. bovis* infections, targeted susceptibility testing should be performed prior to application of antimicrobial agents. For example, *in vitro* antimicrobial sensitivity testing of *M. bovis* isolated from two flocks of sheep in India indicated resistance to the most-used antibiotics, but sensitivity to tylosin and enrofloxacin (Kumar *et al.*, 2012). Treatment with tylosin was effective in promoting recovery within 15 days without recurrence (Kumar *et al.*, 2012). However, conventional identification and antimicrobial susceptibility testing takes approximately two weeks for mycoplasma species. Additionally, there are currently no independently validated clinical breakpoints for antimicrobials specified for veterinary mycoplasma species, which makes data interpretation and correlation to *in vivo* efficacy difficult. Several research groups have demonstrated that high MIC values for *M. bovis* are associated with mutations in genes associated with antimicrobial resistance in other bacteria (Sulyok *et al.*, 2017). Resistance to fluoroquinolones in *M. bovis* due to mutations in the *gyrA* and *parC* genes has been reported, for instance (Khalil *et al.*, 2016; Sato *et al.*, 2013; Sulyok *et al.*, 2017). Lerner *et al.* observed that point mutations in the *M. bovis* 23S rRNA alleles were associated with decreased susceptibility to the macrolides tylosin and tilmicosin

(Lerner et al., 2014). Similar results were found in *M. bovis* isolates obtained from Japanese dairy calves (Sato et al., 2017) and confirmed via whole genome sequencing of Canadian isolates (Kinnear et al., 2020). Amram *et al.* investigated the mechanisms associated with acquired resistance to tetracyclines in *M. bovis* isolates from Israel, the United Kingdom, Germany, Spain, Australia, Hungary, Lithuania, and Cuba; they reported that mutations in the Tet-1 site in the *rrs* alleles of clinical *M. bovis* isolates were associated with decreased susceptibility to tetracycline (Amram et al., 2015). Resistance to tetracycline and spectinomycin is also associated with point mutations in the 16S rRNA gene altering the tetracycline or spectinomycin binding sites (Amram et al., 2015; Khalil et al., 2017; Sulyok et al., 2017). These combined findings indicate that genotypic approaches to assess antimicrobial susceptibility in *M. bovis* could be more useful as a standardised approach than culture-based techniques, as they would not be susceptible to variable results due to growth conditions.

The development of feasible diagnostic methods for the identification of *M. bovis* mutants is necessary to improve accessibility to appropriate antimicrobial therapy. A genome-wide association study to identify genetic markers linked to antimicrobial resistance in *M. bovis* was performed to link genotypes with phenotypes based on epidemiological cut-off thresholds (Bokma et al., 2021a). The authors assert that this approach shortens the present sample-to-result workflow to identify strains with genetic markers associated with acquired fluoroquinolone and macrolide resistance in a rapid and objective way, aiding decision-making in treatment. Mismatch amplification mutation assays and seven high resolution melt tests were designed to enable the rapid and cost-effective simultaneous detection of genetic markers and hot-spot regions related to increased MICs to antibiotics in *M. bovis* (Sulyok et al., 2018).

The efficacy of *M. bovis* treatments involving the combination of antimicrobials with or without other drugs has been tested. A preliminary study evaluated the effectiveness in calves of enrofloxacin given alone; in combination with flunixin meglumine, a nonsteroidal anti-inflammatory drug; or with an additional treatment of pegbovigrastim, an immunostimulatory (Dudek et al., 2019). Enrofloxacin given alone appeared to be the most effective treatment of the *M. bovis* affected calves in this case. A single dose of a combination of florfenicol-flunixin formulation administered subcutaneously to calves showing severe signs of respiratory disease was more effective in alleviating the clinical signs of disease than either florfenicol + flunixin meglumine or florfenicol alone (Thiry et al., 2014).

Combining antibiotics with nanoparticles was tested in a small-scale experiment to treat *M. bovis*-induced rabbit mastitis (Fathi et al., 2019). The authors tested a lincospectin + zinc oxide nanoparticle

and found it to be more effective than lincospectin alone, suggesting that antibiotic-tagged nanoparticles may increase the concentration of antibiotics at the site of bacterium-antibiotic interaction and thus improve their efficacy (Fathi et al., 2019).

Other potential alternative treatments in development include plant-derived antimicrobials such as food-grade trans-cinnamaldehyde, eugenol, and carvacrol which can inhibit the growth of *M. bovis in vitro*. Ranjitkar *et al.* investigated the mechanism of action of carvacrol and found that it affected the expression of 153 genes, including the downregulation of energy generation-related proteins and the pentose phosphate pathway and upregulation of ribosomes and translation-related proteins in *M. bovis* (Ranjitkar et al., 2022). The pathways affected indicate that carvacrol is a plant-derived antimicrobial worthy of further investigation.

Vaccines

In most of the world, there are not any licensed vaccines to prevent the suite of disease symptoms caused by infection with *M. bovis*, most likely because the use of whole-inactivated mycoplasma renders DIVA impossible by conventional tuberculin testing. The notable exception is the USA, where two bacterin vaccines targeting *M. bovis* are available: Myco-B contains a blend of three inactivated field isolates and their soluble antigens, while MpB Guard comprises a mixture of antigens from two field isolates of *M. bovis* and their soluble antigens (reviewed in (Dudek et al., 2021; Perez-Casal et al., 2017)). Previous studies suggest sub-optimal performance of these vaccines in the field, with significant protection observed in less than half of vaccinated calves (Soehnlén et al., 2011), and the risk of adverse reactions in young calves (Maunsell et al., 2009). In 2022, Protivity, a live-attenuated *M. bovis* vaccine, was brought to market in the USA by Zoetis, with the manufacturer reporting a 74% reduction in lung lesions of twice-vaccinated animals compared to unvaccinated control animals (USDA, 2022). However, this comes with caveats: the vaccine strain may also migrate to the joints and cause arthritis, and the duration of immunity and efficacy under field conditions are unknown; moreover, how the vaccine affects diagnostic testing for *M. bovis* is unclear.

Novel vaccine candidates continue to emerge from research groups around the world but have yet to be developed to commercial availability. A major challenge in eliciting effective immune responses is the high level of antigenic diversity of *M. bovis* variable surface proteins (see [Immune evasion](#)). Given the importance of DIVA, improved vaccines should also prioritise this feature in their design.

Novel vaccines

Various strategies have been trialled to generate potential novel vaccine candidates, with most studies highlighting the challenges of inducing protective immunity to experimental challenge with *M. bovis*. The use of an attenuated bacterial vector has shown the most promise among recently attempted strategies.

Inactivated vaccines

Building on earlier work by Nicholas *et al.* (Nicholas *et al.*, 2002), Dudek *et al.* conducted a series of immunological studies characterising the antibody (Dudek and Bednarek, 2017a), cell-mediated adaptive (Dudek and Bednarek, 2017b) and acute phase (Dudek and Bednarek, 2018) responses to an inactivated *M. bovis* vaccine formulated with saponin (which acted both as the inactivator and an adjuvant) and lysozyme dimers. The vaccine induced a gradual increase in total immunoglobulins, with some signs of lymphocyte proliferation and acute-phase response activation, but protection from challenge was not reported in any of the studies.

The same group then characterised the bovine immune response to saponin-inactivated *M. bovis* either alone or in combination with other adjuvants (Dudek *et al.*, 2018). They selected a combination of *M. bovis*, saponin and Emulsigen[®], a commercially available adjuvant, and assessed its ability to protect calves from intratracheal challenge three weeks after a single immunisation (Dudek and Bednarek, 2018). The vaccine induced both mucosal and systemic antibody responses, significantly reduced disease severity and enabled almost all of the calves to clear *M. bovis* from their respiratory tract (Dudek and Bednarek, 2018), thereby representing a potentially promising candidate vaccine warranting further investigation in larger trials.

Live-attenuated vaccines

Zhang *et al.* immunised calves intranasally with two passage-attenuated *M. bovis* strains and challenged them intratracheally 46 days later (Zhang *et al.*, 2014). Both attenuated strains induced *M. bovis*-specific IgG production and induced IFN β production that was detectable in serum; vaccinated animals exhibited significantly milder clinical signs after challenge and shed significantly less *M. bovis* than unvaccinated controls, with the two strains eliciting approximately 70 and 80% protection overall (Zhang *et al.*, 2014).

While intranasal immunisation is desirable for practical and potentially also immunological reasons, a recent study highlighted the need for caution: Bassel *et al.* reported an attempt to reduce the

susceptibility of newly arrived feedlot cattle to BRD by aerosol administration of a crude bacterial lysate of *Staphylococcus aureus* and *Escherichia coli*; they found that the inflammation induced by the lysate at the point of exposure to BRD-related pathogens, instead of protecting from these agents, in fact exacerbated disease susceptibility (Bassel et al., 2021). These findings highlight the need to investigate the optimal pre-exposure vaccination point in such settings, especially for mucosal vaccines, and also point towards a potential accessory role of pre-existing respiratory inflammation in enabling BRD.

Although live attenuated vaccines may induce high levels of immunity to a broad range of potentially protective antigens, they can also cause mild disease symptoms if incompletely attenuated. Before such vaccines could be widely adopted in the field, end-users would need to be aware of the risk of not being able to discriminate between infection with the pathogen and post-vaccine mild illness in the few days following immunisation; treatment with antibiotics at this stage would render vaccines ineffective, and this additional factor should be borne in mind during their development.

Subunit vaccines

Attempts to exploit *M. bovis* by immunisation with either total extracts or membrane fractions (Mulongo et al., 2013b), or with recombinant *M. bovis* glyceraldehyde 3-phosphate dehydrogenase (Prysljak et al., 2013), successfully elicited humoral responses but did not significantly protect from disease. Therefore, these researchers asked whether responses could be strengthened by using a cocktail of *M. bovis* proteins formulated with a combination of adjuvants. Again, despite earlier evidence of immune stimulation by the novel vaccine (Prysljak and Perez-Casal, 2016), this candidate formulation also failed to protect calves from virulent challenge (Prysljak et al., 2017).

Vectored vaccines

Briggs *et al.* generated and tested an attenuated *Mannheimia haemolytica*-vectored *M. bovis* vaccine expressing the cross-strain-conserved Elongation factor Tu and heat-shock protein-70; following a single immunisation, calves were dual-challenged with bovine herpesvirus 1 (to predispose calves towards disease) followed by *M. bovis* and assessed for mycoplasmal load and disease severity (Briggs et al., 2021). While the lungs of control animals exhibited high levels of *M. bovis*, the pathogen could not be isolated from the lungs of two thirds of vaccinated calves, and at a significantly lower level than controls in the remaining animals; accordingly, there were signs of mild disease only in a minority of the vaccinated group (Briggs et al., 2021).

Adjuvants

There have not been any notable advances published in this area since 2012.

Conclusions

M. bovis is responsible for animal mortality, lost productivity, and economic insecurity on cattle farms around the world, and with the rising prevalence of antimicrobial resistance, our options for controlling this pathogen are limited. Many *M. bovis* gene products remain uncharacterised, our understanding of basic aspects of host-pathogen interactions (e.g., the mechanisms underlying the establishment of chronic infection) is limited, and many *in vitro* findings remain to be validated *in vivo*. Still, the studies highlighted above give cause for optimism; great strides have been made in understanding the fundamental biology and epidemiology of *M. bovis*, its interactions with host animals, and the mechanisms underlying its infectivity. Alongside, new diagnostic assays could bring rapid, cost-effective pathogen detection even to remote locations, generating invaluable data on *M. bovis* transmission patterns and allowing more targeted surveillance and control programmes. Promising data from recent vaccine generation studies also open new avenues for controlling *M. bovis* on a large scale. With most of the world still lacking commercial vaccines for *M. bovis* (and therefore relying on antimicrobials to treat diseased animals), bringing an effective new vaccine to market could also reduce antimicrobial usage on many livestock farms, reducing the threat posed by drug resistance.

Future research priorities

Based on the available literature, expert opinion, and previously published reviews (Calcutt et al., 2018; DISCONTTOOLS, 2022), we suggest that the following areas of research into *M. bovis* should be considered high priority:

Biology of the pathogen

- *Ongoing characterisation of M. bovis gene functions, including the use of modern gene editing techniques e.g. CRISPR/Cas to validate*
- *Definition of nutrient requirements in the different host tissues*
- *Comparison of field isolates' virulence and correlation with genomic/proteomic data*
- *Relevance of biofilms, and definition of their on-farm properties*

- *Assessment of the biological significance of intracellular infection*

Diagnosis

- *Standardisation of diagnostic protocols*
- *Development of a cost-effective pen-side test*
- *Antimicrobial sensitivity testing*

Pathogenesis

- *Understanding the factors driving the transition from asymptomatic infection to pathologic M. bovis-associated respiratory disease*
- *Adoption of standardised aerosol challenge method for calves, and design and validation of a similar system suitable for use with adult cattle*
- *Characterisation of host- and pathogen-associated factors underpinning highly pathogenic M. bovis infections of bison*
- *In vivo validation of putative virulence factors identified by genome sequencing and targeted mutation studies*
- *Development of a reproducible intramammary challenge model in small ruminants (or a better/easier/more affordable one in cattle) to allow studies of pathogenesis, local immunity and vaccine efficacy against M. bovis mastitis*
- *Comparative genomics of M. bovis isolated from different tissue sites to generate insight into tissue-specific adaptations/virulence factors*

Immunology

- *Immunogenetics of increased M. bovis resistance, with a focus on innate immune factors that could also protect against other members of the BRD complex*
- *Identification of protective antigens via genomic, proteomic, bioinformatic, and immunological approaches*
- *Increased use of primary cells/tissue explants/field samples: data generated in cell lines are often contradictory and/or with unknown relevance to the in vivo situation*
- *Identification of humoral correlates of protection*
- *Understanding of immune factors underlying polarisation to maladaptive Th17/Th2 versus adaptive Th1 immunity in infected animals*
- *Studies of the potentially protective and/or vaccine-interfering role of maternal immunity*
- *Defining the role of the host immune response in lesion development*

Epidemiology

- *Studies on the economic impacts of reducing antimicrobial use*
- *Understanding the impact of subclinically infected carriers and those cattle with M. bovis arthritis only*
- *Determining the environmental survival/tenacity of M. bovis under different climatic conditions*
- *Defining the role of wildlife in M. bovis transmission*
- *Targeted active surveillance of M. bovis in North American bison populations*
- *Studies to define true prevalence in mastitis, respiratory disease and arthritis in various field settings*

Control

- *Given the importance of DIVA for current control strategies, all new vaccine candidates should be compatible with this aim; therefore, subunit or vectored vaccines are likely preferable*
- *Field testing of the Protivity vaccine under a range of conditions to understand its efficacy*
- *Identification on antigens common to a range of M. bovis strains to facilitate subunit/vectored vaccine development*
- *Modelling and field-testing of promising non-cull control programmes*
- *Identification of effective antibiotic treatment regimens and assessment of novel plant-derived antimicrobials showing promise in preliminary trials, such as carvacrol*

Other mycoplasmas affecting cattle

Introduction

While *M. bovis* is generally the most prevalent and widely researched pathogenic mycoplasma of cattle, other less common species are also associated with bovine disease. These include the respiratory pathogens *M. bovirhinis* and *M. dispar*; the reproductive pathogen *M. bovigenitalium*; and the haemotropic mycoplasmas (haemoplasmas), an understudied class of obligate erythrocyte-associated pathogens that cause infectious anaemia and can be transmitted by arthropod vectors. There is also some speculation among those working in the field that *M. arginini* could play an important role during *M. bovis* pneumonia, but this has yet to be formally established. The study of these pathogens is a much smaller field compared to the more economically significant veterinary mycoplasmas, but studies published since 2015 have delivered valuable new insights into their biology and epidemiology.

Literature review

Biology of the pathogens

Little has been published over the past decade on the molecular biology of the more minor mycoplasmas of cattle, but the generation of new complete sequence data is an important step for the identification of critical proteins, virulence factors, and immune evasion-related factors in future studies of their functionality.

Molecular typing and genome sequencing

A draft genome sequence of *M. bovigenitalium* was published in 2013 (Lucía Manso-Silván et al., 2013), and the complete genome sequence of the Japanese strain HAZ 596 was published four years later (Hata et al., 2017a).

Three complete *M. bovirhinis* genomes have recently been published: the type strain PG43, the Chinese isolate GS01 (S. Chen et al., 2018), and the Japanese isolate HAZ141_2 (Hata et al., 2017b). A GC-rich prophage-like region of the HAZ141_2 genome was found to contain an *aadE-sat4-aphA-3* gene cluster conferring resistance to kanamycin and neomycin (Lysnyansky and Borovok, 2021a),

though an attempt to characterise the impact of genomic rearrangement events within this cluster was inconclusive (Lysnyansky and Borovok, 2021b).

Chen *et al.* published the complete genome sequence of *M. dispar* strain GS01, annotating putative virulence genes and pathogenicity islands (Chen *et al.*, 2019).

Finally, the draft genome sequence of the Mexican *M. wenyonii* strain INIFAP02 was published in 2018 (Quiroz-Castañeda *et al.*, 2018). This strain was later characterised by Flores-García *et al.*, who explored the phylogenetics of 12 reported bovine haemoplasma genomes – including two from *M. wenyonii* and one from ‘*Candidatus Mycoplasma haemobos*’ (*C. M. haemobos*) – to outline their main genomic characteristics and identify B cell epitopes in strain INIFAP02 (Flores-García *et al.*, 2022).

Proteomics and gene characterisation

There have not been any notable advances published in this area since 2015.

Diagnosis

The clinical signs associated with infection by these cattle mycoplasmas can be significant but are often nonspecific, necessitating the development of diagnostic assays that can discriminate them from each other and from other common cattle pathogens (e.g., *M. bovis*).

DNA diagnostics

Though primarily associated with reproductive and respiratory infections respectively, *M. bovis genitalium* and *M. bovirhinis* have both been associated with economically significant cases of cattle mastitis (reviewed in (Parker *et al.*, 2018)). Both are frequently included among the secondary targets for multiplex qPCR assays designed primarily to diagnose *M. bovis* infection, with other mycoplasmas detected via the conserved 16S rRNA gene or 16S-23S rRNA intergenic spacer region (Chauhan *et al.*, 2021; Gioia *et al.*, 2016; Lai *et al.*, 2022; Parker *et al.*, 2017b). High-resolution melting curve assay has been applied to distinguish *M. bovirhinis* from *M. bovis* and other pathogens present in milk (Al-Farha *et al.*, 2018b).

As a cause of granular vulvovaginitis, *M. bovis genitalium* has also been discriminated from *M. bovis* and *Ureaplasma diversum* present in vaginal swabs via nested PCR, targeting partial 16S-23S rRNA intergenic spacer region fragments for species-specific amplification (Voltarelli et al., 2018).

M. dispar was one of a number of mycoplasmas detected in a combined DNA microarray and qPCR study of the respiratory tract of Italian dairy calves; the authors of this study optimised a previously published microarray assay targeting the mycoplasma 23S rRNA and *tuf* genes (Schnee et al., 2012) to identify >70 mycoplasmas and reported particularly high prevalence of *M. dispar* among tested animals (Bottinelli et al., 2017a).

Freeman *et al.* used third-generation Oxford Nanopore metagenomic sequencing to detect *M. dispar* and other mycoplasmas in chronically infected feedlot cattle and to analyse their expression of antimicrobial resistance genes (Freeman et al., 2022). Nasal microbiome sampling has also been used to identify BRD complex mycoplasmas present in the upper respiratory tract, including *M. bovirhinis* and *M. bovis* (Centeno-Martinez et al., 2022).

Finally, Ade & Niethammer *et al.* developed qPCR assays specifically for *M. wenyonii* and *C. M. haemobos* by targeting their dehydrogenase-encoding *gapN* genes (Ade et al., 2018).

Serological diagnostics

A serodiagnostic assay has also been developed for *M. wenyonii*, with Zhao *et al.* using an antigen-specific colloidal gold immunochromatographic test to specifically detect antibodies against this pathogen in cattle serum samples (Y. Zhao et al., 2017b).

Sampling strategies and other developments

There have not been any notable advances published in this area since 2015.

Pathogenesis

Research on the pathogenesis of these cattle mycoplasmas has been limited over the past decade, but a small number of *in vivo* and *ex vivo* studies have been published on their host-pathogen interactions and associated clinical signs.

In vivo and ex vivo studies

Pôrto *et al.* exposed primary bovine epithelial cells from the vagina or endometrium, and PBMC, to *M. bovigenitalium ex vivo* and documented the production of nitric oxide after 48 hours, concluding that immune cells from these sites are potentially involved in the initial recognition of and the response to the pathogen (Pôrto *et al.*, 2021).

A study in Brazil aimed to identify the pathogens present in a cohort of calves with signs of respiratory disease, and documented *M. dispar* in almost 40% of cases (de Oliveira *et al.*, 2016). These data point to *M. dispar* as potentially having a more significant role in the pathogenesis of respiratory disease in this setting than previously appreciated.

Two case studies were recently published on novel presentations of *M. wenyonii*: one report of a dairy cow exhibiting haemolytic anaemia secondary to infection (Gladden, 2015); and another of exophthalmos of the eyes in an infected calf (Alsaad *et al.*, 2021).

A single study reported the possibility of vertical transmission of *M. wenyonii* from infected dams to their neonatal offspring, in addition to the widely accepted arthropod-mediated route (Sasaoka *et al.*, 2015). The authors observed a transmission rate of almost one quarter, in the absence of milk testing positive for the pathogen (Sasaoka *et al.*, 2015).

In vitro studies

There have not been any notable advances published in this area since 2015.

Immunology

There have not been any notable advances published in this area since 2015.

Geographic distribution and epidemiology

The great majority of cattle mycoplasma epidemiology studies published over the past decade have focused on *M. bovis*, but several reports have emerged on the prevalence of the more minor mycoplasmas in disparate geographical regions.

Global situation

The Americas

M. bovis genitalium infections are associated with reproductive and respiratory pathologies, but its prevalence is generally far lower compared to *M. bovis* (Hashem et al., 2022b), and relatively few studies of its epidemiology have been conducted. Infection with *M. bovis genitalium* has been associated with reproductive disorders in Brazil, where it is widespread on beef and dairy cattle farms (Carli et al., 2022; Macêdo et al., 2018).

Haemoplasma infections are particularly widespread in cattle and water buffalo (*Bubalus bubalis*) in Brazil (Santos et al., 2018), though reported prevalence varies widely across the country; in the major dairy-producing municipality Ji-Paraná, herd-level prevalence of *C. M. haemobos* was estimated at >95% (Witter et al., 2017), while only ~2.3% was reported in the Pantanal region (Mello et al., 2019).

Europe

M. dispar is frequently detected alongside *M. bovis* and *M. bovirhinis* in the nasal cavity of beef and dairy cattle, and several studies over the past decade have reported its prevalence levels across Europe in particular (Antonis et al., 2022; Deeney et al., 2021; Gaeta et al., 2018; Szacawa et al., 2016, 2015). *M. dispar* is widely prevalent in Switzerland, for instance, though *Pasteurellaceae* species, *Mannheimia haemolytica* and *Histophilus somni* were more common respiratory pathogens (Schönecker et al., 2020). *M. dispar* and *bovirhinis* also appear to be widely prevalent in North American bison populations, where many animals may be asymptomatic carriers of these pathogens (Register et al., 2021a).

In France, cases of acute milk production loss, anaemia, and oedema led to the first detection of *M. wenyonii* infections in the country, with overall prevalence in Brittany estimated at ~26% (Nouvel et al., 2019). Hornok *et al.* assessed the prevalence of several vector-borne bacterial pathogens among large game animals in Hungary, finding >90% prevalence of *M. wenyonii* in water buffalo (Hornok et al., 2018). Meanwhile, in Bosnia and Herzegovina, Stevanović *et al.* reported the first detection in Europe of *M. wenyonii* DNA in castor bean ticks (*Ixodes ricinus*) feeding on infected cattle (Stevanović et al., 2020). Haemoplasma prevalence studies have also been conducted in Germany (Niethammer et al., 2018) and the United Kingdom (Deeney et al., 2021).

Africa

Boularias *et al.* reported the first detection of *M. wenyonii* and *C. M. haemobos* in northeast Algeria (Boularias et al., 2020) and Byamukama *et al.* conducted the first molecular detection and characterisation of haemoplasma infections in Ugandan cattle and goats, reporting ~32% and 44% positivity, respectively (Byamukama et al., 2020). Reported prevalence levels are higher in Somalia, where nearly 100% of cattle were haemoplasma-positive in a recent diagnostic study (Ferrari et al., 2022).

Asia, the Middle East and Oceania

In 2020, Mashhour *et al.* reported the first detection of *M. dispar* in Iran (Mashhour et al., 2020).

The prevalence of haemoplasmas including *M. wenyonii* has been investigated in several countries including Iraq (Jarad and Alsaad, 2016), Malaysia (Mohd Hasan et al., 2017; Ola-Fadunsin et al., 2017), the Philippines (Galon et al., 2020; Ybañez et al., 2019) and Japan (Tatsukawa et al., 2021).

Surveillance, transmission and risk factors

There have not been any notable advances published in this area since 2015.

Wildlife

There have not been any notable advances published in this area since 2015.

Control of the disease

As many of the cattle mycoplasmas are either commensals or commonly co-infect in *M. bovis*-infected cattle, control measures based on animal management and good biosecurity practices will also be effective in their control. Antimicrobial treatments should be judiciously and specifically applied in treating mycoplasma infections to avoid development of antimicrobial resistance, including in non-target organisms.

Policy

There have not been any notable advances published in this area since 2015.

Therapeutics

There have been few studies assessing the antibiotic sensitivity of *M. dispar* despite it being widely prevalent in the bovine population and exposed to untargeted chemotherapy for many years. Assays of the MIC of *M. dispar* isolates collected in Italy between 2011–2019 found a drift, similar to that seen in *M. bovis*, towards high antimicrobial concentrations, indicative of an ongoing selection process among the isolates (Bottinelli et al., 2020). The genetics or mechanisms of resistance in *M. dispar* were not investigated in the study. Testing antimicrobial susceptibility of bovine mycoplasmas by traditional methods such as broth microdilution is time-consuming because of the culture characteristics of mycoplasmas; thus, rapid detection of resistance-associated mutations would be beneficial in assessing the antimicrobial susceptibility of specific mycoplasma strains. Although rarely identified as a primary pathogen in diseases in many countries (Deeney et al., 2021), mastitis due to *M. californicum* has been on the rise recently in Japan (Hata et al., 2019). A genetic method involving melting curve analysis with a hybridization probe for the rapid detection of mutation loci associated with changes in antimicrobial susceptibility in *M. californicum* has been described (Hata et al., 2019). The authors were able to identify mutation points associated with susceptibility to macrolides and lincosamides within hours, meaning that the method has the potential to allow field veterinarians to make timely decisions about best treatment options.

As a result of the low immunogenicity of *M. dispar* in calves, the use of complex formulations that combine antimicrobials with prophylactic treatments that boost metabolism and immunity are recommended. The therapeutic efficacy of gentaminoseleferon (a combination therapy containing

gentamicin sulfate, aminoseleton, and a mixture of bovine recombinant IFN- α and - γ proteins) was compared with sulfetrisan (a mixture of sulphadimethoxine, erythromycin, and trimethoprim) in calves with respiratory infections that included *M. dispar* (Alhussen et al., 2020). The authors reported that the calves treated with gentaminoseleferon had a shorter recovery time and displayed reduced markers of inflammation in the blood and serum (Alhussen et al., 2020).

Vaccines

There have not been any notable advances published in this area since 2015.

Conclusions

Alongside *M. bovis*, these other mycoplasmas of cattle cause significant economic losses around the world, and their importance in individual infections and in co-infection with other cattle pathogens should not be neglected. The development of multi-target diagnostics (e.g., multiplex qPCR) primarily targeted at *M. bovis* has provided new opportunities for the simultaneous detection of *M. bovis*, *M. bovis genitalium*, *M. bovis rhinis* and *M. dispar*, and emerging molecular technologies may also facilitate a greater range of data collection on the haemoplasmas ((Flores-García et al., 2022); reviewed in (Parker et al., 2018)). Future studies will be required to clarify the epidemiology of these pathogens (including the role of arthropod vectors in haemoplasma transmission in different climates and farm management systems), map their host-pathogen interactions (both alone and in co-infections), and monitor the development of antimicrobial resistance in these populations.

Future research priorities

Based on the available literature and expert opinion, we suggest that the following areas of research into other mycoplasmas affecting cattle should be considered high priority:

Biology of the pathogens

- *More complete sequences alongside functional characterisation of bovine mycoplasma genomes*

- *Comparison and molecular typing of genome sequences to support phylogenetic, evolutionary and epidemiological studies*

Diagnosis

- *Validation and deployment of diagnostic assays for bovine haemoplasmas*
- *Continuing focus on the development of field-capable assays useable in resource-limited settings*

Pathogenesis

- *Clarification of the respiratory pathogenicity of *M. bovis* alone or in co-infections with BRD complex-associated pathogens*
- *Understanding the potential roles of *M. bovis* and *M. paratuberculosis* in clinical mastitis*
- *Continuing study of strain-specific virulence factors*
- *Studies of potential novel clinical presentations of bovine haemoplasma infection*

Immunology

- *Characterisation of host-pathogen interactions and mechanisms underlying immune evasion*

Epidemiology

- *Standardisation of bovine mycoplasma prevalence studies, including sampling methods, sample storage, diagnostic assays, and data interpretation*
- *Identification of region-specific arthropod vectors for bovine haemoplasmas*

Control

- *Continuing studies of antimicrobial sensitivity*
- *Studies of potential vaccine candidates*

Mycoplasmas affecting small ruminants

Introduction

While most of the research into mycoplasmas affecting ruminants has focused on bovines, significant disease burden is also caused in sheep, goats and other Caprinae by a distinct set of mycoplasmas. Herein, we discuss recent research into *M. agalactiae*, the primary (and perhaps sole) cause of contagious agalactia; *M. ovipneumoniae*, which induces respiratory disease in sheep and Caprinae as well as a range of wildlife species from other subfamilies; and two members of the *Mycoplasma mycoides* cluster – *M. mycoides* subsp. *capri* (*Mmc*) and *M. capricolum* subsp. *capripneumoniae* (*Mccp*), which also cause respiratory disease. Alongside, we mention the little research that has been conducted into the rarer small ruminant haemoplasmas – *Mycoplasma ovis* (*M. ovis*) and *Candidatus Mycoplasma haemovis* (*C. M. haemovis*). Although the study of this broad group of varied pathogens has been more limited than of those affecting bovine ruminants, knowledge has been substantially advanced in key areas over the past eight years.

Literature review

Biology of the pathogens

As with the other mycoplasmas discussed above, genome sequencing and molecular typing of small ruminant mycoplasmas is critical for monitoring their transmission patterns and geographical spread and for identifying particularly important bacterial proteins that could be targeted for diagnostics, therapeutics or vaccines. The difficulty of culturing mycoplasmas has historically limited generation of data on their genomes and molecular biology (Chen et al., 2017b), but recent studies have begun to close some of the gaps.

Molecular typing and genome sequencing

Molecular typing is critical for characterising the evolution, population structure, and transmission of small ruminant mycoplasmas. Several different methods have been applied to the molecular epidemiology and phylogeny of *Mccp*. Dupuy *et al.* used a large-scale genomics strategy based on next-generation sequencing to differentiate 24 haplotypes among 25 *Mccp* strains and estimate their phylogenetic history and evolutionary dynamics in Asia and Africa; from this analysis, these authors

projected that *Mccp* likely first emerged less than 300 years ago, potentially explaining its low genetic diversity relative to its high mutation rate (Dupuy et al., 2015). This group later analysed 34 *Mccp* strains from all known endemic regions (comprising areas in Africa, the Middle East and Asia), using core genome analysis and comparison against the Abomsa reference genome to build a phylogenetic tree and identifying transmission and evolution patterns via high-resolution typing. Among other findings, their analysis of isolates from Niger indicated a westward movement of CCPP in Africa, while five strains from Middle Eastern wildlife – specifically, wild goats (*Capra aegagrus*) from Qatar and Arabian sand gazelles (*Gazella marica*) and Arabian and scimitar-horned oryxes (*Oryx leucoryx* and *dammah*, respectively) from the UAE – were classified in the same phylogenetic group (Loire et al., 2020). This latter finding may indicate adaptation to new hosts, but further sequencing studies will be needed to clearly support this hypothesis (Loire et al., 2020).

As with other mycoplasmas discussed in this report, MLST – wherein a small number of conserved housekeeping genes are evaluated among multiple strains to evaluate genomic differences – has been widely applied to the study of these topics in mycoplasmas of small ruminants. MLST was previously used to investigate the molecular epidemiology of contagious caprine pleuropneumonia (CCPP) (Manso-Silván et al., 2011) and a similar strategy was recently applied to *Mmc* specifically. Tatay-Dualde *et al.* adapted a previously published MLST based on five housekeeping genes (Manso-Silván et al., 2007) to type 39 Spanish field isolates of *Mmc*, reporting that this method was able to classify strains by their geographical origins and to distinguish different strains from the same herd and sampling time (Tatay-Dualde et al., 2016). This MLST was later applied to 60 *Mmc* isolates from goats in India, where a new clonal complex consisting of four sequence types was reported to predominate (Subbaiyan et al., 2021).

Einarsdottir *et al.* used a previously developed MLST (Cassirer et al., 2017) to characterise variability among Icelandic isolates of *M. ovipneumoniae*, reporting relatively high genetic diversity and indicating intracellular and cell surface localisation of these bacteria on foetal ovine synovial cells *in vitro* (Einarsdottir et al., 2018). A later study by Lieske *et al.* analysed 10 Dall's sheep (*Ovis dalli dalli*) and 12 caribou (*Rangifer tarandus grantii*) samples in Alaska; four-locus MLST, targeting regions of the 16S rRNA, the 16S-23S intergenic space, and the *rpoB* and *gyrB* housekeeping genes, indicated that all tested samples (collected between 2004-2019 over a wide geographic range) contained a single novel strain type of *M. ovipneumoniae* (Lieske et al., 2022a). The authors reported that this strain type differed by at least five bases from a set of samples they collected from Alaskan domestic sheep and goats and from a large dataset of isolates from domestic and wild small ruminants reported by Kamath

et al. (Kamath *et al.*, 2019), discussed further below. This new, apparently stable strain type has not been associated with population-wide mortality events, but further study is necessary to more closely characterise its properties (Lieske *et al.*, 2022a).

Meanwhile, Olaogun *et al.* developed and applied an MLST method for *Mycoplasma arginini*, which has been isolated from both healthy and diseased small ruminants – these authors reported high genetic diversity between *M. arginini* strains and within herds (Olaogun *et al.*, 2015).

Finally, as mentioned above, Kamath *et al.* published a comprehensive molecular typing study of *M. ovipneumoniae* in domestic small ruminants, wild bighorn sheep (*Ovis canadensis*), and mountain goats (*Oreamnos americanus*) to assess the pathogen's genetic variability and transmission dynamics among these species (Kamath *et al.*, 2019); this study is discussed further in the [Epidemiology](#) section below.

Like other mycoplasmas, the major small ruminant mycoplasmas discussed here have generally small genomes (<1100 kbp) with low G+C content (often <30%) ((Chen *et al.*, 2017b; Yang *et al.*, 2011; Z. Zhang *et al.*, 2022b); reviewed in (Citti *et al.*, 2020)), and the generation of complete sequence data is a vital part of ongoing surveillance and epidemiology studies of these pathogens (DISCONTTOOLS, 2021). The complete genome sequence of *Mccp* strain zly1309F, isolated from a Tibetan antelope (*Pantholops hodgsonii*), was published in 2017 (Hao *et al.*, 2017), and Chen *et al.* published a full-genome analysis of the Chinese strain M1601 that same year (Chen *et al.*, 2017b). In 2020, Ahmad *et al.* reported the first isolation and characterisation of the regional Pakistan strain of *Mccp* (Ahmad *et al.*, 2021), and Yuan *et al.* published the complete annotated genome sequence of the Chinese goat-origin *Mccp* strain 87001 (Yuan *et al.*, 2020). These authors identified many unique genes and potential virulence factors in the strain 87001 genome, including eight virulence genes and four genes encoding putative extracellular proteins that were conserved within five *Mccp* genomes, potentially providing new targets for drug and/or vaccine development (Yuan *et al.*, 2020).

The draft genome sequence of New Zealand *M. ovipneumoniae* isolate 90 was published in 2020 (Bridgeman *et al.*, 2020). Jaÿ *et al.* conducted whole genome sequence analyses as part of their characterisation of antimicrobial resistance in French *M. ovipneumoniae* strains (Jaÿ *et al.*, 2020), and the sequences of two strains (150 and 274) from Bosnia and Herzegovina were reported more recently (Hao *et al.*, 2023). Herndon *et al.* published the draft genome sequence of a new *Mycoplasma* species isolated from the respiratory tract of an Alaska moose (*Alces alces gigas*) (Herndon *et al.*, 2021). This

mycoplasma shares ~91-94% sequence identity with *Mycoplasma conjunctivae* and was previously detected in sheep, goats and other ruminants in the USA (Herndon et al., 2021); future studies will be required to characterise/name this mycoplasma, investigate its molecular properties, and assess its potential for pathogenicity independent of *M. ovipneumoniae*.

Filoussis *et al.* recently published on an unusual outbreak of contagious agalactia in a mixed herd in Greece – this outbreak caused high morbidity in goats but did not appear to affect sheep, and its clinical presentation in goats was limited to mastitis (e.g., no arthritis, respiratory distress, or other common signs were observed) (Filioussis et al., 2022). This group published and analysed the complete genome sequence of this strain (dubbed GrTh01), which was found by MLST to belong to a new sequence type (ST35). GrTh01 contained an especially short genome (~840 kbp) and a minimal accessory genome, lacking numerous genes including the *IS30* transposase gene, the Bacteroides-like surface protein A, most of the variable antigens and the integrative conjugative element (Filioussis et al., 2022).

Finally, Zhang *et al.* sequenced the genome of *Mccp* strain HN-B from Hainan Island, China, and identified strain-specific genes via comparable genomic analysis with other members of the *Mycoplasma mycoides* cluster (Z. Zhang et al., 2022a).

Proteomics and gene characterisation

Studying *Mccp* strains from disparate geographical regions (Oman, Eritrea, Kenya and Turkey), Soayfane *et al.* reported that *Mccp* comprises two major biochemical groups: one that oxidises organic acids and glycerol, and another that can also metabolise sugars (Soayfane et al., 2018).

Churchward *et al.* combined 2D electrophoresis and tandem mass spectrometry to characterise protein products of *Mmc* strain 152F05, reporting 20 proteins with high immunogenicity and six with sequences distinct enough to allow diagnostic discrimination of *Mmc* from other closely related mycoplasmas (Churchward et al., 2015).

Finally, a genomic and phenotypic comparison of 23 ovine and caprine *M. ovipneumoniae* strains was conducted via SDS-PAGE, western blotting, random amplified polymorphic DNA (RAPD), and sequencing of heat shock protein 70 (*hsp70*) gene; this study demonstrated substantial heterogeneity

among these strains and identified four immunodominant antigens with potential applications in serodiagnostics and vaccine development (Maksimović et al., 2017).

Diagnosis

Similar to other mycoplasmas, isolation and culture often considered the gold standard for diagnosis of small ruminant mycoplasmas (Noll et al., 2022). Bacterial culture is also required for avenues of mycoplasma analysis and control (e.g., antimicrobial susceptibility testing and virus/antigen production for vaccines and serodiagnostics), and advances have recently been reported in the validation and optimisation of growth media for *M. ovipneumoniae* (Jennings-Gaines et al., 2016; Z. Maksimović et al., 2020). The effort and time required for mycoplasma culture remain substantially higher compared to molecular detection via PCR, however (reviewed in (Francis et al., 2015a; Maksimović et al., 2022)), and molecular methods are generally the first choice for diagnosis of small ruminant mycoplasmas. Efforts have continued over the past eight years to increase the efficiency, performance and/or ease-of-use of the molecular diagnostic toolkit.

DNA diagnostics

Lin *et al.* designed a TaqMan-based qPCR for detecting *Mmc*, reporting ~1,000-fold higher sensitivity compared to conventional PCR in testing on clinical samples (Lin et al., 2019). Meanwhile, Noll & Highland *et al.* developed a qPCR assay for distinguishing between *M. ovipneumoniae* and a new respiratory mycoplasma they had recently identified in an Alaska moose (*Alces alces gigas*) calf (discussed in [Epidemiology](#)). These authors analysed nucleic acid samples isolated from domestic sheep and goat nasal swabs to compare their assay against conventional PCR and sequencing, reporting 88% and ~90% agreement (for *M. ovipneumoniae* and the novel respiratory mycoplasma, respectively) in their determination of positive vs. negative samples (Noll et al., 2022).

Co-infections between mycoplasmas and other small ruminant pathogens (bacterial and/or viral) are very common, and it is therefore important to have assays available that can reliably discriminate among specific pathogens to inform surveillance and treatment/disease control decisions. Cillara *et al.* developed a PCR-restriction fragment length polymorphism assay targeting the dihydrolipoyl dehydrogenase (*lpdA*) gene for single-tube differentiation between *Mmc* and the closely related *M. capricolum* subspecies *capricolum* (Cillara et al., 2015). Meanwhile, primers targeting *Mccp* have been

included in the development of multiplex PCR tests aimed primarily at detecting peste des petits ruminants virus, as in a one-step multiplex reverse transcription qPCR (RT-qPCR) developed at the International Atomic Energy Agency (Settypalli et al., 2016) and a recently published high-speed multi-well RT-qPCR (dubbed “FastCheck^{FLI} PPR-like”) (Halecker et al., 2020).

As with other veterinary pathogens that are endemic in many rural and/or remote regions, diagnostics for the major mycoplasmas of small ruminants must often balance sensitivity and reliability with ease-of-use and field applicability (reviewed in (Rather et al., 2021)). Isothermal nucleic acid diagnostics are an important part of this active area of research, as they do not require thermocyclers and are therefore more amenable to point-of-care use. Liljander *et al.* developed an isothermal RPA assay for *Mccp* based on a simple fluorescence read-out device that could be powered by a car battery, providing results in less than 45 minutes under simulated field settings. Importantly, this assay worked on goat pleural fluid samples without a DNA extraction step, enhancing its point-of-care useability (Liljander et al., 2015). In diagnostic methods that require it, the choice of DNA extraction protocol can have a significant effect on assay results – Tatay-Dualde *et al.*, for instance, found that an extraction method incorporating an enzymatic protein denaturation step allowed higher *M. agalactiae* PCR detection rates from milk samples compared to one without, possibly due to the inactivation of PCR inhibitors present in these samples (Tatay-Dualde et al., 2015).

Two isothermal RPA assays have recently been published for the detection of *M. ovipneumoniae*. Wang *et al.* developed a 16S rRNA-targeting RPA assay for *M. ovipneumoniae* in sheep that can be run on a portable fluorescence scanner device, demonstrating 100% diagnostic specificity against other mycoplasmas and bacteria and ~91% sensitivity on clinical sheep nasal swab and lung samples (Jinfeng Wang et al., 2020). Gupta *et al.*'s assay targeted a hypothetical protein-encoding gene (WP_069098309.1), and the authors reported sensitivity comparable to conventional qPCR without requiring DNA extraction (Gupta et al., 2021).

LAMP is another promising option for developing field-capable diagnostic assays with reduced equipment and personnel needs compared to conventional qPCR. Rekha *et al.* published details of a LAMP assay targeting the *p40* gene of *M. agalactiae*, reporting 100-fold higher sensitivity compared to PCR (Rekha et al., 2015). The *p40*-amplifying primers used in this study were later applied by Tumino *et al.* in a LAMP system incorporating a portable device with a real-time fluorometer for automatic data interpretation; this test was reported as more sensitive and cost-effective than qPCR when tested on milk samples collected from sheep and goats with contagious agalactia (Tumino et al., 2020).

Meanwhile, Zhang *et al.* developed a LAMP assay against the *M. ovipneumoniae* elongation factor Tu gene, reporting an 86% positive detection rate in clinical sheep lung tissue samples (J. Zhang *et al.*, 2019).

Concordance studies of *M. ovipneumoniae* molecular diagnostics have generally reported a high degree of reproducibility between tests and testing locations. Walsh *et al.* observed a median agreement level of 0.89-0.95 for PCR detection of *M. ovipneumoniae* among nine laboratories in the USA (Walsh *et al.*, 2016). In a later study, three tested PCR assays – the Universal Mycoplasma PCR (van Kuppeveld *et al.*, 1992), the LM40 PCR (Highland *et al.*, 2018; McAuliffe *et al.*, 2003), and an IGS-targeting protocol (Besser *et al.*, 2012) – exhibited generally high agreement with each other, though the LM40 PCR was able to detect *M. ovipneumoniae* in more samples compared to the other two tests (Lieske *et al.*, 2022b).

Serological diagnostics

Molecular assays have been the focus of most published studies of small ruminant mycoplasma diagnosis over the past decade, though ELISAs and latex agglutination testing remain in common use for rapid, cost-effective pen-side detection of infected herds (reviewed in (Maksimović *et al.*, 2022)), and a few new strategies for detecting anti-mycoplasma antibodies have recently been published. Zhu & Qu *et al.* reported their development of a colloidal gold-based immunochromatographic assay for detecting antibodies against *Mccp*, which they compared favourably against the indirect hemagglutination assay (Zhu *et al.*, 2022). Meanwhile, de Dieu *et al.* developed a blocking ELISA for CCPP that displayed 93% and 88% diagnostic sensitivity and specificity, respectively, and good agreement with the commercially available IDEXX CCPP Ab Test (de Dieu *et al.*, 2019).

As with molecular tests, validating the reproducibility of serological diagnostics is critical for generating datasets that can be compared between labs and countries. Sánchez *et al.* compared the performance of three commercial indirect ELISAs for *M. agalactiae* – the CIVTEST Ovis *M. agalactiae* kit from Laboratorios HIPRA, the IDEXX *M. agalactiae* Screening Ab Test, and the ID Screen *M. agalactiae* Indirect ELISA from IDvet – on sera from clinically infected goats, reporting that all three tests exhibited comparable performance (~77-85% sensitivity and 100% specificity) (Sánchez *et al.*, 2022).

Sampling strategies and other developments

An R code-based web app dubbed “Shiny” was recently developed to estimate the probability that a respiratory pathogen (e.g., *M. ovipneumoniae*) is present in a bighorn sheep herd by combining estimated DNA diagnostic assay accuracy levels with a hierarchical Bayesian model of pathogen prevalence (Paterson et al., 2020).

Pathogenesis

M. ovipneumoniae is a major respiratory pathogen of sheep and goats, where it causes both subclinical and clinical infections. The clinical presentation of *M. ovipneumoniae*-associated pneumonia typically includes fever, coughing, lethargy and other common symptoms of respiratory infections, alongside production losses including decreased milk production in ewes (reviewed in (Maksimović et al., 2022)) and reduced average daily weight gain and yield grade carcasses in lambs (Besser et al., 2019). The severity of this disease varies considerably depending on strain-specific virulence, host immune response, and the presence of co-infecting bacterial or viral pathogens (USDA APHIS, 2020). As with many other veterinary mycoplasmas, co-infections are therefore an important concern – exposure to *M. ovipneumoniae* has been shown to exacerbate inflammatory responses to influenza D virus in sheep (Robinson et al., 2022), for instance, and other bacterial pathogens including *Pasteurella multocida* and *Mannheimia haemolytica* have been detected in animals infected with *M. ovipneumoniae* (Lindström et al., 2018; Wood et al., 2017).

M. agalactiae is the primary cause of contagious agalactia in sheep and goats, characterised by arthritis, keratoconjunctivitis, and mastitis that has been associated with significantly lower milk production and decreased milk lactose content in infected ewes ((Gelasakis et al., 2018; Todaro et al., 2015; Tolone et al., 2019); reviewed in (Arteche-Villasol et al., 2022; Jaý and Tardy, 2019)). *M. agalactiae* has also been detected in the brains of some infected animals, and experimental intra-mammary infections of sheep have been reported to cause histopathological changes in the central nervous system ((DISCONTTOOLS, 2021); reviewed in (Rosales et al., 2017)).

Mmc infection causes clinical disease in small ruminants that is also defined by WOAHA as contagious agalactia, though it occurs more frequently in goats (WOAHA, 2023c). It has been argued that *M. agalactiae* should be considered the sole cause of this disease, and the disease caused by *Mmc* (and

other mycoplasmas including *M. capricolum* subspecies *capricolum* and *M. putrefaciens*) be renamed to “caprine respiratory and articular syndrome” to more accurately reflect the pathologies of these mycoplasmas (reviewed in (Migliore et al., 2021)). Regardless, *Mmc* infection is associated with a wide range of clinical presentations including pneumonia, mastitis, arthritis, keratitis and septicaemia in goats (Weldearegay et al., 2019).

Finally, *Mccp* is the causative agent of CCPP in goats, though it can infect sheep and numerous wild small ruminant species as well (reviewed in (Yatoo et al., 2019)). The clinical signs of *Mccp* infection in goats include fever, reduced appetite and respiratory distress, while acute and subacute disease are associated with unilateral serofibrinous pleuropneumonia with severe pleural effusion (WOAH, 2023d). CCPP morbidity and mortality are generally high, making this disease a substantial threat to domestic goat populations in the 40+ countries in which it is endemic (reviewed in (Yatoo et al., 2019)).

In the last eight years, researchers have begun to fill some of the most important gaps in our understanding of the pathologies of these mycoplasmoses, including characterisation of *in vivo* infection dynamics and the use of *in vitro* models to identify virulence factors. This section will discuss a representative set of these studies and the progress that they have made.

In vivo and ex vivo studies

Mycoplasma ovipneumoniae

The degree to which *M. ovipneumoniae* infection *alone* can cause clinical respiratory disease in sheep is unclear. Johnson *et al.* followed a previously published protocol for inoculating specific-pathogen-free domestic lambs with pooled nasal wash fluids from *M. ovipneumoniae*-infected lambs (Besser et al., 2014) and monitored the progress of infection – interestingly, they found that the bacteria stably colonised the upper respiratory tract but did not induce clinical signs (respiratory disease, lung inflammation, etc.), while neither the lambs’ antibody responses nor gamithromycin treatment (to which *M. ovipneumoniae* was susceptible *in vitro*) could clear this infection (T. Johnson et al., 2022) – further research will be necessary to determine the specific mechanisms underlying this resistance.

Compared to domestic sheep, *M. ovipneumoniae* is known to be substantially more dangerous in several wild ruminant species, including bighorn sheep (*Ovis canadensis*) and Norwegian muskox (*Ovibos moschatus*) (Dekelaita et al., 2020; Handeland et al., 2014; T. Johnson et al., 2022). A retrospective comparison of domestic vs. bighorn sheep identified several differences in their lung

immunological responses to *M. ovipneumoniae* – domestic sheep exhibited increased bronchiolar-associated lymph tissue and alveolar IL-17, while bighorn lung samples instead showed higher levels of bronchiolar CD3 and bronchiolar and alveolar CD163 (Grossman et al., 2021). Sinus tumours in bighorns have also been associated with bacterial co-infections (including *M. ovipneumoniae* and leucotoxic *Pasteurella* species) in the upper respiratory sinus (Fox et al., 2015).

Some recent studies have focused specifically on *M. ovipneumoniae* infection in individual sheep breeds, aiming to identify breed-specific factors associated with differences in infection dynamics or host immune response. Mousel *et al.* studied the host genetics associated with the presence of *M. ovipneumoniae* in Polypay, Rambouillet and Suffolk sheep, using principal component and genome-wide association analyses to link specific genomic differences with the mean copy number of *M. ovipneumoniae* DNA in nasal secretions (Mousel et al., 2021). The authors identified 28 single nucleotide polymorphisms (SNPs) on nine chromosomes that were significantly associated with DNA load and linked them to genes in immune function, chromatin organisation and gene silencing pathways (Mousel et al., 2021). Meanwhile, Du *et al.* used high-throughput RNA-seq to profile the lung transcriptome of Bashbay sheep experimentally infected with *M. ovipneumoniae*. They reported 1,048 and 2,823 differentially regulated genes (DEGs) at four and 14 days post-infection, respectively, and analysis of these DEGs in the [KEGG](#) and [Gene Ontology](#) bioinformatics databases indicated enrichment in gene pathways associated with innate immunity and positive regulation of inflammation (Du et al., 2020). This group later conducted a similar analysis in Argali hybrid sheep, where they reported a smaller number of DEGs (367 at 14 days post-infection) that were enriched in the primary immunodeficiency pathway and in Gene Ontology terms related to ciliated motor damage (Z. Li et al., 2020).

Mycoplasma agalactiae

Transcriptomic profiling has also been conducted on sheep mammary glands to characterise changes in response to experimental infection with *M. agalactiae*. Chopra-Dewasthaly *et al.* reported 39 DEGs in mastitis udder tissue, most of which were associated with the innate and adaptive immune responses (Chopra-Dewasthaly et al., 2017). This group has also published several recent studies on potential virulence factors in *M. agalactiae*. Hegde *et al.* screened a library of *M. agalactiae* transposon mutants for putative virulence factors, reporting seven mutants (in genes *uhpT*, *eutD*, *adhT*, and MAG1050, 2540, 3390 and 4460) that were unable to colonise the udders and draining lymph nodes of experimentally infected sheep (Shivanand Hegde et al., 2015). These authors then

used this workflow to identify several sets of genes (including *pdhB*, *oppC* and MAG4460) that appeared to be required for systemic bacterial spread after initial colonisation (Hegde et al., 2016).

M. agalactiae encodes a set of six surface lipoprotein genes (the *vpma* genes) that are controlled from a single promoter; these genes are frequently swapped by the bacterial recombinase Xer1, generating antigen variability and promoting immune evasion (Glew et al., 2002, 2000). Anti-Vpma antibodies may also trigger phase variation in these lipoproteins via an Xer1-independent mechanism (Czurda et al., 2017). After their aforementioned studies of transposon mutants, Hegde *et al.* investigated the potential roles of these Vpma lipoproteins as virulence factors by generating *M. agalactiae* “phase-locked” mutants that expressed only one Vpma each, allowing characterisation of their individual activities *in vitro* and *in vivo*. The authors reported that the six Vpmas promoted cell adhesion *in vitro*, though only VpmaU-locked *M. agalactiae* exhibited a significant reduction in colonisation and multiplication *in vivo* (Chopra-Dewasthaly et al., 2022; Hegde et al., 2018).

Mycoplasma mycoides subspecies capri

After determining an important role for galactofuranose in *Mmc* membrane integrity *in vitro* (Schieck et al., 2016), Jores *et al.* tested whether this capsular polysaccharide acted as a virulence factor *in vivo* – indeed, significant attenuation was observed in a galactofuranose-deficient mutant strain of the highly virulent GM12::YcPmmyc1.1 strain, indicating that glycol-conjugated vaccines may be a promising route for future studies (Jores et al., 2019b).

Research into *Mmc* pathogenesis has been limited by the lack of validated *in vivo* challenge models, which are critical for research on host-pathogen interactions and immunology. Several recent studies have aimed to address this need by validating reliable *in vivo* or *ex vivo* models of *Mmc* infection. Paul *et al.* reported that intratracheal inoculation with *Mmc* was preferable to the intubation method for experimental infections (Paul et al., 2019), while Weldearegay *et al.* published an *ex vivo* caprine precision-cut lung slice model of acute *Mmc* infection; the histopathology of these infections was reported to match *in vivo* findings, and additional data were generated on the tropism of *Mmc* for pulmonary endothelial cells and sub-bronchiolar tissue (Weldearegay et al., 2019).

Mycoplasma capricolum subspecies capripneumoniae

Haematological disruptions (e.g., increased leucocyte counts and decreased erythrocyte count and haemoglobin content) and metabolic acidosis have been reported in *Mccp*-infected goats (El-Deeb et al., 2018; Tharwat, 2021).

Liljander *et al.* established 100% morbidity in unvaccinated outbred goats (*Capra aegagrus hircus*) via repeated intranasal spray infections followed by one trans-tracheal injection with the Kenyan *Mccp* strain ILRI181 (Liljander *et al.*, 2019). These authors used this model to analyse the expression of bacterial glycerol uptake and hydrogen peroxide metabolism genes, finding that the putative virulence factor L- α -glycerophosphateoxidase was expressed by *Mccp in vivo* (Liljander *et al.*, 2019).

In vitro studies

Mycoplasma ovipneumoniae

Xue *et al.* used a sheep primary air-liquid interface epithelial culture model to demonstrate that *M. ovipneumoniae* infection stimulates increased expression of components of the myeloid differentiation factor 88 (MYD88)-dependent TLR signalling pathway, leading to the production of proinflammatory cytokines (Xue *et al.*, 2015). These authors later used this model to investigate *M. ovipneumoniae*-induced apoptosis, reporting that the bacteria quickly bound to ciliated cells and induced ROS- and caspase-3-mediated apoptosis in bronchial epithelial cells (Yanan Li *et al.*, 2016; D. Xue *et al.*, 2017).

Mycoplasma agalactiae

Gaurivaud *et al.* reported that *M. agalactiae* secretes capsular β -(1 \rightarrow 6)-glucan – this event was regulated by a putative synthase encoded by the *gsmA* gene, the expression of which is modulated by high-frequency phase variation that may promote immune evasion (Gaurivaud *et al.*, 2016). Meanwhile, Barbosa *et al.* continued their group's investigation of Vpma phase variation *in vitro* following their characterisation of single Vpma-expressing mutants in experimentally infected animals. These authors used MALDI-TOF MS to study the differences between the *M. agalactiae* type strain PG2 and the American field isolate GM139, which they found to naturally express only VpmaV (Barbosa *et al.*, 2022). Future studies will be needed to characterise the mechanism of this restriction and to quantify its impact on the pathogenicity of strain GM139.

Hegde *et al.* established *in vitro M. agalactiae* infection models in primary sheep epithelial and stromal cells from the mammary gland and uterus (Shrilakshmi Hegde *et al.*, 2015) and Sharma *et al.* reported their development of *oriC* plasmids that were able to be efficiently transformed into *M. agalactiae* (and *M. bovis*), providing new avenues for targeted *in vitro* studies of functional virulence factors in this pathogen (Sharma *et al.*, 2015a).

The *M. agalactiae* genome was previously reported to contain an integrative conjugative element that may promote horizontal gene transfer (Marenda et al., 2005). More recently, Tardy *et al.* identified numerous coding sequences for integrative conjugative elements in the genomes of *M. agalactiae* and *Mmc*, indicating a potential mechanism of chromosome exchange and diversity generation in these species (Tardy et al., 2015).

Mycoplasma mycoides subspecies capri

Bertin *et al.* identified several exopolysaccharides secreted by members of the *Mycoplasma mycoides* cluster, including a galactan from *Mmc* (serovar “Large Colony”) and a glucan from *Mycoplasma mycoides subspecies capri* and *Mccp* (Bertin et al., 2015, 2013). Meanwhile, Wang *et al.* investigated metabolic processes in cultured *Mmc* via RNA-seq, indicating that several genes encoding specific bacterial enzymes (including cytidylate kinase, nicotinate-nucleotide adenyltransferase and dihydrolipoamide dehydrogenase) play particularly important roles in *Mmc* metabolism (Wang et al., 2018).

Jores *et al.* reported that the targeted deletion of 68 non-essential genes from the previously published *Mmc* strain GM12::YCpMmyc1.1 (Lartigue et al., 2009) fully attenuated its virulence (Jores et al., 2019a); these results provide an important platform for the rational design and construction of attenuated strains and open the door for future studies of individual virulence factors in *Mmc* and other pathogenic mycoplasmas.

Lindenwald *et al.* developed an ovine C-type lectin receptor hFc-fusion protein library for investigate the interactions of these important host pattern recognition receptors with pathogens and tested it on *Mmc*, reporting several candidate receptors (including CLEC4A, 4D and 12A) that appeared to interact with the bacterium (Lindenwald et al., 2020). This platform could be a useful tool for future studies of sheep C-type lectin receptors in different mycoplasma infections.

Finally, Strässle *et al.* recently used caprine airway epithelial cells grown under air-liquid interface conditions to establish an *in vitro* system for studying the interactions between these cells and respiratory pathogens; these authors specifically reported the successful infection of these cells (and subsequent replication/colonisation) with influenza D virus and *Mmc* strain GM12 (Strässle et al., 2021).

Mycoplasma capricolum subspecies capripneumoniae

Excepting the research cited above, there have not been any notable advances published in this area since 2015.

Immunology

The immunology of *Mycoplasma* species affecting small ruminants is likely to be as diverse as the combinations of host and pathogen that can be affected: in many cases, basic knowledge is still lacking, with the potential for future gains somewhat limited by a lack of resources, and in some cases the absence of species-specific immunological tools. Despite these obstacles, the studies below report stepwise progress towards a level of understanding that can support the development of improved/first vaccines and/or therapeutics.

Immunogenetics

M. ovipneumoniae is the only mycoplasma affecting small ruminants for which significant research has been conducted into immunogenetics, since 2015. One study aimed to characterise polymorphism within exon 2 in *MHC-DRB1* in differentially *M. ovipneumoniae*-susceptible sheep breeds and how this correlated with relevant immunological differences during experimental infection. Wang *et al.* reported that the more susceptible Hu sheep were most likely to carry the Mval bb- or Haelll ee-digestible MHC genotypes, while in the more *M. ovipneumoniae*-resistant Dorper and D 9 H hybrids, the Mval cc- and Haelll dd- digestible genotypes dominated (K. Wang *et al.*, 2020). Moreover, disease resistance negatively correlated with levels of TNF- α , IFN- γ , IL-4, IL-6, and IL-1 β in serum during infection of sheep, and positively correlated with levels of IL-10 and IL-2 (K. Wang *et al.*, 2020), though the mechanisms potentially linking MHC type and cytokine production in these sheep have yet to be explored.

Another Chinese sheep breed has also been investigated for resistance to mycoplasma infection. Following their work showing an association between mannose-binding lectin (MBL) genotype and resistance of Chinese Merino sheep to *M. ovipneumoniae* (Heng *et al.*, 2018), Zhu *et al.* generated miRNA profiles of resistant and susceptible MBL sheep groups under MBL therapy for *M. ovipneumoniae* infection, identifying marked differences and highlighting miR-432, which targets the

signal transducer and activator of transcription 2 (STAT2) protein, as potentially important (Zhu et al., 2021b).

Although our understanding of the immunogenetic basis for the variable resistance of Chinese sheep breeds to *M. ovipneumoniae* is in its infancy, such studies are providing valuable insights that in future may help inform rational breeding strategies for pathogen-resistance.

Innate immunity

In vivo studies into the innate response to *M. agalactiae* infection have begun to shed light on potentially important pathways. Rodriguez *et al.* reported co-localisation of IL-10, IFN- γ , IL-4 and TNF- α (Rodríguez and Castro, 2015), as well as cyclooxygenase-2 (Rodríguez et al., 2015b), with inflammatory lesions in sections of mammary glands from goats that were naturally or experimentally infected with *M. agalactiae*; alongside, Marinaro *et al.* revealed evidence of prolonged blood leucocyte depletion during experimental infection of goats with *M. agalactiae*, likely indicating recruitment into the affected tissues (Marinaro et al., 2015). Also in the mammary gland, but this time in naturally infected sheep, *M. agalactiae* has been reported to co-localise with NETs; exposing primary ovine neutrophils to *M. agalactiae* or *M. agalactiae* lipoproteins *ex vivo* also induced NET formation, but NETs were subsequently digested by *M. agalactiae*, which the authors proposed as a means of immune escape (Cacciotto et al., 2016). It remains to be established whether *M. agalactiae* also uses the NET-derived nucleotides to support its own replication, as seen for other mycoplasma species (Henthorn et al., 2018).

Several *ex vivo/in vitro* studies have also advanced our knowledge of the innate immune responses to *M. ovipneumoniae*. In primary ovine bronchial epithelial cells, exposure to capsular polysaccharides isolated from *M. ovipneumoniae* increased transcription of several TLRs, as well as production of TNF- α , IL-1 β , IL-8, and IL-10; importantly, these results were recapitulated in experiments with whole *M. ovipneumoniae* and were partially blocked by the addition of antibodies specific for capsular polysaccharides (Jiang et al., 2017). More recently, Zhu *et al.* identified miR509-5p as a potentially important down-regulator of the inflammatory cytokine response to infection in primary sheep respiratory mucosal epithelial cells exposed to *M. ovipneumoniae* (Zhu et al., 2021a).

Murine cells have also been used to model interactions between immune cells and *M. ovipneumoniae*. In primary murine peritoneal macrophages, exposure to either *M. ovipneumoniae* or to its lipid-

associated membrane proteins induced expression of *Tlr2* and the NLR family pyrin domain containing 3 gene, which led to IL-1 β production (Bai et al., 2020). Meanwhile, in a murine alveolar macrophage cell line, *M. ovipneumoniae* exposure induced the transcription of genes encoding IL-1 β , IL-18 and TNF- α , but also induced activation of pro-apoptotic pathways in these cells (Chen et al., 2021), which may represent another means of immune evasion. In a different murine macrophage line, *M. ovipneumoniae* exposure triggered autophagy via a mechanism involving activation of the NOD2 and c-Jun N-terminal kinase pathways, which resulted in reduced pathogen survival *in vitro* (Luo et al., 2020).

Adaptive immunity

In vivo infections with *Mccp* cause profound immunopathology in goats, which IL-17 seems to be important for: in experimentally infected animals, *Il-17A* expression was significantly higher than in uninfected animals, which correlated with high levels of *Il-1 β* , *Il-6* and *Il-23* as well as with expression of neutrophil chemo-attractants, numbers of neutrophils and extent of lung pathology (Ma et al., 2020). More recent work by Grossman *et al.* also indicated high levels of IL-17 in the lungs of domestic sheep naturally infected with *M. ovipneumoniae* (Grossman et al., 2021).

In the case of *M. agalactiae*, studies have focused on the prediction and validation of surface-expressed B cell antigens. The P40 protein of *M. agalactiae* is a known surface antigen with potential for use in a subunit vaccine, yet the epitopes within it were unknown; preliminary analysis has now predicted five B cell epitopes and six T cell epitopes within P40, of which some were reported to have antigenic potential (Forouharmehr and Nassiry, 2015). More recently, Barbosa *et al.* identified additional potentially antigenic proteins that were likely to be expressed on the surface of *M. agalactiae* using bioinformatic analyses combined with experimental validation: this approach highlighted MAG_1560, MAG_6130, and P40, confirmed that they were surface-localised, and demonstrated their recognition by sera from naturally infected sheep and goats (Barbosa et al., 2020). Finally, an immunoproteomic study by Cacciotto *et al.* identified a number of novel conserved *M. agalactiae* antigens via immunoblotting followed by MALDI-TOF MS including MAG_1000, MAG_2220, MAG_1980, phnD, MAG_4740, and MAG_2430 (Cacciotto et al., 2021).

Maternal immunity

Defining the optimal time for first vaccination of young animals requires detailed knowledge of the nature and durability of passively transferred maternal immunity. Abdollahi *et al.* conducted a longitudinal study that compared levels of *M. agalactiae*-specific antibodies in serum samples from goat kids fed colostrum from either vaccinated or unvaccinated does, over the first 100 days of their life; they found that maternal antibodies lasted on average until 56 days post-birth, leading the authors to suggest that 56-70 days of age might be an appropriate window for the administration of the first *M. agalactiae* vaccine to kids (Abdollahi et al., 2022).

New studies on maternal immunity against other mycoplasmas affecting small ruminants have not been published since 2015.

Immune evasion

There have not been any notable advances published in this area since 2015.

Geographic distribution and epidemiology

Small ruminants – primarily domestic sheep (*Ovis aries*) and goats (*Capra hircus*) – are central to the food security and agricultural economies of many countries. Small ruminant production systems are particularly widespread in countries of Asia, the Middle East, and a wide swathe of Western, Central and Eastern Africa (Gilbert et al., 2022a, 2022b). Pathogenic mycoplasmas affecting these species can therefore place substantial socioeconomic burdens on farming communities and consumers of small ruminant products. This section will discuss the current state of research on the global epidemiology of some of the most important of these pathogens.

M. ovipneumoniae is one of the most important mycoplasmas of small ruminants. Highly prevalent worldwide, *M. ovipneumoniae* causes acute and chronic pneumonia in sheep and goats (Besser et al., 2019; Manlove et al., 2019). The pathogen is also capable of infecting numerous wild species primarily via spill-over events from domestic animals (reviewed in (Maksimović et al., 2022)). The lack of widely available validated vaccines or treatments against *M. ovipneumoniae* make it extremely difficult to control (T. Johnson et al., 2022). Estimates of the economic losses attributable to *M. ovipneumoniae* are rare, and such studies are complicated by the chronic nature of *M. ovipneumoniae* and a lack of adequate surveillance and epidemiological data in many endemic regions. A recent study conducted

in the USA estimated that the presence of *M. ovipneumoniae* in a median-sized operation (housing 155 ewes) may cost approximately 637-1,275 USD annually (~764-1,529 USD adjusted for inflation in 2023), though the authors note that this estimate may be confounded by the higher overall disease burden on *M. ovipneumoniae*-positive premises (Manlove et al., 2019).

Another major mycoplasma of small ruminants is *M. agalactiae*, which causes contagious agalactia. This disease occurs in many countries around the world and is associated with mastitis, arthritis, keratoconjunctivitis and abortion (reviewed in (Jař and Tardy, 2019; Kumar et al., 2014)). Commercial vaccines against *M. agalactiae* are in widespread use, but their protective efficacy has generally been found to be low (WOAH, 2023c). Losses from this disease vary widely depending on the scale of the outbreak and the small ruminant populations in which they occur. A recent study in Sicily, for instance, estimated a total cost of 6,600 euros (~7,344 USD) from an outbreak that occurred on a small farm of 200 small ruminants during the dry season; a more significant outbreak on a larger farm (> 1,000 animals) may have caused a loss of ~123,550 euros (~137,500 USD) due to culling of infected animals, purchasing of replacements, and loss of animal products (Loria et al., 2019, 2018b). Three other mycoplasmas – *Mccp*, *M. putrefaciens*, and *Mmc* – also cause a clinical disease of small ruminants that is very similar to contagious agalactia (DISCONTTOOLS, 2021; WOA, 2023c).

Mccp is the causative agent of CCPP and is a member of the “*Mycoplasma mycoides* cluster” alongside *Mmc* (Soayfane et al., 2018), which has historically been associated with high-mortality respiratory infections in goats as well ((Hernandez et al., 2006); reviewed in (Dudek et al., 2022)). Total economic losses due to CCPP in endemic areas have been estimated at ~507 million USD annually (~600 million USD adjusted for inflation in 2023) (reviewed in (Yatoo et al., 2019)).

Finally, small ruminant haemoplasmas – specifically *M. ovis* and *C. M. haemovis* – can cause anaemia, jaundice and mortality, particularly in younger animals; high-risk procedures involving exposed or shared blood (e.g., vaccination, ear-tagging, etc.), especially when blood-sucking arthropods are present, can increase the risk of haemoplasmosis (reviewed in (Windsor, 2022)). *M. ovis* and other haemoplasmas have been detected for the first time in several countries over the last eight years.

Global situation

Many of the epidemiological studies conducted on small ruminant mycoplasmas over the past decade have focused on identifying the prevalence of *M. ovipneumoniae*, *M. agalactiae*, and/or *Mccp* on a small scale (e.g., within individual regions or districts), and a representative set of these are cited below to provide an overall summary of our knowledge of these pathogens' geographical distributions as of 2023.

The Americas

Knowledge of *M. ovipneumoniae* epidemiology among sheep in the USA remains limited. A recent study linked the presence of *M. ovipneumoniae* to a reduction of ~4.3% in annual lamb production on American sheep farms (Manlove et al., 2019). The haemoplasma *M. ovis* also appears to be widespread in the USA, with ~73% herd-level prevalence reported in a USDA survey of sheep farms across the country (Urie et al., 2019).

In Mexico, the first molecular detection of *M. ovis* in sheep blood was reported in 2019 following an outbreak of haemolytic anaemia in Veracruz state (Martínez-Hernández et al., 2019).

Further south, Franco *et al.* published the first detection of *Mmc* in the Brazilian state of São Paulo (Franco et al., 2019). Meanwhile, reports of *M. agalactiae* prevalence in goats of north-eastern Brazil have ranged from ~15-43% (dos Santos et al., 2018; Lopes et al., 2019; Matos et al., 2019), and the presence of *M. agalactiae* in ocular swabs was associated with severe conjunctivitis in Brazilian lambs (Santos et al., 2022). *M. ovis* was also identified in Brazilian sheep in 2019 (Souza et al., 2019) after it had previously been detected in domestic goats and free-ranging cervids in several areas of the country (André et al., 2020; Machado et al., 2017).

Europe

The presence of *Mccp* in Europe was first confirmed in a study of the Thrace region of Turkey (Ozdemir et al., 2005), and a more recent publication confirmed that the pathogen has since spread throughout this region and is now endemic (Ozdemir et al., 2018). *M. ovis* was also identified for the first time in Turkey in 2017, with 9% prevalence reported among healthy sheep and goats in the Adana Province (Aktas and Ozubek, 2017). Studies of small ruminant mycoplasmas over the past decade have generally been scattered across the continent, and representative papers are cited below in approximate order of east-to-west.

M. ovipneumoniae was reported as the most commonly isolated mycoplasma species from small ruminants in Bosnia and Herzegovina between 1995-2015 (Maksimović et al., 2016) and in pneumonic Swedish lambs in 2018 (Lindström et al., 2018). Meanwhile, Bottinelli *et al.* used a DNA microarray assay and PCR to estimate ~22% prevalence for *M. ovipneumoniae* among pneumonic dairy lambs in Italy, where its presence was significantly associated with detection of *Mannheimia haemolytica* (Bottinelli et al., 2017b). In France, a comprehensive study of antimicrobial resistance in circulating veterinary mycoplasmas identified stable clinical and epidemiological trends among small ruminant pathogens, with species in the *Mycoplasma mycoides* cluster showing generally lower levels of drug resistance compared to *M. bovis* (Jaÿ et al., 2021).

M. ovipneumoniae was also the most commonly isolated pathogen in sheep and goats with respiratory disease in England and Wales between 2005-2019 (Deeney et al., 2021).

Finally, Iceland is divided into ruminant quarantine zones to limit the spread of sheep and goat diseases; interestingly, however, 16S rRNA gene analysis of circulating *M. ovipneumoniae* strains indicated that the pathogen appears to be spreading across the country regardless of these zones (Einarsdottir et al., 2018).

Africa

The application of improved diagnostics over the last eight years has confirmed that *Mccp* continues to spread across the African continent, with outbreaks recently observed in Kenya, Ethiopia, Tanzania and other countries (reviewed in (Prats-van der Ham et al., 2015)). *M. ovipneumoniae* has also been detected circulating in sheep and goats in Egypt's Giza Governorate and Nile Delta region (Abdel Halium et al., 2019; Ibrahim et al., 2018; Mousa et al., 2021) and in the large New Valley Governorate (Elnaker et al., 2017). In 2020, Abd-Elrahman *et al.* reported the first detection of CCPP in Egypt following an outbreak in the north-western Matrouh Governorate that caused 30% and 8% case fatality in goats and sheep, respectively (Abd-Elrahman et al., 2020).

M. ovis was first identified in small ruminants in neighbouring Tunisia in 2015 (Rjeibi et al., 2015), and analysis of a 2013 outbreak of anaemia in small ruminants in Egypt's Red Sea Governorate indicated that *M. ovis* was the likely cause, with ~21% and 12.5% prevalence reported in lambs and kids, respectively (Mahran and Ghattas, 2016).

The seroprevalence of *Mccp* was found to range from ~29-64% within the Rift Valley region of Kenya (A. K. Kipronoh et al., 2016), where a separate study found that only ~40% of dairy goat herds were vaccinated against the pathogen (Maitho and Kinyua, 2015). Participatory epidemiology studies have also been conducted among the numerous agro-pastoralist communities of this country, generally emphasising the need to increase the availability of disease control resources (for CCPP, Peste des petits ruminants, and other economically significant diseases of small ruminants) and to improve educational and outreach programmes (Abdilatif et al., 2018; K. A. Kipronoh et al., 2016). CCPP is estimated to cause annual losses of ~1,710 euros (~1,900 USD) per 100-animal herd, and vaccinations with even 20% effectiveness were estimated to provide a favourable cost-benefit balance if they are put into widespread use (Renault et al., 2019).

In Tanzania, Chota *et al.* observed 6.5% and 4.2% *Mccp* seroprevalence among goats and sheep, respectively (Chota et al., 2019). *Mccp* has also been detected in co-infection with small ruminant morbillivirus in Tanzania, with uncertain impacts on the severity and pathogenesis of Peste des petits ruminants (Kgotlele et al., 2019).

Slightly higher prevalence of *Mccp* was reported in Uganda, where Atim *et al.* reported ~18% and 23% seroprevalence among unvaccinated goats in the northern Agago and Otuke districts, respectively (Atim et al., 2016), while Byamukama *et al.* published the first molecular detection of *M. ovis* in goats in Kasese District (Byamukama et al., 2020). CCPP is also widespread in Ethiopia, though there have been few large-scale epidemiology/surveillance studies to track its spread in this country (Asmare et al., 2016). The seroprevalence of *Mccp* in this country has been reported as ~5% among goats in the northern Amhara region (Molla et al., 2023), ~18% in the western Gambella Region (Fasil et al., 2015) and ~31% and 13% in goats and sheep, respectively, of the southern Borena Zone (Teshome et al., 2019).

Finally, a survey of abattoirs in Ilorin, Nigeria, reported a seroprevalence of ~33% for *Mccp* among small ruminants (Olorunshola et al., 2020), while Lysholm *et al.* conducted the first study of *Mccp* exposure levels in Zambian goats and reported ~8% animal-level seroprevalence (Lysholm et al., 2022).

Asia, the Middle East, and Oceania

M. ovipneumoniae is widespread in China, both alone and in co-infection with other economically important pathogens such as *E. coli* (PingYuan et al., 2017; Yun et al., 2022). A study of sheep in

southern Xinjiang, China, identified ~41% PCR-positivity for *M. ovipneumoniae* among these mainly asymptomatic animals, with prevalence especially high in younger (< 3 months old) animals (J. Zhao et al., 2021). This was up from ~18% PCR-positivity in a 2015 study (Cheng et al., 2015), indicating that *M. ovipneumoniae* prevalence may be growing in the Xinjiang region. Meanwhile, Zhang *et al.* reported the first detection of *Mmc* on Hainan Island and published its complete genome sequence (Z. Zhang et al., 2022b). Few studies of small ruminant haemoplasmas have been conducted in China, but one paper reported ~44% and 46% PCR-positivity in goats and sheep, respectively, across eight regions (X. Wang et al., 2017). Fifty-six out of 100 representative isolates were identified as *M. ovis*, while the others were classified as *C. M. haemovis*, marking the first time this haemoplasma has been identified in China (X. Wang et al., 2017).

CCPP causes particularly severe economic losses in India, where control of the disease via culling of disease animals may not be possible (reviewed in (Yatoo et al., 2019)). Parray *et al.* confirmed the presence of CCPP in Pashmina (Changthangi) goats in the trans-Himalayan region of India, with ~10% overall seroprevalence for *Mccp* (Parray et al., 2019) compared to ~40% in both sheep and goats of the south-western Karnataka state (Chandrashekar et al., 2020).

Knowledge of small ruminant mycoplasma epidemiology is also limited in Southeast Asia. The reported prevalence of the haemoplasma *M. ovis* is high in Malaysia, though infections are generally mild (Faez Firdaus et al., 2015; Paul et al., 2021), and the first molecular detection of goat haemoplasmas in the Philippines was published in 2019 (Galon et al., 2019).

M. agalactiae is the primary mycoplasma associated with contagious agalactia in many regions of Iran (Abadi et al., 2019; Hajizadeh et al., 2018; Rahimabadi et al., 2017; Shamsaddini Bafti et al., 2017), and Goudarzi *et al.* reported the first detection of sheep haemoplasmas in Iran in 2019 (Goudarzi et al., 2019). In neighbouring Pakistan, the reported seroprevalence of *Mccp* in goats has varied from ~8% to 28% among districts in Pakistan (M. K. Shah et al., 2017; Shahzad et al., 2016; Ur Rehman et al., 2022)

A handful of studies on small ruminant mycoplasmas have emerged from the Arabian Peninsula. In 2017, El-Deeb *et al.* published the first detection of *Mccp* in the Eastern and Riyadh Provinces of Saudi Arabia (El-Deeb et al., 2017), and the pathogen has subsequently been identified in other regions of the country (Saeed and Osman, 2018). In Oman, Hussain *et al.* observed a total herd-level seroprevalence of ~29% for *Mccp* among 510 sheep and goat herds (Hussain et al., 2021).

Surveillance, transmission and risk factors

In the USA, open farm management practices have been associated with a higher risk of *M. ovipneumoniae* detection within sheep farms (Manlove et al., 2019). Open management, along with herd size and proximity to coastal regions, was also reported as a risk factor for the occurrence of *Mccp* infections in sheep and goat herds in Oman (Hussain et al., 2021).

Bohach *et al.* studied factors associated with contagious agalactia outbreaks among small ruminants in Ukraine, reporting that seroprevalence was significantly associated with animal age (being highest in 1-month-old animals), seasonality (with disease peaks recorded in March-April and June-July), and higher yearly humidity levels (Bohach et al., 2021, 2022). In endemic areas of Sicily, meanwhile, Galluzzo *et al.* were able to isolate *M. agalactiae* from ~9% of hard ticks (primarily *Rhipicephalus bursa*) (Galluzzo et al., 2021); more research will be needed to determine any potential role of these arthropods as vectors for this pathogen. *M. agalactiae* DNA has also been detected in the semen of infected Iranian goat bucks, indicating a potential route of transmission within breeding goat herds (Pourbakhsh et al., 2017).

Selim *et al.* used classification and regression tree analysis to identify risk factors associated with CCPP in Egypt, estimating that the most relevant factors were (in ascending order of importance) communal feeding and watering, animal age >4 years, and herd size >100 animals (Selim et al., 2021). In Ethiopia, Molla *et al.* recently applied multistage cluster sampling to CCPP in the Amhara region, identifying animal-level (e.g., age and Central or Western Highland breed) and herd-level (e.g., the presence of a trade route and mixing with sheep) risk factors for its prevalence (Molla et al., 2023).

Finally, a 2013 outbreak of CCPP among Arabian sand gazelles (*Gazella marica*) in the UAE caused pneumonia and pleurisy in these animals, prompting Lignereux *et al.* to investigate the epidemiology of this event. They developed a computational model of transmission with parameters based on expert opinion and observed mortality data, estimating that the outbreak had an R_0 of 2.3-2.7 and likely originated via transmission of infectious droplets over a distance of at least 50 metres (Lignereux et al., 2018).

Wildlife

M. ovipneumoniae is a major cause of pneumonia among bighorn sheep in the western USA (Besser et al., 2012), and the past decade has seen many studies published on the epidemiology and control of these infections. Population-level prevalence in a study of Montana and Wyoming was estimated at 77% (Butler et al., 2018) and infectious pneumonia outbreaks in bighorn sheep and their subspecies can cause 10-90% mortality (Butler et al., 2018; Shirkey et al., 2021). Many factors contribute to the high variability of bighorn mortality, including host breed, herd population structure, and *M. ovipneumoniae* strain virulence (B. M. Johnson et al., 2022; Spaan et al., 2021). It has been reported that *M. ovipneumoniae* is primarily introduced to these wild populations via spill-over from domestic sheep (Heinse et al., 2016), but the nature of *M. ovipneumoniae* transmission to bighorn sheep remains an area of contention. Transmission of *M. ovipneumoniae* from domestic goats to co-mingled bighorn sheep has also been confirmed under experimental settings, though the resulting pneumonia was substantially milder than that caused by domestic sheep strains of the pathogen (Besser et al., 2017). *M. ovipneumoniae* also infects mountain goats (*Oreamnos americanus*) in the western USA, where its presence alongside other bacterial species (e.g., *Pasteurellaceae*) has been associated with population-limiting effects via mortality in goat kids (Lowrey et al., 2018; Wolff et al., 2019).

Genetic diversity among circulating *M. ovipneumoniae* strains is much higher in domestic than in bighorn sheep, indicating a limited number of spill-over events from domestic to wild animals and subsequent persistence within those wild populations (Kamath et al., 2019). This long-lasting persistence involves the transmission of *M. ovipneumoniae* from carrier females to their naïve lambs, with substantial negative effects on population recovery, and disease control efforts have so far seen limited success in reducing these impacts (reviewed in (Cassirer et al., 2018)). Transmission from chronic carrier ewes appears to play a major role in *M. ovipneumoniae* epidemiology (Manlove et al., 2017; Plowright et al., 2017) and removal of carrier ewes from bighorn sheep populations has been reported to effectively eliminate pneumonia from them, reducing lamb and adult mortality by 72% and 41%, respectively, in a South Dakota herd (Garwood et al., 2020).

Strategies for mitigating and reducing *M. ovipneumoniae* outbreaks among bighorn sheep go hand-in-hand with ongoing efforts to restore bighorn populations in North America, which have recovered since their near-extirmination in the early 20th century but are still far below historical levels (Paterson et al., 2021). One particular effort to reintroduce bighorn sheep to the Black Hills region illustrates the challenges of controlling *M. ovipneumoniae* in these animals: all translocated bighorns were

vaccinated prior to release against an *M. ovipneumoniae* strain known to be circulating in nearby bighorns, but a different strain of *M. ovipneumoniae* caused an outbreak the following year, leading to ~58% mortality and limiting the success of this reintroduction (Werdel et al., 2020). These findings are in agreement with earlier indications that bighorn sheep exhibit strain-specific immunity to *M. ovipneumoniae*, which may facilitate continuing spill-overs and complicate vaccine development efforts (Cassirer et al., 2017). A recent study by Almberg & Manlove *et al.* modelled several factors to predict the most effective actions to aid bighorn populations following an *M. ovipneumoniae* outbreak – they estimated that test-and-remove, depopulation-and-reintroduction, and range expansion were the most promising interventions, while herd augmentation was more likely to lead to worse outcomes (Almberg et al., 2022).

While most efforts to restrict contact between domestic and bighorn sheep focus on large commercial premises, Heinse *et al.* focused on the potential impacts of smaller private sheep and goat farms, reporting 37.5% herd-level prevalence of *M. ovipneumoniae* among a representative sample from Washington state (Heinse et al., 2016). Over a third of surveyed private farmers did not understand the risks of interactions between their animals and wild bighorn sheep, and nearly 80% of farms reported that domestic animals had at some point escaped their enclosures (Heinse et al., 2016).

The majority of detected *M. ovipneumoniae* wildlife infections have occurred in the Bovidae subfamily Caprinae, including bighorn sheep, mountain goats, the Norwegian MuskoX (*Ovibos moschatus*) (Handeland et al., 2014), and the Iberian ibex (*Capra pyrenaica*) (Gómez-Guillamón et al., 2020). However, the pathogen has also been detected in non-Caprinae species including Beira antelope (*Dorcatragus megalotis*) in Qatar (Gull et al., 2014) and moose (*Alces alces*), caribou (*Rangifer tarandus*), and mule deer (*Odocoileus hemionus*) in the USA (Highland et al., 2018). Rovani *et al.* recently identified *M. ovipneumoniae*-associated polymicrobial pneumonia in a deceased barren ground caribou (*R. tarandus granti*) in Alaska (Rovani et al., 2019), though the larger-scale incidence and epidemiology of *M. ovipneumoniae* in this species have not yet been clarified.

Control of the disease

The main control measures for CCPP are slaughter, control of animal movement, antibiotic treatments, and vaccination, which are usually employed in combination. As CCPP is primarily spread via live animals shedding mycoplasma-contaminated droplets, infected animals in developed

countries are usually culled to prevent the spread of disease, because although antibiotic treatment cures infected animals clinically, the animals may remain carriers (EFSA Panel on AHAW et al., 2017; Yattoo et al., 2019). In the EU, because vaccines are neither readily available nor authorised, and there are concerns about antibiotic treatments for CCPP leading to resistant *Mccp* strains, eradication via slaughter is recommended at the herd level for faster and greater efficiency (EFSA Panel on AHAW et al., 2017). This is not usually an acceptable approach in under-developed and developing countries such as India (Yattoo et al., 2019).

Policy

An expert panel assessed CCPP according to the criteria of the EU's Animal Health Law and found it eligible to be listed for EU intervention (EFSA Panel on AHAW et al., 2017). The panel noted that prohibiting the import of goats from infected zones or countries would be the only way to prevent the introduction of *Mccp*, and that restriction of goat movements in the event of CCPP outbreaks would only be possible if CCPP is included in the list of notifiable diseases in all Member States (EFSA Panel on AHAW et al., 2017). The panel further noted that as mortality may be extremely high in wild species, CCPP could pose a risk for endangered species such as markhors (*Capra falconeri*) in Tajikistan. Subsequently, control measures regarding clinical and laboratory sampling procedures, monitoring periods, protection and surveillance zones and duration of implementation of measures were reviewed, and new procedures were developed to support the European Commission in the drafting of legislation relating to the control of CCPP (EFSA Panel on AHAW et al., 2022b).

Control

Vaccination against CCPP is one of the measures that can be implemented to control the disease; however, current vaccines are expensive, variable in quality, and in limited supply, with countries like Ethiopia and Kenya unable to meet their own internal needs (about 2 million doses produced annually) (EFSA Panel on AHAW et al., 2017). In Kenya, where small ruminants and poultry are favoured by female livestock owners over large animals such as water buffalo and cows, low CCPP vaccination rates (~10%) were recorded in the study area of Machakos County (Kaluwa et al., 2022). The authors reported that the reasons for this related to a lack of veterinarian visits and minimal knowledge on livestock diseases combined with a lack of access to cold chain for vaccine storage. Despite the low vaccination rates, the mean number of animals lost to CCPP was low, at approximately 0.6 animals per household, but the impacts on productivity performance were not estimated (Kaluwa et al., 2022). As

in Kenya, the decision to vaccinate animals in Tanzania was mostly influenced by knowledge of disease, with households reporting similar challenges to vaccine use (Williams et al., 2022). In contrast, the CCPP vaccination rate in Tanzania was reported at 62.2% with, only 8.1% reporting that although they considered it a high priority, they did not have access to it (Williams et al., 2022). Although the study by Kaluwa *et al.* focused only on women, the majority (>98%) of respondents in Tanzania did not consider gender to be a barrier to vaccine access (Williams et al., 2022).

A potential source of infection with mycoplasma is venereal transmission via semen. To investigate the likelihood of this means of transmission, the viability of *Mmc* and *M. agalactiae* were assessed at 37°C in diluted semen and ejaculates, leading the authors to recommend screening and use of mycoplasma-free semen for artificial insemination (Gómez-Martín et al., 2015). The presence of *M. agalactiae* was detected by microbiological and molecular techniques in the semen of asymptomatic rams in three different artificial insemination centres in an area of endemic contagious agalactia (Prats-van der Ham et al., 2016). This led the authors to investigate the excretion dynamics of *M. agalactiae* in serial ejaculates from the same rams. *M. agalactiae* was detected in samples from just over a quarter of the rams (26.35%), with most positives (91%) detected by PCR only and only 5% detected by microbiological analysis (Prats-van der Ham et al., 2016). Additionally, of the samples that tested positive for *Mycoplasma* species by culture, 5.47% were subsequently identified by PCR as *Mycoplasma arginini*. The detection of asymptomatic rams infected with *M. agalactiae* highlights the need to implement effective surveillance protocols in artificial insemination centres and motivated the need to determine the most effective way to identify these individuals (Prats-van der Ham et al., 2017a). Microbiological and PCR analysis of auricular swabs, nasal swabs, a serum and a semen sample from each ram were undertaken (Prats-van der Ham et al., 2017a). Based on the specimens which proportionally yielded the greatest number of positive results for *M. agalactiae*, the authors concluded that the most effective way to detect *M. agalactiae*-infected animals is to combine semen and nasal swab samples.

Therapeutics

Antibiotic administration is usually sufficient to cure the symptoms of CCPP if they appear rapidly after infection; however, as goats often do not show overt signs of disease until lung lesions are quite extensive, it is usually advisable to treat the entire flock when CCPP is identified (EFSA Panel on AHAW et al., 2017). *Mccp*, *M. agalactiae* and *M. ovipneumoniae* are susceptible to the same classes of antibiotics used to treat other infections with *Mycoplasma* species, e.g., macrolides, lincosamides,

fluoroquinones, and tetracyclines. However, reduced susceptibility to some has been reported due to the extensive use of antibiotics (Antunes et al., 2015; Prats-van der Ham et al., 2018, 2017b; Rahman et al., 2021; S. S. A. Shah et al., 2017; Tatay-Dualde et al., 2017a).

Sheep in Calabria, Italy, treated for respiratory disease with a single dose of 2.5 mg/kg tulathromycin were asymptomatic after 5-7 days, with symptomology decreasing after 2 days (Naccari et al., 2015). Bacteriological testing prior to treatment indicated the presence of *Mannheimia haemolytica*, *P. multocida*, *M. ovipneumoniae* and *Pseudomonas* species, all of which were highly susceptible to tulathromycin *in vitro*, but not to the other antimicrobials tested (Naccari et al., 2015). Tulathromycin was found to be effective against *Pasteurella* species but not the *Mycoplasma* species co-infecting sheep and goats with infectious pneumonia in Iran (Jafari et al., 2015). Pneumonic goat kids in an unvaccinated flock in Turkey that had previously been treated unsuccessfully with oxytetracycline by the owner were subsequently treated with a single dose of gamithromycin or marbofloxacin (Kacar et al., 2018). *M. haemolytica* and *Mycoplasma* species were identified microbiologically from transtracheal fluid aspirates from six of the kids and washes from the lungs of a necropsied kid, but antimicrobial susceptibility testing was not reported (Kacar et al., 2018). The authors reported that after three weeks, most of the kids treated with gamithromycin or marbofloxacin had fully recovered, but a few in each group still showed symptoms of pneumonia (Kacar et al., 2018). Almost two-thirds (62.5%) of mycoplasma PCR-positive goats treated for 5 days with oxytetracycline for respiratory disease showed a complete recovery (Sumith et al., 2021).

Effective antibiotic treatment relies on the sensitivity of the pathogen to the drug, as well as the correct dosing application. Pharmacokinetic and pharmacodynamic analyses of marbofloxacin were undertaken in lactating goats (Fernández-Varón et al., 2021). Based on the MIC of *M. agalactiae* field strains and the pharmacokinetic and pharmacodynamic analysis by Monte Carlo simulation, a dosage regimen from 8.47 to 11.57 mg/kg every 24 hours was reported as appropriate for a positive therapeutic outcome, although lower doses (1.5 to 4.5 mg/kg) could be more effective with AUC/MIC ratios from 25 to 50 (Fernández-Varón et al., 2021).

The extensive use of antimicrobials for veterinary disease control has caused a decrease in antimicrobial susceptibility in different animal *Mycoplasma* species including *Mccp* (Antunes et al., 2015; Prats-van der Ham et al., 2018; Rahman et al., 2021; S. S. A. Shah et al., 2017), *M. agalactiae* (Prats-van der Ham et al., 2017b; Tatay-Dualde et al., 2017b), and *M. ovipneumoniae* (Zinka Maksimović et al., 2020). Given the economic importance of CCPP in Pakistan, the *in vitro* susceptibility

of field isolates of *Mccp* has been investigated. Although tylosin, oxytetracycline and ceftiofur sodium antibiotics are routinely prescribed by clinicians in cases of CCPP, Shah *et al.* found that all isolates from the Khyber Pakhtunkhwa province of Pakistan were resistant. These authors reported that enrofloxacin was the most effective *in vitro*, followed by gentamycin (S. S. A. Shah *et al.*, 2017). A later study in the same region found that ciprofloxacin had the best *in vitro* anti-mycoplasma activities among the antibiotics they tested (Rahman *et al.*, 2021). The most effective antibiotics against *Mccp* isolates from goats in India according to *in vitro* susceptibility testing, however, were erythromycin and tylosin followed by tetracycline and doxycycline (Kalmegh *et al.*, 2020).

Investigation of the molecular mechanisms underlying antimicrobial resistance has revealed similar mutational 'hot spots' in the *Mmc* genome (e.g., in genes encoding DNA gyrase and topoisomerase IV) to those described for resistance to fluoroquinolones in *Mycoplasma* species and other bacterial species (Antunes *et al.*, 2015). Selection experiments in *Mmc* revealed that high levels of resistance to fluoroquinolones could be attained within a small number of generations (Antunes *et al.*, 2015). A separate study of resistance mechanisms in *M. capricolum* subspecies *capricolum* showed that point mutations in the 23S rRNA encoding genes (A2058G, A2059G and A2062C) and the *rpIV* gene (A89D) were associated with increased MIC values for macrolides and lincosamides (Prats-van der Ham *et al.*, 2018). Applying *in vitro* selection for resistant mutants and studies of field isolates of this bacterium from goats showed that amino acid changes in *gyrA*, *gyrB* and *parC* were associated with higher MIC values for quinolones (Tatay-Dualde *et al.*, 2017a). Interestingly, an investigation of fluoroquinolone resistance genes in Spanish isolates of *Mmc* revealed the presence of an amino acid substitution in codon 83 of the gene *gyrA*, which had not previously been described (Paterna *et al.*, 2016).

A study of antimicrobial resistance and genetic variability in *M. capricolum* subspecies *capricolum* field isolates from Italy and Spain found that doxycycline and the fluoroquinolones enrofloxacin, marbofloxacin, danofloxacin and moxifloxacin were the most effective antimicrobials inhibiting their growth, and that aminoglycosides had high MIC for all isolates (Tatay-Dualde *et al.*, 2017c). Phylogenetic analysis revealed higher genetic diversity than seen in other *Mycoplasma* species, and a common branch for most of the Italian isolates, which were clearly distinct from the Spanish isolates (Tatay-Dualde *et al.*, 2017c). In a similar study, French strains of *M. ovipneumoniae* from goats and sheep were investigated to find the cause for an increase in reported cases (Jaÿ *et al.*, 2020). A high level of genetic diversity was found in the strains, with no evidence of clonal evolution that could thus account for increased incidence of cases. Apart from florfenicol, MIC for antimicrobials were low, although a few isolates showed increased values for tetracyclines, macrolides and lincosamides.

Previously identified mutations in the target ribosomal gene were associated with the increased tetracycline MIC (Jaÿ et al., 2020). The authors noted animal-host clustering in the *Hsp70* gene and whole genome sequence phylogeny, indicating different selective pressures between goats and sheep (Jaÿ et al., 2020). Linked to this, MIC values for all fluoroquinolones and oxytetracycline were significantly lower for *M. ovipneumoniae* isolates from sheep than from goats (Zinka Maksimović et al., 2020).

Associations between MIC values of different antimicrobials and mutations in the 23S rRNA gene and ribosomal proteins L4 and L22 were investigated in field isolates and *in vitro*-selected resistant mutants of *M. agalactiae* (Prats-van der Ham et al., 2017b). The initial increase in the MIC of *M. agalactiae* to tylosin was associated with predicted amino acid changes in L22 (S89L and Q90K/H), whereas mutations at positions 2058 or 2059 of domain V of the 23S rRNA gene appeared at higher MIC values (Prats-van der Ham et al., 2017b). Mutations in the *gyrA*, *gyrB*, *parC* and *parE* genes in the quinolone resistance-determining region (QRDR) of selected *M. agalactiae* field isolates were investigated by *in vitro* selection with enrofloxacin, marbofloxacin and moxifloxacin (Tatay-Dualde et al., 2017b). Variations in fluoroquinolone susceptibility were associated with mutations in *gyrB*, *parC* and *parE*. Mutations at predicted positions 424 of *gyrB* and 429 of *parE* had not previously been described (Tatay-Dualde et al., 2017b). Mutations in *parC* were most frequently detected and, overall, *parC* was the first gene showing alterations when changes in susceptibility to fluoroquinolones occurred. Contrary to other mycoplasmas, acquisition of fluoroquinolone resistance in *M. agalactiae* was related to *gyrB*, *parC* and *parE* (Tatay-Dualde et al., 2017b).

Treatment options that do not rely on antibiotics are necessary given the rapid rate of the mutations that reduce antimicrobial sensitivity in these mycoplasmas. Most farmers in Kenya do not treat their animals with antibiotics but rely on medicinal plants to treat ruminant respiratory diseases (Kama-Kama et al., 2016). Testing the antimycoplasmal activity of organic and aqueous extractions from parts of the 20 ethno-medicinal plants described by the farmers showed that extracts from only five plants – namely *Solanum aculeastrum*, *Albizia coriaria*, *Ekebergia capensis*, *Piliostigma thonningii* and *Euclea divinorum* – were able to inhibit the growth of all the *Mycoplasma* species tested (Kama-Kama et al., 2016). In a subsequent study, only compounds from the berries of *Solanum aculeastrum*, a steroidal alkaloid triglycoside and a long chain fatty alcohol, were found to have moderate inhibitory effects against *Mmc* (Kama-Kama et al., 2017). The activities of these compounds were lower compared to those of the crude extracts (Kama-Kama et al., 2016), possibly due to the loss of synergistic effects of other compounds in these plants or the loss of minor compounds during the extraction process. It was

proposed that structural modification of these compounds may be used to increase their antimycoplasmal activities (Kama-Kama et al., 2017).

It had been found that Argali hybrid sheep are more susceptible to *M. ovipneumoniae* than parent Argali and Bashibai sheep (J. Li et al., 2020). A critical peptide in host innate immune resistance against *M. ovipneumoniae* infection, named short palate, lung, and nasal epithelium clone 1 (SPLUNC1), plays an important anti-inflammatory and bactericidal role in the respiratory tract, and recombinant sheep SPLUNC1 significantly inhibited *M. ovipneumoniae* growth *in vitro* in a dose-dependent manner (J. Li et al., 2020). A small-scale study of the *in vivo* activity of SPLUNC1 to treat *M. ovipneumoniae*-infected Argali hybrid sheep resulted in clinical symptom alleviation and no mortality (J. Li et al., 2020). The differences observed in serum IL-5, IL-6, and IL-9 concentrations and *M. ovipneumoniae* histopathology scores between treated and untreated sheep support the immunoregulatory and therapeutic effects of recombinant SPLUNC1 in treating *M. ovipneumoniae*, providing support for development as a new drug (J. Li et al., 2020).

Vaccines

Current vaccines

Agavac is a commercially available vaccine comprising formalin-/heat-inactivated *M. agalactiae* AG6, formulated with aluminium hydroxide adjuvant, which has been produced by the Pasteur Institute for several decades. Two studies have updated/extended our knowledge of this product: in sheep immunised twice two weeks apart, the antibody response to *M. agalactiae* was detectable from seven days after the first vaccine, and peaked at 21 days after the booster dose, by which point all animals had seroconverted (Botuş et al., 2017); while another report by the same group working at the Pasteur Institute in Romania, found that guinea pigs might be an appropriate model for efficacy studies of this vaccine (Popa et al., 2019). However, previous studies reported concerns on the efficacy of such formalin-inactivated bacterin vaccines against *M. agalactiae*. For example, Agnone *et al.* compared the elicited immune response and disease protection following immunisation of ewes with one of four commercially available or experimental vaccines; they found that a single administration of a novel passage-attenuated live vaccine, or two immunisations with an experimental saponin-inactivated bacterin, conferred markedly improved protection from disease and significantly better limitation of bacterial shedding in milk, compared to the commercial vaccine (Agnone et al., 2013).

Loria *et al.* also provided initial evidence that inactivated vaccines against *M. agalactiae* could reduce disease severity and expedite return to productivity amongst naturally infected ewes: two immunisations with a locally produced formalin-inactivated vaccine led to rapid pathogen clearance and reduced clinical signs under field conditions (Loria *et al.*, 2018a). Further studies are warranted to understand the optimal application of this strategy in outbreak situations.

Novel vaccines

Inactivated vaccines

The production of current inactivated *Mccp* vaccines is slow and costly because of the fastidious culture requirements of the bacterium, which makes it hard to meet demand in some parts of Africa where goat rearing is common. Therefore, novel antigen-sparing strategies are of value: Takele *et al.* reported improved immunogenicity at a lower antigen dose when immunising goats with a whole-culture inactivated vaccine against *Mccp* compared to purified inactivated antigen-based vaccine (Abdollahi *et al.*, 2022).

Another factor affecting the efficacy of vaccines is the method used for inactivation. El-Yazid *et al.* compared vaccines generated from a previously characterised highly pathogenic field strain of *M. agalactiae* that had been inactivated by saponin, formalin, phenol, or sodium hypochlorite; they found that the saponin- and phenol-inactivated vaccines induced the highest antibody titres in both mice and goats, identifying these candidates as most promising for further trials of protective efficacy (El-Yazid *et al.*, 2019). Einarsdottir *et al.* also used formalin-inactivated *M. ovipneumoniae* field isolates as the basis of a set of bacterin vaccines, and found little induction of either specific antibody or cellular immune responses in lambs, even after four immunisations spread across ten months; the authors speculated that this was likely due to prior exposure of the animals in both control and vaccinated groups in the mycoplasma-endemic region of the study (Einarsdottir *et al.*, 2018).

Live-attenuated vaccines

Synthetic biology has been applied to the generation of a candidate live vaccine against *Mccp*. In 2022, Talenton *et al.* published their use of the CRISPR-Cas9 system for efficient genome engineering in the fast-growing strain *Mycoplasma feriruminatoris*, creating an attenuated chassis strain expressing two inactivated surface proteins of *Mccp* (Talenton *et al.*, 2022). This study provides a foundation for future *in vivo* testing and further genomic engineering for the production of live-attenuated vaccine strains, though the authors stress that selection of appropriate heterologous surface antigens will likely be the primary challenge in the use of this system (Talenton *et al.*, 2022).

Subunit vaccines

A single report evidenced the immunogenicity of *M. ovipneumoniae* Hsp70 and elongation factor Tu following three immunisations with the recombinant proteins formulated with complete/incomplete Freund's adjuvant into specific-pathogen-free mice (Fei et al., 2016). Whether this strategy would prove useful in natural target species under field conditions remains to be established.

Vectored vaccines

There have not been any notable advances published in this area since 2015.

Adjuvants

There have not been any notable advances published in this area since 2015.

Conclusions

The various diseases caused by mycoplasmas infecting small ruminants are a truly global problem, with significant financial impact for both large- and small- scale farmers, as well as posing a threat to some species of wildlife. In the past eight years, researchers have reported important advances in our knowledge of the genome sequences of known and new strains of mycoplasmas affecting small ruminants, as well as a new *Mycoplasma* species: such data can now be used to begin to identify novel virulence factors of these diverse pathogens. As tools continue to emerge for genetic manipulation of mycoplasmas and ever-better *ex vivo* tissue culture systems are designed and tested, we can be optimistic that the next eight years of research will see developments towards live-attenuated vaccine strains, underpinned by a more thorough understanding of pathogenicity and immunology at the cellular and molecular levels.

Future research priorities

Based on the available literature, expert opinion, and previously published reviews (DISCONTTOOLS, 2021; Jores et al., 2020), we suggest that the following areas of research into mycoplasmas affecting small ruminants should be considered high priority:

Biology of the pathogens

- *Continued sequencing and functional annotation of complete genomes*
- *Comparison of published genome sequences to identify sites of interest*
- *Standardisation of molecular typing strategies to produce larger-scale international phylogenetic trees and support evolutionary and epidemiological studies*
- *Deeper integration with surveillance to ensure that new small ruminant mycoplasma strains are identified and sequenced as quickly as possible*
- *Characterisation of small ruminant mycoplasma gene products in vitro and in vivo*
- *Development of new methods for reliable cultivation and characterisation of M. ovipneumoniae*

Diagnosis

- *Standardisation of diagnostic assays between laboratories and internationally (e.g., defined protocols, reagents, diagnostic cut-offs, etc.)*
- *Development of rapid, easy-to-use assays capable of pen-side use in rural and/or remote regions*

Pathogenesis

- *Standardisation of the definition of contagious agalactia (i.e., maintaining the current definition vs. redefining the disease caused by Mmc, M. capricolum subspecies capricolum and M. putrefaciens)*
- *Research into the factors associated with reactivation of Mycoplasma and the viral/host mechanisms underlying the development of lesions in mammary gland and lung tissue.*
- *Continuing in vitro identification and in vivo validation of virulence and host tropism determinants within small ruminant mycoplasma proteomes*
- *Characterisation of surface-exposed virulence factors*
- *Development and validation of animal models for studying small ruminant mycoplasma infections in vivo*
- *Characterisation of the specific role of M. ovipneumoniae in pneumonic disease*
- *Characterisation of potential atypical presentations of M. agalactiae (e.g., central nervous system pathology)*

Immunology

- *Increased integration with molecular biology studies to promote immunogenetics*

- *Characterisation of the ability of M. agalactiae to hijack components of innate immunity (e.g., NETs) to promote immune escape*
- *Investigation of the mechanisms of lung immunopathology in Mccp-infected goats and its impacts on the progression and outcomes of CCPP*
- *Characterisation of host- and breed-specific immunological determinants of M. ovipneumoniae-associated pneumonia severity (e.g., in domestic vs. bighorn sheep, in different breeds of domestic sheep, etc.)*
- *Continuing proteomic studies to identify and characterise immune-related virulence factors, particularly in M. ovipneumoniae, M. agalactiae, and Mccp*
- *Definition of immune correlates of protection during infection of naïve and vaccinated animals*

Epidemiology

- *Quantification of small ruminant productivity losses associated with mycoplasma infections*
- *Research into transmission mechanisms, including the roles of aerosol transmission, insect vectors, etc.*
- *Continuing expansion of surveillance capabilities in low- and middle-income countries*
- *Standardised prevalence studies for small ruminant mycoplasmas, and particularly haemoplasmas, in the Americas and Europe*
- *Improved education and outreach programmes for smallholder farmers in endemic regions*
- *Integration of surveillance, molecular typing studies, and computational modelling to estimate risk factors for small ruminant mycoplasma infections*
- *Continued characterisation of circulating strains in wild populations (particularly M. ovipneumoniae in bighorn sheep)*
- *Identification of domestic animal-wildlife interfaces and animal movement networks in these regions*

Control

- *Development of cheaper and more efficient vaccines, that can be produced in greater quantities*
- *Development of a marker vaccine alongside a complementary diagnostic for DIVA testing*
- *Given the apparent genetic diversity and rapid rate of change in antimicrobial susceptibility, testing of alternative drugs and development of new therapeutics (e.g., by screening novel chemicals and plant extracts against pathogenic mycoplasmas) is necessary*

- *Generation of Mccp targeted deletion mutants and confirmation of their attenuation ex vivo and in vivo, alongside immunological studies*
- *Application of systems biology to improve the adjuvant used for the current (bacterin) CCPV vaccine*

Mycoplasmas affecting swine

Introduction

The four primary mycoplasmas that will be discussed in this section – *Mycoplasma flocculare* (*Mfl*), *M. hyopneumoniae* (*Mhp*), *M. hyorhinis* (*Mhr*), and *M. hyosynoviae* (*Mhs*) – are commonly found in the respiratory tracts of both healthy and diseased pigs (Ferrarini et al., 2016). *Mfl* is a commensal bacterium that is closely related to the pathogenic *Mhp* (Paes et al., 2017a; Sonalio et al., 2022), while *Mhr* and *Mhs* have been referred to as commensal and pathogenic in the literature (Ferrarini et al., 2016; Klose et al., 2022a; Roos et al., 2019; Wegner et al., 2020).

Mhp, the primary pathogen of swine enzootic pneumonia, is by far the most clinically significant of these four mycoplasmas. It is widespread across the globe and is one of the most common and economically important bacterial pathogens of the swine respiratory tract (Brewster et al., 2017; Pieters and Maes, 2019; Taylor, 2013). Enzootic pneumonia is associated with a dry, chronic cough and macroscopic cranioventral pulmonary consolidation lesions and, although rarely fatal, has been linked with lower average daily weight gain and feed conversion ratio (reviewed in (Bargen, 2004; Maes et al., 2008)). Additionally, while the economic burden imposed by uncomplicated *Mhp* infections is thought to be relatively small, such infections are rare (Hoist et al., 2015); more often, *Mhp* is found in co-infection with other swine respiratory pathogens such as porcine reproductive and respiratory syndrome virus (PRRSV), swine influenza A virus (sIAV), *Pasteurella multocida*, and *Actinobacillus pleuropneumoniae*, which can increase the severity of these infections and lead to higher mortality rates ((Fablet et al., 2016; Paiva et al., 2023; Tonni et al., 2022); reviewed in (Oba et al., 2020)). Co-infections between *Mhp* and PRRSV, for instance, were estimated to cost 9.69 USD (12.74 USD adjusted for inflation in 2023) per head in a study of a large-scale pig production system in the USA, and *Mhp*-sIAV co-infections were even costlier (Haden et al., 2012). Accordingly, the majority of this section is dedicated to a representative selection of the substantial number of research studies published on *Mhp* over the past decade.

Meanwhile, *Mhr* and *Mhs* are generally considered commensal microbes, but both have been associated with swine polyarthritis, and *Mhr* has recently been reported to contribute to mortality in nursery pigs (Clavijo et al., 2019b, 2017; Roos et al., 2019). *Mfl* has not been individually linked to any pathogenic activity, but it is present in pneumonia-like lesions and has been reported to potentially aggravate these lesions during *Mhp* infection (Ferreira et al., 2021; Fourour et al., 2019c).

Recent research on the swine haemoplasmas (haemotropic mycoplasmas) will also be addressed in this section. These uncultivable organisms comprise the pathogenic *M. suis*, the non-pathogenic *M. parvum*, and the recently discovered *Candidatus Mycoplasma haemosuis* (*C. M. haemosuis*). *M. suis* is the causative agent of infectious anaemia in pigs and can cause high mortality in piglets and feeder pigs in severe cases (Stadler et al., 2021). However, despite its high prevalence in many countries, the biological properties, epidemiology and economic impacts of *M. suis* remain poorly understood.

The studies cited below from 2015-23 have begun to close some important knowledge gaps, but much remains to be done before the threat posed by swine mycoplasmas has been fully neutralised.

Literature review

Biology of the pathogens

The fundamental biology of swine mycoplasmas is very similar to that of the other mycoplasmas discussed in this report: tiny obligate parasitic bacteria that lack a cell wall, are naturally resistant to many antibiotics, and are generally difficult to grow in culture. Molecular biology studies of these organisms published over the past decade have primarily fallen into three general categories: molecular typing, complete genome sequences, and genomic/proteomic studies.

Molecular typing and genome sequencing

The ability to differentiate co-circulating mycoplasma strains is critical for effective surveillance of the porcine respiratory microbiome. To address these needs, many MLST protocols have been published for swine mycoplasmas over the past decade. Tocqueville *et al.* developed two methods for *Mhr* differentiation – a highly sensitive TaqMan qPCR assay targeting the p37 gene and an MLST strategy based on six housekeeping gene fragments – and compared them on a representative set of 33 *Mhr* strains, reporting superior discriminative power by the MLST (Tocqueville et al., 2014). These authors also set up a database for this method as part of [PubMLST](#). A later study used an optimised version of this method (with new primers allowing single-protocol amplification and sequencing) to assess *Mhr* diversity on Swiss and German pig farms, finding that *Mhr* had similar population structure to *Mhp*, with high variability and low clonality (Balestrin et al., 2019; Trüeb et al., 2016). More recently, Büniger *et al.* developed a core genome MLST (cgMLST) workflow for *Mhr* based on 453 target genes and

reported superior typing performance compared to traditional MLST and core genome SNP analysis (Bünger et al., 2021).

An MLVA protocol based on two hypothetical proteins of *Mhr* (MHR_0152 and _0298) was published in 2015 and was used to identify 16 MLVA types within 165 samples in the USA (Dos Santos et al., 2015a). This group next developed an *Mhr* MLST method that included both housekeeping and surface protein-encoding genes, as surface proteins generally face greater selection pressure and can thus be more useful for comparing closely related strains (Clavijo et al., 2019b). Later, Földi *et al.* combined MLVA and MLST for sequence typing of 40 *Mhr* strains from Central Europe, reporting that MLST produced a more robust phylogenetic tree while MLVA allowed differentiation of closely related isolates (Földi et al., 2020).

Following an early report that *Mhp* strains could be sufficiently discriminated by MLST based on just three highly variable targets (the *adk*, *rpoB* and *tpiA* genes) (Mayor et al., 2008), this strategy was applied to study strains circulating within several countries including China (H. Zhang et al., 2021) and Thailand (Tadee et al., 2018). MLVA has also been widely used to discriminate between closely related *Mhp* isolates (e.g., within single farms or individual pigs) (Dos Santos et al., 2015b; Pantoja et al., 2016; Rebaque et al., 2018; Sosa et al., 2019; Tonni et al., 2021) and between circulating field and vaccine strains (Tamiozzo et al., 2015), and efforts have been made to standardise the terminology and classification used for *Mhp* strains based on MLVA (reviewed in (Betlach et al., 2019)). Finally, Felde *et al.* compared four methods of *Mhp* typing (three-gene and seven-gene MLST systems, MLVA, and *p146* gene analysis), reporting that a combination of the minimal MLST, MLVA, and *p146* analysis was most effective sequentially for increasingly smaller-scale, higher-resolution discrimination (Felde et al., 2018b). These same three genes (*adk*, *rpoB* and *tpiA*) were targeted to develop an MLST scheme for *Mfl*, with the authors reporting high discriminatory power; this workflow was also made available on [PubMLST](#) (Fourour et al., 2019a).

Finally, the past eight years have seen the publication of a few new complete genomes for swine mycoplasmas, including *Mfl* strain Ms42^T (Calcutt et al., 2015), *Mhp* strain KM014 (Han et al., 2017), and *Mhr* strains SK76 (Goodison et al., 2013) and DSM 25591 (Käbisch et al., 2021). The first draft genome sequences of seven *Mhs* strains were published in 2014, alongside genomic analysis of putative virulence factors, CRISPR/Cas sites, and other regions of interest within the *Mhs* genome (Bumgardner et al., 2014, 2015).

Proteomics and gene characterisation

Characterisation of mycoplasma genomes, protein products, and the molecular mechanisms underlying transcription and translation is critical for understanding their virulence and pathogenic properties and for the development of effective vaccines. As the primary pathogen of swine enzootic pneumonia, *Mhp* has unsurprisingly been the focus of many of these studies over the past decade. Cattani *et al.* scanned the intergenic regions of all coding sequences in the *Mhp* strain 7448 genome, reporting a total of 1,315 palindromic elements and tandem repeats that may be involved in transcriptional regulation (Cattani *et al.*, 2016), while Siqueira *et al.* identified 47 small RNAs in the genome of *Mhp* and 11 in *Mhr* (Siqueira *et al.*, 2016); this group later conducted a focused analysis of the *Mhp* small RNAs and their associated target sites and regulatory elements, reporting differential expression of target genes in response to oxidative stress conditions in culture (Fritsch *et al.*, 2018). Interestingly, a recent genomic and proteomic study of *Mhp* reported that the pathogen is missing several genes involved in formylated N-terminal methionine processing, indicating that *Mhp* has evolved a translation mechanism that does not require this standard initiator of protein synthesis (Jarocki *et al.*, 2019b). Finally, in Tibet, a study of the local *Mhp* TB1 strain revealed mutations consistent with adaptation to the plateau environment (e.g., in hypoxia-associated genes) (Gang *et al.*, 2019).

Zhu *et al.* reported their identification of the *Mhp* gene *Lpl*, which encodes a lipote protein ligase that is involved in the generation of this critical cofactor for metabolic enzymes (K. Zhu *et al.*, 2020). Ishag *et al.*, meanwhile, transformed *Mhp* and *Mhr* with plasmids encoding GFP driven by the *p97* gene promoter, showing that they could be used to monitor gene transfer and expression *in vitro* (Ishag *et al.*, 2016b, 2016a). This group later developed *oriC*-plasmids and successfully transformed them into *Mhr*, demonstrating proof-of-concept by targeting the *hlyC* gene to produce hemolysin-mutant bacteria (Ishag *et al.*, 2017).

Mycoplasma resistance to fluoroquinolones is often attributable to mutations in the target proteins of these drugs, DNA gyrase and topoisomerase IV (reviewed in (Gautier-Bouchardon, 2018)). Accordingly, a recent molecular investigation of drug resistance in Chinese *Mhr* isolates identified a total of ten point mutations in bacterial DNA gyrase (GyrA) and topoisomerase IV (ParC and ParE) proteins that were associated with reduced susceptibility to fluoroquinolones (J. Li *et al.*, 2022b).

Finally, recent investigations of pathogenic and non-pathogenic *Mhp* strains have produced interesting results for future comparative studies. Garcia-Morante *et al.* reported identical growing phases and maximal titres during culture of the non-pathogenic type strain J and pathogenic 11 and 232 strains, though the J strain exhibited the fastest growth (Garcia-Morante *et al.*, 2018). Meanwhile, a pathogenic and non-pathogenic strain of *Mhp* have both been shown to produce extracellular vesicles *in vitro* (de Souza *et al.*, 2022); this published method for extracellular vesicle isolation will now permit future studies of vesicle composition/contents and their biological relevance.

Diagnosis

Mhp has dominated most research published on the diagnosis of swine mycoplasmas over the last decade, and many techniques have been used to detect *Mhp* in various sample types; diagnostics for *Mhr* and *Mhs* are less common (DISCONTTOOLS, 2016b). Culturing is considered the gold standard, but like all mycoplasmas, *Mhp* is extraordinarily difficult to isolate; more practical methods include immunofluorescence, serology and PCR (Oh *et al.*, 2020). Diagnosis of *Mhp* is made more challenging by its chronic nature and tropism for the lower respiratory tract (reviewed in (Garcia-Morante *et al.*, 2022; Pepovich, 2020)) and the variable sensitivity of diagnostic assays over the course of infection (Sponheim *et al.*, 2021). *Mhp*-induced lung lesions are an important part of the macroscopic detection of enzootic pneumonia – various scoring systems have been published for assessing and categorising these lesions, and methods have been developed for comparing the results of these different systems (reviewed in (Garcia-Morante *et al.*, 2016)). Laboratory diagnostics are then required to positively identify the pathogen (Silva *et al.*, 2022). As with other mycoplasmas, these assays are mainly divided into nucleic acid diagnostics and serodiagnostics; however, advances have also been made in sampling strategies and other diagnostic avenues, and these will be discussed below as well.

DNA diagnostics

The high frequency of co-infections in the swine respiratory tract has spurred the development of assays intended for the simultaneous detection and differentiation of individual pathogens. These include a multiplex TaqMan qPCR for distinguishing *Mhp*, *Mhr* and *Mfl* by targeting the *p102*, *p37* and *fruA* genes (Fourour *et al.*, 2018); a duplex qPCR assay for discriminating *Mhp* and *Mhr* in several pig clinical sample types (YuZi *et al.*, 2019); and multiplex qPCR assays for detecting *Mhp* and other swine respiratory pathogens in a single run (Rao *et al.*, 2023; Sunaga *et al.*, 2020). Lung *et al.* developed a

prototype automated microarray assay and associated multiplex PCRs for diagnosis of *Mhp* and seven other important viral and bacterial pathogens of swine (Lung et al., 2017). Meanwhile, as in their publication on *M. bovis*, Goecke *et al.* developed a protocol for evaluating enzootic pig pathogens (including *Mhp* and *Mhr*) on the high-throughput BioMark qPCR platform, reporting similar performance and substantial efficiency gains compared to traditional qPCR (Goecke et al., 2020). Digital PCR has also been applied for direct quantification of *Mhp* within bronchoalveolar lavage samples (Beuckelaere et al., 2022).

As mentioned in other sections, high-resolution melting curve analysis is another option for the differentiation of closely related pathogens from the same sample. One such assay was recently developed for both swine and bovine mycoplasma infections, distinguishing between *Mhp*, *Mhr* and *Mhs* cultured from swine lung samples while also detecting *M. bovis* from bovine lungs (Ahani Azari et al., 2020).

These studies have presented many new options for simultaneous diagnosis of multiple porcine respiratory pathogens; meanwhile, other groups have focused on the development of field-capable assays via isothermal molecular diagnostics that do not require a thermocycler. A LAMP procedure targeting the *p36* gene was developed for *Mhp*, and the authors reported 100% concordance with traditional qPCR when tested on lung tissue samples from experimentally infected swine (Liu et al., 2015). Meanwhile, combining an *mhp165*-targeted isothermal RPA assay with lateral flow strip detection provided 100% diagnostic specificity and ~89% sensitivity, requiring < 20 minutes for visual readout of test results (Liu et al., 2019).

Alongside, two studies specifically addressed the suitability of different sample types for PCR analysis, aiming to clarify which of the many sampling techniques currently in use may provide the best molecular diagnostic sensitivities. Pieters *et al.* compared five sample types (nasal and laryngeal swabs, oral and tracheobronchial lavage fluids, and blood) for PCR diagnosis of pigs experimentally infected with *Mhp*, finding that laryngeal swabs from 5+ days post-inoculation provided the highest sensitivity for DNA detection (Pieters et al., 2017). Meanwhile, Poeta Silva *et al.* recently compared two commercial DNA extraction methods and three PCR protocols for measuring within-pen *Mhp* prevalence from pen-based oral fluid samples – the authors reported the best performance from a combination of the MagMAX-96 Pathogen RNA/DNA kit and the RealPCR*M hyo DNA Mix (Poeta Silva et al., 2022).

Advances have also been made in molecular detection of the uncultivable haemoplasmas (reviewed in (Quiroz-Castañeda et al., 2020)). Giemsa staining has been used to detect *M. suis* within swine erythrocytes (Stadler et al., 2021), but the sensitivity of this test has been compared poorly against a TaqMan qPCR assay targeting the 16S rRNA gene (Guimaraes et al., 2011b; Normand et al., 2020). Given the likely underdiagnosis of swine haemoplasmas and relatively limited data available on their epidemiology, further development and field validation of haemoplasma diagnostics – particularly, new assays capable of differentiating *M. suis*, *M. parvum*, and the newly identified *C. M. haemosuis* (discussed in more detail in [Epidemiology](#)) – will be important for monitoring the spread of these diseases and identifying associated risk factors.

Serological diagnostics

Serodiagnostics are relatively simple and low-cost compared to molecular methods, making them an attractive choice for rapid herd-level diagnoses and disease surveillance studies. Several *Mhp* ELISAs are commercially available, and new serological assays continue to be reported sporadically in the literature (MaoJun et al., 2016). Poeta Silva *et al.* compared the efficacy of six commercial *Mhp* ELISAs against PCR under experimental and field conditions, reporting the highest performance from the BioChek SK108 Mhyo and IDEXX *M. hyo* Ab test ELISAs (which both detect anti-P46 antibodies) and the Hipra Civtest Suis Mhyo (a two-well indirect ELISA) (Poeta Silva et al., 2020).

Loreck *et al.* reported their development of a miniaturised protein microarray able to simultaneously detect IgG against ten swine pathogens including *Mhp*, achieving 98% diagnostic sensitivity and 80% specificity for this pathogen compared to the IDEXX ELISA (Loreck et al., 2019). These authors then applied this microarray to high-throughput screening of swine meat juice and serum samples; subsequent receiver operating characteristic analysis showed a relatively high area under the curve (AUC) value of 0.84 for *Mhp* in serum samples (Loreck et al., 2020).

DIVA is critical for monitoring *Mhp* vaccination programmes and understanding the true prevalence of naturally infected animals. However, many commonly used commercial ELISAs for *Mhp* diagnosis are unable to distinguish vaccinated pigs (Clavijo et al., 2021a; Meens et al., 2010; Scalisi et al., 2022), and the development of DIVA-compatible serodiagnostics has therefore been an active research area over the past eight years. Bai *et al.* tested the DIVA capability of a previously published indirect ELISA for secretory IgA (sIgA) against *Mhp* (Feng et al., 2010), reporting that sIgA was detected only in experimentally infected unvaccinated pigs and could be used to distinguish them from vaccinated

animals (Bai et al., 2018). Meanwhile, it was previously reported that serum from bacterin-immunised pigs did not react with the *Mhp* immunogenic lipoprotein Mhp366 (Meens et al., 2010), and this protein was later used to develop indirect ELISAs for discriminating between porcine convalescent sera and sera from bacterin-immunised pigs (Ding et al., 2021, 2019; Tian et al., 2021).

Notably, the dynamics of *Mhp* infection (characterised as slow and chronic, with a delayed antibody response by the host animal) and the variability of *Mhp* surface antigens can lead to false negatives from serological tests (Bogema et al., 2012; Gomes Neto et al., 2014; Petersen et al., 2016). A microarray study of cross-reactivity also reported that *Mfl* infections could produce false positive responses from *Mhp* serodiagnostics, illustrating the need for caution in selecting, validating and interpreting these assays (Petersen et al., 2016).

Sampling strategies and other developments

Tracheobronchial swabs have been validated for qPCR testing to assess herd-level prevalence and/or confirm a positive serological diagnosis of *Mhp* (Vangroenweghe et al., 2018, 2015a), and high agreement has been reported between PCR results obtained from these samples and from lung tissue (Burrough et al., 2018). A comparison of laryngeal swabs and deep tracheal catheters for the detection of *Mhp* in naturally infected pigs indicated that the latter sample type provided higher qPCR sensitivity at all tested timepoints (Sponheim et al., 2020). These authors later conducted a detailed investigation of PCR on pooled deep tracheal catheter samples for herd-level diagnosis of *Mhp*, concluding that pooling three or five samples at a time was a cost-effective strategy for detecting low-prevalence *Mhp* among experimentally infected pigs (Sponheim et al., 2021).

A PCR study of tonsil samples indicated that detection of *Mhr* in pre-weaning piglets could predict the development of lameness later in production (Roos et al., 2019). This group also analysed oral fluids collected from swine pens in the USA, finding that detection of *Mhs*, but not *Mhr*, in this sample type was associated with lameness (Pillman et al., 2019).

Jenvey *et al.* reported substantially higher diagnostic sensitivity in detecting anti-*Mhp* antibodies in colostrum (75%) vs. serum (45%) via the commercial Ingezim M.Hyo Compac Blocking ELISA (Jenvey et al., 2015). Finally, Jenvey *et al.* reported substantially higher diagnostic sensitivity in detecting anti-*Mhp* antibodies in colostrum (75%) vs. serum (45%) via the commercial Ingezim M.Hyo Compac Blocking ELISA (Jenvey et al., 2015).

Efforts have been made to mitigate the substantial difficulties of culturing *Mhp*, which along with other mycoplasmas is notoriously fastidious and is often overgrown by *Mhr* in primary culture (reviewed in (Kobisch and Friis, 1996)). Cook *et al.* developed a solid medium for the culture of *Mhp* from *Mhr*-contaminated clinical samples, including purified agar and DEAE-dextran in Friis medium (Kobisch and Friis, 1996) and using a low concentration of kanamycin to selectively eliminate the less-resistant *Mhr* (Cook *et al.*, 2016). Burgos *et al.* recently reported their development of a serum-free medium capable of supporting large-scale *Mhp* production (e.g., for vaccines), using the J strain to demonstrate proof-of-concept (Burgos *et al.*, 2023).

Meanwhile, Pereira *et al.* compared two fluorescence-based methods – immunohistochemistry (IHC) and fluorescence *in situ* hybridisation (FISH) – for the detection of *Mhp* and/or *Mhs* in lung tissue, reporting higher diagnostic sensitivity (~76% vs. 40%) and specificity (100% vs. 73%) by FISH (Pereira *et al.*, 2017). *In situ* hybridisation methods have also been combined with next-generation sequencing to facilitate associations between specific genome sequences of emerging swine pathogens (including *Mhr*) and the histopathological lesions they cause (reviewed in (Resende *et al.*, 2019a)).

Finally, some studies have investigated potential biomarkers that could indicate *Mhp* infection in pigs. Nair *et al.* profiled serum metabolites in experimentally infected pigs, reporting a significant increase in α -aminobutyric acid and long-chain fatty acids at two and three weeks post-inoculation (Nair *et al.*, 2019a).

Pathogenesis

In the field, pigs are commonly infected with more than one species of mycoplasma at a given time; this can make it difficult to distinguish between the pathogenic effects caused by the different organisms, or by the interactions between them. Accordingly, many studies published over the past decade have focused on *in vitro* or *ex vivo* characterisation of co-infections between two mycoplasmas (generally including *Mhp*), including the ways in which different co-infections can affect the severity of clinical signs.

In vivo and ex vivo studies

A large study of 400 lungs from pigs slaughtered in Brazil identified a significant correlation between lesion severity and the level of infection with *Mhp*, but not with *Mfl*, and a negative correlation with the level of *Mhr*; interestingly, lesion severity only positively correlated with *Mfl* and *Mhr* co-infection, and negatively correlated with *Mhp* and *Mfl* co-infection, suggestive of competition between the pathogens (Ferreira et al., 2021). Recent data from fattening pigs in the field showed that *Mhr* infection was more common in the presence of *Mhp* but confirmed that lesion severity did not correlate with co-infection by these pathogens, rather being associated with the presence of mixed-genotype *Mhr* infection (Tonni et al., 2022). This conclusion was also reached by Michiels *et al.* in their study spanning three pigs herds in Belgium (Michiels et al., 2017b). Similarly, Fourour *et al.* did not find any relationship between lesion severity and *Mhp-Mhr* co-infection, but did report worse lesion scores in specific-pathogen-free piglets experimentally infected with *Mhp* and *Mfl*; however, pigs co-infected with *Mhp* and either *Mfl* or *Mhr* exhibited significantly slower growth than those infected with only *Mhp*, indicative of an additive effect on their health (Fourour et al., 2019a).

Alongside pathogen co-infection or genetic diversity, emerging evidence suggests that early-life microbiota may influence *Mhp* susceptibility in the first few months of age: Nair *et al.* found that differences in the gut microbiota of piglets at three weeks of age correlated with the extent of lung lesions after experimental challenge with *Mhp* five weeks later; specifically, richness in bacteria within the short-chain-fatty-acid-producing taxa *Ruminococcus_2*, as well as general bacterial diversity, were significantly associated with lower lesion scores (Nair et al., 2019b), though the underlying mechanisms are not yet clear.

Mhr commonly colonises the respiratory tract of pigs yet does not always cause disease (DISCONTTOOLS, 2016b). Thus, understanding the factors determining the variable pathogenicity of *Mhr* is an active area of research: differences in virulence between strains of *Mhr* are known and have been recently experimentally evidenced (J. Wang et al., 2022a), while *Mhr* and not *Mhp* seropositivity has been implicated in the pathogenesis of pneumonia during co-infection with PRRSV (JungAh et al., 2016). *Mhr* may also spread outside of the respiratory tract and can cause systemic inflammation in the form of polyserositis and/or arthritis of the joints. Moreover, Bünger *et al.* presented a case series of eight piglets from four different farms in Austria, which had presented with central nervous system symptoms and had tested positive for *Mhr* alone at post-mortem; these data represent the first evidence that *Mhr* might be a cause of meningitis in swine (Bünger et al., 2020). A single case report

also documented *Mhr* as the sole pathogen isolated in an incident of piglet pericarditis (Ustulin et al., 2021).

Although clinical characterisation of *Mhp* infection is well established, the latest molecular detection techniques now enable direct studies of the colonisation, dissemination and persistence of the mycoplasma within the host during the course of infection. Using qPCR, Almeida *et al.* found that intra-tracheally inoculated *Mhp* strain 232 preferentially colonised the lower respiratory tract, with levels of the mycoplasma peaking at day 28 post-inoculation and persisting until the end of the experiment on day 56; moreover, levels of *Mhp* in bronchoalveolar lavage fluid at days 14 and 21 post-inoculation were significantly positively correlated with the extent of microscopic lesions on day 56 post-inoculation (Almeida et al., 2021). These data confirmed and broadened the conclusions of the group's previous work showing that the *Mhp* load correlated positively with lesion severity at all timepoints tested during experimental infection, and that the mRNA expression level of the cytokines IL-6 and IFN- γ significantly positively correlated with lung lesion score (Almeida et al., 2020).

In vitro studies

Potential insight into the factors underpinning the differential virulence of *Mhp*, *Mfl* and *Mhr* have been gleaned by the integration of genome-wide metabolic network analysis, metabolomic experiments, and secretome studies. Regarding their metabolic features, Ferrarini *et al.* highlighted key differences in glycerol metabolism that are associated with the ability of *Mycoplasma* species to produce cytotoxic H₂O₂ and could be a primary reason for the virulence of *Mhp* and *Mhr*; alongside, the authors detected differences in the metabolism of myo-inositol, amino sugar, and carbohydrates, which could explain the tissue specificity of the different pathogens (Ferrarini et al., 2016). Trueeb *et al.* also shed light on the differential virulence of *Mhp* and *Mhr* by focusing on the identification of species-specific genes that were non-essential for their growth in culture: among these genes, those involved in metabolism stood out, with *Mhp* again uniquely possessing genes involved in myo-inositol and sialic acid pathways, which could enable it to use additional/alternative energy metabolism pathways (Trueeb et al., 2019). This is one of few studies in which *Mhp* mutants have been successfully generated, due to the challenges of working with this fastidious organism: another notable success was the creation of site-specific P97-mutants of *Mhp* by Clampitt *et al.* using recombination (Clampitt et al., 2021).

Further work has added to our understanding by comparing the secretomes of a newborn pig tracheal cell line (NPT_r) following exposure to pathogenic and non-pathogenic strains of *Mhp* or to *Mfl*, and the secretomes of the mycoplasmas themselves: the authors found that the secretion of known and putative virulence factors by pathogenic *Mhp* correlated with the production of damage-associated molecular patterns and extracellular proteases, consistent with cell death, in NPT_r cells, while *Mfl* secreted approximately 50% fewer proteins and did not cause cell death during *in vitro* infection of these cells (Leal Zimmer et al., 2019). Interestingly, a preceding study that characterised the secretomes of *Mhp* and *Mfl* cultured in medium identified far fewer proteins, yet similar patterns emerged: *Mhp* exhibited a larger and more complex secretome, with significantly more known and putative virulence factors including adhesins, methylases, nucleases, and antigenic lipoproteins; while *Mfl* secreted just two (Paes et al., 2017a), despite the two species having a much higher level of genomic and transcriptional similarity (Siqueira et al., 2014).

Proteomic studies have also contributed to our knowledge of virulence determinants among mycoplasmas affecting swine. Yu *et al.* compared the proteomes of virulent and attenuated *Mhp* strains, identifying seven putative virulence factors with significantly differential abundance between the strains; the most highly differentially expressed was fructose-1,6-bisphosphate aldolase, which bound fibronectin and mediated attachment of *Mhp* to swine tracheal epithelial cells *in vitro* (Yanfei Yu et al., 2018a). Alongside, the effects of post-translational proteolytic processing of adhesion-related surface proteins upon pathogenicity have begun to be elucidated. Building on their previous work that characterised the proteomes of *Mhp* and *Mfl* (Paes et al., 2018), researchers working in Brazil have compared the processing of five orthologous adhesion-related proteins in pathogenic and non-pathogenic strains of *Mhp* and in *Mfl*, identifying distinct antigenic proteoforms that could be involved in the differential virulence of the strains/species (Machado et al., 2020).

One study has focused on the effects of *Mhp* infection upon the transcriptome of host NPT_r cells, identifying over 1200 genes as well as 170 miRNAs whose expression was significantly affected by infection; among these, the authors highlighted increased expression of genes associated with redox homeostasis and antioxidant defence, and decreased expression of those involved in cytoskeleton and ciliary function (Mucha et al., 2020).

The means by which pathogens make their initial contact with host cells and begin to invade host tissues are critical to dissect and understand, as they can give key insights into preventative measures. Initial work identified the variable lipoprotein family as *Mhr* adhesins in porcine cell lines (Xiong et al.,

2016); more recent studies reported that the *Mhr* surface-bound glycolytic enzyme, enolase, can specifically and strongly bind porcine plasminogen and the extracellular matrix (ECM) protein fibronectin and can mediate adhesion to the PK-15 porcine kidney cell line (J. Wang et al., 2022b). The same group also characterised the *Mhr* surface proteins GAPDH (Jia Wang et al., 2021) and DnaK (which belongs to the HSP-70 family) (Y. Li et al., 2022) and shed further light on the variable lipoprotein family (J. Li et al., 2022a), finding that they too bound host plasminogen, as well as several ECM proteins; moreover, DnaK was itself recognised by sera from pigs immunised with an *Mhr* bacterin, suggesting its natural immunogenicity (Y. Li et al., 2022).

Similar *in vitro* characterisation of the *Mhp* virulence factor NADH-dependent flavin oxidoreductase revealed its binding to a porcine bronchial epithelial cell line, in which it induced oxidative stress and apoptosis pathways, as well as its interaction with plasminogen and fibronectin (Xie et al., 2021); NADH oxidase from *Mhp* behaved similarly in the same assays, and additionally induced lactate dehydrogenase release from the bronchial epithelial cells (Hao et al., 2022b). These data complemented previous work by the same group, showing that elongation factor thermo unstable (EF-Tu) acts as a novel adhesin on the *Mhp* surface *in vitro* (Yanfei Yu et al., 2018b). The ability of *Mhp* to bind fibronectin may be critical: early work showed that *Mhp* could induce fibronectin deposition on a PK-15 cell monolayer and co-localised with deposits of fibronectin on the ciliated epithelium of the airway at the site of infection *in vivo* (Raymond et al., 2015), while a follow-up study by the same group revealed that fibronectin binding allowed *Mhp* to interact with integrin β 1, allowing the pathogen to gain entry into PK-15 cells and establish an intracellular niche (first within recycling endosomes, and then in the cytoplasm) (Raymond et al., 2018c). Alongside, the same group evidenced the ability of *Mhp* to bind extracellular actin on PK-15 cells, which was critical for efficient adhesion to, and infection of, these cells (Raymond et al., 2018b); while Jarocki *et al.* showed that MHJ_0125, a leucine aminopeptidase, is expressed on the surface of *Mhp* and binds heparin, foreign DNA, and plasminogen, thereby acting as a novel adhesin (Jarocki et al., 2015). Lastly, Ni *et al.* observed that *Mhp*-derived lipid-associated membrane proteins induced apoptosis in a porcine lung epithelial cell line via activation of caspases -3 and -8, and stimulated the production of nitric oxide and superoxide, which could contribute to pathogenicity (Ni et al., 2015). Similarly, *Mhp* putative type I signal peptidase induced apoptosis in PK-15 cells via caspase-3 activation (Paes et al., 2017b).

These types of proteomic analyses can also be used to compare pathogenic and non-pathogenic strains arising from the same parental mycoplasma, as a way of identifying virulence determinants. Li *et al.* found that the pathogenic *Mhp* 168 strain and its passage-attenuated equivalent, 168L,

expressed significantly different levels of 70 proteins in culture: among these were proteins involved in myo-inositol metabolism, which were more highly expressed by strain 168L, while strain 168 expressed higher levels of proteins involved in nucleoside metabolism which might help to defend against damage from host-derived reactive oxygen species (Li et al., 2019).

While these studies are important and interesting, there is a note of caution on the use of *in vitro* approaches to generate broad conclusions. This is elegantly illustrated by a study that compared the transcriptomes of *Mhp* grown in culture and isolated from the lungs of experimentally infected pigs, showing that *in vivo Mhp* upregulated the expression of 22 genes including those encoding the mycoplasma F1-like ATPase, and genes involved in nucleotide metabolism, spermidine transport and glycerol-3-phosphate transport; while simultaneously the mycoplasma population down-regulated expression of 30 genes with products related to glycerol uptake, cilium adhesion, cell division and myo-inositol metabolism (Kamminga et al., 2020). These data urge caution in extrapolating conclusions from *in vitro*-generated results to the *in vivo* setting without additional validation; this is especially important when the proposed use of the insight is towards improved strategies for vaccination or treatment.

M. suis is a less well-studied mycoplasma affecting pigs that can cause anaemia and associated productivity losses (Stadler et al., 2014), accompanied by generalised immunosuppression (do Nascimento et al., 2018), which could be particularly relevant in cases of co-infection with other pathogenic mycoplasmas. Therefore, understanding the interactions of *M. suis* with its target porcine red blood cells is a potentially important area of research. Song *et al.* built on previous work that identified a novel potential adhesion factor within the *M. suis* genome, o-sialoglycoprotein endopeptidase (Guimaraes et al., 2011a), showing that this protein could bind Band3 and glycophorin A on porcine erythrocytes, and thereby mediate adhesion of *M. suis* to its target cells (Song et al., 2018). Similarly, *M. suis* protein MSG1 (latterly re-annotated as GAPDH) was shown to bind β -actin *in vitro* and on porcine red blood cells (Zhang et al., 2015)

Finally, original genomics studies of *Mhp* shed valuable light on its biology and pathogenesis and the identity of potential virulence factors, many of which have since been confirmed by experimental study. However, since the original annotation was conducted, knowledge has moved forward; re-annotation in light of these advances is now a productive line of work. A recent study improved the level of *Mhp* genome annotation from 65% to 87%, identifying novel putative virulence factors among the 244 proteins of previously unknown function and validating their findings by comparative studies

in pathogenic and non-pathogenic strains; this study also identified putative epitopes within each of the 144 proteins of unknown function that were predicted to be surface-located (Tavares et al., 2022).

Immunology

Immunological research into mycoplasmas affecting swine has been highly productive in recent years. The field has made marked advances in our understanding of immunogenetics which have led to the breeding and detailed characterisation of resistant lines and the discovery that these lines may also respond better to vaccination, further increasing their protection from disease. Alongside, studies of the innate and adaptive responses to infection have furthered our insight into protective and pathologic mechanisms operative during infection with *Mhp* and have identified potential candidate antigens and epitopes for inclusion in novel vaccine strategies.

Of note, while some studies have cautioned about the risks of inferring between model and natural host species, or between immortalised cell lines and primary cells, other *in vitro* experiments have indicated novel mechanisms of immune evasion that could be highly relevant *in vivo* – for example, the discovery that *Mhp* may be able to both induce and then degrade macrophage and neutrophil extracellular traps as a source of nucleotides to support its own replication (Henthorn et al., 2018; Peng et al., 2019) represents an exciting step forwards in our knowledge of this pathogen.

Immunogenetics

Some breeds of pig are more susceptible than others to *Mhp* infection, and considerable advances have been made towards understanding the basis of resistance versus susceptibility, especially for the Landrace breed. Researchers working in China and Japan have reported important, stepwise progress towards not only generating a line of Landrace pigs more resistant to mycoplasmal pneumonia of swine (MPS), but also towards understanding the immunological and genetic basis of their increased resistance. After selective breeding over five generations for increased MPS-resistance, as well as high meat production, Kadowaki *et al.* observed significant decreases in MPS severity, indicating a heritable genetic basis (Kadowaki et al., 2012). Interestingly, when the researchers investigated immunological characteristics of the resistant line, they found that they had a significantly higher proportion of granulocytes among total blood leucocytes and exhibited lower recall PBMC proliferative responses *ex vivo* following vaccination against *Mhp* compared to non-resistant pigs (Shimazu et al., 2013), as

well as higher IFN- γ in blood following *Mhp* vaccination (Sakuma et al., 2020). Moreover, the group then identified that the ratio of granulocytes to lymphocytes in peripheral blood, as well as higher phagocytic activity, were key immune correlates of MPS resistance in these pigs (Okamura et al., 2016). These traits were partially linked to the LR-0.13 and LR-0.23 swine leucocyte antigen haplotypes (Ando et al., 2016). Delving deeper into the genetic basis for the difference in resistance seen between the lines, Uemoto *et al.* conducted an SNP- and haplotype-based genome-wide association study, identifying several genomic regions associated with immune parameters as potentially important: their analysis highlighted regions involved in granulocyte-to-lymphocyte ratio, cortisol levels in blood, and activity of the complement alternative pathway in serum; within these were included genes related to Th1 and Th17 responses as well as NK cell activity and the acute phase protein response (Uemoto et al., 2021). Alongside, the group identified higher levels of IL-12p40 expression in the hilar lymph nodes, lung, and spleen of the resistant line compared to controls, during experimental infection, which correlated with lower lesion scores (Sakuma et al., 2020).

Borjigin *et al.* also studied MPS-resistant Landrace lines, finding significantly higher levels of salivary IgA, TLR2 and TLR4 and of IFN- γ – as above – in their blood, and lower frequencies of B cells, after bacterin vaccination against *Mhp* (Borjigin et al., 2016a). Importantly, preliminary evidence suggests that crossbreeding of such MPS-resistant Landrace pigs with less-resistant breeds could allow transfer of favourable immunological traits (Borjigin et al., 2016c), and a partial increase in MPS resistance (Borjigin et al., 2017), to the resultant offspring.

Similar studies have also begun in other breeds of pig. Comparative transcriptional profiling of the lungs of pigs from the more susceptible Jiangquhai and less susceptible Duroc breeds revealed higher expression of *CXCL10*, *CCL4*, *IL6* and *IFNG* genes in the latter at four weeks post-infection with *Mhp*, which likely reflects a more effective immune response in the resistant breed (Ni et al., 2019). However, attempts to identify genomic regions linked with the production of higher titres of *Mhp*-specific antibodies in commercially reared groups of Landrace-cross-Large White sows did not identify any strong associations (Sanglard et al., 2020). Similarly, attempts to generate an *Mhp*-resistant Large White pig line based on PBMC immune responses proved so far unsuccessful, with the selected line exhibiting a higher level of pulmonary lesions compared to the non-selected controls (Borjigin et al., 2016b).

Alongside, other studies have enhanced our understanding of the role of immunogenetics in antibody responses to vaccination. Blanc *et al.* identified two genomic regions in which SNPs mapped to

immunity-related genes that were associated with antibody levels at three weeks post-vaccination, as well as significant differences in the blood transcriptome in low-, high- and enduring- responders, including pathways related to antiviral immunity and dendritic cells (Blanc et al., 2021). There is some evidence that the gut microbiota of piglets at the time of vaccination could additionally help predict the level of antibody response to *Mhp* vaccines (Munyaka et al., 2020).

Innate immunity

Identifying and characterising the innate immune cells present locally during infection of the lung with *Mhp* is key to understanding the initiation of immunity and of potential immunopathology. Nueangphuet *et al.* collected lung tissue from naturally infected pigs and identified IL-8-expressing neutrophils and M2-polarised IL-10-producing macrophages in the intra-alveolar space and in lung lesions, respectively (Nueangphuet et al., 2021). Interestingly, IL-8 expression was previously correlated with the development of lung lesions in pigs experimentally infected with *Mhp* (Almeida et al., 2020), while the role of IL-10 in the *Mhp*-infected lung is less clear.

Studies of porcine immune cells have also been conducted to try and understand the difference in pathogenicity of different species of mycoplasma. By exposing porcine PBMC *ex vivo* to live and inactivated *Mhp* and *Mhr* at a range of MOIs, Trueeb *et al.* identified immune signatures that were common and specific to these more- and less-pathogenic bacteria, respectively (Trueeb et al., 2020). Their study showed that an MOI >100 of live or inactivated mycoplasmas activated TNF- α production by monocytes, while *Mhp* was significantly less able to activate CD21⁺IgM⁺ B cells than was *Mhr*, and that both mycoplasmas induced CD40 upregulation by conventional and plasmacytoid dendritic cells (DCs) (Trueeb et al., 2020). These findings raise interesting questions warranting further investigation *in vivo* and/or with a focus on more physiological levels of pathogen exposure.

The interaction of mycoplasmas with DCs is especially important to understand, given these cells' pivotal role in initiating and shaping immune responses to pathogens. Fourour *et al.* exposed porcine bone marrow-derived DCs (BMDCs) to varying virulent strains of *Mhp*, *Mhr*, and/or *Mfl* *in vitro*, individually or in pairs, at an MOI approximating 50, and compared the expression of key cytokines as well as measuring BMDC viability (Fourour et al., 2019b). Interestingly, they found that all tested strains initiated the production of IL-6, IL-8, IL-10, IL-12, and TNF- α by porcine BMDCs; however, *Mhp* induced lower IL-12 production than the other species, which would be expected to favour a Th1 response, while *Mfl* exhibited highest induction of TNF- α which could initiate pulmonary inflammation

(Fourour et al., 2019b). The combination arm of the study revealed that *Mhp* and *Mfl* co-exposure led to significantly increased IL-10 production, which the authors speculated might downregulate the immune response and favour pathogen persistence *in vivo* (Fourour et al., 2019b). These data partially align with earlier work that also detected high expression of IL-10 in porcine BMDCs exposed to *Mhp* *in vitro*, which was accompanied by decreased expression of IL-12 and IFN- γ , together suggesting promotion of a Th2 type adaptive response (Shen et al., 2017), though these findings have yet to be translated to the *in vivo* setting.

In vitro studies in porcine cell lines have also identified potentially relevant interactions between mycoplasmas affecting swine and components of host innate immune pathways. For example, Wei *et al.* infected the 3D4/21 porcine alveolar macrophage (PAM) cell line with *Mhp* and observed activation of the nucleotide-binding oligomerization domain-containing protein (NOD)1-RIP2 signalling pathway, possibly through NOD recognition of the *Mhp* protein Mhp1; knock-down of NOD1 led to decreased activation of the TRIF-MYD88 pathway, coupled with lower transcription of the gene encoding TNF- α (Liu et al., 2022). However, given the recently documented significant genetic differences between primary PAMs and the 3D4/21 PAM cell line (Li et al., 2022), any data generated in this system must be interpreted with extreme caution and will require further validation in primary cells.

Adaptive immunity

Characterising the local adaptive immune response is as important as understanding innate immunity at the site of infection and provides required background knowledge for the rational design of vaccines with durable responses. Towards this aim, Li *et al.* reported that the mucosal and systemic antibody response to experimental infection of pigs with *Mhp* was dominated by IgA from ten days post-infection; they also observed co-localisation of IgA-producing cells with CD11c⁺ DCs and macrophages in the lung and hilar lymph nodes (Henthorn et al., 2018; Peng et al., 2019). Using murine cells cultured *ex vivo*, the authors then identified a role for TLRs 2 and 4 in DC- and macrophage-mediated stimulation of *Mhp*-specific IgA-producing B cells (X. Li et al., 2020), which warrants follow-up study in porcine cells.

Taking a different approach to understanding the antibody response to *Mhp*, Petersen *et al.* showed that mycoplasma recombinant protein arrays can be used to gain additional insight: using pig sera from naturally or experimentally *Mhp*-infected animals, they found that the previously reported potential vaccine antigen P97 was poorly recognised, while several P97/P102 paralogues were

recognised more strongly (Petersen et al., 2019). The authors also noted key differences in antigen recognition by the porcine sera used in this study and those reported in studies of antigen recognition by sera from rabbits used in *Mhp* vaccine trials (Petersen et al., 2019); these data urge caution in extrapolating results from one species to another. Together, the characterisation of the antibody repertoire during infection is important to gain insight into immunodominant antigens, and therefore guide rational vaccine development.

More recently, Ning *et al.* screened 27 surface/secreted *Mhp* proteins for their recognition by sera from convalescent naturally infected pigs or from vaccinated animals; 24 of those proteins were recognised by at least one convalescent serum sample and 15 were recognised by at least six, among which Mhp367 and Mhp677 were bound by all convalescent samples (Ning et al., 2020). Interestingly, the recognition profile of sera from vaccinated animals was also highly variable and somewhat different, but consistently these sera did not react with Mhp462, while seven out of 11 convalescent sera did (Ning et al., 2020); this could form the basis of a differential test for animals with a history of infection versus vaccination (DIVA). In addition, during their reverse vaccinology approach, Li *et al.* identified 35 non-redundant B cell epitopes across four immunodominant *Mhp* antigens, including three adhesins and one membrane nuclease (Li et al., 2022). A similar study by Zhu *et al.* highlighted the 17-amino acid core epitope of the immunogenic *Mhr* protein P37 (Zhu et al., 2019). Together, these studies have generated a list of potential epitopes/antigens on which further study and/or the development of subunit and vectored vaccines could be based.

In the case of *Mhr*, sub-clinical colonisation of pigs is commonly observed in the field, but the immunological mechanisms underlying persistent infection are poorly understood. Merodio *et al.* established asymptomatic infection in caesarean-delivered colostrum-deprived piglets by inoculating them four times with a field isolate of *Mhr*, and detected specific IgA production at two weeks post-infection, with IgG appearing two weeks later; neither of these antibody sub-classes cleared the infection during the six weeks of study (Merodio et al., 2021). While this may be a useful model to study some aspects of asymptomatic infection, it should be borne in mind that the means of establishing this state do not resemble those of field conditions, and therefore additional validation of data generated in this system is warranted.

Maternal immunity

Lauritsen *et al.* found that piglets born to sows infected with *Mhs* received significant protection from challenge at 4.5 weeks of age, which was partially attributed to passively transferred maternal antibodies; some of these piglets also mounted a PBMC proliferative response to the pathogen, but the relationship between this response and protection was not clear (Lauritsen *et al.*, 2017). By comparison, immunologically naïve piglets exhibited high frequencies of *Mhs*-positive tissues and overt disease (Lauritsen *et al.*, 2017). More recently, researchers have uncovered evidence of maternal *Mhp*-specific T cells being transferred to offspring via milk (Biebaut *et al.*, 2021), though the relative roles of antibodies and cell-mediated immunity in protecting offspring has yet to be defined.

While maternally derived immunity can be useful in protecting very young offspring, the presence of immune cells or antibodies may interfere with successful vaccination of these animals. However, a recent study of the effects of maternal immunity on vaccine responses concluded that IgA⁺ B cells transferred from the sow could play a positive role in response to *Mhp* vaccination at one week of age (Martelli *et al.*, 2021). This is broadly in support of the preceding literature evidencing the lack of interference by maternally derived antibodies on vaccination of young piglets against *Mhp* (Martelli *et al.*, 2006; Wilson *et al.*, 2013).

Immune evasion

Few studies have focused on *Mhp* immune evasion strategies, though there is ample evidence for their existence. *Ex vivo* experiments suggest that *Mhp* is able to adhere to, but evade phagocytic uptake by, primary PAMs (Deeney *et al.*, 2019). However, a different study using primary PAMs alongside the 3D4/21 PAM cell line showed that intracellular *Mhp* significantly inhibits cellular autophagy during infection by inducing autophagosome formation and preventing lysosome fusion, thereby promoting its own survival and proliferation (Wen *et al.*, 2022). In porcine PBMC, exposure to *Mhp*-derived lipid-associated membrane proteins led to high levels of nitric oxide and ROS in the supernatant, and attendant increases in monocyte and lymphocyte apoptosis (Bai *et al.*, 2015). Thus, *Mhp* may exert distinct immune-evasive actions on PAMs and monocytes/lymphocytes in the blood.

Interesting data have also emerged about a possible interaction of *Mhp* with macrophages and neutrophils. An *in vitro* study using a human cell line showed *Mhp*'s potential ability to degrade the extracellular chromatin used by macrophages and neutrophils to form extracellular traps (NETs), using

the traps as a source of nucleotides for DNA replication (Henthorn et al., 2018). Later work with primary porcine neutrophils showed that *Mhp* exposure induced the formation of NETs *in vitro* which were rapidly degraded, at least partly due to the action of the Mhp597 nuclease (Peng et al., 2019). These data point to a potentially important mechanism of immune evasion that directly supports mycoplasma growth, and so warrants further investigation *in vivo*.

Lastly, although *Mhp* is well-known to induce ciliary paralysis in the respiratory tract, thereby reducing pathogen clearance, few studies have shed light on this phenomenon. A notable exception is the work of Jaroki *et al.* who showed that two surface-exposed peptidases can degrade several peptides that together regulate ciliary beat frequency, inflammation and innate immunity in the lung: bradykinin, substance P, neurokinin and neuropeptide Y (Jarocki et al., 2019a). These peptidases could therefore represent key colonisation- and persistence- promoting factors of *Mhp*.

Geographic distribution and epidemiology

Given the clinical significance of *Mhp* infections, this pathogen has unsurprisingly dominated the field of swine mycoplasma epidemiology research over the past decade. This section will therefore deal primarily with *Mhp*, while also including a handful of studies that have addressed the epidemiology of *Mhr* and *Mhs*. Numerous studies have also begun to address knowledge gaps in the epidemiology of the haemoplasmas (particularly *M. suis*, the causative agent of infectious anaemia in pigs). Previously believed to be rickettsial organisms, 16S rRNA gene sequencing of haemoplasmas has led to their reclassification as mycoplasmas (reviewed in (Tasker, 2022)), and our understanding of the prevalence and epidemiology of haemoplasma infections has slowly increased over the past decade.

Global situation

The Americas

Mhp is widespread in North and South America, and its presence has been significantly associated with swine mortality in wean-to-finish systems in the USA (Magalhães et al., 2022). A report on diagnostic cases submitted to the Iowa State University's Veterinary Diagnostic Laboratory presented ~27% PCR-positivity for *Mhp*, with higher prevalence observed in the autumn season and in finishing-age pigs (Rawal et al., 2018). Meanwhile, *Mhs* was the most common cause of swine joint- or leg-

associated lameness in a recent retrospective study in Iowa state (Canning et al., 2019), and the severity of this lameness was reported to vary between clinical isolates (Gomes-Neto et al., 2016).

Swine enzootic pneumonia is a similarly serious problem and frequent cause of death in pig farms of Brazil (Gonzaga et al., 2020; Piva et al., 2020) and Argentina (Cappuccio et al., 2018), particularly in combination with sIAV infection (De Conti et al., 2021; Rech et al., 2018). Biondo *et al.* studied the lungs of captive wild boar in a slaughterhouse in Brazil – signs of pneumonia were extremely common, and *Mhp* was detected in ~59% of samples (often in co-infections with *Mhs* and/or other swine lung pathogens) (Biondo et al., 2021). For domestic pigs, a recent survey of various production systems in the Central-West, Southeast, and South regions of Brazil reported ~39% prevalence of *Mhp* and a high rate of co-infections with other bacterial and viral respiratory pathogens (Balestrin et al., 2022), though much higher prevalence has been reported in slaughter pigs of South Brazil (Pacce et al., 2019).

Swine haemoplasma infections are also apparently widespread in Brazil. ~76-80% PCR-positivity was recently reported among swine in the country's South and Northeast regions (Gatto et al., 2019; Toledo et al., 2016), and up to 82% positivity was observed specifically for *M. suis* in extensive pig production systems in the state of Maranhão (dos Santos Martins et al., 2019). Petri *et al.* conducted a molecular survey of *M. suis* prevalence in finishing pigs in Minas Gerais state, finding ~60% positivity and a weak but significant correlation between pathogen burden and lower average daily weight gain (Petri et al., 2020).

Europe

As in the Americas, many recent studies from Europe have focused on assessing the prevalence of *Mhp* infections in various countries and farming conditions. *Mhp* was reported to be the main pathogen associated with pneumonia and pericarditis in Ireland (Rodrigues da Costa et al., 2020) and with mycoplasma-like lung lesions in Spain and Portugal ((Pallarés et al., 2021); reviewed in (Maes et al., 2023)). It was the second most common cause of pneumonia in a study of Austrian pigs (after *Pneumocystis* species, with which it often co-infects) (Kureljusić et al., 2016), and Deffner *et al.* found that 75% of pen-based oral fluid samples from 16 German and Austrian pig farms were positive for *Mhp* DNA (Deffner et al., 2022). *Mhr* was also commonly detected (~79%) in the upper respiratory tracts of German domestic pigs (Bunke et al., 2020). In Belgium and the Netherlands, a study of peri- and post-weaned piglets found that *Mhp* prevalence increased with age (~7% at 3-5 weeks and ~11% at 6-11 weeks) and was negatively associated with some climatic variables (e.g., precipitation) (Vangroenweghe et al., 2015b).

In Italy, meanwhile, Giacomini *et al.* studied the dynamics of *Mhp* seroconversion in one-, two- and three-site production systems, reporting higher prevalence in older animals and in one- and two-site vs. three-site systems (Giacomini *et al.*, 2016). *Mhr* (alone or in co-infection with *Haemophilus parasuis*) has also been reported to be a primary cause of polyserositis and the most common bacterium detected among pigs with recurrent arthritis in a high-density breeding area of Italy (Salogni *et al.*, 2022, 2020). *Mhs* also causes severe lameness in some Italian pig farms, and frequent relapse was observed following antibiotic treatment for this condition (Moronato *et al.*, 2017).

A study of gestating sows in ten French herds reported an average of 53% PCR-positivity for *M. suis* among these animals (Brissonnier *et al.*, 2020), higher than the 30% prevalence previously reported in Germany (Stadler *et al.*, 2019). In 2020, the novel haemoplasma species dubbed “*Candidatus Mycoplasma haemosuis*” (*C. M. haemosuis*) was detected in a German pig with clinical signs more suggestive of infection with *M. suis*, indicating possible pathogenic properties by this new haemoplasma (Stadler *et al.*, 2020). This group later developed a new qPCR assay for *C. M. haemosuis* detection on a larger scale, reporting a farm-level prevalence of ~14% on piglet-producing farms and 45% on fattening farms in Germany (Ade *et al.*, 2022).

Africa

Despite the rapid recent growth of Africa’s pig production systems and the prevalence of respiratory infectious diseases within them, relatively few studies have been conducted on the epidemiology of the pathogens responsible for these diseases (reviewed in (Oba *et al.*, 2020)). Despite containing one of the largest pig populations in Africa, Nigeria has seen few studies of enzootic pneumonia, for instance. The data that are available indicate that prevalence is high – a retrospective study of post-mortem records in Ibadan state reported ~50% incidence of pneumonia, most of which was attributable to *Mhp* infection (Olaniyi *et al.*, 2020). Several studies have also explored the prevalence of infectious anaemia in Nigerian swine, though many of these use the old classification of *Eperythrozoon* for the causative organism (Igbokwe and Maduka, 2018; Ogbaje *et al.*, 2015; Olaosebikan *et al.*, 2018).

Finally, *Mhp* was the third most prevalent swine respiratory pathogen after *Metastrongylus* species helminth infections and *A. pleuropneumoniae* in a study of slaughtered pigs in Uganda (Oba *et al.*, 2021), and a more recent study reported a significant association between the presence of *Mhp* and *Strongyles* species in this country (Oba *et al.*, 2023).

Asia, the Middle East and Oceania

In China, the prevalence of *Mhp* appears to be increasing, with a recent analysis of clinical samples indicating a rise in positivity rate from 7.2% in 2018 to 43.8% in 2020 (H. Zhang et al., 2021). Detection rates were even higher in a study of slaughterhouses in the Shanxi province, where 77% of PCR-tested lung samples were positive for *Mhp* (Yue et al., 2021). Similarly, the prevalence of *M. suis* is also trending upwards; seroprevalence in domestic pigs of eastern China was reported as ~26% in 2014 and 38% in 2016, with cases particularly concentrated in the Shanghai region during the summer and autumn seasons (ZhongYang et al., 2017). Meanwhile, *C. M. haemosuis* was first identified in 2017 in the Zhejiang province of China, where 26.5% of clinically healthy pigs were PCR-positive for it (Fu et al., 2017).

Acharya *et al.* reported an overall *Mhp* seroprevalence of ~23% in the western districts of neighbouring Nepal, where several factors (e.g., the use of improved vs. local breeds and continuous production vs. all-in all-out systems) were associated with high risk of detection (Acharya et al., 2019). Interestingly, a seroprevalence survey in Brazil reported that all-in all-out management was associated with a decreased likelihood of detecting *Mhp* antibodies, indicating that region-specific differences (e.g., in climate, other farm management variables, etc.) may impact this particular risk factor (Baraldi et al., 2019).

In South Korea, *Mhp* was the second most common respiratory pathogen of pigs (after *H. parasuis*) in a survey of oral fluid samples from commercial pig farms, with ~68% and 88% animal- and farm-level prevalence, respectively (Cheong et al., 2017). Slightly lower farm-level prevalence (~64%) was reported in a later study utilising nested PCR on laryngeal swabs for diagnosis, where the authors identified several risk factors (e.g., larger herd size and higher gilt replacement rates) for higher *Mhp* detection rates among weaning piglets (Oh et al., 2020). *C. M. haemosuis* was also detected in a single pig in South Korea following this haemoplasma's first reported detection in China (MinGoo et al., 2019).

Limited data are available on the epidemiology of swine enzootic pneumonia in Southeast Asia, where pig farming is predominantly based in smallholder operations that may have limited access to animal health information and disease control resources. Lee *et al.* conducted a rare seroprevalence survey in Vietnam, finding 46% prevalence of *Mhp* and high levels of co-infections in swine farms of the Bac Giang and Nghe An provinces (Lee et al., 2020). *Mhp* has also been reported as a common co-infection

with porcine circovirus type 2 (PCV2) in this country (Dinh et al., 2021). Meanwhile, Thongmeesee *et al.* reported ~37% prevalence of haemoplasma infections within commercial pig farms of Thailand and identified a putative novel species via genomic analysis (Thongmeesee et al., 2022).

Surveillance, transmission and risk factors

While direct contact is the primary means of *Mhp* transmission ((DISCONTTOOLS, 2016b); reviewed in (Sibila et al., 2009)), potential routes of indirect transmission remain poorly understood (Garza-Moreno et al., 2022); despite the general fragility of mycoplasmas, for instance, *Mhp* was found able to survive on dry surfaces for 8+ days in cold temperatures (Browne et al., 2017) and is known to form biofilms on abiotic surfaces in an extracellular DNA-dependent process (Raymond et al., 2018a), though the implications of *Mhp* environmental survival on its transmission remain unclear. Dam-to-piglet transmission is also thought to play an important role in the maintenance of enzootic pneumonia on commercial farms (Biebaut et al., 2022), though it has not been detected in all studies (Takeuti et al., 2017a). Insufficiently long quarantine of gilts before introduction to the herd has been hypothesised as an important risk factor for *Mhp* infection (Biebaut et al., 2022). A study of gilts in Brazil reported that most were PCR-positive for *Mhp* for 1-3 months in natural infections (though some were positive at later timepoints), with smaller *Mhp*-negative subpopulations existing within positive herds (Takeuti et al., 2017b).

As these and other studies have begun to clarify the transmission routes and patterns of *Mhp*, others have addressed certain risk factors associated with increased odds of disease occurrence and maintenance in commercial pig populations. Increasing concentrations of particulate matter were significantly associated with higher odds of pneumonia lesions, higher severity of these lesions, and greater likelihood of PCR-positivity for *Mhp*, indicating the importance of environmental respiratory factors beyond the causative bacterium itself (Michiels et al., 2015). Computational modelling has also been applied to *Mhp* epidemiology – Nathues *et al.* developed a stochastic compartmental model to simulate within-herd transmission of *Mhp* within closed pig herds and estimate the effect of various farm management and control strategies on disease severity (Nathues et al., 2016).

Meanwhile, the swine microbiome is increasingly recognised as an important factor in the progression of various diseases (reviewed in (Aluthge et al., 2019)), and this aspect of swine health has recently been addressed with regards to *Mhp* infection. In a recent study of the associations between environmental bacteria and the swine microbiome, Valeris-Chacin *et al.* reported that the presence of

Mhp was associated with reduced alpha diversity and increased levels of other pathogens and *Mhr* in swine tracheal fluids (Valeris-Chacin et al., 2021). Similar results were observed in a later analysis of commercial swine herds in Brazil, where *Mhp* infection was associated with significant changes in the composition of the lung microbiota (Sonalio et al., 2022). Experimental infection with *Mhr* has also been found to alter the components and metabolism of the swine gut microbiome (Zhang et al., 2023), and both *Mhr* and *Mhp* were significantly associated with the presence of lung lesions in a recent metagenomic sequencing study of swine lung lavage fluid samples (Li et al., 2023).

Meanwhile, surveillance for *Mhp* is often conducted via serodiagnostics on pen-based oral fluid samples, as these methods are relatively simple, cost-effective, and non-invasive to the tested animals (Clavijo et al., 2021a). However, the sensitivity of this sampling-testing combination can be too low to detect relatively small-scale transmission events (e.g., from the introduction of one *Mhp*-infected gilt to a naïve population), necessitating more invasive and labour-intensive methods to achieve adequate detection rates (Betlach et al., 2020). Inconsistent results have also been reported from PCR testing of oral fluids for *Mhp* in different pens or at different timepoints (Hernandez-Garcia et al., 2017).

In a recent field comparison of different surveillance methods, Clavijo *et al.* reported that PCR analysis of tracheal samples allowed the quickest high-probability detection of *Mhp* (Clavijo et al., 2021a). Garza-Moreno *et al.* also validated the detection of *Mhp* DNA via environmental sampling in pig farms of the Midwest USA – they reported that *Mhp* could be detected in air, swine surface swabs, and stall swabs on farms with clinical infections, while the latter two sample types were also suitable on farms with only subclinical infections (Garza-Moreno et al., 2022).

Monitoring of herd-level mortality data and antimicrobial and vaccine usage levels has been validated for surveillance on Danish swine farms, where Lopes Antunes *et al.* reported that changes in these information streams could be used as an early-warning system for the presence of *Mhp* and other respiratory pathogens prior to confirmatory diagnostic testing (Lopes Antunes et al., 2019). Alongside, in an observational study of finishing pigs, Pessoa *et al.* found evidence to support the use of coughing frequency to complement post-mortem data (e.g., the prevalence of lung lesions at slaughter) and improve on-farm respiratory disease management (Pessoa et al., 2021).

While a less economically significant pathogen than *Mhp*, *Mhr* is known to cause polyserositis and arthritis (Clavijo et al., 2017) and has also been associated with outbreaks of conjunctivitis on swine farms in the USA (Resende et al., 2019b); however, its epidemiology remains poorly understood. The

prevalence of *Mhr* on commercial pig farms has been reported to vary significantly with animal age (e.g., 8% in preweaning piglets vs. ~98% in postweaning pigs) (Clavijo et al., 2019a, 2017). Luehrs *et al.* analysed 1,375 pig lungs from Swiss and German farms with a history of chronic respiratory disease and found that, while *Mhr* was significantly more common in pneumonic lungs, its presence alone was not associated with clinical signs or lung lesions, and co-infection with *Mhr* did not appear to worsen the lesions caused by *Mhp* infection (Luehrs et al., 2017).

Several recent studies have also addressed epidemiological questions surrounding swine haemoplasmas. *M. suis* is spread primarily via parenteral exposure or bites, and the detection of PCR-positive pre-suckling piglets on German farms indicates that vertical transmission may occur as well (Stadler et al., 2019). *M. suis* has also been detected in blood-free fluids (e.g., saliva and urine) from infected animals (Dietz et al., 2014), though a later study of oral transmission indicated that the epidemiological relevance of blood-free transmission routes is minimal (Ade et al., 2021). In their analysis of *C. M. haemosuis* prevalence among German pig farms, these authors also identified PCR-positive piglets immediately after birth (prior to colostrum intake), suggesting that this newly identified haemoplasma is capable of vertical transmission (Ade et al., 2022).

Schwartz *et al.* isolated haemoplasmas including *M. suis* from stable flies (*Stomoxys calcitrans*) in Austrian pig farms, indicating that it might facilitate transmission of this pathogen (Schwarz et al., 2020). *M. suis* DNA was also detected in ~15% of sampled hog lice (*Haematopinus suis*) in Argentina (Acosta et al., 2019), and haemoplasma DNA was present in ~9% of wild boar-associated *Amblyomma* species ticks in Brazil (de Souza Santana et al., 2022). Further studies will be needed to clarify the potential roles of these arthropods in swine haemoplasma transmission.

Wildlife

Mhp is harboured by many wild boar (*Sus scrofa*) populations, where it causes similar respiratory pathology as in domestic pigs (Risco et al., 2015). The involvement of wild boars in the epidemiology of *Mhp* among domestic pigs is still poorly understood (reviewed in (Maes et al., 2018)). Studies in several countries have reported similar levels of *Mhp* seroprevalence among wild boar populations – e.g., approximately 20% in the USA (Baroch et al., 2015), 25% in Sweden (Malmsten et al., 2018), and 21% in the Tuscany region of Italy (Bertelloni et al., 2020). Interestingly, no *Mhp* antibodies were reported in a serosurvey of Greek wild boars, where the most common respiratory pathogen by far was *A. pleuropneumoniae* (Touloudi et al., 2015).

Estimates of *Mhp* seroprevalence in wild boars of Brazil have varied – Severo *et al.* reported ~20% seroprevalence (Severo *et al.*, 2021), but a more recent survey of respiratory pathogens in Brazilian wild boars found little evidence of *Mhp* (da Silva Andrade *et al.*, 2022). Further analyses will be needed to clarify any potential role for these animals in *Mhp* epidemiology in this region. Findings on haemoplasmas, which also infect wild boars, have been more concordant: Dias *et al.* identified 50% PCR-positivity for *M. suis* in Brazilian wild boars (Dias *et al.*, 2019), while a later study identified similar prevalence (~59%) in both wild boars and hunting dogs in two regions of Brazil (though there was no indication of cross-species transmission) (Fernandes *et al.*, 2022).

In Switzerland, Batista Linhares *et al.* observed ~26% *Mhp* PCR-positivity among wild boars and identified their population density and the occurrence of enzootic pneumonia in domestic pigs as significant risk factors (Batista Linhares *et al.*, 2015). Interestingly, while these authors had hypothesised that spill-over from wild boars to domestic pigs might be responsible for ongoing sporadic outbreaks on Swiss pig farms, their data suggested that the reverse (transmission from domestic pigs to wild boars) was in fact more likely to occur (Batista Linhares *et al.*, 2015). In studying a population of European wild boars, meanwhile, Goedbloed *et al.* reported that *Mhp* seroprevalence was higher among animals genetically determined to be wild boar-domestic pig hybrids, suggesting that the immune genes of domestic swine may increase their vulnerability to this pathogen (Goedbloed *et al.*, 2015).

Finally, Pearson *et al.* modelled the risk of pathogen transmission from wild boars to domestic pigs in Australia, estimating that *Mhp* had the highest probability of exposure to free-ranging domestic pigs (Pearson *et al.*, 2016).

Control of the disease

Although specific elimination programmes have been introduced, *Mhp*-specific biosecurity and control measures have not been developed, but if general strategies are followed, *Mhp*-free status and the prevention of the introduction of new strains into herds can be achieved (Maes *et al.*, 2018). Disease control strategies for *Mhp* infections in pig herds include management and biosecurity practices, administration of antimicrobial drugs, and application of bacterins. The implementation of strict all-in-all-out production practices allows for adequate cleaning and disinfection to reduce the

bacterial load in the environment before new animals enter the premises, and thus reduces the risk of *Mhp* and other pathogen infections. Other management practices such as proper purchase policy and gilt acclimation strategies, age-segregation, optimal stocking densities, prevention of other respiratory diseases, and optimal housing and climatic conditions will contribute to the control of infection (Pieters and Maes, 2019). It has been found, however, that implementation of the above-mentioned practices, alone or in combination, generally provide only partial protection (Robbins et al., 2019). One reason for the apparent failure of the all-in-all-out management strategy to control disease was addressed by Fitzgerald *et al.*, who noted that implementation of strict all-in-all-out practices is difficult in farrow-to-finish farms as most lack facilities exclusively dedicated to slow-growing and/or sick pigs (Fitzgerald et al., 2020). This means that pigs are often regrouped at various times according to their body weight in an effort to achieve uniformity in slaughter weight. These authors proposed that an extension to the vaccination programme to include sows and gilts may be beneficial to controlling the infection spread within the herd (Fitzgerald et al., 2020).

Policy

A standardised system for classifying the *Mhp* status of swine breeding herds in the USA was developed by industry bodies with leading US 'actors', based on epidemiological and ecological features of *Mhp* at the herd level (Clavijo et al., 2021b). The authors envisage that the classification could be used as a guide for *Mhp* management by both swine producers and veterinarians to characterise the health status of farms and set realistic goals for control or elimination of the pathogen (Clavijo et al., 2021b).

A national *Mhp* elimination programme was implemented in Norway in 1994 followed by population-wide surveillance and documentation (Gulliksen et al., 2021). The strategy involved partial depopulation of all *Mhp*-positive farrow-to-feed and farrow-to-finish herds, with total depopulation in all positive finisher herds. All units and pens of affected herds were cleaned and disinfected using sodium hypochlorite or potassium peroxydisulfate (Virkon S®). Between 1994 and 2009, 4% of individual samples and 12.4% of the herds were defined as positive, and in 2009, the Norwegian pig population was declared free from *Mhp* (Gulliksen et al., 2021). There has been ongoing surveillance, and between 2009 and 2019, a total of 44,228 individual serum samples have been analysed and found negative for the presence of antibodies against *Mhp*. This strategy's success is thought to be due to factors such as moderate-to-low prevalence of the pathogen, the well-documented and effective eradication protocol adopted, accurate diagnostic tests, and farming practices such as small herd sizes

and low herd density in most parts of the country, combined with the negligible import of live pigs. Seropositive samples detected in 2016 and 2017 were from herds vaccinating against *Mhp* (Gulliksen et al., 2021).

Although outbreaks of enzootic pneumonia in pigs caused by *Mhp* dropped drastically from >200 in 2003 to two cases in 2013 following an elimination programme implemented in 2004 in Switzerland, it was not possible to eliminate the pathogen from Swiss pig production (Overesch and Kuhnert, 2017). The *Mhp* strains involved in the outbreaks were genotyped using extended MLST to try to understand the sources and routes of infection (Overesch and Kuhnert, 2017). This typing revealed that most of the cases in 2014/2015 were due to two *Mhp* sequence types, identical to those harboured by wild boar. As there was insufficient evidence to assign wild boar as a reservoir, the authors concluded that wild boar are more likely to be the recipient rather than the transmitter of *Mhp* (Overesch and Kuhnert, 2017). They suggested that, as *Mhp* can be transmitted by air over distances of 5-10 km, implementing a monitoring scheme in wild boar in combination with genotyping of all available samples from domestic pigs and comparing the sequences against the PubMLST database of sequence types for *Mhp* could be useful in the tracing of strains on an international level to direct actions for combating enzootic pneumonia (Overesch and Kuhnert, 2017).

The elimination programme implemented in 2004 in Switzerland was based on total depopulation strategies of affected fattening farms as well as partial depopulation in breeding farms (Scalisi et al., 2022). The seroprevalence of *Mhp* in domestic pigs on 968 farms was tested 15 years later and found to be 0.98% (Scalisi et al., 2022). Several samples gave suspect results, and the authors speculated that samples that reacted weakly could be a result of cross-reactivity with antibodies mounted against *Mfl* a commensal of the porcine respiratory tract (Scalisi et al., 2022). Only one of the 968 farms enrolled in the study had a large proportion of strongly positive samples indicating an ongoing infection with *Mhp*. Seropositivity derived from vaccination could be ruled out due to Swiss legislation against vaccination and importation of vaccinated pigs. The role of wild boar as a reservoir was once again raised as the authors noted that the geographical distribution of the farms that tested seropositive for sows in their study corresponded approximately to the general distribution of reported cases in the past and overlaps in part with the wild boar population (Scalisi et al., 2022).

The costs of elimination were largely paid by farmers in the national programme in Norway, with about 40% of the analysis costs covered by the farmers, and 40–50% paid by the Norwegian Pig Health Service through collective funds from a pork levy all farmers are required to pay, with small

contributions from Norsvin SA and the Norwegian Veterinary Institute, and the final 10-20% paid by the abattoirs (Gulliksen et al., 2021). It was estimated in 2009 that the annual economic benefit of freedom from *Mhp* in the Norwegian pig population (1.5 million pigs slaughtered per year) was 7-18 million Norwegian kroner (approximately 0.65-1.68 million USD, 0.52-1.35 million GBP in 2023) (Gulliksen et al., 2021).

Control

The introduction of *Mhp* via fomites is not the highest risk for farms; the highest risk is incoming pigs (Maes et al., 2018). To improve the effectiveness of biosecurity strategies for *Mhp* disease prevention, it is important to identify the means by which the pathogen can be introduced and transmitted. A Bayesian Belief Network was employed to identify and quantify the probability of disease occurrence in Canadian swine farms (Cox et al., 2016). Pathogen introduction and transmission were increased when spilt feed (feed that did not fall directly in a feeding trough) was not cleaned up and fed to the pigs or disposed of immediately; by spreading manure from external sources onto land adjacent to the pigs; and in farms that were within 10 km (~6.21 miles) of another swine farm (Cox et al., 2016).

Gilt acclimation focused on reducing the bacterial shedding at first farrowing is used in efforts to control the vertical transmission of *Mhp*. Although the main strategy used to acclimate gilts in Europe and North America is vaccination, intentional exposure is also used as a means to limit *Mhp* infection at weaning. A survey of gilt acclimation strategies used in 18 European countries was carried out (Garza-Moreno et al., 2017). Of the 321 farms for which information was obtained, 278 had gilt isolation sites available for acclimation, and of those, 225 had specific acclimation procedures for *Mhp* (Garza-Moreno et al., 2017). Vaccination against *Mhp* was the most common acclimation procedure, followed by vaccination and animal exposure, with either culled sows or pigs, and a combination of vaccination and both types of live animal exposure (Garza-Moreno et al 2017). Although inadequate acclimation would leave gilts as a potential source of infection of offspring, only 23.7% of farms verified the acclimation process by ELISA, PCR, or both (Garza-Moreno et al., 2017).

The success of natural exposure to *Mhp* is important in gilt acclimation to prevent outbreaks and recirculation of pathogen. Intentional infection of pigs with *Mhp* in experimental settings is usually done via intratracheal inoculation, as this allows the application of infectious doses of inoculum to the pig's lower respiratory tract, promoting reliable *Mhp* colonization (Figueras Gourgues et al., 2020). However, intratracheal application is labour-intensive, time-consuming, and invasive, making

application in agricultural settings undesirable. A procedure for the intratracheal administration of lung tissue homogenate containing *Mhp* for acclimation of replacement gilts was described (Robbins et al., 2019). The procedure was tested under field conditions for the development of a herd-specific lung homogenate that encompasses herd-specific pathogen exposure (Robbins et al., 2019).

An experiment to evaluate the optimum seeder-to-naïve gilt ratio to achieve successful natural exposure was also carried out (Roos et al., 2016). *Mhp* strain 232 was used in the study as its infection dynamics are well understood, and the exposure was set by dividing the gilts into six groups of 10 with different ratios of seeder-to-naïve animals (Roos et al., 2016). The ideal ratio of six seeders per group of 10 gilts was required for successful exposure to *Mhp* in a 4-week exposure period (Roos et al., 2016). As an alternative to natural exposure as an acclimation strategy, nebulisation technology that would mimic the natural conditions of *Mhp* infection was compared to intratracheal inoculation (Figueras Gourgues et al., 2020). No statistically significant differences in the proportion of *Mhp* positives or in tracheobronchial swab pooled samples were detected between batches early after exposure via intratracheal or nebuliser inoculation (Figueras Gourgues et al., 2020). Unfortunately, the *Mhp* status of the gilts at first farrowing was not tested, and the authors were not able to determine the efficacy of the acclimation protocol in reducing bacterial shedding (Figueras Gourgues et al., 2020). Furthermore, while nebulisation may be a more convenient method to infect gilts for acclimation, it may pose some risks in terms of biosecurity and biocontainment or may be precluded by law for these reasons; therefore, further investigation would be required before introduction as a controlled exposure acclimation method.

A whole-herd partial budget model using field data to determine the economic value of programmes to eliminate *Mhp* from breeding herds in the USA was developed (Silva et al., 2019). The authors used retrospective data from 2004-2017 from 70 breeding herds that implemented herd closure or whole-herd medication protocols to eliminate *Mhp*, to determine the payback period of each. Although partial depopulation has been successfully applied in *Mhp* elimination programmes in Switzerland and Norway, the most common protocols in the USA are herd closure with herd medication, and whole-herd medication without herd closure. The herd closure with medication is an adaptation of the Swiss protocol that allows non-interrupting farrowing to minimise production losses (Silva et al., 2019). The whole-herd medication with no closure uses antibiotics only. Based on the estimated probabilities of success for the herd closure with medication protocol of 83%, and the medication protocol of 58%, the payback periods for eliminating *Mhp* from breed-to-finish operations was 2.18 months for the herd closure and 6.90 months for the medication protocol (Silva et al., 2019). If the authors assumed

a 100% success rate to eliminate *Mhp* using the herd closure or medication protocols, the payback periods would be 1.8 and 3.2 months, respectively. The lower success rate and higher project cost per sow (due to the cost of antibiotics) compared to herd closure made the medication protocol less feasible and the herd closure protocol economically better (Silva et al., 2019). Interestingly, a survival analysis by Yeske *et al.* compared the time-to-detection of *Mhp* in breed-to-wean farms after the application of herd closure and medication or whole-herd medication and found that farms that employed the herd closure and medication eradication method remained *Mhp*-negative for a longer period compared to whole-herd medication. The authors noted that, as this was an observational study, they were unable to separate the true efficacy of the eradication method from any potential reintroduction of the pathogen due to biosecurity breaches (Yeske et al., 2020).

The financial cost of *Mhp* positivity was estimated in 56 farrow-to-finish pig farms in Ireland using the Teagasc Pig Production Model (Calderón Díaz et al., 2020). Financial risk analysis was conducted by Monte Carlo simulation within this model using the Microsoft Excel add-in @Risk (Calderón Díaz et al., 2020). Using these methods, the authors estimated that annual mean profit was reduced by 41% in *Mhp*-positive farms. The authors note, however, that *Mhp*-positive farms were more likely to also be positive for PRRSV and/or sIAV compared to *Mhp*-negative farms, and these co-infections may contribute to the higher financial losses observed (Calderón Díaz et al., 2020). Their modelling provides evidence to support the adoption of effective disease control measures and/or to implement eradication programmes (Calderón Díaz et al., 2020). Finally, Paz-Sánchez *et al.* recommended that pigs that do not reach the optimal weight at slaughter age be sent to slaughter regardless to minimise economic losses and the risk of reinfection (Paz-Sánchez et al., 2021).

Therapeutics

The practice of metaphylaxis or strategic use of antibiotics in the absence of clinical disease or a positive *Mhp* test has been demonstrated to be beneficial in terms of pig growth and productivity, but not always in the control of pathogens (Maes et al., 2020). A study using strategic medication with Aivlosin at 2.5 mg tylvalosin/kg in drinking water (for seven days at weaning and when moved to finisher barn) resulted in increased average daily weight gain and decreased the average number of days in finishing (Pallarés et al., 2015). This treatment also significantly reduced mycoplasma-like lung lesions, and *Mhp* was not detected by qPCR in samples from lungs with lesions, in contrast to the controls that were positive for *Mhp* (Pallarés et al., 2015). Similar findings of increased average daily gains in pigs given antibiotics in feed were made in a study by Puls *et al.*, but there was no effect of

the antibiotic feeding programme on the incidence of morbidity and mortality (Puls et al., 2019). A study that involved three experimental groups receiving metaphylactic treatment with tilmicosin, valnemulin, tulathromycin, and a control group found no differences in the median of the degree of lung injury between groups; however, individuals treated with valnemulin had fewer lungs with lesions suggestive of swine enzootic pneumonia, indicating a lower incidence of co-infections (Stingelin et al., 2022). The antibiotic treatments produced better performance results, lower mortality, but there was no difference in *Mhp* DNA (copies/ μ L) in bronchoalveolar lavage fluid at slaughter (Stingelin et al., 2022). Although growth parameters are early indicators of subclinical or preclinical disease, strategic use of antibiotics alone may not be enough to control *Mhp*-associated pneumonia, and alternatives that do not risk the development of antimicrobial resistance may be more beneficial. Colostrum supplementation increased pig homogeneity of weight and average daily gain and decreased the use of antibiotics and mortality due to diarrhoea (Miguel et al., 2021). A study of dietary fibre intake and growth performance of piglets found that dietary fibre treatment improved the growth performance and reduced the mortality rate of piglets during the weaning period (BoShuai et al., 2018). Dietary supplementation may be preferable to metaphylaxis and its accompanying risks for resistance development in improving productivity and pig health.

Antimicrobial sensitivities of porcine mycoplasmas from different geographic regions have been tested and reported, but there are currently no clinical breakpoints available to facilitate data interpretation and correlation of MICs with *in vivo* efficacy (de Jong et al., 2021a; Maes et al., 2020). The antimicrobial susceptibilities of *Mhp* isolates associated with respiratory disease between 2010 to 2012 in Belgium, Spain and the UK were tested at a central laboratory (Klein et al., 2017). The highest *Mhp* MIC₉₀ values were for enrofloxacin, marbofloxacin and florfenicol in strains from the UK. Later MIC testing of isolates collected between 2015-2016 from Belgium, France, Germany, Great Britain, Hungary, Italy and Spain found similar MIC_{50/90} results (Klein et al., 2017) except for the MIC₅₀ of oxytetracycline, which was more than two dilution steps higher (de Jong et al., 2021a).

Some studies have tested the antimicrobial sensitivities of *Mhp* and *Mhr*. Field isolates of *Mhp* and *Mhr* obtained from enzootic pneumonia-like lung lesions during 2009-2011 in Korea were compared to reference strains *Mhp* (ATCC 25934) and *Mhr* (ATCC 27717) (JiSung et al., 2016). Korean *Mhp* and *Mhr* isolates are highly susceptible to tylvalosin but somewhat resistant to chlortetracycline (JiSung et al., 2016). Hungarian *Mhr* strains isolated between 2014 and 2017 were most sensitive to tetracyclines and pleuromutilins (Bekó et al., 2019a). Field isolates of *Mhp*, *Mhr* and *Mhs* from clinical samples collected in Southern European countries between 2013 and 2018 were most sensitive to tylvalosin

and valnemulin but resistant to lincomycin (Rosales et al., 2020). Meanwhile, Käbisch *et al.* recently used the *Mhr* type strain DSM 25591 to establish a repeatable protocol for antimicrobial susceptibility testing of this bacterium, aiming to promote inter-laboratory standardisation and more targeted use of antimicrobials (Käbisch et al., 2023).

The antibiotic susceptibility by broth micro-dilution method and mismatch amplification mutation assay (MAMA) were tested in 76 *Mhr* isolates from Belgium, Germany, Hungary, Italy and Poland collected between 2019 and 2021 (Klein et al., 2022). Isolates were sensitive to low concentrations of tiamulin, doxycycline, oxytetracycline and florfenicol and to moderate concentrations of enrofloxacin. For the tested macrolides and lincomycin, a bimodal MIC pattern was observed. Interestingly, resistance to macrolides and lincomycin in three of the isolates was not associated with SNP A2066G in the 23S rRNA gene (Klein et al., 2022).

A review of the use of antimicrobials for the treatment of *Mhp* described the resistance mechanisms that have been reported (Maes et al., 2020). Acquired resistance to macrolides and lincosamides in field strains of *Mhp* has been associated with A2058G, A2059G and A2064G (*E. coli* numbering) point mutations in domain V of the 23S rRNA gene. Mutations in domain II of 23S rRNA or in proteins L4 and L22 that have been identified in other *Mycoplasma* species have not been described in *Mhp* to date. Meanwhile, QRDR mutations have also been associated with quinolone resistance in *Mhp*, where two specific mutations (G921A and G1179A) in the gene encoding topoisomerase IV subunit A were linked to an increased MIC value for enrofloxacin in the Chinese HNSH strain (Rui and Qiu, 2023). Reduced susceptibility to marbofloxacin in *Mhp* was associated with an S80F or an D84N in the ParC QRDR, while reduced susceptibility to flumequine and enrofloxacin was associated with an S80Y substitution in the ParC QRDR, and an extra A83V mutation in GyrA further reduced enrofloxacin susceptibility in one strain. These and two additional mutations were found in the GyrA QRDR: G81A and E87G of Hungarian *Mhp* field isolates (Felde et al., 2018a). These studies suggest that ParC could be the primary target of fluoroquinolones in *Mhp* (Maes et al., 2020). Initially, single mutations observed in strains showed moderately reduced susceptibility, while subsequent double substitutions in the *parC* and *gyrA* genes were associated with higher MIC values (Felde et al., 2018a; Maes et al., 2020). Although strains with increased resistance have been identified, to date, no mechanism(s) of resistance to tetracyclines, aminoglycosides/aminocyclitols, pleuromutilins or amphenicols has been described in *Mhp* (Maes et al., 2020).

MAMAs and high-resolution melting (HRM) analysis designed for the rapid detection of antimicrobial resistance-associated mutations have been designed (Felde et al., 2020). The results of the MAMA and HRM assays matched the results of the MIC susceptibility method for the *Mhp* field isolates tested (Felde et al., 2020). A separate study has developed a MAMA to detect the mutation of the 23S rRNA gene at nucleotide position 2058 associated with resistance to macrolides and lincomycin (Földi et al., 2021). These molecular assays are convenient and cost-effective and provide information about the antimicrobial susceptibility of *Mhp* to critically important antimicrobials in a significantly shorter time compared to conventional MIC tests (Felde et al., 2020; Földi et al., 2021).

Vaccines

There are many vaccines currently available to protect against *Mhp*, spanning mono-, bi- and tri-valent bacterins, while in China a live-attenuated mycoplasma vaccine based on strain 168L is also used. However, the performance of the current vaccines is not optimal, with none advertising either complete clinical protection or the prevention of colonisation (DISCONTTOOLS, 2016b). Housing and management practices may also impact their efficacy, as illustrated in a recent study in Greece, where, despite a 98.3% vaccination rate, almost 50% of pig lungs contained lesions consistent with *Mhp* pneumonia (Lisgara et al., 2022). Most of these vaccines are generally administered intramuscularly, though we know that this may not be the optimal approach either immunologically or practically: in summary, there is room for improvement of the vaccines themselves, the way they are used, and how they are incorporated into wider herd-management practices.

Although the challenge of complete protection by vaccines has yet to be overcome, marked progress has been made. The development of new multi-valent formulations that offer comparable immunity to single-shot vaccines but with practical advantages for the farmer, and welfare advantages for their stock, is a notable advance. Meanwhile, researchers have been working hard to devise and test novel vaccination approaches and new formulations of existing agents.

Current vaccines

The introduction of a new trivalent vaccine against porcine circovirus (PCV) 2a/b and *Mhp* by Zoetis in 2019, under the tradenames Foster[®] Gold PCV MH in the USA and Asia/CircoMax[®] Myco in Europe, spurred a flurry of research studies: as well as inactivated *Mhp*, the inclusion of killed PCV2b offered, for the first time, the potential for cross-protection against the genetically similar PCV2d genotype, which has become the most prevalent strain globally in recent years and seems able to evade

immunity induced by vaccines against PCV2a (Huan et al., 2018). Researchers from the parent company provided evidence of long-lived immunity, with a single vaccination at approximately three weeks of age conferring significant protection from challenge six months later (Gracia et al., 2021). Other studies have since tested the value of this vaccine under more diverse field and experimental conditions. Um *et al.* showed that either one or two immunisations offer good protection against *Mhp* in terms of reduction in infectious load and improved growth characteristics in healthy piglets within a field herd with existing PCV2 and enzootic pneumonia, both in its own right (Um et al., 2021a), and when compared to the bivalent Porcilis® PCV M Hyo (MSD Animal Health) (Um et al., 2021b). Moreover, immunological and growth performance in the field was better following Fosterera® Gold immunisation of piglets from a commercial farm compared to vaccination with the bivalent Ingelvac FLEXcombo (Boehringer Ingelheim) and Porcilis® (MSD Animal Health) (S. Yang et al., 2022).

Fosterera® Gold is also one of the commercially available vaccines that has proven amenable to needle-free delivery, exhibiting comparable induction of specific antibodies and reduction in pathology when applied via intramuscular injection or by either of two needle-free injection devices to pigs under field conditions (Cho et al., 2022). Similarly, co-administration of a single dose of each of two commercially available PCV and *Mhp* vaccines using an intra-dermal needle-free delivery device conferred complete protection from clinical signs and significantly reduced the pathology associated with co-challenge three weeks later (Lee et al., 2021). A single small trial reported the effective adaptation of an attenuated *Mhp* vaccine licensed in China to aerosol delivery, showing that piglets exposed to the aerosol in a sealed chamber and challenged 42 days later were partially protected from lung lesions, comparable to the protection elicited by intra-pulmonary injection of the same vaccine (Hao et al., 2022a). However, using this method, only one in three piglets exhibited a specific sIgA response in the lung, while all piglets vaccinated via the intra-pulmonary route exhibited sIgA responses (Hao et al., 2022a). By contrast, when Li *et al.* compared the immunological effects of administering a live-attenuated *Mhp* strain (*Mhp* 168), which has been used to control the disease in China, once via intramuscular or intrapulmonary injection or twice intranasally, they found that the intrapulmonary route was significantly better at inducing specific IgA production in the respiratory mucosa (PengCheng et al., 2015).

Numerous trials have added to our knowledge of the performance of more established commercially available vaccines under experimental challenge or field conditions. Among the monovalent products, a single immunisation with the *Mhp* bacterin vaccine Hyogen® (CEVA Santé Animale) at three weeks of age led to improved weight gain and fewer *Mhp*-associated lung lesions at slaughter under field

conditions, compared to unvaccinated animals (Kim et al., 2021). Alongside, a field study demonstrated increased production and decreased lung lesions in pigs vaccinated once with Ingelvac MycoFLEX® (Boehringer Ingelheim) at three weeks of age (Pepovich, 2019). Similarly, a single immunisation of the inactivated *Mhp* vaccine Hyogen® was sufficient to protect piglets from subsequent co-challenge with low- and high-virulence strains of *Mhp* (Michiels et al., 2017a). Lastly, Cvjetković *et al.* conducted a large field study in an Austrian farrow-to-finish farm that compared a single immunisation with Hyogen® at approximately three weeks of age against two immunisations with Stellamune® Mycoplasma (Eli Lilly) at four days and roughly three weeks of age, finding that the former provided significantly superior protection against extension of lung lesions and prevalence of bronchopneumonia at the point of slaughter (Cvjetković et al., 2018). A recent study focused on characterising the immune response to Ingelvac MycoFLEX® along the lifespan of commercially bred piglets reared on farms in which *Mhp* had previously been shown to be circulating: interestingly, despite vaccination at 16 days of age, all piglets (whether born to sows with anti-*Mhp* antibodies or not) exhibited declining levels of antibodies during the course of their lives, returning to baseline from three months; while *ex vivo* recall T cell proliferative and cytokine responses peaked at one month and also then declined, but were present until the end of the experiment at six months (Biebaut et al., 2023).

Studies of bivalent vaccines including *Mhp* have also evidenced a level of efficacy that is relevant to producers. The PCV2 recombinant vector/*Mhp* bacterin vaccine, Circo/MycoGard® (Pharmgate Animal Health) conferred partial protection from dual challenge of piglets 25 days after a single immunisation (Ahn et al., 2021); while Suh *et al.* found that an intradermally administered bivalent vaccine comprising killed recombinant *Mhp* expressing a PCV2a capsid protein also provided partial protection from experimental challenge in piglets vaccinated once and exposed to either single or co-challenge approximately one month later (Suh et al., 2022). Another study compared two commercially available bivalent *Mhp*/PCV vaccines, Porcilis® PCV M Hyo (Intervet) and Suvaxyn® Circo+MH RTU (Zoetis), in a field setting in which both pathogens were present, finding that the two vaccines each conferred significant protection from disease and the associated reduced growth performance of piglets, but that Porcilis® PCV M Hyo offered superior responses under the tested conditions (López-Lorenzo et al., 2021). Similarly, in a field study at a Dutch farrow-to-finish farm with both PCV2 and *Mhp* present in the herd, piglets vaccinated once at three weeks of age with Porcilis® PCV M Hyo exhibited improved protection from both PCV2 and lung lesions at slaughter compared to those vaccinated concurrently with both CircoFLEX® and MycoFLEX®, or their unvaccinated littermates (Kaalberg et al., 2017). These data also supported earlier work in Poland which found that Porcilis® PCV M Hyo was well-tolerated

by immunised piglets and significantly protected them from the adverse effects of circulating PCV2 and *Mhp* (Witvliet et al., 2015).

Potentially important insight into the utility of multivalent versus multiple monovalent vaccines has also been generated: Oh *et al.* showed that a trivalent vaccine (3FLEX[®], Boehringer Ingelheim Vetmedica) including *Mhp* gave comparable protection against *Mhp* challenge compared to monovalent vaccination with MycoFLEX[®] 35 days later, though immunity to PRRSV was poorer following multivalent immunisation compared to after administration of monovalent Ingelvac PRRS[®] MLV (Boehringer Ingelheim) (Oh et al., 2019). However, another recent study suggested that co-immunisation against PCV (Porcilis PCV ID), PRRSV (Porcilis PRRS ID), *Lawsonia intracellularis* (Porcilis Lawsonia ID) and *Mhp* (Porcilis M Hyo ID ONCE) via the intradermal route did not compromise protection from individual pathogen challenge (Horsington et al., 2021); likewise, single- and co-immunisation against *Mhp* (Hyogen[®]) and PCV2 (Circovac[®]) induced comparable immune and protective features following challenge with either pathogen (Sibila et al., 2020). In contrast, co-immunisation with Ingelvac[®] Circoflex[®] and Ingelvac[®] Mhyo did not protect against lung lesions to the same level as the bivalent Porcilis[®] PCV M. Hyo vaccine under field conditions, though overall growth parameters were comparable between these groups (Pagot et al., 2017).

As well as optimal choice of the vaccine itself for the setting, vaccine efficacy at both the individual and herd levels can be impacted by life-stage/age of the animal. Immunisation of sows against *Mhp* may confer a useful level of protection upon their progeny, but results vary: while Arsenakis *et al.* concluded that sow vaccination could be useful, they also found that responses were highly variable between herds (Arsenakis et al., 2019); more recently, De Conti *et al.* showed that the parity of sows was a determining factor in their own vaccine responses and that the immunity also passed to their offspring, suggesting that vaccination efforts should be focused on primiparous sows (De Conti et al., 2022). On the piglet side, Yang *et al.* showed that vaccination against *Mhp* was more effective at reducing pathogen shedding and protecting growth performance when administered at one week of age than at three weeks of age, as part of a multi-pathogen immunisation and challenge experiment (Yang et al., 2020).

Alongside *Mhp*, *Mhr* is an important pathogen in commercial swine production, but until recently there was not a vaccine available. In 2019, this changed: following the development of a suitable challenge model (Martinson et al., 2018a) and the demonstration of the candidate vaccine's ability to partially protect colostrum-deprived piglets from clinical disease caused by *Mhr* and to decrease the

impact of infection on daily weight gain following infection (Martinson et al., 2019, 2018b), the first *Mhr* vaccine was licensed. Brought to market by Boehringer Ingelheim Animal Health under the trade name Ingelvac® MycoMAX, this binary ethyleneimine (BEI)-inactivated bacterin vaccine could help to markedly decrease the impact of *Mhr* infection on commercial swine farmers; however, widespread testing under field conditions has yet, to our knowledge, to be conducted. Alongside, an ELISA based on the *Mhr* protein p37 has been developed that is able to measure specific antibody responses to this pathogen and discriminate them from responses to closely related mycoplasmas (Bumgardner et al., 2018).

Novel vaccines

Inactivated vaccines

Alongside the commercially available bacterin vaccines against *Mhp*, several studies have reported new inactivated vaccines. For example, in 2019, Matthijs *et al.* published two studies describing their work towards a novel bacterin vaccine against *Mhp*, based on the highly virulent and antigenically distinct F7.2C strain: in the first study, they trialed a range of different formulations, identifying microparticle and oil-in-water formulations as effective at delivering a TLR ligand cocktail designed to enhance cellular immune responses, and successfully using cationic liposomes to deliver a ligand for Mincle (macrophage inducible C-type lectin) that elicited Th17 cells (Matthijs et al., 2019b). The group then took these three most promising candidates into trials of protection, finding that the oil-in-water formulation including TLR 1/2, 7/8 and 9 ligands offered the highest level of clinical protection, coupled with the greatest reduction in pathogen shedding and increased levels of IgA in the lung (Matthijs et al., 2019a). However, none of the vaccines offered complete protection from disease, and it is not yet clear how their performance compares to that of commercially available vaccines, or under field conditions: these promising results warrant further study.

In their initial study, Matthijs *et al.* also reported links between the blood transcriptome of animals in the first day post-vaccination and the magnitude of the later-observed immune responses, finding that activation of transcriptional modules consistent with a strong innate response, followed by their rapid down-regulation, was associated with a protective adaptive response to the vaccine (Matthijs et al., 2019b). Around the same time, Munyaka *et al.* identified differentially expressed genes in the peripheral blood of *Mhp* bacterin-immunised piglets that were also associated with high and low serological responses, including upregulated expression of genes involved in activation of the immune response at two days post-vaccination, followed by their down-regulation at day six (Munyaka et al., 2019). These data together begin to shape our understanding of post-vaccine immune correlates of

protection, which could also be relevant when assessing the responses of MPS-resistant swine breeds to infection and vaccination.

A series of studies has described investigations of an oral bacterin vaccine against *Mhp*, comprising a blend of total *Mhp* antigens with nanostructured mesoporous silica, designed to allow slow release in the intestine and thereby promote mucosal immunity; indeed, IgA responses in the respiratory mucosa of slaughter pigs were comparable to those elicited by intramuscular immunisation with a commercial bacterin vaccine, as was the level of protection from lung lesions following experimental challenge, though the oral vaccine did not induce detectable levels of systemic IgG, while – at least in this study – the commercial vaccine did (Mechler-Dreibi et al., 2021). Following on from this work, the oral vaccine was administered to piglets in which it similarly induced specific immune responses, but did not perform as well as the conventional vaccine in terms of immune parameters or protection from challenge after a single immunisation (Ferreira et al., 2023); though emerging evidence suggests that combining this oral vaccine with a commercially available bacterin boost, may enhance the protective response under field conditions (Storino et al., 2023).

Live-attenuated vaccines

Li *et al.* reported the successful generation and characterisation of a passage-attenuated strain of *Mhp* ES-2: after 200 passages, the attenuated strain was non-pathogenic in pigs and had lost over 37 kbp of its genome, including genes involved in alcohol dehydrogenation (which is linked to production of H₂O₂ under anaerobic conditions) and those encoding the LppA family lipoprotein and transcription elongation factor GreA, which are known virulence factors (Z. Li et al., 2021). The immunogenicity of the strain in terms of its ability to protect from pathogenic challenge has yet to be assessed.

Subunit vaccines

Several groups have made marked progress towards the development of a defined subunit vaccine, though many candidates remain at an early stage of development. Using reverse vaccinology, Li *et al.* generated a recombinant subunit vaccine comprising 11 predicted major histocompatibility complex (MHC)I/MHCII-binding epitopes from within an *Mhp* membrane nuclease, reporting strong immunogenicity in mice and piglets (Li et al., 2022). However, it is not yet clear whether the responses detected would protect pigs from challenge. Similarly, de Oliveira *et al.* constructed a chimeric protein comprising *Mhp* antigenic proteins P97R1, P46, P95 and P42, which was recognised by sera from convalescent pigs, and injected it into mice; they found that whether the protein was formulated as an adjuvanted subunit vaccine, or as an inactivated bacterin vectored by *E. coli*, it induced strong

systemic IgG responses, with an IgG1 bias (N. R. de Oliveira et al., 2017). More recently, a study in mice reported a strong Th1 cellular response and the generation of specific antibodies following two immunisations with an adjuvanted chimeric protein incorporating B and T cell epitopes from *Mhp* P46 and P65, and from PRRSV-GP5 and M proteins (Gao et al., 2022).

The *Mhp* protein P97 is the target of two additional novel subunit vaccines. In 2019, Ferriera *et al.* reported interesting preliminary results comparing intranasal and intramuscular administration of a novel *Mhp* P97- *E. coli* heat-labile-enterotoxin-fusion protein, designed to elicit strong mucosal immunity; they found that intranasal administration alone was able to completely protect piglets from lung lesions and colonisation of the respiratory tract following virulent challenge, despite the lack of detectable seroconversion in the blood (Ferreira et al., 2019). At around the same time, Hahn *et al.* were granted a patent in the USA for a vaccine formulation based on recombinant *Mhp* P97 protein, after demonstrating its superior performance compared to a commercially available inactivated *Mhp* vaccine (Hahn et al., 2019). Taken together, this antigen may well form the basis of a successful subunit vaccine in the future.

Vectored vaccines

A single study reported preliminary testing of a recombinant baculovirus-vectored vaccine expressing a chimeric *Mhp* protein comprising the known antigens P97R1, P46 and P42, alongside the PCV2 capsid protein: the vaccine successfully induced both specific antibodies and lymphocyte proliferation in mice and piglets; however, the pig responses were inferior compared to those elicited by a commercially available bacterin vaccine (Tao et al., 2019).

Adjuvants

Adjuvants can have a profound effect on both the magnitude and type of immune response elicited by a vaccine, and therefore its efficacy. Galliher-Beckley *et al.* reported the development of an inexpensive, plant-based, thermostable and antigen-sparing oil-in-water adjuvant, and demonstrated equivalent or superior strength and duration of antibody responses in piglets to inactivated *Mhp* compared to a commercially available *Mhp* bacterin vaccine (Galliher-Beckley et al., 2015). Another plant-based adjuvant, fucoidan, similarly showed promise in increasing antibody responses to *Mhp* antigen in mice (SuYeon and HongGu, 2015), but has yet to be tested in pigs, to our knowledge.

Nanoparticles may also be able to enhance responses to both subunit and whole-inactivated vaccines against *Mhp*. Virginio *et al.* concluded from mouse immunisation studies that mesoporous silica

nanoparticles elicited superior humoral and cell-mediated immune responses to an *Mhp* Hsp70 polypeptide domain compared to conventional alum-based adjuvant (Virginio et al., 2017). While, more recently, combining inactivated *Mhp* with a chitosan-coated nanoemulsion was found to be a promising basis for a dry powder vaccine for nasal vaccination: Canelli *et al.* observed found that a single intra-nasal immunisation with the novel vaccine induced significantly higher humoral and cell-mediated immune responses – most notably including high levels of IgA in the respiratory mucosa – to *Mhp* compared to intra-muscular injection with an unspecified commercially available bacterin vaccine (Canelli et al., 2023).

Rational testing of promising novel vaccine candidates in combination with appropriate conventional or novel adjuvants is a key strategy to advance the field of vaccine research.

Conclusions

Mhp remains a highly prevalent and economically important pathogen of swine populations worldwide, and the challenges inherent in its study (including the difficulty of culturing mycoplasmas and the chronic nature of *Mhp* infections) continue to limit our knowledge of its biology, transmission, and other important factors. However, recent studies have greatly expanded our understanding of *Mhp* despite these limitations, including the identification of many previously unknown factors in the biology, pathology and immunology of this disease. Over the past eight years, researchers have defined new methods for typing and diagnosing *Mhp*, which have facilitated higher-resolution studies of this pathogen's evolution and opened new avenues for on-farm surveillance, and the continuing generation of novel vaccine candidates has provided a firm basis for the validation and field testing of new control measures. Altogether, the progress made over the past decade in understanding and managing swine mycoplasma infections has been considerable and has placed a solid foundation for future research to address the many questions that remain.

Alongside these advances, the potential roles of *Mfl*, *Mhr* and *Mhs* – alone and/or in co-infection with *Mhp* – have also been studied, and new strategies are now available for their detection, molecular classification, and control. The same is true for the haemoplasmas, though the recent identification of the putatively pathogenic *C. M. haemosuis* has raised new questions that will require many studies to answer over the coming years.

Future research priorities

Based on the available literature, expert opinion, and previously published reviews (DISCONTTOOLS, 2016b; Maes et al., 2021, 2018; Sargeant et al., 2019), we suggest that the following areas of research into mycoplasmas affecting swine should be considered high priority:

Biology of the pathogens

- *Genome phylogeny studies, including data on disease association, to better understand the global distribution and evolution of swine mycoplasmas*
- *Deeper understanding of relationships between swine mycoplasmas and their associations with clinical disease and the wider respiratory microbiome*

Diagnosis

- *Further work to optimise sensitive, specific, affordable methods of surveillance for early detection of infection within populations*
- *Development of DIVA-capable serodiagnostics*
- *Continuing development of rapid and easy-to-use pen-side diagnostics*
- *Improved capabilities for sampling live animals*

Pathogenesis

- *Improved molecular tools (mutagenesis methods) to dissect and confirm the role of putative virulence factors as future candidates for vaccines or surveillance*
- *Research into the relationships among infections with mycoplasmas, other pathogenic bacteria, and viruses*
- *Continuing characterisation of the roles of glycerol and myoinositol metabolism in Mhp virulence*
- *Clarification of Mhp strain-specific differences in disease severity*

Immunology

- *Further work to understand and learn how to mitigate the immune-dysregulatory effects of Mhp, especially in the challenge of mixed infections*
- *Ongoing investigation of the mycoplasma genome to clarify the mechanisms by which these pathogens regulate the host immune response*

- *Combinatorial/cross-breeding studies to maximise the benefits of immune-resistance traits identified in different breeds/studies*
- *Assessment of the in vivo significance of innate immune findings made in vitro, for example, the degradation of NETs/METs and the use of derived nucleotides for replication*
- *Transition away from in vitro studies in the 3D4/21 PAM cell line due to documented differences related to gene insertion and immortalisation*
- *Characterisation of the relative importance of maternally derived antibodies and cell-mediated immunity in protecting offspring*

Epidemiology

- *Increasing focus on Mhp epidemiology and control in Africa*
- *Work to validate existing empirical assumptions around gilt acclimation methods aimed at reducing shedding in parity-1 litters*
- *Further work to fully understand infection dynamics of Mhp, Mhr and Mhs in the suckling period, and consequent susceptibility of piglets in the immediate post-weaning periods*
- *Updating of old research to describe risk factors for aerosol transmission of Mhp between farms*
- *Continued integration of molecular biology studies (e.g., genome sequencing and molecular typing) and comparison against the PubMLST database to monitor the evolution and geographic spread of swine mycoplasmas*
- *Computational modelling of risk factors and estimated transmission networks*
- *Investigation of the prevalence of C. M. haemosuis under different geographical and farm management conditions*
- *Research into the economic impacts of Mhr and Mhs infections*

Control

- *Work to assess the value of or need for updating isolates included in existing commercial bacterins*
- *Strategies for improving the use of antibiotics and other treatment strategies to minimise both clinical disease and the potential for antibiotic resistance development*
- *Development of alternatives to antibiotics for the treatment of infected animals*
- *Implementation of effective surveillance and monitoring schemes in wild boar populations*
- *Development of improved vaccines with greater protective efficacy and/or ability to inhibit disease transmission within swine herds*

- *More work to understand the effect of sow vaccination on reduction of shedding/transmission in the suckling period*
- *More work to identify adjuvants that deliver optimised mucosal immunity*
- *Continued studies of the potential generation of Mhp-resistant pig breeds and related immunogenetic patterns*
- *Standardisation of vaccine validation study protocols (e.g., housing of animals, inoculation route, etc.); inclusion of best-performing commercial vaccine as the gold-standard control*
- *Determination of duration of immunity offered by new trivalent Mhp/PCV2(a/b) vaccine under field conditions*

Mycoplasmas affecting poultry

Introduction

Mycoplasma gallisepticum (*M. gal*) and *Mycoplasma synoviae* (*M. syn*) are the most important pathogenic mycoplasmas of poultry, causing acute or chronic respiratory disease and substantial economic losses in poultry farming systems globally (reviewed in (Chaidez-Ibarra et al., 2022; Yadav et al., 2022b)). The most economically important host animals of these highly transmissible pathogens are chickens and turkeys, but a variety of wild birds are also susceptible to various strains (e.g., the widespread conjunctivitis caused by *M. gal* in American house finches (*Haemorrhous mexicanus*)) (Weitzman et al., 2020).

M. gal has been an established global pathogen for decades, and its clinical presentations in domestic poultry reduce meat and egg production, increase embryo morbidity, and require expensive control measures that can contribute to overuse of antibiotics and establishment of antimicrobial resistance (De la Cruz et al., 2020; Giram et al., 2022; WOA, 2022b). Studies of its economic impact are rare, but annual losses due to *M. gal* in the USA alone have been estimated at 118-150 million USD (~241-307 million USD adjusted for inflation in 2023) (Evans et al., 2005; Patterson, 1994).

Similar to *M. gal*, *M. syn* infection is associated with acute or chronic respiratory disease, but its tropism for joints also causes arthritis and lameness in infected birds (WOA, 2022b). *M. syn* has historically been considered a less significant pathogen compared to *M. gal*, but the increasing occurrence of *M. syn*-associated synovitis and eggshell apex abnormalities (which significantly reduce the strength of eggshells produced by infected birds) has attracted greater attention from researchers and policymakers over the past 15 years (Feberwee et al., 2009; Jeon et al., 2014).

Both *M. gal* and *M. syn* are highly prevalent in poultry populations across the world, and disease surveillance and management programmes are lacking in many countries. Commercial vaccines against *M. gal* have been available for many years, and vaccines against *M. syn* have more recently become available ((European Medicines Agency, 2021); reviewed in (Mugunthan et al., 2023)). However, control of these pathogens is complicated by many factors including the inconsistent protective efficacy of these vaccines, the prevalence of chronic disease among *M. gal*/*M. syn*-infected poultry, and a rising trend of antimicrobial resistance (reviewed in (Giram et al., 2022; Mugunthan et al., 2023; Yadav et al., 2022b)).

This section will cover some of the many papers that have been published on the biology, epidemiology, and control of *M. gal* and *M. syn* over the past eight years, highlighting the important advances that have been made in solidifying our understanding of these critical poultry pathogens and reducing their economic impact.

Literature review

Biology of the pathogens

The basic biology of *M. gal* and *M. syn* is similar to the other mycoplasmas described above, with small genome sizes (~820 to 990 kbp in both species, depending on the strain) that belie their molecular complexity and pathogenicity in poultry (Leigh et al., 2019; Papazisi et al., 2003; Xu et al., 2020b; Zhu et al., 2018). Unlike *M. bovis*, numerous vaccines against *M. gal* and *M. syn* are commercially available, including the ts-11, 6/85 and F-strain vaccine strains for *M. gal* and the MS-H and MS1 strains for *M. syn* (reviewed in (Kaboudi and Jbenyeni, 2019; Mugunthan et al., 2023)). The widespread uptake of these vaccines on poultry farms across the world has made molecular typing a particularly important tool for differentiating *M. gal* and *M. syn* field isolates from vaccine strains (Couto et al., 2016), as well as tracking their geographical spread, evolution and molecular diversity. This section will primarily discuss the progress that has been made over the past decade in molecular typing/phylogenetic methods for *M. gal* and *M. syn*, emphasising the application of new sequencing technologies to the collection and comparison of genomic data from these species.

Molecular typing and genome sequencing

Mycoplasma gallisepticum

The *mgc2* gene, which encodes a virulence factor involved in bacterial motility (Indikova et al., 2014), was recently validated as a reliable phylogenetic marker (De la Cruz et al., 2020) and has been widely used for characterisation and differentiation of *M. gal* isolates. Notably, Matucci *et al.* recently reported their identification of an atypical *M. gal* strain, isolated from Italian turkeys, with an *mgc2* variant that was unable to be sequenced by conventional endpoint PCR primers and required an alternative PCR protocol (Matucci et al., 2023). The variable cytoadhesin gene *pvpA* has also been used for molecular characterisation of *M. gal* (Boguslavsky et al., 2000; Manimaran et al., 2021), and

Hashemi *et al.* combined this technique with high-resolution melting curve analysis for a phylogenetic study of Iranian *M. gal* isolates (Hashemi *et al.*, 2018).

Other recent studies have reported that at least two partial *M. gal* genes (e.g., the *gapA* and *mgc2* genes) are needed to satisfactorily differentiate *M. gal* isolates (Limsatanun *et al.*, 2022). One response has been to supplement or replace these single gene-targeted sequencing methods with MLST, which displays generally higher discriminative power. Bekó *et al.* developed an MLST assay based on six housekeeping genes, reporting a high level of discrimination and identifying 57 separate sequence types from 130 *M. gal* strains (Bekó *et al.*, 2019b). This method was later used in a study of Italian *M. gal* isolates similar to the vaccine strains 6/85 and ts-11 – here, the authors found that *mgc2* sequencing was only able to identify 6/85-like strains, while MLST also differentiated ts-11-like strains at a higher resolution (Matucci *et al.*, 2020). Ghanem *et al.* developed a core genome MLST (cgMLST) workflow for *M. gal*, using 425 conserved genes to differentiate isolates based on whole-genome sequencing data; initial validation on a set of isolates from different continents demonstrated high-resolution differentiation and good agreement with epidemiological data (Ghanem *et al.*, 2018). In Iran, a smaller-scale gene-targeted sequencing workflow was developed for *M. gal* strain differentiation based on the complete *mgc2* and *pvpA* gene sequences, with the authors reporting higher discriminatory power compared to typing based on partial gene sequences (Bashashati and Banani, 2020).

As the above studies indicate, the continuing generation of complete sequence data is vital for tracking the epidemiology and evolution of *M. gal*, and the advancement of next- and third-generation sequencing technologies has facilitated a growing number of reports of complete genome sequences. Leigh *et al.* used Illumina and MinION Nanopore to sequence two derivatives of the original F-strain isolate (a laboratory-maintained F99 strain and the commercial AviPro vaccine strain) (Leigh *et al.*, 2019) and later published the sequences of three isolates (K4043, K4421A and K5234) that are extremely similar to the 6/85 vaccine strain (Leigh and Evans, 2022).

Mycoplasma synoviae

Molecular typing tools for *M. syn* have also seen significant developments over the past decade. The first target identified for molecular typing in this species was the variable lipoprotein and haemagglutinin A (*vlhA*) gene, which is part of a gene family contained in a single region of the *M. syn* genome (Béjaoui Khiari *et al.*, 2010). While most of the *vlhA* gene is semi- or highly variable, playing an important role in *M. syn* antigenic variation by altering the immunogenic surface haemagglutinin

(Noormohammadi et al., 2000), an upstream segment in the gene's conserved region is present as a single copy in the genome and can be sequenced to discriminate and type *M. syn* strains (El-Gazzar et al., 2012). *vlhA* sequencing broadly replaced earlier, more labour-intensive methods of *M. syn* molecular typing (Dijkman et al., 2016), and recent studies have characterised *M. syn* strains via *vlhA* sequence comparison in several countries, including Egypt (Tawfik et al., 2018), Pakistan (Rasool et al., 2018), India (Rajkumar et al., 2020), and China (ShiKai et al., 2017b). This latter study reported no significant link between pathogenicity and the analysed 5'-end of the *vlhA* gene, highlighting the difficulties that remain in predicting *M. syn* virulence based on sequence data (ShiKai et al., 2017b).

While *vlhA* typing is a relatively simple and reliable method for gaining phylogenetic information on *M. syn* isolates, *vlhA* partial sequences can vary substantially even between closely related strains, making it difficult to determine the genetic closeness of two isolates based on this method alone (Dijkman et al., 2014; El-Gazzar et al., 2016). Therefore, as for *M. gal*, MLST has also been applied as a more discriminative typing method for *M. syn*. Three independent MLST workflows for *M. syn* were published in 2016. Cizelj *et al.* based their method on six loci including three polymorphic genes (5'-*vlhA*, *cysP* and *nanH*), reporting good discrimination and separation of genotypes into clusters of epidemiologically linked strains (Cizelj et al., 2015); El-Gazzar *et al.* combined an MLST workflow with *vlhA* typing, using internal sequences from seven housekeeping genes to differentiate isolates at higher resolution (El-Gazzar et al., 2016); and Dijkman *et al.* selected five target genes to monitor for SNPs and reported higher discriminatory power compared to *vlhA* typing (Dijkman et al., 2016). MLVA has also been used for *M. syn* molecular typing, displaying similar discriminative power as a cost-effective alternative to MLST in a recent comparative study of *M. syn* isolates from 15 countries (Kreizinger et al., 2018).

Alongside their cgMLST method for *M. gal*, Ghanem *et al.* developed a similar workflow for *M. syn*, using 302 core genes to type whole-genome sequences from geographically disparate isolates and reporting high discriminatory power and agreement with epidemiological studies (Ghanem and El-Gazzar, 2018). Meanwhile, a standard MLST method (based on seven housekeeping genes) was employed in a molecular analysis of *M. syn* strains in China, finding that all analysed isolates belonged to a new phylogenetic group independent of previously reported strains (X. Zhang et al., 2021b).

Finally, several new *M. syn* genome sequences have been published over the past decade, including strains HN01 and 5-9 from China (Xu et al., 2020b; X. Zhang et al., 2021a). Zhu *et al.* used Illumina and MinION Nanopore methods to obtain the complete genome sequence of the widely used MS-H live

attenuated vaccine strain and compared it against an older American strain (WVU-1853) and a more recent Brazilian strain (MS53), identifying unique genetic features in MS-H that could be used for new DIVA diagnostics (Zhu et al., 2018).

Proteomics and gene characterisation

Mycoplasma gallisepticum

A protocol was recently published for targeted mutagenesis in *M. gal* via its endogenous CRISPR/Cas system, editing the *ksgA* gene to produce a distinct phenotype by abrogating resistance to the aminoglycoside kasugamycin (Mahdizadeh et al., 2020a). These authors later expanded this system to include simultaneous targeting of the *mnuA* nuclease gene (Klose et al., 2022b). This workflow could provide a significant new opportunity to identify the functions of *M. gal* gene products, many of which remain uncharacterised.

Mycoplasma synoviae

There have not been any notable advances published in this area since 2015.

Diagnosis

As with other pathogenic mycoplasmas, isolation and culturing is the gold standard for diagnosing infections with *M. gal* or *M. syn*; however, the time and effort involved in culturing mycoplasmas makes this impractical for rapid diagnosis (Gondal et al., 2015; Khalifa et al., 2013) and can lead to false negative results (Ammar et al., 2016a; Bukte and Gandge, 2018; Muhammad et al., 2018; Qasem et al., 2015). Instead, serological tests (e.g., serum plate agglutination or ELISA) are commonly used to screen flocks for infection, and positive results are confirmed via molecular assays (Yadav et al., 2021). Multiple diagnostics can also be applied to provide a clear picture of vaccine behaviour within a poultry population – a study of the MS-H strain within Italian broiler breeders, for instance, used serology and PCR to evaluate the transmission patterns of this vaccine at different production stages (Moronato et al., 2018).

DNA diagnostics

As co-infections between *M. gal* and *M. syn* are common, diagnostic assays able to detect and discriminate between these pathogens are useful for poultry premises in regions with high prevalence of both pathogens. One reported duplex qPCR assay used TaqMan minor groove binder probes targeting the *mgc2* and *vlhA* genes of *M. gal* and *M. syn*, respectively; the authors reported that the use of these probes simplified testing and improved specificity compared to similar assays (Ehtisham-ul-Haque et al., 2015). Meanwhile, Yadav *et al.* developed a duplex assay targeting the 16S-23S intergenic spacer region of *M. gal* and *vlhA* in *M. syn*, reporting ~94% diagnostic specificity and 100% specificity compared to single-species PCR (Yadav et al., 2022a).

Li *et al.* used duplex PCR to discriminate *M. syn* from non-mycoplasma respiratory pathogens (e.g., avian reovirus) (Li et al., 2015). Croville *et al.* took this a step further, publishing proof-of-concept for detecting 15 avian respiratory pathogens (including *M. gal* and *M. syn* alongside other common bacteria and viruses) in simultaneous qPCR assays on a commercial Biomark high-throughput PCR nanofluidic system (Croville et al., 2018).

PCR has also been combined with high-resolution melt curve analysis (Ghorashi et al., 2015) or restriction digestion (Zakeri and Pourbakhsh, 2017) to differentiate between vaccine and field mycoplasma strains, which is critical for appropriately monitoring transmission patterns and evaluating the efficacy of vaccine programmes. Two assays were recently developed for discriminating field *M. syn* from the MS-H vaccine strain: a qPCR test to detect differences in the *obg* gene (Dijkman et al., 2017) and a combination of nested PCR and high-resolution melting curve analysis targeting an adenine deletion in the vaccine's *oppF-1* gene (Zhu et al., 2017). Ricketts *et al.* published a combination of PCRs for discriminating *M. gal* vaccine strain ts-11 from the virulent R_{low} field strain via mutations in *vlhA* and the hypothetical protein gene *mg0359* (Ricketts et al., 2017).

As discussed in other sections, isothermal DNA amplification-based diagnostics promote the development of field-capable assays by removing the need for a thermocycler and (to a varying extent) experienced laboratory personnel to run the assay. Kuo *et al.* evaluated GeneReach's commercial POCKIT *M. synoviae* detection kit, an insulated isothermal PCR assay that targets the *vlhA* gene of *M. syn*, on synovial fluid and respiratory tract swab samples from Taiwanese poultry farms, reporting ~98% agreement with reference qPCR and no cross-reaction with *M. gal* or other economically significant poultry pathogens (Kuo et al., 2017). The popular LAMP approach has also been applied to

poultry mycoplasmas; Kursa *et al.* developed a *vlhA*-targeted LAMP assay and tested it on Polish field isolates of *M. syn*, reporting 1,000-fold higher sensitivity versus conventional PCR after 1 hour in a 63°C water bath (Kursa *et al.*, 2015). LAMP assays for *M. gal* diagnosis have targeted the *mgc2* (Ehtisham-ul-Haque *et al.*, 2017) or *pdhA* (FanQing *et al.*, 2015) genes, with results generally indicating high speed and sensitivity.

Alongside LAMP, a polymerase spiral reaction has been developed for *M. syn* diagnosis, reportedly providing 100-fold higher sensitivity over PCR and allowing visual readout of assay results (QianQian *et al.*, 2019); meanwhile, Xia *et al.* developed a recombinase-aided amplification assay for *M. syn*, combining it with a lateral flow dipstick for visual readout – the authors reported an agreement rate of ~95% with traditional PCR when tested on clinical samples, with a total assay time of 25 minutes (Xia *et al.*, 2022).

As the above studies indicate, most molecular diagnostics for *M. syn* have targeted the conserved *vlhA* gene, but other targets of interest have recently been identified within the *M. syn* genome. Xu *et al.* identified and developed SYBR green-based qPCR assays against two conserved *M. syn* genes (dubbed VY93_RS02250 and _RS02300), reporting 100% sensitivity and specificity in testing clinical samples (Xu *et al.*, 2021).

Finally, Bekő *et al.* developed rapid MAMAs to identify antimicrobial resistance-associated mutations in *M. syn* strains, reporting high coincidence with traditional *in vitro* sensitivity tests (Bekő *et al.*, 2020b). MAMAs have also been applied to differentiate between vaccine and field strains of *M. gal* (Sulyok *et al.*, 2018) and *M. syn* (Kreizinger *et al.*, 2015).

Serological diagnostics

The simplicity and ease-of-use of serological assays make them particularly suitable for assessing herd-level prevalence before moving to more sensitive, and more complicated, molecular assays. Serum plate agglutination assays have been widely reported in the literature, but their false positive rate is often high compared to ELISA (Ezatkah *et al.*, 2015). A recent comparison of commercial serodiagnostics (one rapid plate agglutination test and three ELISAs each against *M. gal*, *M. syn*, and *M. gal*+*M. syn*) found that the specificity of the agglutination test was too low for reliable discrimination of *M. gal*/*M. syn* from other poultry mycoplasmas (Ferberwee *et al.*, 2020).

Some in-house serum plate agglutination tests have been reported to out-perform specific ELISAs (Manimaran et al., 2020; Wanasawaeng et al., 2015), and in-house serological assays against regional *M. gal*/*M. syn* isolates may perform comparably to commercial kits at a lower cost (Rasool et al., 2017). In Egypt, for instance, Elyazeed *et al.* compared commercial ELISAs and PCR against in-house ELISA kits and a lateral flow assay targeting the local *M. gal* strain EGY1-2017; they observed a strong correlation between the compared ELISAs, though the lateral flow assay fared worse relative to PCR (~78% sensitivity and 92% specificity) (Elyazeed et al., 2020).

The reliability and relative simplicity of the ELISA platform has facilitated the development of several new tests for *M. gal*/*M. syn* diagnosis over the past eight years. An indirect ELISA based on the recombinant C-terminus of the *M. syn* OppF protein was reported to discriminate between antibody responses against the MS-H vaccine and its parental Australian field strain 86079/7NS, owing to a stable frameshift mutation in the vaccine's *oppF* gene (Kordafshari et al., 2020, 2019). Later, Yadav *et al.* published a whole cell-based indirect ELISA and a dot blot assay for the detection of *M. gal* and *M. syn* antibodies, reporting superior performance by the ELISA (Yadav et al., 2021).

In addition to traditional antibody-based ELISAs, nucleic acid aptamers are increasingly popular antibody detection reagents, as they are produced chemically and are more stable and modifiable compared to monoclonal antibodies (Thivyanathan and Gorenstein, 2012). A single-stranded DNA aptamer (Apt-236) that binds the *M. gal* PvpA protein was recently used to develop an indirect blocking enzyme-linked aptamer assay, with the study authors reporting an overall coincidence rate of ~92% with a commercial ELISA from IDEXX (Fu et al., 2021).

Sampling strategies and other developments

As new diagnostics continue to be developed, it is also important to develop new sampling techniques and to evaluate existing ones. For instance, Ball *et al.* recently reported that plastic swabs performed significantly better than wooden swabs in the collection of oropharyngeal samples for mycoplasma culture or molecular analysis (Ball et al., 2020), and Assen *et al.* validated molecular analysis of poultry dust particles for monitoring *M. gal* and *M. syn* vaccine uptake and pathogen status (Assen et al., 2022).

Finally, Lorenc *et al.* developed an optical technique for determining whether eggshells were produced by *M. syn*-infected hens based on changes in the shells' transmittance spectra (Lorenc et al., 2019).

This group then published proof-of-concept for using reflected light spectrometry combined with a machine learning algorithm to make this determination, reporting F-scores of 95% for white eggshells and 85% for brown shells (Pakuła et al., 2021). Later, these authors expanded this technique using a multispectral portable fibre-optic reflectometer and signal processing patch; this system performed worse for white but better for brown shells (Pakuła et al., 2022).

Pathogenesis

M. gal has been recognised for many years as an economically important pathogen of domestic poultry, causing chronic respiratory disease and infectious sinusitis associated with increased mortality and reduced weight gain, egg production and egg hatchability (reviewed in (Mugunthan et al., 2023)). *M. gal* infection also disturbs energy metabolism in the lungs, where reduced ATPase activity has been reported in association with cell damage, inflammation and oxidative stress (Ishfaq et al., 2020b), and induces pathological changes in immune organs, including cellular abnormalities, apoptosis and increased oxidative stress in spleen and thymus cells (Hu et al., 2021).

The immune dysfunction induced by *M. gal* infection increases the risk of co-infections with other pathogens, and numerous studies have reported more significant *M. gal*-associated pathologies in co-infected animals. *M. gal*-induced clinical disease was more severe in house finches (*Haemorrhous mexicanus*) chronically infected with *Plasmodium* (Dhondt et al., 2017b) or coccidia (Weitzman et al., 2020), for instance; prior *M. gal* infection also reduced antibody titres produced in response to Newcastle disease virus vaccination, and this immune response was even lower in birds co-infected with *E. coli* (Awad et al., 2019). Sid *et al.* studied co-infection with *M. gal* and influenza A virus (IAV) in chicken tracheal organ cultures (TOC), reporting that IAV infection promotes bacterial growth while *M. gal* infection may promote or inhibit IAV replication depending on the timing of bacteria-host interactions (Sid et al., 2016). A later *in vivo* study by Canter *et al.* added to this complex picture, reporting that chickens were significantly more likely to recover from virulent *M. gal* strain R_{low} infection if they had previously been infected with the low-pathogenic IAV H3N8 (Canter et al., 2020). Rürger *et al.* used *in vitro* chicken TOCs to analyse co-infection with *M. gal* and avian metapneumovirus (AMPV), another widespread respiratory pathogen of poultry (Rürger et al., 2021). This study revealed an interesting pattern of competition between the two pathogens wherein pre-infection with AMPV (followed by *M. gal*) enhanced viral replication and innate immunity, while switching the order of infection reduced bacterial attachment, replication, and pathology in poultry (Rürger et al., 2021).

M. syn also causes respiratory disease but infects the synovial membranes as well, leading to lameness alongside similar or slightly lower levels of mortality, egg abnormalities and decreased egg production ((Kursa et al., 2019a); reviewed in (Yadav et al., 2022b)). Atypical presentations such as meningeal vasculitis and encephalitis have also been reported (reviewed in (Rosales et al., 2017)). Like *M. gal*, *M. syn*-associated immune dysregulation in infected animals increases the odds of debilitating co-infections (Giram et al., 2022; Masukagami et al., 2018; Reck et al., 2019; Zhang et al., 2020). A report from Argentina indicated that *M. syn* may also be capable of infecting erythrocytes, thereby promoting chronic infection and allowing bacterial avoidance of antibiotic treatments (Uriarte et al., 2015).

The mechanisms underlying mycoplasma tropism and pathogenesis are complex, involving multifaceted host-pathogen crosstalk and adaptive bacterial alterations at the proteomic, genomic and metabolomic levels (Matyushkina et al., 2016). Meanwhile, “antagonistic coevolution” (reciprocal adaptations in pathogenic mycoplasmas and their host animals) leads to the continuous generation of new bacterial strains and different patterns of host-pathogen interaction (Bonneaud et al., 2018). Identifying the nature of these changes, the cellular and bacterial factors involved, and their impact on virulence is critical for a deeper understanding of *M. gal* and *M. syn* biology and potential routes of control, treatment and vaccination. This section will discuss some of the many advances made over the past decade in these fields.

In vivo and ex vivo studies

Mycoplasma gallisepticum

M. gal causes chronic respiratory disease by adhering to and subsequently damaging the cilia and mucosa of tracheal epithelial cells (TECs) (Rüger et al., 2022). Unsurprisingly, this damage is associated with significant changes in gene expression: RNA-seq studies of tracheal cells from experimentally infected chickens have identified thousands of DEGs, including many associated with the cell cycle and/or immune defence (e.g., TLRs and the JAK/STAT and MAPK signalling pathways) and mechanical repair (e.g., the ERK-MLCK pathway that regulates tight junction proteins in the trachea) (Beudet et al., 2017; C. Wu et al., 2022). Prior vaccination has been found to alter this response; chickens vaccinated with the live attenuated vaccine candidate Vaxsafe MG (strain ts-304) and challenged with the virulent strain Ap3AS, for instance, displayed significantly less dysregulation of transcriptional pathways involved in inflammation, cell replication, and mechanical repair compared to unvaccinated birds (Kulappu Arachchige et al., 2020).

The damage caused in the *M. gal*-infected trachea is accompanied by an accumulation of leucocytes in the tracheal submucosa, where Majumder *et al.* found that the interaction of mycoplasma lipid-associated membrane proteins with TLR2 on TECs induced NF- κ B-dependent expression of pro-inflammatory cytokines and leucocyte chemoattractants within 90 minutes of infection (Majumder *et al.*, 2014). *M. gal* infection has also been reported to damage the chicken thymus by activating the TLR2/MYD88/NF- κ B signalling pathway and the NLRP3 inflammasome, leading to inflammation and immune damage (Chen *et al.*, 2020). Interestingly, pathological changes to the respiratory and gut microbiomes have also been observed in *M. gal*-infected poultry, causing reduced pulmonary immune responses and increased sensitivity to secondary infection by *E. coli* or *Serratia marcescens* (Jian Wang *et al.*, 2021b, 2021a, 2020). The authors of these studies reported several effective countermeasures (including supplementation with the probiotic *Lactobacillus salivarius* and treatment with TLR2 ligand or IL-17) to promote *M. gal* clearance in the lungs, reduce pulmonary damage and restore immunological function (Jian Wang *et al.*, 2021b, 2021a). A link between microbiome and *M. gal* virulence was also observed in house finches, where *M. gal*-induced conjunctivitis is common; disrupting the ocular microbiome with cefazolin (to which mycoplasmas are naturally resistant) increased *M. gal* sialidase enzyme and cytoadherence activity in experimentally infected finches, associated with significantly more severe conjunctival inflammation (Thomason *et al.*, 2017). As next-generation sequencing-based protocols are continuing to improve the efficiency of microbiomics assays, large-scale characterisation of these bacterial populations in poultry (e.g., the recent profiling of the upper respiratory microbiome in turkeys (Kursa *et al.*, 2021)) may be a valuable avenue for dissecting host-pathogen interactions and microbiome-associated virulence factors.

Like most pathogenic mycoplasmas, *M. gal* expresses many proteins that have yet to be characterised, and many of the mechanisms underlying its virulence are therefore unknown (Butenko *et al.*, 2017; Tseng *et al.*, 2017a). The identification of new virulence factors is critical to our understanding of *M. gal* biology and to the development of effective countermeasures; this is particularly important in light of the upward trend in virulence observed in *M. gal* isolates over the past 20 years, which has been attributed to adaptations in immune manipulation in response to growing host resistance (Bonneaud *et al.*, 2020; Tardy *et al.*, 2019). Many studies published over the past eight years have therefore aimed to pinpoint and characterise the precise functionality of *M. gal* gene products. The conserved bacterial protein SpxA is one recently described putative virulence factor – in their study of phase transition in *M. gal* during host cell invasion, Matyushkina *et al.* reported that SpxA is a critical regulator of this

process, modulating the expression of key factors in metabolism, translation and adhesion to facilitate adaptation to the host environment (Matyushkina et al., 2016).

Studies of the *M. gal* surface proteome have reported functions for several previously unknown factors involved in adhesion and host-cell pathogen interactions. MGA_0676, formerly reported as a putative lipoprotein but otherwise uncharacterised, was identified as a membrane-localised calcium-dependent cytotoxic nuclease that translocates to the nucleus of infected cells and induces apoptosis (Xu et al., 2015). The mechanism underlying this activity was later studied in detail in DF-1 cells, revealing an interaction between MGA_0676's staphylococcal nuclease region and the Thif domain of NAE (NEDD8-activating enzyme E1 regulatory subunit) that led specifically to NF- κ B-mediated apoptosis (Peng et al., 2018). *M. gal*-associated apoptosis has also been reported in chicken PBMCs, mediated by adherence of the *M. gal* membrane protein and protective antigen GroEL (heat shock protein 60) to annexin A2 on the surface of these cells (Tan et al., 2015; Yu et al., 2019). Finally, the *M. gal* membrane proteins GapA and CrmA are known to play important roles in cell adhesion and motility (May et al., 2006), and a recent study in *ex vivo* chicken TOC showed that both proteins are virulence factors that promote adherence, colonisation and tracheal lesion development (Rüger et al., 2022).

Alongside these targeted studies of individual proteins, high-throughput screening technologies have been applied to search for critical proteins within the entire *M. gal* genome. Ron *et al.* applied *in vivo* induced antigen technology to identify 13 putative virulence factors in the R_{low} strain (five previously known and eight newly identified); the immunogenicity and expression levels of these proteins were then validated in experimentally infected chickens (Ron et al., 2015). Tseng *et al.* conducted signature-tagged transposon mutagenesis followed by experimental infection of chickens to identify *M. gal* virulence factors, reporting five new specific mutants (three with insertions in the MGA_0220/*oppD*₁ gene and two in hypothetical genes) with reduced persistence in the respiratory tract (Tseng et al., 2017a). This group then combined metabolomic profiling with bioinformatics analysis to classify MGA_0220 as a likely peptide transporter, while MGA_1102 (one of the two previously identified hypothetical genes) displayed properties consistent with a membrane-associated peptidase (Masukagami et al., 2018). Wang *et al.* used a similar transposon mutagenesis system to pinpoint ten genes associated with biofilm formation, which is thought to promote *M. gal* maintenance in commercial flocks (Chen et al., 2012; Y. Wang et al., 2017).

Finally, the 43 members of the variable lipoprotein hemagglutinin A (*vlhA*) gene family have long been thought to play important roles in *M. gal* immune evasion and pathogenesis (Noormohammadi, 2007), and a recent comparison of *vlhA* expression in *M. gal* strains of varying virulence (including R_{low} and the vaccine strains GT5 and Mg7) supported this – Pflaum *et al.* found evidence for a non-random, temporally regulated progression of *vlhA* gene expression during the first 48 hours of *M. gal* infection in chickens, suggesting that *vlhA* phase variation is an adaptive response to changes in the tracheal environment during colonisation (Pflaum *et al.*, 2018, 2016). An *in silico* modelling study has also been performed on the *vlhA* proteins, predicting their 3D structures, subcellular localisation and potential functional characteristics via combined application of several publicly available modelling tools (Mugunthan and Harish, 2022).

Mycoplasma synoviae

M. syn emerged as an economically significant pathogen of domestic birds decades after *M. gal*, and relatively fewer studies of its pathogenesis have been published over the past decade compared to *M. gal*. However, the growing prevalence of *M. syn* has necessitated a deeper understanding of its functional proteome and host-pathogen interactions (reviewed in (Kaboudi and Jbenyeni, 2019; Mugunthan *et al.*, 2023; Yadav *et al.*, 2022b)). The complexity of mycoplasma virulence was highlighted in a recent comparison of the whole genome sequences of the widely used MS-H vaccine strain and its parent strain (86079/7NS) – only 32 SNPs were identified in the MS-H genome, with 11 predicted to alter the secondary structure of associated proteins (Ling *et al.*, 2019).

M. syn infection significantly alters gene expression in the host animal – a recent transcriptomic study of chicken tracheal and spleen cells identified 861 and 753 DEGs, respectively, between control vs. *M. syn*-infected birds, with most of these genes relating to cell metabolism and/or immune pathways (Chen *et al.*, 2022); similar findings were previously reported in chicken chondrocytes as well (Cizelj *et al.*, 2016). The immune response to *M. gal* and *M. syn* infections is discussed in more detail in the [Immunology](#) section.

Liu *et al.* specifically investigated the mechanisms by which *M. syn* induces synovial infection and arthritis, analysing the transcriptome and proteome of cultured primary chicken synovial fibroblasts after *M. syn* infection (R. Liu *et al.*, 2020). The authors identified 149 genes that were differentially regulated at both the mRNA and protein levels, including factors involved in proliferation, inflammation, angiogenesis and tissue remodelling (R. Liu *et al.*, 2020). One of these proliferation-associated factors was serum amyloid A, which was shown in a subsequent study to accelerate the

cell cycle and promote replication in chicken synovial fibroblasts (R. Liu et al., 2021). Future studies will be needed to clarify the role of increased fibroblast proliferation in *M. syn*-associated synovitis. Pathological infiltration of immune cells is also associated with *M. syn* synovitis, and interactions between *M. syn* and synovial sheath cells have been reported to increase macrophage recruitment via chemokine and inflammatory cytokine release (Xu et al., 2020a).

In vitro studies

Mycoplasma gallisepticum

The *M. gal* surface lipoprotein pMGA was reported to interact with chicken apolipoprotein A-I, leading to cilia loss and cell damage *in vitro* (Fuli et al., 2016). Meanwhile, *M. gal*-associated TLR2 activation has been associated with increased ERK pathway-mediated autophagy in macrophages *in vitro* (Lu et al., 2017). Majumder *et al.* later confirmed their findings in an *in vitro* co-culture model of chicken macrophages and TECs, reporting that infection with a virulent *M. gal* strain (R_{low}) induced significantly higher levels of chemotaxis compared to the less virulent R_{high} strain (Majumder and Silbart, 2016).

M. gal-infected TECs were also found to upregulate miRNA-146a, which inhibits TLR-2 signalling and may serve as a counterbalance to the observed pro-inflammatory processes (Majumder et al., 2014). Altered miRNA profiles have been reported in *M. gal*-infected lung cells as well, where they may regulate major signalling processes including the MAPK, Wnt, JAK/STAT and PI3K/Akt/NF- κ B pathways (Kang et al., 2019; Y. Zhao et al., 2017a). Several studies have focused specifically on *in vitro* characterisation of individual miRNAs during *M. gal* infection. The miRNA gga-miR-101-3p is upregulated in *M. gal*-infected DF-1 cells, and the subsequent inhibition of host EZH2 (enhancer of zeste homolog 2) expression may impact T cell function (J. Chen et al., 2015). Upregulated gga-miR-24-3p, meanwhile, was reported to decrease proliferation and increase apoptosis by targeting Ras-related protein-B (Y. Wang et al., 2021). Conversely, the FOXO3-targeting gga-miR-223 is downregulated during *M. gal* infection, causing a similar phenotype (reduced proliferation, increased apoptosis) *in vitro* (Yin et al., 2021). Finally, Zou *et al.* reported high levels of gga-miR-193a in exosomes derived from *M. gal*-infected primary chicken type II pneumocytes, and internalisation of these exosomes by DF-1 cells decreased proliferation and increased apoptosis and proinflammatory cytokine secretion via the RAS/ERK signalling pathway (Zou et al., 2022). The role of miRNAs in poultry mycoplasma infections is discussed further in [Immunology](#).

Mycoplasma synoviae

As with *M. gal*, much of the proteome of *M. syn* remains uncharacterised, leaving gaps in our knowledge of its pathogenicity and our ability to produce new vaccine candidates (Q. Sun et al., 2022). Bao *et al.* characterised the alpha and beta subunits of the *M. syn* pyruvate dehydrogenase complex E1 (pdhA and pdhB), finding that both were capable of binding chicken plasminogen and were required for optimal binding to the DF-1 chicken cell line *in vitro* (Bao et al., 2021). A similar study was later conducted on the metabolic enzyme dihydrolipoamide dehydrogenase, finding that it also localised to the cell membrane, bound both fibronectin and plasminogen, and was required for binding to DF-1 cells (Qi et al., 2022).

Finally, as mentioned above, a relatively small number of SNPs separate the attenuated *M. syn* vaccine strain MS-H from its parental strain 86079/7NS, and re-isolation of vaccine strains from vaccinated flocks has identified isolates with reversions to the parental sequence specifically in the *obgE*, *oppF* and *gadph* genes (Klose et al., 2022a). A recent *in vitro* study reported that these changes altered the metabolism and growth kinetics of the mutated MS-H *in vitro* (including alterations in peptide/amino acid uptake, glycerophospholipid metabolism, and the arginine deiminase pathway), indicating a potential mechanism underlying the attenuation of this vaccine strain (Klose et al., 2023).

Immunology

Our knowledge of the immune response to *M. gal* and *M. syn* remains rudimentary, but – at least in the case of *M. gal* – progress is being made. The studies reported below illustrate the power of *in vivo* transcriptional studies to generate data that can be used to formulate testable hypotheses for future work and highlight an emerging role for non-coding mRNAs that warrants further investigation. Yet, most studies have been performed in far from field-like conditions, calling for further validation before their conclusions can be fully accepted.

Mycoplasma gallisepticum

M. gal infection causes severe lymphoproliferative lesions along the respiratory tract of both chickens and turkeys; therefore, the immune response to this agent is both friend and foe. What remains unclear is where the protective response ends, and immunopathology begins; this is necessary

knowledge for deepening our understanding of the disease and for the development of improved vaccines.

Immunogenetics

There have not been any notable advances published in this area since 2015.

Innate immunity

In their rare study of the *in vivo* response to *M. gal*, Beaudet *et al.* reported the changing transcriptional profile of the chicken trachea during the first week post-infection: they identified over 2500 significantly differentially expressed genes between *M. gal* R_{low} -infected and control chickens, including many involved in innate immune signalling pathways (TLR, MAPK, JAK/STAT and NOD-like receptor), as well as increased transcription of genes encoding TLRs 4 and 16 and ILs -1 β and -8 (Beaudet *et al.*, 2017). A subsequent study of the earliest days post-infection additionally revealed upregulation of expression of genes encoding IL-6, IL-12 β and IL-22, among others, in response to R_{low} but not to attenuated *M. gal* strains: a possible hint as to the difference in immunological trajectory leading to protection versus pathology (Beaudet *et al.*, 2019). These data represent an invaluable resource to guide future studies of the early phases of the immune response to *M. gal*, and as a validation benchmark for studies in other, less physiological, systems.

In recent years there has been a growing appreciation of the potential role of miRNAs in the regulation of biological pathways with relevance to diseases of chickens (reviewed in (Wang, 2020)). Following their initial identification of miRNAs that were differentially expressed in the lungs of embryonic chickens infected with *M. gal* (Y. Zhao *et al.*, 2017a), *in vitro* studies in embryonic chicken lung cells and an embryonic chicken fibroblast cell line (DF-1) showed that *M. gal* infection increased expression of miR-142-3p, leading to decreased expression of pro-inflammatory cytokine genes and limiting apoptosis (Yang *et al.*, 2021). Similar experiments by the same group then revealed increased expression of miR-33-5p during infection with *M. gal*, which also inhibited the expression of pro-inflammatory cytokines and of *M. gal*-induced apoptosis-related genes (Y. Sun *et al.*, 2022). Alongside, *M. gal* infection also led to decreased expression of the long-noncoding RNA, lnc90386, which normally binds to, and reduces the effects of, miR-33-5p (Y. Sun *et al.*, 2022). Another miR, miR-130b-3p, has been proposed to assist cells in defending against *M. gal*, with overexpression of this miRNA leading to increased cell proliferation during infection *in vitro* (Yuan *et al.*, 2018); while miR-21, by contrast, promoted proinflammatory cytokine expression by embryonic chicken lung cells and the DF-1 cell line after exposure to *M. gal* (Zhao *et al.*, 2019). Lastly, a recent study showed that miR-181a-5p

contained in exosomes from *M. gal*-infected chicken pneumocytes was taken up by DF-1 cells *in vitro*, where it targeted PPM1B leading to NF- κ B upregulation and increased transcription of genes encoding TLR2, MYD88, TNF- α and IL-1 β (Sun et al., 2021).

DF-1 cells and chicken embryos have also been used to look at TLR expression and the potential role of these receptors in *M. gal* infection. An initial study of DF-1 cells detected abundant expression of TLR6, but not TLR2, while both TLRs were expressed at comparable mRNA levels in the lungs of embryonic chicks; infection with *M. gal* increased expression of both TLRs in both systems, and led to activation of NF- κ B and transcription of inflammatory cytokine genes including those encoding IL-2, IL-6 and TNF- α (Tian et al., 2016). A subsequent study suggested that TLR2 expressed by DF-1 cells has an important role in the response to *M. gal*-derived lipid-associated membrane proteins, again leading to activation of NF- κ B and, here, to expression of IL- β (Ying Yu et al., 2018).

The relevance of these *in vitro* findings to *in vivo* infections of chickens remains to be assessed.

Adaptive immunity

A single study has investigated the adaptive immune response to *M. gal* infection in adult chickens. Kulappu Arachchige *et al.* examined the cellular immune response to *M. gal* in the tracheal mucosa of experimentally infected birds with or without prior vaccination: they found that protection was associated with lower levels of transcription of genes encoding IL-2, IL-6, RANTES and CXCL-14, higher levels of IFN- γ , and greater numbers of infiltrating B cells, compared to those seen in unvaccinated birds; while the pathology of primary *M. gal* infection in the absence of vaccination correlated with increased transcription of genes encoding IFN- γ , IL-17, RANTES and CXCL-14, and decreased mRNA expression of IL-2 (Kulappu Arachchige et al., 2021b). NK cells did not appear to play a role in protection (Kulappu Arachchige et al., 2021b).

Complementing this work, Miao *et al.* have been investigating the role of the respiratory microbiota in shaping mucosal immunity in the lung during *M. gal* infection of chickens. They found that the altered microbiota resulting from *M. gal* infection induced inflammatory/oxidative damage when transferred to the trachea of control uninfected chickens; moreover, the authors detected evidence of altered ratios of CD4⁺-to-CD8⁺ in chickens receiving *M. gal*-infection microbiota, which was associated with a possible Th1/Th2 imbalance (Miao et al., 2022a). These interesting findings warrant further investigation, including assessment of the possible effects of mycoplasma co-transferred with the tracheal microbiota of infected chickens.

Although most studies of *M. gal* immunology focus on chickens or their derived cell lines, two papers described investigations of the local adaptive immune response to *M. gal* infection in turkeys. Wijesurendra *et al.* observed the infiltration of lymphocytes into the tracheal mucosa of turkeys that were experimentally infected with virulent *M. gal* via the aerosol route two weeks previously (Wijesurendra *et al.*, 2017, 2015); the authors also detected specific antibody responses at seven and 14 days post-challenge, which varied in magnitude according to the *M. gal* strain used but could not be correlated with local B cell infiltration due to the absence of reagents for detecting turkey B cells (Wijesurendra *et al.*, 2017). More detailed analysis of the turkey immune response to infection has yet to be achieved.

Maternal immunity

Although the transfer of maternal antibody to chicks via both the egg yolk and the egg white is known to occur (Hamal *et al.*, 2006), and has the potential to interfere with vaccination – as most recently illustrated for avian influenza (Maas *et al.*, 2011); there have not been any studies of the effect of maternal immunity on either protection from *M. gal* or interference with vaccination against this pathogen. A recent study also reported heritable effects of maternal immune activation upon chicks' ability to mount responses to a model antigen vaccine (Verwoolde *et al.*, 2022), but the impact of these findings on immunity to mycoplasmas affecting poultry is similarly unknown.

Immune evasion

In their study of the adaptive immune response to *M. gal*, Kulappu Arachchige *et al.* also identified signs of immune evasion by the pathogen. When the authors compared the vaccination-induced protective response to that induced by virulent *M. gal* in the absence of prior immunity, they found that *M. gal* induced immune dysregulation in the tracheal mucosa, characterised by high expression of the genes encoding IFN- γ and IL-17, coupled with decreased IL-2 expression, which was associated with fewer CD8⁺T cells and B cells infiltrating the area (Kulappu Arachchige *et al.*, 2021b).

Alongside, Zhang *et al.* injected the virulent *M. gal* strain R_{LOW} into the bilateral air sacs of chickens and saw profound changes within the bursa of Fabricius: infected birds exhibited a significant infiltration of inflammatory cells coupled with lymphocyte apoptosis within the first week of infection, which correlated with increased levels of inflammatory cytokines and the expression of genes involved in the production of reactive oxygen species (ROS) in the bursa (Zhang *et al.*, 2020). Ishfaq *et al.* also documented signs of immune evasion/dysregulation during *M. gal* infection, finding that the bursa of

chickens exposed to *M. gal* contained numerous apoptotic cells and expressed high levels of genes encoding proinflammatory cytokines, coupled with evidence of CD8⁺ T cell depletion (Ishfaq et al., 2021b)

Mycoplasma synoviae

A single study has investigated the immune response to *M. syn*. Omotainse *et al.* reported the infiltration of B cells and CD4⁺ T cells into the tracheas of chickens inoculated with virulent *M. syn* 7NS intra-ocularly, also finding that infection induced increased mRNA expression of the Th1 cytokine IFN- γ (Omotainse et al., 2022). By contrast, the vaccine strain, MS-H, which is derived from 7NS, elicited a predominantly Th17 response (Omotainse et al., 2022).

Geographic distribution and epidemiology

While many new strategies for the management and control of *M. gal* and *M. syn* are under development (discussed in [Control of the disease](#)), our understanding of many basic aspects of their epidemiology (e.g., regional prevalence, transmission patterns, the role of wild birds, etc.) remains limited. Over the past decade, published studies have begun to fill in some of the most pressing research gaps in this field. Many groups have conducted country-level studies of mycoplasma prevalence within poultry farms, using molecular techniques (e.g., PCR targeting the 16S rRNA or *vlyA* gene) or serodiagnostics to detect *M. gal* and *M. syn* and draw conclusions based on small-scale transmission patterns. Meanwhile, the potential roles of wild bird species as reservoirs or maintenance hosts have been explored around the world.

Global situation

The Americas

Most of the recent studies on poultry mycoplasma epidemiology in the USA have focused on the western states (e.g., California, where *M. gal* and *M. syn* have been highly prevalent for decades (Mohammed et al., 1986)). Ramsubeik *et al.* investigated the factors associated with *M. gal* positivity in commercial turkeys in California, diagnosing numerous co-infections with *E. coli* and *M. gal*, *Bordetella avium* or *O. rhinotracheale* (Ramsubeik et al., 2021). An earlier study of small poultry flocks

in this state reported *M. gal* or *M. syn* co-infections in ~37% of birds infected with *A. paragallinarum* (Clothier et al., 2019).

Brochu *et al.* studied the prevalence of bacterial and viral pathogens within non-commercial poultry flocks in Ontario, Canada, reporting that 36% and 23% of animals were positive for *M. syn* and *M. gal*, respectively (Brochu et al., 2019a). Multifactorial respiratory diseases – commonly co-infections with *M. gal*, *M. syn*, *E. coli* and/or *Avibacterium* species – were the most common primary cause of clinical signs or mortality in the tested flocks (Brochu et al., 2019b). A later study in Quebec identified *M. syn* as being particularly widespread in layer farms, though its impact on production parameters was estimated to be relatively small (Bergeron et al., 2021).

M. gal and *M. syn* are also present in the West Indies – in Trinidad, their combined prevalence has been estimated at ~32% within backyard poultry farms (Jordan et al., 2018), and a study of apparently healthy unvaccinated free-roaming backyard chickens on St. Kitts reported seroprevalence of 37% (Bolfá et al., 2019).

In Brazil, currently the world's largest exporter and second-largest producer of chicken meat (Aquino, 2022), poor biosecurity on backyard poultry farms facilitates extremely high prevalence of *M. gal* and *M. syn* (L. G. S. de Oliveira et al., 2017). In 2015, *M. syn* was detected in only 14% of backyard chickens in Minas Gerais state, but its prevalence increased dramatically over the next five years (Batista et al., 2020; Silva et al., 2015, 2021), and it is now one of the primary causes of avian infectious arthritis in the country (Reck et al., 2019). At the commercial level, mycoplasma prevalence has been estimated at ~7% and 35% for *M. gal* and *M. syn* in Brazil's Federal District (dos Santos et al., 2021).

Europe

Several reports from Europe have highlighted the growing prevalence of *M. syn*, which has supplanted *M. gal* as the dominant mycoplasma of poultry in some regions (particularly those with pre-existing control programmes for *M. gal*) (Landman, 2014). *M. syn* is widespread in Spain (Cortés et al., 2021) and is gaining prevalence in Poland (Kursa et al., 2019b), while high levels of *M. syn* have been reported among Portuguese broiler breeder flocks (Moreira et al., 2015). A large-scale study in Belgium reported ~13% prevalence of *M. syn* among broiler chickens, compared to ~3% for *M. gal* (Michiels et al., 2016).

The neighbouring Netherlands instituted a compulsory *M. gal* monitoring and control programme in 2001, which appears to have substantially decreased the prevalence of this pathogen within commercial chicken and turkey flocks (ter Veen et al., 2021). A similar programme was implemented for *M. syn* in 2013 (Landman, 2014).

In the UK, the combined flock-level prevalence of *M. gal* and *M. syn* has been estimated at 45%, but further research and surveillance are needed to improve our understanding of their circulation in these flocks (Ball et al., 2018). Similar findings were reported from Italy; a study in Ragusa confirmed that *M. gal* and *M. syn* are actively circulating in both commercial and rural layer farms, with overall animal-level prevalence of 12.5% for *M. gal* and ~23% for *M. syn* (Galluzzo et al., 2022).

Africa

Relatively few studies of poultry mycoplasma prevalence have been reported from Africa, and most that are available have focused on the continent's more populous countries. Estimates of the prevalence of *M. gal* in Egyptian commercial poultry farms have varied widely (e.g., from ~9% up to 62%) (Abdelaziz et al., 2019; Marouf et al., 2022b). A recent comprehensive investigation of chicken flocks in Giza agreed with the lower end of this range, reporting ~11% seroprevalence, while *M. syn* was slightly more common at 13% (El-Ashram et al., 2021). High levels of mycoplasma infection have also been detected on Algerian poultry farms (though the responsible mycoplasma species were not identified), where they are reportedly controlled via significant overuse of antibiotics (Berghiche et al., 2018).

M. gal is also highly prevalent within the growing poultry production system of Nigeria, with ~74% prevalence reported among apparently healthy layer chickens in the city of Ibadan (Bakre et al., 2021). Meanwhile, *M. syn* was reported for the first time in Ethiopia (Hutton et al., 2017), where *M. gal* also remains widespread in large- and small-scale commercial poultry farms (Habte et al., 2022; Jibril et al., 2018; Shiferaw et al., 2022).

Finally, in South Africa, the prevalence of *M. gal* was estimated at ~56% in rural chicken flocks; alongside other common pathogens like Newcastle disease virus and H6N2 avian influenza, *M. gal* places a heavy economic burden on these small-scale poultry systems and increases the risk of antimicrobial overuse (Simbizi et al., 2021).

Asia, the Middle East and Oceania

M. gal is an established pathogen of farmed poultry across Asia, and the prevalence of *M. syn* has also been increasing. *M. syn* is widespread in China (ShiKai et al., 2017a), though seroprevalence analyses have reported highly variable rates depending on the region studied, with province-level estimates ranging from ~5% to 100% (J. Xue et al., 2017). A recent study of unvaccinated chicken flocks in the south-eastern Fujian province demonstrated high rates of *M. syn* infection alongside horizontal and vertical transmission (ChenYan et al., 2022). In central China, *M. syn* was reported at a much higher prevalence in layers than in broilers (~74% versus 20%, respectively) (Sui et al., 2022).

Mycoplasmas also impact the rapidly expanding poultry sector in India, where egg and broiler production was rising by ~8-10% annually prior to the COVID-19 pandemic (Mani and Beillard, 2021). Bacterial septicaemia, primarily attributable to *E. coli* with worryingly high levels of antimicrobial resistance, can involve co-infections with *M. gal* and *M. syn* (Kaore et al., 2018; Krishnegowda et al., 2022; Rama Raju et al., 2017), and infections by 3+ respiratory pathogens (e.g., *E. coli*, *M. gal*, *M. syn*, Newcastle disease virus, influenza A virus, etc.) are also common (Chaudhari et al., 2018; Gowthaman et al., 2017). A recent overview of mycoplasma prevalence within Indian commercial breeder and layer farms reported that ~6.5% of tested birds were PCR-positive for *M. gal* and ~24% for *M. syn*, while a further 15.5% were co-infected with both pathogens (Giram et al., 2022). However, the prevalence of *M. gal* in particular may be much higher in broiler breeders, where mycoplasma infections are generally found to be more common (Baksi et al., 2016). Reported *M. gal* prevalence is similarly high in neighbouring Bangladesh (Ganapathy et al., 2021; Raquib et al., 2021; Uddin et al., 2016), where surveillance of poultry mycoplasma pathogens is limited (Chowdhury et al., 2018).

Few recent reports on poultry mycoplasma prevalence have emerged from Southeast Asia. In Vietnam, *M. gal* was the third most common bacterial pathogen of poultry (after *Avibacterium paragallinarum* and *Ornithobacterium rhinotracheale*) in recent studies of the Mekong Delta region (Van et al., 2021, 2020).

Meanwhile, Siddique *et al.* analysed mycoplasma prevalence and antimicrobial resistance among broiler and layer poultry in Pakistan, reporting 61.5% positivity (primarily *M. gal*) and high levels of resistance by both *M. gal* and *M. syn* to the fluoroquinolone enrofloxacin (Siddique et al., 2020). Similar findings were reported from Saudi Arabia, where *M. gal* isolates exhibited increasing resistance to seven of 10 tested antimicrobials (Elbehiry et al., 2016).

In Iran, the reported prevalence of *M. syn* was substantially higher than *M. gal* in commercial poultry flocks of the western Khuzestan region (Gharibi et al., 2018), but *M. gal* remained slightly more widespread in Punjab (Shoaib, 2019). Whether these differences reflect actual regional variables, diagnostic test selection, or both is unclear. Rasoulinezhad *et al.* conducted a larger-scale study of *M. syn* in this country, reporting ~52% and 33% prevalence in backyard and commercial farms, respectively (Rasoulinezhad et al., 2018). *M. gal* and *M. syn* have both also been detected on ostrich farms, which are common in Iran (Moomivand et al., 2017). Finally, phylogenetic analysis of circulating *M. gal* isolates has shown high sequence similarity with Pakistani and Indian strains, pointing to cross-border transmission networks (Rasoulinezhad et al., 2017).

Surveillance, transmission and risk factors

Within infected poultry populations, *M. gal* can transmit to other animals horizontally (via direct contact) or vertically (transovarian, through the egg) (reviewed in (Mugunthan et al., 2023)). Horizontal transmission allows *M. gal* to spread rapidly ($R_0 \geq 4.5$) upon introduction to a flock (Feberwee et al., 2005), with animal-to-animal contact, aerosolised pathogen, contaminated food and fomites, and biofilm formation contributing to its transmission (Chen et al., 2012; Dhondt et al., 2007). Vaccines (primarily the F-strain, ts-11 and 6/85 strains) have been used for decades to limit the spread of *M. gal* and have been partially successful in reducing its associated production losses (Michiels et al., 2016; Whithear, 1996), though new and improved vaccines are needed to improve disease control and reduce antibiotic usage (reviewed in (Ishfaq et al., 2020a) and discussed further in [Vaccines](#)).

Like *M. gal*, *M. syn* is capable of both horizontal and vertical transmission, and recent studies of *M. syn* transmission parameters have indicated that vertical transmission was the primary route of infection on Dutch layer farms (Feberwee et al., 2017; ter Veen et al., 2020). The deployment of vaccines against *M. syn* (e.g., the MS-H strain) has been reported to reduce or prevent clinical signs, but it does not appear to prevent infection by field *M. syn* (Dijkman et al., 2017).

Wildlife

The epidemiology of *M. gal* and *M. syn* within wild birds remains poorly understood in many regions, and although available studies generally report low prevalence in these populations, their potential roles in transmission and/or as a pathogen reservoir in certain environments cannot be excluded (Michiels et al., 2016). The emergence of new host tropisms appears to be a relatively rare event –

transmission of *M. gal* from infected American house finches to other avian species is likely a common occurrence, for example, but recent findings suggest that within-host mutations are necessary for the establishment of productive infection in new hosts (i.e., close contact alone is not sufficient) (Staley et al., 2018b).

Many groups have reported their investigations of *M. gal* and/or *M. syn* in specific wild bird populations; for instance, *M. gal* has been detected in pigeons (*Columba livia*) in Iran (Ghohestani et al., 2018), eastern wild turkey (*Meleagris gallopavo silvestris*) in Canada (MacDonald et al., 2019), starlings (*Sturnus vulgaris*) in Iraq (Hamad et al., 2019), and gamebirds in Britain (Welchman et al., 2022). Several studies have been published on the prevalence of *M. gal* among wild bird populations in Germany, but none so far have reported a positive case (Fischer et al., 2022b, 2022a; Liebing et al., 2020; Prüter et al., 2018).

In Brazil, both *M. gal* and *M. syn* have been isolated from wild Muscovy ducks (*Cairina moschata*), feral pigeons, and several species of captive wild bird in the Rio de Janeiro Zoo (Ferreira et al., 2016; Magalhães et al., 2020b, 2020a). Despite this, Brazilian wildlife has not been demonstrated to play a major role in the maintenance or transmission of mycoplasmas, even in areas where large wild bird populations live in close proximity to commercial poultry farms (Guimarães et al., 2016). As important epidemiological variables (e.g., climate, human-animal-wildlife interaction patterns, farm density, etc.) can vary between geographical regions, however, it will be important in the future to expand these studies to cover a wider range of farming systems and wildlife populations.

In the USA, *M. gal* was first detected in house finches in the early 1990s, and it remains a significant bacterial pathogen causing conjunctivitis in this species (Dhondt et al., 2017a; Van et al., 2018). The density of bird feeders, which promote the gathering of many birds in a single location, has been found to be significantly associated with *M. gal* transmission among house finches (Adelman et al., 2015; Moyers et al., 2018; Van et al., 2018). A study of finches in Arizona reported an interesting geographical pattern – *M. gal* was detected in ~12% of birds captured in Green Valley near the border with Mexico, but not in birds from further north, suggesting that the relative lack of connectivity between urban regions and the more remote, arid habitats of southwestern Arizona limits the spread of infectious disease between these bird populations (Staley et al., 2018a).

While house finches are the most commonly observed wild hosts of *M. gal* in the USA, house finch-associated strains of *M. gal* have been detected in several other species belonging to the Fringillidae

and Corvidae families (Allen et al., 2018; Ley et al., 2016). *M. gal* also appears to be common in American raptor species, which have been reported to mount effective immune responses against the pathogen (Wrobel et al., 2016). Finally, a recent increase in the incidence of *M. gal*-associated conjunctivitis among purple finches (*Haemorhous purpureus*) in central New York sparked concern, though purple finch experimental infections and population data indicate that an *M. gal* epidemic would be unlikely to cause significant population decline as it did for house finches (Reinoso-Pérez et al., 2023).

Most studies of mycoplasma prevalence in wild birds have focused on one or a small number of species, making it difficult to draw broader conclusions on the impact of region-specific climatic factors or to extrapolate to other species. To address these issues, Sawicka-Durkalec *et al.* recently conducted a large-scale molecular and phylogenetic investigation of *M. gal* and *M. syn* in >1,100 wild birds from 55 species – however, while ~44% of tested birds were mycoplasma-positive, none were specifically positive for *M. gal* or *M. syn* (Sawicka-Durkalec et al., 2021).

Control of the disease

Current control measures for mycoplasma infections in the poultry industry are based on strict biosecurity practices, particularly in breeder flocks, to maintain the mycoplasma-free status, together with control programmes that include regularly performed diagnostic tests (More et al., 2017), vaccination, and antibiotic treatment using tetracyclines, macrolides (tylosin, tilmicosin), fluoroquinolones (enrofloxacin, difloxacin), and pleuromutilins (tiamulin) (Helmy et al., 2020). In a report commissioned by EFSA, the authors caution that although antibiotic treatments reduce clinical signs of the infection and improve the flock's performance, they do not eliminate *M. gal* infection in a flock and thus vertical transmission of the infection from adult carriers is likely (More et al., 2017). Vaccination to control mycoplasma infections is usually applied in commercial layer flocks, especially with multi-age systems, but there are limitations for their use in other contexts. For example, due to the short life of broilers, vaccination cannot be applied; vaccination is not performed in breeder flocks to avoid positive immunological responses to the vaccine strain during surveillance programmes; and there is not any commercial vaccine available for turkeys (More et al., 2017).

Maintaining effective biosecurity involves regular cleaning and disinfection of facilities where birds are kept, particularly in clearing poultry facilities following *M. gal* outbreaks. As airborne particulate

matter (food, drinking water, feathers, droppings, or dust) can act as a substrate for survival of microorganisms, *M. gal* can survive in the air of different reservoirs of poultry farms (Adell et al., 2015). The application of an air disinfectant, containing a mixture of Despadac®, monoethylene glycol, and water, using a thermo-nebuliser to reduce airborne *M. gal* in a commercial laying hen house was evaluated in Spain (Adell et al., 2015). Unfortunately, the treatment was not effective in reducing the concentration of mesophilic aerobic bacteria and *M. gal* in this study (Adell et al., 2015). A later study employed a NebuPure™ dispersal unit to produce a semi-dry fog of an electrochemically activated disinfecting solution, and the authors reported that this largely automated system was effective in disinfecting *M. gal*-contaminated facilities under experimental conditions (Evans et al., 2017). These opposing results may be due to key differences in their designs: the facilities tested (isolated steel experimental chambers vs a commercial laying hen house); the nebuliser itself; and the disinfectant aerosolised in each. This method deserves further evaluation, as it may be an effective means to clear facilities and equipment of mycoplasmas and other environmentally deposited avian pathogens.

Policy

M. gal eradication programmes via culling were carried out in Europe during the 1980s when many chicken and turkey flocks were infected with *M. gal*; nowadays, culling is implemented only in *M. gal*-positive breeder farms to avoid disease spread to production farms and other breeder farms (More et al., 2017). The adoption of strong biosecurity measures such as have been applied in the EU for more than 30 years, together with regular diagnostic testing to avoid contamination of poultry breeder flocks by *M. gal* or *M. meleagridis*, are effective in preventing the introduction of disease (More et al., 2017). As neither *M. gal* or *M. meleagridis* are zoonotic or highly contagious agents, infected birds with no clinical signs or lesions can be killed on-farm or in slaughterhouses for human consumption.

The biosecurity risk associated with imports of chilled or frozen chicken meat and meat products for the introduction of exotic *Mycoplasma* species into New Zealand was assessed (Cobb and Smith, 2015) and deemed to be extremely low. The authors estimated the likelihood of exposure via this route to be negligible and concluded that exotic *Mycoplasma* species were not likely to be introduced via this route.

Therapeutics

Antibiotics have been used intensively to treat *M. gal*-infected poultry flocks, which over time has resulted in the emergence and spread of resistant bacteria. A review of antimicrobial resistance in poultry pathogens (Nhung et al., 2017) found that the susceptibility to antibiotics of *M. gal* and *M. syn* field strains from Israel, Jordan, Iran, and Thailand, were (in increasing order): erythromycin, chlortetracycline, enrofloxacin, tylosin, and doxycycline. A more recent systematic review of 23 eligible studies that employed the microdilution MIC test based on the guidelines described by (Hannan, 2000) showed that enrofloxacin, oxytetracycline, and tylosin had the highest number of resistant *M. gal* isolates in most of the geographical distributions (Taiyari et al., 2021). The studies that were included in this analysis were from North and South America, Europe, Asia, the Middle East, and Africa (Taiyari et al., 2021). The most frequent antibiotic to which *M. gal* field isolates showed resistance was enrofloxacin (70% of the countries) followed by tylosin (54% of the countries).

A wide range of MIC values was observed in *M. gal* and *M. syn* isolates from chickens in Pakistan both for oxytetracycline and chlortetracycline (Khatoon et al., 2018); the macrolide tilmicosin was the most efficacious drug with a narrow MIC range. *In vitro* testing has also demonstrated high efficacy by macrolides, with tylvalosin being the most effective drug against both *M. gal* and *M. syn* Egyptian field isolates (El-Hamid et al., 2019). This finding was confirmed in later studies of isolates from broiler and layer chickens in Egyptian farms (Bastamy et al., 2022; Emam et al., 2020) and agrees with other research results for *M. syn* isolates in Central and Eastern Europe (Kreizinger et al., 2017). All *M. syn* isolates collected between 2012 and 2017 in Italy showed high MIC values of erythromycin and enrofloxacin (Catania et al., 2019) but, concerningly, tilmicosin MIC values showed a time-dependent increase, indicating an on-going selection process for resistant strains.

An assessment of antimicrobial susceptibility of *M. gal* and *M. syn* isolates from chickens and turkeys obtained from France, Germany, Great Britain, Hungary, Italy and Spain during 2014-2016 found bimodal MIC distributions for the fluoroquinolone enrofloxacin and the macrolides spiramycin, tilmicosin and tylosin, indicating that both species have sub-populations that are less susceptible *in vitro* to those antimicrobials (de Jong et al., 2021b). Bimodal distributions of MIC values for all drugs tested apart from doxycycline, tiamulin, and florfenicol were found in *M. gal* isolates collected in Italy between 2010 and 2020 (Bottinelli et al., 2022). Interestingly, a statistically significant trend toward low MICs of erythromycin, tylosin, tilmicosin, spiramycin, tiamulin and lincomycin was observed, indicating a return to susceptibility of *M. gal* toward these drugs (Bottinelli et al., 2022). All the studies

undertaken to date emphasise the need to continue studying MIC values to aid veterinarians in selecting appropriate treatments for *M. gal* and *M. syn*.

Studies to understand the molecular bases for resistance development in *M. gal* and *M. syn* have identified mutations in the QRDR of the 23S rRNA, with the A2058G and A2059G mutations the most common (Bekó et al., 2020a, 2019b; Beylefeld et al., 2018; Lysnyansky et al., 2015; Taiyari et al., 2021). The presence of either or both of these point mutations was responsible for macrolide resistance development in *M. gal* and *M. syn* (Ammar et al., 2016b; Bekó et al., 2020a; Lysnyansky et al., 2015), with all tested *M. syn* isolates having a G2057A transition in the 23S rRNA consistent with previously described intrinsic resistance to erythromycin (Lysnyansky et al., 2015). Mutations resulting in amino acid changes in the 50S ribosomal protein L22 were associated with decreased susceptibility to macrolides in *M. syn* (Bekó et al., 2020a). A study of the parC QRDR in *M. syn* strains from China identified a C254T mutation resulting in an amino acid change that gave rise to enrofloxacin resistance (Zhang et al., 2022). Comparative proteomic analyses of a tylosin-resistant *M. gal* mutant and a susceptible parent strain identified thirteen proteins as differentially expressed in the resistant strain compared to the susceptible strain (Xi et al., 2015). Among the differentially expressed proteins were enzymes that promote the formylation of initiator tRNA, elongation factors Tu and G, and enzymes involved in energy production. These results, together with previous findings of mutations in 23S rRNA or ribosomal proteins, indicate that resistance to macrolides is achieved through alterations in processes involved in protein translation. First reports were made of a transversion mutation at position 2621 (corresponding to 2611 in *E. coli* numbering) in one of the Egyptian *M. gal* isolates (Ammar et al., 2016b), and a point mutation D420N, which has been associated with quinolone resistance, in a South African *M. syn* strain (Beylefeld et al., 2018).

As previously mentioned, the lifespan of broiler chickens is short (5–6 weeks). There may be times when the treatment of several infections is required, which can result in interactions between antimicrobial drugs (Gbylik-Sikorska et al., 2018). As enrofloxacin and doxycycline were the most frequently detected antibacterial drugs in drinking water samples from dispensers on poultry farms, two studies to determine the impact of trace enrofloxacin on the pharmacokinetics of doxycycline in chickens were carried out (Gbylik-Sikorska et al., 2018, 2016). The highest maximum doxycycline tissue concentration was in the liver of *M. gal*-infected chickens also receiving trace doses of enrofloxacin (Gbylik-Sikorska et al., 2016), and trace amounts of enrofloxacin caused statistically significant changes in the doxycycline pharmacokinetic profile (Gbylik-Sikorska et al., 2018). The authors of these studies recommended that doxycycline should not be administered in combination with enrofloxacin,

and that the water supply systems on farms should be regularly cleaned and tested for antibiotic residues to avoid adverse interactions (Gbylik-Sikorska et al., 2018, 2016).

Alternatives to antibiotics

Given the rise in antimicrobial resistance in *Mycoplasma* species and the need to avoid antibiotic residues in animal products, alternative novel antimicrobials are needed to provide therapeutic choice in controlling infections. Recent high-throughput screening of a library of small molecules identified ten molecules with low MICs (0.78–100 µM) and efficacy against multiple *M. gal* strains (primarily the R-strain) and *M. gal* biofilm (Helmy et al., 2020). Of these ten molecules, six were tested in three-week-old chickens infected with *M. gal*, and two were found to be effective growth inhibitors of *M. gal*. These are promising novel antimicrobials that can be further characterised and developed for therapeutic use (Helmy et al., 2020).

Plant extracts and essential oils may also have antibacterial effects. Tea tree (*Melaleuca alternifolia*) essential oil administered through the feed to naturally *M. syn*-infected laying hens showed positive results compared to different antibiotics (Puvača et al., 2020). A commercial mixture of plant essential oils, Toldin CRD, was tested in broiler chickens experimentally infected with *M. gal* in comparison to tilmicosin (Hashem et al., 2022a). Toldin CRD exhibited immunostimulant and anti-inflammatory activities via significant downregulation of expression of the genes encoding TNF-α and IL-6, reduction of lysozyme, myeloperoxidase, and nitric oxide levels, and increase in IgG levels. Although immunohistochemistry and qPCR results demonstrated statistically significant reductions in the levels of *M. gal* antigens and *M. gal* loads in the Toldin CRD-treated group, these were inferior to tilmicosin (Hashem et al., 2022a).

The potential preventive and therapeutic effects of Chinese herbal medicinal formulae were investigated in chickens infected with the *M. gal* MG-HS strain (Y. Wang et al., 2022). Histopathological analysis showed that these formulae could significantly alleviate the severe respiratory inflammation induced by *M. gal* infection, and that this was associated with reduced expression of *M. gal* adhesion protein pMGA1.2 (Y. Wang et al., 2022). Meanwhile, glycyrrhizic acid inhibited MG-HS strain proliferation *in vitro* and reduced pMGA1.2 expression in the lungs of broiler chickens (Hu et al., 2022). The effect of adding chlorogenic acid extract from Japanese honeysuckle (*Lonicera japonica*) to drinking water was also investigated, with the authors reporting increased body weight and reduced seropositivity after six weeks (Müştak et al., 2015). Understanding the mechanism of action of these

and other plant extracts will allow us to further explore their potential as alternatives to antibiotics for treating mycoplasma infections in poultry.

The protective effects of methylsulfonylmethane, a naturally occurring organosulphur compound, were assessed in *M. gal*-induced inflammatory injury in chicken trachea and HD11 cells (Miao et al., 2022b). The action of methylsulfonylmethane to reduce inflammatory injury was through the repression of NF- κ B and the ERK/JNK-MAPK signalling pathway and the suppression of proinflammatory cytokines in both the trachea and HD11 cells (Miao et al., 2022b). The action of baicalin, a flavonoid extracted from *Scutellaria baicalensis* and used as a traditional medicine in East Asia, seems to be via a similar mechanism. Oral baicalin treatment of *M. gal*-infected chicks effectively prevented oxidative stress and splenocyte apoptosis via opposite modulation of NF- κ B and Nrf2/HO-1 (Ishfaq et al., 2019). Baicalin treatment also attenuated the level of proinflammatory cytokines and suppressed NF- κ B expression at both protein and mRNA levels in the chicken bursa of Fabricius in an *M. gal* infection model (Ishfaq et al., 2021a). Meanwhile, *in vitro* studies have indicated that baicalin treatment may reduce *M. gal*-induced oxidative stress, alleviate lung inflammation, and attenuate the expression of pro-inflammatory genes during infection (Chen et al., 2023; Ishfaq et al., 2021b; JiChang et al., 2019; Wu et al., 2020; Zou et al., 2021).

Vaccines

Mycoplasma gallisepticum

There are various commercially available vaccines for *M. gal*, including those based on inactivated mycoplasmas, a recombinant fowlpox-vectored vaccine, and three live-attenuated vaccines: each has their own advantages and disadvantages (reviewed in (Ishfaq et al., 2020a)). Studies in this area have variously aimed to characterise the existing vaccines further, or to improve upon their performance by the design and testing of novel vaccines.

Current vaccines

Understanding the immune response to live-attenuated vaccine strains can give important insights into protective immunity. Towards this aim, Beaudet *et al.* reported on the early transcriptional profile in the trachea of chickens immunised with the attenuated vaccine strains Mg7 and GT5, finding that, despite marked differences in response to the two strains, low expression of IL-8, IL-1 β and CCL4 was a common feature of vaccine exposure that was not seen in birds inoculated with virulent *M. gal* (Beaudet et al., 2019).

Other studies have looked at the route of administration of commercially available vaccines against *M. gal*. While a recent study reported the failure of *in ovo* injection of *M. gal* ts-11 to elicit immune responses in chicks (Alqhtani et al., 2022), more promising data have emerged using the live-attenuated vaccine against *M. gal* F-strain. Elliot *et al.* first trialled the Poulvac Myco F vaccine, produced by Zoetis, and identified a low dose that elicited specific IgM production at six weeks of age in approximately half of *in ovo* vaccinated birds (a comparable response to the normal post-hatch immunisation method, but much earlier), at the cost of approximately 10% mortality in injected eggs (Elliott et al., 2018), and was unaffected by the post-immunisation egg disinfection step that is used during commercial *in ovo* injection protocols (Elliott et al., 2020). Moreover, those birds that had responded to the *in ovo* vaccine were able to transmit the vaccine strain to their pen-mates, further increasing vaccine responses across the flock (Elliott et al., 2019). The same group most recently investigated how early the IgM response began to emerge after hatching, finding that detectable levels of antibody were present as early as seven days post-hatch (Elliott et al., 2022). *In ovo* administration of the 6/85 vaccine at a medium dose (1.73×10^2 CFU) was also lately shown to have a significant protective effect on hatchlings while avoiding the increased mortality associated with higher doses (Alqhtani et al., 2023). Formal establishment of the onset and extent of protection following this method of immunisation has yet to be published, but the comprehensive results of these initial and logically developed studies are highly promising.

In the field, infection of chickens with common avian pathogens at the time of *M. gal* vaccination may occur; therefore, it is important to understand the impact that this might have on vaccine efficacy. Recent studies found that responses to live-attenuated *M. gal* vaccines were adversely impacted by co-infection with chicken anaemia virus (Kulappu Arachchige et al., 2021a; Prezotto et al., 2016) and infectious bursal disease virus (Kulappu Arachchige et al., 2021a), while they were not significantly affected by co-infection with Newcastle disease virus (Riaz et al., 2021).

Novel vaccines

Inactivated vaccines

Marouf *et al.* trialled a locally produced formalin-inactivated pentavalent vaccine against a range of pathogens affecting chickens: *M. gal*, *M. syn*, and *Salmonella enterica* serovars Typhimurium, Enteritidis, and Kentucky (Marouf et al., 2022a). The authors found that immunising chicks at one and four weeks of age reduced mortality from either *M. gal* or *M. syn* infection from 100% at three weeks, to zero; moreover, vaccinated chicks appeared to clear the bacteria during the first week post-

infection, while control animals continued to shed the pathogens up to two weeks post-infection (Marouf et al., 2022a). Protection was associated with high levels of *M. gal*- and *M. syn*-specific antibody production, which was rapidly elicited by the initial vaccination and boosted by the second (Marouf et al., 2022a). These data show the potential of such a vaccine to protect against a suite of bacterial diseases affecting chickens and warrants further investigation in larger study groups, and in different species.

The means of inactivation used during the preparation of vaccines from live microorganisms can affect the availability and immunogenicity of some antigens. Atalla *et al.* reported the application of 1, 5-iodonaphthylazide followed by UV light exposure to *M. gal*, finding that this protocol enabled the retention of lipoproteins and was able to elicit significant titres of *M. gal*-specific antibodies at two weeks post-immunisation of chickens (Atalla et al., 2015).

Taking a different approach, Kumosani *et al.* used solubilised total antigens of *M. gal* and H9A2 avian influenza virus, encapsulated in cationic liposomes with or without immune-stimulating *Echinacea* extract, to twice immunise groups of 20-day-old broiler chicks by aerosol exposure, before virulent challenge with both pathogens one week after boosting (Kumosani et al., 2020). This large and well-conducted study found that that highest concentration of specific antibodies was elicited in the presence of echinacea extract, and that the vaccine conferred significant protection from *M. gal* colonisation as well as from losses in productivity associated with infection (Kumosani et al., 2020). However, in the absence of commercially available vaccine groups for comparison, it is difficult to know whether this approach represents an improvement on the currently available resources for disease control.

Live-attenuated vaccines

Following their early work showing that the commercial live-attenuated ts-11-based vaccine “Vaxsafe MG” contained two *M. gal* variants, one of which retained a functional GapA cytoadhesin gene – designated ts-304 – and the other not (Kanci et al., 2004), researchers at the University of Melbourne have continued to test and characterise the GapA⁺ variant as a vaccine candidate. First demonstrating that the strain was safe and effective at a range of doses in chickens (Shil et al., 2011), the researchers went on to show that a single immunisation of ts-304 could protect chickens from virulent challenge four weeks later (Kanci Condello et al., 2020b), with protection lasting to the final timepoint of 57 weeks post-immunisation, representing life-long immunity for commercial layer or breeder chickens (Kanci Condello et al., 2020a).

Tseng *et al.* also reported the development of a novel rationally attenuated *M. gal* strain and tested its safety and efficacy in chickens (Tseng *et al.*, 2017b). Following their identification of the *M. gal oppD* gene as encoding a putative oligopeptide transporter acting as a virulence factor (Tseng *et al.*, 2017a), the authors generated an attenuated Ap3AS lacking this gene, and used it to immunise five-week old chickens once before challenging them with the virulent parental strain two weeks later (Tseng *et al.*, 2017b). The attenuated strain did not induce antibodies against *M. gal*, but it did elicit an antibody response that was comparable to those reported for the commercial ts-11 vaccine by four weeks after immunisation; moreover, the *OppD* mutant protected chickens from pathology when exposed to virulent *M. gal* (Tseng *et al.*, 2017b).

Furthermore, despite early studies that revealed a lack of efficacy (Alessandri *et al.*, 2005) or even pathology (Lin and Kleven, 1982; My and Sh, 1984) induced by immunisation of turkeys with live-attenuated vaccines against *M. gal* that elicited a degree of protection in chickens, evidence is emerging that ts-304 is also effective in this species. Wijesurendra *et al.* tested the GapA⁺ ts-11 vaccine strain in turkeys, finding evidence of reduced T cell infiltration into the trachea which was correlated with less severe disease after challenge with the virulent Ap3AS strain; moreover, despite an absence of detectable antibody induction after vaccination, immunised turkeys did raise significantly higher antibody responses to challenge than their non-immunised counterparts (Wijesurendra *et al.*, 2017). More detailed analysis of safety and efficacy at a range of doses led the group to conclude that *M. gal* ts-304 was a safe and effective vaccine for turkeys, able to elicit long-lasting protection in the absence of adverse effects (Kanci *et al.*, 2018).

Commercially available live-attenuated vaccines are based on the *M. gal* 6/85, F, or ts-11 strains, which vary in their virulence, immunogenicity, and protective efficacy; however, few data exist on the potential of the K-strain of *M. gal* as a vaccine candidate. Ferguson-Noel *et al.* initially reported that the K2101 strain of *M. gal* was both a safe and an effective vaccine in three-week-old chickens (Ferguson-Noel *et al.*, 2012), then went on to show that the K-strain vaccine performed as well as the F-strain vaccine in both broiler and layer chickens (Ferguson-Noel and Williams, 2015).

Subunit vaccines

A single study reported promising results from a novel plant-produced vaccine against *M. gal*. Shi *et al.* generated genetically engineered wheat expressing the T1 gene to produce seeds containing this protein, as an oral vaccine for chickens; after two feedings of powdered seeds two weeks apart, chicks

mounted specific antibody responses and were similarly protected from *M. gal* challenge compared to birds receiving a commercial eye-drop administered live-attenuated vaccine (Shi et al., 2023). The clear advantages offered by plant-based vaccine production, alongside the ease of administration of oral vaccines, justify further follow-up of this interesting work.

Vectored vaccines

Zhang *et al.* reported comparable protection to a commercially available F-36 live-attenuated *M. gal* strain by twice immunising week-old chicks with a recombinant adenovirus bearing *M. gal* TM-1 protein, and challenging them with virulent *M. gal* two weeks later; interestingly, the level of protection from *M. gal* was the same when the adenoviral vector also expressed the S1 spike glycoprotein of infectious bronchitis virus, marking this approach as promising for both mono- and bi-valent vaccination of chickens (Zhang et al., 2018). It would also be interesting to trial this vaccine in turkeys.

Adjuvants

There have not been any notable advances published in this area since 2015.

Mycoplasma synoviae

Current vaccines

Omotainse *et al.* reported that the tracheal response of chickens to the MS-H vaccine strain was characterised by the transcription of IL-17A and the infiltration of CD4⁺CD25⁻ T cells, B cells and macrophages (Omotainse et al., 2022).

Novel vaccines

A single report has been published on a novel inactivated vaccine targeting *M. syn.* Gong *et al.* subcutaneously immunised day-old broiler chicks once with BEI-inactivated *M. syn* strain CHN-WF224-2016 formulated with different adjuvants and challenged them six weeks later with the virulent *M. syn* strain CHN-BXJ2-2015 (Gong et al., 2020). The authors found that, compared to chitosan- and sodium polyacrylate- based adjuvants, the mineral oil-based adjuvant elicited superior cellular and antibody responses that were associated with high levels of protection (Gong et al., 2020).

Conclusions

M. gal and *M. syn* remain highly prevalent and economically damaging pathogens of poultry across much of the world. Key to the future containment and control of these mycoplasmas will be the expansion of existing surveillance networks, which will likely require international coordination between policymakers and researchers to accurately map transmission patterns, animal movement networks, and risk factors for *M. gal* and *M. syn*. Improving our capacity to track the spread of different poultry mycoplasma strains will also allow the targeted use of disease treatment and control measures, benefitting efforts to reduce the massive overuse of antimicrobials to which *M. gal* and *M. syn* are prime contributors.

In the meantime, our understanding of the fundamental biology, infection pathways, and host-pathogen interactions of these mycoplasmas has been greatly expanded over the past decade, though many of their gene products remain uncharacterised. The application of emerging technologies (e.g., the CRISPR/Cas system, which was recently adapted to *M. gal* (Ipoutcha et al., 2022)) promises to expand the existing repertoire of laboratory techniques for investigating the molecular biology, pathogenesis and immunity of *M. gal* and *M. syn*. The many promising new diagnostic tests and vaccine candidates described above will also need to be tested under a variety of field settings to ensure that they are broadly applicable for *M. gal* detection and control.

Future research priorities

Based on the available literature and expert opinion, we suggest that the following areas of research into mycoplasmas affecting poultry should be considered high priority:

Biology of the pathogens

- *Continuing generation of complete genome sequences to support molecular and epidemiology studies*
- *High-throughput characterisation of *M. gal* and *M. syn* proteomes and smaller-scale studies of individual proteins of unknown function*

Diagnosis

- *Field validation of isothermal molecular diagnostic assays to facilitate pen-side use*

- *Replacement of agglutination tests with validated ELISAs*
- *Standardisation and validation of in-house serodiagnostics against commercial standards*

Pathogenesis

- *Continued identification and functional characterisation of putative virulence factors*
- *Further assessment of the poultry microbiome, its variations between breeds and species, and its interactions with M. gal and M. syn*

Immunology

- *Immunogenetics of resistance/susceptibility to mycoplasma-driven disease in commercial poultry species*
- *Studies to discriminate between a protective versus pathologic immune response, and the factors driving the emergence of one over the other*
- *Understanding of the influence of maternal immunity on resistance/susceptibility to disease caused by mycoplasmas and how this should inform optimal timing of vaccination of chicks/eggs*

Epidemiology

- *Expanded surveillance of M. syn in domestic poultry flocks, particularly in Africa*
- *Standardisation of prevalence studies (e.g., sample types, diagnostic assays, etc.)*
- *Clarification of the importance of vertical transmission in the spread and maintenance of M. syn*
- *Large-scale (e.g., multi-species) investigations of M. gal and M. syn in wild bird populations*
- *Characterisation of transmission dynamics at interfaces between domestic and wild birds*
- *Impact of ecological/climatological variables on M. gal/M. syn maintenance and transmission*

Control

- *Assessment of antimicrobial susceptibility in veterinary Mycoplasma spp. requires standardised laboratory methods and agreed interpretive criteria for clinical breakpoints to facilitate correlation of MICs with in vivo efficacy of antibiotics*
- *Development of novel effective means of controlling M. gal in light of efforts to reduce reliance on antibiotics*
- *Further study of the potential of identified lead candidates for plant-derived antimicrobials suitable for use against Mycoplasma species affecting poultry*

Conclusions

The studies described in this report present important advances in all fields of veterinary mycoplasma research, from basic biology to vaccine development and policy recommendations. Great strides have been made in characterising mycoplasma proteins, host-pathogen interactions (including transcriptional and metabolic changes), and the mechanisms of immune evasion. However, many mycoplasma gene products remain uncharacterised, and post-translational processing events that may control the functions of virulence factors (e.g., adhesion proteins) are not well-understood. The great diversity of veterinary mycoplasmas means that approaches for studying one species are not always suitable for studying another, and the development of molecular biological tools targeted to individual species (e.g., new sequencing and genome editing protocols, *in vitro* models, etc.) will therefore continue to be an important research avenue. The continuing generation and annotation of complete sequences (and the periodic re-annotation of past genomic studies in light of new data) is also an important priority.

Meanwhile, the effective application of next-generation techniques (e.g., single-cell RNA-seq) to veterinary immunology relies on the development of a broader selection of immunological reagents and funding for basic studies of host species immunology. Experimental challenge models often focus on replicating gross pathological findings but exclude the effects of transmission routes and field-like levels of pathogen exposure. While it is commonly noted that route of vaccine administration will modify immunological outcomes, for example, the extent of mucosal immunity, the field appears slow to act on the impact of the challenge method and the associated potential for creating research artifacts. While replicating near field-like challenges may be technically difficult, such a system would allow a higher level of confidence in the data generated, ultimately requiring fewer studies/animals to definitively resolve a research question compared to multiple (sometimes contradictory) reports stemming from non-field-like artificial challenge models.

The same is often true for cell lines and *in vitro* cultured mycoplasmas, which may not faithfully replicate *in vivo* processes and host-pathogen interactions – therefore, it is important that key findings be proven replicable in primary cells or *in vivo*. Otherwise, we run the risk of basing vaccination strategies and other control measures on non-physiological data, causing problems or failures further down the line.

The properties of many pathogenic veterinary mycoplasmas – including high transmissibility, vertical transmission, and frequency of chronic infections – make surveillance a complicated endeavour,

especially in rural and/or remote areas with limited access to veterinary services and diagnostic laboratories. While mycoplasma prevalence reports have become more frequent in these areas, there is a pressing need to tie these small-scale studies together to draw a cohesive picture of disease transmission patterns and risk factors. This standardisation should go hand-in-hand with the development and validation of effective, reproducible, and (ideally) field-deployable diagnostics to reduce uncertainty and allow direct comparison between among datasets.

Many gaps remain in the linking of research findings with practical applications and policy as well. Socio-political considerations impact the allocation of disease surveillance and control resources, and therefore affect the transmission patterns of clinically significant veterinary mycoplasmas. Some mycoplasma-associated diseases are relatively neglected due to their primary endemic geographical locations (e.g., CBPP in sub-Saharan Africa and parts of Asia) or the species at risk (e.g., CCPP in goats, which are not as economically important in the Global North) despite the huge impact these diseases have on the livelihood of affected farmers. In the case of CBPP, several successful partnerships between field centres and high-resource settings have enabled some access to additional technology for detailed analysis, and this should be encouraged to accelerate disease research and improve the efficacy and availability of current vaccines.

Altogether, our understanding of veterinary mycoplasmas and our repertoire of disease surveillance and management methods have grown significantly over the past decade. The studies covered in this report encourage optimism in the future of veterinary mycoplasma control while highlighting the particular importance of increased standardisation and coordination between laboratories and nations in combating these diseases. The authors of this report hope that it will be a useful resource for researchers and policymakers as we enter the next decade of research into these complex organisms.

Acknowledgements

Commissioning team: This report was commissioned by the STAR-IDAZ IRC and the USDA-ARS. Within these organisations, we wish to thank the following people for their guidance and assistance in preparing the report (arranged in alphabetical order): Georgina Grell (CABI, UK), Alex Morrow (CABI, UK), Roxann Motroni (USDA-ARS, USA), Madeline Newman (Defra, UK), and Rachel Wood (CABI, UK).

We wish to thank and acknowledge the contributions of the following researchers for reviewing the content of the report (arranged in alphabetical order): Mark Ackerman (USDA-ARS, USA), Jeff Caswell (University of Guelph, Canada), Rohana Dassanayake (USDA-ARS, USA), Jeff Evans (USDA-ARS, USA), Patrice Gaurivaud (ANSES, France), Bryan Kaplan (USDA-ARS, USA), Dominiek Maes (Ghent University, Belgium), Musa Mulongo (ILRI, Canada), Robin Nicholas (The Oaks, UK), Jose Perez-Casal (Vaccine and Infectious Disease Organization, Canada), Flavio Sacchini (IZS, Teramo, Italy), Massimo Scacchia (IZS, Teramo, Italy), and Dan Tucker (University of Cambridge, UK).

We also wish to thank and acknowledge the contributions of the following researchers for providing current/future research updates & personal views on priority research gaps from the groups of (arranged in alphabetical order): Trevor Alexander (Agriculture and Agri-Food Canada, Canada), Glenn Browning (Asia-Pacific Centre for Animal Health, Australia), Jeff Evans (USDA-ARS, USA), Miklós Gyuranecz (Veterinary Medical Research Institute, Hungary), and Jose Perez-Casal (Vaccine and Infectious Disease Organization, Canada).

References

- Abadi, E.H., Saadati, D., Najimi, M., Hassanpour, M., 2019. A study on *Mycoplasma agalactiae* and *Chlamydia abortus* in aborted ovine fetuses in Sistan and Baluchestan region, Iran. *Arch. Razi Inst.* 74, 295–301.
- Abdel Halium, M.M., Salib, F.A., Marouf, S.A., Abdel Massieh, E.S., 2019. Isolation and molecular characterization of *Mycoplasma* spp. in sheep and goats in Egypt. *Vet. World* 12, 664–670. <https://doi.org/10.14202/vetworld.2019.664-670>
- Abdela, N., Yune, N., 2017. Seroprevalence and Distribution of Contagious Bovine Pleuropneumonia in Ethiopia: Update and Critical Analysis of 20 Years (1996–2016) Reports. *Front. Vet. Sci.* 4, 100. <https://doi.org/10.3389/fvets.2017.00100>
- Abdelaziz, A.M., Mohamed, M.H.A., Fayez, M.M., Al-Marri, T., Qasim, I., Al-Amer, A.A., 2019. Molecular survey and interaction of common respiratory pathogens in chicken flocks (field perspective). *Vet. World* 12, 1975–1986.
- Abd-Elrahman, A.H., Khafaga, A.F., Abas, O.M., 2020. The first identification of contagious caprine pleuropneumonia (CCPP) in sheep and goats in Egypt: molecular and pathological characterization. *Trop. Anim. Health Prod.* 52, 1179–1186. <https://doi.org/10.1007/s11250-019-02116-5>
- Abdilatif, M.H., Onono, J.O., Mutua, F.K., 2018. Analysis of pastoralists' perception on challenges and opportunities for sheep and goat production in Northern Kenya. *Trop. Anim. Health Prod.* 50, 1701–1710. <https://doi.org/10.1007/s11250-018-1613-8>
- Abdo, E.-M., Nicolet, J., Frey, J., 2000. Antigenic and Genetic Characterization of Lipoprotein LppQ from *Mycoplasma mycoides* subsp. *mycoides* SC. *Clin. Diagn. Lab. Immunol.* 7, 588–595.
- Abdollahi, M., Lotfollahzadeh, S., Salehi, T.Z., Moosakhani, F., Raoofi, A., 2022. Assessment of the duration of maternal-derived antibodies specific to the *Mycoplasma agalactiae* vaccine in goat kids. *Vet. Med. Sci.* 8, 2119–2125. <https://doi.org/10.1002/vms3.888>
- Abusara, A.M., Abdelgadir, A.E., 2014. Retrospective study of clinical cases presented at veterinary hospitals in Khartoum State, Sudan. *J. Vet. Med. Anim. Health* 6, 34–43.
- Acharya, N., Bhatta, K., Prajapati, M., Sapkota, S., Acharya, K.P., 2019. Sero-prevalence and associated risk factors of *Mycoplasma hyopneumoniae* infection in Kailali and Kanchanpur District of Far Western, Nepal. *Comp. Clin. Pathol.* 28, 977–983. <https://doi.org/10.1007/s00580-018-2865-4>
- Acosta, D.B., Ruiz, M., Sanchez, J.P., 2019. First molecular detection of *Mycoplasma suis* in the pig louse *Haematopinus suis* (Phthiraptera: Anoplura) from Argentina. *Acta Trop.* 194, 165–168. <https://doi.org/10.1016/j.actatropica.2019.04.007>
- Adamu, J.Y., Wawegama, N.K., Kanci Condello, A., Marena, M.S., Markham, P.F., Browning, G.F., Tivendale, K.A., 2020. *Mycoplasma bovis* Membrane Protein MilA Is a Multifunctional Lipase with Novel Lipid and Glycosaminoglycan Binding Activity. *Infect. Immun.* 88, e00945-19. <https://doi.org/10.1128/IAI.00945-19>
- Ade, J., Niethammer, F., Schade, B., Schilling, T., Hoelzle, K., Hoelzle, L.E., 2018. Quantitative analysis of *Mycoplasma wenyonii* and 'Candidatus *Mycoplasma haemobos*' infections in cattle using novel gapN-based realtime PCR assays. *Vet. Microbiol.* 220, 1–6. <https://doi.org/10.1016/j.vetmic.2018.04.028>
- Ade, J., Ritzmann, M., Wöstmann, C., Eddicks, M., Reese, S., Hoelzle, K., Hoelzle, L.E., Stadler, J., 2021. Update on shedding and transmission routes of porcine haemotrophic mycoplasmas in naturally and experimentally infected pigs. *Porc. Health Manag.* 7, 49. <https://doi.org/10.1186/s40813-021-00229-8>
- Ade, J., Stadler, J., Ritzmann, M., Zübert, C., Hoelzle, K., Hoelzle, L.E., 2022. Occurrence of 'Candidatus *Mycoplasma haemosuis*' in fattening pigs, sows and piglets in Germany using a novel gap-based quantitative real-time PCR assay. *BMC Vet. Res.* 18, 40. <https://doi.org/10.1186/s12917-022-03147-1>

- Adell, E., Calvet, S., Pérez-Bonilla, A., Jiménez-Belenguer, A., García, J., Herrera, J., Cambra-López, M., 2015. Air disinfection in laying hen houses: Effect on airborne microorganisms with focus on *Mycoplasma gallisepticum*. *Biosyst. Eng.* 129, 315–323. <https://doi.org/10.1016/j.biosystemseng.2014.10.010>
- Adelman, J.S., Moyers, S.C., Farine, D.R., Hawley, D.M., 2015. Feeder use predicts both acquisition and transmission of a contagious pathogen in a North American songbird. *Proc. R. Soc. B Biol. Sci.* 282, 20151429. <https://doi.org/10.1098/rspb.2015.1429>
- Adorno, B.M.V., Salina, A., Fernandes Joaquim, S., De Freitas Guimarães, F., Churocof Lopes, B., Menozzi, B., Langoni, H., 2021. Presence of mollicutes and *Mycoplasma bovis* in nasal swabs from calves and in milk from cows with clinical mastitis. *Veterinária E Zootec.* 28, 1–9. <https://doi.org/10.35172/rvz.2021.v28.520>
- Aebi, M., Bodmer, M., Frey, J., Pilo, P., 2012. Herd-specific strains of *Mycoplasma bovis* in outbreaks of mycoplasmal mastitis and pneumonia. *Vet. Microbiol.* 157, 363–368. <https://doi.org/10.1016/j.vetmic.2012.01.006>
- Aebi, M., Borne, B.H. van den, Raemy, A., Steiner, A., Pilo, P., Bodmer, M., 2015. *Mycoplasma bovis* infections in Swiss dairy cattle: a clinical investigation. *Acta Vet. Scand.* 57.
- Agnone, A., La Manna, M., Sireci, G., Puleio, R., Usticano, A., Ozdemir, U., Nicholas, R.A.J., Chiaracane, V., Dieli, F., Di Marco, V., Loria, G.R., 2013. A comparison of the efficacy of commercial and experimental vaccines for contagious agalactia in sheep. *Small Rumin. Res.* 112, 230–234. <https://doi.org/10.1016/j.smallrumres.2012.12.022>
- Ahani Azari, A., Amanollahi, R., Jafari Jozani, R., Trott, D.J., Hemmatzadeh, F., 2020. High-resolution melting curve analysis: a novel method for identification of *Mycoplasma* species isolated from clinical cases of bovine and porcine respiratory disease. *Trop. Anim. Health Prod.* 52, 1043–1047. <https://doi.org/10.1007/s11250-019-02098-4>
- Ahmad, F., Khan, H., Khan, F.A., Carson, B.D., Sadique, U., Ahmad, I., Saeed, M., Rehman, F.U., Rehman, H.U., 2021. The first isolation and molecular characterization of *Mycoplasma capricolum* subsp. *capripneumoniae* Pakistan strain: A causative agent of contagious caprine pleuropneumonia. *J. Microbiol. Immunol. Infect.* 54, 710–717. <https://doi.org/10.1016/j.jmii.2020.06.002>
- Ahmad, Z., Babar, S., Abbas, F., Awan, M.A., Shafee, M., Tariq, M.M., Mengal, M.A., Rashid, N., Amin, S., Taj, K., Ali, M., 2014. Prevalence of *Mycoplasma bovis* in respiratory tract of cattle slaughtered in Balochistan, Pakistan. *Pak. Vet. J.* 34, 46–49.
- Ahn, Y., Yang, S., Oh, T., Park, K.H., Cho, H., Suh, J., Chae, C., 2021. Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and *Mycoplasma hyopneumoniae* Against an Experimental Dual Challenge. *Front. Vet. Sci.* 8, 652313. <https://doi.org/10.3389/fvets.2021.652313>
- Ajitkumar, P., Barkema, H.W., De Buck, J., 2012. Rapid identification of bovine mastitis pathogens by high-resolution melt analysis of 16S rDNA sequences. *Vet. Microbiol.* 155, 332–340. <https://doi.org/10.1016/j.vetmic.2011.08.033>
- Aktas, M., Ozubek, S., 2017. A molecular survey of small ruminant hemotropic mycoplasmosis in Turkey, including first laboratory confirmed clinical cases caused by *Mycoplasma ovis*. *Vet. Microbiol.* 208, 217–222. <https://doi.org/10.1016/j.vetmic.2017.08.011>
- Alessandri, E., Massi, P., Paganelli, F., Prandini, F., Saita, M., 2005. Field trials with the use of a live attenuated temperature-sensitive vaccine for the control of *Mycoplasma gallisepticum* infection in meat-type turkeys. *Ital. J. Anim. Sci.* 4, 282–286. <https://doi.org/10.4081/ijas.2005.282>
- Al-Farha, A.A.-B., Khazandi, M., Hemmatzadeh, F., Jozani, R., Tearle, R., Hoare, A., Petrovski, K., 2018a. Evaluation of three cryoprotectants used with bovine milk affected with *Mycoplasma bovis* in different freezing conditions. *BMC Res. Notes* 11, 216. <https://doi.org/10.1186/s13104-018-3325-6>

- Al-Farha, A.A.-B., Petrovski, K., Jozani, R., Hoare, A., Hemmatzadeh, F., 2018b. Discrimination between some *Mycoplasma* spp. and *Acholeplasma laidlawii* in bovine milk using high resolution melting curve analysis. *BMC Res. Notes* 11, 107. <https://doi.org/10.1186/s13104-018-3223-y>
- Al-Farha, A.A.-B., Wawegama, N., Hemmatzadeh, F., Firestone, S., Moffat, J., Kojouri, G.A., Ahani Azari, A., Amanollahi, R., Hoare, A., Petrovski, K., 2020. Application of an indirect MiLA ELISA for the detection of *Mycoplasma bovis* antibodies in bovine milk. *Turk. J. Vet. Anim. Sci.* 44, 752–755. <https://doi.org/10.3906/vet-1811-62>
- Alhaji, N.B., Ankeli, P.I., Ikpa, L.T., Babalobi, O.O., 2020. Contagious Bovine Pleuropneumonia: Challenges and Prospects Regarding Diagnosis and Control Strategies in Africa. *Vet. Med. Res. Rep.* 11, 71–85. <https://doi.org/10.2147/VMRR.S180025>
- Alhaji, N.B., Babalobi, O.O., 2016. Qualitative and quantitative impacts assessment of contagious bovine pleuropneumonia in Fulani pastoral herds of North-central Nigeria: the associated socio-cultural factors. *Prev. Vet. Med.* 128, 124–134.
- Alhaji, N.B., Babalobi, O.O., 2015. Participatory epidemiology of ethnoveterinary practices Fulani pastoralists used to manage contagious bovine pleuropneumonia and other cattle ailments in Niger State, Nigeria. *J. Vet. Med.* 2015, 460408.
- Alhussen, M.A., Naef, H., Vatnikov, Y.A., 2020. Effects of gentamino-seleferon on blood parameters during treatment of *Mycoplasma dispar* respiratory infection in calves. *Vet. World* 13, 2197–2202. <https://doi.org/10.14202/vetworld.2020.2197-2202>
- Allen, C.R., Mara, A., Tulman, E.R., Ley, D.H., Geary, S.J., 2018. House finch (*haemorrhous mexicanus*)–associated *mycoplasma gallisepticum* identified in lesser goldfinch (*spinus psaltria*) and western scrub jay (*aphelocoma californica*) using strain-specific quantitative pcr. *J. Wildl. Dis.* 54, 180. <https://doi.org/10.7589/2017-04-079>
- Almberg, E.S., Manlove, K.R., Cassirer, E.F., Ramsey, J., Carson, K., Gude, J., Plowright, R.K., 2022. Modelling management strategies for chronic disease in wildlife: Predictions for the control of respiratory disease in bighorn sheep. *J. Appl. Ecol.* 59, 693–703. <https://doi.org/10.1111/1365-2664.14084>
- Almeida, H.M.S., Mechler-Dreibi, M.L., Sonálio, K., Ferraz, M.E.S., Storino, G.Y., Barbosa, F.O., Maes, D., Montassier, H.J., de Oliveira, L.G., 2020. Cytokine expression and *Mycoplasma hyopneumoniae* burden in the development of lung lesions in experimentally inoculated pigs. *Vet. Microbiol.* 244, 108647. <https://doi.org/10.1016/j.vetmic.2020.108647>
- Almeida, H.M.S., Mechler-Dreibi, M.L., Sonálio, K., Ferreira, M.M., Martinelli, P.E.B., Gatto, I.R.H., Maes, D., Montassier, H.J., Oliveira, L.G., 2021. Dynamics and chronology of *Mycoplasma hyopneumoniae* strain 232 infection in experimentally inoculated swine. *Porc. Health Manag.* 7, 42. <https://doi.org/10.1186/s40813-021-00221-2>
- Alqhtani, A.H., Fatemi, S.A., Elliott, K.E.C., Branton, S.L., Evans, J.D., Leigh, S.A., Gerard, P.D., Peebles, E.D., 2022. Effects of the In Ovo Vaccination of the ts-11 Strain of *Mycoplasma gallisepticum* in Layer Embryos and Posthatch Chicks. *Animals* 12, 1120. <https://doi.org/10.3390/ani12091120>
- Alqhtani, A.H., Fatemi, S.A., Elliott, K.E.C., Branton, S.L., Evans, J.D., Peebles, E.D., 2023. Effects of the In ovo Administration of the 6/85 *Mycoplasma gallisepticum* Vaccine on Layer Chicken Embryo Hatchability and Early Posthatch Performance. *Animals* 13, 1228. <https://doi.org/10.3390/ani13071228>
- Alsaad, K.M., Jarad, A., Tarik, A.S., 2021. The Exophthalmos of Eyes as An Unusual and Unregistered Sign of *Mycoplasma wenyonii* Infection in Newborn Calves in Basrah, Iraq. *Egypt. J. Vet. Sci.* 52, 293–299. <https://doi.org/10.21608/ejvs.2021.72714.1229>
- Aluthge, N.D., Van Sambeek, D.M., Carney-Hinkle, E.E., Li, Y.S., Fernando, S.C., Burkey, T.E., 2019. The pig microbiota and the potential for harnessing the power of the microbiome to improve growth and health. *J. Anim. Sci.* 97, 3741–3757. <https://doi.org/10.1093/jas/skz208>

- Ambroset, C., Peticca, A., Tricot, A., Tardy, F., 2022. Genomic features of *Mycoplasma bovis* subtypes currently circulating in France. *BMC Genomics* 23, 603. <https://doi.org/10.1186/s12864-022-08818-9>
- Ammar, A., Abd El-Hamid, M., Hashem, Y., El-Malt, R., Mohamed, H., 2021. *Mycoplasma bovis*: Taxonomy, Characteristics, Pathogenesis and Antimicrobial Resistance. *Zagazig Vet. J.* 49, 444–461. <https://doi.org/10.21608/zvzj.2021.103834.1160>
- Ammar, A.M., El-Aziz, N.K.A., El-Wanis, S.A., Bakry, N.R., 2016a. Molecular versus conventional culture for detection of respiratory bacterial pathogens in poultry. *Cell. Mol. Biol.* 62, 52–56.
- Ammar, A.M., El-Aziz, N.K.A., Gharib, A.A., Ahmed, H.K., Lameay, A.E., 2016b. Mutations of domain V in 23S ribosomal RNA of macrolide-resistant *Mycoplasma gallisepticum* isolates in Egypt. *J. Infect. Dev. Ctries.* 10, 807–813.
- Amram, E., Freed, M., Khateb, N., Mikula, I., Blum, S., Spersger, J., Sharir, B., Ozeri, R., Harrus, S., Lysnyansky, I., 2013. Multiple locus variable number tandem repeat analysis of *Mycoplasma bovis* isolated from local and imported cattle. *Vet. J.* 197, 286–290. <https://doi.org/10.1016/j.tvjl.2013.03.023>
- Amram, E., Mikula, I., Schnee, C., Ayling, R.D., Nicholas, R.A.J., Rosales, R.S., Harrus, S., Lysnyansky, I., 2015. 16S rRNA Gene Mutations Associated with Decreased Susceptibility to Tetracycline in *Mycoplasma bovis*. *Antimicrob. Agents Chemother.* 59, 796–802. <https://doi.org/10.1128/AAC.03876-14>
- Andersson, A.-M., Aspán, A., Wisselink, H.J., Smid, B., Ridley, A., Pelkonen, S., Autio, T., Lauritsen, K.T., Kensø, J., Gaurivaud, P., Tardy, F., 2019. A European inter-laboratory trial to evaluate the performance of three serological methods for diagnosis of *Mycoplasma bovis* infection in cattle using latent class analysis. *BMC Vet. Res.* 15, 369. <https://doi.org/10.1186/s12917-019-2117-0>
- Ando, A., Shigenari, A., Kojima-Shibata, C., Nakajoh, M., Suzuki, K., Kitagawa, H., Shiina, T., Inoko, H., Uenishi, H., 2016. Association of swine leukocyte antigen class II haplotypes and immune-related traits in a swine line selected for resistance to mycoplasmal pneumonia. *Comp. Immunol. Microbiol. Infect. Dis.* 48, 33–40. <https://doi.org/10.1016/j.cimid.2016.07.004>
- André, M.R., Duarte, J.M.B., Gonçalves, L.R., Sacchi, A.B.V., Jusi, M.M.G., Machado, R.Z., 2020. New records and genetic diversity of *Mycoplasma ovis* in free-ranging deer in Brazil. *Epidemiol. Infect.* 148, e6. <https://doi.org/10.1017/S0950268819002218>
- Andrés-Lasheras, S., Zaheer, R., Ha, R., Lee, C., Jelinski, M., McAllister, T.A., 2020. A direct qPCR screening approach to improve the efficiency of *Mycoplasma bovis* isolation in the frame of a broad surveillance study. *J. Microbiol. Methods* 169, 105805. <https://doi.org/10.1016/j.mimet.2019.105805>
- Anholt, R.M., Klima, C., Allan, N., Matheson-Bird, H., Schatz, C., Ajitkumar, P., Otto, S.J., Peters, D., Schmid, K., Olson, M., McAllister, T., Ralston, B., 2017. Antimicrobial Susceptibility of Bacteria That Cause Bovine Respiratory Disease Complex in Alberta, Canada. *Front. Vet. Sci.* 4, 207. <https://doi.org/10.3389/fvets.2017.00207>
- Anjum, A., Aslam, A., Akhtar, R., Yaqub, T., Khan, M.-R., Sultan, R., Usman, S., Durrani, A.Z., Usman, M., 2019a. Molecular Detection and Pathological Investigation of Contagious Bovine Pleuropneumonia in Selected Districts of Punjab, Pakistan. *Pak. J. Zool.* 52. <https://doi.org/10.17582/journal.pjz/20190706160736>
- Anjum, A., Aslam, A., Akhtar, R., Yaqub, T., Naseer, J., Mushtaq, A., Munir, M.A., Khan, A. ullah, 2019b. Seroprevalence of contagious bovine pleuropneumonia in cattle of Punjab, Pakistan and assessment of risk factors. *Indian J. Anim. Res.* 55, 101–104. <https://doi.org/10.18805/IJAR.B-1130>
- Anjum, A., Usman, S., Aslam, A., Faiz, M., Usman, S., Imran, M.S., Hussain, I., Usman, M., Badar, S., Iqbal, M.Z., Dar, A., Haq, H.M.A., 2020. Prevalence and molecular detection of contagious bovine pleuropneumonia in large ruminants in Punjab, Pakistan. *Trop. Biomed.* 37, 273–281.

- Ankeli, P.I., Raji, M.A., Kazeem, H.M., Tambuwal, F.M., Francis, M.I., Ikpa, L.T., Fagbamila, I.O., Luka, P.D., Nwankpa, N.D., 2017. Seroprevalence of contagious bovine pleuropneumonia in Plateau State, North-central Nigeria. *Bull. Anim. Health Prod. Afr.* 65, 359–368.
- Antonis, A.F.G., Swanenburg, M., Wisselink, H.J., Smid, B., van Klink, E., Hagens, T.J., 2022. Respiratory pathogens in veal calves: Inventory of circulating pathogens. *Vet. Microbiol.* 274, 109571. <https://doi.org/10.1016/j.vetmic.2022.109571>
- Antunes, N.T., Assunção, P., Poveda, J.B., Tavío, M.M., 2015. Mechanisms involved in quinolone resistance in *Mycoplasma mycoides* subsp. *capri*. *Vet. J.* 204, 327–332. <https://doi.org/10.1016/j.tvjl.2015.04.018>
- Anyika, K.C., Okaiyeto, S.O., Sackey, A.K., Kwanashie, C.N., Ikpa, L.T., 2021. Seroprevalence of contagious bovine pleuropneumonia in three selected south-eastern states of Nigeria. *Sokoto J. Vet. Sci.* 19, 49–54. <https://doi.org/10.4314/sokjvs.v19i1.7>
- Appelt, S., Aly, S.S., Tonooka, K., Glenn, K., Xue, Z., Lehenbauer, T.W., Marco, M.L., 2019. Development and comparison of loop-mediated isothermal amplification and quantitative polymerase chain reaction assays for the detection of *Mycoplasma bovis* in milk. *J. Dairy Sci.* 102, 1985–1996. <https://doi.org/10.3168/jds.2018-15306>
- Aquino, C., 2022. Poultry and Products Annual, Brazil (No. BR2022- 0051). USDA.
- Arcangioli, M.-A., Lurier, T., Hauray, K., Tardy, F., 2021. Large-size fattening calves' lots fed with automatic milk feeders may have an increased risk for *Mycoplasma bovis* infection spread and for antibiotic use. *Animal* 15, 100397. <https://doi.org/10.1016/j.animal.2021.100397>
- Archer, F., Bobet-Erny, A., Gomes, M., 2021. State of the art on lung organoids in mammals. *Vet. Res.* 52, 77. <https://doi.org/10.1186/s13567-021-00946-6>
- Arede, M., Nielsen, P.K., Ahmed, S.S.U., Halasa, T., Nielsen, L.R., Toft, N., 2016. A space-time analysis of *Mycoplasma bovis*: bulk tank milk antibody screening results from all Danish dairy herds in 2013–2014. *Acta Vet. Scand.* 58.
- Arsenakis, I., Michiels, A., Schagemann, G., Gomez-Duran, C.O., Boyen, F., Haesebrouck, F., Maes, D.G.D., 2019. Effects of pre-farrowing sow vaccination against *Mycoplasma hyopneumoniae* on offspring colonisation and lung lesions. *Vet. Rec.* 184, 222–222. <https://doi.org/10.1136/vr.104972>
- Arteche-Villasol, N., Fernández, M., Gutiérrez-Expósito, D., Pérez, V., 2022. Pathology of the Mammary Gland in Sheep and Goats. *J. Comp. Pathol.* 193, 37–49. <https://doi.org/10.1016/j.jcpa.2022.02.007>
- Ashraf, A., Imran, M., Yaqub, T., Tayyab, M., Shehzad, W., Mingala, C.N., Chang, Y.-F., 2018. Development and validation of a loop-mediated isothermal amplification assay for the detection of *Mycoplasma bovis* in mastitic milk. *Folia Microbiol. (Praha)* 63, 373–380. <https://doi.org/10.1007/s12223-017-0576-x>
- Asmare, K., Abayneh, T., Mekuria, S., Ayelet, G., Sibhat, B., Skjerve, E., Szonyi, B., Wieland, B., 2016. A meta-analysis of contagious caprine pleuropneumonia (CCPP) in Ethiopia. *Acta Trop.* 158, 231–239.
- Assen, A.M., Yegoraw, A.A., Walkden-Brown, S.W., Gerber, P.F., 2022. Molecular-based monitoring of live vaccines in dust samples from experimental and commercial chicken flocks and its potential use as a screening test. *Res. Vet. Sci.* 143, 50–57. <https://doi.org/10.1016/j.rvsc.2021.12.015>
- Atalla, H., Lysnyansky, I., Raviv, Y., Rottem, S., 2015. *Mycoplasma gallisepticum* Inactivated by Targeting the Hydrophobic Domain of the Membrane Preserves Surface Lipoproteins and Induces a Strong Immune Response. *PLOS ONE* 10, e0120462. <https://doi.org/10.1371/journal.pone.0120462>
- Atim, S.A., Ayebazibwe, C., Mwiine, F.N., Erume, J., Tweyongyere, R., 2016. A Survey for Contagious Caprine Pleuropneumonia in Agago and Otuke Districts in Northern Uganda. *Open J. Vet. Med.* 06, 9–14. <https://doi.org/10.4236/ojvm.2016.61002>

- Attoh-Kotoku, V., Emikpe, B.O., Obuadey, D., Ishola, O., Osafo, E.K., Donkoh, A., Folitse, R., 2018. Patterns and direct financial implications of contagious pleuropneumonia in cattle slaughtered in Kumasi abattoir, Ghana. *Anim. Res. Int.* 15, 2937–2943.
- Autio, T., Tuunainen, E., Nauholz, H., Pirkkalainen, H., London, L., Pelkonen, S., 2021. Overview of Control Programs for Cattle Diseases in Finland. *Front. Vet. Sci.* 8, 688936. <https://doi.org/10.3389/fvets.2021.688936>
- Awad, N.F.S., Abd El-Hamid, M.I., Hashem, Y.M., Erfan, A.M., Abdelrahman, B.A., Mahmoud, H.I., 2019. Impact of single and mixed infections with *Escherichia coli* and *Mycoplasma gallisepticum* on Newcastle disease virus vaccine performance in broiler chickens: an *in vivo* perspective. *J. Appl. Microbiol.* 127, 396–405. <https://doi.org/10.1111/jam.14303>
- Aye, R., Mwirigi, M.K., Frey, J., Pilo, P., Jores, J., Naessens, J., 2015. Cyto-adherence of *Mycoplasma mycoides* subsp. *mycoides* to bovine lung epithelial cells. *BMC Vet. Res.* 11.
- Aye, R., Weldearegay, Y.B., Lutta, H.O., Chuma, F., Pich, A., Jores, J., Meens, J., Naessens, J., 2018. Identification of targets of monoclonal antibodies that inhibit adhesion and growth in *Mycoplasma mycoides* subspecies *mycoides*. *Vet. Immunol. Immunopathol.* 204, 11–18. <https://doi.org/10.1016/j.vetimm.2018.09.002>
- Ayling, R.D., Rosales, R.S., Barden, G., Gosney, F.L., 2014. Changes in antimicrobial susceptibility of *Mycoplasma bovis* isolates from Great Britain. *Vet. Rec.* 175, 486–486. <https://doi.org/10.1136/vr.102303>
- Bahir, W., Omar, O., Rosales, R.S., Hlusek, M., Ziay, G., Schauwers, W., Whatmore, A.M., Nicholas, R.A.J., 2017. Search for OIE-listed ruminant mycoplasma diseases in Afghanistan. *BMC Vet. Res.* 13, 149. <https://doi.org/10.1186/s12917-017-1067-7>
- Bahiru, A., Assefa, A., 2020. Prioritization of Economically Important Cattle Diseases Using Participatory Epidemiology Tools in Lalibela, Sekota, and Ziquala Districts of Amhara Region, Northern Ethiopia. *Vet. Med. Int.* 2020, 1–4. <https://doi.org/10.1155/2020/5439836>
- Bai, F., Ni, B., Liu, M., Feng, Z., Xiong, Q., Shao, G., 2015. *Mycoplasma hyopneumoniae*-derived lipid-associated membrane proteins induce inflammation and apoptosis in porcine peripheral blood mononuclear cells *in vitro*. *Vet. Microbiol.* 175, 58–67. <https://doi.org/10.1016/j.vetmic.2014.11.013>
- Bai, F., Wu, J., Liu, B., Wang, X., Shi, X., Lv, T., Wang, Y., Hao, Y., 2020. *Mycoplasma ovipneumoniae*-derived lipid-associated membrane proteins induce cytokine secretion in mouse peritoneal macrophages through TLR2 signalling. *Res. Vet. Sci.* 132, 474–480. <https://doi.org/10.1016/j.rvsc.2020.07.022>
- Bai, Y., Gan, Y., Hua, L.-Z., Nathues, H., Yang, H., Wei, Y.-N., Wu, M., Shao, G.-Q., Feng, Z.-X., 2018. Application of a sIgA-ELISA method for differentiation of *Mycoplasma hyopneumoniae* infected from vaccinated pigs. *Vet. Microbiol.* 223, 86–92. <https://doi.org/10.1016/j.vetmic.2018.07.023>
- Bai, Z., Shi, L., Hu, C., Chen, X., Qi, J., Ba, X., Peng, Q., Chen, Y., Chen, H., Guo, A., 2011. Development of a loop-mediated isothermal amplification assay for sensitive and rapid detection of *Mycoplasma bovis*. *Afr. J. Biotechnol.* 10, 12333–12338. <https://doi.org/10.4314/ajb.v10i57>
- Bakre, A.A., Anifowose, O.R., Adegbenro, M.A., 2021. Seroprevalence of *Mycoplasma gallisepticum* in apparently healthy layer chickens in commercial farms in Ibadan. *Sokoto J. Vet. Sci.* 19, 205–209.
- Baksi, S., Bhumika, F.S., Trivedi, B., Rao, N., 2016. Seroprevalence of *Mycoplasma gallisepticum* in different parts of India. *Indian J. Comp. Microbiol. Immunol. Infect. Dis.* 37, 63–66.
- Balestrin, E., Kuhnert, P., Wolf, J.M., Wolf, L.M., Fonseca, A.S.K., Ikuta, N., Lunge, V.R., Siqueira, F.M., 2019. Clonality of *Mycoplasma hyopneumoniae* in swine farms from Brazil. *Vet. Microbiol.* 238, 108434. <https://doi.org/10.1016/j.vetmic.2019.108434>
- Balestrin, E., Wolf, J.M., Wolf, L.M., Fonseca, A.S.K., Ikuta, N., Siqueira, F.M., Lunge, V.R., 2022. Molecular detection of respiratory coinfections in pig herds with enzootic pneumonia: a

- survey in Brazil. *J. Vet. Diagn. Invest.* 34, 310–313. <https://doi.org/10.1177/10406387211069552>
- Balish, M., Bertaccini, A., Blanchard, A., Brown, D., Browning, G., Chalker, V., Frey, J., Gasparich, G., Hoelzle, L., Knight, T., Knox, C., Kuo, C.-H., Manso-Silvan, L., May, M., Pollack, J.D., Ramirez, A.S., Spergser, J., Taylor-Robinson, D., Volokhov, D., Zhao, Y., 2019. Recommended rejection of the names *Malacoplasma* gen. nov., *Mesomycoplasma* gen. nov., *Metamycoplasma* gen. nov., *Metamycoplasmataceae* fam. nov., *Mycoplasmodaceae* fam. nov., *Mycoplasmodales* ord. nov., *Mycoplasmodes* gen. nov., *Mycoplasma* gen. nov. [Gupta, Sawnani, Adeolu, Alnajjar and Oren 2018] and all proposed species comb. nov. placed therein. *Int. J. Syst. Evol. Microbiol.* 69, 3650–3653. <https://doi.org/10.1099/ijsem.0.003632>
- Ball, C., Felice, V., Ding, Y., Forrester, A., Catelli, E., Ganapathy, K., 2020. Influences of swab types and storage temperatures on isolation and molecular detection of *Mycoplasma gallisepticum* and *Mycoplasma synoviae*. *Avian Pathol.* 49, 106–110. <https://doi.org/10.1080/03079457.2019.1675865>
- Ball, C., Forrester, A., Ganapathy, K., 2018. Co-circulation of genetically diverse population of vaccine related and unrelated respiratory mycoplasmas and viruses in UK poultry flocks with health or production problems. *Vet. Microbiol.* 225, 132–138. <https://doi.org/10.1016/j.vetmic.2018.09.009>
- Baluka, S.A., Hisali, E., Wasswa, F., Ocaido, M., Mugisha, A., 2013. Socio-economic risk factors associated with foot and mouth disease, and contagious bovine pleuropneumonia outbreaks in Uganda. *Livest. Res. Rural Dev.* 25.
- Baluka, S.A., Ocaido, M., Mugisha, A., 2014. Prevalence and economic importance of Foot and Mouth Disease, and Contagious Bovine Pleuropneumonia Outbreaks in cattle in Isingiro and Nakasongola Districts of Uganda. *Discourse J. Agric. Food Sci.* 2, 107–117.
- Bao, S., Ding, X., Yu, S., Xing, X., Ding, C., 2021. Characterization of pyruvate dehydrogenase complex E1 alpha and beta subunits of *Mycoplasma synoviae*. *Microb. Pathog.* 155, 104851. <https://doi.org/10.1016/j.micpath.2021.104851>
- Baquero, M., Vulikh, K., Wong, C., Domony, M., Burrows, D., Marom, D., Perez-Casal, J., Cai, H.Y., Caswell, J.L., 2021. Effects of inflammatory stimuli on responses of macrophages to *Mycoplasma bovis* infection. *Vet. Microbiol.* 262, 109235. <https://doi.org/10.1016/j.vetmic.2021.109235>
- Baraldi, T.G., Cruz, N.R.N., Pereira, D.A., Galdeano, J.V.B., Gatto, I.R.H., Silva, A.F.D., Panzardi, A., Linhares, D.C.L., Mathias, L.A., Oliveira, L.G. de, 2019. Antibodies against *Actinobacillus pleuropneumoniae*, *Mycoplasma hyopneumoniae* and influenza virus and their relationships with risk factors, clinical signs and lung lesions in pig farms with one-site production systems in Brazil. *Prev. Vet. Med.* 171.
- Barberio, A., Flaminio, B., De Vliegheer, S., Supre, K., Kromker, V., Garbarino, C., Arrigoni, N., Zanardi, G., Bertocchi, L., Gobbo, F., Catania, S., Moroni, P., 2016. Short communication: In vitro antimicrobial susceptibility of *Mycoplasma bovis* isolates identified in milk from dairy cattle in Belgium, Germany, and Italy. *J. Dairy Sci.* 99, 6578–6584. <https://doi.org/10.3168/jds.2015-10572>
- Barbosa, M.S., Alves, R.P. dos S., Rezende, I. de S., Pereira, S.S., Campos, G.B., Freitas, L.M., Chopra-Dewasthaly, R., Ferreira, L.C. de S., Guimaraes, A.M. de S., Marques, L.M., Timenetsky, J., 2020. Novel antigenic proteins of *Mycoplasma agalactiae* as potential vaccine and serodiagnostic candidates. *Vet. Microbiol.* 251, 108866. <https://doi.org/10.1016/j.vetmic.2020.108866>
- Barbosa, M.S., Spergser, J., Marques, L.M., Timenetsky, J., Rosengarten, R., Chopra-Dewasthaly, R., 2022. Predominant Single Stable VpmaV Expression in Strain GM139 and Major Differences with *Mycoplasma agalactiae* Type Strain PG2. *Animals* 12, 265. <https://doi.org/10.3390/ani12030265>

- Bargen, L.E., 2004. A system response to an outbreak of enzootic pneumonia in grow/finish pigs. *Can. Vet. J.* 45, 856–859.
- Barnewall, R., Marsh, I., Williams, T., Cusack, P., Sales, N., Galea, F., Szentirmay, A., Quinn, J., 2022. Efficiency-corrected PCR quantification for identification of prevalence and load of respiratory disease-causing agents in feedlot cattle. *Aust. Vet. J.* 100, 539–549. <https://doi.org/10.1111/avj.13200>
- Baroch, J.A., Gagnon, C.A., Lacouture, S., Gottschalk, M., 2015. Exposure of feral swine (*Sus scrofa*) in the United States to selected pathogens. *Can. J. Vet. Res.* 79, 74–78.
- Bashashati, M., Banani, M., 2020. Complete Sequence-Based Genotyping of *mgc2/pvpA* Genes in Chicken-Derived *Mycoplasma gallisepticum* Isolates of Iran. *Avian Dis.* 64. <https://doi.org/10.1637/aviandiseases-D20-00032>
- Basheir, B.O., ElMalik, K.H., Abdelgadir, A.E., Gameel, A. a. R., 2012. Traditional and modern practices in the diagnosis, treatment and prevention of animal diseases in South Kordofan State, Sudan. *J. Cell Anim. Biol.* 6, 213–225.
- Bassel, L.L., Kaufman, E.I., Alsop, S.A., Buchan, J., Hewson, J., McCandless, E.E., Tiwari, R., Sharif, S., Vulikh, K., Caswell, J.L., 2021. Effect of aerosolized bacterial lysate on development of naturally occurring respiratory disease in beef calves. *J. Vet. Intern. Med.* 35, 655–665. <https://doi.org/10.1111/jvim.16032>
- Bastamy, M., Raheel, I., Ellakany, H., Orabi, A., 2022. Study of Minimum Inhibitory Concentration Against a Local Field Isolates of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* from Egyptian Broiler and Layer Chicken Flocks. *Int. J. Vet. Sci.* 11, 98–103. <https://doi.org/10.47278/journal.ijvs/2021.081>
- Batista, I., Hoepers, P., Silva, M., Nunes, P., Diniz, D., Freitas, A., Cossi, M., Fonseca, B., 2020. Circulation of Major Respiratory Pathogens in Backyard Poultry and their Association with Clinical Disease and Biosecurity. *Braz. J. Poult. Sci.* 22, eRBCA-2019-1225. <https://doi.org/10.1590/1806-9061-2019-1225>
- Batista Linhares, M., Belloy, L., Origgi, F.C., Lechner, I., Segner, H., Ryser-Degiorgis, M.-P., 2015. Investigating the Role of Free-Ranging Wild Boar (*Sus scrofa*) in the Re-Emergence of Enzootic Pneumonia in Domestic Pig Herds: A Pathological, Prevalence and Risk-Factor Study. *PLOS ONE* 10, e0119060. <https://doi.org/10.1371/journal.pone.0119060>
- Beaudet, J., Tulman, E.R., Pflaum, K., Canter, J.A., Silbart, L.K., Geary, S.J., 2019. Immunologic pathways in protective versus maladaptive host responses to attenuated and pathogenic strains of *Mycoplasma gallisepticum*. *Infect. Immun.* 87.
- Beaudet, J., Tulman, E.R., Pflaum, K., Liao, X., Kutish, G.F., Szczepanek, S.M., Silbart, L.K., Geary, S.J., 2017. Transcriptional Profiling of the Chicken Tracheal Response to Virulent *Mycoplasma gallisepticum* Strain R_{low}. *Infect. Immun.* 85, e00343-17. <https://doi.org/10.1128/IAI.00343-17>
- Becker, C.A.M., Ambroset, C., Huleux, A., Vialatte, A., Colin, A., Tricot, A., Arcangioli, M.-A., Tardy, F., 2020. Monitoring *Mycoplasma bovis* Diversity and Antimicrobial Susceptibility in Calf Feedlots Undergoing a Respiratory Disease Outbreak. *Pathogens* 9, 593. <https://doi.org/10.3390/pathogens9070593>
- Becker, C.A.M., Thibault, F.M., Arcangioli, M.-A., Tardy, F., 2015. Loss of diversity within *Mycoplasma bovis* isolates collected in France from bovines with respiratory diseases over the last 35 years. *Infect. Genet. Evol.* 33, 118–126. <https://doi.org/10.1016/j.meegid.2015.04.019>
- Bednarek, D., Ayling, R.D., Nicholas, R.A.J., Dudek, K., Szymańska-Czerwińska, M., 2012. Serological survey to determine the occurrence of respiratory *Mycoplasma* infections in the Polish cattle population. *Vet. Rec.* 171, 45. <https://doi.org/10.1136/vr.100545>
- Behura, S.K., Tizioto, P.C., JaeWoo, K., Grupioni, N.V., Seabury, C.M., Schnabel, R.D., Gershwin, L.J., Eenennaam, A.L. van, Toaff-Rosenstein, R., Neiberghs, H.L., Regitano, L.C.A., Taylor, J.F., 2017. Tissue tropism in host transcriptional response to members of the bovine respiratory disease complex. *Sci. Rep.* 7.

- Beidel, C.R., Kristula, M.A., Aceto, H.W., Smith, B.I., 2016. Case report - utilizing formic acid to effectively eliminate *Mycoplasma bovis* in unpasteurized fresh raw milk. *Bov. Pract.* 50, 137–141.
- Béjaoui Khiari, A., Guériri, I., Ben Mohammed, R., Ben Abdelmoumen Mardassi, B., 2010. Characterization of a variant *vlhA* gene of *Mycoplasma synoviae*, strain WVU 1853, with a highly divergent haemagglutinin region. *BMC Microbiol.* 10, 6. <https://doi.org/10.1186/1471-2180-10-6>
- Bekő, K., Felde, O., Sulyok, K.M., Kreizinger, Z., Hrivnák, V., Kiss, K., Biksi, I., Jerzsele, Á., Gyuranecz, M., 2019a. Antibiotic susceptibility profiles of *Mycoplasma hyorhinis* strains isolated from swine in Hungary. *Vet. Microbiol.* 228, 196–201.
- Bekő, K., Kreizinger, Z., Kovács, Á.B., Sulyok, K.M., Marton, S., Bányai, K., Catania, S., Feberwee, A., Wiegel, J., Dijkman, R., ter Veen, C., Lysnyansky, I., Gyuranecz, M., 2020a. Mutations potentially associated with decreased susceptibility to fluoroquinolones, macrolides and lincomycin in *Mycoplasma synoviae*. *Vet. Microbiol.* 248, 108818. <https://doi.org/10.1016/j.vetmic.2020.108818>
- Bekő, K., Kreizinger, Z., Sulyok, K.M., Kovács, Á.B., Gróznér, D., Catania, S., Bradbury, J., Lysnyansky, I., Olaogun, O.M., Czanik, B., Ellakany, H., Gyuranecz, M., 2019b. Genotyping *Mycoplasma gallisepticum* by multilocus sequence typing. *Vet. Microbiol.* 231, 191–196. <https://doi.org/10.1016/j.vetmic.2019.03.016>
- Bekő, K., Kreizinger, Z., Yvon, C., Saller, O., Catania, S., Feberwee, A., Gyuranecz, M., 2020b. Development of molecular assays for the rapid and cost-effective determination of fluoroquinolone, macrolide and lincosamide susceptibility of *Mycoplasma synoviae* isolates. *PLOS ONE* 15, e0241647. <https://doi.org/10.1371/journal.pone.0241647>
- Bell, C.J., Blackburn, P., Elliott, M., Patterson, T.I.A.P., Ellison, S., Lahuerta-Marin, A., Ball, H.J., 2014. Investigation of polymerase chain reaction assays to improve detection of bacterial involvement in bovine respiratory disease. *J. Vet. Diagn. Invest.* 26, 631–634. <https://doi.org/10.1177/1040638714540166>
- Bello, M., Lawan, M.K., Aluwong, T., Sanusi, M., 2015. Management of slaughter houses in northern Nigeria and the safety of meat produced for human consumption. *Food Control* 49, 34–39. <https://doi.org/10.1016/j.foodcont.2013.09.007>
- Bergeron, N., Hébert, G., Pelletier, M.C., Cai, H.Y., Brochu-Morin, M.-E., Vaillancourt, J.-P., 2021. Prevalence of *Mycoplasma synoviae* and Its Impact on Productivity in Commercial Poultry Farms in Quebec, Canada. *Avian Dis.* 65. <https://doi.org/10.1637/21-00057>
- Berghiche, A., Khenenou, T., Kouzi, A., Labiad, I., 2018. An investigation on the predominant diseases, its diagnosis, and commonly used drugs in the poultry farms in the North-Eastern regions of Algeria. *Vet. World* 11, 986–989. <https://doi.org/10.14202/vetworld.2018.986-989>
- Bertelloni, F., Mazzei, M., Cilia, G., Forzan, M., Felicoli, A., Sagona, S., Bandecchi, P., Turchi, B., Cerri, D., Fratini, F., 2020. Serological Survey on Bacterial and Viral Pathogens in Wild Boars Hunted in Tuscany. *EcoHealth* 17, 85–93. <https://doi.org/10.1007/s10393-020-01475-y>
- Bertin, C., Pau-Roblot, C., Courtois, J., Manso-Silván, L., Tardy, F., Poumarat, F., Citti, C., Sirand-Pugnet, P., Gaurivaud, P., Thiaucourt, F., 2015. Highly dynamic genomic loci drive the synthesis of two types of capsular or secreted polysaccharides within the *Mycoplasma mycoides* cluster. *Appl. Environ. Microbiol.* 81, 676–687. <https://doi.org/10.1128/AEM.02892-14>
- Bertin, C., Pau-Roblot, C., Courtois, J., Manso-Silván, L., Thiaucourt, F., Tardy, F., Grand, D.L., Poumarat, F., Gaurivaud, P., 2013. Characterization of Free Exopolysaccharides Secreted by *Mycoplasma mycoides* Subsp. *mycoides*. *PLOS ONE* 8, e68373. <https://doi.org/10.1371/journal.pone.0068373>
- Besser, T.E., Cassirer, E.F., Potter, K.A., Foreyt, W.J., 2017. Exposure of bighorn sheep to domestic goats colonized with *Mycoplasma ovipneumoniae* induces sub-lethal pneumonia. *PLOS ONE* 12, e0178707. <https://doi.org/10.1371/journal.pone.0178707>

- Besser, T.E., Cassirer, E.F., Potter, K.A., Lahmers, K., Oaks, J.L., Shanthalingam, S., Srikumaran, S., Foreyt, W.J., 2014. Epizootic Pneumonia of Bighorn Sheep following Experimental Exposure to *Mycoplasma ovipneumoniae*. PLOS ONE 9, e110039. <https://doi.org/10.1371/journal.pone.0110039>
- Besser, T.E., Highland, M.A., Baker, K., Cassirer, E.F., Anderson, N.J., Ramsey, J.M., Mansfield, K., Bruning, D.L., Wolff, P., Smith, J.B., Jenks, J.A., 2012. Causes of Pneumonia Epizootics among Bighorn Sheep, Western United States, 2008–2010. *Emerg. Infect. Dis.* 18, 406–414. <https://doi.org/10.3201/eid1803.111554>
- Besser, T.E., Levy, J., Ackerman, M., Nelson, D., Manlove, K., Potter, K.A., Busboom, J., Benson, M., 2019. A pilot study of the effects of *Mycoplasma ovipneumoniae* exposure on domestic lamb growth and performance. PLOS ONE 14, e0207420. <https://doi.org/10.1371/journal.pone.0207420>
- Betlach, A.M., Maes, D., Garza-Moreno, L., Tamiozzo, P., Sibila, M., Haesebrouck, F., Segalés, J., Pieters, M., 2019. *Mycoplasma hyopneumoniae* variability: Current trends and proposed terminology for genomic classification. *Transbound. Emerg. Dis.* 66, 1840–1854. <https://doi.org/10.1111/tbed.13233>
- Betlach, A.M., Valeris-Chacin, R., Singer, R.S., Allerson, M., Pieters, M., 2020. Natural transmission and detection of *Mycoplasma hyopneumoniae* in a naïve gilt population. *Vet. Microbiol.* 248, 108819. <https://doi.org/10.1016/j.vetmic.2020.108819>
- Beuckelaere, L., Haspeslagh, M., Biebaut, E., Boyen, F., Haesebrouck, F., Krejci, R., Meyer, E., Gleerup, D., De Spiegelaere, W., Devriendt, B., Maes, D., 2022. Different local, innate and adaptive immune responses are induced by two commercial *Mycoplasma hyopneumoniae* bacterins and an adjuvant alone. *Front. Immunol.* 13, 1015525. <https://doi.org/10.3389/fimmu.2022.1015525>
- Beyene, T.J., Eshetu, A., Abdu, A., Wondimu, E., Beyi, A.F., Tufa, T.B., Ibrahim, S., Revie, C.W., 2017. Assisting differential clinical diagnosis of cattle diseases using smartphone-based technology in low resource settings: a pilot study. *BMC Vet. Res.* 13, 323. <https://doi.org/10.1186/s12917-017-1249-3>
- Beylefeld, A., Wambulawaye, P., Bwala, D.G., Gouws, J.J., Lukhele, O.M., Wandrag, D.B.R., Abolnik, C., 2018. Evidence for multidrug resistance in nonpathogenic mycoplasma species isolated from South African poultry. *Appl. Environ. Microbiol.* 84, 01660–18.
- Biebaut, E., Beuckelaere, L., Boyen, F., Haesebrouck, F., Gomez-Duran, C.-O., Devriendt, B., Maes, D., 2023. Long-term follow-up of *Mycoplasma hyopneumoniae*-specific immunity in vaccinated pigs. *Vet. Res.* 54, 16. <https://doi.org/10.1186/s13567-023-01145-1>
- Biebaut, E., Beuckelaere, L., Boyen, F., Haesebrouck, F., Gomez-Duran, C.-O., Devriendt, B., Maes, D., 2021. Transfer of *Mycoplasma hyopneumoniae*-specific cell mediated immunity to neonatal piglets. *Vet. Res.* 52, 96. <https://doi.org/10.1186/s13567-021-00968-0>
- Biebaut, E., Chantziaras, I., Boyen, F., Devriendt, B., Haesebrouck, F., Gomez-Duran, C.-O., Maes, D., 2022. Influence of parity and reproductive stage on the prevalence of *Mycoplasma hyopneumoniae* in breeding animals in belgian farrow-to-finish pig herds. *Porc. Health Manag.* 8, 26. <https://doi.org/10.1186/s40813-022-00267-w>
- Billy, I.L., Balami, A.G., Sackey, A.K.B., Tekdek, L.B., Sa'idu, S.N.A., Okaiyeto, S.O., 2015. Awareness, knowledge and practices of pastoralists towards contagious bovine pleuro pneumonia in Kaduna State, Nigeria. *J. Vet. Med. Anim. Health* 7, 296–301.
- Biondo, N., Ludwig Takeuti, K., Montes, J.H., Lopes de Almeida, L., Pinto de Andrade, C., Zlotowski, P., Driemeier, D., Santos Neves de Barcellos, D.E., 2021. Bacterial Pneumonia in Captive Wild Boars in Southern Brazil - Etiological and Pathological Causes. *Acta Sci. Vet.* 49. <https://doi.org/10.22456/1679-9216.118917>
- Blanc, F., Maroilley, T., Revilla, M., Lemonnier, G., Leplat, J.-J., Billon, Y., Ravon, L., Bouchez, O., Bidanel, J.-P., Bed'Hom, B., Pinard-van der Laan, M.-H., Estellé, J., Rogel-Gaillard, C., 2021. Influence of genetics and the pre-vaccination blood transcriptome on the variability of antibody levels

- after vaccination against *Mycoplasma hyopneumoniae* in pigs. *Genet. Sel. Evol.* 53, 24. <https://doi.org/10.1186/s12711-021-00614-5>
- Bogema, D.R., Deutscher, A.T., Woolley, L.K., Seymour, L.M., Raymond, B.B.A., Tacchi, J.L., Padula, M.P., Dixon, N.E., Minion, F.C., Jenkins, C., Walker, M.J., Djordjevic, S.P., 2012. Characterization of cleavage events in the multifunctional cilium adhesin Mhp684 (P146) reveals a mechanism by which *Mycoplasma hyopneumoniae* regulates surface topography. *mBio* 3, e00282-11. <https://doi.org/10.1128/mBio.00282-11>
- Boguslavsky, S., Menaker, D., Lysnyansky, I., Liu, T., Levisohn, S., Rosengarten, R., García, M., Yogev, D., 2000. Molecular Characterization of the *Mycoplasma gallisepticum* pvpA Gene Which Encodes a Putative Variable Cytadhesin Protein. *Infect. Immun.* 68, 3956–3964.
- Bohach, D.M., Stegny, B.T., Bohach, M.V., Pavlov, S.L., Bolotin, V.I., 2021. Age and seasonal pattern of contagious agalactia in small ruminants in Ukraine. *J. Vet. Res.* 65, 67–72. <https://doi.org/10.2478/jvetres-2021-0014>
- Bohach, M.V., Bolotin, V.I., Bohach, D.M., Piven, O.T., Pyvovarova, I.V., 2022. Influence of natural and climatic conditions on the distribution and forms of contagious agalactia in sheep in Bessarabia, Ukraine. *J. Vet. Res.* 66, 345–351. <https://doi.org/10.2478/jvetres-2022-0047>
- Bokma, J., Boone, R., Deprez, P., Pardon, B., 2020a. Herd-level analysis of antimicrobial use and mortality in veal calves: Do herds with low usage face higher mortality? *J. Dairy Sci.* 103, 909–914. <https://doi.org/10.3168/jds.2019-16764>
- Bokma, J., Gille, L., De Bleecker, K., Callens, J., Haesebrouck, F., Pardon, B., Boyen, F., 2020b. Antimicrobial Susceptibility of *Mycoplasma bovis* Isolates from Veal, Dairy and Beef Herds. *Antibiotics* 9, 882. <https://doi.org/10.3390/antibiotics9120882>
- Bokma, J., Van Driessche, L., Deprez, P., Haesebrouck, F., Vahl, M., Weesendorp, E., Deurenberg, R.H., Pardon, B., Boyen, F., 2020c. Rapid Identification of *Mycoplasma bovis* Strains from Bovine Bronchoalveolar Lavage Fluid with Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry after Enrichment Procedure. *J. Clin. Microbiol.* 58, e00004-20. <https://doi.org/10.1128/JCM.00004-20>
- Bokma, J., Vereecke, N., De Bleecker, K., Callens, J., Ribbens, S., Nauwynck, H., Haesebrouck, F., Theuns, S., Boyen, F., Pardon, B., 2020d. Phylogenomic analysis of *Mycoplasma bovis* from Belgian veal, dairy and beef herds. *Vet. Res.* 51, 121. <https://doi.org/10.1186/s13567-020-00848-z>
- Bokma, J., Vereecke, N., Nauwynck, H., Haesebrouck, F., Theuns, S., Pardon, B., Boyen, F., 2021a. Genome-Wide Association Study Reveals Genetic Markers for Antimicrobial Resistance in *Mycoplasma bovis*. *Microbiol. Spectr.* 9, e00262-21. <https://doi.org/10.1128/Spectrum.00262-21>
- Bokma, J., Vereecke, N., Pas, M.L., Chantillon, L., Vahl, M., Weesendorp, E., Deurenberg, R.H., Nauwynck, H., Haesebrouck, F., Theuns, S., Boyen, F., Pardon, B., 2021b. Evaluation of Nanopore Sequencing as a Diagnostic Tool for the Rapid Identification of *Mycoplasma bovis* from Individual and Pooled Respiratory Tract Samples. *J. Clin. Microbiol.* 59, e01110-21. <https://doi.org/10.1128/JCM.01110-21>
- Bolfa, P., Callanan, J.J., Ketzis, J., Marchi, S., Cheng, T., Huynh, H., Lavinder, T., Boey, K., Hamilton, C., Kelly, P., 2019. Infections and pathology of free-roaming backyard chickens on St. Kitts, West Indies. *J. Vet. Diagn. Invest.* 31, 343–349. <https://doi.org/10.1177/1040638719843638>
- Bonneaud, C., Giraudeau, M., Tardy, L., Staley, M., Hill, G.E., McGraw, K.J., 2018. Rapid Antagonistic Coevolution in an Emerging Pathogen and Its Vertebrate Host. *Curr. Biol.* 28, 2978-2983.e5. <https://doi.org/10.1016/j.cub.2018.07.003>
- Bonneaud, C., Tardy, L., Hill, G.E., McGraw, K.J., Wilson, A.J., Giraudeau, M., 2020. Experimental evidence for stabilizing selection on virulence in a bacterial pathogen. *Evol. Lett.* 4, 491–501. <https://doi.org/10.1002/evl3.203>
- Booker, C.W., Abutarbush, S.M., Morley, P.S., Jim, G.K., Pittman, T.J., Schunicht, O.C., Perrett, T., Wildman, B.K., Fenton, R.K., Guichon, P.T., Janzen, E.D., 2008. Microbiological and

- histopathological findings in cases of fatal bovine respiratory disease of feedlot cattle in western Canada. *Can. Vet. J.* 49, 473–481.
- Borjigin, L., Shimazu, T., Katayama, Y., Li, M., Satoh, T., Watanabe, K., Kitazawa, H., Roh, S., Aso, H., Katoh, K., Uchida, T., Suda, Y., Sakuma, A., Nakajo, M., Suzuki, K., 2016a. Immunogenic properties of Landrace pigs selected for resistance to mycoplasma pneumonia of swine. *Anim. Sci. J.* 87, 321–329. <https://doi.org/10.1111/asj.12440>
- Borjigin, L., Shimazu, T., Katayama, Y., MeiHua, L., Satoh, T., Watanabe, K., Kitazawa, H., SangGun, R., Aso, H., Katoh, K., Uchida, T., Suda, Y., Sakuma, A., Nakajo, M., Suzuki, K., 2016b. Immunogenic properties and mycoplasmal pneumonia of swine (MPS) lung lesions in Large White pigs selected for higher peripheral blood immune capacity. *Anim. Sci. J.* 87, 638–645.
- Borjigin, L., Shimazu, T., Katayama, Y., Watanabe, K., Kitazawa, H., Roh, S., Aso, H., Katoh, K., Satoh, M., Suda, Y., Sakuma, A., Nakajo, M., Suzuki, K., 2017. Effects of mycoplasmal pneumonia of swine (MPS) lung lesion-selected Landrace pigs on MPS resistance and immune competence in three-way crossbred pigs. *Anim. Sci. J.* 88, 575–585. <https://doi.org/10.1111/asj.12698>
- Borjigin, L., Shimazu, T., Katayama, Y., Watanabe, K., Kitazawa, H., Roh, S., Aso, H., Katoh, K., Uchida, T., Suda, Y., Sakuma, A., Nakajo, M., Suzuki, K., 2016c. Mycoplasma pneumonia of swine (MPS) resistance and immune characteristics of pig lines generated by crossing an MPS pulmonary lesion selected Landrace line and a highly immune capacity selected Large White line. *Anim. Sci. J.* 87, 972–981. <https://doi.org/10.1111/asj.12529>
- BoShuai, L., WenJing, W., XiaoYan, Z., Xiao, S., JunNan, X., DeFeng, L., YaLei, C., ChengZhang, W., YingHua, S., 2018. Response of gut microbiota to dietary fiber and metabolic interaction with SCFAs in piglets. *Front. Microbiol.* 9.
- Bottinelli, M., Gastaldelli, M., Picchi, M., Dall’Ora, A., Cristovao Borges, L., Ramírez, A.S., Matucci, A., Catania, S., 2022. The Monitoring of Mycoplasma gallisepticum Minimum Inhibitory Concentrations during the Last Decade (2010–2020) Seems to Reveal a Comeback of Susceptibility to Macrolides, Tiamulin, and Lincomycin. *Antibiotics* 11, 1021. <https://doi.org/10.3390/antibiotics11081021>
- Bottinelli, M., Merenda, M., Gastaldelli, M., Picchi, M., Stefani, E., Nicholas, R.A.J., Catania, S., 2020. The pathogen Mycoplasma dispar Shows High Minimum Inhibitory Concentrations for Antimicrobials Commonly Used for Bovine Respiratory Disease. *Antibiotics* 9, 460. <https://doi.org/10.3390/antibiotics9080460>
- Bottinelli, M., Passamonti, F., Rampacci, E., Stefanetti, V., Pochiero, L., Coletti, M., Rueca, F., Hyatt, D.R., Schnee, C., 2017a. DNA microarray assay and real-time PCR as useful tools for studying the respiratory tract Mycoplasma populations in young dairy calves. *J. Med. Microbiol.* 66, 1342–1349. <https://doi.org/10.1099/jmm.0.000571>
- Bottinelli, M., Schnee, C., Lepri, E., Stefanetti, V., Filippini, G., Gobbi, M., Sebastianelli, M., Antenucci, P., Rampacci, E., Coletti, M., Passamonti, F., 2017b. Investigation on mycoplasma populations in pneumonic dairy lamb lungs using a DNA microarray assay. *Small Rumin. Res.* 147, 96–100. <https://doi.org/10.1016/j.smallrumres.2016.12.038>
- Botuş, D., Ene, G., Culcescu, M., Popa, V., Daneş, M., 2017. Evaluation of immune response in sheep after vaccination against contagious agalactia. *Lucr. Stiintifice - Univ. Stiinte Agric. Banat. Timisoara Med. Vet.* 50, 30–38.
- Boularias, G., Azzag, N., Gandoin, C., Bouillin, C., Chomel, B., Haddad, N., Boulouis, H.-J., 2020. Bovines Harbor a Diverse Array of Vector-Borne Pathogens in Northeast Algeria. *Pathogens* 9, 883. <https://doi.org/10.3390/pathogens9110883>
- Bras, A.L., Barkema, H.W., Woodbury, M., Ribble, C., Perez-Casal, J., Windeyer, M.C., 2016. Risk factors for Mycoplasma bovis-associated disease in farmed bison (*Bison bison*) herds in western Canada: A case-control study. *Prev. Vet. Med.* 129, 67–73. <https://doi.org/10.1016/j.prevetmed.2016.05.011>
- Bras, A.L., Barkema, H.W., Woodbury, M.R., Ribble, C.S., Perez-Casal, J., Windeyer, M.C., 2017a. Clinical presentation, prevalence, and risk factors associated with Mycoplasma bovis-

- associated disease in farmed bison (*Bison bison*) herds in western Canada. *J. Am. Vet. Med. Assoc.* 250, 1167–1175. <https://doi.org/10.2460/javma.250.10.1167>
- Bras, A.L., Suleman, M., Woodbury, M., Register, K., Barkema, H.W., Perez-Casal, J., Windeyer, M.C., 2017b. A serologic survey of *Mycoplasma* spp. in farmed bison (*Bison bison*) herds in western Canada. *J. Vet. Diagn. Invest.* 29, 513–521. <https://doi.org/10.1177/1040638717710057>
- Brewster, V.R., Maiti, H.C., Tucker, A.W., Nevel, A., 2017. Associations between EP-like lesions and pleuritis and post trimming carcass weights of finishing pigs in England. *Livest. Sci.* 201, 1–4. <https://doi.org/10.1016/j.livsci.2017.04.012>
- Bridgeman, B.J., Gupta, S.K., Murray, A., Dukkipati, V.S.R., Altermann, E., Wedlock, D.N., 2020. Draft Genome Sequence of a New Zealand Isolate of *Mycoplasma ovipneumoniae*. *Microbiol. Resour. Announc.* 9, e01375-19. <https://doi.org/10.1128/MRA.01375-19>
- Briggs, R.E., Billing, S.R., Boatwright, W.D., Chriswell, B.O., Casas, E., Dassanayake, R.P., Palmer, M.V., Register, K.B., Tatum, F.M., 2021. Protection against *Mycoplasma bovis* infection in calves following intranasal vaccination with modified-live Mannheimia haemolytica expressing *Mycoplasma* antigens. *Microb. Pathog.* 161, 105159. <https://doi.org/10.1016/j.micpath.2021.105159>
- Brissonnier, M., Normand, V., Lebret, A., Moalic, P.-Y., Guyomard, A.-S., Bachy, V., Berton, P., Auvigne, V., Bouchet, F., Boulbria, G., 2020. Frequency of infection with *Mycoplasma suis* in gestating sows using qPCR on ten commercial French herds, and impact of the infection on clinical, haematological and biochemical parameters. *Porc. Health Manag.* 6, 13. <https://doi.org/10.1186/s40813-020-00152-4>
- Brochu, N.M., Guerin, M.T., Varga, C., Lillie, B.N., Brash, M.L., Susta, L., 2019a. A two-year prospective study of small poultry flocks in Ontario, Canada, part 1: prevalence of viral and bacterial pathogens. *J. Vet. Diagn. Invest.* 31, 327–335. <https://doi.org/10.1177/1040638719843577>
- Brochu, N.M., Guerin, M.T., Varga, C., Lillie, B.N., Brash, M.L., Susta, L., 2019b. A two-year prospective study of small poultry flocks in Ontario, Canada, part 2: causes of morbidity and mortality. *J. Vet. Diagn. Invest.* 31, 336–342. <https://doi.org/10.1177/1040638719843575>
- Browne, C., Loeffler, A., Holt, H.R., Chang, Y.M., Lloyd, D.H., Nevel, A., 2017. Low temperature and dust favour *in vitro* survival of *Mycoplasma hyopneumoniae*: time to revisit indirect transmission in pig housing. *Lett. Appl. Microbiol.* 64, 2–7. <https://doi.org/10.1111/lam.12689>
- Bukte, S.R., Gandge, R.S., 2018. Rapid serum agglutination, cultural isolation and PCR for detection of *M. gallisepticum* and *M. synoviae* infection in poultry. *Indian J. Anim. Sci.* 88, 397–401.
- Bumgardner, E., Bey, R.F., Kittichotirat, W., Bumgarner, R.E., Lawrence, P.K., 2014. Genome Sequences of Seven *Mycoplasma hyosynoviae* Strains Isolated from the Joint Tissue of Infected Swine (*Sus scrofa*). *Genome Announc.* 2, e00552-14. <https://doi.org/10.1128/genomeA.00552-14>
- Bumgardner, E.A., Bey, R.F., Lawrence, P.K., 2018. A p37-based ELISA used to monitor anti-*Mycoplasma hyorhinis* IgG in serum from pigs immunized with inactivated *M. hyorhinis* vaccines. *J. Vet. Diagn. Invest.* 30, 755–759. <https://doi.org/10.1177/1040638718784753>
- Bumgardner, E.A., Kittichotirat, W., Bumgarner, R.E., Lawrence, P.K., 2015. Comparative genomic analysis of seven *Mycoplasma hyosynoviae* strains. *MicrobiologyOpen* 4, 343–359. <https://doi.org/10.1002/mbo3.242>
- Bünger, M., Brunthaler, R., Unterweger, C., Loncaric, I., Dippel, M., Ruczizka, U., Schwarz, L., Griessler, A., Voglmayr, T., Verhovsek, D., Ladinig, A., Spargser, J., 2020. *Mycoplasma hyorhinis* as a possible cause of fibrinopurulent meningitis in pigs? - a case series. *Porc. Health Manag.* 6, 38. <https://doi.org/10.1186/s40813-020-00178-8>
- Bünger, M., Posch, M., Wiesauer, J., Loncaric, I., Cabal Rosel, A., Ruppitsch, W., Ladinig, A., Spargser, J., 2021. A core genome multilocus sequence typing scheme for *Mycoplasma hyorhinis*. *Vet. Microbiol.* 262, 109249. <https://doi.org/10.1016/j.vetmic.2021.109249>
- Bunke, J., Receveur, K., Oeser, A.C., Gutschmann, I., Schubert, S., Podschun, R., Zell, R., Fickenscher, H., Krumbholz, A., 2020. Epidemiology of bacteria and viruses in the respiratory tract of humans and domestic pigs. *APMIS* 128, 451–462. <https://doi.org/10.1111/apm.13046>

- Bürki, N., Josi, C., Bürki, S., Schweizer, M., Pilo, P., 2018. *Mycoplasma bovis* co-infection with bovine viral diarrhoea virus in bovine macrophages. *Vet. Res.* 49.
- Burgos, R., Garcia-Ramallo, E., Shaw, D., Lluch-Senar, M., Serrano, L., 2023. Development of a Serum-Free Medium To Aid Large-Scale Production of *Mycoplasma*-Based Therapies. *Microbiol. Spectr.* e0485922. <https://doi.org/10.1128/spectrum.04859-22>
- Bürki, S., Frey, J., Pilo, P., 2015. Virulence, persistence and dissemination of *Mycoplasma bovis*. *Vet. Microbiol., Special Issue: VETPATH 2014 - Pathogenesis of Bacterial Infections of Animals* 179, 15–22. <https://doi.org/10.1016/j.vetmic.2015.02.024>
- Bürki, S., Spersger, J., Bodmer, M., Pilo, P., 2016. A dominant lineage of *Mycoplasma bovis* is associated with an increased number of severe mastitis cases in cattle. *Vet. Microbiol.* 196, 63–66. <https://doi.org/10.1016/j.vetmic.2016.10.016>
- Burrough, E.R., Schwartz, A.P., Gauger, P.C., Harmon, K.M., Krull, A.C., Schwartz, K.J., 2018. Comparison of postmortem airway swabs and lung tissue for detection of common porcine respiratory pathogens by bacterial culture and polymerase chain reaction assays. *J. Swine Health Prod.* 26, 246–252.
- Butenko, I., Vanyushkina, A., Pobeguts, O., Matyushkina, D., Kovalchuk, S., Gorbachev, A., Anikanov, N., Fisunov, G., Govorun, V., 2017. Response induced in *Mycoplasma gallisepticum* under heat shock might be relevant to infection process. *Sci. Rep.* 7, 11330. <https://doi.org/10.1038/s41598-017-09237-7>
- Butler, C.J., Edwards, W.H., Paterson, J.T., Proffitt, K.M., Jennings-Gaines, J.E., Killion, H.J., Wood, M.E., Ramsey, J.M., AlMBERG, E.S., Dewey, S.R., McWhirter, D.E., Courtemanch, A.B., White, P.J., Rotella, J.J., Garrott, R.A., 2018. Respiratory pathogens and their association with population performance in Montana and Wyoming bighorn sheep populations. *PLOS ONE* 13, e0207780. <https://doi.org/10.1371/journal.pone.0207780>
- Byamukama, B., Tumwebaze, M.A., Tayebwa, D.S., Byaruhanga, J., Angwe, M.K., Li, J., Galon, E.M., Liu, M., Li, Y., Ji, S., Moumouni, P.F.A., Ringo, A., Lee, S.-H., Vudriko, P., Xuan, X., 2020. First Molecular Detection and Characterization of Hemotropic *Mycoplasma* Species in Cattle and Goats from Uganda. *Animals* 10, 1624. <https://doi.org/10.3390/ani10091624>
- Cacciotto, C., Addis, M.F., Pagnozzi, D., Coradduzza, E., Pittau, M., Alberti, A., 2021. Identification of conserved *Mycoplasma agalactiae* surface antigens by immunoproteomics. *Vet. Immunol. Immunopathol.* 236, 110239. <https://doi.org/10.1016/j.vetimm.2021.110239>
- Cacciotto, C., Cubeddu, T., Addis, M.F., Anfossi, A.G., Tedde, V., Tore, G., Carta, T., Rocca, S., Chessa, B., Pittau, M., Alberti, A., 2016. *Mycoplasma* lipoproteins are major determinants of neutrophil extracellular trap formation: *Mycoplasma* lipoproteins: determinants of NET formation. *Cell. Microbiol.* 18, 1751–1762. <https://doi.org/10.1111/cmi.12613>
- Cai, H.Y., McDowall, R., Parker, L., Kaufman, E.I., Caswell, J.L., 2019. Changes in antimicrobial susceptibility profiles of *Mycoplasma bovis* over time. *Can. J. Vet. Res.* 83, 34–41.
- Calcutt, M.J., Foecking, M.F., Heidari, M.B., McIntosh, M.A., 2015. Complete genome sequence of *Mycoplasma flocculare* strain Ms42T (ATCC 27399T). *Genome Announc.* 3.
- Calcutt, M.J., Lysnyansky, I., Sachse, K., Fox, L.K., Nicholas, R. a. J., Ayling, R.D., 2018. Gap analysis of *Mycoplasma bovis* disease, diagnosis and control: an aid to identify future development requirements. *Transbound. Emerg. Dis.* 65, 91–109.
- Calderón Bernal, J.M., Fernández, A., Arnal, J.L., Baselga, C., Benito Zuñiga, A., Fernández-Garyzábal, J.F., Vela Alonso, A.I., Cid, D., 2023. Cluster analysis of bovine respiratory disease (BRD)-associated pathogens shows the existence of two epidemiological patterns in BRD outbreaks. *Vet. Microbiol.* 280, 109701. <https://doi.org/10.1016/j.vetmic.2023.109701>
- Calderón Díaz, J.A., Fitzgerald, R.M., Shalloo, L., Rodrigues da Costa, M., Niemi, J., Leonard, F.C., Kyriazakis, I., García Manzanilla, E., 2020. Financial Analysis of Herd Status and Vaccination Practices for Porcine Reproductive and Respiratory Syndrome Virus, Swine Influenza Virus, and *Mycoplasma hyopneumoniae* in Farrow-to-Finish Pig Farms Using a Bio-Economic Simulation Model. *Front. Vet. Sci.* 7, 556674. <https://doi.org/10.3389/fvets.2020.556674>

- Canelli, E., Ferrari, L., Borghetti, P., Candela, F., Abiakam, N.S., Bianchera, A., Buttini, F., Magi, G.E., Sonvico, F., Martelli, P., Bettini, R., 2023. Nano-adjuvanted dry powder vaccine for the mucosal immunization against airways pathogens. *Front. Vet. Sci.* 10, 1116722. <https://doi.org/10.3389/fvets.2023.1116722>
- Canning, P., Costello, N., Mahan-Riggs, E., Schwartz, K.J., Skoland, K., Crim, B., Ramirez, A., Linhares, D., Gauger, P., Karriker, L., 2019. Retrospective study of lameness cases in growing pigs associated with joint and leg submissions to a Veterinary Diagnostic Laboratory. *J. Swine Health Prod.* 27, 118–124.
- Canter, J.A., Tulman, E.R., Beaudet, J., Lee, D.H., May, M., Szczepanek, S.M., Geary, S.J., 2020. Transcriptional and pathological host responses to coinfection with virulent or attenuated *Mycoplasma gallisepticum* and low-pathogenic avian influenza A virus in chickens. *Infect. Immun.* 88.
- Cantón, G., Llada, I., Margineda, C., Urtizbiría, F., Fanti, S., Scioli, V., Fiorentino, M.A., Louge Uriarte, E., Morrell, E., Sticotti, E., Tamiozzo, P., 2022. *Mycoplasma bovis*-pneumonia and polyarthritits in feedlot calves in Argentina: First local isolation. *Rev. Argent. Microbiol.* 54, 299–304. <https://doi.org/10.1016/j.ram.2022.02.005>
- Cappuccio, J.A., Dibarbora, M., Bessone, F.A., Olivera, V.S., Lozada, I., Alustiza, F.E., Quiroga, A., Pérez, E.M., Zielinski, G.C., Perfumo, C.J., Pereda, A.J., Pérez, D.R., 2018. Evaluation of pig pneumonia at slaughter using polymerase chain reaction and histopathology in Argentina. *J. Swine Health Prod.* 26, 304–308.
- Carli, S.D., Dias, M.E., da Silva, M.E.R.J., Breyer, G.M., Siqueira, F.M., 2022. Survey of beef bulls in Brazil to assess their role as source of infectious agents related to cow infertility. *J. Vet. Diagn. Invest.* 34, 54–60. <https://doi.org/10.1177/10406387211050636>
- Carozza, M., Rodrigues, V., Unterfinger, Y., Galea, S., Couplier, M., Klonjkowski, B., Thiaucourt, F., Totté, P., Richardson, J., 2015. An adenoviral vector expressing lipoprotein A, a major antigen of *Mycoplasma mycoides* subspecies *mycoides*, elicits robust immune responses in mice. *Vaccine* 33, 141–148. <https://doi.org/10.1016/j.vaccine.2014.10.088>
- Casas, E., Falkenberg, S.M., Dassanayake, R.P., Register, K.B., Neill, J.D., 2022. MicroRNA profiles for different tissues from calves challenged with *Mycoplasma bovis* or challenged with *Mycoplasma bovis* and bovine viral diarrhoea virus. *PLOS ONE* 17, e0271581. <https://doi.org/10.1371/journal.pone.0271581>
- Cassirer, E.F., Manlove, K.R., Almborg, E.S., Kamath, P.L., Cox, M., Wolff, P., Roug, A., Shannon, J., Robinson, R., Harris, R.B., Gonzales, B.J., Plowright, R.K., Hudson, P.J., Cross, P.C., Dobson, A., Besser, T.E., 2018. Pneumonia in bighorn sheep: Risk and resilience. *J. Wildl. Manag.* 82, 32–45. <https://doi.org/10.1002/jwmg.21309>
- Cassirer, E.F., Manlove, K.R., Plowright, R.K., Besser, T.E., 2017. Evidence for strain-specific immunity to pneumonia in bighorn sheep: Immunity in Bighorn Sheep. *J. Wildl. Manag.* 81, 133–143. <https://doi.org/10.1002/jwmg.21172>
- Castillo-Alcala, F., Bateman, K.G., Cai, H.Y., Schott, C.R., Parker, L., Clark, M.E., McRaid, P., McDowall, R.M., Foster, R.A., Archambault, M., Caswell, J.L., 2012. Prevalence and genotype of *Mycoplasma bovis* in beef cattle after arrival at a feedlot. *Am. J. Vet. Res.* 73, 1932–1943. <https://doi.org/10.2460/ajvr.73.12.1932>
- Catania, S., Bottinelli, M., Fincato, A., Gastaldelli, M., Barberio, A., Gobbo, F., Vicenzoni, G., 2019. Evaluation of Minimum Inhibitory Concentrations for 154 *Mycoplasma synoviae* isolates from Italy collected during 2012-2017. *PLOS ONE* 14.
- Cattani, A.M., Siqueira, F.M., Guedes, R.L.M., Schrank, I.S., 2016. Repetitive Elements in *Mycoplasma hyopneumoniae* Transcriptional Regulation. *PLOS ONE* 11, e0168626. <https://doi.org/10.1371/journal.pone.0168626>
- Centeno-Martinez, R.E., Glidden, N., Mohan, S., Davidson, J.L., Fernández-Juricic, E., Boerman, J.P., Schoonmaker, J., Pillai, D., Koziol, J., Ault, A., Verma, M.S., Johnson, T.A., 2022. Identification

- of bovine respiratory disease through the nasal microbiome. *Anim. Microbiome* 4, 15. <https://doi.org/10.1186/s42523-022-00167-y>
- Chaidez-Ibarra, M.A., Velazquez, D.Z., Enriquez-Verdugo, I., Castro del Campo, N., Rodriguez-Gaxiola, M.A., Montero-Pardo, A., Diaz, D., Gaxiola, S.M., 2022. Pooled molecular occurrence of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* in poultry: A systematic review and meta-analysis. *Transbound. Emerg. Dis.* 69, 2499–2511. <https://doi.org/10.1111/tbed.14302>
- Chandrashekar, K.M., Kumar, G.S.N., Chandrashekhara, N., Punya, J., Ranganath, L., 2020. Seroprevalence of contagious caprine pleuropneumonia in small ruminants in Karnataka, India. *Indian J. Anim. Sci.* 90, 967–970.
- Chao, Han, Liu, Li, Peng, Lu, Zhu, Hu, Dong, Hu, Chen, Chen, Khan, Chen, Guo, 2019. Calves Infected with Virulent and Attenuated *Mycoplasma bovis* Strains Have Upregulated Th17 Inflammatory and Th1 Protective Responses, Respectively. *Genes* 10, 656. <https://doi.org/10.3390/genes10090656>
- Chaudhari, S.V., Joshi, B.P., Joshi, C.G., Shah, R.K., Bhandari, B.B., Ghodasara, D.J., 2018. Etiopathological studies on low pathogenic avian influenza and molecular detection of concurrent infections in broiler chicken. *Indian J. Vet. Pathol.* 42, 51. <https://doi.org/10.5958/0973-970X.2018.00009.3>
- Chauhan, K., Aly, S.S., Lehenbauer, T.W., Tonooka, K.H., Glenn, K., Rossitto, P., Marco, M.L., 2021. Development of a multiplex qPCR assay for the simultaneous detection of *Mycoplasma bovis*, *Mycoplasma* species, and *Acholeplasma laidlawii* in milk. *PeerJ* 9, e11881. <https://doi.org/10.7717/peerj.11881>
- Chen, C., Li, J., Zhang, W., Shah, S.W.A., Ishfaq, M., 2020. *Mycoplasma gallisepticum* triggers immune damage in the chicken thymus by activating the TLR-2/MyD88/NF-κB signaling pathway and NLRP3 inflammasome. *Vet. Res.* 51, 52. <https://doi.org/10.1186/s13567-020-00777-x>
- Chen, H., Yu, S., Hu, M., Han, X., Chen, D., Qiu, X., Ding, C., 2012. Identification of biofilm formation by *Mycoplasma gallisepticum*. *Vet. Microbiol.* 161, 96–103. <https://doi.org/10.1016/j.vetmic.2012.07.013>
- Chen, Junfeng, Huddleston, J., Buckley, R.M., Malig, M., Lawhon, S.D., Skow, L.C., Lee, M.O., Eichler, E.E., Andersson, L., Womack, J.E., 2015. Bovine NK-lysin: Copy number variation and functional diversification. *Proc. Natl. Acad. Sci.* 112, E7223–E7229. <https://doi.org/10.1073/pnas.1519374113>
- Chen, J., Wang, Z., Bi, D., Hou, Y., Zhao, Y., Sun, J., Peng, X., 2015. gga-miR-101-3p Plays a Key Role in *Mycoplasma gallisepticum* (HS Strain) Infection of Chicken. *Int. J. Mol. Sci.* 16, 28669–28682. <https://doi.org/10.3390/ijms161226121>
- Chen, J., Yang, C., Tizioto, P.C., Huang, H., Lee, M.O.K., Payne, H.R., Lawhon, S.D., Schroeder, F., Taylor, J.F., Womack, J.E., 2016. Expression of the Bovine NK-Lysin Gene Family and Activity against Respiratory Pathogens. *PLOS ONE* 11, e0158882. <https://doi.org/10.1371/journal.pone.0158882>
- Chen, J., Zhou, Y., Zhu, E., Yang, P., Li, M., Zhang, S., Yue, J., Wen, M., Wang, K., Cheng, Z., 2021. *Mycoplasma ovipneumoniae* induces caspase-8-dependent extrinsic apoptosis and p53- and ROS-dependent intrinsic apoptosis in murine alveolar macrophages. *Virulence* 12, 2703–2720. <https://doi.org/10.1080/21505594.2021.1984714>
- Chen, S., Hao, H., Yan, X., Liu, Y., Chu, Y., 2019. Genome-Wide Analysis of *Mycoplasma dispar* Provides Insights into Putative Virulence Factors and Phylogenetic Relationships. *G3 Genes Genomes Genet.* 9, 317–325. <https://doi.org/10.1534/g3.118.200941>
- Chen, S., Hao, H., Zhao, P., Gao, P., He, Y., Ji, W., Wang, Z., Lu, Z., Liu, Y., Chu, Y., 2017a. Complete Genome Sequence of *Mycoplasma bovis* Strain 08M. *Genome Announc.* 5, e00324-17. <https://doi.org/10.1128/genomeA.00324-17>
- Chen, S., Hao, H., Zhao, P., Liu, Y., Chu, Y., 2018. Genome-wide analysis of *Mycoplasma bovirhinis* GS01 reveals potential virulence factors and phylogenetic relationships. *G3 Genes Genomes Genet.* 8, 1417–1424.

- Chen, S., Hao, H., Zhao, P., Thiaucourt, F., He, H., Gao, P., Guo, H., Ji, W., Wang, Z., Lu, Z., Chu, Y., Liu, Y., 2017b. Genome-wide analysis of the first sequenced *Mycoplasma capricolum* subsp. *capripneumoniae* strain M1601. *G3 Genes Genomes Genet.* 7, 2899–2906.
- Chen, W., Sun, Q., Yan, Z., Zhou, Q., Cao, Y., Chen, F., Wei, X., 2022. Transcriptional profiling of the chicken tracheal and splenic response to virulent *Mycoplasma synoviae*. *Poult. Sci.* 101, 101660. <https://doi.org/10.1016/j.psj.2021.101660>
- Chen, X., Huang, J., Zhu, H., Guo, Y., Khan, F.A., Menghwar, H., Zhao, G., Guo, A., 2018. P27 (MBOV_RS03440) is a novel fibronectin binding adhesin of *Mycoplasma bovis*. *Int. J. Med. Microbiol.* 308, 848–857. <https://doi.org/10.1016/j.ijmm.2018.07.006>
- Chen, X., Ishfaq, M., Wang, J., 2023. Baicalin ameliorates *Mycoplasma gallisepticum*-induced inflammatory injury via inhibiting STIM1-regulated ceramide accumulation in DF-1 cells. *Poult. Sci.* 102, 102687. <https://doi.org/10.1016/j.psj.2023.102687>
- Chenais, E., Fischer, K., 2018. Increasing the Local Relevance of Epidemiological Research: Situated Knowledge of Cattle Disease Among Basongora Pastoralists in Uganda. *Front. Vet. Sci.* 5, 119. <https://doi.org/10.3389/fvets.2018.00119>
- Cheng, C., Jun, Q., Qingling, M., Zhengxiang, H., Yu, M., Xuepeng, C., Zibing, C., Jinsheng, Z., Zaichao, Z., Kuojun, C., Chuangfu, C., 2015. Serological and molecular survey of sheep infected with *Mycoplasma ovipneumoniae* in Xinjiang, China. *Trop. Anim. Health Prod.* 47, 1641–1647. <https://doi.org/10.1007/s11250-015-0908-2>
- Cheng, X., Nicolet, J., Miserez, R., Kuhnert, P., Krampe, M., Pilloud, T., Abdo, E.M., Griot, C., Frey, J., 1996. Characterization of the gene for an immunodominant 72 kDa lipoprotein of *Mycoplasma mycoides* subsp. *mycoides* small colony type. *Microbiol. Read. Engl.* 142 (Pt 12), 3515–3524. <https://doi.org/10.1099/13500872-142-12-3515>
- ChenYan, W., ZhongBao, L., BaoQin, H., Bin, J., ShiZhong, Z., GuoQing, S., Bo, H., 2022. Investigation of *Mycoplasma synoviae* infection in unvaccinated chicken flocks during 2018-2020 in Fujian. *Chin. J. Prev. Vet. Med.* 44, 697–703.
- Cheong, Y., Oh, C., Lee, K., Cho, K., 2017. Survey of porcine respiratory disease complex-associated pathogens among commercial pig farms in Korea via oral fluid method. *J. Vet. Sci.* 18, 283. <https://doi.org/10.4142/jvs.2017.18.3.283>
- Cho, H., Ahn, Y., Oh, T., Suh, J., Chae, C., 2022. Non-Inferiority Field Study Comparing the Administrations by Conventional Needle-Syringe and Needle-Free Injectors of a Trivalent Vaccine Containing Porcine Circovirus Types 2a/2b and *Mycoplasma hyopneumoniae*. *Vaccines* 10, 358. <https://doi.org/10.3390/vaccines10030358>
- Chopra-Dewasthaly, R., Dagn, A., Lohinger, C., Brunthaler, R., Flöck, M., Kargl, M., Hegde, S., Spersger, J., Rosengarten, R., 2022. Sheep Infection Trials with ‘Phase-Locked’ Vpma Expression Variants of *Mycoplasma agalactiae*—Towards Elucidating the Role of a Multigene Family Encoding Variable Surface Lipoproteins in Infection and Disease. *Microorganisms* 10, 815. <https://doi.org/10.3390/microorganisms10040815>
- Chopra-Dewasthaly, R., Korb, M., Brunthaler, R., Ertl, R., 2017. Comprehensive RNA-Seq Profiling to Evaluate the Sheep Mammary Gland Transcriptome in Response to Experimental *Mycoplasma agalactiae* Infection. *PLOS ONE* 12, e0170015. <https://doi.org/10.1371/journal.pone.0170015>
- Chota, A., Shirima, G., Kusiluka, L., 2019. Risk factors associated with *Mycoplasma capricolum* subspecies *capripneumoniae* and morbillivirus infection in small ruminants in Tanzania. *Trop. Anim. Health Prod.* 51, 1807–1815. <https://doi.org/10.1007/s11250-019-01981-4>
- Chowdhury, M., Habib, M., Hossain, M., Rima, U., Saha, P., Islam, M., Chowdhury, S., Kamaruddin, K., Chowdhury, Smzh, Khan, M., 2018. Passive surveillance on occurrence of deadly infectious, noninfectious and zoonotic diseases of livestock and poultry in Bangladesh and remedies. *SAARC J. Agric.* 16, 129–144. <https://doi.org/10.3329/sja.v16i1.37429>
- Churchward, C.P., Rosales, R.S., Gielbert, A., Domínguez, M., Nicholas, R.A.J., Ayling, R.D., 2015. Immunoproteomic characterisation of *Mycoplasma mycoides* subspecies *capri* by mass

- spectrometry analysis of two-dimensional electrophoresis spots and western blot. *J. Pharm. Pharmacol.* 67, 364–371. <https://doi.org/10.1111/jphp.12344>
- Cillara, G., Manca, M.G., Longheu, C., Tola, S., 2015. Discrimination between *Mycoplasma mycoides* subsp. *capri* and *Mycoplasma capricolum* subsp. *capricolum* using PCR-RFLP and PCR. *Vet. J.* 205, 421–423. <https://doi.org/10.1016/j.tvjl.2015.05.013>
- Cirone, F., Padalino, B., Tullio, D., Capozza, P., Losurdo, M., Lanave, G., Pratelli, A., 2019. Prevalence of Pathogens Related to Bovine Respiratory Disease Before and After Transportation in Beef Steers: Preliminary Results. *Animals* 9, 1093. <https://doi.org/10.3390/ani9121093>
- Citti, C., Baranowski, E., Dordet-Frisoni, E., Faucher, M., Nouvel, L.-X., 2020. Genomic Islands in *Mycoplasmas*. *Genes* 11. <https://doi.org/10.3390/genes11080836>
- Cizelj, I., Berčič, R.L., Slavec, B., Narat, M., Dovč, P., Benčina, D., 2015. Multilocus sequence analysis for *Mycoplasma synoviae* molecular genotyping. *Br. Poult. Sci.* 56, 658–665. <https://doi.org/10.1080/00071668.2015.1113506>
- Cizelj, I., Dušanić, D., Benčina, D., Narat, M., 2016. *Mycoplasma* and host interaction: In vitro gene expression modulation in *Mycoplasma synoviae* and infected chicken chondrocytes. *Acta Vet. Hung.* 64, 26–37. <https://doi.org/10.1556/004.2016.003>
- Clampitt, J.M., Madsen, M.L., Minion, F.C., 2021. Construction of *Mycoplasma hyopneumoniae* P97 Null Mutants. *Front. Microbiol.* 12, 518791. <https://doi.org/10.3389/fmicb.2021.518791>
- Clavijo, M.J., Davies, P., Morrison, R., Bruner, L., Olson, S., Rosey, E., Rovira, A., 2019a. Temporal patterns of colonization and infection with *Mycoplasma hyorhinis* in two swine production systems in the USA. *Vet. Microbiol.* 234, 110–118.
- Clavijo, M.J., Hu, D., Krantz, S., Cano, J.P., Pereira Maróstica, T., Henao-Diaz, A., Poeta Silva, A.P.S., Hemker, D., Tapia, E., Zimmerman, S., Fano, E., Polson, D., Fitzgerald, R., Tucker, A., Main, R., Wang, C., Zimmerman, J.J., Rotolo, M.L., 2021a. *Mycoplasma hyopneumoniae* Surveillance in Pig Populations: Establishing Sampling Guidelines for Detection in Growing Pigs. *J. Clin. Microbiol.* 59, e03051-20. <https://doi.org/10.1128/JCM.03051-20>
- Clavijo, M.J., Murray, D., Oliveira, S., Rovira, A., 2017. Infection dynamics of *Mycoplasma hyorhinis* in three commercial pig populations. *Vet. Rec.* 181, 68–68. <https://doi.org/10.1136/vr.104064>
- Clavijo, M.J., Pantoja, L.G., Holtkamp, D.J., Yeske, P., Johnson, C., Sprague, M., Fano, E., Main, R., McDowell, E., Painter, T., Becton, L., Baumert, D., Glowzinski, L., Snelson, H., Maschhoff, A., 2021b. Establishing *Mycoplasma hyopneumoniae* herd status classification criteria for breeding herds. *J. Swine Health Prod.* 29, 319–326.
- Clavijo, M.J., Sreevatsan, S., Johnson, T.J., Rovira, A., 2019b. Molecular epidemiology of *Mycoplasma hyorhinis* porcine field isolates in the United States. *PLOS ONE* 14, e0223653. <https://doi.org/10.1371/journal.pone.0223653>
- Clothier, K.A., Torain, A., Reinl, S., 2019. Surveillance for *Avibacterium paragallinarum* in autopsy cases of birds from small chicken flocks using a real-time PCR assay. *J. Vet. Diagn. Invest.* 31, 364–367. <https://doi.org/10.1177/1040638719844297>
- Cobb, S.P., Smith, H., 2015. The spread of non-OIE-listed avian diseases through international trade of chicken meat: an assessment of the risks to New Zealand. *Rev. Sci. Tech. OIE* 34, 795–812. <https://doi.org/10.20506/rst.34.3.2396>
- Conrad, C.C., Daher, R.K., Stanford, K., Amoako, K.K., Boissinot, M., Bergeron, M.G., Alexander, T., Cook, S., Ralston, B., Zaheer, R., Niu, Y.D., McAllister, T., 2020. A Sensitive and Accurate Recombinase Polymerase Amplification Assay for Detection of the Primary Bacterial Pathogens Causing Bovine Respiratory Disease. *Front. Vet. Sci.* 7, 208. <https://doi.org/10.3389/fvets.2020.00208>
- Cook, B.S., Beddow, J.G., Manso-Silvan, L., Maglennon, G.A., Rycroft, A.N., 2016. Selective medium for culture of *Mycoplasma hyopneumoniae*. *Vet. Microbiol.* 195, 158–164. <https://doi.org/10.1016/j.vetmic.2016.09.022>

- Cortés, V., Sevilla-Navarro, S., García, C., Tudón, A., Marín, C., Catalá-Gregori, P., 2021. Seroprevalence and prevalence of *Mycoplasma synoviae* in laying hens and broiler breeders in Spain. *Poult. Sci.* 100, 100911. <https://doi.org/10.1016/j.psj.2020.11.076>
- Couto, R.M., Braga, J.F.V., Gomes, S.Y.M., Resende, M., Martins, N.R.S., Ecco, R., 2016. Natural concurrent infections associated with infectious laryngotracheitis in layer chickens. *J. Appl. Poult. Res.* 25, 113–128. <https://doi.org/10.3382/japr/pfv075>
- Cowled, B.D., Sergeant, E.S.G., Leslie, E.E.C., Crosbie, A., Burroughs, A., Kingston, O., Neill, M., Sawford, K., van Andel, M., 2022. Use of scenario tree modelling to plan freedom from infection surveillance: *Mycoplasma bovis* in New Zealand. *Prev. Vet. Med.* 198, 105523. <https://doi.org/10.1016/j.prevetmed.2021.105523>
- Cox, R., Revie, C.W., Hurnik, D., Sanchez, J., 2016. Use of Bayesian Belief Network techniques to explore the interaction of biosecurity practices on the probability of porcine disease occurrence in Canada. *Prev. Vet. Med.* 131, 20–30. <https://doi.org/10.1016/j.prevetmed.2016.06.015>
- Croville, G., Foret, C., Heuillard, P., Senet, A., Delpont, M., Mouahid, M., Ducatez, M.F., Kichou, F., Guerin, J.-L., 2018. Disclosing respiratory co-infections: a broad-range panel assay for avian respiratory pathogens on a nanofluidic PCR platform. *Avian Pathol.* 47, 253–260. <https://doi.org/10.1080/03079457.2018.1430891>
- Cusack, P.M.V., 2023. Evaluation of practices used to reduce the incidence of bovine respiratory disease in Australian feedlots (to November 2021). *Aust. Vet. J.* <https://doi.org/10.1111/avj.13239>
- Cvjetković, V., Sipos, S., Szabó, I., Sipos, W., 2018. Clinical efficacy of two vaccination strategies against *Mycoplasma hyopneumoniae* in a pig herd suffering from respiratory disease. *Porc. Health Manag.* 4.
- Czurda, S., Hegde, S.M., Rosengarten, R., Chopra-Dewasthaly, R., 2017. Xer1-independent mechanisms of *Vpma* phase variation in *Mycoplasma agalactiae* are triggered by *Vpma*-specific antibodies. *Int. J. Med. Microbiol.* 307, 443–451. <https://doi.org/10.1016/j.ijmm.2017.10.005>
- da Silva Andrade, J., Loiko, M.R., Schmidt, C., Vidaletti, M.R., Lopes, B.C., Cerva, C., Varela, A.P.M., Tochetto, C., Maciel, A.L.G., Bertagnolli, A.C., Rodrigues, R.O., Roehe, P.M., Lunge, V.R., Mayer, F.Q., 2022. Molecular survey of porcine respiratory disease complex pathogens in Brazilian wild boars. *Prev. Vet. Med.* 206, 105698. <https://doi.org/10.1016/j.prevetmed.2022.105698>
- Daniel, G., Abdurahaman, M., Tuli, G., Deresa, B., 2016. Contagious bovine pleuropneumonia: seroprevalence and risk factors in Western Oromia, Ethiopia. *Onderstepoort J. Vet. Res.* 83.
- Dassanayake, R.P., Falkenberg, S.M., Register, K.B., Samorodnitsky, D., Nicholson, E.M., Reinhardt, T.A., 2018. Antimicrobial activity of bovine NK-lysin-derived peptides on *Mycoplasma bovis*. *PLOS ONE* 13, e0197677. <https://doi.org/10.1371/journal.pone.0197677>
- De Conti, E.R., Takeuti, K.L., Fiúza, A.T.L., de Almeida, L.L., de Barcellos, D.E.S.N., Bortolozzo, F.P., 2022. Effect of sow mass vaccination against *Mycoplasma hyopneumoniae* on the humoral immune response of newborn piglets. *Trop. Anim. Health Prod.* 54, 249. <https://doi.org/10.1007/s11250-022-03266-9>
- De Conti, E.R., Takeuti, K.L., Schwertz, C.I., Bianchi, R.M., Driemeier, D., de Barcellos, D.E.S.N., 2021. Agents of pneumonia in slaughtered pigs in southern Brazil. *Pesqui. Veterinária Bras.* 41, e06669. <https://doi.org/10.1590/1678-5150-pvb-6669>
- de Dieu, B.J., Charles, B.S., Nwankpa, N., Chitsungo, E., Moustapha Boukary, C.R., Maina, N., Tefera, T.A., Nwankpa, R.V., Mwangi, N., Mathurin Koffi, Y., 2019. Development and Evaluation of Epitope-Blocking ELISA for Detection of Antibodies against Contagious Caprine Pleuropneumonia in Goat Sera. *Vet. Sci.* 6, 82. <https://doi.org/10.3390/vetsci6040082>
- de Jong, A., Youala, M., Klein, U., El Garch, F., Moyaert, H., Simjee, S., Maes, D., Gyuranecz, M., Pridmore, A., Thomson, J.R., Ayling, R.D., 2021a. Antimicrobial susceptibility monitoring of

- Mycoplasma hyopneumoniae* isolated from seven European countries during 2015–2016. *Vet. Microbiol.* 253, 108973. <https://doi.org/10.1016/j.vetmic.2020.108973>
- de Jong, A., Youala, M., Klein, U., El Garch, F., Simjee, S., Moyaert, H., Rose, M., Gautier-Bouchardon, A.V., Catania, S., Ganapathy, K., Gyuranecz, M., Möller Palau-Ribes, F., Pridmore, A., Ayling, R.D., 2021b. Minimal inhibitory concentration of seven antimicrobials to *Mycoplasma gallisepticum* and *Mycoplasma synoviae* isolates from six European countries. *Avian Pathol.* 50, 161–173. <https://doi.org/10.1080/03079457.2020.1861216>
- De la Cruz, L., Barrera, M., Rios, L., Corona-González, B., Bulnes, C.A., Díaz-Sánchez, A.A., A. Agüero, J., Lobo-Rivero, E., Pérez, L.J., 2020. Unraveling the Global Phylodynamic and Phylogeographic Expansion of *Mycoplasma gallisepticum*: Understanding the Origin and Expansion of This Pathogen in Ecuador. *Pathogens* 9, 674. <https://doi.org/10.3390/pathogens9090674>
- de Oliveira, B.A.F.D., Gaeta, N.C., Ribeiro, B.L.M., Alemán, M. a. R., Marques, L.M., Timenetsky, J., Melville, P.A., Marques, J.A., Marville, V., Gregory, L., 2016. Determination of bacterial aetiologic factor on tracheobronchial lavage in relation to clinical signs of bovine respiratory disease. *J. Med. Microbiol.* 65, 1137–1142.
- de Oliveira, L.G.S., Boabaid, F.M., Lorenzett, M.P., Rolim, V., dos Santos, H.F., Driemeier, D., Cruz, C.E.F., 2017. Outbreaks of mycoplasmosis and histomoniasis in a southern Brazilian flock of ornamental birds. *Acta Sci. Vet.* 45.
- de Oliveira, N.R., Jorge, S., Gomes, C.K., Rizzi, C., Pacce, V.D., Collares, T.F., Monte, L.G., Dellagostin, O.A., 2017. A novel chimeric protein composed of recombinant *Mycoplasma hyopneumoniae* antigens as a vaccine candidate evaluated in mice. *Vet. Microbiol.* 201, 146–153. <https://doi.org/10.1016/j.vetmic.2017.01.023>
- de Oliveira, T.E.S., Scuisato, G.S., Fritzen, J.T.T., Silva, D.C., Massi, R.P., Pelaquim, I.F., Silva, L.E., Flores, E.F., Lima Santos, R., Pretto-Giordano, L.G., Lisbôa, J.A.N., Alfieri, A.A., Headley, S.A., 2022. Infectious Disease Agents Associated with Pulmonary Alterations in Aborted Bovine Fetuses. *Animals* 12, 1596. <https://doi.org/10.3390/ani12131596>
- de Souza, L.F.L., Campbell, G., Arthuso, G.G.S., Gonzaga, N.F., Alexandrino, C.R., Assao, V.S., Moreira, M.A.S., Da Cunha, M., Chang, Y.-F., Silva-Júnior, A., 2022. Identification of extracellular vesicles from J strain and wild isolate of *Mycoplasma hyopneumoniae*. *Braz. J. Microbiol.* 53, 1081–1084. <https://doi.org/10.1007/s42770-022-00726-0>
- de Souza Santana, M., Hoppe, E.G.L., Carraro, P.E., Calchi, A.C., de Oliveira, L.B., do Amaral, R.B., Mongruel, A.C.B., Machado, D.M.R., Burger, K.P., Barros-Batesti, D.M., Machado, R.Z., André, M.R., 2022. Molecular detection of vector-borne agents in wild boars (*Sus scrofa*) and associated ticks from Brazil, with evidence of putative new genotypes of *Ehrlichia*, *Anaplasma*, and haemoplasmas. *Transbound. Emerg. Dis.* 69. <https://doi.org/10.1111/tbed.14632>
- Dedieu, L., Balcer-Rodrigues, V., 2006. Viable *Mycoplasma mycoides* ssp. *mycoides* small colony-mediated depression of the bovine cell responsiveness to the mitogen concanavalin A. *Scand. J. Immunol.* 64, 376–381. <https://doi.org/10.1111/j.1365-3083.2006.01799.x>
- Dedieu, L., Balcer-Rodrigues, V., Cisse, O., Diallo, M., Niang, M., 2006. Characterisation of the lymph node immune response following *Mycoplasma mycoides* subsp. *Mycoides* SC infection in cattle. *Vet. Res.* 37, 579–591. <https://doi.org/10.1051/vetres:2006020>
- Dedieu, L., Balcer-Rodrigues, V., Yaya, A., Hamadou, B., Cisse, O., Diallo, M., Niang, M., 2005a. Gamma interferon-producing CD4 T-cells correlate with resistance to *Mycoplasma mycoides* subsp. *mycoides* S.C. infection in cattle. *Vet. Immunol. Immunopathol.* 107, 217–233. <https://doi.org/10.1016/j.vetimm.2005.04.011>
- Dedieu, L., Chapey, E., Balcer-Rodrigues, V., 2005b. *Mycoplasma mycoides* ssp. *mycoides* biotype small colony-secreted components induce apoptotic cell death in bovine leucocytes. *Scand. J. Immunol.* 62, 528–538. <https://doi.org/10.1111/j.1365-3083.2005.01690.x>
- Dedieu, L., Totte, P., Rodrigues, V., Vilei, E.M., Frey, J., 2010. Comparative analysis of four lipoproteins from *Mycoplasma mycoides* subsp. *mycoides* Small Colony identifies LppA as a major T-cell

- antigen. *Comp. Immunol. Microbiol. Infect. Dis.* 33, 279–290. <https://doi.org/10.1016/j.cimid.2008.08.011>
- Deeney, A.S., Collins, R., Ridley, A.M., 2021. Identification of *Mycoplasma* species and related organisms from ruminants in England and Wales during 2005–2019. *BMC Vet. Res.* 17, 325. <https://doi.org/10.1186/s12917-021-03037-y>
- Deeney, A.S., Maglennon, G.A., Chapat, L., Crussard, S., Jolivet, E., Rycroft, A.N., 2019. *Mycoplasma hyopneumoniae* evades phagocytic uptake by porcine alveolar macrophages in vitro. *Vet. Res.* 50.
- Deffner, P., Maurer, R., Cvjetković, V., Sipos, W., Krejci, R., Ritzmann, M., Eddicks, M., 2022. Cross-sectional study on the in-herd prevalence of *Mycoplasma hyopneumoniae* at different stages of pig production. *Vet. Rec.* 191. <https://doi.org/10.1002/vetr.1317>
- Dekelaita, D.J., Epps, C.W., Stewart, K.M., Sedinger, J.S., Powers, J.G., Gonzales, B.J., Abella-Vu, R.K., Darby, N.W., Hughson, D.L., 2020. Survival of Adult Female Bighorn Sheep Following a Pneumonia Epizootic. *J. Wildl. Manag.* 84, 1268–1282. <https://doi.org/10.1002/jwmg.21914>
- Desrochers, A., Francoz, D., 2014. Clinical Management of Septic Arthritis in Cattle. *Vet. Clin. North Am. Food Anim. Pract., Bovine Orthopedics* 30, 177–203. <https://doi.org/10.1016/j.cvfa.2013.11.006>
- Devi, V.R., Poumarat, F., Grand, D. le, Rosengarten, R., Hermeyer, K., Hewicker-Trautwein, M., 2014. Histopathological findings, phenotyping of inflammatory cells, and expression of markers of nitritative injury in joint tissue samples from calves after vaccination and intraarticular challenge with *Mycoplasma bovis* strain 1067. *Acta Vet. Scand.* 56.
- Dhondt, A.A., Dhondt, K.V., Hawley, D.M., Jennelle, C.S., 2007. Experimental evidence for transmission of *Mycoplasma gallisepticum* in house finches by fomites. *Avian Pathol. J. WVPA* 36, 205–208. <https://doi.org/10.1080/03079450701286277>
- Dhondt, A.A., Dhondt, K.V., Hochachka, W.M., Ley, D.H., Hawley, D.M., 2017a. Response of House Finches Recovered from *Mycoplasma gallisepticum* to Reinfection with a Heterologous Strain. *Avian Dis.* 61, 437–441. <https://doi.org/10.1637/11571-122016-Reg.1>
- Dhondt, A.A., Dhondt, K.V., Nazeri, S., 2017b. Apparent effect of chronic Plasmodium infections on disease severity caused by experimental infections with *Mycoplasma gallisepticum* in house finches. *Int. J. Parasitol. Parasites Wildl.* 6, 49–53. <https://doi.org/10.1016/j.ijppaw.2017.03.003>
- Di Federico, M., Ancora, M., Luciani, M., Krasteva, I., Sacchini, F., Orsini, G., Di Febo, T., Di Lollo, V., Mattioli, M., Scacchia, M., Marruchella, G., Cammà, C., 2020. Pro-Inflammatory Response of Bovine Polymorphonuclear Cells Induced by *Mycoplasma mycoides* subsp. *mycoides*. *Front. Vet. Sci.* 7, 142. <https://doi.org/10.3389/fvets.2020.00142>
- Di Federico, M., Orsini, M., Ancora, M., Marcacci, M., Di Domenico, M., Krasteva, I., Zilli, K., Musa, J.A., Francis, M.I., Sacchini, F., Scacchia, M., Cammà, C., 2019. Draft Genome Sequences of *Mycoplasma mycoides* subsp. *mycoides* Strains APF9 and AP108, Isolated in Nigeria in 2014 to 2016. *Microbiol. Resour. Announc.* 8, e00783-19. <https://doi.org/10.1128/MRA.00783-19>
- Di Provvido, A., Di Teodoro, G., Muuka, G., Marruchella, G., Scacchia, M., 2018. Lung lesion score system in cattle: proposal for contagious bovine pleuropneumonia. *Trop. Anim. Health Prod.* 50, 223–228. <https://doi.org/10.1007/s11250-017-1409-2>
- Di Teodoro, G., Marruchella, G., Di Provvido, A., D’Angelo, A.R., Orsini, G., Di Giuseppe, P., Sacchini, F., Scacchia, M., 2020. Contagious Bovine Pleuropneumonia: A Comprehensive Overview. *Vet. Pathol.* 57, 476–489. <https://doi.org/10.1177/0300985820921818>
- Di Teodoro, G., Marruchella, G., Di Provvido, A., Orsini, G., Ronchi, G.F., D’Angelo, A.R., D’Alterio, N., Sacchini, F., Scacchia, M., 2018a. Respiratory explants as a model to investigate early events of contagious bovine pleuropneumonia infection. *Vet. Res.* 49, 5. <https://doi.org/10.1186/s13567-017-0500-z>
- Di Teodoro, G., Marruchella, G., Mosca, F., Di Provvido, A., Sacchini, F., Tiscar, P.G., Scacchia, M., 2018b. Polymorphonuclear cells and reactive oxygen species in contagious bovine

- pleuropneumonia: New insight from in vitro investigations. *Vet. Immunol. Immunopathol.* 201, 16–19. <https://doi.org/10.1016/j.vetimm.2018.04.011>
- Dias, G.B., do Amaral, R.B., Gatto, I.R.H., Lopera, I.M., de Oliveira, L.G., Lux Hoppe, E.G., Machado, R.Z., André, M.R., 2019. Molecular detection of *Mycoplasma suis* in captive white-lipped peccaries (*Tayassu pecari*) and wild boars (*Sus scrofa*) in Brazil. *Comp. Immunol. Microbiol. Infect. Dis.* 63, 94–96. <https://doi.org/10.1016/j.cimid.2019.01.013>
- Dietz, S., Mack, S.-L., Hoelzle, K., Becker, K., Jannasch, C., Stadler, J., Ritzmann, M., Hoelzle, L.E., 2014. Quantitative PCR analysis of *Mycoplasma suis* shedding patterns during experimental infection. *Vet. Microbiol.* 172, 581–585. <https://doi.org/10.1016/j.vetmic.2014.06.019>
- Dijkman, R., Feberwee, A., Landman, W.J.M., 2017. Development, validation and field evaluation of a quantitative real-time PCR able to differentiate between field *Mycoplasma synoviae* and the MS-H-live vaccine strain. *Avian Pathol.* 46, 403–415. <https://doi.org/10.1080/03079457.2017.1296105>
- Dijkman, R., Feberwee, A., Landman, W.J.M., 2016. Development and evaluation of a multi-locus sequence typing scheme for *Mycoplasma synoviae*. *Avian Pathol.* 45, 426–442. <https://doi.org/10.1080/03079457.2016.1154135>
- Dijkman, R., Feberwee, A., Landman, W.J.M., 2014. Variable lipoprotein haemagglutinin (vlhA) gene sequence typing of mainly Dutch *Mycoplasma synoviae* isolates: comparison with vlhA sequences from Genbank and with amplified fragment length polymorphism analysis. *Avian Pathol. J. WVPA* 43, 465–472. <https://doi.org/10.1080/03079457.2014.958980>
- Ding, H., Wen, Y., Xu, Z., Zhou, B., Tlili, C., Tian, Y., Wang, Z., Ning, Y., Xin, J., 2021. Development of an ELISA for distinguishing convalescent sera with *Mycoplasma hyopneumoniae* infection from hyperimmune sera responses to bacterin vaccination in pigs. *Vet. Med. Sci.* 7, 1831–1840. <https://doi.org/10.1002/vms3.539>
- Ding, H., Zhou, Y., Wang, H., 2019. Development of an indirect ELISA for detecting humoral immunodominant proteins of *Mycoplasma hyopneumoniae* which can discriminate between inactivated bacterin-induced hyperimmune sera and convalescent sera. *BMC Vet. Res.* 15.
- Dinh, P.X., Nguyen, M.N., Nguyen, H.T., Tran, V.H., Tran, Q.D., Dang, K.H., Vo, D.T., Le, H.T., Nguyen, N.T.T., Nguyen, T.T., Do, D.T., 2021. Porcine circovirus genotypes and their copathogens in pigs with respiratory disease in southern provinces of Vietnam. *Arch. Virol.* 166, 403–411. <https://doi.org/10.1007/s00705-020-04878-y>
- DISCONTTOOLS, 2022. *Mycoplasma bovis* [WWW Document]. URL <https://www.discontools.eu/database/82-mycoplasma-bovis.html>
- DISCONTTOOLS, 2021. Contagious agalactia [WWW Document]. URL <https://www.discontools.eu/database/71-small-ruminant-mastitis-m-agalactiae.html>
- DISCONTTOOLS, 2016a. Contagious bovine pleuropneumonia [WWW Document]. URL <https://www.discontools.eu/database/39-contagious-bovine-pleuro-pneumonia.html>
- DISCONTTOOLS, 2016b. Swine Mycoplasmas (scores for *M. hyopneumoniae*) [WWW Document]. DISCONTTOOLS. URL <https://www.discontools.eu/database/72-swine-mycoplasmas-scores-for-m-hyopneumoniae.html>
- do Nascimento, N.C., Guimaraes, A.M.S., dos Santos, A.P., Chu, Y., Marques, L.M., Messick, J.B., 2018. RNA-Seq based transcriptome of whole blood from immunocompetent pigs (*Sus scrofa*) experimentally infected with *Mycoplasma suis* strain Illinois. *Vet. Res.* 49, 49. <https://doi.org/10.1186/s13567-018-0546-6>
- Dos Santos, L.F., Clavijo, M.J., Sreevatsan, S., Rovira, A., Moreira, M.A.S., Pieters, M., 2015a. Genotyping of *Mycoplasma hyorhinis* using multiple-locus variable number tandem repeat analysis. *J. Microbiol. Methods* 111, 87–92. <https://doi.org/10.1016/j.mimet.2015.02.003>
- Dos Santos, L.F., Sreevatsan, S., Torremorell, M., Moreira, M.A.S., Sibila, M., Pieters, M., 2015b. Genotype distribution of *Mycoplasma hyopneumoniae* in swine herds from different geographical regions. *Vet. Microbiol.* 175, 374–381. <https://doi.org/10.1016/j.vetmic.2014.11.018>

- dos Santos Martins, M.S., Silva, L.D., Miranda, L.M., Lima, C.A.A., do Amaral, R.B., Machado, R.Z., André, M.R., Braga, M. do S.C.O., do Rosário, C.J.R.M., Melo, F.A., Pereira, J.G., 2019. Molecular detection of *Mycoplasma suis* in extensive pig production systems in the State of Maranhão, northeast Brazil. *Rev. Bras. Parasitol. Veterinária* 28, 306–309. <https://doi.org/10.1590/s1984-296120180099>
- dos Santos, M.M., do Nascimento, E.R., Barreto, M.L., Gonçalves, V.S.P., Santana, Â.P., 2021. Incidence of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* in broiler flocks at the Federal District of Brazil and its surrounding areas. *Semina Ciênc. Agrár.* 42, 2407–2418. <https://doi.org/10.5433/1679-0359.2021v42n4p2407>
- dos Santos, S.B., de Melo, R.P.B., da Silva, L.T.R., de Oliveira, J.M.B., Abad, A.C.A., Pinheiro Júnior, J.W., Mota, R.A., 2018. Epidemiology of *Mycoplasma agalactiae* and *Mycoplasma mycoides* cluster in flocks of northeastern Brazil. *Ciênc. Rural* 48. <https://doi.org/10.1590/0103-8478cr20170427>
- Du, Z., Sun, Y., Wang, J., Liu, H., Yang, Y., Zhao, N., 2020. Comprehensive RNA-Seq profiling of the lung transcriptome of Bashbay sheep in response to experimental *Mycoplasma ovipneumoniae* infection. *PLOS ONE* 15, e0214497. <https://doi.org/10.1371/journal.pone.0214497>
- Dudek, K., Bednarek, D., 2018. Saponin-based *Mycoplasma bovis* vaccine containing lysozyme dimer adjuvant stimulates acute phase response in calves. *J. Vet. Res.* 62, 269–273.
- Dudek, K., Bednarek, D., 2017a. Humoral immunity in the calves experimentally vaccinated against *Mycoplasma bovis* infections. *Med. Weter.* 73, 425–428. <https://doi.org/10.21521/mw.5739>
- Dudek, K., Bednarek, D., 2017b. T- and B-cell response analysis following calf immunisation with experimental *Mycoplasma bovis* vaccine containing saponin and lysozyme dimer. *J. Vet. Res.* 61, 433–437.
- Dudek, K., Bednarek, D., 2012. Last survey of *Mycoplasma bovis* prevalence in Polish cattle affected with respiratory syndrome. *Bull. Vet. Inst. Puławy* 56, 447–451.
- Dudek, K., Bednarek, D., Ayling, R.D., Kycko, A., Reichert, M., 2019. Preliminary study on the effects of enrofloxacin, flunixin meglumine and pegbovigrastim on *Mycoplasma bovis* pneumonia. *BMC Vet. Res.* 15, 371. <https://doi.org/10.1186/s12917-019-2122-3>
- Dudek, K., Bednarek, D., Ayling, R.D., Szacawa, E., 2013. Immunomodulatory effect of *Mycoplasma bovis* in experimentally infected calves. *Bull. Vet. Inst. Puławy* 57, 499–506.
- Dudek, K., Bednarek, D., Ayling, R.D., Szczotka, M., Iwan, E., Kocki, J., 2018. Analysis of the immune response of calves to various saponin-based adjuvants for an experimental *Mycoplasma bovis* vaccine. *Acta Vet. Hung.* 66, 226–240. <https://doi.org/10.1556/004.2018.021>
- Dudek, K., Bednarek, D., Szacawa, E., Ayling, R.D., Krzysiak, M.K., Marczuk, J., 2015. A serological and molecular study on the occurrence of mycoplasmas in European bison (*Bison bonasus*) from two areas of Eastern Poland. *Pol. J. Vet. Sci.* 18, 881–883.
- Dudek, K., Nicholas, R.A.J., Szacawa, E., Bednarek, D., 2020. *Mycoplasma bovis* Infections—Occurrence, Diagnosis and Control. *Pathogens* 9, 640. <https://doi.org/10.3390/pathogens9080640>
- Dudek, K., Sevimli, U., Migliore, S., Jafarizadeh, A., Loria, G.R., Nicholas, R.A.J., 2022. Vaccines for *Mycoplasma* Diseases of Small Ruminants: A Neglected Area of Research. *Pathogens* 11, 75. <https://doi.org/10.3390/pathogens11010075>
- Dudek, K., Szacawa, E., Nicholas, R.A.J., 2021. Recent Developments in Vaccines for Bovine Mycoplasmoses Caused by *Mycoplasma bovis* and *Mycoplasma mycoides* subsp. *mycoides*. *Vaccines* 9, 549. <https://doi.org/10.3390/vaccines9060549>
- Dupuy, V., Manso-Silván, L., Barbe, V., Thebault, P., Dordet-Frisoni, E., Citti, C., Poumarat, F., Blanchard, A., Breton, M., Sirand-Pugnet, P., Thiaucourt, F., 2012. Evolutionary History of Contagious Bovine Pleuropneumonia Using Next Generation Sequencing of *Mycoplasma mycoides* Subsp. *mycoides* “Small Colony.” *PLOS ONE* 7, e46821. <https://doi.org/10.1371/journal.pone.0046821>

- Dupuy, V., Verdier, A., Thiaucourt, F., Manso-Silván, L., 2015. A large-scale genomic approach affords unprecedented resolution for the molecular epidemiology and evolutionary history of contagious caprine pleuropneumonia. *Vet. Res.* 46.
- Dyer, N., Hansen-Lardy, L., Krogh, D., Schaan, L., Schamber, E., 2008. An Outbreak of Chronic Pneumonia and Polyarthritits Syndrome Caused by *Mycoplasma Bovis* in Feedlot Bison (Bison Bison). *J. Vet. Diagn. Invest.* 20, 369–371. <https://doi.org/10.1177/104063870802000321>
- Dyer, N., Register, K.B., Miskimins, D., Newell, T., 2013. Necrotic pharyngitis associated with *Mycoplasma bovis* infections in American bison (*Bison bison*). *J. Vet. Diagn. Invest.* 25, 301–303. <https://doi.org/10.1177/1040638713478815>
- EFSA Panel on AHAW, Nielsen, S.S., Alvarez, J., Bicout, D.J., Calistri, P., Canali, E., Drewe, J.A., Garin-Bastuji, B., Gonzales Rojas, J.L., Gortázar, C., Herskin, M., Michel, V., Miranda Chueca, M.Á., Padalino, B., Pasquali, P., Spoolder, H., Ståhl, K., Velarde, A., Viltrop, A., Winckler, C., Gubbins, S., Stegeman, J.A., Thiaucourt, F., Antoniou, S., Aznar, I., Papanikolaou, A., Zancanaro, G., Roberts, H.C., 2022a. Assessment of the control measures for category A diseases of Animal Health Law: Contagious Bovine Pleuropneumonia. *EFSA J.* 20. <https://doi.org/10.2903/j.efsa.2022.7067>
- EFSA Panel on AHAW, Nielsen, S.S., Alvarez, J., Bicout, D.J., Calistri, P., Canali, E., Drewe, J.A., Garin-Bastuji, B., Gonzales Rojas, J.L., Gortázar, C., Herskin, M., Michel, V., Miranda Chueca, M.Á., Padalino, B., Pasquali, P., Spoolder, H., Ståhl, K., Velarde, A., Viltrop, A., Winckler, C., Gubbins, S., Stegeman, J.A., Thiaucourt, F., Antoniou, S., Aznar, I., Papanikolaou, A., Zancanaro, G., Roberts, H.C., 2022b. Assessment of the control measures for category A diseases of Animal Health Law: Contagious Caprine Pleuropneumonia. *EFSA J.* 20. <https://doi.org/10.2903/j.efsa.2022.7068>
- EFSA Panel on AHAW, Nielsen, S.S., Bicout, D.J., Calistri, P., Canali, E., Drewe, J.A., Garin-Bastuji, B., Gonzales Rojas, J.L., Gortazar Schmidt, C., Herskin, M., Michel, V., Miranda Chueca, M.A., Padalino, B., Pasquali, P., Roberts, H.C., Spoolder, H., Stahl, K., Velarde, A., Viltrop, A., Winckler, C., Dewulf, J., Guardabassi, L., Hilbert, F., Mader, R., Baldinelli, F., Alvarez, J., 2021. Assessment of animal diseases caused by bacteria resistant to antimicrobials: sheep and goats. *EFSA J.* 19. <https://doi.org/10.2903/j.efsa.2021.6956>
- EFSA Panel on AHAW, More, S., Bøtner, A., Butterworth, A., Calistri, P., Depner, K., Edwards, S., Garin-Bastuji, B., Good, M., Gortázar Schmidt, C., Michel, V., Miranda, M.A., Nielsen, S.S., Raj, M., Sihvonen, L., Spoolder, H., Stegeman, J.A., Thulke, H., Velarde, A., Willeberg, P., Winckler, C., Baldinelli, F., Broglia, A., Candiani, D., Beltrán-Beck, B., Kohnle, L., Bicout, D., 2017. Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): contagious caprine pleuropneumonia. *EFSA J.* 15. <https://doi.org/10.2903/j.efsa.2017.4996>
- Egwu, G.O., Adamu, M., Mshelia, G.D., Bukar-Kolo, Y.M., 2012. A sustainable laboratory approach for contagious bovine pleuropneumonia (CBPP) monitoring in Nigeria: comparison between two serological tests in an endemic area complimented with post mortem lesions. *Afr. J. Microbiol. Res.* 6, 5890–5895.
- Ehtisham-ul-Haque, S., Kiran, M., Waheed, U., Younus, M., 2017. Real-time loop-mediated isothermal amplification (LAMP) of *mgc2* gene of *Mycoplasma gallisepticum*. *J. Vet. Res.* 61, 439–444.
- Ehtisham-ul-Haque, S., Rahman, S.U., Khan, M.I., Younus, M., Awais, M.M., Nasir, A., 2015. A simplified duplex real-time PCR incorporating TaqMan minor groove binder (MGB) probes and an exogenous internal positive control for the simultaneous detection of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* cultures. *Veterinárni Medicína* 60, 268–273.
- Einarsdottir, T., Gunnarsson, E., Hjartardottir, S., 2018. Icelandic ovine *Mycoplasma ovipneumoniae* are variable bacteria that induce limited immune responses in vitro and in vivo. *J. Med. Microbiol.* 67, 1480–1490. <https://doi.org/10.1099/jmm.0.000818>

- El-Ashram, S., Hashad, M.E., Abdel-Alim, G.A., Abdelhamid, T., N. Deif, H., 2021. Seroprevalence of mycoplasmosis in broiler, layer, and native chickens in Giza, Egypt. PLOS ONE 16, e0254220. <https://doi.org/10.1371/journal.pone.0254220>
- Elbehiry, A., Al-Dubaib, M., Marzouk, E., 2016. Serological, rapid molecular characterization and antibiotic resistance for field isolates of *Mycoplasma gallisepticum* in chicken in Saudi Arabia. Alex. J. Vet. Sci. 49, 70–79.
- El-Deeb, W., Almujailli, A.A., Eljalii, I., Elmoslemany, A., 2018. Clinical and biochemical studies on contagious caprine pleuropneumonia with special reference to lipoproteins profile and fibrinogen levels. Lucr. Științifice - Med. Vet. Univ. Științe Agric. Și Med. Vet. Ion Ionescu Brad Iași 61, 31–38.
- El-Deeb, W., Almujailli, A.A., Eljalii, I., Elmoslemany, A., Fayez, M., 2017. Contagious caprine pleuropneumonia: The first isolation and molecular characterization of *Mycoplasma capricolum* subsp. *capripneumoniae* in the Kingdom of Saudi Arabia. Acta Trop. 168, 74–79. <https://doi.org/10.1016/j.actatropica.2017.01.017>
- El-Gazzar, M., Ghanem, M., McDonald, K., Ferguson-Noel, N., Raviv, Z., Slemmons, R.D., 2016. Development of Multilocus Sequence Typing (MLST) for *Mycoplasma synoviae*. Avian Dis. 61, 25. <https://doi.org/10.1637/11417-040516-Reg>
- El-Gazzar, M.M., Wetzel, A.N., Raviv, Z., 2012. The genotyping potential of the *Mycoplasma synoviae* *vlhA* gene. Avian Dis. 56, 711–719. <https://doi.org/10.1637/10200-041212-Reg.1>
- El-Hamid, M.I.A., Awad, N.F.S., Hashem, Y.M., Abdel-Rahman, M.A., Abdelaziz, A.M., Mohammed, I. a. A., Abo-Shama, U.H., 2019. In vitro evaluation of various antimicrobials against field mycoplasma *gallisepticum* and mycoplasma *synoviae* isolates in Egypt. Poult. Sci. 98, 6281–6288.
- Elliott, K.E.C., Branton, S.L., Evans, J.D., Magee, C.L., Peebles, E.D., 2022. Onset of the humoral immune response of layer chicks vaccinated in ovo with strain F *Mycoplasma gallisepticum* vaccine and evidence of male-biased mortality. Poult. Sci. 101, 101761. <https://doi.org/10.1016/j.psj.2022.101761>
- Elliott, K.E.C., Branton, S.L., Evans, J.D., Peebles, E.D., 2020. Evaluation of the potential influence of the disinfection cycle on the efficacy of strain F *Mycoplasma gallisepticum* vaccine administered by in ovo injection to layer hatching eggs,,. J. Appl. Poult. Res. 29, 673–683. <https://doi.org/10.1016/j.japr.2020.05.001>
- Elliott, K.E.C., Branton, S.L., Evans, J.D., Peebles, E.D., 2019. Occurrence of horizontal transmission in layer chickens after administration of an in ovo strain F *Mycoplasma gallisepticum* vaccine , ,. Poult. Sci. 98, 4492–4497. <https://doi.org/10.3382/ps/pez306>
- Elliott, K.E.C., Branton, S.L., Evans, J.D., Peebles, E.D., 2018. Early post-hatch survival and humoral immune response of layer chickens when in ovo vaccinated with strain F *Mycoplasma gallisepticum*. Poult. Sci. 97, 3860–3869. <https://doi.org/10.3382/ps/pey282>
- Elnaker, Y., Ibrahim, N., Diab, M., 2017. Microbiological and Epidemiological Studies on Sheep and Goat Deaths in New Valley Governorates, Egypt. Alex. J. Vet. Sci. 55, 28. <https://doi.org/10.5455/ajvs.274801>
- Elyazeed, H.A., Al-Atfeehy, N.M., Abotaleb, R., Sayed, R., Marouf, S., 2020. Preparation of ELISA and Lateral Flow Kits for rapid Diagnosis of *Mycoplasma gallisepticum* in Poultry. Sci. Rep. 10, 9056. <https://doi.org/10.1038/s41598-020-65848-7>
- El-Yazid, H.A., Soliman, R., Wasif, I.M., Selim, S. a. E., Balata, M., Mahmood, Z., Seida, A.A., 2019. Protective efficacy of the inactivated adjuvant vaccines against *Mycoplasma agalactiae* infection in goats. Int. J. Vet. Sci. 8, 14–19.
- Emam, M., Hashem, Y.M., El-Hariri, M., El-Jakee, J., 2020. Detection and antibiotic resistance of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* among chicken flocks in Egypt. Vet. World 13, 1410–1416. <https://doi.org/10.14202/vetworld.2020.1410-1416>

- Endalew, M.A., Wakene, F.S., 2021. Retrospective study on livestock vaccine coverage and trends in Digelu-tijo district, Arsi zone. *Int. J. Agric. Ext.* 8, 219–224. <https://doi.org/10.33687/008.03.3394>
- Entrican, G., Charlier, J., Dalton, L., Messori, S., Sharma, S., Taylor, R., Morrow, A., 2021. Construction of generic roadmaps for the strategic coordination of global research into infectious diseases of animals and zoonoses. *Transbound. Emerg. Dis.* 68, 1513–1520. <https://doi.org/10.1111/tbed.13821>
- Enyaru, J.C.K., Biryomumaisho, S., Balyeidhusa, A.S.P., Ebong, C., Musoni, A., Manzi, M., Rutagwenda, T., Zimurinda, J., Asiiimwe, T., Gahakwa, D., 2012. Comparison of competitive ELISA, PCR and loop mediated isothermal amplification of mycoplasmal DNA in confirmatory diagnosis of an outbreak of contagious bovine pleuropneumonia in Eastern Rwanda. *Int. J. Anim. Vet. Adv.* 4, 22–28.
- Epp, T., Uehlinger, F.D., Wojnarowicz, C., Malhi, P.S., Sayi, S., Woodbury, M.R., 2018. Observations of mortality in farmed bison in the Canadian prairies: 2103 – 2016. *Prev. Vet. Med.* 157, 1–7. <https://doi.org/10.1016/j.prevetmed.2018.05.014>
- European Medicines Agency, 2021. MS-H Vaccine [WWW Document]. Eur. Med. Agency. URL <https://www.ema.europa.eu/en/medicines/veterinary/EPAR/ms-h-vaccine>
- Evans, J.D., Branton, S.L., Collier, S.D., Brooks, J.P., Purswell, J.L., 2017. Application of a micro-aerosolized disinfectant to clear *Mycoplasma gallisepticum* from contaminated facilities. *J. Appl. Poult. Res.* 26, 416–420. <https://doi.org/10.3382/japr/pfx010>
- Evans, J.D., Leigh, S.A., Branton, S.L., Collier, S.D., Pharr, G.T., Bearson, S.M.D., 2005. *Mycoplasma gallisepticum*: Current and Developing Means to Control the Avian Pathogen. *J. Appl. Poult. Res.* 14, 757–763. <https://doi.org/10.1093/japr/14.4.757>
- Ezatkhah, M., Amini, M., Bafti, M.S., Alimolaei, M., 2015. Diagnosis of *Mycoplasma synoviae* by plate agglutination and ELISA tests in commercial broiler chickens. *Online J. Vet. Res.* 19, 593–597.
- Fablet, C., Marois-Créhan, C., Grasland, B., Simon, G., Rose, N., 2016. Factors associated with herd-level PRRSV infection and age-time to seroconversion in farrow-to-finish herds. *Vet. Microbiol.* 192, 10–20. <https://doi.org/10.1016/j.vetmic.2016.06.006>
- Faez Firdaus, A.J., Nurul Hafizah, B. a. J., Mohammed, K., Tijjani, A., Chung LimTeik [Chung, L.T.E., Abba, Y., Sadiq, M.A., Saharee, A.A., 2015. Hemotropic *Mycoplasma ovis* infection in goats with concurrent gastrointestinal parasitism in Malaysia. *J. Adv. Vet. Anim. Res.* 2, 464–468.
- Fanelli, A., Cirilli, M., Lucente, M.S., Zarea, A.A.K., Buonavoglia, D., Tempesta, M., Greco, G., 2021. Fatal Calf Pneumonia Outbreaks in Italian Dairy Herds Involving *Mycoplasma bovis* and Other Agents of BRD Complex. *Front. Vet. Sci.* 8, 742785. <https://doi.org/10.3389/fvets.2021.742785>
- FanQing, Z., ShiJun, B., ShengQing, Y., JingHua, C., Lei, T., XvSheng, Q., CuiPing, S., Ya, D., RongMei, F., Chan, D., 2015. Development of a loop-mediated isothermal amplification targeting a gene within the pyruvate dehydrogenase complex, the *pdhA* gene, for rapid detection of *Mycoplasma gallisepticum*. *J. Vet. Diagn. Invest.* 27, 260–267.
- FAO, 2004. Towards sustainable CBPP control programmes for Africa, in: Proceedings of the 3rd Meeting of the FAO-OIE-OAU/IBAR-IAEA Consultative Group on CBPP. FAO, Rome, Italy, pp. 1–46.
- Fasil, A., Yilkal, A., Maximillan, B., Getnet, A., 2015. Epidemiological study of Contagious Caprine Pleuropneumonia (CCPP) in selected districts of Gambella Region, Western Ethiopia. *Afr. J. Agric. Res.* 10, 2470–2479.
- Fathi, A., Almuhammady, A., Mona, M., Hala, M., Marwa, S., 2019. Histopathological changes after treatment of *Mycoplasma bovis* infected Does with Zinc oxide nanoparticles as a new tool. *Egypt. J. Vet. Sci.* 50, 21–28. <https://doi.org/10.21608/ejvs.2019.19940.1133>
- Feberwee, A., de Wit, J.J., Landman, W.J.M., 2009. Induction of eggshell apex abnormalities by *Mycoplasma synoviae*: field and experimental studies. *Avian Pathol. J. WVPA* 38, 77–85. <https://doi.org/10.1080/03079450802662772>

- Feberwee, A., Dijkman, R., Klinkenberg, D., Landman, W.J.M., 2017. Quantification of the horizontal transmission of *Mycoplasma synoviae* in non-vaccinated and MS-H-vaccinated layers. *Avian Pathol.* 46, 346–358. <https://doi.org/10.1080/03079457.2017.1282602>
- Feberwee, A., Dijkman, R., Wiegel, J., ter Veen, C., Bataille, H., Bouwstra, R., de Wit, S., 2020. Rate of false positive reactions in 11 *M. gallisepticum* and *M. synoviae* serological tests in samples obtained from SPF birds inoculated with heterologous mycoplasma species. *Avian Pathol.* 49, 179–184. <https://doi.org/10.1080/03079457.2019.1702148>
- Feberwee, A., Mekkes, D.R., Klinkenberg, D., Vernooij, J.C.M., Gielkens, A.L.J., Stegeman, J.A., 2005. An experimental model to quantify horizontal transmission of *Mycoplasma gallisepticum*. *Avian Pathol. J. WVPA* 34, 355–361. <https://doi.org/10.1080/03079450500180770>
- Fei, J., JinYan, H., Navarro-Alvarez, N., Jian, X., Xia, L., Peng, L., WenXue, W., 2016. Elongation factor Tu and heat shock protein 70 are membrane-associated proteins from *Mycoplasma ovipneumoniae* capable of inducing strong immune response in mice. *PLOS ONE* 11.
- Felde, O., Kreizinger, Z., Sulyok, K.M., Hrivnák, V., Kiss, K., Jerzsele, Á., Biksi, I., Gyuranecz, M., 2018a. Antibiotic susceptibility testing of *Mycoplasma hyopneumoniae* field isolates from Central Europe for fifteen antibiotics by microbroth dilution method. *PLOS ONE* 13, e0209030. <https://doi.org/10.1371/journal.pone.0209030>
- Felde, O., Kreizinger, Z., Sulyok, K.M., Marton, S., Bányai, K., Korbuly, K., Kiss, K., Biksi, I., Gyuranecz, M., 2018b. Genotyping *Mycoplasma hyopneumoniae* isolates based on multi-locus sequence typing, multiple-locus variable-number tandem repeat analysis and analysing gene p146. *Vet. Microbiol.* 222, 85–90. <https://doi.org/10.1016/j.vetmic.2018.07.004>
- Felde, O., Kreizinger, Z., Sulyok, K.M., Wehmann, E., Gyuranecz, M., 2020. Development of molecular biological tools for the rapid determination of antibiotic susceptibility of *Mycoplasma hyopneumoniae* isolates. *Vet. Microbiol.* 245, 108697. <https://doi.org/10.1016/j.vetmic.2020.108697>
- Feng, Z.-X., Shao, G.-Q., Liu, M.-J., Wang, H.-Y., Gan, Y., Wu, X.-S., 2010. Development and validation of a SIgA-ELISA for the detection of *Mycoplasma hyopneumoniae* infection. *Vet. Microbiol.* 143, 410–416. <https://doi.org/10.1016/j.vetmic.2009.11.038>
- Ferguson-Noel, N.M., Laibinis, V.A., Kleven, S.H., 2012. Evaluation of *Mycoplasma gallisepticum* K-strain as a live vaccine in chickens. *Avian Dis.* 56, 44–50. <https://doi.org/10.1637/9833-061411-Reg.1>
- Ferguson-Noel, N.M., Williams, S.M., 2015. The efficacy of *Mycoplasma gallisepticum* K-strain live vaccine in broiler and layer chickens. *Avian Pathol.* 44, 75–80. <https://doi.org/10.1080/03079457.2015.1005054>
- Fernandes, A.J., Elshafie, N.O., Kmetiuk, L.B., Ullmann, L.S., Brandão, A.P.D., Haisi, A., Wilpe Bach, R., Barros-Filho, I.R., Araújo Junior, J.P., Barbosa, D.S., Biondo, A.W., Santos, A.P., 2022. Hemotropic mycoplasmas (hemoplasmas) in wild boars, hunting dogs, and hunters from two Brazilian regions. *Transbound. Emerg. Dis.* 69, 908–912. <https://doi.org/10.1111/tbed.14038>
- Fernández-Varón, E., García-Romero, E., Serrano-Rodríguez, J.M., Cárceles, C.M., García-Galán, A., Cárceles-García, C., Fernández, R., Muñoz, C., de la Fe, C., 2021. PK/PD Analysis of Marbofloxacin by Monte Carlo Simulation against *Mycoplasma agalactiae* in Plasma and Milk of Lactating Goats after IV, SC and SC-Long Acting Formulations Administration. *Animals* 11, 1104. <https://doi.org/10.3390/ani11041104>
- Ferrari, L.D.R., Hassan-Kadle, A.A., Collere, F.C.M., Coradi, V.S., Ibrahim, A.M., Osman, A.M., Shair, M.A., André, M.R., Vieira, T.S.W.J., Machado, R.Z., Vieira, R.F.C., 2022. Hemoplasmas and ticks in cattle from Somalia. *Acta Trop.* 236, 106696. <https://doi.org/10.1016/j.actatropica.2022.106696>
- Ferrarini, M.G., Siqueira, F.M., Mucha, S.G., Palama, T.L., Jobard, É., Elena-Herrmann, B., Vasconcelos, A.T.R., Tardy, F., Schrank, I.S., Zaha, A., Sagot, M.F., 2016. Insights on the virulence of swine respiratory tract mycoplasmas through genome-scale metabolic modeling. *BMC Genomics* 17.

- Ferreira, G.C., Sanches, T.V.C., Mechler-Dreibi, M.L., Almeida, H.M.S., Storino, G.Y., Sonalio, K., Petri, F.A.M., Martins, T.S., Cides da Silva, L.C., Montassier, H.J., Sant'Anna, O.A., Fantini, M.C.A., de Oliveira, L.G., 2023. Efficacy evaluation of a novel oral silica-based vaccine in inducing mucosal immunity against *Mycoplasma hyopneumoniae*. *Res. Vet. Sci.* 158, 141–150. <https://doi.org/10.1016/j.rvsc.2023.03.018>
- Ferreira, M.M., Mechler-Dreibi, M.L., Sonalio, K., Almeida, H.M. de S., Ferraz, M.E.S., Jacintho, A.P.P., Maes, D., de Oliveira, L.G., 2021. Co-infections by *Mycoplasma hyopneumoniae*, *Mycoplasma hyorhinis* and *Mycoplasma flocculare* in macroscopic lesions of lung consolidation of pigs at slaughter. *Vet. Microbiol.* 258, 109123. <https://doi.org/10.1016/j.vetmic.2021.109123>
- Ferreira, M.R.A., Fonseca Finger, P., Georg Magalhães, C., Pouey da Cunha, C.E., Moreira Júnior, C., Deon Kich, J., Morés, N., Nunes Moreira, Â., Antônio Dellagostin, O., Rochedo Conceição, F., 2019. Protection Efficacy of the rLTB-R1 Chimera against Experimental Swine Mycoplasma Pneumonia. *Acta Sci. Vet.* 47. <https://doi.org/10.22456/1679-9216.90862>
- Ferreira, V., Dias, R., Raso, T., 2016. Screening of Feral Pigeons (*Columba livia*) for Pathogens of Veterinary and Medical Importance. *Rev. Bras. Ciênc. Avícola* 18, 701–704. <https://doi.org/10.1590/1806-9061-2016-0296>
- Figueras Gourgues, S., Fano, E., Alegre Sabaté, A., López Grasa, E., Hernández Caravaca, I., García Vázquez, F.A., Rodríguez Vega, V., Garcia-Morante, B., 2020. Assessment of nebulization technology for gilt exposure to *Mycoplasma hyopneumoniae* as an acclimation strategy. *J. Swine Health Prod.* 28, 294–301.
- Filioussis, G., Bramis, G., Petridou, E., Giadinis, N.D., Nouvel, L.-X., Citti, C., Frey, J., 2022. *Mycoplasma agalactiae* ST35: a new sequence type with a minimal accessory genome primarily affecting goats. *BMC Vet. Res.* 18, 29. <https://doi.org/10.1186/s12917-021-03128-w>
- Fischer, A., Santana-Cruz, I., Hegerman, J., Gourel, H., Schieck, E., Lambert, M., Nadendla, S., Wesonga, H., Miller, R.A., Vashee, S., Weber, J., Meens, J., Frey, J., Jores, J., 2015. High quality draft genomes of the *Mycoplasma mycoides* subsp. *mycoides* challenge strains Afadé and B237. *Stand. Genomic Sci.* 10, 1–11. <https://doi.org/10.1186/s40793-015-0067-0>
- Fischer, A., Shapiro, B., Muriuki, C., Heller, M., Schnee, C., Bongcam-Rudloff, E., Vilei, E.M., Frey, J., Jores, J., 2012. The Origin of the 'Mycoplasma mycoides Cluster' Coincides with Domestication of Ruminants. *PLOS ONE* 7, e36150. <https://doi.org/10.1371/journal.pone.0036150>
- Fischer, L., Liebing, J., Völker, I., Baudler, L., Gethöffer, F., Voigt, U., Heffels-Redmann, U., Wohlsein, P., Siebert, U., Lierz, M., 2022a. Occurrence and relevance of *Mycoplasma* spp. in free-ranging pheasants from northwestern Germany. *Eur. J. Wildl. Res.* 68, 7. <https://doi.org/10.1007/s10344-021-01557-4>
- Fischer, L., Möller Palau-Ribes, F., Kipper, S., Weiss, M., Landgraf, C., Lierz, M., 2022b. Absence of *Mycoplasma* spp. in nightingales (*Luscinia megarhynchos*) and blue (*Cyanistes caeruleus*) and great tits (*Parus major*) in Germany and its potential implication for evolutionary studies in birds. *Eur. J. Wildl. Res.* 68, 2. <https://doi.org/10.1007/s10344-021-01554-7>
- Fitzgerald, R.M., O'Shea, H., Manzanilla, E.G., Moriarty, J., McGlynn, H., Calderón Díaz, J.A., 2020. Associations between animal and herd management factors, serological response to three respiratory pathogens and pluck lesions in finisher pigs on a farrow-to-finish farm. *Porc. Health Manag.* 6, 34. <https://doi.org/10.1186/s40813-020-00173-z>
- Flores-García, D.L., Aguilar-Díaz, H., Amaro-Estrada, I., Martínez-Ocampo, F., Quiroz-Castañeda, R.E., 2022. An Update of Bovine Hemoplasmas Based on Phylogenetic and Genomics Analysis. *Microorganisms* 10, 1916. <https://doi.org/10.3390/microorganisms10101916>
- Földi, D., Bekő, K., Felde, O., Kreizinger, Z., Kovács, Á.B., Tóth, F., Bányai, K., Kiss, K., Biksi, I., Gyuranecz, M., 2020. Genotyping *Mycoplasma hyorhinis* by multi-locus sequence typing and multiple-locus variable-number tandem-repeat analysis. *Vet. Microbiol.* 249, 108836. <https://doi.org/10.1016/j.vetmic.2020.108836>
- Földi, D., Kreizinger, Z., Bekő, K., Belec, N., Bányai, K., Kiss, K., Biksi, I., Gyuranecz, M., 2021. Development of a molecular biological assay for the detection of markers related to decreased

- susceptibility to macrolides and lincomycin in *Mycoplasma hyorhinis*. *Acta Vet. Hung.* 69, 110–115. <https://doi.org/10.1556/004.2021.00026>
- Forouharmehr, A., Nassiry, M.R., 2015. B and T-cell epitopes prediction of the P40 antigen for developing mycoplasma agalactiae vaccine using bioinformatic tools. *Genet. Third Millenn.* 13, 3954–3961.
- Fourour, S., Fablet, C., Tocqueville, V., Dorenlor, V., Eono, F., Eveno, E., Kempf, I., Marois-Créhan, C., 2018. A new multiplex real-time TaqMan[®] PCR for quantification of *Mycoplasma hyopneumoniae*, *M. hyorhinis* and *M. flocculare*: exploratory epidemiological investigations to research mycoplasmal association in enzootic pneumonia-like lesions in slaughtered pigs. *J. Appl. Microbiol.* 125, 345–355. <https://doi.org/10.1111/jam.13770>
- Fourour, S., Lucas, P., Touzain, F., Tocqueville, V., Gautier-Bouchardon, A.V., Kempf, I., Marois-Créhan, C., 2019a. Genomic polymorphism of *Mycoplasma flocculare* revealed by a newly developed multilocus sequence typing scheme. *Vet. Microbiol.* 237, 108422. <https://doi.org/10.1016/j.vetmic.2019.108422>
- Fourour, S., Marois-Créhan, C., Martelet, L., Fablet, C., Kempf, I., Gottschalk, M., Segura, M., 2019b. Intra-Species and Inter-Species Differences in Cytokine Production by Porcine Antigen-Presenting Cells Stimulated by *Mycoplasma hyopneumoniae*, *M. hyorhinis*, and *M. flocculare*. *Pathogens* 8, 34. <https://doi.org/10.3390/pathogens8010034>
- Fourour, S., Tocqueville, V., Paboeuf, F., Lediguerher, G., Morin, N., Kempf, I., Marois-Créhan, C., 2019c. Pathogenicity study of *Mycoplasma hyorhinis* and *M. flocculare* in specific-pathogen-free pigs pre-infected with *M. hyopneumoniae*. *Vet. Microbiol.* 232, 50–57. <https://doi.org/10.1016/j.vetmic.2019.04.010>
- Fox, K.A., Rouse, N.M., Huyvaert, K.P., Griffin, K.A., Killion, H.J., Jennings-Gaines, J., Edwards, W.H., Quackenbush, S.L., Miller, M.W., 2015. Bighorn sheep (*Ovis canadensis*) sinus tumors are associated with coinfections by potentially pathogenic bacteria in the upper respiratory tract. *J. Wildl. Dis.* 51, 19–27.
- Fox, L.K., Kirk, J.H., Britten, A., 2005. *Mycoplasma mastitis*: a review of transmission and control. *J. Vet. Med. B Infect. Dis. Vet. Public Health* 52, 153–160. <https://doi.org/10.1111/j.1439-0450.2005.00845.x>
- Francis, M.I., Ejeh, E.F., Raji, M.A., Egwu, G.O., 2015a. Methods of isolation and identification of mycoplasma species of ruminants in Africa - a review. *Bull. Anim. Health Prod. Afr.* 63, 411–431.
- Francis, M.I., Raji, M.A., Kazeem, H.M., Suleiman, M.M., 2015b. ELISA-based serological survey of *Mycoplasma bovis* in cattle in three local government areas in Adamawa State, Nigeria. *J. Adv. Vet. Anim. Res.* 2, 170–174.
- Franco, M.F., Gaeta, N.C., Alemán, M.A.R., Mellville, P.A., Timenetsky, J., Balara, M.F.A., Gregory, L., 2019. Bacteria isolated from the lower respiratory tract of sheep and their relationship to clinical signs of sheep respiratory disease. *Pesqui. Veterinária Bras.* 39, 796–801. <https://doi.org/10.1590/1678-5150-pvb-6315>
- Francoz, D., Buczinski, S., Bélanger, A.M., Forté, G., Labrecque, O., Tremblay, D., Wellemans, V., Dubuc, J., 2015. Respiratory Pathogens in Québec Dairy Calves and Their Relationship with Clinical Status, Lung Consolidation, and Average Daily Gain. *J. Vet. Intern. Med.* 29, 381–387. <https://doi.org/10.1111/jvim.12531>
- Freeman, C.N., Herman, E.K., Abi Younes, J., Ramsay, D.E., Erikson, N., Stothard, P., Links, M.G., Otto, S.J.G., Waldner, C., 2022. Evaluating the potential of third generation metagenomic sequencing for the detection of BRD pathogens and genetic determinants of antimicrobial resistance in chronically ill feedlot cattle. *BMC Vet. Res.* 18, 211. <https://doi.org/10.1186/s12917-022-03269-6>
- Fritsch, T.E., Siqueira, F.M., Schrank, I.S., 2018. Global analysis of sRNA target genes in *Mycoplasma hyopneumoniae*. *BMC Genomics* 19, 767. <https://doi.org/10.1186/s12864-018-5136-5>

- Fu, P., Sun, Z., Yu, Z., Zhang, Y., Shen, J., Zhang, H., Xu, W., Jiang, F., Chen, H., Wu, W., 2014a. Enzyme Linked Aptamer Assay: Based on a Competition Format for Sensitive Detection of Antibodies to *Mycoplasma bovis* in Serum. *Anal. Chem.* 86, 1701–1709. <https://doi.org/10.1021/ac4042203>
- Fu, P., Wang, F., Zhang, Yunke, Qiao, X., Zhang, Yuewei, Zhou, W., Yan, X., Wu, W., 2021. The application of aptamer Apt-236 targeting PvpA protein in the detection of antibodies against *Mycoplasma gallisepticum*. *Anal. Methods* 13, 3068–3076. <https://doi.org/10.1039/D1AY00515D>
- Fu, P., ZhenHong, S., YueWei, Z., ZiQiang, Y., HaiYan, Z., Dan, S., Fei, J., WenXue, W., 2014b. Development of a direct competitive ELISA for the detection of *Mycoplasma bovis* infection based on a monoclonal antibody of P48 protein. *BMC Vet. Res.* 10.
- Fu, Y., Shi, T., Xu, L., Wei, W., Lu, F., Zhang, X., Yuan, X., Li, J., Lv, J., Fang, W., 2017. Identification of a novel *Hemoplasma* species from pigs in Zhejiang province, China. *J. Vet. Med. Sci.* 79, 864–870. <https://doi.org/10.1292/jvms.16-0545>
- Fuli, H., ChengCheng, Z., DingRen, B., Wei, T., Jiao, C., JianJun, S., XiuLi, P., 2016. *Mycoplasma gallisepticum* (HS strain) surface lipoprotein pMGA interacts with host apolipoprotein A-I during infection in chicken. *Appl. Microbiol. Biotechnol.* 100, 1343–1354.
- FuRong, Z., XueLiang, Z., MinJun, X., SiYang, H., DongHui, Z., HuiYan, X., HuiQun, S., FengCai, Z., 2012. First report of *Mycoplasma bovis* infection in dairy cattle in Guangzhou, subtropical southern China. *Afr. J. Microbiol. Res.* 6, 5668–5671.
- Gaeta, N.C., Ribeiro, B.L.M., Alemán, M.A.R., Yoshihara, E., Nassar, A.F.C., Marques, L.M., Timenetsky, J., Gregory, L., 2018. Bacterial pathogens of the lower respiratory tract of calves from Brazilian rural settlement herds and their association with clinical signs of bovine respiratory disease. *Pesqui. Veterinária Bras.* 38, 374–381. <https://doi.org/10.1590/1678-5150-pvb-5323>
- Gagea, M.I., Bateman, K.G., Shanahan, R.A., van Dreumel, T., McEwen, B.J., Carman, S., Archambault, M., Caswell, J.L., 2006. Naturally occurring *Mycoplasma bovis*-associated pneumonia and polyarthritis in feedlot beef calves. *J. Vet. Diagn. Investig. Off. Publ. Am. Assoc. Vet. Lab. Diagn. Inc* 18, 29–40. <https://doi.org/10.1177/104063870601800105>
- Gallier-Beckley, A., Pappan, L.K., Madera, R., Burakova, Y., Waters, A., Nickles, M., Li, X., Nietfeld, J., Schlup, J.R., Zhong, Q., McVey, S., Dritz, S.S., Shi, J., 2015. Characterization of a novel oil-in-water emulsion adjuvant for swine influenza virus and *Mycoplasma hyopneumoniae* vaccines. *Vaccine* 33, 2903–2908. <https://doi.org/10.1016/j.vaccine.2015.04.065>
- Galluzzo, P., Migliore, S., Galuppo, L., Condorelli, L., Hussein, H.A., Licitra, F., Coltraro, M., Sallemi, S., Antoci, F., Cascone, G., Puleio, R., Loria, G.R., 2022. First Molecular Survey to Detect *Mycoplasma gallisepticum* and *Mycoplasma synoviae* in Poultry Farms in a Strategic Production District of Sicily (South-Italy). *Animals* 12, 962. <https://doi.org/10.3390/ani12080962>
- Galluzzo, P., Migliore, S., Puleio, R., Galuppo, L., La Russa, F., Blanda, V., Tumino, S., Torina, A., Ridley, A., Loria, G.R., 2021. Detection of *Mycoplasma agalactiae* in Ticks (*Rhipicephalus bursa*) Collected by Sheep and Goats in Sicily (South-Italy), Endemic Area for Contagious Agalactia. *Microorganisms* 9, 2312. <https://doi.org/10.3390/microorganisms9112312>
- Galon, E.M.S., Adjou Moumouni, P.F., Ybañez, R.H.D., Macalanda, A.M.C., Liu, M., Efstratiou, A., Ringo, A.E., Lee, S.-H., Gao, Y., Guo, H., Li, J., Tumwebaze, M.A., Byamukama, B., Li, Y., Ybañez, A.P., Xuan, X., 2019. Molecular evidence of hemotropic mycoplasmas in goats from Cebu, Philippines. *J. Vet. Med. Sci.* 81, 869–873. <https://doi.org/10.1292/jvms.19-0042>
- Galon, E.M.S., Ybañez, R.H.D., Adjou Moumouni, P.F., Tumwebaze, M.A., Fabon, R.J.A., Callanta, M.R.R., Labutong, K.J.E., Salazar, G.B., Liu, M., Li, J., Byamukama, B., Li, Y., Ji, S., Lee, S.-H., Ybañez, A.P., Claveria, F.G., Xuan, X., 2020. Molecular survey of tick-borne pathogens infecting backyard cattle and water buffaloes in Quezon province, Philippines. *J. Vet. Med. Sci.* 82, 886–890. <https://doi.org/10.1292/jvms.19-0636>

- Ganapathy, K., Ball, C., Kabiraj, C.K., Nooruzzaman, M., Chowdhury, E.H., Islam, M.R., 2021. *Mycoplasma gallisepticum* detection in Bangladesh table egg laying chicken flocks. *Pak. Vet. J.* 41, 306–308.
- Gang, Q., YaPei, R., BenChi, Y., Tao, L., ZhaoJing, H., Xiang, L., LiHong, Z., ShuCheng, H., Kun, L., ZhaoQing, H., 2019. Identification and genomic analysis of a pathogenic strain of *Mycoplasma hyopneumoniae* (TB1) isolated from Tibetan pigs. *DNA Cell Biol.* 38, 922–932.
- Gao, X., Bao, S., Xing, X., Fu, X., Zhang, Y., Xue, H., Wen, F., Wei, Y., 2018. Fructose-1,6-bisphosphate aldolase of *Mycoplasma bovis* is a plasminogen-binding adhesin. *Microb. Pathog.* 124, 230–237. <https://doi.org/10.1016/j.micpath.2018.08.032>
- Gao, Z., Chen, L., Song, T., Pan, X., Li, X., Lu, G., Tang, Y., Wu, X., Zhao, B., Zhang, R., 2022. A candidate multi-epitope vaccine against porcine reproductive and respiratory syndrome virus and *Mycoplasma hyopneumoniae* induces robust humoral and cellular response in mice. *Vaccine* 40, 2370–2378. <https://doi.org/10.1016/j.vaccine.2022.03.021>
- García-Galán, A., De la Fe, C., Gomis, J., Bataller, E., Sánchez, A., Quereda, J.J., García-Roselló, E., Gómez-Martín, A., 2020. The addition of *Lactobacillus* spp. negatively affects *Mycoplasma bovis* viability in bovine cervical mucus. *BMC Vet. Res.* 16, 251. <https://doi.org/10.1186/s12917-020-02454-9>
- García-Galán, Ana, Gómez-Martín, Á., Bataller, E., Gomis, J., Sánchez, A., Gadea, J., Vieira, L.A., García-Roselló, E., De la Fe, C., 2020. The Addition of *Lactobacillus* spp., Enrofloxacin or Doxycycline Negatively Affects the Viability of *Mycoplasma bovis* in Diluted Bovine Semen. *Animals* 10, 837. <https://doi.org/10.3390/ani10050837>
- García-Morante, B., Dors, A., León-Kempis, R., Pérez de Rozas, A., Segalés, J., Sibila, M., 2018. Assessment of the in vitro growing dynamics and kinetics of the non-pathogenic J and pathogenic 11 and 232 *Mycoplasma hyopneumoniae* strains. *Vet. Res.* 49, 45. <https://doi.org/10.1186/s13567-018-0541-y>
- García-Morante, B., Maes, D., Sibila, M., Betlach, A.M., Sponheim, A., Canturri, A., Pieters, M., 2022. Improving *Mycoplasma hyopneumoniae* diagnostic capabilities by harnessing the infection dynamics. *Vet. J.* 288, 105877. <https://doi.org/10.1016/j.tvjl.2022.105877>
- García-Morante, B., Segalés, J., Fraile, L., Pérez de Rozas, A., Maiti, H., Coll, T., Sibila, M., 2016. Assessment of *Mycoplasma hyopneumoniae*-induced pneumonia using different lung lesion scoring systems: a comparative review. *J. Comp. Pathol.* 154, 125–134.
- Garwood, T.J., Lehman, C.P., Walsh, D.P., Cassirer, E.F., Besser, T.E., Jenks, J.A., 2020. Removal of chronic *Mycoplasma ovipneumoniae* carrier ewes eliminates pneumonia in a bighorn sheep population. *Ecol. Evol.* 10, 3491–3502. <https://doi.org/10.1002/ece3.6146>
- Garza-Moreno, L., Segalés, J., Pieters, M., Romagosa, A., Sibila, M., 2017. Survey on *Mycoplasma hyopneumoniae* gilt acclimation practices in Europe. *Porc. Health Manag.* 3, 21. <https://doi.org/10.1186/s40813-017-0069-y>
- Garza-Moreno, L., Vilalta, C., Pieters, M., 2022. Environmental detection of *Mycoplasma hyopneumoniae* in breed-to-wean farms. *Res. Vet. Sci.* 145, 188–192. <https://doi.org/10.1016/j.rvsc.2022.02.009>
- Gatto, I.R.H., Sonálio, K., Amaral, R.B. do, Morés, N., Dalla Costa, O.A., André, M.R., de Oliveira, L.G., 2019. High frequency and molecular characterization of porcine hemotrophic mycoplasmas in Brazil. *Vet. Microbiol.* 231, 33–39. <https://doi.org/10.1016/j.vetmic.2019.02.024>
- Gaurivaud, P., Baranowski, E., Pau-Roblot, C., Sagné, E., Citti, C., Tardy, F., 2016. *Mycoplasma agalactiae* Secretion of β -(1→6)-Glucan, a Rare Polysaccharide in Prokaryotes, Is Governed by High-Frequency Phase Variation. *Appl. Environ. Microbiol.* 82, 3370–3383. <https://doi.org/10.1128/AEM.00274-16>
- Gaurivaud, P., Ganter, S., Villard, A., Manso-Silvan, L., Chevret, D., Boulé, C., Monnet, V., Tardy, F., 2018. Mycoplasmas are no exception to extracellular vesicles release: Revisiting old concepts. *PLOS ONE* 13, e0208160. <https://doi.org/10.1371/journal.pone.0208160>

- Gaurivaud, P., Lakhdar, L., Le Grand, D., Poumarat, F., Tardy, F., 2014. Comparison of *in vivo* and *in vitro* properties of capsulated and noncapsulated variants of *Mycoplasma mycoides* subsp. *mycoides* strain Afadé: a potential new insight into the biology of contagious bovine pleuropneumonia. *FEMS Microbiol. Lett.* 359, 42–49. <https://doi.org/10.1111/1574-6968.12579>
- Gaurivaud, P., Persson, A., Grand, D.L., Westberg, J., Solsona, M., Johansson, K.-E., Poumarat, F., 2004. Variability of a glucose phosphotransferase system permease in *Mycoplasma mycoides* subsp. *mycoides* Small Colony. *Microbiol. Read. Engl.* 150, 4009–4022. <https://doi.org/10.1099/mic.0.27247-0>
- Gautier-Bouchardon, A.V., 2018. Antimicrobial Resistance in *Mycoplasma* spp. *Microbiol. Spectr.* 6, 6.4.07. <https://doi.org/10.1128/microbiolspec.ARBA-0030-2018>
- Gautier-Bouchardon, A.V., Ferré, S., Le Grand, D., Paoli, A., Gay, E., Poumarat, F., 2014. Overall Decrease in the Susceptibility of *Mycoplasma bovis* to Antimicrobials over the Past 30 Years in France. *PLOS ONE* 9, e87672. <https://doi.org/10.1371/journal.pone.0087672>
- Gbylik-Sikorska, M., Gajda, A., Posyniak, A., 2018. Pharmacokinetic depletion phase of doxycycline in healthy and *Mycoplasma gallisepticum* -infected chicken broilers after coadministration of enrofloxacin traces. *J. Vet. Pharmacol. Ther.* 41, 166–169. <https://doi.org/10.1111/jvp.12433>
- Gbylik-Sikorska, M., Posyniak, A., Sniegocki, T., Sell, B., Gajda, A., Sawicka, A., Olszewska-Tomczyk, M., Bladek, T., Tomczyk, G., Zmudzki, J., 2016. Influence of enrofloxacin traces in drinking water to doxycycline tissue pharmacokinetics in healthy and infected by *Mycoplasma gallisepticum* broiler chickens. *Food Chem. Toxicol.* 90, 123–129.
- Geidam, Y.A., Ayi, V.K., Umar, I.I., Sunday, J., Musa, D., Goni, B., Mwapu, D.N., 2013. Participatory disease surveillance in the detection of trans-boundary animal diseases (TADS) in Borno State of arid north-eastern Nigeria. *Bull. Anim. Health Prod. Afr.* 61, 231–239.
- Gelasakis, A.I., Angelidis, A., Giannakou, R., Arsenos, G., 2018. Bacterial subclinical mastitis and its effect on milk quality traits in low-input dairy goat herds. *Vet. Rec.* 183, 449–449. <https://doi.org/10.1136/vr.104804>
- Gelgie, A.E., Korsá, M.G., Kerro Dego, O., 2022. *Mycoplasma bovis* Mastitis. *Curr. Res. Microb. Sci.* 3, 100123. <https://doi.org/10.1016/j.crmicr.2022.100123>
- Ghanem, M., El-Gazzar, M., 2018. Development of *Mycoplasma synoviae* (MS) core genome multilocus sequence typing (cgMLST) scheme. *Vet. Microbiol.* 218, 84–89. <https://doi.org/10.1016/j.vetmic.2018.03.021>
- Ghanem, M., LeYi, W., Yan, Z., Edwards, S., Lu, A., Ley, D., El-Gazzar, M., 2018. Core genome multilocus sequence typing: a standardized approach for molecular typing of *Mycoplasma gallisepticum*. *J. Clin. Microbiol.* 56.
- Gharibi, D., Ghadimipour, R., Mayahi, M., 2018. Detection of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* among commercial poultry in Khuzestan province, Iran. *Arch. Razi Inst.* 73, 139–146.
- Ghohestani, S., Zeinali, T., Razmyar, J., Kalidari, G., Bassami, M., 2018. Isolation and molecular identification of *Mycoplasma* spp. from pigeons in the north-east of Iran. *Iran. J. Vet. Med.* 12.
- Ghorashi, S.A., Kanci, A., Noormohammadi, A.H., 2015. Evaluation of the capacity of PCR and high-resolution melt curve analysis for identification of mixed infection with *Mycoplasma gallisepticum* strains. *PLOS ONE* 10.
- Giacomini, E., Ferrari, N., Pitozzi, A., Remistani, M., Giardiello, D., Maes, D., Alborali, G.L., 2016. Dynamics of *Mycoplasma hyopneumoniae* seroconversion and infection in pigs in the three main production systems. *Vet. Res. Commun.* 40, 81–88. <https://doi.org/10.1007/s11259-016-9657-6>
- Gilbert, M., Cinardi, G., Da Re, D., Wint, W.G.R., Wisser, D., Robinson, T.P., 2022a. Global goats distribution in 2015 (5 minutes of arc). <https://doi.org/10.7910/DVN/YYG6ET>
- Gilbert, M., Cinardi, G., Da Re, D., Wint, W.G.R., Wisser, D., Robinson, T.P., 2022b. Global sheep distribution in 2015 (5 minutes of arc). <https://doi.org/10.7910/DVN/VZOYHM>

- Gille, L., Evrard, J., Callens, J., Supré, K., Grégoire, F., Boyen, F., Haesebrouck, F., Deprez, P., Pardon, B., 2020. The presence of *Mycoplasma bovis* in colostrum. *Vet. Res.* 51, 54. <https://doi.org/10.1186/s13567-020-00778-w>
- Gille, L., Pilo, P., Valgaeren, B.R., Van Driessche, L., Van Loo, H., Bodmer, M., Bürki, S., Boyen, F., Haesebrouck, F., Deprez, P., Pardon, B., 2016. A new predilection site of *Mycoplasma bovis*: Postsurgical seromas in beef cattle. *Vet. Microbiol.* 186, 67–70. <https://doi.org/10.1016/j.vetmic.2016.02.011>
- Gioia, G., Addis, M.F., Santisteban, C., Gross, B., Nydam, D.V., Sipka, A.S., Virkler, P.D., Watters, R.D., Wieland, M., Zurakowski, M.J., Moroni, P., 2021. *Mycoplasma* species isolated from bovine milk collected from US dairy herds between 2016 and 2019. *J. Dairy Sci.* 104, 4813–4821. <https://doi.org/10.3168/jds.2020-19171>
- Gioia, G., Werner, B., Nydam, D.V., Moroni, P., 2016. Validation of a mycoplasma molecular diagnostic test and distribution of mycoplasma species in bovine milk among New York State dairy farms. *J. Dairy Sci.* 99, 4668–4677.
- Giovannini, A., Bellini, S., Salman, M.D., Caporale, V., 2000. Spatial risk factors related to outbreaks of contagious bovine pleuropneumonia in northern Italy (1990-1993). *Rev. Sci. Tech. Int. Off. Epizoot.* 19, 764–772. <https://doi.org/10.20506/rst.19.3.1242>
- Giovannini, S., Zanoni, M.G., Saligni, C., Cinotti, S., Alborali, G.L., 2013. *Mycoplasma bovis* infection in respiratory disease of dairy calves less than one month old. *Res. Vet. Sci.* 95, 576–579. <https://doi.org/10.1016/j.rvsc.2013.05.008>
- Giram, P., Bhutada, P., Prajapati, C., Koratkar, S.S., Patil, S., Hooda, D., Rale, V., Tongaonkar, S.S., 2022. Percent positivity and phylogenetic analysis of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* in commercial poultry from the different States of India. *Vet. World* 15, 1843–1851. <https://doi.org/10.14202/vetworld.2022.1843-1851>
- Gladden, N., 2015. A case report of *Mycoplasma wenyonii* associated immune-mediated haemolytic anaemia in a dairy cow. *Cattle Pract.* 23.
- Glew, M.D., Marendra, M., Rosengarten, R., Citti, C., 2002. Surface diversity in *Mycoplasma agalactiae* is driven by site-specific DNA inversions within the *vpma* multigene locus. *J. Bacteriol.* 184, 5987–5998. <https://doi.org/10.1128/JB.184.21.5987-5998.2002>
- Glew, M.D., Papazisi, L., Poumarat, F., Bergonier, D., Rosengarten, R., Citti, C., 2000. Characterization of a multigene family undergoing high-frequency DNA rearrangements and coding for abundant variable surface proteins in *Mycoplasma agalactiae*. *Infect. Immun.* 68, 4539–4548. <https://doi.org/10.1128/IAI.68.8.4539-4548.2000>
- Goecke, N.B., Hjulsager, C.K., Krog, J.S., Skovgaard, K., Larsen, L.E., 2020. Development of a high-throughput real-time PCR system for detection of enzootic pathogens in pigs. *J. Vet. Diagn. Invest.* 32, 51–64. <https://doi.org/10.1177/1040638719890863>
- Goecke, N.B., Nielsen, B.H., Petersen, M.B., Larsen, L.E., 2021. Design of a High-Throughput Real-Time PCR System for Detection of Bovine Respiratory and Enteric Pathogens. *Front. Vet. Sci.* 8, 677993. <https://doi.org/10.3389/fvets.2021.677993>
- Goedbloed, D.J., van Hooff, P., Lutz, W., Megens, H.-J., van Wieren, S.E., Ydenberg, R.C., Prins, H.H.T., 2015. Increased *Mycoplasma hyopneumoniae* Disease Prevalence in Domestic Hybrids Among Free-Living Wild Boar. *EcoHealth* 12, 571–579. <https://doi.org/10.1007/s10393-015-1062-z>
- Gomes Neto, J.C., Strait, E.L., Raymond, M., Ramirez, A., Minion, F.C., 2014. Antibody responses of swine following infection with *Mycoplasma hyopneumoniae*, *M. hyorhinis*, *M. hyosynoviae* and *M. flocculare*. *Vet. Microbiol.* 174, 163–171. <https://doi.org/10.1016/j.vetmic.2014.08.008>
- Gomes-Neto, J.C., Raymond, M., Bower, L., Ramirez, A., Madson, D.M., Strait, E.L., Rosey, E.L., Rapp-Gabrielson, V.J., 2016. Two clinical isolates of *Mycoplasma hyosynoviae* showed differing pattern of lameness and pathogen detection in experimentally challenged pigs. *J. Vet. Sci.* 17, 489. <https://doi.org/10.4142/jvs.2016.17.4.489>

- Gómez-Guillamón, F., Díaz-Cao, J.M., Camacho-Sillero, L., Cano-Terriza, D., Alcaide, E.M., Cabezón, Ó., Arenas, A., García-Bocanegra, I., 2020. Spatiotemporal monitoring of selected pathogens in Iberian ibex (*Capra pyrenaica*). *Transbound. Emerg. Dis.* 67, 2259–2265. <https://doi.org/10.1111/tbed.13576>
- Gómez-Martín, A., Uc, N., Vieira, L.A., Gadea, J., Cadenas, J., Sánchez, A., De la Fe, C., 2015. Survival capacity of *Mycoplasma agalactiae* and *Mycoplasma mycoides* subsp *capri* in the diluted semen of goat bucks and their effects on sperm quality. *Theriogenology* 83, 911–919. <https://doi.org/10.1016/j.theriogenology.2014.11.029>
- Gondaira, S., Higuchi, H., Iwano, H., Nakajima, K., Kawai, K., Hashiguchi, S., Konnai, S., Nagahata, H., 2015. Cytokine mRNA profiling and the proliferative response of bovine peripheral blood mononuclear cells to *Mycoplasma bovis*. *Vet. Immunol. Immunopathol.* 165, 45–53.
- Gondaira, S., Higuchi, H., Iwano, H., Nishi, K., Nebu, T., Nakajima, K., Nagahata, H., 2018. Innate immune response of bovine mammary epithelial cells to *Mycoplasma bovis*. *J. Vet. Sci.* 19, 79. <https://doi.org/10.4142/jvs.2018.19.1.79>
- Gondaira, S., Higuchi, H., Nishi, K., Iwano, H., Nagahata, H., 2017. *Mycoplasma bovis* escapes bovine neutrophil extracellular traps. *Vet. Microbiol.* 199, 68–73. <https://doi.org/10.1016/j.vetmic.2016.12.022>
- Gondaira, S., Nishi, K., Fujiki, J., Iwano, H., Watanabe, R., Eguchi, A., Hirano, Y., Higuchi, H., Nagahata, H., 2021a. Innate immune response in bovine neutrophils stimulated with *Mycoplasma bovis*. *Vet. Res.* 52, 58. <https://doi.org/10.1186/s13567-021-00920-2>
- Gondaira, S., Nishi, K., Iwano, H., Fujiki, J., Watanabe, R., Eguchi, A., Hirano, Y., Higuchi, H., Nagahata, H., 2021b. Transcriptome analysis of *Mycoplasma bovis* stimulated bovine peripheral blood mononuclear cells. *Vet. Immunol. Immunopathol.* 232, 110166. <https://doi.org/10.1016/j.vetimm.2020.110166>
- Gondaira, S., Nishi, K., Tanaka, T., Yamamoto, T., Nebu, T., Watanabe, R., Konnai, S., Hayashi, T., Kiku, Y., Okamoto, M., Matsuda, K., Koiwa, M., Iwano, H., Nagahata, H., Higuchi, H., 2020. Immunosuppression in Cows following Intramammary Infusion of *Mycoplasma bovis*. *Infect. Immun.* 88, e00521-19. <https://doi.org/10.1128/IAI.00521-19>
- Gondal, M.A., Rabbani, M., Muhammad, K., Yaqub, T., Babar, M.E., Sheikh, A.A., Ahmad, A., Shabbir, M.Z., Khan, M.I., 2015. Characterization of *Mycoplasma gallisepticum* isolated from commercial poultry flocks. *JAPS J. Anim. Plant Sci.* 25, 108–113.
- Gong, X., Chen, Q., Ferguson-Noel, N., Stipkovits, L.P., Szathmary, S., YongSheng, L., FuYing, Z., 2020. Evaluation of protective efficacy of inactivated *Mycoplasma synoviae* vaccine with different adjuvants. *Vet. Immunol. Immunopathol.* 220.
- Gonzaga, N.F., de Souza, L.F.L., Santos, M.R., Assao, V.S., Rycroft, A., Deeney, A.S., Fietto, J.L.R., Bressan, G.C., Moreira, M.A.S., Silva-Júnior, A., 2020. Antimicrobial susceptibility and genetic profile of *Mycoplasma hyopneumoniae* isolates from Brazil. *Braz. J. Microbiol.* 51, 377–384. <https://doi.org/10.1007/s42770-019-00185-0>
- Goodison, S., Urquidi, V., Kumar, D., Reyes, L., Rosser, C.J., 2013. Complete Genome Sequence of *Mycoplasma hyorhinis* Strain SK76. *Genome Announc.* 1, e00101-12. <https://doi.org/10.1128/genomeA.00101-12>
- Goto, S., Konnai, S., Hirano, Y., Kohara, J., Okagawa, T., Maekawa, N., Sajiki, Y., Watari, K., Minato, E., Kobayashi, A., Gondaira, S., Higuchi, H., Koiwa, M., Tajima, M., Taguchi, E., Uemura, R., Yamada, S., Kaneko, M.K., Kato, Y., Yamamoto, K., Toda, M., Suzuki, Y., Murata, S., Ohashi, K., 2020. Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN- γ by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in *Mycoplasma bovis* Infection. *Front. Vet. Sci.* 7, 12. <https://doi.org/10.3389/fvets.2020.00012>
- Goto, S., Konnai, S., Okagawa, T., Nishimori, A., Maekawa, N., Gondaira, S., Higuchi, H., Koiwa, M., Tajima, M., Kohara, J., Ogasawara, S., Kato, Y., Suzuki, Y., Murata, S., Ohashi, K., 2017. Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN- γ production via PD-1/PD-L1

- blockade in bovine mycoplasmosis. *Immun. Inflamm. Dis.* 5, 355–363. <https://doi.org/10.1002/iid3.173>
- Goudarzi, G., Tavakoli, M., Ezatpour, B., Kooshki, H., Hosseini-Chegeni, A., 2019. Molecular detection of *Theileria ovis* (Apicomplexa: Theileriidae), *Anaplasma ovis* (Rickettsiales: Anaplasmataceae), and *Mycoplasma* sp. (Tenericutes: Mycoplasmataceae) from sheep blood in western Iran. *Comp. Clin. Pathol.* 28, 1661–1666.
- Gourgues, G., Barré, A., Beaudoin, E., Weber, J., Magdelenat, G., Barbe, V., Schieck, E., Jores, J., Vashee, S., Blanchard, A., Lartigue, C., Sirand-Pugnet, P., 2016. Complete Genome Sequence of *Mycoplasma mycoides* subsp. *mycoides* T1/44, a Vaccine Strain against Contagious Bovine Pleuropneumonia. *Genome Announc.* 4, e00263-16. <https://doi.org/10.1128/genomeA.00263-16>
- Gowthaman, V., Singh, S.D., Dhama, K., Srinivasan, P., Saravanan, S., Gopala Krishna Murthy, T.R., Ramakrishnan, M.A., 2017. Molecular Survey of Respiratory and Immunosuppressive Pathogens Associated with Low Pathogenic Avian Influenza H9N2 Subtype and Virulent Newcastle Disease Viruses in Commercial Chicken Flocks. *J. Poult. Sci.* 54, 179–184. <https://doi.org/10.2141/jpsa.0160032>
- Gracia, J.C., Smutzer, M., Taylor, L., Balasch, M., Bandrick, M., 2021. One Dose of a Novel Vaccine Containing Two Genotypes of Porcine Circovirus (PCV2a and PCV2b) and *Mycoplasma hyopneumoniae* Conferred a Duration of Immunity of 23 Weeks. *Vaccines* 9, 834. <https://doi.org/10.3390/vaccines9080834>
- Grossman, P.C., Schneider, D.A., Herndon, D.R., Knowles, D.P., Highland, M.A., 2021. Differential pulmonary immunopathology of domestic sheep (*Ovis aries*) and bighorn sheep (*Ovis canadensis*) with *Mycoplasma ovipneumoniae* infection: A retrospective study. *Comp. Immunol. Microbiol. Infect. Dis.* 76, 101641. <https://doi.org/10.1016/j.cimid.2021.101641>
- Guimaraes, A.M.S., Santos, A.P., SanMiguel, P., Walter, T., Timenetsky, J., Messick, J.B., 2011a. Complete Genome Sequence of *Mycoplasma suis* and Insights into Its Biology and Adaption to an Erythrocyte Niche. *PLOS ONE* 6, e19574. <https://doi.org/10.1371/journal.pone.0019574>
- Guimaraes, A.M.S., Vieira, R.F.C., Poletto, R., Vemulapalli, R., Santos, A.P., de Moraes, W., Cubas, Z.S., Santos, L.C., Marchant-Forde, J.N., Timenetsky, J., Biondo, A.W., Messick, J.B., 2011b. A quantitative TaqMan PCR assay for the detection of *Mycoplasma suis*. *J. Appl. Microbiol.* 111, 417–425. <https://doi.org/10.1111/j.1365-2672.2011.05053.x>
- Guimarães, M., Hurtado, R., Bello, C., Vanstreels, R., Ferreira, A., 2016. Surveillance for Newcastle disease virus, avian influenza virus and *Mycoplasma gallisepticum* in wild birds near commercial poultry farms surrounded by Atlantic rainforest remnants, Southeastern Brazil. *Rev. Bras. Ciênc. Avícola* 18, 387–394. <https://doi.org/10.1590/1806-9061-2015-0164>
- Gull, J.M., Hebel, C., Deb, A., Arif, A., Clauss, M., Hatt, J.-M., Hammer, S., 2014. Blood values of captive beira antelope (*Dorcatragus megalotis*) prior to and during an outbreak of fibrinous pleuropneumonia syndrome (FPPS). *J. Zoo Wildl. Med. Off. Publ. Am. Assoc. Zoo Vet.* 45, 735–743. <https://doi.org/10.1638/2013-0073.1>
- Gulliksen, S.M., Baustad, B., Framstad, T., Jørgensen, A., Skomsøy, A., Kjelvik, O., Gjestvang, M., Grøntvedt, C.A., Lium, B., 2021. Successful eradication of *Mycoplasma hyopneumoniae* from the Norwegian pig population – 10 years later. *Porc. Health Manag.* 7, 37. <https://doi.org/10.1186/s40813-021-00216-z>
- Gupta, R.S., Oren, A., 2020. Necessity and rationale for the proposed name changes in the classification of Mollicutes species. Reply to: ‘Recommended rejection of the names *Malacoplasma* gen. nov., *Mesomycoplasma* gen. nov., *Metamycoplasma* gen. nov., *Metamycoplasmataceae* fam. nov., *Mycoplasmoidaceae* fam. nov., *Mycoplasmoidales* ord. nov., *Mycoplasmoides* gen. nov., *Mycoplasmopsis* gen. nov. [Gupta, Sawnani, Adeolu, Alnajjar and Oren 2018] and all proposed species comb. nov. placed therein’, by M. Balish et al. (*Int J Syst Evol Microbiol*, 2019;69:3650–3653). *Int. J. Syst. Evol. Microbiol.* 70, 1431–1438. <https://doi.org/10.1099/ijsem.0.003869>

- Gupta, R.S., Sawnani, S., Adeolu, M., Alnajar, S., Oren, A., 2018. Phylogenetic framework for the phylum Tenericutes based on genome sequence data: proposal for the creation of a new order Mycoplasmoidales ord. nov., containing two new families Mycoplasmoidaceae fam. nov. and Metamycoplasmataceae fam. nov. harbouring Eperythrozoon, Ureaplasma and five novel genera. *Antonie Van Leeuwenhoek* 111, 1583–1630. <https://doi.org/10.1007/s10482-018-1047-3>
- Gupta, R.S., Son, J., Oren, A., 2019. A phylogenomic and molecular markers based taxonomic framework for members of the order Entomoplasmatales: proposal for an emended order Mycoplasmatales containing the family Spiroplasmataceae and emended family Mycoplasmataceae comprised of six genera. *Antonie Van Leeuwenhoek* 112, 561–588. <https://doi.org/10.1007/s10482-018-1188-4>
- Gupta, S.K., Deng, Q., Gupta, T.B., Maclean, P., Jores, J., Heiser, A., Wedlock, D.N., 2021. Recombinase polymerase amplification assay combined with a dipstick-readout for rapid detection of *Mycoplasma ovipneumoniae* infections. *PLOS ONE* 16, e0246573. <https://doi.org/10.1371/journal.pone.0246573>
- Haapala, V., Pohjanvirta, T., Vähänikkilä, N., Halkilahti, J., Simonen, H., Pelkonen, S., Soveri, T., Simojoki, H., Autio, T., 2018. Semen as a source of *Mycoplasma bovis* mastitis in dairy herds. *Vet. Microbiol.* 216, 60–66. <https://doi.org/10.1016/j.vetmic.2018.02.005>
- Habte, T., Gerber, P.F., Ibrahim, F., Groves, P.J., Walkden-Brown, S.W., 2022. Seroprevalence of major respiratory diseases of chickens in central Ethiopia in different chicken production systems. *Poult. Sci.* 101, 102065. <https://doi.org/10.1016/j.psj.2022.102065>
- Haden, C., Painter, T., Fangman, T., Holtkamp, D., 2012. Assessing production parameters and economic impact of swine influenza, PRRS and *Mycoplasma hyopneumoniae* on finishing pigs in a large production system. *Proc AASV* 75–76.
- Hahn, T.W., Barate, K.A., Kim, K.J., Shin, W.S., 2019. Vaccine Composition Comprising Recombinant Protein for Preventing Swine *Mycoplasma* Infection. US20190177375A1.
- Hajizadeh, A., Ghaderi, R., Ayling, R.D., 2018. Species of *Mycoplasma* causing contagious agalactia in small ruminants in Northwest Iran. *Vet. Ital.* 54, 205–210.
- Hale, H.H., Helmboldt, C.F., Plastring, W.N., Stula, E.F., 1962. Bovine mastitis caused by a *Mycoplasma* species. *Cornell Vet.* 52, 582–591.
- Halecker, S., Mettenleiter, T.C., Beer, M., Hoffmann, B., 2020. “FastCheckFLI PPR-like”—A Molecular Tool for the Fast Genome Detection of PPRV and Differential Diagnostic Pathogens. *Viruses* 12, 1227. <https://doi.org/10.3390/v12111227>
- Hamad, M.A., Al-Aalim, A.M., Alchalaby, A.Y.H., 2019. Diagnosis of *Mycoplasma* from Starlings Lungs. *J. Pure Appl. Microbiol.* 13, 2273–2279. <https://doi.org/10.22207/JPAM.13.4.41>
- Hamal, K.R., Burgess, S.C., Pevzner, I.Y., Erf, G.F., 2006. Maternal Antibody Transfer from Dams to Their Egg Yolks, Egg Whites, and Chicks in Meat Lines of Chickens. *Poult. Sci.* 85, 1364–1372. <https://doi.org/10.1093/ps/85.8.1364>
- Han, J., Park, B.-S., Shin, D.-J., Song, S.-Y., Jeong, Y.-J., Lee, N., 2017. Complete Genome Sequence of *Mycoplasma hyopneumoniae* Strain KM014, a Clinical Isolate from South Korea. *Genome Announc.* 5, e01012-17. <https://doi.org/10.1128/genomeA.01012-17>
- Handeland, K., Tengs, T., Kokotovic, B., Vikøren, T., Ayling, R.D., Bergsjø, B., Sigurðardóttir, O.G., Bretten, T., 2014. *Mycoplasma ovipneumoniae*--a primary cause of severe pneumonia epizootics in the Norwegian Muskox (*Ovibos moschatus*) population. *PLOS ONE* 9, e106116. <https://doi.org/10.1371/journal.pone.0106116>
- Hannan, P.C.T., 2000. Guidelines and recommendations for antimicrobial minimum inhibitory concentration (MIC) testing against veterinary mycoplasma species. *Vet. Res.* 31, 373–395. <https://doi.org/10.1051/vetres:2000100>
- Hao, F., Bai, Y., Xie, X., Yuan, T., Wei, Y., Xiong, Q., Gan, Y., Zhang, L., Zhang, Z., Shao, G., Feng, Z., 2022a. Phenotypic characteristics and protective efficacy of an attenuated *Mycoplasma*

- hyopneumoniae vaccine by aerosol administration. *Vaccine* 40, 6074–6083. <https://doi.org/10.1016/j.vaccine.2022.08.072>
- Hao, F., Xie, X., Feng, Z., Chen, R., Wei, Y., Liu, J., Xiong, Q., Shao, G., Lin, J., 2022b. NADH oxidase of *Mycoplasma hyopneumoniae* functions as a potential mediator of virulence. *BMC Vet. Res.* 18, 126. <https://doi.org/10.1186/s12917-022-03230-7>
- Hao, H., Chen, S., Li, Y., Sun, H., Zhao, P., Jian, Y., Gao, Y., Wu, C., Liu, Y., Chu, Y., 2017. Complete Genome Sequence of *Mycoplasma capricolum* subsp. *capripneumoniae* Strain zly1309F, Isolated from Endangered Tibetan Antelope. *Genome Announc.* 5, e00496-17. <https://doi.org/10.1128/genomeA.00496-17>
- Hao, H., Maksimović, Z., Ma, L., Rifatbegović, M., Chen, S., Yan, X., Fu, L., Chu, Y., 2023. Complete Genome Sequences of *Mycoplasma ovipneumoniae* Strains 150 and 274, Isolated from Different Regions in Bosnia and Herzegovina. *Microbiol. Resour. Announc.* 12, e00011-23. <https://doi.org/10.1128/mra.00011-23>
- Hashem, Y.M., Abd El-Hamid, M.I., Awad, N.F.S., Ibrahim, D., Elshater, N.S., El-Malt, R.M.S., Hassan, W.H., Abo-Shama, U.H., Nassan, M.A., El-Bahy, S.M., Samy, O.M., El Sharkawy, R.B., Algabri, N., Elnahriry, S.S., 2022a. Insights into growth-promoting, anti-inflammatory, immunostimulant, and antibacterial activities of Toldin CRD as a novel phytobiotic in broiler chickens experimentally infected with *Mycoplasma gallisepticum*. *Poult. Sci.* 101, 102154. <https://doi.org/10.1016/j.psj.2022.102154>
- Hashem, Y.M., Mousa, W.S., Abdeen, E.E., Abdelkhalek, H.M., Nooruzzaman, M., El-Askary, A., Ismail, K.A., Megahed, A.M., Abdeen, A., Soliman, E.A., Wareth, G., 2022b. Prevalence and Molecular Characterization of *Mycoplasma* Species, *Pasteurella multocida*, and *Staphylococcus aureus* Isolated from Calves with Respiratory Manifestations. *Animals* 12, 312. <https://doi.org/10.3390/ani12030312>
- Hashemi, S., Mahzounieh, M., Sheikhi, N., Ebrahimi, A., 2018. Application of high-resolution melting-curve analysis on *pvpA* gene for detection and classification of *Mycoplasma gallisepticum* strains. *Microb. Pathog.* 124, 365–371. <https://doi.org/10.1016/j.micpath.2018.06.032>
- Hata, E., Nagai, K., Murakami, K., 2019. Mutations associated with change of susceptibility to lincosamides and/or macrolides in field and laboratory-derived *Mycoplasma californicum* strains in Japan, and development of a rapid detection method for these mutations. *Vet. Microbiol.* 229, 81–89. <https://doi.org/10.1016/j.vetmic.2018.12.017>
- Hata, E., Nagai, K., Murakami, K., 2017a. Complete Genome Sequence of *Mycoplasma bovis* Strain HAZ 596 from a Bovine Vagina in Japan. *Genome Announc.* 5, e01554-16. <https://doi.org/10.1128/genomeA.01554-16>
- Hata, E., Nagai, K., Murakami, K., 2017b. Complete Genome Sequence of *Mycoplasma bovis* Strain HAZ141_2 from Bovine Nasal Discharge in Japan. *Genome Announc.* 5, e01000-17. <https://doi.org/10.1128/genomeA.01000-17>
- Haydock, L.A.J., Fenton, R.K., Sergejewich, L., Veldhuizen, R.A.W., Smerek, D., Ojkic, D., Caswell, J.L., 2023. Bronchopneumonia with interstitial pneumonia in beef feedlot cattle: Characterization and laboratory investigation. *Vet. Pathol.* 60, 214–225. <https://doi.org/10.1177/03009858221146092>
- Hazelton, M.S., Morton, J.M., Bosward, K.L., Sheehy, P.A., Parker, A.M., Dwyer, C.J., Niven, P.G., House, J.K., 2018a. Isolation of *Mycoplasma* spp. and serological responses in bulls prior to and following their introduction into *Mycoplasma bovis*-infected dairy herds. *J. Dairy Sci.* 101, 7412–7424. <https://doi.org/10.3168/jds.2018-14457>
- Hazelton, M.S., Sheehy, P.A., Bosward, K.L., Parker, A.M., Morton, J.M., Dwyer, C.J., Niven, P.G., House, J.K., 2018b. Shedding of *Mycoplasma bovis* and antibody responses in cows recently diagnosed with clinical infection. *J. Dairy Sci.* 101, 584–589. <https://doi.org/10.3168/jds.2017-13512>
- Headley, S.A., Okano, W., Balbo, L.C., Marcasso, R.A., Oliveira, T.E., Alfieri, A.F., Negri Filho, L.C., Michelazzo, M.Z., Rodrigues, S.C., Baptista, A.L., Saut, J.P.E., Alfieri, A.A., 2018. Molecular

- survey of infectious agents associated with bovine respiratory disease in a beef cattle feedlot in southern Brazil. *J. Vet. Diagn. Invest.* 30, 249–251. <https://doi.org/10.1177/1040638717739945>
- Hegde, Shrilakshmi, Gabriel, C., Kragl, M., Chopra-Dewasthaly, R., 2015. Sheep primary cells as *in vitro* models to investigate *Mycoplasma agalactiae* host cell interactions. *Pathog. Dis.* 73, ftv048. <https://doi.org/10.1093/femspd/ftv048>
- Hegde, S., Zimmermann, M., Flöck, M., Brunthaler, R., Spergser, J., Rosengarten, R., Chopra-Dewasthaly, R., 2016. Genetic loci of *Mycoplasma agalactiae* involved in systemic spreading during experimental intramammary infection of sheep. *Vet. Res.* 47.
- Hegde, S., Zimmermann, M., Rosengarten, R., Chopra-Dewasthaly, R., 2018. Novel role of Vpmas as major adhesins of *Mycoplasma agalactiae* mediating differential cell adhesion and invasion of Vpma expression variants. *Int. J. Med. Microbiol.* 308, 263–270. <https://doi.org/10.1016/j.ijmm.2017.11.010>
- Hegde, Shivanand, Hegde, Shrilakshmi, Zimmermann, M., Flöck, M., Spergser, J., Rosengarten, R., Chopra-Dewasthaly, R., 2015. Simultaneous Identification of Potential Pathogenicity Factors of *Mycoplasma agalactiae* in the Natural Ovine Host by Negative Selection. *Infect. Immun.* 83, 2751–2761. <https://doi.org/10.1128/IAI.00403-15>
- Heinse, L.M., Hardesty, L.H., Harris, R.B., 2016. Risk of pathogen spillover to bighorn sheep from domestic sheep and goat flocks on private land. *Wildl. Soc. Bull.* 40, 625–633.
- Heller, M., Gicheru, N., Tjipura-Zaire, G., Muriuki, C., Yu, M., Botelho, A., Naessens, J., Jores, J., Liljander, A., 2016. Development of a Novel Cocktail Enzyme-Linked Immunosorbent Assay and a Field-Applicable Lateral-Flow Rapid Test for Diagnosis of Contagious Bovine Pleuropneumonia. *J. Clin. Microbiol.* 54, 1557–1565. <https://doi.org/10.1128/JCM.03259-15>
- Helmy, Y.A., Kathayat, D., Ghanem, M., Jung, K., Closs, G., Deblais, L., Srivastava, V., El-Gazzar, M., Rajashekar, G., 2020. Identification and characterization of novel small molecule inhibitors to control *Mycoplasma gallisepticum* infection in chickens. *Vet. Microbiol.* 247, 108799. <https://doi.org/10.1016/j.vetmic.2020.108799>
- Heng, Y., Cong, Y., YanPing, L., ManJun, Z., JingBo, C., ZongSheng, Z., 2018. Association study between Mannose-Binding Lectin (MBL) polymorphisms and serum MBL protein levels after *Mycoplasma ovipneumoniae* infection in sheep. *Kafkas Üniversitesi Vet. Fakültesi Derg.* 24, 17–23.
- Henthorn, C.R., Chris Minion, F., Sahin, O., 2018. Utilization of macrophage extracellular trap nucleotides by *Mycoplasma hyopneumoniae*. *Microbiology* 164, 1394–1404. <https://doi.org/10.1099/mic.0.000717>
- Hermeyer, K., Buchenau, I., Thomasmeyer, A., Baum, B., Spergser, J., Rosengarten, R., Hewicker-Trautwein, M., 2012. Chronic pneumonia in calves after experimental infection with *Mycoplasma bovis* strain 1067: characterization of lung pathology, persistence of variable surface protein antigens and local immune response. *Acta Vet. Scand.* 54.
- Hermeyer, Kathrin, Peters, M., Brüggmann, M., Jacobsen, B., Hewicker-Trautwein, M., 2012. Demonstration of *Mycoplasma bovis* by immunohistochemistry and in situ hybridization in an aborted bovine fetus and neonatal calf. *J. Vet. Diagn. Invest.* 24, 364–369. <https://doi.org/10.1177/1040638711435145>
- Hernandez, L., Lopez, J., St-Jacques, M., Ontiveros, L., Acosta, J., Handel, K., 2006. *Mycoplasma mycoides* subsp. *capri* associated with goat respiratory disease and high flock mortality. *Can. Vet. J.* 47, 366–369.
- Hernandez-Garcia, J., Robben, N., Magnée, D., Eley, T., Dennis, I., Kayes, S.M., Thomson, J.R., Tucker, A.W., 2017. The use of oral fluids to monitor key pathogens in porcine respiratory disease complex. *Porc. Health Manag.* 3, 7. <https://doi.org/10.1186/s40813-017-0055-4>
- Herndon, D.R., Beckmen, K.B., Highland, M.A., 2021. Draft Genome Sequence of a Novel *Mycoplasma* Species Identified from the Respiratory Tract of an Alaska Moose (*Alces alces gigas*). *Microbiol. Resour. Announc.* 10, e01371-20. <https://doi.org/10.1128/MRA.01371-20>

- Heuvelink, A., Reugebrink, C., Mars, J., 2016. Antimicrobial susceptibility of *Mycoplasma bovis* isolates from veal calves and dairy cattle in the Netherlands. *Vet. Microbiol.* 189, 1–7. <https://doi.org/10.1016/j.vetmic.2016.04.012>
- Higa, Y., Uemura, R., Yamazaki, W., Goto, S., Goto, Y., Sueyoshi, M., 2016. An improved loop-mediated isothermal amplification assay for the detection of *Mycoplasma bovis*. *J. Vet. Med. Sci.* 78, 1343–1346. <https://doi.org/10.1292/jvms.15-0459>
- Highland, M.A., Herndon, D.R., Bender, S.C., Hansen, L., Gerlach, R.F., Beckmen, K.B., 2018. *Mycoplasma ovipneumoniae* in Wildlife Species beyond Subfamily *Caprinae*. *Emerg. Infect. Dis.* 24, 2384–2386. <https://doi.org/10.3201/eid2412.180632>
- Hoist, S., Yeske, P., Pieters, M., 2015. Elimination of *Mycoplasma hyopneumoniae* from breed-to-wean farms: a review of current protocols with emphasis on herd closure and medication. *J. Swine Health Prod.* 23, 321–330.
- Hornok, S., Sugár, L., Fernández de Mera, I.G., de la Fuente, J., Horváth, G., Kovács, T., Micsutka, A., Gönczi, E., Flaisz, B., Takács, N., Farkas, R., Meli, M.L., Hofmann-Lehmann, R., 2018. Tick- and fly-borne bacteria in ungulates: the prevalence of *Anaplasma phagocytophilum*, haemoplasmas and rickettsiae in water buffalo and deer species in Central Europe, Hungary. *BMC Vet. Res.* 14, 98. <https://doi.org/10.1186/s12917-018-1403-6>
- Horsington, J., Witvliet, M., Jacobs, A.A.C., Segers, R.P.A.M., 2021. Efficacy of Simultaneous Intradermal Vaccination of Swine against Porcine Circovirus 2, Porcine Reproductive and Respiratory Syndrome Virus, *Mycoplasma hyopneumoniae* and *Lawsonia intracellularis*. *Animals* 11, 2225. <https://doi.org/10.3390/ani11082225>
- Howson, E.L.A., Kurosaki, Y., Yasuda, J., Takahashi, M., Goto, H., Gray, A.R., Mioulet, V., King, D.P., Fowler, V.L., 2017. Defining the relative performance of isothermal assays that can be used for rapid and sensitive detection of foot-and-mouth disease virus. *J. Virol. Methods* 249, 102–110. <https://doi.org/10.1016/j.jviromet.2017.08.013>
- Hu, F., Luo, R., Duan, S., Guo, Q., Wang, L., Jiang, G., Fan, C., Zou, M., Wang, T., Wang, Y., Sun, Y., Peng, X., 2022. Evaluation of Glycyrrhizic Acid Therapeutic Effect and Safety in *Mycoplasma gallisepticum* (HS Strain)-Infected Arbor Acres Broilers. *Animals* 12, 1285. <https://doi.org/10.3390/ani12101285>
- Hu, W., Zhang, W., Shah, S.W.A., Ishfaq, M., Li, J., 2021. *Mycoplasma gallisepticum* infection triggered histopathological changes, oxidative stress and apoptosis in chicken thymus and spleen. *Dev. Comp. Immunol.* 114, 103832. <https://doi.org/10.1016/j.dci.2020.103832>
- Huan, C., Fan, M., Cheng, Q., Wang, X., Gao, Q., Wang, W., Gao, S., Liu, X., 2018. Evaluation of the Efficacy and Cross-Protective Immunity of Live-Attenuated Chimeric PCV1-2b Vaccine Against PCV2b and PCV2d Subtype Challenge in Pigs. *Front. Microbiol.* 9.
- Huang, Y., Zheng, Q., Niu, J., Tang, J., Wang, B., Abarike, E.D., Lu, Y., Cai, J., Jian, J., 2018. NK-lysin from *Oreochromis niloticus* improves antimicrobial defence against bacterial pathogens. *Fish Shellfish Immunol.* 72, 259–265. <https://doi.org/10.1016/j.fsi.2017.11.002>
- Hübschle, O.J.B., Tjipura-Zaire, G., Abusugra, I., di Francesca, G., Mettler, F., Pini, A., Morein, B., 2003. Experimental field trial with an immunostimulating complex (ISCOM) vaccine against contagious bovine pleuropneumonia. *J. Vet. Med. B Infect. Dis. Vet. Public Health* 50, 298–303. <https://doi.org/10.1046/j.1439-0450.2003.00659.x>
- Hurri, E., Ohlson, A., Lundberg, Å., Aspán, A., Pedersen, K., Tråvén, M., 2022. Herd-level prevalence of *Mycoplasma bovis* in Swedish dairy herds determined by antibody ELISA and PCR on bulk tank milk and herd characteristics associated with seropositivity. *J. Dairy Sci.* 105, 7764–7772. <https://doi.org/10.3168/jds.2021-21390>
- Hussain, M.H., Asi, M.N., Al-Uahmadi, S.S.R., Al-Subhi, A.H.A., Al-Senaidi, N.Y.A., Al-Subhi, R.S.N., Al-Beloushi, M.K.I., Al-Sinani, F.S.S., Al-Riyami, B.S.T., Mansoor, M.K., Saqib, M., El-Tahir, H.A., Al-Makhladi, S.S., Al-Rawahi, A.H., Al-Maawali, M.G., 2021. Seroprevalence and Associated Risk Factors of Contagious Caprine Pleuropneumonia in the Small Ruminants of Oman. *Pak. Vet. J.* 41, 45–50. <https://doi.org/10.29261/pakvetj/2020.086>

- Hutton, S., Bettridge, J., Christley, R., Habte, T., Ganapathy, K., 2017. Detection of infectious bronchitis virus 793B, avian metapneumovirus, *Mycoplasma gallisepticum* and *Mycoplasma synoviae* in poultry in Ethiopia. *Trop. Anim. Health Prod.* 49, 317–322. <https://doi.org/10.1007/s11250-016-1195-2>
- Ibrahim, N.A., El-Beskawy, M.A., Dina Elshafay, Y., Abd-Elmoaty, A.M., Elnaker, Y.F., 2018. *Mycoplasma ovipneumoniae*: isolation and molecular identification in diseased sheep flock in delta region, Egypt. *Assiut Vet. Med. J.* 64, 70–76.
- Igbokwe, I.O., Maduka, C.V., 2018. Disease burden affecting pig production in Nigeria: review of current issues and challenges. *Rev. D'Élevage Médecine Vét. Pays Trop.* 71, 87–95.
- Iles, R.A., Choi, Y., Kagundu, S., Gatumu, H., 2022. Estimating willingness-to-pay for a livestock vaccine among the marginalized: The role of reflective thought in discrete choice experiments. *Prev. Vet. Med.* 201, 105592. <https://doi.org/10.1016/j.prevetmed.2022.105592>
- Iles, R.A., Gatumu, H., Kagundu, S., Draheim, C., 2019. Information sharing and willingness-to-pay for CBPP vaccine in rural Kenya. *Vaccine* 37, 1659–1666. <https://doi.org/10.1016/j.vaccine.2019.01.072>
- Indikova, I., Vronka, M., Szostak, M.P., 2014. First identification of proteins involved in motility of *Mycoplasma gallisepticum*. *Vet. Res.* 45, 1–14. <https://doi.org/10.1186/s13567-014-0099-2>
- Ipoutcha, T., Rideau, F., Gourgues, G., Arfi, Y., Lartigue, C., Blanchard, A., Sirand-Pugnet, P., 2022. Genome Editing of Veterinary Relevant Mycoplasmas Using a CRISPR-Cas Base Editor System. *Appl. Environ. Microbiol.* 88, e00996-22. <https://doi.org/10.1128/aem.00996-22>
- Ishag, H.Z.A., Liu, M.J., Yang, R.S., Xiong, Q.Y., Feng, Z.X., Shao, G.Q., 2016a. A replicating plasmid-based vector for GFP expression in *Mycoplasma hyopneumoniae*. *Genet. Mol. Res.* 15.
- Ishag, H.Z.A., MaoJun, L., RuoSong, Y., QiYan, X., ZhiXin, F., GuoQing, S., 2016b. GFP as a marker for transient gene transfer and expression in *Mycoplasma hyorhinis*. *SpringerPlus* 5.
- Ishag, H.Z.A., Xiong, Q., Liu, M., Feng, Z., Shao, G., 2017. Development of oriC-plasmids for use in *Mycoplasma hyorhinis*. *Sci. Rep.* 7, 10596. <https://doi.org/10.1038/s41598-017-10519-3>
- Ishfaq, M., ChunLi, C., JiaXin, B., Wei, Z., ZhiYong, W., Jian, W., YuHao, L., ErJie, T., Hamid, S., Rui, L., LiangJun, D., JiChang, L., 2019. Baicalin ameliorates oxidative stress and apoptosis by restoring mitochondrial dynamics in the spleen of chickens via the opposite modulation of NF-κB and Nrf2/HO-1 signaling pathway during *Mycoplasma gallisepticum* infection. *Poult. Sci.* 98, 6296–6310.
- Ishfaq, M., Hu, W., Khan, M.Z., Ahmad, I., Guo, W., Li, J., 2020a. Current status of vaccine research, development, and challenges of vaccines for *Mycoplasma gallisepticum*. *Poult. Sci.* 99, 4195–4202. <https://doi.org/10.1016/j.psj.2020.06.014>
- Ishfaq, M., Wu, Z., Wang, J., Li, R., Chen, C., Li, J., 2021a. Baicalin alleviates *Mycoplasma gallisepticum*-induced oxidative stress and inflammation via modulating NLRP3 inflammasome-autophagy pathway. *Int. Immunopharmacol.* 101, 108250. <https://doi.org/10.1016/j.intimp.2021.108250>
- Ishfaq, M., Zhang, W., Ali Shah, S.W., Wu, Z., Wang, J., Ding, L., Li, J., 2020b. The effect of *Mycoplasma gallisepticum* infection on energy metabolism in chicken lungs: Through oxidative stress and inflammation. *Microb. Pathog.* 138, 103848. <https://doi.org/10.1016/j.micpath.2019.103848>
- Ishfaq, M., Zhang, W., Liu, Y., Wang, J., Wu, Z., Shah, S.W., Li, R., Miao, Y., Chen, C., Li, J., 2021b. Baicalin attenuated *Mycoplasma gallisepticum* -induced immune impairment in chicken bursa of fabricius through modulation of autophagy and inhibited inflammation and apoptosis. *J. Sci. Food Agric.* 101, 880–890. <https://doi.org/10.1002/jsfa.10695>
- Itoh, M., Hirano, Y., Yamakawa, K., Yasutomi, I., Kuramoto, K., Furuoka, M., Yamada, K., 2020. Combination of procedure for ultra rapid extraction (PURE) and loop-mediated isothermal amplification (LAMP) for rapid detection of *Mycoplasma bovis* in milk. *J. Vet. Med. Sci.* 82, 875–880. <https://doi.org/10.1292/jvms.19-0695>

- Jafari, A.M., Bazargani, T.T., Heravi, H.A., Torabi, M., 2015. A survey on the efficacy of tulathromycin in the treatment of infectious pneumonia of small ruminants in Iran. *Iran. J. Vet. Sci. Technol.* 7, 28–35.
- Jamilu, R.Y., Bawa, J.A., Sanusi, J., Bakari, N.A., 2015. A field survey on the assessment of awareness about Contagious Bovine Pleuropneumonia (CBPP) in rural pastoral communities of Dutsinma region, Katsina state, Nigeria. *Sci. J. Vet. Adv.* 4, 1–12.
- Jamilu, R.Y., Kabir, J., Salisu, U.S., 2018. Seroepidemiology of contagious bovine pleuropneumonia (CBPP) in Katsina State, Nigeria. *Bull. Anim. Health Prod. Afr.* 66, 79–83.
- Jarad, A., Alsaad, K.M., 2016. Clinical, hematological and diagnostic studies of *Mycoplasma wenyonii* infection in cattle of Basrah Governorate Basrah, Iraq. *Basrah J. Vet. Res.* 15, 37–53.
- Jarocki, V.M., Raymond, B.B.A., Tacchi, J.L., Padula, M.P., Djordjevic, S.P., 2019a. *Mycoplasma hyopneumoniae* surface-associated proteases cleave bradykinin, substance P, neurokinin A and neuropeptide Y. *Sci. Rep.* 9, 14585. <https://doi.org/10.1038/s41598-019-51116-w>
- Jarocki, V.M., Santos, J., Tacchi, J.L., Raymond, B.B.A., Deutscher, A.T., Jenkins, C., Padula, M.P., Djordjevic, S.P., 2015. MHJ_0461 is a multifunctional leucine aminopeptidase on the surface of *Mycoplasma hyopneumoniae*. *Open Biol.* 5, 140175. <https://doi.org/10.1098/rsob.140175>
- Jarocki, V.M., Steele, J.R., Widjaja, M., Tacchi, J.L., Padula, M.P., Djordjevic, S.P., 2019b. Formylated N-terminal methionine is absent from the *Mycoplasma hyopneumoniae* proteome: Implications for translation initiation. *Int. J. Med. Microbiol.* 309, 288–298. <https://doi.org/10.1016/j.ijmm.2019.03.005>
- Jaÿ, M., Ambroset, C., Tricot, A., Colin, A., Tardy, F., 2020. Population structure and antimicrobial susceptibility of *Mycoplasma ovipneumoniae* isolates in France. *Vet. Microbiol.* 248, 108828. <https://doi.org/10.1016/j.vetmic.2020.108828>
- Jaÿ, M., Poumarat, F., Colin, A., Tricot, A., Tardy, F., 2021. Addressing the Antimicrobial Resistance of Ruminant *Mycoplasmas* Using a Clinical Surveillance Network. *Front. Vet. Sci.* 8, 667175. <https://doi.org/10.3389/fvets.2021.667175>
- Jaÿ, M., Tardy, F., 2019. Contagious Agalactia In Sheep And Goats: Current Perspectives. *Vet. Med. Res. Rep.* 10, 229–247. <https://doi.org/10.2147/VMRR.S201847>
- Jaye, C., Noller, G., Bryan, M., Doolan-Noble, F., 2022. ‘The day I killed my cows was the day I walked away’: *Mycoplasma bovis*, moral economy and moral capital. *J. Rural Stud.* 95, 86–94. <https://doi.org/10.1016/j.jrurstud.2022.08.001>
- Jelinski, M., Kinnear, A., Gesy, K., Andrés-Lasheras, S., Zaheer, R., Weese, S., McAllister, T.A., 2020. Antimicrobial Sensitivity Testing of *Mycoplasma bovis* Isolates Derived from Western Canadian Feedlot Cattle. *Microorganisms* 8, 124. <https://doi.org/10.3390/microorganisms8010124>
- Jenke, C., Lindstedt, B.A., Harmsen, D., Karch, H., Brandal, L.T., Mellmann, A., 2011. Comparison of Multilocus Variable-Number Tandem-Repeat Analysis and Multilocus Sequence Typing for Differentiation of Hemolytic-Uremic Syndrome-Associated *Escherichia coli* (HUSEC) Collection Strains. *J. Clin. Microbiol.* 49, 3644–3646. <https://doi.org/10.1128/JCM.05035-11>
- Jennings-Gaines, J.E., Edwards, W.H., Wood, M.E., Fox, K.A., Wolfe, L.L., Miller, M.W., Killion, H.J., 2016. An Improved Method for Culturing *Mycoplasma ovipneumoniae* from Field Samples, in: *Proceedings of the 20th Biennial Symposium of the Northern Wild Sheep and Goat Council.* Moscow, Idaho and Pullman, Washington, USA, pp. 83–88.
- Jenvey, C.J., Reichel, M.P., Cockcroft, P.D., 2015. *Erysipelothrix rhusiopathiae* and *Mycoplasma hyopneumoniae*: The sensitivities of enzyme-linked immunosorbent assays for detecting vaccinated sows of unknown disease status using serum and colostrum, and the correlation of the results for sow serum, colostrum, and piglet serum. *J. Vet. Diagn. Invest.* 27, 211–216. <https://doi.org/10.1177/1040638714568111>
- Jeon, E.-O., Kim, J.-N., Lee, H.-R., Koo, B.-S., Min, K.-C., Han, M.-S., Lee, S.-B., Bae, Y.-J., Mo, J.-S., Cho, S.-H., Lee, C.-H., Mo, I.-P., 2014. Eggshell apex abnormalities associated with *Mycoplasma*

- synoviae infection in layers. *J. Vet. Sci.* 15, 579–582. <https://doi.org/10.4142/jvs.2014.15.4.579>
- Jiang, Z., Song, F., Li, Y., Xue, D., Deng, G., Li, M., Liu, X., Wang, Y., 2017. Capsular Polysaccharide is a Main Component of *Mycoplasma ovipneumoniae* in the Pathogen-Induced Toll-Like Receptor-Mediated Inflammatory Responses in Sheep Airway Epithelial Cells. *Mediators Inflamm.* 2017, 1–15. <https://doi.org/10.1155/2017/9891673>
- Jibril, Y., Asfaw, Y., Gebregziabher, B., Issa, A., 2018. Seroprevalence of *Mycoplasma gallisepticum* in domestic chickens, East Shewa, Ethiopia. *Ethiop. Vet. J.* 22, 74. <https://doi.org/10.4314/evj.v22i1.6>
- JiChang, L., ZuJian, Q., WanYing, H., Wei, Z., Shah, S.W.A., Ishfaq, M., 2019. Baicalin mitigated *Mycoplasma gallisepticum*-induced structural damage and attenuated oxidative stress and apoptosis in chicken thymus through the Nrf2/HO-1 defence pathway. *Vet. Res.* 50.
- Jimbo, S., Suleman, M., Maina, T., Prysliak, T., Mulongo, M., Perez-Casal, J., 2017. Effect of *Mycoplasma bovis* on bovine neutrophils. *Vet. Immunol. Immunopathol.* 188, 27–33. <https://doi.org/10.1016/j.vetimm.2017.04.011>
- JiSung, J., KiJu, K., SoYeon, P., BoKyoung, P., HyungMin, U., Coulier, M., TaeWook, H., 2016. In vitro antibiotic susceptibility of field isolates of *Mycoplasma hyopneumoniae* and *Mycoplasma hyorhinis* from Korea. *Korean J. Vet. Res.* 56, 109–111.
- Johnson, B.M., Stroud-Settles, J., Roug, A., Manlove, K., 2022. Disease Ecology of a Low-Virulence *Mycoplasma ovipneumoniae* Strain in a Free-Ranging Desert Bighorn Sheep Population. *Animals* 12, 1029. <https://doi.org/10.3390/ani12081029>
- Johnson, M., MacGlover, C., Peckham, E., Killion, H., Allen, S.E., Creekmore, T., Edwards, W.H., Blaeser, M., Davison, M., Schwalbe, E., Wray, A.K., Bragg, T.K., Sondgeroth, K.S., Malmberg, J.L., 2022. Source and seasonality of epizootic mycoplasmosis in free-ranging pronghorn (*Antilocapra americana*). *J. Wildl. Dis.* 58. <https://doi.org/10.7589/JWD-D-21-00117>
- Johnson, T., Jones, K., Jacobson, B.T., Scheerer, J., Adams, N., Thornton, I., Mosdal, C., Jones, S., Jutila, M., Rynda-Apple, A., Besser, T., Bimczok, D., 2022. Experimental infection of specific-pathogen-free domestic lambs with *Mycoplasma ovipneumoniae* causes asymptomatic colonization of the upper airways that is resistant to antibiotic treatment. *Vet. Microbiol.* 265, 109334. <https://doi.org/10.1016/j.vetmic.2022.109334>
- Jordan, A.B., Bolfa, P., Marchi, S., Hemmings, S., Major, T., Suepaul, R., Blake, L., Oura, C., 2018. Detection of Antibodies to Seven Priority Pathogens in Backyard Poultry in Trinidad, West Indies. *Vet. Sci.* 5, 11. <https://doi.org/10.3390/vetsci5010011>
- Jordan, A.G., Sadler, R.J., Sawford, K., van Andel, M., Ward, M., Cowled, B.D., 2021. *Mycoplasma bovis* outbreak in New Zealand cattle: An assessment of transmission trends using surveillance data. *Transbound. Emerg. Dis.* 68, 3381–3395. <https://doi.org/10.1111/tbed.13941>
- Jores, J., Baldwin, C., Blanchard, A., Browning, G.F., Colston, A., Gerdts, V., Goovaerts, D., Heller, M., Juleff, N., Labroussaa, F., Liljander, A., Muuka, G., Nene, V., Nir-Paz, R., Sacchini, F., Summerfield, A., Thiaucourt, F., Unger, H., Vashee, S., Wang, X., Salt, J., 2020. Contagious Bovine and Caprine Pleuropneumonia: a research community's recommendations for the development of better vaccines. *Npj Vaccines* 5, 1–9. <https://doi.org/10.1038/s41541-020-00214-2>
- Jores, J., Ma, L., Ssajjakambwe, P., Schieck, E., Liljander, A., Chandran, S., Stoffel, M.H., Cippa, V., Arfi, Y., Assad-Garcia, N., Falquet, L., Sirand-Pugnet, P., Blanchard, A., Lartigue, C., Posthaus, H., Labroussaa, F., Vashee, S., 2019a. Removal of a Subset of Non-essential Genes Fully Attenuates a Highly Virulent *Mycoplasma* Strain. *Front. Microbiol.* 10, 664. <https://doi.org/10.3389/fmicb.2019.00664>
- Jores, J., Mariner, J.C., Naessens, J., 2013. Development of an improved vaccine for contagious bovine pleuropneumonia: an African perspective on challenges and proposed actions. *Vet. Res.* 44.
- Jores, J., Meens, J., Buettner, F.F.R., Linz, B., Naessens, J., Gerlach, G.F., 2009. Analysis of the immunoproteome of *Mycoplasma mycoides* subsp. *mycoides* small colony type reveals

- immunogenic homologues to other known virulence traits in related *Mycoplasma* species. *Vet. Immunol. Immunopathol.* 131, 238–245. <https://doi.org/10.1016/j.vetimm.2009.04.016>
- Jores, J., Nkando, I., Sterner-Kock, A., Haider, W., Poole, J., Unger, H., Muriuki, C., Wesonga, H., Taracha, E.L.N., 2008. Assessment of in vitro interferon-gamma responses from peripheral blood mononuclear cells of cattle infected with *Mycoplasma mycoides* ssp. *mycoides* small colony type. *Vet. Immunol. Immunopathol.* 124, 192–197. <https://doi.org/10.1016/j.vetimm.2008.02.019>
- Jores, J., Schieck, E., Liljander, A., Sacchini, F., Posthaus, H., Lartigue, C., Blanchard, A., Labroussaa, F., Vashee, S., 2019b. In vivo role of capsular polysaccharide in *Mycoplasma mycoides*. *J. Infect. Dis.* 219, 1559–1563. <https://doi.org/10.1093/infdis/jiy713>
- Josi, C., Bürki, S., Stojiljkovic, A., Wellnitz, O., Stoffel, M.H., Pilo, P., 2018. Bovine Epithelial in vitro Infection Models for *Mycoplasma bovis*. *Front. Cell. Infect. Microbiol.* 8.
- Josi, C., Bürki, S., Vidal, S., Dordet-Frisoni, E., Citti, C., Falquet, L., Pilo, P., 2019. Large-scale analysis of the *Mycoplasma bovis* genome identified non-essential, adhesion- and virulence-related genes. *Front. Microbiol.* 10.
- JungAh, L., YuRi, O., Hwang, M.A., JoongBok, L., SeungYong, P., ChangSeon, S., InSoo, C., SangWon, L., 2016. *Mycoplasma hyorhinis* is a potential pathogen of porcine respiratory disease complex that aggravates pneumonia caused by porcine reproductive and respiratory syndrome virus. *Vet. Immunol. Immunopathol.* 177, 48–51.
- Jungi, T.W., Krampe, M., Sileghem, M., Griot, C., Nicolet, J., 1996. Differential and strain-specific triggering of bovine alveolar macrophage effector functions by mycoplasmas. *Microb. Pathog.* 21, 487–498. <https://doi.org/10.1006/mpat.1996.0078>
- Junqueira, N.B., Salina, A., Oliveira, G.C., Mettifogo, E., Joaquim, S.F., Guimarães, F.F., Dalanezi, F.M., Langoni, H., 2020. Detection of clinical bovine mastitis caused by *Mycoplasma bovis* in Brazil. *J. Dairy Res.* 87, 306–308. <https://doi.org/10.1017/S0022029920000205>
- Justice-Allen, A., Trujillo, J., Corbett, R., Harding, R., Goodell, G., Wilson, D., 2010. Survival and replication of *Mycoplasma* species in recycled bedding sand and association with mastitis on dairy farms in Utah. *J. Dairy Sci.* 93, 192–202. <https://doi.org/10.3168/jds.2009-2474>
- Kaalberg, L., Geurts, V., Jolie, R., 2017. A field efficacy and safety trial in the Netherlands in pigs vaccinated at 3 weeks of age with a ready-to-use porcine circovirus type 2 and *Mycoplasma hyopneumoniae* combined vaccine. *Porc. Health Manag.* 3, 23. <https://doi.org/10.1186/s40813-017-0070-5>
- Käbisch, L., Schink, A.-K., Hanke, D., Semmler, T., Kehrenberg, C., Schwarz, S., 2021. Whole-Genome Sequence of the *Mycoplasma* (Mesomycoplasma) *hyorhinis* DSM 25591 Type Strain. *Microbiol. Resour. Announc.* 10, e00164-21. <https://doi.org/10.1128/MRA.00164-21>
- Käbisch, L., Schink, A.-K., Höltig, D., Sperser, J., Kehrenberg, C., Schwarz, S., 2023. Towards a Standardized Antimicrobial Susceptibility Testing Method for *Mycoplasma hyorhinis*. *Microorganisms* 11, 994. <https://doi.org/10.3390/microorganisms11040994>
- Kaboudi, K., Jbenyeni, A., 2019. *Mycoplasma synoviae* infection in layers: diagnosis and control measures – a review. *Arch. Vet. Med.* 12, 63–82. <https://doi.org/10.46784/e-avm.v12i2.63>
- Kacar, Y., Batmaz, H., Yilmaz, O.E., Mecitoglu, Z., 2018. Comparing clinical effects of marbofloxacin and gamithromycin in goat kids with pneumonia. *J. S. Afr. Vet. Assoc.* 89. <https://doi.org/10.4102/jsava.v89i0.1558>
- Kadowaki, H., Suzuki, E., Kojima-Shibata, C., Suzuki, K., Okamura, T., Onodera, W., Shibata, T., Kano, H., 2012. Selection for resistance to swine mycoplasmal pneumonia over 5 generations in Landrace pigs. *Livest. Sci.* 147, 20–26. <https://doi.org/10.1016/j.livsci.2012.03.014>
- Kairu-Wanyoike, S.W., Kaitibie, S., Taylor, N.M., Gitau, G.K., Heffernan, C., Schnier, C., Kiara, H., Taracha, E., McKeever, D., 2013. Exploring farmer preferences for contagious bovine pleuropneumonia vaccination: A case study of Narok District of Kenya. *Prev. Vet. Med.* 110, 356–369. <https://doi.org/10.1016/j.prevetmed.2013.02.013>

- Kairu-Wanyoike, S.W., Kiara, H., Heffernan, C., Kaitibie, S., Gitau, G.K., McKeever, D., Taylor, N.M., 2014. Control of contagious bovine pleuropneumonia: Knowledge, attitudes, perceptions and practices in Narok district of Kenya. *Prev. Vet. Med.* 115, 143–156. <https://doi.org/10.1016/j.prevetmed.2014.03.029>
- Kairu-Wanyoike, S.W., Taylor, N.M., Heffernan, C., Kiara, H., 2017. Micro-economic analysis of the potential impact of contagious bovine pleuropneumonia and its control by vaccination in Narok district of Kenya. *Livest. Sci.* 197, 61–72. <https://doi.org/10.1016/j.livsci.2017.01.002>
- Kalmegh, A.N., Anbazhagan, S., Rana, R., Dubal, Z.B., Chaudhuri, P., 2020. Antimicrobial susceptibility profiles of *Mycoplasma mycoides* subsp. *capri* field isolates from goats in India. *Indian J. Anim. Sci.* 90, 1123–1125.
- Kaluwa, C., Oduma, J., Abdirahman, F.A., Kitoga, B.K., Opondoh, A.A., Muchibi, J., Bagnol, B., Rosenbaum, M., Onchaga, S., Stanley, M., Amuguni, J.H., 2022. Using the Women Empowerment in Livestock Index (WELI) to Examine Linkages between Women Smallholder Livestock Farmers' Empowerment and Access to Livestock Vaccines in Machakos County of Kenya: Insights and Critiques. *Vaccines* 10, 1868. <https://doi.org/10.3390/vaccines10111868>
- Kama-Kama, F., Midiwo, J., Nganga, J., Maina, N., Schiek, E., Omosa, L.K., Osanjo, G., Naessens, J., 2016. Selected ethno-medicinal plants from Kenya with in vitro activity against major African livestock pathogens belonging to the “*Mycoplasma mycoides* cluster”. *J. Ethnopharmacol.* 192, 524–534.
- Kama-Kama, F., Omosa, L.K., Nganga, J., Maina, N., Osanjo, G., Yaouba, S., Ilias, M., Midiwo, J., Naessens, J., 2017. Antimycoplasmal Activities of Compounds from *Solanum aculeastrum* and *Piliostigma thonningii* against Strains from the *Mycoplasma mycoides* Cluster. *Front. Pharmacol.* 8, 920. <https://doi.org/10.3389/fphar.2017.00920>
- Kamath, P.L., Manlove, K., Cassirer, E.F., Cross, P.C., Besser, T.E., 2019. Genetic structure of *Mycoplasma ovipneumoniae* informs pathogen spillover dynamics between domestic and wild caprinae in the western United States. *Sci. Rep.* 9.
- Kammaing, T., Benis, N., Martins dos Santos, V., Bijlsma, J.J.E., Schaap, P.J., 2020. Combined Transcriptome Sequencing of *Mycoplasma hyopneumoniae* and Infected Pig Lung Tissue Reveals Up-Regulation of Bacterial F1-Like ATPase and Down-Regulation of the P102 Cilium Adhesin in vivo. *Front. Microbiol.* 11, 1679. <https://doi.org/10.3389/fmicb.2020.01679>
- Kanci, A., Browning, G.F., Geary, S.J., Papazisi, L., Gorton, T.S., Markham, P.F., 2004. Is an unstable repeat sequence responsible for the attenuation of the *Mycoplasma gallisepticum* vaccine strain ts-11? Presented at the 15th Congress of the International Organization for Mycoplasmaology, Athens, GA, USA, p. 118.
- Kanci, A., Wawegama, N.K., Marendia, M.S., Mansell, P.D., Browning, G.F., Markham, P.F., 2017. Reproduction of respiratory mycoplasmosis in calves by exposure to an aerosolised culture of *Mycoplasma bovis*. *Vet. Microbiol.* 210, 167–173. <https://doi.org/10.1016/j.vetmic.2017.09.013>
- Kanci, A., Wijesurendra, D.S., Wawegama, N.K., Underwood, G.J., Noormohammadi, A.H., Markham, P.F., Browning, G.F., 2018. Evaluation of *Mycoplasma gallisepticum* (MG) ts-304 vaccine as a live attenuated vaccine in turkeys. *Vaccine* 36, 2487–2493. <https://doi.org/10.1016/j.vaccine.2018.02.117>
- Kanci Condello, A., Kulappu Arachchige, S.N., Shil, P.K., Underwood, G.J., Noormohammadi, A.H., Markham, P.F., Wawegama, N.K., Browning, G.F., 2020a. Duration of protective immunity induced by *Mycoplasma gallisepticum* strain ts-304 vaccine in chickens. *Vet. Microbiol.* 251, 108883. <https://doi.org/10.1016/j.vetmic.2020.108883>
- Kanci Condello, A., Underwood, G.J., Shil, P.K., Noormohammadi, A.H., Markham, P.F., Wawegama, N.K., Browning, G.F., 2020b. *Mycoplasma gallisepticum* strain ts-304 is a safe and effective live attenuated vaccine for use in chickens. *Vet. Microbiol.* 244, 108654. <https://doi.org/10.1016/j.vetmic.2020.108654>

- Kang, Z., Yun, H., YaBo, Z., YingFei, S., MengYun, Z., YaLi, F., XiuLi, P., 2019. Upregulated gga-miR-16-5p inhibits the proliferation cycle and promotes the apoptosis of MG-infected DF-1 cells by repressing PI3R1-mediated the PI3K/Akt/NF- κ B pathway to exert anti-inflammatory effect. *Int. J. Mol. Sci.* 20.
- Kaore, M., Singh, K.P., Palanivelu, M., Kumar, M.A., Reddy, M.R., Kurkure, N.V., 2018. Patho-epidemiology of respiratory disease complex pathogens (RDPs) in commercial chicken. *Indian J. Vet. Pathol.* 42, 231. <https://doi.org/10.5958/0973-970X.2018.00056.1>
- Kassaye, D., Molla, W., 2012. Seroprevalence of contagious bovine pleuropneumonia at export quarantine centers in and around Adama, Ethiopia. *Trop. Anim. Health Prod.* 45, 275–279. <https://doi.org/10.1007/s11250-012-0212-3>
- Kawai, K., Higuchi, H., Iwano, H., Iwakuma, A., Onda, K., Sato, R., Hayashi, T., Nagahata, H., Oshida, T., 2014. Antimicrobial susceptibilities of *Mycoplasma* isolated from bovine mastitis in Japan: Antimicrobial Susceptibility of *Mycoplasma*. *Anim. Sci. J.* 85, 96–99. <https://doi.org/10.1111/asj.12144>
- Kgotlele, T., Chota, A., Chubwa, C.C., Nyasebwa, O., Lyimo, B., Torsson, E., Karimuribo, E., Kasanga, C.J., Wensman, J.J., Misinzo, G., Shirima, G., Kusiluka, L., 2019. Detection of peste des petits ruminants and concurrent secondary diseases in sheep and goats in Ngorongoro district, Tanzania. *Comp. Clin. Pathol.* 28, 755–759. <https://doi.org/10.1007/s00580-018-2848-5>
- Khalifa, K.A., Sidahmed Abdelrahim, E., Badwi, M., Mohamed, A.M., 2013. Isolation and Molecular Characterization of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* in Chickens in Sudan. *J. Vet. Med.* 2013, 208026. <https://doi.org/10.1155/2013/208026>
- Khalil, D., Becker, C.A.M., Tardy, F., 2017. Monitoring the Decrease in Susceptibility to Ribosomal RNAs Targeting Antimicrobials and Its Molecular Basis in Clinical *Mycoplasma bovis* Isolates over Time. *Microb. Drug Resist.* 23, 799–811. <https://doi.org/10.1089/mdr.2016.0268>
- Khalil, D., Becker, C.A.M., Tardy, F., 2016. Alterations in the Quinolone Resistance-Determining Regions and Fluoroquinolone Resistance in Clinical Isolates and Laboratory-Derived Mutants of *Mycoplasma bovis*: Not All Genotypes May Be Equal. *Appl. Environ. Microbiol.* 82, 1060–1068. <https://doi.org/10.1128/AEM.03280-15>
- Khan, F.A., Faisal, M., Chao, J., Liu, K., Chen, X., Zhao, G., Menghwar, H., Zhang, H., Zhu, X., Rasheed, M.A., He, C., Hu, C., Chen, Y., Baranowski, E., Chen, H., Guo, A., 2016. Immunoproteomic identification of MbovP579, a promising diagnostic biomarker for serological detection of *Mycoplasma bovis* infection. *Oncotarget* 7, 39376–39395. <https://doi.org/10.18632/oncotarget.9799>
- Khatoon, H., Afzal, F., Tahir, M.F., Hussain, M., Khan, S.U., 2018. Prevalence of mycoplasmosis and antibiotic susceptibility of *Mycoplasma gallisepticum* in commercial chicken flocks of Rawalpindi division, Pakistan. *Pak. Vet. J.* 38, 446–448.
- Kim, S., Oh, T., Yang, S., Park, K., Cho, H., Chae, C., 2021. Field evaluation of a new single-dose *Mycoplasma hyopneumoniae* bacterin effects on growth performance. *J. Swine Health Prod.* 29, 180–188.
- Kinnear, A., McAllister, T.A., Zaheer, R., Waldner, M., Ruzzini, A.C., Andrés-Lasheras, S., Parker, S., Hill, J.E., Jelinski, M.D., 2020. Investigation of Macrolide Resistance Genotypes in *Mycoplasma bovis* Isolates from Canadian Feedlot Cattle. *Pathogens* 9, 622. <https://doi.org/10.3390/pathogens9080622>
- Kinnear, A., Waldner, M., McAllister, T.A., Zaheer, R., Register, K., Jelinski, M., 2021. Application of Four Genotyping Methods to *Mycoplasma bovis* Isolates Derived from Western Canadian Feedlot Cattle. *J. Clin. Microbiol.* 59, e00044-21. <https://doi.org/10.1128/JCM.00044-21>
- Kipronoh, A.K., Ombui, J.N., Kiara, H.K., Binopal, Y.S., Gitonga, E., Wesonga, H.O., 2016. Prevalence of contagious caprine pleuro-pneumonia in pastoral flocks of goats in the Rift Valley region of Kenya. *Trop. Anim. Health Prod.* 48, 151–155. <https://doi.org/10.1007/s11250-015-0934-0>

- Kipronoh, K.A., Ombui, J.N., Kiara, H.K., Binepal, Y.S., Wesonga, H.O., Gitonga, E.K., Bett, B., 2016. Contagious caprine pleuro-pneumonia, knowledge, attitudes and control practices among pastoralists in the Rift Valley region, Kenya. *Bull. Anim. Health Prod. Afr.* 64, 289–297.
- Klein, U., de Jong, A., Moyaert, H., El Garch, F., Leon, R., Richard-Mazet, A., Rose, M., Maes, D., Pridmore, A., Thomson, J.R., Ayling, R.D., 2017. Antimicrobial susceptibility monitoring of *Mycoplasma hyopneumoniae* and *Mycoplasma bovis* isolated in Europe. *Vet. Microbiol.* 204, 188–193. <https://doi.org/10.1016/j.vetmic.2017.04.012>
- Klein, U., de Jong, A., Youala, M., El Garch, F., Stevenin, C., Moyaert, H., Rose, M., Catania, S., Gyuranecz, M., Pridmore, A., Ayling, R.D., 2019. New antimicrobial susceptibility data from monitoring of *Mycoplasma bovis* isolated in Europe. *Vet. Microbiol.* 238, 108432. <https://doi.org/10.1016/j.vetmic.2019.108432>
- Klein, U., Földi, D., Belec, N., Hrivnák, V., Somogyi, Z., Gastaldelli, M., Merenda, M., Catania, S., Dors, A., Siesenop, U., Vyt, P., Kreizinger, Z., Depondt, W., Gyuranecz, M., 2022. Antimicrobial susceptibility profiles of *Mycoplasma hyorhinis* strains isolated from five European countries between 2019 and 2021. *PLOS ONE* 17, e0272903. <https://doi.org/10.1371/journal.pone.0272903>
- Klose, S.M., De Souza, D.P., Disint, J.F., Andrews, D.M., Underwood, G.J., Morrow, C.J., Marena, M.S., Noormohammadi, A.H., 2023. Reversion of mutations in a live mycoplasma vaccine alters its metabolism. *Vaccine* 41, 3358–3366. <https://doi.org/10.1016/j.vaccine.2023.04.045>
- Klose, S.M., Omotainse, O.S., Zare, S., Vaz, P.K., Armat, P., Shil, P., Wawegama, N., Kanci Condello, A., O'Rourke, D., Disint, J.F., Andrews, D.M., Underwood, G.J., Morrow, C.J., Marena, M.S., Noormohammadi, A.H., 2022a. Virulence factors of *Mycoplasma synoviae*: Three genes influencing colonization, immunogenicity, and transmissibility. *Front. Microbiol.* 13.
- Klose, S.M., Wawegama, N., Sansom, F.M., Marena, M.S., Browning, G.F., 2022b. Efficient disruption of the function of the *mnuA* nuclease gene using the endogenous CRISPR/Cas system in *Mycoplasma gallisepticum*. *Vet. Microbiol.* 269, 109436. <https://doi.org/10.1016/j.vetmic.2022.109436>
- Kobisch, M., Friis, N.F., 1996. Swine mycoplasmoses. *Rev. Sci. Tech. Int. Off. Epizoot.* 15, 1569–1605. <https://doi.org/10.20506/rst.15.4.983>
- Koczula, K.M., Gallotta, A., 2016. Lateral flow assays. *Essays Biochem.* 60, 111–120. <https://doi.org/10.1042/EBC20150012>
- Kong, L.-C., Gao, D., Jia, B.-Y., Wang, Z., Gao, Y.-H., Pei, Z.-H., Liu, S.-M., Xin, J.-Q., Ma, H.-X., 2016. Antimicrobial susceptibility and molecular characterization of macrolide resistance of *Mycoplasma bovis* isolates from multiple provinces in China. *J. Vet. Med. Sci.* 78, 293–296. <https://doi.org/10.1292/jvms.15-0304>
- Kordafshari, S., Marena, M.S., O'Rourke, D., Shil, P., Noormohammadi, A.H., 2019. Mutation of *oppF* gene in the *Mycoplasma synoviae* MS-H vaccine strain and its implication for differential serological responses to vaccination versus field challenge. *Vet. Microbiol.* 231, 48–55. <https://doi.org/10.1016/j.vetmic.2019.02.029>
- Kordafshari, S., Shil, P., Marena, M.S., Olaogun, O.M., Konsak-Ilievski, B., Disint, J., Noormohammadi, A.H., 2020. Preliminary comparative analysis of the genomes of selected field reisolates of the *Mycoplasma synoviae* vaccine strain MS-H reveals both stable and unstable mutations after passage in vivo. *BMC Genomics* 21, 598. <https://doi.org/10.1186/s12864-020-06995-z>
- Krasteva, I., Inglis, N.F., Sacchini, F., Nicholas, R., Ayling, R., Churchward, C.P., March, J., Lainson, A., Mclean, K., Hughes, V., Imrie, L., Manson, E., Clark, J., Pini, A., Smith, D.G.E., 2015. Proteomic characterisation of two strains of *Mycoplasma mycoides* subsp. *mycoides* of differing pathogenicity. *J. Proteomics Bioinform.* 8.
- Krasteva, I., Liljander, A., Fischer, A., Smith, D.G.E., Inglis, N.F., Scacchia, M., Pini, A., Jores, J., Sacchini, F., 2014. Characterization of the in vitro core surface proteome of *Mycoplasma mycoides* subsp. *mycoides*, the causative agent of contagious bovine pleuropneumonia. *Vet. Microbiol.* 168, 116–123. <https://doi.org/10.1016/j.vetmic.2013.10.025>

- Kreizinger, Z., Gróznér, D., Sulyok, K.M., Nilsson, K., Hrivnák, V., Benčina, D., Gyuranecz, M., 2017. Antibiotic susceptibility profiles of *Mycoplasma synoviae* strains originating from Central and Eastern Europe. *BMC Vet. Res.* 13, 342. <https://doi.org/10.1186/s12917-017-1266-2>
- Kreizinger, Z., Sulyok, K.M., Bekó, K., Kovács, Á.B., Gróznér, D., Felde, O., Marton, S., Bányai, K., Catania, S., Benčina, D., Gyuranecz, M., 2018. Genotyping *Mycoplasma synoviae*: Development of a multi-locus variable number of tandem-repeats analysis and comparison with current molecular typing methods. *Vet. Microbiol.* 226, 41–49. <https://doi.org/10.1016/j.vetmic.2018.10.012>
- Kreizinger, Z., Sulyok, K.M., Pásztor, A., Erdélyi, K., Felde, O., Povazsán, J., Kőrösi, L., Gyuranecz, M., 2015. Rapid, Simple and Cost-Effective Molecular Method to Differentiate the Temperature Sensitive (ts+) MS-H Vaccine Strain and Wild-Type *Mycoplasma synoviae* Isolates. *PLOS ONE* 10, e0133554. <https://doi.org/10.1371/journal.pone.0133554>
- Krishnegowda, D.N., Singh, B.R., Mariappan, A.K., Munuswamy, P., Singh, K.P., Monalisa sahuo, Saminathan, M., Ramalingam, R., Chellappa, M.M., Singh, V., Dhama, K., Reddy, M.R., 2022. Molecular epidemiological studies on avian pathogenic *Escherichia coli* associated with septicemia in chickens in India. *Microb. Pathog.* 162, 105313. <https://doi.org/10.1016/j.micpath.2021.105313>
- Kryszak, D.E., 2006. Chronic pneumonia and polyarthritis syndrome in a feedlot calf. *Can. Vet. J.* 47, 1019–1022.
- Krzysiak, M.K., Dudek, K., Krajewska, M., Bednarek, D., Szulowski, K., 2014. Serological studies to determine the occurrence of Johne's disease and mycoplasma infection in the Northern-East Polish population of European bison (*Bison bonasus*). *Pol. J. Vet. Sci.* 17, 721–723.
- Kudirkiene, E., Aagaard, A.K., Schmidt, L.M.B., Pansri, P., Krogh, K.M., Olsen, J.E., 2021. Occurrence of major and minor pathogens in calves diagnosed with bovine respiratory disease. *Vet. Microbiol.* 259, 109135. <https://doi.org/10.1016/j.vetmic.2021.109135>
- Kulappu Arachchige, S.N., Kanci Condello, A., Zhu, L., Shil, P.K., Tivendale, K.A., Underwood, G.J., Noormohammadi, A.H., Browning, G.F., Wawegama, N.K., 2021a. Effects of immunosuppression on the efficacy of vaccination against *Mycoplasma gallisepticum* infection in chickens. *Vet. Microbiol.* 260, 109182. <https://doi.org/10.1016/j.vetmic.2021.109182>
- Kulappu Arachchige, S.N., Wawegama, N.K., Coppo, M.J.C., Derseh, H.B., Vaz, P.K., Kanci Condello, A., Omotainse, O.S., Noormohammadi, A.H., Browning, G.F., 2021b. Mucosal immune responses in the trachea after chronic infection with *Mycoplasma gallisepticum* in unvaccinated and vaccinated mature chickens. *Cell. Microbiol.* 23. <https://doi.org/10.1111/cmi.13383>
- Kulappu Arachchige, S.N., Young, N.D., Shil, P.K., Legione, A.R., Kanci Condello, A., Browning, G.F., Wawegama, N.K., 2020. Differential Response of the Chicken Trachea to Chronic Infection with Virulent *Mycoplasma gallisepticum* Strain Ap3AS and Vaxsafe MG (Strain ts-304): a Transcriptional Profile. *Infect. Immun.* 88, e00053-20. <https://doi.org/10.1128/IAI.00053-20>
- Kumar, A., Rahal, A., Chakraborty, S., Verma, A.K., Dhama, K., 2014. *Mycoplasma agalactiae*, an Etiological Agent of Contagious Agalactia in Small Ruminants: A Review. *Vet. Med. Int.* 2014, 286752. <https://doi.org/10.1155/2014/286752>
- Kumar, A., Verma, A.K., Gangwar, N.K., Rahal, A., 2012. Isolation, Characterization and Antibiogram of *Mycoplasma bovis* in Sheep Pneumonia. *Asian J. Anim. Vet. Adv.* 7, 149–157. <https://doi.org/10.3923/ajava.2012.149.157>
- Kumar, R., Register, K., Christopher-Hennings, J., Moroni, P., Gioia, G., Garcia-Fernandez, N., Nelson, J., Jelinski, M.D., Lysnyansky, I., Bayles, D., Alt, D., Scaria, J., 2020. Population Genomic Analysis of *Mycoplasma bovis* Elucidates Geographical Variations and Genes associated with Host-Types. *Microorganisms* 8, 1561. <https://doi.org/10.3390/microorganisms8101561>
- Kumosani, T., Yaghmoor, S., Abdulaal, W.H., Barbour, E., 2020. Evaluation in broilers of aerosolized nanoparticles vaccine encapsulating imuno-stimulant and antigens of avian influenza

- virus/*Mycoplasma gallisepticum*. *BMC Vet. Res.* 16, 319. <https://doi.org/10.1186/s12917-020-02539-5>
- Kuo, H.-C., Lo, D.-Y., Chen, C.-L., Tsai, Y.-L., Ping, J.-F., Lee, C.-H., Lee, P.-Y.A., Chang, H.-F.G., 2017. Rapid and sensitive detection of *Mycoplasma synoviae* by an insulated isothermal polymerase chain reaction-based assay on a field-deployable device. *Poult. Sci.* 96, 35–41. <https://doi.org/10.3382/ps/pew228>
- Kureljušić, B., Weissenbacher-Lang, C., Nedorost, N., Stixenberger, D., Weissenböck, H., 2016. Association between *Pneumocystis* spp. and co-infections with *Bordetella bronchiseptica*, *Mycoplasma hyopneumoniae* and *Pasteurella multocida* in Austrian pigs with pneumonia. *Vet. J.* 207, 177–179.
- Kursa, O., Pakuła, A., Tomczyk, G., Paško, S., Sawicka, A., 2019a. Eggshell apex abnormalities caused by two different *Mycoplasma synoviae* genotypes and evaluation of eggshell anomalies by full-field optical coherence tomography. *BMC Vet. Res.* 15, 1. <https://doi.org/10.1186/s12917-018-1758-8>
- Kursa, O., Tomczyk, G., Sawicka, A., 2019b. Prevalence and phylogenetic analysis of *Mycoplasma synoviae* strains isolated from Polish chicken layer flocks. *J. Vet. Res.* 63, 41–49.
- Kursa, O., Tomczyk, G., Sawicka-Durkalec, A., Giza, A., Słomiany-Szwarc, M., 2021. Bacterial communities of the upper respiratory tract of turkeys. *Sci. Rep.* 11, 2544. <https://doi.org/10.1038/s41598-021-81984-0>
- Kursa, O., Woźniakowski, G., Tomczyk, G., Sawicka, A., Minta, Z., 2015. Rapid detection of *Mycoplasma synoviae* by loop-mediated isothermal amplification. *Arch. Microbiol.* 197, 319–325. <https://doi.org/10.1007/s00203-014-1063-2>
- Lachowicz-Wolak, A., Klimowicz-Bodys, M.D., Płoneczka-Janeczko, K., Bykowy, M., Siedlecka, M., Cinciała, J., Rypuła, K., 2022. The Prevalence, Coexistence, and Correlations between Seven Pathogens Detected by a PCR Method from South-Western Poland Dairy Cattle Suffering from Bovine Respiratory Disease. *Microorganisms* 10, 1487. <https://doi.org/10.3390/microorganisms10081487>
- Lai, J., Lin, H., Hsu, P., Gondaira, S., Higuchi, H., Nagahata, H., 2022. A novel polymerase chain reaction assay for the detection of seven *Mycoplasma* species of cattle origin. *World J. Microbiol. Biotechnol.* 38, 128. <https://doi.org/10.1007/s11274-022-03312-6>
- Landman, W.J.M., 2014. Is *Mycoplasma synoviae* outrunning *Mycoplasma gallisepticum*? A viewpoint from the Netherlands. *Avian Pathol. J. WVPA* 43, 2–8. <https://doi.org/10.1080/03079457.2014.881049>
- Lartigue, C., Vashee, S., Algire, M.A., Chuang, R.-Y., Benders, G.A., Ma, L., Noskov, V.N., Denisova, E.A., Gibson, D.G., Assad-Garcia, N., Alperovich, N., Thomas, D.W., Merryman, C., Hutchison, C.A., Smith, H.O., Venter, J.C., Glass, J.I., 2009. Creating bacterial strains from genomes that have been cloned and engineered in yeast. *Science* 325, 1693–1696. <https://doi.org/10.1126/science.1173759>
- Lauritsen, K.T., Hagedorn-Olsen, T., Jungersen, G., Riber, U., Stryhn, H., Friis, N.F., Lind, P., Kristensen, B., 2017. Transfer of maternal immunity to piglets is involved in early protection against *Mycoplasma hyosynoviae* infection. *Vet. Immunol. Immunopathol.* 183, 22–30. <https://doi.org/10.1016/j.vetimm.2016.12.002>
- Laven, R., 2019. *Mycoplasma bovis* in New Zealand: where have we been and where are we going? *Livestock* 24, 266–272. <https://doi.org/10.12968/live.2019.24.6.266>
- Le Goff, C., Thiaucourt, F., 1998. A competitive ELISA for the specific diagnosis of contagious bovine pleuropneumonia (CBPP). *Vet. Microbiol.* 60, 179–191. [https://doi.org/10.1016/s0378-1135\(98\)00156-4](https://doi.org/10.1016/s0378-1135(98)00156-4)
- Leal Zimmer, F.M. dos A., Paludo, G.P., Moura, H., Barr, J.R., Ferreira, H.B., 2019. Differential secretome profiling of a swine tracheal cell line infected with mycoplasmas of the swine respiratory tract. *J. Proteomics* 192, 147–159. <https://doi.org/10.1016/j.jprot.2018.08.018>

- Lee, D.F., Thompson, C.L., Baynes, R.E., Enomoto, H., Smith, G.W., Chambers, M.A., 2022. Development and evaluation of a bovine lung-on-chip (bLOC) to study bovine respiratory diseases. *Vitro Models* 1, 333–346. <https://doi.org/10.1007/s44164-022-00030-z>
- Lee, H.S., Bui, V.N., Nguyen, H.X., Bui, A.N., Hoang, T.D., Nguyen-Viet, H., Grace Randolph, D., Wieland, B., 2020. Seroprevalences of multi-pathogen and description of farm movement in pigs in two provinces in Vietnam. *BMC Vet. Res.* 16, 15. <https://doi.org/10.1186/s12917-020-2236-7>
- Lee, S.-I., Jeong, C.-G., ul Salam Mattoo, S., Nazki, S., Prasad Aganja, R., Kim, S.-C., Khatun, A., Oh, Y., Noh, S.-H., Lee, S.-M., Kim, W.-I., 2021. Protective immunity induced by concurrent intradermal injection of porcine circovirus type 2 and *Mycoplasma hyopneumoniae* inactivated vaccines in pigs. *Vaccine* 39, 6691–6699. <https://doi.org/10.1016/j.vaccine.2021.07.043>
- Leigh, S.A., Evans, J.D., 2022. Complete Genome Sequences of Three *Mycoplasma gallisepticum* 6/85-like Isolates. *Microbiol. Resour. Announc.* 11, e00244-22. <https://doi.org/10.1128/mra.00244-22>
- Leigh, S.A., Evans, J.D., Branton, S.L., 2019. Complete genome sequences of two *Mycoplasma gallisepticum* F-strain variants. *Microbiol. Resour. Announc.* 8.
- Lerner, U., Amram, E., Ayling, R.D., Mikula, I., Gerchman, I., Harrus, S., Teff, D., Yogev, D., Lysnyansky, I., 2014. Acquired resistance to the 16-membered macrolides tylosin and tilmicosin by *Mycoplasma bovis*. *Vet. Microbiol.* 168, 365–371. <https://doi.org/10.1016/j.vetmic.2013.11.033>
- Lewerin, S.S., Wolff, C., Masembe, C., Ståhl, K., Boqvist, S., Franko, M.A., 2018. Methodological aspects of serosurveillance in resource-poor settings. *Vet. Rec. Open* 5. <https://doi.org/10.1136/vetreco-2017-000273>
- Ley, D.H., Hawley, D.M., Geary, S.J., Dhondt, A.A., 2016. House Finch (*Haemorhous mexicanus*) Conjunctivitis, and *Mycoplasma* spp. Isolated from North American Wild Birds, 1994–2015. *J. Wildl. Dis.* 52, 669–673. <https://doi.org/10.7589/2015-09-244>
- Li, G., Shu, Jinqi, Jin, J., Shu, Jianhong, Feng, H., Chen, J., He, Y., 2022. Development of a Multi-Epitope Vaccine for *Mycoplasma hyopneumoniae* and Evaluation of Its Immune Responses in Mice and Piglets. *Int. J. Mol. Sci.* 23, 7899. <https://doi.org/10.3390/ijms23147899>
- Li, H., ZhiXun, X., LiJi, X., XianWen, D., ZhiQin, X., SiSi, L., JiaoLing, H., TingTing, Z., JiaXun, F., 2015. A duplex real-time PCR assay for the detection and quantification of avian reovirus and *Mycoplasma synoviae*. *Viol. J.* 12.
- Li, J., Huang, T., Zhang, M., Tong, X., Chen, J., Zhang, Z., Huang, F., Ai, H., Huang, L., 2023. Metagenomic sequencing reveals swine lung microbial communities and metagenome-assembled genomes associated with lung lesions—a pilot study. *Int. Microbiol. Off. J. Span. Soc. Microbiol.* <https://doi.org/10.1007/s10123-023-00345-1>
- Li, J., Liu, H., Zhao, N., Wang, J., Yang, Y., Sun, Y., 2020. Therapeutic effects of recombinant SPLUNC1 on *Mycoplasma ovipneumoniae*-infected Argali hybrid sheep. *Res. Vet. Sci.* 133, 174–179. <https://doi.org/10.1016/j.rvsc.2020.09.010>
- Li, J., Wang, J., Shao, J., Li, Y., Yu, Y., Shao, G., Feng, Z., Xiong, Q., 2022a. The variable lipoprotein family participates in the interaction of *Mycoplasma hyorhinis* with host extracellular matrix and plasminogen. *Vet. Microbiol.* 265, 109310. <https://doi.org/10.1016/j.vetmic.2021.109310>
- Li, J., Wei, Y., Wang, J., Li, Y., Shao, G., Feng, Z., Xiong, Q., 2022b. Characterization of Mutations in DNA Gyrase and Topoisomerase IV in Field Strains and In Vitro Selected Quinolone-Resistant *Mycoplasma hyorhinis* Mutants. *Antibiotics* 11, 494. <https://doi.org/10.3390/antibiotics11040494>
- Li, R., Wang, Jinfeng, Sun, X., Liu, L., Wang, Jianchang, Yuan, W., 2021. Direct and Rapid Detection of *Mycoplasma bovis* in Bovine Milk Samples by Recombinase Polymerase Amplification Assays. *Front. Cell. Infect. Microbiol.* 11, 639083. <https://doi.org/10.3389/fcimb.2021.639083>

- Li, S., Fang, L., Liu, W., Song, T., Zhao, F., Zhang, R., Wang, D., Xiao, S., 2019. Quantitative Proteomic Analyses of a Pathogenic Strain and Its Highly Passaged Attenuated Strain of *Mycoplasma hyopneumoniae*. *BioMed Res. Int.* 2019, 1–18. <https://doi.org/10.1155/2019/4165735>
- Li, X., Zhang, X., Luo, Y., Liu, R., Sun, Y., Zhao, S., Yu, M., Cao, J., 2022. Large Fragment InDels Reshape Genome Structure of Porcine Alveolar Macrophage 3D4/21 Cells. *Genes* 13, 1515. <https://doi.org/10.3390/genes13091515>
- Li, X., Zhang, Y., Yin, B., Liang, J., Jiang, F., Wu, W., 2020. Toll-like receptor 2 (TLR2) and TLR4 mediate the IgA immune response induced by *Mycoplasma hyopneumoniae*. *Infect. Immun.* 88.
- Li, Yanan, Jiang, Z., Xue, D., Deng, G., Li, M., Liu, X., Wang, Y., 2016. *Mycoplasma ovipneumoniae* induces sheep airway epithelial cell apoptosis through an ERK signalling-mediated mitochondria pathway. *BMC Microbiol.* 16.
- Li, Y., Wang, J., Liu, B., Yu, Y., Yuan, T., Wei, Y., Gan, Y., Shao, J., Shao, G., Feng, Z., Tu, Z., Xiong, Q., 2022. DnaK Functions as a Moonlighting Protein on the Surface of *Mycoplasma hyorhinis* Cells. *Front. Microbiol.* 13, 842058. <https://doi.org/10.3389/fmicb.2022.842058>
- Li, Yuan, Wang, Y., Wang, R., Zhu, Y., Liu, S., Wang, Q., Shao, J., Chen, Y., Gao, L., Zhou, C., Liu, H., Wang, X., Zheng, H., Xin, J., 2016. Changes in pathogenicity and immunogenicity of *Mycoplasma mycoides* subsp. *mycoides* strains revealed by comparative genomics analysis. *Sci. Rep.* 6, 19081.
- Li, Z., Du, Z., Sun, Y., Wang, J., Liu, H., Yang, Y., Zhao, N., 2020. Comprehensive RNA-Seq profiling of the lung transcriptome of Argali hybrid sheep in response to experimental *Mycoplasma ovipneumoniae* infection. *Res. Vet. Sci.* 132, 57–68. <https://doi.org/10.1016/j.rvsc.2020.05.014>
- Li, Z., Wang, Y., Zhang, Y., Tang, X., Wang, X., Liu, W., Qian, Y., Zhu, Y., Chen, H., Tan, C., 2021. Attenuation of *Mycoplasma hyopneumoniae* Strain ES-2 and Comparative Genomic Analysis of ES-2 and Its Attenuated Form ES-2L. *Front. Vet. Sci.* 8, 696262. <https://doi.org/10.3389/fvets.2021.696262>
- Liebing, J., Völker, I., Curland, N., Wohlsein, P., Baumgärtner, W., Braune, S., Runge, M., Moss, A., Rautenschlein, S., Jung, A., Ryll, M., Raue, K., Strube, C., Schulz, J., Heffels-Redmann, U., Fischer, L., Gethöffer, F., Voigt, U., Lierz, M., Siebert, U., 2020. Health status of free-ranging ring-necked pheasant chicks (*Phasianus colchicus*) in North-Western Germany. *PLOS ONE* 15, e0234044. <https://doi.org/10.1371/journal.pone.0234044>
- Lieske, C.L., Gerlach, R., Francis, M., Beckmen, K.B., 2022a. Multilocus Sequence Typing of *Mycoplasma ovipneumoniae* Detected in Dall's Sheep (*Ovis dalli dalli*) and Caribou (*Rangifer tarandus grantii*) in Alaska, USA. *J. Wildl. Dis.* 58. <https://doi.org/10.7589/JWD-D-21-00098>
- Lieske, C.L., Herndon, D.R., Highland, M.A., Beckmen, K.B., 2022b. Laboratory concordance study for the molecular detection of *Mycoplasma ovipneumoniae*. *J. Wildl. Dis.* 58. <https://doi.org/10.7589/JWD-D-21-00118>
- Lignereux, L., Chaber, A.-L., Saegerman, C., Manso-Silván, L., Peyraud, A., Apolloni, A., Thiaucourt, F., 2018. Unexpected field observations and transmission dynamics of contagious caprine pleuropneumonia in a sand gazelle herd. *Prev. Vet. Med.* 157, 70–77. <https://doi.org/10.1016/j.prevetmed.2018.06.002>
- Liljander, A., Sacchini, F., Stoffel, M.H., Schieck, E., Stokar-Regenscheit, N., Labroussaa, F., Heller, M., Salt, J., Frey, J., Falquet, L., Goovaerts, D., Jores, J., 2019. Reproduction of contagious caprine pleuropneumonia reveals the ability of convalescent sera to reduce hydrogen peroxide production in vitro. *Vet. Res.* 50, 10. <https://doi.org/10.1186/s13567-019-0628-0>
- Liljander, A., Yu, M., O'Brien, E., Heller, M., Nepper, J.F., Weibel, D.B., Gluecks, I., Younan, M., Frey, J., Falquet, L., Jores, J., 2015. Field-Applicable Recombinase Polymerase Amplification Assay for Rapid Detection of *Mycoplasma capricolum* subsp. *capripneumoniae* | *Journal of Clinical Microbiology*. *J. Clin. Microbiol.* 53, 2810–2815. <https://doi.org/10.1128/JCM.00623-15>

- Limsatanun, A., Pakpinyo, S., Limpavithayakul, K., Prasertsee, T., 2022. Targeted sequencing analysis of *Mycoplasma gallisepticum* isolates in chicken layer and breeder flocks in Thailand. *Sci. Rep.* 12, 9900. <https://doi.org/10.1038/s41598-022-14066-4>
- Lin, M.Y., Kleven, S.H., 1982. Pathogenicity of Two Strains of *Mycoplasma gallisepticum* in Turkeys. *Avian Dis.* 26, 360–364. <https://doi.org/10.2307/1590106>
- Lin, Y., Jiang, J., Zhang, J., You, W., Hu, Q., 2019. Development of a TaqMan real-time PCR for detection of the *Mycoplasma mycoides* subsp. *capri*. *Small Rumin. Res.* 175, 31–36. <https://doi.org/10.1016/j.smallrumres.2019.02.014>
- Lindenwald, D.L., Monteiro, J.T., Rautenschlein, S., Meens, J., Jung, K., Becker, S.C., Lepenies, B., 2020. Ovine C-type lectin receptor hFc-fusion protein library – A novel platform to screen for host-pathogen interactions. *Vet. Immunol. Immunopathol.* 224, 110047. <https://doi.org/10.1016/j.vetimm.2020.110047>
- Lindström, L., Tauni, F.A., Vargmar, K., 2018. Bronchopneumonia in Swedish lambs: a study of pathological changes and bacteriological agents. *Acta Vet. Scand.* 60.
- Ling, Z., Shahid, M.A., Markham, J., Browning, G.F., Noormohammadi, A.H., Marenda, M.S., 2019. Comparative genomic analyses of *Mycoplasma synoviae* vaccine strain MS-H and its wild-type parent strain 86079/7NS: implications for the identification of virulence factors and applications in diagnosis of *M. synoviae*. *Avian Pathol.* 48, 537–548.
- Lisgara, M., Poulaki, K., Kalogeropoulos, L., Skampardonis, V., Katsafadou, A.I., 2022. Frequency and severity of enzootic pneumonia-like lesions in Greek swine herds and their association with different vaccination protocols against *Mycoplasma hyopneumoniae*. *J. Appl. Anim. Res.* 50, 540–547. <https://doi.org/10.1080/09712119.2022.2110499>
- Liu, L., Li, R., Zhang, R., Wang, Jinfeng, An, Q., Han, Q., Wang, Jianchang, Yuan, W., 2019. Rapid and sensitive detection of *Mycoplasma hyopneumoniae* by recombinase polymerase amplification assay. *J. Microbiol. Methods* 159, 56–61. <https://doi.org/10.1016/j.mimet.2019.02.015>
- Liu, M.J., Du, G.M., Bai, F.F., Wu, Y.Z., Xiong, Q.Y., Feng, Z.X., Li, B., Shao, G.Q., 2015. A rapid and sensitive loop-mediated isothermal amplification procedure (LAMP) for *Mycoplasma hyopneumoniae* detection based on the p36 gene. *Genet. Mol. Res.* 14, 4677–4680.
- Liu, R., Xu, B., Yu, S., Zhang, J., Sun, H., Liu, C., Lu, F., Pan, Q., Zhang, X., 2020. Integrated Transcriptomic and Proteomic Analyses of the Interaction Between Chicken Synovial Fibroblasts and *Mycoplasma synoviae*. *Front. Microbiol.* 11, 576. <https://doi.org/10.3389/fmicb.2020.00576>
- Liu, R., Xu, B., Zhang, J., Sun, H., Liu, C., Lu, F., Pan, Q., Zhang, X., 2021. *Mycoplasma synoviae* induces serum amyloid A upregulation and promotes chicken synovial fibroblast cell proliferation. *Microb. Pathog.* 154, 104829. <https://doi.org/10.1016/j.micpath.2021.104829>
- Liu, W., Jiang, P., Yang, K., Song, Q., Yuan, F., Liu, Z., Gao, T., Zhou, D., Guo, R., Li, C., Sun, P., Tian, Y., 2022. *Mycoplasma hyopneumoniae* Infection Activates the NOD1 Signaling Pathway to Modulate Inflammation. *Front. Cell. Infect. Microbiol.* 12, 927840. <https://doi.org/10.3389/fcimb.2022.927840>
- Liu, Y., Deng, Z., Xu, S., Liu, G., Lin, Y., Khan, S., Gao, J., Qu, W., Kastelic, J.P., Han, B., 2021. *Mycoplasma bovis* subverts autophagy to promote intracellular replication in bovine mammary epithelial cells cultured in vitro. *Vet. Res.* 52, 130. <https://doi.org/10.1186/s13567-021-01002-z>
- Liu, Y., Zhou, M., Xu, S., Khan, M.A., Shi, Y., Qu, W., Gao, J., Liu, G., Kastelic, J.P., Han, B., 2020. *Mycoplasma bovis*-generated reactive oxygen species and induced apoptosis in bovine mammary epithelial cell cultures. *J. Dairy Sci.* 103, 10429–10445. <https://doi.org/10.3168/jds.2020-18599>
- Loire, E., Ibrahim, A.I., Manso-Silván, L., Lignereux, L., Thiaucourt, F., 2020. A whole-genome worldwide molecular epidemiology approach for contagious caprine pleuropneumonia. *Heliyon* 6, e05146. <https://doi.org/10.1016/j.heliyon.2020.e05146>
- Lopes Antunes, A.C., Jensen, V.F., Toft, N., 2019. Outcomes From Using Mortality, Antimicrobial Consumption, and Vaccine Use Data for Monitoring Endemic Diseases in Danish Swine Herds. *Front. Vet. Sci.* 6, 41. <https://doi.org/10.3389/fvets.2019.00041>

- Lopes, L.F.V., Silva, E.C. da, Moraes, A.C.A. de, Silva, E.R. da, Santoro, K.R., Batista, Â.M.V., Barbosa, S.B.P., 2019. *Mycoplasma agalactiae* and the *Mycoplasma mycoides* cluster in goat herds in the states of Pernambuco and Paraíba, Brazil. *Semina Ciênc. Agrár.* 40, 2261. <https://doi.org/10.5433/1679-0359.2019v40n5Supl1p2261>
- López-Lorenzo, G., Prieto, A., López-Novo, C., Díaz, P., López, C.M., Morrondo, P., Fernández, G., Díaz-Cao, J.M., 2021. Efficacy of Two Commercial Ready-To-Use PCV2 and *Mycoplasma hyopneumoniae* Vaccines under Field Conditions. *Animals* 11, 1553. <https://doi.org/10.3390/ani11061553>
- Loreck, K., Mitrenga, S., Heinze, R., Ehricht, R., Engemann, C., Lueken, C., Ploetz, M., Greiner, M., Meemken, D., 2020. Use of meat juice and blood serum with a miniaturised protein microarray assay to develop a multi-parameter IgG screening test with high sample throughput potential for slaughtering pigs. *BMC Vet. Res.* 16, 106. <https://doi.org/10.1186/s12917-020-02308-4>
- Loreck, K., Mitrenga, S., Meemken, D., Heinze, R., Reissig, A., Mueller, E., Ehricht, R., Engemann, C., Greiner, M., 2019. Development of a miniaturized protein microarray as a new serological IgG screening test for zoonotic agents and production diseases in pigs. *PLOS ONE* 14, e0217290. <https://doi.org/10.1371/journal.pone.0217290>
- Lorenc, Z., Paško, S., Kurska, O., Pakuła, A., Sałbut, L., 2019. Spectral technique for detection of changes in eggshells caused by *Mycoplasma synoviae*. *Poult. Sci.* 98, 3481–3487. <https://doi.org/10.3382/ps/pez150>
- Loria, G.R., Puleio, R., Agnello, S., Marogna, G., Nicholas, R.A.J., 2018a. Can vaccines for contagious agalactia reduce disease progression in infected animals: a preliminary study? *Vet. Rec. Case Rep.* 6. <https://doi.org/10.1136/vetreccr-2018-000715>
- Loria, G.R., Puleio, R., Filioussis, G., Rosales, R.S., Nicholas, R. a. J., 2019. Contagious agalactia: costs and control revisited. *Rev. Sci. Tech. Int. Off. Epizoot.* 38, 695–702. <https://doi.org/10.20506/rst.38.3.3018>
- Loria, G.R., Puleio, R., Nicholas, R.A.J., 2018b. Contagious Agalactia: Economic Losses and Good Practice. *J. Bacteriol. Mycol.* 5, 1076.
- Lowrey, B., Butler, C.J., Edwards, W.H., Wood, M.E., Dewey, S.R., Fralick, G.L., Jennings-Gaines, J., Killion, H., McWhirter, D.E., Miyasaki, H.M., Stewart, S.T., White, K.S., White, P.J., Garrott, R.A., 2018. A Survey of Bacterial Respiratory Pathogens in Native and Introduced Mountain Goats (*Oreamnos americanus*). *J. Wildl. Dis.* 54, 852–858. <https://doi.org/10.7589/2018-02-025>
- Loy, J.D., Leger, L., Workman, A.M., Clawson, M.L., Bulut, E., Wang, B., 2018. Development of a multiplex real-time PCR assay using two thermocycling platforms for detection of major bacterial pathogens associated with bovine respiratory disease complex from clinical samples. *J. Vet. Diagn. Invest.* 30, 837–847. <https://doi.org/10.1177/1040638718800170>
- Lu, Z., Xie, D., Chen, Y., Tian, E., Muhammad, I., Chen, X., Miao, Y., Hu, W., Wu, Z., Ni, H., Xin, J., Li, Y., Li, J., 2017. TLR2 mediates autophagy through ERK signaling pathway in *Mycoplasma gallisepticum* -infected RAW264.7 cells. *Mol. Immunol.* 87, 161–170. <https://doi.org/10.1016/j.molimm.2017.04.013>
- Lubbers, B.V., Renter, D.G., Hesse, R.A., Peddireddi, L., Zerse, M.T., Cox, E.A., Meyer, B.D., 2017. Prevalence of respiratory viruses and *Mycoplasma bovis* in U.S. cattle and variability among herds of origin, production systems and season of year. *Bov. Pract.* 51, 159–164.
- Luehrs, A., Siegenthaler, S., Grütznert, N., grosse Beilage, E., Kuhnert, P., Nathues, H., 2017. Occurrence of *Mycoplasma hyorhinis* infections in fattening pigs and association with clinical signs and pathological lesions of Enzootic Pneumonia. *Vet. Microbiol.* 203, 1–5. <https://doi.org/10.1016/j.vetmic.2017.02.001>
- Lung, O., Ohene-Adjei, S., Buchanan, C., Joseph, T., King, R., Erickson, A., Detmer, S., Ambagala, A., 2017. Multiplex PCR and Microarray for Detection of Swine Respiratory Pathogens. *Transbound. Emerg. Dis.* 64, 834–848. <https://doi.org/10.1111/tbed.12449>

- Luo, H., Wu, X., Xu, Z., Hao, X., Wang, Y., Li, M., 2020. NOD2/c-Jun NH₂-Terminal Kinase Triggers Mycoplasma ovipneumoniae-Induced Macrophage Autophagy. *J. Bacteriol.* 202. <https://doi.org/10.1128/JB.00689-19>
- Luo, Y., Li, C., Zhou, Z., Gong, Z., Zhu, C., Lei, A., 2021. Biological functions of IL-17-producing cells in mycoplasma respiratory infection. *Immunology* 164, 223–230. <https://doi.org/10.1111/imm.13346>
- Lutta, H.O., Wesonga, H.O., Odongo, D., Thiaucourt, F., Naessens, J., 2017. Inoculation of Mycoplasma mycoides mycoides by endotracheal intubation produces a milder disease than by contact transmission. *Bull. Anim. Health Prod. Afr.* 65, 481–489.
- Lysholm, S., Lindahl, J.F., Dautu, G., Johansson, E., Bergkvist, P.K., Munyeme, M., Wensman, J.J., 2022. Seroepidemiology of selected transboundary animal diseases in goats in Zambia. *Prev. Vet. Med.* 206, 105708. <https://doi.org/10.1016/j.prevetmed.2022.105708>
- Lysnyansky, I., Ayling, R.D., 2016. Mycoplasma bovis: mechanisms of resistance and trends in antimicrobial susceptibility. *Front. Microbiol.* 7.
- Lysnyansky, I., Borovok, I., 2021a. A GC-Rich Prophage-Like Genomic Region of Mycoplasma bovirhinis HAZ141_2 Carries a Gene Cluster Encoding Resistance to Kanamycin and Neomycin. *Antimicrob. Agents Chemother.* 65, e01010-20. <https://doi.org/10.1128/AAC.01010-20>
- Lysnyansky, I., Borovok, I., 2021b. The aadE*-sat4-aphA-3 Gene Cluster of Mycoplasma bovirhinis HAZ141_2 Undergoes Genomic Rearrangements Influencing the Primary Promoter Sequence. *Antibiotics* 10, 1335. <https://doi.org/10.3390/antibiotics10111335>
- Lysnyansky, I., Freed, M., Rosales, R.S., Mikula, I., Khateb, N., Gerchman, I., van Straten, M., Levisohn, S., 2016. An overview of Mycoplasma bovis mastitis in Israel (2004–2014). *Vet. J.* 207, 180–183. <https://doi.org/10.1016/j.tvjl.2015.10.057>
- Lysnyansky, I., Gerchman, I., Flaminio, B., Catania, S., 2015. Decreased Susceptibility to Macrolide–Lincosamide in Mycoplasma synoviae Is Associated with Mutations in 23S Ribosomal RNA. *Microb. Drug Resist.* 21, 581–589. <https://doi.org/10.1089/mdr.2014.0290>
- Lysnyansky, I., Mikula, I., Ozeri, R., Bellaiche, M., Nicholas, R. a. J., Straten, M. van, 2017. Mycoplasma bovis seroprevalence in Israeli dairy herds, feedlots and imported cattle. *Isr. J. Vet. Med.* 72, 13–16.
- Ma, W.-T., Gu, K., Yang, R., Tang, X.-D., Qi, Y.-X., Liu, M.-J., Chen, D.-K., 2020. Interleukin-17 mediates lung injury by promoting neutrophil accumulation during the development of contagious caprine pleuropneumonia. *Vet. Microbiol.* 243, 108651. <https://doi.org/10.1016/j.vetmic.2020.108651>
- Maas, R., Rosema, S., van Zoelen, D., Venema, S., 2011. Maternal immunity against avian influenza H5N1 in chickens: limited protection and interference with vaccine efficacy. *Avian Pathol. J. WVPA* 40. <https://doi.org/10.1080/03079457.2010.541226>
- MacDonald, A.M., Jardine, C.M., Rejman, E., Barta, J.R., Bowman, J., Cai, H.Y., Susta, L., Nemeth, N.M., 2019. High prevalence of Mycoplasma and Eimeria species in free-ranging eastern wild turkeys (Meleagris gallopavo silvestris) in Ontario, Canada. *J. Wildl. Dis.* 55, 54. <https://doi.org/10.7589/2017-11-273>
- Macêdo, A.A.M., Oliveira, J.M.B., Silva, B.P., Borges, J.M., Soares, L.B.F., Silva, G.M., Santos, S.B., Mota, R.A., Pinheiro-Júnior, J.W., 2018. Occurrence of Mycoplasma bovirhinis and Ureaplasma diversum in dairy cattle from Pernambuco state, Brazil. *Arq. Bras. Med. Veterinária E Zootec.* 70, 1798–1806. <https://doi.org/10.1590/1678-4162-10132>
- Machado, C.A.L., Vidotto, O., Conrado, F.O., Santos, N.J.R., Valente, J.D.M., Barbosa, I.C., Trindade, P.W.S., Garcia, J.L., Biondo, A.W., Vieira, T.S.W.J., Vieira, R.F.C., 2017. Mycoplasma ovis infection in goat farms from northeastern Brazil. *Comp. Immunol. Microbiol. Infect. Dis.* 55, 1–5. <https://doi.org/10.1016/j.cimid.2017.08.004>
- Machado, L.D.P.N., Paes, J.A., Souza dos Santos, P., Ferreira, H.B., 2020. Evidences of differential endoproteolytic processing on the surfaces of Mycoplasma hyopneumoniae and Mycoplasma flocculare. *Microb. Pathog.* 140, 103958. <https://doi.org/10.1016/j.micpath.2019.103958>

- Maes, D., Boyen, F., Devriendt, B., Kuhnert, P., Summerfield, A., Haesebrouck, F., 2021. Perspectives for improvement of *Mycoplasma hyopneumoniae* vaccines in pigs. *Vet. Res.* 52, 67. <https://doi.org/10.1186/s13567-021-00941-x>
- Maes, D., Boyen, F., Haesebrouck, F., Gautier-Bouchardon, A.V., 2020. Antimicrobial treatment of *Mycoplasma hyopneumoniae* infections. *Vet. J.* 259–260, 105474. <https://doi.org/10.1016/j.tvjl.2020.105474>
- Maes, D., Segales, J., Meyns, T., Sibila, M., Pieters, M., Haesebrouck, F., 2008. Control of *Mycoplasma hyopneumoniae* infections in pigs. *Vet. Microbiol.* 126, 297–309. <https://doi.org/10.1016/j.vetmic.2007.09.008>
- Maes, D., Sibila, M., Kuhnert, P., Segalés, J., Haesebrouck, F., Pieters, M., 2018. Update on *Mycoplasma hyopneumoniae* infections in pigs: knowledge gaps for improved disease control. *Transbound. Emerg. Dis.* 65, 110–124.
- Maes, D., Sibila, M., Pieters, M., Haesebrouck, F., Segalés, J., de Oliveira, L.G., 2023. Review on the methodology to assess respiratory tract lesions in pigs and their production impact. *Vet. Res.* 54, 1–17. <https://doi.org/10.1186/s13567-023-01136-2>
- Magalhães, B.S.N., Pereira, V.L.A., Dias, T.S., Machado, L.S., Silva, M.M., Nascimento, E.R., Mendes-de-Almeida, F., Almosny, N.R.P., 2020a. Investigation of *Mycoplasma* spp. in birds of the Rio de Janeiro Zoo by isolation and PCR. *Pesqui. Veterinária Bras.* 40, 220–225. <https://doi.org/10.1590/1678-5150-pvb-6447>
- Magalhães, B.S.N., Pereira, V.L.A., Machado, L.S., Dias, T.S., Balthazar, D.A., Barreto, M.L., Troccoli, F., Cunha, N.C., Nascimento, E.R., Almeida, F.M., Almosny, N.R., 2020b. Occurrence of Avian *Mycoplasmas* in Free-Living Muscovy-Ducks (*Cairina Moschata*). *Braz. J. Poult. Sci.* 22, eRBCA-2020-1352. <https://doi.org/10.1590/1806-9061-2020-1352>
- Magalhães, E.S., Zimmerman, J.J., Thomas, P., Moura, C.A.A., Trevisan, G., Holtkamp, D.J., Wang, C., Rademacher, C., Silva, G.S., Linhares, D.C.L., 2022. Whole-herd risk factors associated with wean-to-finish mortality under the conditions of a Midwestern USA swine production system. *Prev. Vet. Med.* 198, 105545. <https://doi.org/10.1016/j.prevetmed.2021.105545>
- Mahdizadeh, S., Sansom, F.M., Lee, S.-W., Browning, G.F., Marendra, M.S., 2020a. Targeted mutagenesis of *Mycoplasma gallisepticum* using its endogenous CRISPR/Cas system. *Vet. Microbiol.* 250, 108868. <https://doi.org/10.1016/j.vetmic.2020.108868>
- Mahdizadeh, S., Sawford, K., van Andel, M., Browning, G.F., 2020b. Efficacy of citric acid and sodium hypochlorite as disinfectants against *Mycoplasma bovis*. *Vet. Microbiol.* 243, 108630. <https://doi.org/10.1016/j.vetmic.2020.108630>
- Mahmood, F., Khan, A., Hussain, R., Khan, I.A., Abbas, R.Z., Ali, H.M., Younus, M., 2017. Patho-bacteriological investigation of an outbreak of *Mycoplasma bovis* infection in calves - Emerging stealth assault. *Microb. Pathog.* 107, 404–408. <https://doi.org/10.1016/j.micpath.2017.04.003>
- Mahran, O.M., Ghattas, S.G., 2016. Eperythrozoon ovis infections of sheep and goats in Shalateen, Abu-Ramad and Halaeeb, Red Sea Governorate, Egypt. *Egypt. J. Agric. Res.* 94, 397–406.
- Maina, T., Prysliak, T., Perez-Casal, J., 2019. *Mycoplasma bovis* delay in apoptosis of macrophages is accompanied by increased expression of anti-apoptotic genes, reduced cytochrome C translocation and inhibition of DNA fragmentation. *Vet. Immunol. Immunopathol.* 208, 16–24. <https://doi.org/10.1016/j.vetimm.2018.12.004>
- Mair, G., Vilei, E.M., Wade, A., Frey, J., Unger, H., 2013. Isothermal loop-mediated amplification (lamp) for diagnosis of contagious bovine pleuro-pneumonia. *BMC Vet. Res.* 9.
- Maitho, T., Kinyua, J.W., 2015. Factors and diseases influencing dairy goats production among small scale farmers in Laikipia East District, Kenya. *Int. J. Livest. Res.* 5, 43–48.
- Majekodunmi, A.O., Dongkum, C., Idehen, C., Langs, D.T., Welburn, S.C., 2018. Participatory epidemiology of endemic diseases in West African cattle – Ethnoveterinary and bioveterinary knowledge in Fulani disease control. *One Health* 5, 46–56. <https://doi.org/10.1016/j.onehlt.2018.03.001>

- Majumder, S., Silbart, L.K., 2016. Interaction of *Mycoplasma gallisepticum* with Chicken Tracheal Epithelial Cells Contributes to Macrophage Chemotaxis and Activation. *Infect. Immun.* 84, 266–274. <https://doi.org/10.1128/IAI.01113-15>
- Majumder, S., Zappulla, F., Silbart, L.K., 2014. *Mycoplasma gallisepticum* Lipid Associated Membrane Proteins Up-regulate Inflammatory Genes in Chicken Tracheal Epithelial Cells via TLR-2 Ligation through an NF- κ B Dependent Pathway. *PLOS ONE* 9, e112796. <https://doi.org/10.1371/journal.pone.0112796>
- Maksimović, Z., Bačić, A., Rifatbegović, M., 2016. Mycoplasmas isolated from ruminants in Bosnia and Herzegovina between 1995 and 2015. *Vet. Sarajevo* 65, 27–31.
- Maksimović, Zinka, Bačić, A., Rifatbegović, M., 2020. Antimicrobial Susceptibility of Caprine and Ovine *Mycoplasma ovipneumoniae* Isolates. *Microb. Drug Resist.* 26, 1271–1274. <https://doi.org/10.1089/mdr.2019.0465>
- Maksimović, Z., De la Fe, C., Amores, J., Gómez-Martín, Á., Rifatbegović, M., 2017. Comparison of phenotypic and genotypic profiles among caprine and ovine *Mycoplasma ovipneumoniae* strains. *Vet. Rec.* 180, 180–180. <https://doi.org/10.1136/vr.103699>
- Maksimović, Z., De La Fe, C., Rifatbegović, M., 2020. Assessment of in vitro growth characteristics of *Mycoplasma ovipneumoniae*. *Rev. Sci. Tech. Int. Off. Epizoot.* 39, 711–716. <https://doi.org/10.20506/rst.39.3.3172>
- Maksimović, Z., Rifatbegović, M., Loria, G.R., Nicholas, R.A.J., 2022. *Mycoplasma ovipneumoniae*: A Most Variable Pathogen. *Pathogens* 11, 1477. <https://doi.org/10.3390/pathogens11121477>
- Malmberg, J.L., O'Toole, D., Creekmore, T., Peckham, E., Killion, H., Vance, M., Ashley, R., Johnson, M., Anderson, C., Vasquez, M., Sandidge, D., Mildenerger, J., Hull, N., Bradway, D., Cornish, T., Register, K.B., Sondgeroth, K.S., 2020. *Mycoplasma bovis* Infections in Free-Ranging Pronghorn, Wyoming, USA. *Emerg. Infect. Dis.* 26, 2807–2814. <https://doi.org/10.3201/eid2612.191375>
- Malmsten, A., Magnusson, U., Ruiz-Fons, F., González-Barrio, D., Dalin, A.-M., 2018. A serologic survey of pathogens in wild boar (*Sus scrofa*) in Sweden. *J. Wildl. Dis.* 54, 229. <https://doi.org/10.7589/2017-05-120>
- Mamo, Y., Bitew, M., Teklemariam, T., Soma, M., Gebre, D., Abera, T., Benti, T., Deneke, Y., 2018. Contagious Bovine Pleuropneumonia: Seroprevalence and Risk Factors in Gimbo District, Southwest Ethiopia. *Vet. Med. Int.* 2018, 1–7. <https://doi.org/10.1155/2018/5729296>
- Mani, R., Beillard, M.J., 2021. India's Poultry Market - A Snapshot of 2020-21 (No. IN2021- 0105). USDA.
- Maniloff, J., Morowitz, H.J., 1972. Cell biology of the mycoplasmas. *Bacteriol. Rev.* 36, 263–290.
- Manimaran, K., Mishra, A., Harini, V., Shivachandra, S.B., Meenambigai, T.V., Raj, G.D., 2021. Cloning of cytoadhesin protein gene (*pvpA*) and expression analysis of recombinant fusion protein of *Mycoplasma gallisepticum*. *Indian J. Anim. Sci.* 91, 96–99.
- Manimaran, K., Mishra, A., Roy, P., Kumanan, K., 2020. Development of a Promising Agglutination Based Diagnostic Kit for Detection of *Mycoplasma gallisepticum* (MG) Infection in Chickens. *Indian J. Anim. Res.* 55, 849–852. <https://doi.org/10.18805/IJAR.B-4129>
- Manlove, K., Branam, M., Baker, K., Bradway, D., Cassirer, E.F., Marshall, K.L., Miller, R.S., Sweeney, S., Cross, P.C., Besser, T.E., 2019. Risk factors and productivity losses associated with *Mycoplasma ovipneumoniae* infection in United States domestic sheep operations. *Prev. Vet. Med.* 168, 30–38. <https://doi.org/10.1016/j.prevetmed.2019.04.006>
- Manlove, K.R., Cassirer, E.F., Plowright, R.K., Cross, P.C., Hudson, P.J., Hoye, B., 2017. Contact and contagion: probability of transmission given contact varies with demographic state in bighorn sheep. *J. Anim. Ecol.* 86, 908–920.
- Manning, A., 2020. *Mycoplasma* spp. mastitis — approach to diagnosis. *Livestock* 25, 170–172. <https://doi.org/10.12968/live.2020.25.4.170>
- Manso-Silván, L., Dupuy, V., Chu, Y., Thiaucourt, F., 2011. Multi-locus sequence analysis of *Mycoplasma capricolum* subsp. *capripneumoniae* for the molecular epidemiology of

- contagious caprine pleuropneumonia. *Vet. Res.* 42, 1–10. <https://doi.org/10.1186/1297-9716-42-86>
- Manso-Silván, L., Dupuy, V., Lysnyansky, I., Ozdemir, U., Thiaucourt, F., 2013. Phylogeny and molecular typing of *Mycoplasma agalactiae* and *Mycoplasma bovis* by multilocus sequencing. *Vet. Microbiol.* 161, 104–112.
- Manso-Silván, L., Perrier, X., Thiaucourt, F., 2007. Phylogeny of the *Mycoplasma mycoides* cluster based on analysis of five conserved protein-coding sequences and possible implications for the taxonomy of the group. *Int. J. Syst. Evol. Microbiol.* 57, 2247–2258. <https://doi.org/10.1099/ijs.0.64918-0>
- Manso-Silván, Lucía, Tardy, F., Baranowski, E., Barré, A., Blanchard, A., Breton, M., Couture, C., Citti, C., Dordet-Frisoni, E., Dupuy, V., Gaurivaud, P., Jacob, D., Lemaitre, C., Nikolski, M., Nouvel, L.-X., Poumarat, F., Thébault, P., Theil, S., Thiaucourt, F., Sirand-Pugnet, P., 2013. Draft Genome Sequences of *Mycoplasma alkalescens*, *Mycoplasma arginini*, and *Mycoplasma bovigenitalium*, Three Species with Equivocal Pathogenic Status for Cattle. *Genome Announc.* 1, e00348-13. <https://doi.org/10.1128/genomeA.00348-13>
- MaJun, L., GaiMei, D., Yue, Z., YuZi, W., HaiYan, W., Bin, L., Yun, B., ZhiXin, F., QiYan, X., FangFang, B., Browning, G.F., GuoQing, S., 2016. Development of a blocking ELISA for detection of *Mycoplasma hyopneumoniae* infection based on a monoclonal antibody against protein P65. *J. Vet. Med. Sci.* 78, 1319–1322.
- March, J.B., Waite, E.R., Litamoi, J.K., 2002. Re-suspension of T(1)44 vaccine cultures of *Mycoplasma mycoides* subsp. *mycoides* SC in 1 molar MgSO(4) causes a drop in pH and a rapid reduction in titre. *FEMS Immunol. Med. Microbiol.* 34, 97–103. <https://doi.org/10.1111/j.1574-695X.2002.tb00609.x>
- Marenda, M.S., Sagné, E., Poumarat, F., Citti, C., 2005. Suppression subtractive hybridization as a basis to assess *Mycoplasma agalactiae* and *Mycoplasma bovis* genomic diversity and species-specific sequences. *Microbiology* 151, 475–489. <https://doi.org/10.1099/mic.0.27590-0>
- Margineda, C., Zielinski, G., Jurado, S., Alejandra, F., Mozgovej, M., Alcaraz, A., Lopez, A., 2017. *Mycoplasma bovis* pneumonia in feedlot cattle and dairy calves in Argentina. *Braz. J. Vet. Pathol.* 10, 79–86. <https://doi.org/10.24070/bjvp.1983-0246.v10i2p79-86>
- Marinero, M., Greco, G., Tarsitano, E., Ventrella, G., Camero, M., Corrente, M., Rezza, G., Buonavoglia, D., 2015. Changes in peripheral blood leucocytes of sheep experimentally infected with *Mycoplasma agalactiae*. *Vet. Microbiol.* 175, 257–264. <https://doi.org/10.1016/j.vetmic.2014.12.001>
- Marobela-Raborokgwe, C., Nicholas, R., Ayling, R., Bashiruddin, J.B., 2003. Comparison of complement fixation test, immunoblotting, indirect ELISA, and competitive ELISA for detecting antibodies to *Mycoplasma mycoides* subspecies *mycoides* small colony (SC) in naturally infected cattle from the 1995 outbreak in Botswana. *Onderstepoort J. Vet. Res.* 70, 21–27.
- Marouf, S., Ibrahim, H.M., El-Naggar, M.S., Swelum, A.A., Alqhtani, A.H., El-Saadony, M.T., El-Tarabily, K.A., Salem, H.M., 2022a. Inactivated pentavalent vaccine against mycoplasmosis and salmonellosis for chickens. *Poult. Sci.* 101, 102139. <https://doi.org/10.1016/j.psj.2022.102139>
- Marouf, S., Khalf, M.A., Alorabi, M., El-Shehawi, A.M., El-Tahan, A.M., El-Hack, M.E.A., El-Saadony, M.T., Salem, H.M., 2022b. *Mycoplasma gallisepticum*: a devastating organism for the poultry industry in Egypt. *Poult. Sci.* 101, 101658. <https://doi.org/10.1016/j.psj.2021.101658>
- Martelli, P., Saleri, R., Andrani, M., Cavalli, V., De Angelis, E., Ferrari, L., Borghetti, P., 2021. Immune B cell responsiveness to single-dose intradermal vaccination against *Mycoplasma hyopneumoniae*. *Res. Vet. Sci.* 141, 66–75. <https://doi.org/10.1016/j.rvsc.2021.10.006>
- Martelli, P., Terreni, M., Guazzetti, S., Cavirani, S., 2006. Antibody Response to *Mycoplasma hyopneumoniae* Infection in Vaccinated Pigs with or without Maternal Antibodies induced by Sow Vaccination. *J. Vet. Med. Ser. B* 53, 229–233. <https://doi.org/10.1111/j.1439-0450.2006.00952.x>

- Martínez-Hernández, J.M., Ballados-González, G.G., Fernández-Bandala, D., Martínez-Soto, S., Velázquez-Osorio, V., Martínez-Rodríguez, P.B., Cruz-Romero, A., Grostieta, E., Lozano-Sardaneta, Y., Colunga Salas, P., Becker, I., Sánchez-Montes, S., 2019. Molecular detection of *Mycoplasma ovis* in an outbreak of hemolytic anemia in sheep from Veracruz, Mexico. *Trop. Anim. Health Prod.* 51, 243–248.
- Martinson, B., Minion, F.C., Jordan, D., 2018a. Development and optimization of a cell-associated challenge model for *Mycoplasma hyorhinis* in 7-week-old cesarean-derived, colostrum-deprived pigs. *Can. J. Vet. Res.* 82, 12–23.
- Martinson, B., Zoghby, W., Barrett, K., Bryson, L., Christmas, R., Minion, F.C., Kroll, J., 2018b. Efficacy of an inactivated *Mycoplasma hyorhinis* vaccine in pigs. *Vaccine* 36, 408–412. <https://doi.org/10.1016/j.vaccine.2017.11.063>
- Martinson, B., Zoghby, W., Barrett, K., Bryson, L., Kroll, J., 2019. Duration of immunity for an inactivated *Mycoplasma hyorhinis* vaccine in pigs. *Vet. Microbiol.* 230, 273–277. <https://doi.org/10.1016/j.vetmic.2019.02.021>
- Mashhour, S.T., Nourian, A., Mohammadzadeh, A., Mahmoodi Koochi, P., 2020. *Mycoplasma* Infection in the Lungs of Cattle: The First Identification of *Mycoplasma dispar* in Iran. *Iran. J. Vet. Med.* 14. <https://doi.org/10.22059/ijvm.2020.295162.1005049>
- Masiga, W.N., 1972. Comparative susceptibility of *Bos indicus* and *Bos taurus* to contagious bovine pleuropneumonia, and the efficacy of the T1 broth culture vaccine. *Vet. Rec.* 90, 499–502. <https://doi.org/10.1136/vr.90.18.499>
- Masiga, W.N., Windsor, R.S., 1978. Some evidence of an age susceptibility to contagious bovine pleuropneumonia. *Res. Vet. Sci.* 24, 328–333.
- Masukagami, Y., Nijagal, B., Mahdizadeh, S., Tseng, C.-W., Dayalan, S., Tivendale, K.A., Markham, P.F., Browning, G.F., Sansom, F.M., 2019. A combined metabolomic and bioinformatic approach to investigate the function of transport proteins of the important pathogen *Mycoplasma bovis*. *Vet. Microbiol.* 234, 8–16. <https://doi.org/10.1016/j.vetmic.2019.05.008>
- Masukagami, Y., Nijagal, B., Tseng, C.-W., Dayalan, S., Tivendale, K.A., Markham, P.F., Browning, G.F., Sansom, F.M., 2018. Metabolite profiling of *Mycoplasma gallisepticum* mutants, combined with bioinformatic analysis, can reveal the likely functions of virulence-associated genes. *Vet. Microbiol.* 223, 160–167. <https://doi.org/10.1016/j.vetmic.2018.08.001>
- Matos, R.A.T., Santos, S.B., Alves, R.V., Silva, E.J., Marinho, M.L., Júnior, J.W.P., Mota, R.A., Garino Júnior, F., 2019. Occurrence and risk factors associated with *Mycoplasma agalactiae* infection in dairy goat herds of Paraíba State, Brazil. *Pesqui. Veterinária Bras.* 39, 93–98. <https://doi.org/10.1590/1678-5150-pvb-5538>
- Matthijs, A.M.F., Auray, G., Boyen, F., Schoos, A., Michiels, A., García-Nicolás, O., Barut, G.T., Barnier-Quer, C., Jakob, V., Collin, N., Devriendt, B., Summerfield, A., Haesebrouck, F., Maes, D., 2019a. Efficacy of three innovative bacterin vaccines against experimental infection with *Mycoplasma hyopneumoniae*. *Vet. Res.* 50.
- Matthijs, A.M.F., Auray, G., Jakob, V., García-Nicolás, O., Braun, R.O., Keller, I., Bruggman, R., Devriendt, B., Boyen, F., Guzman, C.A., Michiels, A., Haesebrouck, F., Collin, N., Barnier-Quer, C., Maes, D., Summerfield, A., 2019b. Systems Immunology Characterization of Novel Vaccine Formulations for *Mycoplasma hyopneumoniae* Bacterins. *Front. Immunol.* 10, 1087. <https://doi.org/10.3389/fimmu.2019.01087>
- Matucci, A., Stefani, E., Gastaldelli, M., Rossi, I., De Grandi, G., Gyuranecz, M., Catania, S., 2020. Molecular Differentiation of *Mycoplasma gallisepticum* Outbreaks: A Last Decade Study on Italian Farms Using GTS and MLST. *Vaccines* 8, 665. <https://doi.org/10.3390/vaccines8040665>
- Matucci, A., Stefani, E., Tondo, A., Righetti, V., Bottinelli, M., Gavazzi, L., Merenda, M., Catania, S., 2023. Isolation and characterization of an atypical *Mycoplasma gallisepticum* strain showing a new *mgc2* variant. *Vet. Microbiol.* 282, 109768. <https://doi.org/10.1016/j.vetmic.2023.109768>

- Matyushkina, D., Pobeguts, O., Butenko, I., Vanyushkina, A., Anikanov, N., Bukato, O., Evsyutina, D., Bogomazova, A., Lagarkova, M., Semashko, T., Garanina, I., Babenko, V., Vakhitova, M., Ladygina, V., Fisunov, G., Govorun, V., 2016. Phase Transition of the Bacterium upon Invasion of a Host Cell as a Mechanism of Adaptation: a *Mycoplasma gallisepticum* Model. *Sci. Rep.* 6, 35959. <https://doi.org/10.1038/srep35959>
- Maunsell, F., Brown, M.B., Powe, J., Ivey, J., Woolard, M., Love, W., Simecka, J.W., 2012. Oral Inoculation of Young Dairy Calves with *Mycoplasma bovis* Results in Colonization of Tonsils, Development of Otitis Media and Local Immunity. *PLOS ONE* 7, e44523. <https://doi.org/10.1371/journal.pone.0044523>
- Maunsell, F.P., Donovan, G.A., Risco, C., Brown, M.B., 2009. Field evaluation of a *Mycoplasma bovis* bacterin in young dairy calves. *Vaccine* 27, 2781–2788. <https://doi.org/10.1016/j.vaccine.2009.02.100>
- Maunsell, F.P., Woolums, A.R., Francoz, D., Rosenbusch, R.F., Step, D.L., Wilson, D.J., Janzen, E.D., 2011. *Mycoplasma bovis* infections in cattle. *J. Vet. Intern. Med.* 25, 772–783. <https://doi.org/10.1111/j.1939-1676.2011.0750.x>
- May, M., Papazisi, L., Gorton, T.S., Geary, S.J., 2006. Identification of Fibronectin-Binding Proteins in *Mycoplasma gallisepticum* Strain R. *Infect. Immun.* 74, 1777–1785. <https://doi.org/10.1128/IAI.74.3.1777-1785.2006>
- Mayor, D., Jores, J., Korczak, B.M., Kuhnert, P., 2008. Multilocus sequence typing (MLST) of *Mycoplasma hyopneumoniae*: A diverse pathogen with limited clonality. *Vet. Microbiol.* 127, 63–72. <https://doi.org/10.1016/j.vetmic.2007.08.010>
- Mbiri, P., Kandiwa, E., Mushonga, B., Samkange, A., Bishi, A., Madzingira, O., Chitate, F., 2020. Incidence of Contagious Bovine Pleuropneumonia in the Northern Regions of Namibia. *Alex. J. Vet. Sci.* 66, 100. <https://doi.org/10.5455/ajvs.90846>
- McAloon, C.I., McAloon, C.G., Tratalos, J., O’Grady, L., McGrath, G., Guelbenzu, M., Graham, D.A., O’Keeffe, K., Barrett, D.J., More, S.J., 2022. Seroprevalence of *Mycoplasma bovis* in bulk milk samples in Irish dairy herds and risk factors associated with herd seropositive status. *J. Dairy Sci.* 105, 5410–5419. <https://doi.org/10.3168/jds.2021-21334>
- McAuliffe, L., Ayling, R.D., Ellis, R.J., Nicholas, R.A.J., 2008. Biofilm-grown *Mycoplasma mycoides* subsp. *mycoides* SC exhibit both phenotypic and genotypic variation compared with planktonic cells. *Vet. Microbiol.* 129, 315–324. <https://doi.org/10.1016/j.vetmic.2007.11.024>
- McAuliffe, L., Hatchell, F.M., Ayling, R.D., King, A.I.M., Nicholas, R. a. J., 2003. Detection of *Mycoplasma ovipneumoniae* in *Pasteurella*-vaccinated sheep flocks with respiratory disease in England. *Vet. Rec.* 153, 687–688. <https://doi.org/10.1136/vr.153.22.687>
- McCarthy, M.-C., O’Grady, L., McAloon, C.G., Mee, J.F., 2021. Longitudinal Prevalence of Antibodies to Endemic Pathogens in Bulk Tank Milk Samples From Dairy Herds Engaged or Not in Contract Heifer Rearing. *Front. Vet. Sci.* 8, 785128. <https://doi.org/10.3389/fvets.2021.785128>
- McDaniel, A.J., Derscheid, R.J., 2021. MALDI-TOF mass spectrometry and high-resolution melting PCR for the identification of *Mycoplasma bovis* isolates. *BMC Vet. Res.* 17, 170. <https://doi.org/10.1186/s12917-021-02870-5>
- Mechler-Dreibi, M.L., Almeida, H.M.S., Sonalio, K., Martines, M.A.C., Petri, F.A.M., Zambotti, B.B., Ferreira, M.M., Storino, G.Y., Martins, T.S., Montassier, H.J., Sant’Anna, O.A., Fantini, M.C.A., de Oliveira, L.G., 2021. Oral vaccination of piglets against *Mycoplasma hyopneumoniae* using silica SBA-15 as an adjuvant effectively reduced consolidation lung lesions at slaughter. *Sci. Rep.* 11, 22377. <https://doi.org/10.1038/s41598-021-01883-2>
- Meens, J., Bolotin, V., Frank, R., Böhmer, J., Gerlach, G.-F., 2010. Characterization of a highly immunogenic *Mycoplasma hyopneumoniae* lipoprotein Mhp366 identified by peptide-spot array. *Vet. Microbiol.* 142, 293–302. <https://doi.org/10.1016/j.vetmic.2009.10.007>
- Mehinagic, K., Pilo, P., Vidondo, B., Stokar-Regenscheit, N., 2019. Coinfection of Swiss cattle with bovine parainfluenza virus 3 and *Mycoplasma bovis* at acute and chronic stages of bovine

- respiratory disease complex. *J. Vet. Diagn. Invest.* 31, 674–680. <https://doi.org/10.1177/1040638719861686>
- Mekuriaw, Z., Harris-Coble, L., 2021. Ethiopia's livestock systems: overview and areas of inquiry. Feed the Future Innovation Lab for Livestock Systems, Gainesville, FL, USA.
- Mello, V.V.C. de, Ramos, I.A. de S., Herrera, H.M., Mendes, N.S., Calchi, A.C., Campos, J.B.V., Macedo, G.C., Alves, J.V.A., Machado, R.Z., André, M.R., 2019. Occurrence and genetic diversity of hemoplasmas in beef cattle from the Brazilian Pantanal, an endemic area for bovine trypanosomiasis in South America. *Comp. Immunol. Microbiol. Amp Infect. Dis.* 66.
- Menghwar, H., Guo, A., Chen, Y., Lysnyansky, I., Parker, A.M., Prysliak, T., Perez-Casal, J., 2022. A core genome multilocus sequence typing (cgMLST) analysis of *Mycoplasma bovis* isolates. *Vet. Microbiol.* 273, 109532. <https://doi.org/10.1016/j.vetmic.2022.109532>
- Menghwar, H., Perez-Casal, J., 2022. Comparative genomic analysis of Canadian *Mycoplasma bovis* strains isolated from Bison and Cattle. *Comp. Immunol. Microbiol. Infect. Dis.* 87, 101835. <https://doi.org/10.1016/j.cimid.2022.101835>
- Menghwar, H., Prysliak, T., Perez-Casal, J., 2021a. Phylogeny of *Mycoplasma bovis* isolates from cattle and bison based on multi locus sequence typing and multiple-locus variable-number tandem repeats. *Vet. Microbiol.* 258, 109124. <https://doi.org/10.1016/j.vetmic.2021.109124>
- Menghwar, H., Prysliak, T., Perez-Casal, J., 2021b. Complete Genome Sequences of Four Canadian *Mycoplasma bovis* Strains Isolated from Bison and Cattle. *Microbiol. Resour. Announc.* 10, e00136-21. <https://doi.org/10.1128/MRA.00136-21>
- Merodio, M., McDaniel, A., Poonsuk, K., Magtoto, R., Ferreyra, F.S.M., Meiroz-De-Souza-Almeida, H., Ross, R.F., Gimenez-Lirola, L., Arruda, B., Derscheid, R., 2021. Evaluation of colonization, variable lipoprotein-based serological response, and cellular immune response of *Mycoplasma hyorhinis* in experimentally infected swine. *Vet. Microbiol.* 260, 109162. <https://doi.org/10.1016/j.vetmic.2021.109162>
- Miao, Y., Niu, D., Wang, Z., Wang, J., Wu, Z., Bao, J., Hu, W., Guo, Y., Li, R., Ishfaq, M., Li, J., 2022a. *Mycoplasma gallisepticum* induced inflammation-mediated Th1/Th2 immune imbalance via JAK/STAT signaling pathway in chicken trachea: Involvement of respiratory microbiota. *Vet. Microbiol.* 265, 109330. <https://doi.org/10.1016/j.vetmic.2021.109330>
- Miao, Y., Niu, D., Wang, Z., Wang, J., Wu, Z., Bao, J., Jin, X., Li, R., Ishfaq, M., Li, J., 2022b. Methylsulfonylmethane ameliorates inflammation via NF- κ B and ERK/JNK-MAPK signaling pathway in chicken trachea and HD11 cells during *Mycoplasma gallisepticum* infection. *Poult. Sci.* 101, 101706. <https://doi.org/10.1016/j.psj.2022.101706>
- Michiels, A., Arsenakis, I., Boyen, F., Krejci, R., Haesebrouck, F., Maes, D., 2017a. Efficacy of one dose vaccination against experimental infection with two *Mycoplasma hyopneumoniae* strains. *BMC Vet. Res.* 13, 274. <https://doi.org/10.1186/s12917-017-1195-0>
- Michiels, A., Piepers, S., Ulens, T., Ransbeeck, N. van, Pozo Sacristán, R. del, Sierens, A., Haesebrouck, F., Demeyer, P., Maes, D., 2015. Impact of particulate matter and ammonia on average daily weight gain, mortality and lung lesions in pigs. *Prev. Vet. Med.* 121, 99–107.
- Michiels, A., Vranckx, K., Piepers, S., Del Pozo Sacristán, R., Arsenakis, I., Boyen, F., Haesebrouck, F., Maes, D., 2017b. Impact of diversity of *Mycoplasma hyopneumoniae* strains on lung lesions in slaughter pigs. *Vet. Res.* 48, 2. <https://doi.org/10.1186/s13567-016-0408-z>
- Michiels, T., Welby, S., Vanrobaeys, M., Quinet, C., Rouffaer, L., Lens, L., Martel, A., Butaye, P., 2016. Prevalence of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* in commercial poultry, racing pigeons and wild birds in Belgium. *Avian Pathol.* 45, 244–252. <https://doi.org/10.1080/03079457.2016.1145354>
- Migliore, S., Puleio, R., Nicholas, R.A.J., Loria, G.R., 2021. *Mycoplasma agalactiae*: The Sole Cause of Classical Contagious Agalactia? *Animals* 11, 1782. <https://doi.org/10.3390/ani11061782>
- Miguel, J., Mitjana, O., Tejedor, M.T., Martínez, A., Falceto, M.V., 2021. Supplementing Colostrum from Multiparous Sows: Effects on Performance and Health in Piglets from Gilts in Farm Conditions. *Animals* 11, 2563. <https://doi.org/10.3390/ani11092563>

- Minda, A.G., Kemal, K., Dagim, B., Aynalem, T., 2017. Sero-epidemiological investigation and risk factors for contagious bovine pleuro pneumonia infection of cattle in Dello Mena and Sawena Districts of Bale Zone, South Eastern Ethiopia. *J. Public Health Epidemiol.* 9, 122–132. <https://doi.org/10.5897/JPHE2016.0853>
- MinGoo, S., OhDeog, K., DongMi, K., 2019. Prevalence and phylogenetic analysis of hemoplasma species in domestic pigs in Korea. *Parasit. Vectors* 12.
- Ministry for Primary Industries, 2023. *Mycoplasma bovis* in New Zealand [WWW Document]. URL <https://www.mpi.govt.nz/biosecurity/mycoplasma-bovis/mycoplasma-bovis-in-new-zealand/>
- Mitchell, J.D., Goh, S., McKellar, Q.A., McKeever, D.J., 2013a. In vitro pharmacodynamics of gamithromycin against *Mycoplasma mycoides* subspecies *mycoides* Small Colony. *Vet. J.* 197, 806–811. <https://doi.org/10.1016/j.tvjl.2013.05.025>
- Mitchell, J.D., McKellar, Q.A., McKeever, D.J., 2013b. Evaluation of antimicrobial activity against *Mycoplasma mycoides* subsp. *mycoides* Small Colony using an in vitro dynamic dilution pharmacokinetic/pharmacodynamic model. *J. Med. Microbiol.* 62, 56–61. <https://doi.org/10.1099/jmm.0.045971-0>
- Mitchell, J.D., McKellar, Q.A., McKeever, D.J., 2012. Pharmacodynamics of Antimicrobials against *Mycoplasma mycoides mycoides* Small Colony, the Causative Agent of Contagious Bovine Pleuropneumonia. *PLOS ONE* 7, e44158. <https://doi.org/10.1371/journal.pone.0044158>
- Mitiku, F., Hartley, C.A., Sansom, F.M., Coombe, J.E., Mansell, P.D., Beggs, D.S., Browning, G.F., 2018. The major membrane nuclease MnuA degrades neutrophil extracellular traps induced by *Mycoplasma bovis*. *Vet. Microbiol.* 218, 13–19. <https://doi.org/10.1016/j.vetmic.2018.03.002>
- Modise, B.M., Kgotlele, T., Masoba, K.P.O., Dipuo, K., Keokilwe, L., Marobela-Raborokgwe, C., 2018. The experience of contagious bovine pleuropneumonia ring trials in Botswana. *Rev. Sci. Tech. OIE* 37, 897–906. <https://doi.org/10.20506/rst.37.3.2894>
- Mohammed, H.O., Carpenter, T.E., Yamamoto, R., McMartin, D.A., 1986. Prevalence of *Mycoplasma gallisepticum* and *M. synoviae* in commercial layers in southern and central California. *Avian Dis.* 30, 519–526.
- Mohd Hasan, L.I., Kho, K.L., Koh, F.X., Hassan Nizam, Q.N., Tay, S.T., 2017. Molecular evidence of hemoplasmas in Malaysian cattle and ticks. *Trop. Biomed.* 34, 668–674.
- Molla, W., Zegeye, A., Mekonnen, S.A., Fentie, T., Berju, A., Nigatu, S., Kenubih, A., Haile, B., Jemberu, W.T., 2023. Risk factors associated with contagious caprine pleuropneumonia in goats of Amhara region, Ethiopia. *Prev. Vet. Med.* 215, 105909. <https://doi.org/10.1016/j.prevetmed.2023.105909>
- Moomivand, H., Pourbakhsh, S.A., Jamshidian, M., 2017. Isolation and identification of pathogenic mycoplasmas in ostrich farms using PCR and culture methods. *J. Hell. Vet. Med. Soc.* 68, 647–652.
- Moore, S.J., O’Dea, M.A., Perkins, N., Barnes, A., O’Hara, A.J., 2014. Mortality of live export cattle on long-haul voyages: pathologic changes and pathogens. *J. Vet. Diagn. Invest.* 26, 252–265. <https://doi.org/10.1177/1040638714522465>
- Moore, S.J., O’Dea, M.A., Perkins, N., O’Hara, A.J., 2015. Estimation of nasal shedding and seroprevalence of organisms known to be associated with bovine respiratory disease in Australian live export cattle. *J. Vet. Diagn. Invest.* 27, 6–17. <https://doi.org/10.1177/1040638714559741>
- More, S., Bøtner, A., Butterworth, A., Calistri, P., Depner, K., Edwards, S., Garin-Bastuji, B., Good, M., Gortázar Schmidt, C., Michel, V., Miranda, M.A., Nielsen, S.S., Raj, M., Sihvonen, L., Spooler, H., Stegeman, J.A., Thulke, H., Velarde, A., Willeberg, P., Winckler, C., Baldinelli, F., Broglia, A., Candiani, D., Beltrán-Beck, B., Kohnle, L., Bicout, D., 2017. Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): contagious bovine pleuropneumonia. *EFSA J.* 15, e04995. <https://doi.org/10.2903/j.efsa.2017.4995>

- Moreira, F.A., Cardoso, L., Coelho, A.C., 2015. Epidemiological survey on *Mycoplasma synoviae* infection in Portuguese broiler breeder flocks. *Vet. Ital.* 51, 93–98.
- Morimoto, M., Kenri, T., Ohmori, T., Teshima, K., Shibuya, K., Sasakawa, C., Suzuki, M., 2019. Complete genome sequence of *Mycoplasma bovis* strain KG4397, isolated from cattle in Japan. *Microbiol. Resour. Announc.* 8.
- Moronato, M.L., Cecchinato, M., Facchetti, G., Mainenti, M., Gobbo, F., Catania, S., 2018. Application of different laboratory techniques to monitor the behaviour of a *Mycoplasma synoviae* vaccine (MS-H) in broiler breeders. *BMC Vet. Res.* 14, 357. <https://doi.org/10.1186/s12917-018-1669-8>
- Moronato, M.L., Ustulin, M., Vio, D., Nicholas, R.A.J., Catania, S., 2017. Diagnosis and control of a severe outbreak of lameness caused by *Mycoplasma hyosynoviae* in a closed pig unit. *Vet. Rec. Case Rep.* 5. <https://doi.org/10.1136/vetreccr-2017-000500>
- Mousa, W.S., Zaghawa, A.A., Elsify, A.M., Nayel, M.A., Ibrahim, Z.H., Al-Kheraije, K.A., Elhalafawy, H.R., El-Shafey, D., Anis, A., Salama, A.A., 2021. Clinical, histopathological, and molecular characterization of *Mycoplasma* species in sheep and goats in Egypt. *Vet. World* 14, 2561–2567. <https://doi.org/10.14202/vetworld.2021.2561-2567>
- Mousel, M.R., White, S.N., Herndon, M.K., Herndon, D.R., Taylor, J.B., Becker, G.M., Murdoch, B.M., 2021. Genes involved in immune, gene translation and chromatin organization pathways associated with *Mycoplasma ovipneumoniae* presence in nasal secretions of domestic sheep. *PLOS ONE* 16, e0247209. <https://doi.org/10.1371/journal.pone.0247209>
- Moyers, S.C., Adelman, J.S., Farine, D.R., Thomason, C.A., Hawley, D.M., 2018. Feeder density enhances house finch disease transmission in experimental epidemics. *Philos. Trans. R. Soc. B Biol. Sci.* 373, 20170090. <https://doi.org/10.1098/rstb.2017.0090>
- Mucha, S.G., Ferrarini, M.G., Moraga, C., Di Genova, A., Guyon, L., Tardy, F., Rome, S., Sagot, M.-F., Zaha, A., 2020. *Mycoplasma hyopneumoniae* J elicits an antioxidant response and decreases the expression of ciliary genes in infected swine epithelial cells. *Sci. Rep.* 10, 13707. <https://doi.org/10.1038/s41598-020-70040-y>
- Mugunthan, S.P., Harish, M.C., 2022. In silico structural homology modeling and functional characterization of *Mycoplasma gallisepticum* variable lipoprotein hemagglutinin proteins. *Front. Vet. Sci.* 9, 943831. <https://doi.org/10.3389/fvets.2022.943831>
- Mugunthan, S.P., Kannan, G., Chandra, H.M., Paital, B., 2023. Infection, Transmission, Pathogenesis and Vaccine Development against *Mycoplasma gallisepticum*. *Vaccines* 11, 469. <https://doi.org/10.3390/vaccines11020469>
- Muhammad, F., Hussain, J., Fareed, S.K., Ahmed Khan, T., Ahmed Khan, S., Ahmad, A., 2018. Diagnosis of avian mycoplasmas: a comparison between PCR and culture technique. *Arch. Razi Inst.* 73, 239–244.
- Mulongo, M., Frey, J., Smith, K., Schnier, C., Wesonga, H., Naessens, J., McKeever, D., 2015. Vaccination of Cattle with the N Terminus of LppQ of *Mycoplasma mycoides* subsp. *mycoides* Results in Type III Immune Complex Disease upon Experimental Infection. *Infect. Immun.* 83, 1992–2000. <https://doi.org/10.1128/IAI.00003-15>
- Mulongo, M., Frey, J., Smith, K., Schnier, C., Wesonga, H., Naessens, J., McKeever, D., 2013a. Cattle immunized against the pathogenic I- α -glycerol-3-phosphate oxidase of *Mycoplasma mycoides* subs. *mycoides* fail to generate neutralizing antibodies and succumb to disease on challenge. *Vaccine* 31, 5020–5025. <https://doi.org/10.1016/j.vaccine.2013.08.100>
- Mulongo, M., Prysliak, T., Perez-Casal, J., 2013b. Vaccination of feedlot cattle with extracts and membrane fractions from two *Mycoplasma bovis* isolates results in strong humoral immune responses but does not protect against an experimental challenge. *Vaccine* 31, 1406–1412. <https://doi.org/10.1016/j.vaccine.2012.12.055>
- Mulongo, M., Prysliak, T., Scruten, E., Napper, S., Perez-Casal, J., 2014. *In Vitro* Infection of Bovine Monocytes with *Mycoplasma bovis* Delays Apoptosis and Suppresses Production of Gamma

- Interferon and Tumor Necrosis Factor Alpha but Not Interleukin-10. *Infect. Immun.* 82, 62–71. <https://doi.org/10.1128/IAI.00961-13>
- Munyaka, P.M., Blanc, F., Estellé, J., Lemonnier, G., Leplat, J.-J., Rossignol, M.-N., Jardet, D., Plastow, G., Billon, Y., Willing, B.P., Rogel-Gaillard, C., 2020. Discovery of Predictors of *Mycoplasma hyopneumoniae* Vaccine Response Efficiency in Pigs: 16S rRNA Gene Fecal Microbiota Analysis. *Microorganisms* 8, 1151. <https://doi.org/10.3390/microorganisms8081151>
- Munyaka, P.M., Kommadath, A., Fohse, J., Wilkinson, J., Diether, N., Stothard, P., Estellé, J., Rogel-Gaillard, C., Plastow, G., Willing, B.P., 2019. Characterization of whole blood transcriptome and early-life fecal microbiota in high and low responder pigs before, and after vaccination for *Mycoplasma hyopneumoniae*. *Vaccine* 37, 1743–1755. <https://doi.org/10.1016/j.vaccine.2019.02.016>
- Murai, K., Higuchi, H., 2019. Prevalence and risk factors of *Mycoplasma bovis* infection in dairy farms in northern Japan. *Res. Vet. Sci.* 123, 29–31. <https://doi.org/10.1016/j.rvsc.2018.12.006>
- Müştak, H.K., Torun, E., Özen, D., Yücel, G., Akan, M., Diker, K.S., 2015. Effect of *Lonicera japonica* extract on *Mycoplasma gallisepticum* in naturally infected broiler flocks. *Br. Poult. Sci.* 56, 299–303. <https://doi.org/10.1080/00071668.2015.1022711>
- Muuka, G., Otina, B., Wesonga, H., Bowa, B., Gicheru, N., Stuke, K., Poole, E.J., Salt, J., Colston, A., 2019. Evaluation of new generation macrolides for the treatment and metaphylaxis of contagious bovine pleuropneumonia (CBPP) in cattle experimentally infected with *Mycoplasma mycoides* subspecies *mycoides*. *BMC Vet. Res.* 15, 451. <https://doi.org/10.1186/s12917-019-2197-x>
- Muuka, G., Songolo, N., Kabilika, S., Hang'ombe, B.M., Nalubamba, K.S., Muma, J.B., 2012. Challenges of controlling contagious bovine pleuropneumonia in sub-Saharan Africa: A Zambian perspective. *Trop. Anim. Health Prod.* 45, 9–15. <https://doi.org/10.1007/s11250-012-0235-9>
- Muuka, G.M., Songolo, A., Kabilika, S., Sikwese, H., Bowa, B., Kabunda, O., 2017. Observations of oxytetracycline treatment effects in a contagious bovine pleuropneumonia naturally infected herd in Zambia. *J. Vet. Med. Anim. Health* 9, 110–115. <https://doi.org/10.5897/JVMAH2017.0573>
- Muuka, G.M., Songolo, N., Kabilika, S., Fandamu, P., Buonavoglia, D., Scacchia, M., 2013. Private sector involvement in the control of contagious bovine pleuropneumonia (CBPP) in the Kazungula district of Zambia benefitted the community and the control strategy. *Trop. Anim. Health Prod.* 45, 699–703. <https://doi.org/10.1007/s11250-013-0351-1>
- Mwirigi, M., Nkando, I., Aye, R., Soi, R., Ochanda, H., Berberov, E., Potter, A., Gerdt, V., Perez-Casal, J., Naessens, J., Wesonga, H., 2016a. Experimental evaluation of inactivated and live attenuated vaccines against *Mycoplasma mycoides* subsp. *mycoides*. *Vet. Immunol. Immunopathol.* 169, 63–67. <https://doi.org/10.1016/j.vetimm.2015.12.006>
- Mwirigi, M., Nkando, I., Olum, M., Attah-Poku, S., Ochanda, H., Berberov, E., Potter, A., Gerdt, V., Perez-Casal, J., Wesonga, H., Soi, R., Naessens, J., 2016b. Capsular polysaccharide from *Mycoplasma mycoides* subsp. *mycoides* shows potential for protection against contagious bovine pleuropneumonia. *Vet. Immunol. Immunopathol.* 178, 64–69. <https://doi.org/10.1016/j.vetimm.2016.07.002>
- My, L., Sh, K., 1984. Evaluation of attenuated strains of *Mycoplasma gallisepticum* as vaccines in young chickens. *Avian Dis.* 28.
- Naccari, V., Giofrè, F., Naccari, F., 2015. Tulathromycin in the treatment of respiratory infections in sheep. *Int. J. Anim. Vet. Adv.* 7, 34–39.
- Naikare, H., Bruno, D., Mahapatra, D., Reinisch, A., Raleigh, R., Sprowls, R., 2015. Development and Evaluation of a Novel Taqman Real-Time PCR Assay for Rapid Detection of *Mycoplasma bovis*: Comparison of Assay Performance with a Conventional PCR Assay and Another Taqman Real-Time PCR Assay. *Vet. Sci.* 2, 32–42. <https://doi.org/10.3390/vetsci2010032>
- Nair, M.S., Dan, Y., Chi, C., Pieters, M., 2019a. Serum metabolite markers of early *Mycoplasma hyopneumoniae* infection in pigs. *Vet. Res.* 50.

- Nair, M.S., Eucker, T., Martinson, B., Neubauer, A., Victoria, J., Nicholson, B., Pieters, M., 2019b. Influence of pig gut microbiota on *Mycoplasma hyopneumoniae* susceptibility. *Vet. Res.* 50.
- Nathues, H., Fournie, G., Wieland, B., Pfeiffer, D.U., Stärk, K.D.C., 2016. Modelling the within-herd transmission of *Mycoplasma hyopneumoniae* in closed pig herds. *Porc. Health Manag.* 2.
- Neder, V.E., Amadio, A.F., Calvinho, L.F., 2022. Detection by multiplex PCR of *Mycoplasma* species associated with dairy cattle in Argentina. *Rev. Argent. Microbiol.* 54, 158–161. <https://doi.org/10.1016/j.ram.2021.07.001>
- Negash, W., Dubie, T., 2021. Contagious bovine pleuropneumonia: Seroprevalence and its associated risk factors in selected districts of Afar region, Ethiopia. *Vet. Med. Sci.* 7, 1671–1677. <https://doi.org/10.1002/vms3.566>
- Neiberger, H.L., Seabury, C.M., Wojtowicz, A.J., Wang, Z., Scraggs, E., Kiser, J.N., Neupane, M., Womack, J.E., Eenennaam, A.V., Hagevoort, G.R., Lehenbauer, T.W., Aly, S., Davis, J., Taylor, J.F., The Bovine Respiratory Disease Complex Coordinated Agricultural Project Research Team, 2014. Susceptibility loci revealed for bovine respiratory disease complex in pre-weaned holstein calves. *BMC Genomics* 15, 1164. <https://doi.org/10.1186/1471-2164-15-1164>
- Newton, L.G., Norris, R., 2000. Clearing a Continent: The Eradication of Bovine Pleuropneumonia from Australia. *Csiro Publishing.*
- N’Goran, E., 2020. Susceptibility and prevalence of the main zoonotic diseases in Tonpki region, Western Ivory Coast, West Africa. *Healthy Aging Res.* 9.
- Nguyen, D.V., Truong, C.K.T., 2015. Seroprevalence of *Mycoplasma bovis* Infection in Dairy Cows in Ho Chi Minh, Vietnam. *Open J. Vet. Med.* 05, 123–126. <https://doi.org/10.4236/ojvm.2015.55016>
- Nhung, N.T., Chansiripornchai, N., Carrique-Mas, J.J., 2017. Antimicrobial resistance in bacterial poultry pathogens: a review. *Front. Vet. Sci.* 4.
- Ni, B., Bai, F.F., Wei, Y., Liu, M.J., Feng, Z.X., Xiong, Q.Y., Hua, L.Z., Shao, G.Q., 2015. Apoptosis induced by lipid-associated membrane proteins from *Mycoplasma hyopneumoniae* in a porcine lung epithelial cell line with the involvement of caspase 3 and the MAPK pathway. *Genet. Mol. Res.* 14, 11429–11443. <https://doi.org/10.4238/2015.September.25.10>
- Ni, L., Song, C., Wu, X., Zhao, X., Wang, X., Li, B., Gan, Y., 2019. RNA-seq transcriptome profiling of porcine lung from two pig breeds in response to *Mycoplasma hyopneumoniae* infection. *PeerJ* 7, e7900. <https://doi.org/10.7717/peerj.7900>
- Niang, M., Sery, A., Doucouré, M., Koné, M., N’Diaye, M., Amanfu, W., Thiaucourt, F., 2010. Experimental studies on the effect of long-acting oxytetracycline treatment in the development of sequestra in contagious bovine pleuropneumonia- infected cattle. *J. Vet. Med. Anim. Health* 2(4), 35–45.
- Nicholas, R. a. J., 2011. Bovine mycoplasmosis: silent and deadly. *Vet. Rec.* 168, 459–462. <https://doi.org/10.1136/vr.d2468>
- Nicholas, R. a. J., Ayling, R.D., 2003. *Mycoplasma bovis*: disease, diagnosis, and control. *Res. Vet. Sci.* 74, 105–112. [https://doi.org/10.1016/s0034-5288\(02\)00155-8](https://doi.org/10.1016/s0034-5288(02)00155-8)
- Nicholas, R. a. J., Fox, L.K., Lysnyansky, I., 2016. *Mycoplasma mastitis* in cattle: to cull or not to cull. *Vet. J.* 216, 142–147.
- Nicholas, R.A.J., Ayling, R.D., Stipkovits, L.P., 2002. An experimental vaccine for calf pneumonia caused by *Mycoplasma bovis*: clinical, cultural, serological and pathological findings. *Vaccine* 20, 3569–3575. [https://doi.org/10.1016/S0264-410X\(02\)00340-7](https://doi.org/10.1016/S0264-410X(02)00340-7)
- Nielsen, P.K., Petersen, M.B., Nielsen, L.R., Halasa, T., Toft, N., 2015. Latent class analysis of bulk tank milk PCR and ELISA testing for herd level diagnosis of *Mycoplasma bovis*. *Prev. Vet. Med.* 121, 338–342.
- Niethammer, F.M., Ade, J., Hoelzle, L.E., Schade, B., 2018. Hemotrophic mycoplasma in Simmental cattle in Bavaria: prevalence, blood parameters, and transplacental transmission of ‘Candidatus *Mycoplasma haemobos*’ and *Mycoplasma wenyonii*. *Acta Vet. Scand.* 60, 74. <https://doi.org/10.1186/s13028-018-0428-y>

- Ning, Y., Zhou, Y., Wang, Z., Wen, Y., Xu, Z., Tian, Y., Yang, M., Wang, X., Yang, Y., Ding, H., 2020. Elevated Mhp462 antibody induced by natural infection but not in vitro culture of *Mycoplasma hyopneumoniae*. *Heliyon* 6, e04832. <https://doi.org/10.1016/j.heliyon.2020.e04832>
- Nishi, K., Gondaira, S., Fujiki, J., Katagata, M., Sawada, C., Eguchi, A., Iwasaki, T., Iwano, H., Higuchi, H., 2021a. Invasion of *Mycoplasma bovis* into bovine synovial cells utilizing the clathrin-dependent endocytosis pathway. *Vet. Microbiol.* 253, 108956. <https://doi.org/10.1016/j.vetmic.2020.108956>
- Nishi, K., Gondaira, S., Okamoto, M., Matsuda, K., Sato, A., Kato, T., Sasagawa, M., Tanaka, T., Higuchi, H., 2021b. Inflammatory cytokine mRNA and protein levels in the synovial fluid of *Mycoplasma arthritis calves*. *J. Vet. Med. Sci.* 83, 31–35. <https://doi.org/10.1292/jvms.20-0491>
- Nishi, K., Gondaira, S., Okamoto, M., Nebu, T., Koiwa, M., Ohtsuka, H., Murai, K., Matsuda, K., Fujiki, J., Iwano, H., Nagahata, H., Higuchi, H., 2019. Effect of *Mycoplasma bovis* on expression of inflammatory cytokines and matrix metalloproteinases mRNA in bovine synovial cells. *Vet. Immunol. Immunopathol.* 216, 109920. <https://doi.org/10.1016/j.vetimm.2019.109920>
- Njoga, E.O., Ilo, S.U., Nwobi, O.C., Onwumere-Idolor, O.S., Ajibo, F.E., Okoli, C.E., Jaja, I.F., Oguttu, J.W., 2023. Pre-slaughter, slaughter and post-slaughter practices of slaughterhouse workers in Southeast, Nigeria: Animal welfare, meat quality, food safety and public health implications. *PLOS ONE* 18, e0282418. <https://doi.org/10.1371/journal.pone.0282418>
- Nkando, I., Ndinda, J., Kuria, J., Naessens, J., Mbithi, F., Schnier, C., Gicheru, M., McKeever, D., Wesonga, H., 2012. Efficacy of two vaccine formulations against contagious bovine pleuropneumonia (CBPP) in Kenyan indigenous cattle. *Res. Vet. Sci.* 93, 568–573. <https://doi.org/10.1016/j.rvsc.2011.08.020>
- Nkando, I., Perez-Casal, J., Mwirigi, M., Prysliak, T., Townsend, H., Berberov, E., Kuria, J., Mugambi, J., Soi, R., Liljander, A., Jores, J., Gerdtts, V., Potter, A., Naessens, J., Wesonga, H., 2016. Recombinant *Mycoplasma mycoides* proteins elicit protective immune responses against contagious bovine pleuropneumonia. *Vet. Immunol. Immunopathol.* 171, 103–114. <https://doi.org/10.1016/j.vetimm.2016.02.010>
- Noah, E.Y., Kimera, S.I., Kusiluka, L.J.M., Wambura, P., 2015. Abattoir surveillance demonstrates contagious bovine pleuropneumonia is widespread in Tanzania. *Trop. Anim. Health Prod.* 47, 1607–1613. <https://doi.org/10.1007/s11250-015-0907-3>
- Nobrega, D., Andres-Lasher, S., Zaheer, R., McAllister, T., Homerosky, E., Anholt, R.M., Dorin, C., 2021. Prevalence, Risk Factors, and Antimicrobial Resistance Profile of Respiratory Pathogens Isolated From Suckling Beef Calves to Reprocessing at the Feedlot: A Longitudinal Study. *Front. Vet. Sci.* 8, 764701. <https://doi.org/10.3389/fvets.2021.764701>
- Nocard, E., Roux, E.R., Borrel, A., 1898. Le microbe de la peripneumonie. *Ann. Inst. Pasteur* 12, 240–262.
- Noll, L.W., Highland, M.A., Hamill, V.A., Tsui, W.N.T., Porter, E.P., Lu, N., Sebhatu, T., Brown, S., Herndon, D.R., Grossman, P.C., Bai, J., 2022. Development of a real-time PCR assay for detection and differentiation of *Mycoplasma ovipneumoniae* and a novel respiratory-associated *Mycoplasma* species in domestic sheep and goats. *Transbound. Emerg. Dis.* 69. <https://doi.org/10.1111/tbed.14477>
- Noormohammadi, A.H., 2007. Role of phenotypic diversity in pathogenesis of avian mycoplasmosis. *Avian Pathol.* 36, 439–444. <https://doi.org/10.1080/03079450701687078>
- Noormohammadi, A.H., Markham, P.F., Kanci, A., Whithear, K.G., Browning, G.F., 2000. A novel mechanism for control of antigenic variation in the haemagglutinin gene family of mycoplasma synoviae. *Mol. Microbiol.* 35, 911–923. <https://doi.org/10.1046/j.1365-2958.2000.01766.x>
- Normand, V., Boulbria, G., Brissonnier, M., Bachy, V., Moalic, P.-Y., Berton, P., Bouchet, F., Lebreton, A., 2020. Comparison of qPCR and blood smear microscopy for the diagnosis of *Mycoplasma suis*

- in a French veterinary practice. *Porc. Health Manag.* 6, 3. <https://doi.org/10.1186/s40813-019-0143-8>
- Nouvel, L.X., Hygonenq, M.-C., Catays, G., Martinelli, E., Le Page, P., Collin, É., Inokuma, H., Schelcher, F., Citti, C., Maillard, R., 2019. First detection of *Mycoplasma wenyonii* in France: Identification, evaluation of the clinical impact and development of a new specific detection assay. *Comp. Immunol. Microbiol. Infect. Dis.* 63, 148–153. <https://doi.org/10.1016/j.cimid.2019.01.010>
- Nueangphuet, P., Suwanruengsri, M., Fuke, N., Uemura, R., Hirai, T., Yamaguchi, R., 2021. Neutrophil and M2-polarized Macrophage Infiltration, Expression of IL-8 and Apoptosis in *Mycoplasma hyopneumoniae* Pneumonia in Swine. *J. Comp. Pathol.* 189, 31–44. <https://doi.org/10.1016/j.jcpa.2021.09.004>
- Nuvey, F.S., Fink, G., Hattendorf, J., Mensah, G.I., Addo, K.K., Bonfoh, B., Zinsstag, J., 2023. Access to vaccination services for priority ruminant livestock diseases in Ghana: Barriers and determinants of service utilization by farmers. *Prev. Vet. Med.* 215, 105919. <https://doi.org/10.1016/j.prevetmed.2023.105919>
- Nwankwo, I.O., Onunkwo, J.I., Onyema, C.V., 2019. Postmortem prevalence of fasciolosis and Contagious Bovine Pleuropneumonia (CBP) and economic losses in cattle at Nsukka Abattoir, Nigeria. *Anim. Res. Int.* 16, 3418–3426.
- Oba, P., Dione, M.M., Wieland, B., Mwiine, F.N., Erume, J., 2021. Correlations between lung pneumonic lesions and serologic status for key respiratory pathogens in slaughtered pigs in northern Uganda. *Porc. Health Manag.* 7, 53. <https://doi.org/10.1186/s40813-021-00233-y>
- Oba, P., Wieland, B., Mwiine, F.N., Erume, J., Dione, M.M., 2023. Co-infections of respiratory pathogens and gastrointestinal parasites in smallholder pig production systems in Uganda. *Parasitol. Res.* 122, 953–962. <https://doi.org/10.1007/s00436-023-07797-4>
- Oba, P., Wieland, B., Mwiine, F.N., Erume, J., Gertzell, E., Jacobson, M., Dione, M.M., 2020. Status and gaps of research on respiratory disease pathogens of swine in Africa. *Porc. Health Manag.* 6, 5. <https://doi.org/10.1186/s40813-020-0144-7>
- Odongo, M.O., Mutuku, M.M., Mwirigi, M., Mwendwa, L., 2013. Evaluation of the sensitivity and specificity of latex agglutination and complement fixation tests in the field diagnosis of contagious bovine. *Kenya Vet.* 37, 44–50.
- Ogbaje, C.I., Tsorun, T.I., Victor, I., 2015. Survey of haemoparasites of pigs in major pig markets/farms in Makurdi metropolis. *Niger. Vet. J.* 36, 1130–1134.
- Oh, T., Park, K.H., Yang, S., Jeong, J., Kang, I., Park, C., Chae, C., 2019. Evaluation of the efficacy of a trivalent vaccine mixture against a triple challenge with *Mycoplasma hyopneumoniae*, PCV2, and PRRSV and the efficacy comparison of the respective monovalent vaccines against a single challenge. *BMC Vet. Res.* 15, 342. <https://doi.org/10.1186/s12917-019-2091-6>
- Oh, Y., Baek, J., Lee, J., Cho, S.-H., Park, C., 2020. The first assessment to detect *Mycoplasma hyopneumoniae* by sampling laryngeal swabs to investigate sow stability in South Korea. *BMC Vet. Res.* 16, 452. <https://doi.org/10.1186/s12917-020-02663-2>
- Ohtsuka, H., Nakazono, M., Kondoh, T., Higuchi, H., Tajima, M., Koiwa, M., 2020. Cytokine levels of peripheral blood mononuclear cells in the clinical cases of Holstein calves infected with *Mycoplasma bovis*. *J. Vet. Med. Sci.* 82, 27–30. <https://doi.org/10.1292/jvms.19-0161>
- Okaiyeto, S.O., Danbirni, S., Allam, L., Akam, E., Pewan, S.B., Kudi, A.C., 2013. On-farm diagnosis of contagious bovine pleuropneumonia in nomadic herds using latex agglutination test (LAT). *J. Vet. Med. Anim. Health* 5, 94–98.
- Okamura, T., Maeda, K., Onodera, W., Kadowaki, H., Kojima-Shibata, C., Suzuki, E., Uenishi, H., Satoh, M., Suzuki, K., 2016. Correlated responses of respiratory disease and immune capacity traits of Landrace pigs selected for *Mycoplasmal pneumonia of swine* (MPS) lesion: CORRELATED RESPONSE OF IMMUNE TRAITS. *Anim. Sci. J.* 87, 1099–1105. <https://doi.org/10.1111/asj.12560>

- Ola-Fadunsin, S.D., Maizatul, A.M., Ibrahim, A.R., Amlizawathy, A., Chandrawathani, P., Jesse, F.F.A., Sani, R.A., Sharma, R.S.K., 2017. Molecular prevalence and species co-infection of bovine haemoparasites in Peninsular Malaysia. *Malays. J. Vet. Res.* 8, 13–22.
- Olaniyi, M.O., Awoyomi, O.J., Akinniyi, O., Adebisi, A.A., Alaka, O.O., Ajayi, O.L., Jubril, A.J., Jarikre, T.A., Emikpe, B.O., 2020. Retrospective study of swine respiratory diseases in Ogun and Oyo States, Nigeria: Immunohistochemical detection of *Mycoplasma hyopneumoniae*. *Sokoto J. Vet. Sci.* 18, 72–82. <https://doi.org/10.4314/sokjvs.v18i2.3>
- Olaogun, O.M., Kanci, A., Barber, S.R., Tivendale, K.A., Markham, P.F., Marenda, M.S., Browning, G.F., 2015. Genetic diversity of *Mycoplasma arginini* isolates based on multilocus sequence typing. *Vet. Microbiol.* 180, 123–128.
- Olaosebikan, O.O., Alaka, O.O., Ajadi, A.A., 2018. Haematological changes associated with porcine haemoparasitic infections in Ibadan, Oyo State, Nigeria. *Niger. Vet. J.* 39, 217–226.
- Oliveira, T.E.S., Pelaquim, I.F., Flores, E.F., Massi, R.P., Valdiviezo, M.J.J., Pretto-Giordano, L.G., Alfieri, A.A., Saut, J.P.E., Headley, S.A., 2020. *Mycoplasma bovis* and viral agents associated with the development of bovine respiratory disease in adult dairy cows. *Transbound. Emerg. Dis.* 67, 82–93. <https://doi.org/10.1111/tbed.13223>
- Oliveira, T.E.S., Scuisato, G.S., Pelaquim, I.F., Cunha, C.W., Cunha, L.S., Flores, E.F., Pretto-Giordano, L.G., Lisbôa, J.A.N., Alfieri, A.A., Saut, J.P.E., Jorge da Cunha, P.H., Headley, S.A., 2021. The Participation of a Malignant Catarrhal Fever Virus and *Mycoplasma bovis* in the Development of Single and Mixed Infections in Beef and Dairy Cattle With Bovine Respiratory Disease. *Front. Vet. Sci.* 8, 691448. <https://doi.org/10.3389/fvets.2021.691448>
- Oliveira, V.H.S., Dall Agnol, A.M., Fritzen, J.T.T., Lorenzetti, E., Alfieri, A.A., Alfieri, A.F., 2020. Microbial diversity involved in the etiology of a bovine respiratory disease outbreak in a dairy calf rearing unit. *Comp. Immunol. Microbiol. Infect. Dis.* 71, 101494. <https://doi.org/10.1016/j.cimid.2020.101494>
- Olorunshola, I.D., Daodu, B.O., Ajiboye, B., Folaranmi, E.B., Nicholas, R.A.J., Adegboye, D.S., Peters, A.R., 2020. Seroprevalence of contagious bovine pleuropneumonia and contagious caprine pleuropneumonia in the Middle-Belt of Nigeria. *Afr. J. Microbiol. Res.* 14, 25–31. <https://doi.org/10.5897/AJMR2019.9262>
- Olorunshola, I.D., Peters, A.R., Scacchia, M., Nicholas, R.A.J., 2017. Contagious bovine pleuropneumonia - never out of Africa? *CABI Rev.* 2017, 1–7. <https://doi.org/10.1079/PAVSNR201712019>
- Omotainse, O.S., Wawegama, N.K., Kulappu Arachchige, S.N., C. Coppo, M.J., Vaz, P.K., Woodward, A.P., Kordafshari, S., Bogeski, M., Stevenson, M., Noormohammadi, A.H., Stent, A.W., 2022. Tracheal cellular immune response in chickens inoculated with *Mycoplasma synoviae* vaccine, MS-H or its parent strain 86079/7NS. *Vet. Immunol. Immunopathol.* 251, 110472. <https://doi.org/10.1016/j.vetimm.2022.110472>
- Onono, J.O., Wieland, B., Rushton, J., 2014. Estimation of impact of contagious bovine pleuropneumonia on pastoralists in Kenya. *Prev. Vet. Med.* 115, 122–129. <https://doi.org/10.1016/j.prevetmed.2014.03.022>
- Onono, J.O., Wieland, B., Suleiman, A., Rushton, J., 2017. Policy analysis for delivery of contagious bovine pleuropneumonia control strategies in sub-Saharan Africa. *Rev. Sci. Tech. OIE* 36, 195–205. <https://doi.org/10.20506/rst.36.1.2621>
- Orsini, M., Krasteva, I., Marcacci, M., Ancora, M., Ciammaruconi, A., Gentile, B., Lista, F., Pini, A., Scacchia, M., Sacchini, F., Cammà, C., 2015. Whole-Genome Sequencing of *Mycoplasma mycoides* subsp. *mycoides* Italian Strain 57/13, the Causative Agent of Contagious Bovine Pleuropneumonia. *Genome Announc.* 3, e00197-15. <https://doi.org/10.1128/genomeA.00197-15>
- Otina, B., Kitala, P., Bebora, L., Olum, M., Kipronoh, A., Chesang, L., Stuke, K., Wesonga, H., 2022. Effects of Long Acting Oxytetracycline on Contagious Bovine Pleuropneumonia Experimentally Infected Cattle. *Tanzan. J. Sci.* 48, 954–961. <https://dx.doi.org/10.4314/tjs.v48i4.20>

- Overesch, G., Kuhnert, P., 2017. Persistence of *Mycoplasma hyopneumoniae* sequence types in spite of a control program for enzootic pneumonia in pigs. *Prev. Vet. Med.* 145, 67–72. <https://doi.org/10.1016/j.prevetmed.2017.06.007>
- Özdemir, S., 2020. Expression Profiles of Inflammation-related MicroRNAs in *Mycoplasma bovis* Infected Milk of Holstein-Friesian and Doğu Anadolu Kırmızısı Cows. *Kahramanmaraş Sütçü İmam Üniversitesi Tarım Ve Doğa Derg.* 23, 762–771. <https://doi.org/10.18016/ksutarimdog.vi.661708>
- Ozdemir, U., Ozdemir, E., March, J.B., Churchward, C., Nicholas, R. a. J., 2005. Contagious caprine pleuropneumonia in the Thrace region of Turkey. *Vet. Rec.* 156, 286–287. <https://doi.org/10.1136/vr.156.9.286>
- Ozdemir, Ü., Türkyılmaz, M.A., Sayı, O., Erpek, Ş. H., Nicholas, R.A.J., 2018. Survey of contagious caprine pleuropneumonia in goat herds in the Thrace region of Turkey. *Rev. Sci. Tech. - Off. Int. Épizooties* 37, 831–836.
- Pacce, V.D., Oliveira, N.R. de, Jorge, S., Dellagostin, O.A., 2019. Occurrence of *Mycoplasma hyopneumoniae* in slaughter pigs from Southern Brazil. *Braz. J. Vet. Res. Anim. Sci.* 56, e150072. <https://doi.org/10.11606/issn.1678-4456.bjvras.2019.150072>
- Padalino, B., Cirone, F., Zappaterra, M., Tullio, D., Ficco, G., Giustino, A., Ndiana, L.A., Pratelli, A., 2021. Factors Affecting the Development of Bovine Respiratory Disease: A Cross-Sectional Study in Beef Steers Shipped From France to Italy. *Front. Vet. Sci.* 8, 627894. <https://doi.org/10.3389/fvets.2021.627894>
- Paes, J.A., Lorenzatto, K.R., de Moraes, S.N., Moura, H., Barr, J.R., Ferreira, H.B., 2017a. Secretomes of *Mycoplasma hyopneumoniae* and *Mycoplasma flocculare* reveal differences associated to pathogenesis. *J. Proteomics* 154, 69–77. <https://doi.org/10.1016/j.jprot.2016.12.002>
- Paes, J.A., Machado, L.D.P.N., dos Anjos Leal, F.M., De Moraes, S.N., Moura, H., Barr, J.R., Ferreira, H.B., 2018. Comparative proteomics of two *Mycoplasma hyopneumoniae* strains and *Mycoplasma flocculare* identified potential porcine enzootic pneumonia determinants. *Virulence* 9, 1230–1246. <https://doi.org/10.1080/21505594.2018.1499379>
- Paes, J.A., Virginio, V.G., Cancela, M., Leal, F.M.A., Borges, T.J., Jaeger, N., Bonorino, C., Schrank, I.S., Ferreira, H.B., 2017b. Pro-apoptotic effect of a *Mycoplasma hyopneumoniae* putative type I signal peptidase on PK(15) swine cells. *Vet. Microbiol.* 201, 170–176. <https://doi.org/10.1016/j.vetmic.2017.01.024>
- Pagot, E., Rigaut, M., Roudaut, D., Panzavolta, L., Jolie, R., Duivon, D., 2017. Field efficacy of Porcilis® PCV M Hyo versus a licensed commercially available vaccine and placebo in the prevention of PRDC in pigs on a French farm: a randomized controlled trial. *Porc. Health Manag.* 3, 3. <https://doi.org/10.1186/s40813-016-0051-0>
- Paiva, R.C., Moura, C.A., Thomas, P., Haberl, B., Greiner, L., Rademacher, C.J., Silva, A.P.S.P., Trevisan, G., Linhares, D.C.L., Silva, G.S., 2023. Risk factors associated with sow mortality in breeding herds under one production system in the Midwestern United States. *Prev. Vet. Med.* 213, 105883. <https://doi.org/10.1016/j.prevetmed.2023.105883>
- Pakuła, A., Paśko, S., Kurska, O., Komar, R., 2021. Reflected Light Spectrometry and AI-Based Data Analysis for Detection of Rapid Chicken Eggshell Change Caused by *Mycoplasma synoviae*. *Appl. Sci.* 11, 7799. <https://doi.org/10.3390/app11177799>
- Pakuła, A., Żołnowski, W., Paśko, S., Kurska, O., Marć, P., Jaroszewicz, L.R., 2022. Multispectral Portable Fibre-Optic Reflectometer for the Classification of the Origin of Chicken Eggshells in the Case of *Mycoplasma synoviae* Infections. *Sensors* 22, 8690. <https://doi.org/10.3390/s22228690>
- Pallarés, F., Añón, J., Rodríguez-Gómez, I., Gómez-Laguna, J., Fabrè, R., Sánchez-Carvajal, J., Ruedas-Torres, I., Carrasco, L., 2021. Prevalence of mycoplasma-like lung lesions in pigs from commercial farms from Spain and Portugal. *Porc. Health Manag.* 7, 26. <https://doi.org/10.1186/s40813-021-00204-3>
- Pallarés, F.J., Lasa, C., Roozen, M., Ramis, G., 2015. Use of tylvalosin in the control of porcine enzootic pneumonia. *Vet. Rec. Open* 2. <https://doi.org/10.1136/vetrec-2014-000079>

- Pansri, P., Katholm, J., Krogh, K.M., Aagaard, A.K., Schmidt, L.M.B., Kudirkiene, E., Larsen, L.E., Olsen, J.E., 2020. Evaluation of novel multiplex qPCR assays for diagnosis of pathogens associated with the bovine respiratory disease complex. *Vet. J.* 256, 105425. <https://doi.org/10.1016/j.tvjl.2020.105425>
- Pantoja, L.G., Pettit, K., Dos Santos, L.F., Tubbs, R., Pieters, M., 2016. *Mycoplasma hyopneumoniae* genetic variability within a swine operation. *J. Vet. Diagn. Invest.* 28, 175–179. <https://doi.org/10.1177/1040638716630767>
- Papazisi, L., Gorton, T.S., Kutish, G., Markham, P.F., Browning, G.F., Nguyen, D.K., Swartzell, S., Madan, A., Mahairas, G., Geary, S.J., 2003. The complete genome sequence of the avian pathogen *Mycoplasma gallisepticum* strain R(low). *Microbiol. Read. Engl.* 149, 2307–2316. <https://doi.org/10.1099/mic.0.26427-0>
- Pardon, B., Callens, J., Maris, J., Allais, L., Van Praet, W., Deprez, P., Ribbens, S., 2020. Pathogen-specific risk factors in acute outbreaks of respiratory disease in calves. *J. Dairy Sci.* 103, 2556–2566. <https://doi.org/10.3168/jds.2019-17486>
- Parker, A.M., House, J.K., Hazelton, M.S., Bosward, K.L., Mohler, V.L., Maunsell, F.P., Sheehy, P.A., 2016a. Milk acidification to control the growth of *Mycoplasma bovis* and *Salmonella* Dublin in contaminated milk. *J. Dairy Sci.* 99, 9875–9884. <https://doi.org/10.3168/jds.2016-11537>
- Parker, A.M., House, J.K., Hazelton, M.S., Bosward, K.L., Morton, J.M., Sheehy, P.A., 2017a. Bulk tank milk antibody ELISA as a biosecurity tool for detecting dairy herds with past exposure to *Mycoplasma bovis*. *J. Dairy Sci.* 100, 8296–8309. <https://doi.org/10.3168/jds.2016-12468>
- Parker, A.M., House, J.K., Hazelton, M.S., Bosward, K.L., Sheehy, P.A., 2017b. Comparison of culture and a multiplex probe PCR for identifying *Mycoplasma* species in bovine milk, semen and swab samples. *PLOS ONE* 12, e0173422. <https://doi.org/10.1371/journal.pone.0173422>
- Parker, A.M., Sheehy, P.A., Hazelton, M.S., Bosward, K.L., House, J.K., 2018. A review of mycoplasma diagnostics in cattle. *J. Vet. Intern. Med.* 32, 1241–1252. <https://doi.org/10.1111/jvim.15135>
- Parker, A.M., Shukla, A., House, J.K., Hazelton, M.S., Bosward, K.L., Kokotovic, B., Sheehy, P.A., 2016b. Genetic characterization of Australian *Mycoplasma bovis* isolates through whole genome sequencing analysis. *Vet. Microbiol.* 196, 118–125. <https://doi.org/10.1016/j.vetmic.2016.10.010>
- Parray, O.R., Yatoo, Mohd.I., Muheet, Ahmed Bhat, R., Ullah Malik, H., Bashir, S.T., Nabi Magray, S., 2019. Seroepidemiology and risk factor analysis of contagious caprine pleuropneumonia in Himalayan Pashmina Goats. *Small Rumin. Res.* 171, 23–36. <https://doi.org/10.1016/j.smallrumres.2018.12.004>
- Paterna, A., Tatay-Dualde, J., Amores, J., Prats-van der Ham, M., Sánchez, A., de la Fe, C., Contreras, A., Corrales, J.C., Gómez-Martín, Á., 2016. In vitro assessment of the antimicrobial susceptibility of caprine isolates of *Mycoplasma mycoides* subsp. *capri*. *Vet. J.* 214, 96–101. <https://doi.org/10.1016/j.tvjl.2016.05.010>
- Paterson, J.T., Butler, C., Garrott, R., Proffitt, K., 2020. How sure are you? A web-based application to confront imperfect detection of respiratory pathogens in bighorn sheep. *PLOS ONE* 15, e0237309. <https://doi.org/10.1371/journal.pone.0237309>
- Paterson, J.T., Proffitt, K., Rotella, J., McWhirter, D., Garrott, R., 2021. Drivers of variation in the population dynamics of bighorn sheep. *Ecosphere* 12. <https://doi.org/10.1002/ecs2.3679>
- Patterson, P.H., 1994. Coping with *Mycoplasma gallisepticum*. *Interviews* 7, 1–3.
- Paul, B.T., Jesse, F.F.A., Chung, E.L.T., Che-Amat, A., Mohd-Azmi, M.L., 2021. Prevalence and risk factors of Haemotropic *Mycoplasma* ovisinfection in selected smallholder sheep and goat flocks in Malaysia. *Thai J. Vet. Med.* 51, 259. <https://doi.org/10.14456/TJVM.2021.33>
- Paul, S., Schieck, E., Liljander, A., Robert, T., Enock, M., Ann, K., Ann, N., Frank, M., 2019. An alternative caprine infection model for *Mycoplasma mycoides*. *Afr. J. Biotechnol.* 18, 1077–1082.
- Paz-Sánchez, Y., Herráez, P., Quesada-Canales, Ó., Poveda, C.G., Díaz-Delgado, J., Quintana-Montesdeoca, M. del P., Plamenova Stefanova, E., Andrada, M., 2021. Assessment of Lung

- Disease in Finishing Pigs at Slaughter: Pulmonary Lesions and Implications on Productivity Parameters. *Animals* 11, 3604. <https://doi.org/10.3390/ani11123604>
- Pearson, H.E., Toribio, J.-A.L.M.L., Lapidge, S.J., Hernández-Jover, M., 2016. Evaluating the risk of pathogen transmission from wild animals to domestic pigs in Australia. *Prev. Vet. Med.* 123, 39–51. <https://doi.org/10.1016/j.prevetmed.2015.11.017>
- Peng, L., Jian, X., HongMei, R., Xia, L., YunKe, Z., Fei, J., WenXue, W., 2018. Mechanism of apoptosis induction by mycoplasmal nuclease MGA_0676 in chicken embryo fibroblasts. *Front. Cell. Infect. Microbiol.* 8.
- Peng, L., YunKe, Z., Xia, L., WenYan, Z., XuNi, L., Fei, J., WenXue, W., 2019. *Mycoplasma hyopneumoniae* Mhp597 is a cytotoxicity, inflammation and immunosuppression associated nuclease. *Vet. Microbiol.* 235, 53–62.
- PengCheng, L., YunFeng, L., GuoQing, S., QingHua, Y., Qian, Y., 2015. Comparison of immune responses to intranasal and intrapulmonary vaccinations with the attenuated *Mycoplasma hyopneumoniae* 168 strain in pigs. *J. Vet. Med. Sci.* 77, 519–525.
- Penterman, P.M., Holzhauser, M., van Engelen, E., Smits, D., Velthuis, A.G.J., 2022. Dynamics of *Mycoplasma bovis* in Dutch dairy herds during acute clinical outbreaks. *Vet. J.* 283–284, 105841. <https://doi.org/10.1016/j.tvjl.2022.105841>
- Pepovich, R., 2020. Enzootic pneumonia of pigs - diagnostic notes (review). *Bulg. J. Agric. Sci.* 26, 1062–1068.
- Pepovich, R., 2019. Efficacy of single-dose *Mycoplasma hyopneumoniae* vaccine for the control of enzootic pneumonia in pigs. *Bulg. J. Agric. Sci.* 25, 1039–1043.
- Pereira, C.E.R., Vannucci, F.A., Gabardo, M. de P., dos Santos, L.F., Mores, N., Guedes, R.M.C., 2017. *Mycoplasma hyorhinis* infection in early cases of mycoplasmal pneumonia in swine and evaluation of diagnostic assays. *Pesqui. Veterinária Bras.* 37, 1057–1063. <https://doi.org/10.1590/s0100-736x2017001000003>
- Perez-Casal, J., 2020. Pathogenesis and Virulence of *Mycoplasma bovis*. *Vet. Clin. North Am. Food Anim. Pract.* 36, 269–278. <https://doi.org/10.1016/j.cvfa.2020.02.002>
- Perez-Casal, J., Prysliak, T., Maina, T., Suleman, M., Jimbo, S., 2017. Status of the development of a vaccine against *Mycoplasma bovis*. *Vaccine* 35, 2902–2907. <https://doi.org/10.1016/j.vaccine.2017.03.095>
- Perez-Casal, J., Prysliak, T., Maina, T., YeJun, W., Townsend, H., Berverov, E., Nkando, I., Wesonga, H., Liljander, A., Jores, J., Naessens, J., Gerdts, V., Potter, A., 2015. Analysis of immune responses to recombinant proteins from strains of *Mycoplasma mycoides* subsp. *mycoides*, the causative agent of contagious bovine pleuropneumonia. *Vet. Immunol. Immunopathol.* 168, 103–110.
- Pessoa, J., Rodrigues da Costa, M., García Manzanilla, E., Norton, T., McAloon, C., Boyle, L., 2021. Managing respiratory disease in finisher pigs: Combining quantitative assessments of clinical signs and the prevalence of lung lesions at slaughter. *Prev. Vet. Med.* 186, 105208. <https://doi.org/10.1016/j.prevetmed.2020.105208>
- Petersen, A.C., Clampitt, J.M., Minion, F.C., 2019. Analysis of swine antigen-specific antibody responses to *Mycoplasma hyopneumoniae* infection determined by protein microarray. *Vet. Microbiol.* 230, 195–201. <https://doi.org/10.1016/j.vetmic.2019.02.010>
- Petersen, A.C., Oneal, D.C., Seibel, J.R., Poel, K., Daum, C.L., Djordjevic, S.P., Minion, F.C., 2016. Cross reactivity among the swine mycoplasmas as identified by protein microarray. *Vet. Microbiol.* 192, 204–212. <https://doi.org/10.1016/j.vetmic.2016.07.023>
- Petersen, M.B., Pedersen, J., Holm, D.L., Denwood, M., Nielsen, L.R., 2018a. A longitudinal observational study of the dynamics of *Mycoplasma bovis* antibodies in naturally exposed and diseased dairy cows. *J. Dairy Sci.* 101, 7383–7396. <https://doi.org/10.3168/jds.2017-14340>
- Petersen, M.B., Pedersen, L., Pedersen, L.M., Nielsen, L.R., 2020. Field Experience of Antibody Testing against *Mycoplasma bovis* in Adult Cows in Commercial Danish Dairy Cattle Herds. *Pathogens* 9, 637. <https://doi.org/10.3390/pathogens9080637>

- Petersen, M.B., Wawegama, N.K., Denwood, M., Markham, P.F., Browning, G.F., Nielsen, L.R., 2018b. *Mycoplasma bovis* antibody dynamics in naturally exposed dairy calves according to two diagnostic tests. *BMC Vet. Res.* 14, 258. <https://doi.org/10.1186/s12917-018-1574-1>
- Petri, F.A.M., Sonalio, K., de Souza Almeida, H.M., Ferraz, M.E.S., Storino, G.Y., de Souza, M.R., André, M.R., de Oliveira, L.G., 2020. Porcine hemothropic mycoplasmas infection associated with productive impact in intensive pig production. *Porc. Health Manag.* 6, 33. <https://doi.org/10.1186/s40813-020-00171-1>
- Pettersson, B., Leitner, T., Ronaghi, M., Bölske, G., Uhlen, M., Johansson, K.E., 1996. Phylogeny of the *Mycoplasma mycoides* cluster as determined by sequence analysis of the 16S rRNA genes from the two rRNA operons. *J. Bacteriol.* 178, 4131–4142. <https://doi.org/10.1128/jb.178.14.4131-4142.1996>
- Pflaum, K., Tulman, E.R., Beaudet, J., Canter, J., Geary, S.J., 2018. Variable Lipoprotein Hemagglutinin A Gene (*v/hA*) Expression in Variant *Mycoplasma gallisepticum* Strains *In Vivo*. *Infect. Immun.* 86, e00524-18. <https://doi.org/10.1128/IAI.00524-18>
- Pflaum, K., Tulman, E.R., Beaudet, J., Liao, X., Geary, S.J., 2016. Global Changes in *Mycoplasma gallisepticum* Phase-Variable Lipoprotein Gene *v/hA* Expression during *In Vivo* Infection of the Natural Chicken Host. *Infect. Immun.* 84, 351–355. <https://doi.org/10.1128/IAI.01092-15>
- Piccinini, R., Gosney, F., Snel, G.G.M., Luini, M.V., Nicholas, R.A.J., 2015. Environmental survival of *Mycoplasma bovis* on a white veal farm. *Vet. Rec. Case Rep.* 3. <https://doi.org/10.1136/vetreccr-2015-000207>
- Pieters, M., Daniels, J., Rovira, A., 2017. Comparison of sample types and diagnostic methods for in vivo detection of *Mycoplasma hyopneumoniae* during early stages of infection. *Vet. Microbiol.* 203, 103–109. <https://doi.org/10.1016/j.vetmic.2017.02.014>
- Pieters, M., Maes, D., 2019. Mycoplasmosis, in: *Diseases of Swine*. Hoboken, NJ, USA, pp. 863–883.
- Pillman, D., Nair, M.S., Schwartz, J., Pieters, M., 2019. Detection of *Mycoplasma hyorhinis* and *Mycoplasma hyosynoviae* in oral fluids and correlation with pig lameness scores. *Vet. Microbiol.* 239.
- Pilo, P., Frey, J., Vilei, E.M., 2007. Molecular mechanisms of pathogenicity of *Mycoplasma mycoides* subsp. *mycoides* SC. *Vet. J.* 174, 513–521. <https://doi.org/10.1016/j.tvjl.2006.10.016>
- Pilo, P., Vilei, E.M., Peterhans, E., Bonvin-Klotz, L., Stoffel, M.H., Dobbelaere, D., Frey, J., 2005. A metabolic enzyme as a primary virulence factor of *Mycoplasma mycoides* subsp. *mycoides* small colony. *J. Bacteriol.* 187, 6824–6831. <https://doi.org/10.1128/JB.187.19.6824-6831.2005>
- PingYuan, X., YunChao, P., XuXiang, O., ShengGuo, T., 2017. Seroprevalence of *Mycoplasma ovipneumoniae* in goats in Hunan province, China. *Thai J. Vet. Med.* 47, 395–399.
- Pinho, L., Thompson, G., Rosenbusch, R., Carvalheira, J., 2012. Genotyping of *Mycoplasma bovis* isolates using multiple-locus variable-number tandem-repeat analysis. *J. Microbiol. Methods* 88, 377–385. <https://doi.org/10.1016/j.mimet.2012.01.003>
- Piva, M.M., Schwertz, C.I., Bianchi, R.M., Kemper, R.T., Henker, L.C., Nagae, R.Y., Cê, T.R.M., Barcellos, D.E.S.N., Driemeier, D., Pavarini, S.P., 2020. Causes of death in growing-finishing pigs in two technified farms in southern Brazil. *Pesqui. Veterinária Bras.* 40, 758–775. <https://doi.org/10.1590/1678-5150-pvb-6708>
- Plowright, R.K., Manlove, K.R., Besser, T.E., Páez, D.J., Andrews, K.R., Matthews, P.E., Waits, L.P., Hudson, P.J., Cassirer, E.F., 2017. Age-specific infectious period shapes dynamics of pneumonia in bighorn sheep. *Ecol. Lett.* 20, 1325–1336. <https://doi.org/10.1111/ele.12829>
- Poeta Silva, A.P.S., Magtoto, R.L., Souza Almeida, H.M., McDaniel, A., Magtoto, P.D., Derscheid, R.J., Merodio, M.M., Matias Ferreyra, F.S., Gatto, I.R.H., Baum, D.H., Clavijo, M.J., Arruda, B.L., Zimmerman, J.J., Giménez-Lirola, L.G., 2020. Performance of Commercial *Mycoplasma hyopneumoniae* Serum Enzyme-Linked Immunosorbent Assays under Experimental and Field Conditions. *J. Clin. Microbiol.* 58, e00485-20. <https://doi.org/10.1128/JCM.00485-20>

- Poeta Silva, A.P.S.P., Storino, G.Y., Ferreyra, F.S.M., Zhang, M., Miller, J.M., Harmon, K.M., Gauger, P.C., Witbeck, W., Doolittle, K., Zimmerman, S., Wang, C., Derscheid, R.J., Clavijo, M.J., Arruda, B.L., Zimmerman, J.J., 2022. Effect of testing protocol and within-pen prevalence on the detection of *Mycoplasma hyopneumoniae* DNA in oral fluid samples. *Prev. Vet. Med.* 204, 105670. <https://doi.org/10.1016/j.prevetmed.2022.105670>
- Pohjanvirta, T., Vähänikkilä, N., Talvitie, V., Pelkonen, S., Autio, T., 2021. Suitability of Nasal and Deep Nasopharyngeal Swab Sampling of Calves in the *Mycoplasma bovis* Control Program. *Front. Vet. Sci.* 8, 689212. <https://doi.org/10.3389/fvets.2021.689212>
- Popa, V., Culcescu, M., Botus, D., Floarea, A., Popa, M., Dinu, H., Daneş, M., 2019. Efficacy assessment of the Agavac vaccine destined for contagious agalactia prophylaxis in small ruminants, on guinea pig: short communication. *Lucr. Stiintifice - Univ. Stiinte Agric. Banat. Timisoara Med. Vet.* 52, 72–79.
- Pôrto, R.N.G., Junqueira-Kipnis, A.P., de Oliveira Viu, M.A., Teixeira, R.C., Gambarini, M.L., 2021. Evaluation of *in vitro* Activation of Bovine Endometrial and Vaginal Epithelial and Blood Mononuclear Cells to Produce Nitric Oxide in Response to *Mycoplasma bovis*, *Mycoplasma bovigenitalium* and *Ureaplasma diversum*. *Acta Vet. (Beogr.)* 71, 137–146. <https://doi.org/10.2478/acve-2021-0012>
- Pourbakhsh, S.A., Abtin, A., Ashtari, A., Kheirkhah, B., Bayatzadeh, M.A., Ahangaran, S., 2017. Isolation and detection of *Mycoplasma agalactiae* from semen samples of goats. *Arch. Razi Inst.* 72, 159–164.
- Prats-van der Ham, M., de la Fe, C., Amores, J., Paterna, A., Tatay-Dualde, J., Gómez-Martín, Á., 2015. Contagious caprine pleuropneumonia (CCPP) and other emergent mycoplasmal diseases affecting small ruminants in arid lands. *J. Arid Environ.* 119, 9–15. <https://doi.org/10.1016/j.jaridenv.2015.03.006>
- Prats-van der Ham, M., Tatay-Dualde, J., de la Fe, C., Paterna, A., Sánchez, A., Corrales, J.C., Contreras, A., Gómez-Martín, Á., 2017a. Detecting asymptomatic rams infected with *Mycoplasma agalactiae* in ovine artificial insemination centers. *Theriogenology* 89, 324–328.e1. <https://doi.org/10.1016/j.theriogenology.2016.09.014>
- Prats-van der Ham, M., Tatay-Dualde, J., de la Fe, C., Paterna, A., Sánchez, A., Corrales, J.C., Contreras, A., Gómez-Martín, Á., 2017b. Molecular resistance mechanisms of *Mycoplasma agalactiae* to macrolides and lincomycin. *Vet. Microbiol.* 211, 135–140. <https://doi.org/10.1016/j.vetmic.2017.10.012>
- Prats-van der Ham, M., Tatay-Dualde, J., de la Fe, C., Paterna, A., Sánchez, A., Corrales, J.C., Contreras, A., Gómez-Martín, Á., 2016. Presence of *Mycoplasma agalactiae* in semen of naturally infected asymptomatic rams. *Theriogenology* 86, 791–794. <https://doi.org/10.1016/j.theriogenology.2016.02.033>
- Prats-van der Ham, M., Tatay-Dualde, J., Gómez-Martín, Á., Corrales, J.C., Contreras, A., Sánchez, A., de la Fe, C., 2018. 23S rRNA and L22 ribosomal protein are involved in the acquisition of macrolide and lincosamide resistance in *Mycoplasma capricolum* subsp. *capricolum*. *Vet. Microbiol.* 216, 207–211. <https://doi.org/10.1016/j.vetmic.2018.02.014>
- Prezotto, C., Marin, S., Araújo, T., Barbosa, F., Barrios, P., Gomes, A., Peconick, A., Resende, M., Sousa, R., Martins, N., 2016. Experimental Coinfection of Chicken Anemia Virus and *Mycoplasma gallisepticum* Vaccine Strains in Broiler Chicks. *Rev. Bras. Ciênc. Avícola* 18, 475–480. <https://doi.org/10.1590/1806-9061-2016-0235>
- Prüter, H., Czirják, G.Á., Twietmeyer, S., Harder, T., Grund, C., Mühlendorfer, K., Lüscho, D., 2018. Sane and sound: a serologic and molecular survey for selected infectious agents in neozootic Egyptian geese (*Alopochen aegyptiacus*) in Germany. *Eur. J. Wildl. Res.* 64, 71. <https://doi.org/10.1007/s10344-018-1231-9>
- Prysljak, T., Maina, T., Perez-Casal, J., 2018. Th-17 cell mediated immune responses to *Mycoplasma bovis* proteins formulated with Montanide ISA61 VG and curdlan are not sufficient for

- protection against an experimental challenge with *Mycoplasma bovis*. *Vet. Immunol. Immunopathol.* 197, 7–14. <https://doi.org/10.1016/j.vetimm.2018.01.004>
- Pryšliak, T., Maina, T., Yu, L., Suleman, M., Jimbo, S., Perez-Casal, J., 2017. Induction of a balanced IgG1/IgG2 immune response to an experimental challenge with *Mycoplasma bovis* antigens following a vaccine composed of Emulsigen™, IDR peptide1002, and poly I:C. *Vaccine* 35, 6604–6610. <https://doi.org/10.1016/j.vaccine.2017.10.037>
- Pryšliak, T., Menghwar, H., Perez-Casal, J., 2023. Complement-mediated killing of *Mycoplasma bovis* does not play a role in the protection of animals against an experimental challenge. *Vaccine* 41, 1743–1752. <https://doi.org/10.1016/j.vaccine.2023.02.021>
- Pryšliak, T., Perez-Casal, J., 2016. Immune responses to *Mycoplasma bovis* proteins formulated with different adjuvants. *Can. J. Microbiol.* 62, 492–504. <https://doi.org/10.1139/cjm-2015-0762>
- Pryšliak, T., van der Merwe, J., Lawman, Z., Wilson, D., Townsend, H., van Drunen Littel-van den Hurk, S., Perez-Casal, J., 2011. Respiratory disease caused by *Mycoplasma bovis* is enhanced by exposure to bovine herpes virus 1 (BHV-1) but not to bovine viral diarrhoea virus (BVDV) type 2. *Can. Vet. J. Rev. Veterinaire Can.* 52, 1195–1202.
- Pryšliak, T., van der Merwe, J., Perez-Casal, J., 2013. Vaccination with recombinant *Mycoplasma bovis* GAPDH results in a strong humoral immune response but does not protect feedlot cattle from an experimental challenge with *M. bovis*. *Microb. Pathog.* 55, 1–8. <https://doi.org/10.1016/j.micpath.2012.12.001>
- Puls, C.L., Allee, G.L., Hammer, J.M., Carr, S.N., 2019. Effects of different antibiotic feeding programs on morbidity and mortality and growth performance of nursery pigs housed in a wean-to-finish facility. *Transl. Anim. Sci.* 3, 123–129. <https://doi.org/10.1093/tas/txy096>
- Puvača, N., Lika, E., Tufarelli, V., Bursić, V., Ljubojević Pelić, D., Nikolova, N., Petrović, A., Prodanović, R., Vuković, G., Lević, J., Giannenas, I., 2020. Influence of Different Tetracycline Antimicrobial Therapy of *Mycoplasma (Mycoplasma synoviae)* in Laying Hens Compared to Tea Tree Essential Oil on Table Egg Quality and Antibiotic Residues. *Foods* 9, 612. <https://doi.org/10.3390/foods9050612>
- Qasem, J.A., Al-Mouqati, S.A., Al-Ali, E.M., Ben-Haji, A., 2015. Application of molecular and serological methods for rapid detection of *Mycoplasma gallisepticum* infection (Avian mycoplasmosis). *Pak. J. Biol. Sci.* 18, 81–87.
- Qi, J., Guo, A., Cui, P., Chen, Y., Mustafa, R., Ba, X., Hu, C., Bai, Z., Chen, X., Shi, L., Chen, H., 2012. Comparative Geno-Plasticity Analysis of *Mycoplasma bovis* HB0801 (Chinese Isolate). *PLOS ONE* 7, e38239. <https://doi.org/10.1371/journal.pone.0038239>
- Qi, J., Wang, Y., Li, H., Shang, Y., Gao, S., Ding, C., Liu, X., Wang, S., Li, T., Tian, M., Yu, S., 2022. *Mycoplasma synoviae* dihydrolipoamide dehydrogenase is an immunogenic fibronectin/plasminogen binding protein and a putative adhesin. *Vet. Microbiol.* 265, 109328. <https://doi.org/10.1016/j.vetmic.2021.109328>
- QianQian, W., Xin, X., QinXi, C., KeJing, Z., YiTing, Z., ZhiBin, Z., YunChao, K., LunGuang, Y., Jun, J., YingZuo, B., QingMei, X., 2019. Rapid and visible detection of *Mycoplasma synoviae* using a novel polymerase spiral reaction assay. *Poult. Sci.* 98, 5355–5360.
- Quiroz-Castañeda, R.E., Amaro-Estrada, I., Rodríguez-Camarillo, S., Aguilar-Díaz, J.H., 2020. Hemotrophic mycoplasmas, occurrence and detection methods in animals of veterinary importance. *Rev. Salud Anim.* 42.
- Quiroz-Castañeda, R.E., Martínez-Ocampo, F., Dantán-González, E., 2018. Draft Genome Sequence of *Mycoplasma wenyonii*, a Second Hemotropic *Mycoplasma* Species Identified in Mexican Bovine Cattle. *Microbiol. Resour. Announc.* 7, e00875-18. <https://doi.org/10.1128/MRA.00875-18>
- Rahimabadi, E., Asadpour, Y., Pourbakhsh, S.A., Sayeban, P., 2017. Isolation and identification of *Mycoplasma agalactiae* by culture and polymerase chain reaction methods in the sheep herds in Guilan province, Iran. *Arch. Razi Inst.* 72, 219–223.

- Rahman, M., Khan, F.A., Sadique, U., Ahmad, I., Ahmad, S., Ahmad, F., Khan, H., Saeed, M., Rehman, F.U., Hussain, I., Khan, M.F., Haque, M.I. ul, Rehman, H., 2021. In-vitro Susceptibility of *Mycoplasma capricolum* Subsp. *capripneumoniae* Pakistan Strain to Commercially Available Quinolones. *Pak. J. Zool.* 53. <https://doi.org/10.17582/journal.pjz/20191231101203>
- Rajkumar, S., Reddy, M.R., Somvanshi, R., 2020. Molecular Typing of Indian *Mycoplasma synoviae* Isolates. *Indian J. Anim. Res.* 55, 1091–1095. <https://doi.org/10.18805/IJAR.B-4153>
- Rama Raju, S.S.B., Satyanarayana, M., Sridhar, K., 2017. Chronic Respiratory Disease (CRD) in desi birds complicated by *E. coli* infection. *Blue Cross Book 2017*, 59–62.
- Ramsubeik, S., Stoute, S., Shivaprasad, H.L., Mete, A., Pitesky, M., 2021. A retrospective study to identify concomitant pathogens in *Mycoplasma gallisepticum* positive commercial turkeys and the development of a predictive model of *Mycoplasma gallisepticum* serologic status in California (2008–2019). *J. Appl. Poult. Res.* 30, 100177. <https://doi.org/10.1016/j.japr.2021.100177>
- Ranjitkar, S., Duan, J.E., Srirattana, K., Alqahtani, F., Tulman, E.R., Mandoiu, I., Venkitanarayanan, K., Tian, X., 2022. Transcriptomic Responses of *Mycoplasma bovis* Upon Treatments of trans-Cinnamaldehyde, Carvacrol, and Eugenol. *Front. Microbiol.* 13, 888433. <https://doi.org/10.3389/fmicb.2022.888433>
- Rao, J., Wei, X., Li, H., Zhang, Z., Liu, J., Lian, M., Cao, W., Yuan, L., Dou, B., Tian, Y., Chen, H., Li, J., Bei, W., 2023. Novel Multiplex PCR Assay and Its Application in Detecting Prevalence and Antibiotic Susceptibility of Porcine Respiratory Bacterial Pathogens in Guangxi, China. *Microbiol. Spectr.* 11, e0397122. <https://doi.org/10.1128/spectrum.03971-22>
- Raquib, A., Uddin, A., Nurozzaman, S.M., Uddin, M.M., Ahsan, G., Rahman, Md Masudur, Rahman, Md Mahfujur, 2021. Seroprevalence of *Mycoplasma gallisepticum* infection in layer chickens of Bangladesh. *Iraqi J. Vet. Sci.* 36, 9–13. <https://doi.org/10.33899/ijvs.2020.127511.1506>
- Rasheed, M.A., JingJing, Q., XiFang, Z., ChenFei, H., Menghwar, H., Khan, F.A., Gang, Z., Zubair, M., ChangMin, H., YingYu, C., HuanChun, C., AiZhen, G., 2017. Comparative genomics of *Mycoplasma bovis* strains reveals that decreased virulence with increasing passages might correlate with potential virulence-related factors. *Front. Cell. Infect. Microbiol.* 7.
- Rasool, A., Anjum, A.A., Rabbani, M., Lateef, M., Akhter, F., Afroz, H., Muhammad, J., Nawaz, M., 2018. Molecular characterization and phylogenetic analysis of *Mycoplasma synoviae* isolated from chicken. *JAPS J. Anim. Plant Sci.* 28, 491–497.
- Rasool, A., Anjum, A.A., Rabbani, M., Lateef, M., Nawaz, M., Akhtar, F., Kanwal, A., Sattar, S., 2017. Preparation of *Mycoplasma synoviae* antigens and evaluation by Rapid Slide Agglutination and Enzyme Linked Immunosorbent Assay. *JAPS J. Anim. Plant Sci.* 27, 841–847.
- Rasoulinezhad, S., Bozorgmehrifard, M.H., Hosseini, H., Sheikhi, N., Charkhkar, S., 2018. Molecular detection of *Mycoplasma synoviae* from backyard and commercial turkeys in some parts of Iran. *Arch. Razi Inst.* 73, 79–85.
- Rasoulinezhad, S., Bozorgmehrifard, M.H., Hosseini, H., Sheikhi, N., Charkhkar, S., 2017. Molecular detection and phylogenetic analysis of *Mycoplasma gallisepticum* from backyard and commercial turkey flocks in Iran. *Vet. Res. Forum* 8, 293–298.
- Rather, I.U.H., Parray, O.R., Ain, Q.U., Bhat, R.A., Muheet, M., Wani, S., Mushtaq, M., Parrah, J.U., Muhee, A., Dhama, K., Malik, Y.S., Yatoo, M.I., 2021. A mini-review on diagnosis of contagious caprine pleuropneumonia. *Indian J. Anim. Sci.* 91, 687–691.
- Rawal, G., Arruda, P., Rademacher, C., Ran, B., Linhares, D.C.L., 2018. General overview of the detection of *Mycoplasma hyopneumoniae* DNA by quantitative polymerase chain reaction in diagnostic cases submitted to the Iowa State University Veterinary Diagnostic Laboratory from 2004 to 2016. *J. Swine Health Prod.* 26, 309–315.
- Raymond, B.B.A., Jenkins, C., Seymour, L.M., Tacchi, J.L., Widjaja, M., Jarocki, V.M., Deutscher, A.T., Turnbull, L., Whitchurch, C.B., Padula, M.P., Djordjevic, S.P., 2015. Proteolytic processing of the cilium adhesin MHJ_0194 (P123) in *Mycoplasma hyopneumoniae* generates a functionally diverse array of cleavage fragments that bind multiple host molecules: Cleavage

- fragments of P97 are multifunctional adhesins. *Cell. Microbiol.* 17, 425–444. <https://doi.org/10.1111/cmi.12377>
- Raymond, B.B.A., Jenkins, C., Turnbull, L., Whitchurch, C.B., Djordjevic, S.P., 2018a. Extracellular DNA release from the genome-reduced pathogen *Mycoplasma hyopneumoniae* is essential for biofilm formation on abiotic surfaces. *Sci. Rep.* 8, 10373. <https://doi.org/10.1038/s41598-018-28678-2>
- Raymond, B.B.A., Madhkoor, R., Schleicher, I., Uphoff, C.C., Turnbull, L., Whitchurch, C.B., Rohde, M., Padula, M.P., Djordjevic, S.P., 2018b. Extracellular actin is a receptor for *Mycoplasma hyopneumoniae*. *Front. Cell. Infect. Microbiol.* 8.
- Raymond, B.B.A., Turnbull, L., Jenkins, C., Madhkoor, R., Schleicher, I., Uphoff, C.C., Whitchurch, C.B., Rohde, M., Djordjevic, S.P., 2018c. *Mycoplasma hyopneumoniae* resides intracellularly within porcine epithelial cells. *Sci. Rep.* 8, 17697. <https://doi.org/10.1038/s41598-018-36054-3>
- Razin, S., Yogev, D., Naot, Y., 1998. Molecular Biology and Pathogenicity of *Mycoplasmas*. *Microbiol. Mol. Biol. Rev.* 62, 1094–1156. <https://doi.org/10.1128/MMBR.62.4.1094-1156.1998>
- Rebaque, F., Camacho, P., Parada, J., Lucchesi, P., Ambrogi, A., Tamiozzo, P., 2018. Persistence of the same genetic type of *Mycoplasma hyopneumoniae* in a closed herd for at least two years. *Rev. Argent. Microbiol.* 50, 147–150. <https://doi.org/10.1016/j.ram.2017.05.002>
- Rech, R.R., Gava, D., Silva, M.C., Fernandes, L.T., Haach, V., Ciacci-Zanella, J.R., Schaefer, R., 2018. Porcine respiratory disease complex after the introduction of H1N1/2009 influenza virus in Brazil. *Zoonoses Public Health* 65, e155–e161. <https://doi.org/10.1111/zph.12424>
- Reck, C., Menin, Á., Canever, M.F., Pilatic, C., Miletti, L.C., 2019. Molecular detection of *Mycoplasma synoviae* and avian reovirus infection in arthritis and tenosynovitis lesions of broiler and breeder chickens in Santa Catarina State, Brazil. *J. S. Afr. Vet. Assoc.* 90. <https://doi.org/10.4102/jsava.v90i0.1970>
- Register, K.B., Bayles, D.O., Ma, H., Windeyer, M.C., Perez-Casal, J., Bras, A.L., Suleman, M., Woodbury, M., Jelinski, M.D., Alt, D.P., 2020a. Complete Genome Sequences of 16 *Mycoplasma bovis* Isolates from Canadian Bison and Cattle. *Microbiol. Resour. Announc.* 9, e00325-20. <https://doi.org/10.1128/MRA.00325-20>
- Register, K.B., Boatwright, W.D., Gesy, K.M., Thacker, T.C., Jelinski, M.D., 2018a. Mistaken identity of an open reading frame proposed for PCR-based identification of *Mycoplasma bovis* and the effect of polymorphisms and insertions on assay performance. *J. Vet. Diagn. Invest.* 30, 637–641. <https://doi.org/10.1177/1040638718764799>
- Register, K.B., Jelinski, M.D., Waldner, M., Boatwright, W.D., Anderson, T.K., Hunter, D.L., Hamilton, R.G., Burrage, P., Shury, T., Bildfell, R., Wolff, P.L., Miskimins, D., Derscheid, R.J., Woodbury, M.R., 2019. Comparison of multilocus sequence types found among North American isolates of *Mycoplasma bovis* from cattle, bison, and deer, 2007–2017. *J. Vet. Diagn. Invest.* 31, 899–904. <https://doi.org/10.1177/1040638719874848>
- Register, K.B., Jones, L.C., Boatwright, W.D., Shury, T.K., Woodbury, M., Hamilton, R.G., Treanor, J., Dyer, N., Nol, P., 2021a. Prevalence of *Mycoplasma* spp. in the Respiratory Tract of Healthy North American Bison (*Bison bison*) and Comparison with Serum Antibody Status. *J. Wildl. Dis.* 57. <https://doi.org/10.7589/JWD-D-20-00198>
- Register, K.B., Lysnyansky, I., Jelinski, M.D., Boatwright, W.D., Waldner, M., Bayles, D.O., Pilo, P., Alt, D.P., 2020b. Comparison of Two Multilocus Sequence Typing Schemes for *Mycoplasma bovis* and Revision of the PubMLST Reference Method. *J. Clin. Microbiol.* 58, e00283-20. <https://doi.org/10.1128/JCM.00283-20>
- Register, K.B., Olsen, S.C., Sacco, R.E., Ridpath, J., Falkenberg, S., Briggs, R., Kanipe, C., Madison, R., 2018b. Relative virulence in bison and cattle of bison-associated genotypes of *Mycoplasma bovis*. *Vet. Microbiol.* 222, 55–63. <https://doi.org/10.1016/j.vetmic.2018.06.020>
- Register, K.B., Parker, M., Patyk, K.A., Sweeney, S.J., Boatwright, W.D., Jones, L.C., Woodbury, M., Hunter, D.L., Treanor, J., Kohr, M., Hamilton, R.G., Shury, T.K., Nol, P., 2021b. Serological

- evidence for historical and present-day exposure of North American bison to *Mycoplasma bovis*. *BMC Vet. Res.* 17, 18. <https://doi.org/10.1186/s12917-020-02717-5>
- Register, K.B., Sacco, R.E., Olsen, S.C., 2013a. Evaluation of enzyme-linked immunosorbent assays for detection of *Mycoplasma bovis*-specific antibody in bison sera. *Clin. Vaccine Immunol.* 20, 1405–1409.
- Register, K.B., Thole, L., Rosenbush, R.F., Minion, F.C., 2015. Multilocus sequence typing of *Mycoplasma bovis* reveals host-specific genotypes in cattle versus bison. *Vet. Microbiol.* 175, 92–98. <https://doi.org/10.1016/j.vetmic.2014.11.002>
- Register, K.B., Woodbury, M.R., Davies, J.L., Trujillo, J.D., Perez-Casal, J., Burrage, P.H., Clark, E.G., Windeyer, M.C., 2013b. Systemic mycoplasmosis with dystocia and abortion in a North American bison (*Bison bison*) herd. *J. Vet. Diagn. Invest.* 25, 541–545. <https://doi.org/10.1177/1040638713495029>
- Reinoso-Pérez, M.T., Dhondt, K.V., Levitskiy, A.A., Dupont, G., Tulman, E.R., Geary, S.J., Dhondt, A.A., 2023. Are Purple Finches (*Haemorhous purpureus*) the Next Host for a Mycoplasmal Conjunctivitis Epidemic? *Avian Dis.* 67, 42–48. <https://doi.org/10.1637/aviandiseases-D-22-00047>
- Rekha, V., Rana, R., Thomas, P., Viswas, K.N., Singh, V.P., Agarwal, R.K., Arun, T.R., Karthik, K., Sophia, I., 2015. Development of loop-mediated isothermal amplification test for the diagnosis of contagious agalactia in goats. *Trop. Anim. Health Prod.* 47, 581–587. <https://doi.org/10.1007/s11250-015-0767-x>
- Renault, V., Hambe, H.A., Vlaenderen, G. van, Timmermans, E., Mohamed, A.M., Ethgen, O., Saegerman, C., 2019. Economic impact of contagious caprine pleuropneumonia and cost-benefit analysis of the vaccination programmes based on a one-year continuous monitoring of flocks in the arid and semi-arid lands of Kenya. *Transbound. Emerg. Dis.* 66, 2523–2536.
- Resende, T.P., Marshall Lund, L., Rossow, S., Vannucci, F.A., 2019a. Next-Generation Sequencing Coupled With in situ Hybridization: A Novel Diagnostic Platform to Investigate Swine Emerging Pathogens and New Variants of Endemic Viruses. *Front. Vet. Sci.* 6, 403. <https://doi.org/10.3389/fvets.2019.00403>
- Resende, T.P., Pieters, M., Vannucci, F.A., 2019b. Swine conjunctivitis outbreaks associated with *Mycoplasma hyorhinis*. *J. Vet. Diagn. Invest.* 31, 766–769. <https://doi.org/10.1177/1040638719865767>
- Rhodes, S.G., Buddle, B.M., Hewinson, R.G., Vordermeier, H.M., 2000. Bovine tuberculosis: immune responses in the peripheral blood and at the site of active disease. *Immunology* 99, 195–202. <https://doi.org/10.1046/j.1365-2567.2000.00944.x>
- Riaz, R., Muhammad, K., Rabbani, M., Iqbal, M.A., Khan, A.R., Sarfaraz, S., Naseer, M., Majeed, K., 2021. Immunomodulatory Effect of New Castle Disease Virus on Inactivated *Mycoplasma gallisepticum* Vaccine Response in Broilers. *Pak. J. Zool.* 53. <https://doi.org/10.17582/journal.pjz/20190701160742>
- Ricketts, C., Pickler, L., Maurer, J., Ayyampalayam, S., García, M., Ferguson-Noel, N.M., 2017. Identification of Strain-Specific Sequences That Distinguish a *Mycoplasma gallisepticum* Vaccine Strain from Field Isolates. *J. Clin. Microbiol.* 55, 244–252. <https://doi.org/10.1128/JCM.00833-16>
- Ridley, A., Hateley, G., 2018. *Mycoplasma bovis* investigations in cattle. *Vet. Rec.* 183, 256–258.
- Risco, D., Cuesta, J.M., Fernández-Llario, P., Salguero, F.J., Gonçalves, P., García-Jiménez, W.L., Martínez, R., Velarde, R., de Mendoza, M.H., Gómez, L., de Mendoza, J.H., 2015. Pathological observations of porcine respiratory disease complex (PRDC) in the wild boar (*Sus scrofa*). *Eur. J. Wildl. Res.* 61, 669–679. <https://doi.org/10.1007/s10344-015-0937-1>
- Rjeibi, M.R., Darghouth, M.A., Omri, H., Souidi, K., Rekik, M., Gharbi, M., 2015. First molecular isolation of *Mycoplasma ovis* from small ruminants in North Africa. *Onderstepoort J. Vet. Res.* 82.

- Robbins, R.C., Betlach, A.M., Mondragon-Evans, M.R., Pieters, M., 2019. Development of a herd-specific lung homogenate for exposure to *Mycoplasma hyopneumoniae* under field conditions. *J. Swine Health Prod.* 27, 221–227.
- Robinson, E., Schulein, C., Jacobson, B.T., Jones, K., Sago, J., Huber, V., Jutila, M., Bimczok, D., Rynda-Apple, A., 2022. Pathophysiology of Influenza D Virus Infection in Specific-Pathogen-Free Lambs with or without Prior *Mycoplasma ovipneumoniae* Exposure. *Viruses* 14, 1422. <https://doi.org/10.3390/v14071422>
- Rodrigues da Costa, M., Fitzgerald, R.M., Manzanilla, E.G., O’Shea, H., Moriarty, J., McElroy, M.C., Leonard, F.C., 2020. A cross-sectional survey on respiratory disease in a cohort of Irish pig farms. *Ir. Vet. J.* 73, 24. <https://doi.org/10.1186/s13620-020-00176-w>
- Rodrigues, V., Holzmüller, P., Puech, C., Wesonga, H., Thiaucourt, F., Manso-Silvan, L., 2015. Whole Blood Transcriptome Analysis of *Mycoplasma mycoides* Subsp. *mycoides*-Infected Cattle Confirms Immunosuppression but Does Not Reflect Local Inflammation. *PLOS ONE* 10, e0139678. <https://doi.org/10.1371/journal.pone.0139678>
- Rodriguez, F., Castro, P., 2015. Differential Cytokine Expression in Natural and Experimental Mastitis Induced by *Mycoplasma agalactiae* in Dairy Goats. *Reprod. Domest. Anim.* 50, 159–163. <https://doi.org/10.1111/rda.12457>
- Rodriguez, F., Gonzalez, J.F., Arbelo, M., Zucca, D., Fernandez, A., 2015a. Cytokine expression in lungs of calves spontaneously infected with *Mycoplasma bovis*. *Vet. Res. Commun.* 39, 69–72. <https://doi.org/10.1007/s11259-014-9620-3>
- Rodriguez, F., Poveda, J.B., Jaber, J.R., Oros, J., Rodriguez, J.L., 2015b. Expression of cyclooxygenase-2 in the mammary gland tissue of goats affected with caprine contagious agalactia. *Vet. J.* 204, 125–127. <https://doi.org/10.1016/j.tvjl.2015.02.001>
- Roger, F.L., Solano, P., Bouyer, J., Porphyre, V., Berthier, D., Peyre, M., Bonnet, P., 2017. Advocacy for identifying certain animal diseases as “neglected.” *PLoS Negl. Trop. Dis.* 11, e0005843. <https://doi.org/10.1371/journal.pntd.0005843>
- Ron, M., Gorelick-Ashkenazi, A., Levisohn, S., Nir-Paz, R., Geary, S.J., Tulman, E., Lysnyansky, I., Yogev, D., 2015. *Mycoplasma gallisepticum* in vivo induced antigens expressed during infection in chickens. *Vet. Microbiol.* 175, 265–274. <https://doi.org/10.1016/j.vetmic.2014.12.007>
- Roos, L.R., Fano, E., Homwong, N., Payne, B., Pieters, M., 2016. A model to investigate the optimal seeder-to-naive ratio for successful natural *Mycoplasma hyopneumoniae* gilt exposure prior to entering the breeding herd. *Vet. Microbiol.* 184, 51–58.
- Roos, L.R., Surendran Nair, M., Rendahl, A.K., Pieters, M., 2019. *Mycoplasma hyorhinis* and *Mycoplasma hyosynoviae* dual detection patterns in dams and piglets. *PLOS ONE* 14, e0209975. <https://doi.org/10.1371/journal.pone.0209975>
- Rosales, R.S., Churchward, C.P., Schnee, C., Sachse, K., Lysnyansky, I., Catania, S., Iob, L., Ayling, R.D., Nicholas, R.A.J., 2015. Global Multilocus Sequence Typing Analysis of *Mycoplasma bovis* Isolates Reveals Two Main Population Clusters. *J. Clin. Microbiol.* 53, 789–794. <https://doi.org/10.1128/JCM.01910-14>
- Rosales, R.S., Puleio, R., Loria, G.R., Catania, S., Nicholas, R.A.J., 2017. *Mycoplasmas*: Brain invaders? *Res. Vet. Sci.* 113, 56–61. <https://doi.org/10.1016/j.rvsc.2017.09.006>
- Rosales, R.S., Ramirez, A.S., Tavio, M.M., Poveda, C., Poveda, J.B., 2020. Antimicrobial susceptibility profiles of porcine mycoplasmas isolated from samples collected in southern Europe. *BMC Vet. Res.* 16, 324. <https://doi.org/10.1186/s12917-020-02512-2>
- Rosengarten, R., Yogev, D., 1996. Variant colony surface antigenic phenotypes within mycoplasma strain populations: implications for species identification and strain standardization. *J. Clin. Microbiol.* 34, 149–158. <https://doi.org/10.1128/jcm.34.1.149-158.1996>
- Rossetti, B.C., Frey, J., Pilo, P., 2010. Direct detection of *Mycoplasma bovis* in milk and tissue samples by real-time PCR. *Mol. Cell. Probes* 24, 321–323. <https://doi.org/10.1016/j.mcp.2010.05.001>

- Rovani, E.R., Beckmen, K.B., Highland, M.A., 2019. *Mycoplasma ovipneumoniae* Associated with Polymicrobial Pneumonia in a Free-Ranging Yearling Barren Ground Caribou (*Rangifer tarandus granti*) from Alaska, USA. *J. Wildl. Dis.* 55, 733. <https://doi.org/10.7589/2018-08-188>
- Rüger, N., Sid, H., Meens, J., Szostak, M.P., Baumgärtner, W., Bexter, F., Rautenschlein, S., 2021. New Insights into the Host–Pathogen Interaction of *Mycoplasma gallisepticum* and Avian Metapneumovirus in Tracheal Organ Cultures of Chicken. *Microorganisms* 9, 2407. <https://doi.org/10.3390/microorganisms9112407>
- Rüger, N., Szostak, M.P., Rautenschlein, S., 2022. The expression of GapA and CrmA correlates with the *Mycoplasma gallisepticum* in vitro infection process in chicken TOCs. *Vet. Res.* 53, 66. <https://doi.org/10.1186/s13567-022-01085-2>
- Rui, Y., Qiu, G., 2023. Drug Susceptibility Test and Analysis of Quinolone Resistance Genes in *Mycoplasma hyopneumoniae* Vaccine Strains and Field Isolates from China. *Infect. Drug Resist.* 16, 2075–2087. <https://doi.org/10.2147/IDR.S407579>
- Rweyemamu, M., Paskin, R., Benkirane, A., Martin, V., Roeder, P., Wojciechowski, K., 2000. Emerging Diseases of Africa and the Middle East. *Ann. N. Y. Acad. Sci.* 916, 61–70. <https://doi.org/10.1111/j.1749-6632.2000.tb05275.x>
- Sacchini, F., Liljander, A.M., Heller, M., Poole, E.J., Posthaus, H., Schieck, E., Jores, J., 2020. Reproduction of contagious bovine pleuropneumonia via aerosol-based challenge with *Mycoplasma mycoides* subsp. *mycoides*. *Acta Vet. Scand.* 62, 62. <https://doi.org/10.1186/s13028-020-00560-0>
- Sacchini, F., Luciani, M., Salini, R., Scacchia, M., Pini, A., Lelli, R., Naessens, J., Poole, J., Jores, J., 2012. Plasma levels of TNF- α , IFN- γ , IL-4 and IL-10 during a course of experimental contagious bovine pleuropneumonia. *BMC Vet. Res.* 8.
- Sacchini, F., Naessens, J., Awino, E., Heller, M., Hlinak, A., Haider, W., Sterner-Kock, A., Jores, J., 2011. A minor role of CD4+ T lymphocytes in the control of a primary infection of cattle with *Mycoplasma mycoides* subsp. *mycoides*. *Vet. Res.* 42, 77. <https://doi.org/10.1186/1297-9716-42-77>
- Sachse, K., Salam, H.S.H., Diller, R., Schubert, E., Hoffmann, B., Hotzel, H., 2010. Use of a novel real-time PCR technique to monitor and quantitate *Mycoplasma bovis* infection in cattle herds with mastitis and respiratory disease. *Vet. J. Lond. Engl.* 197, 299–303. <https://doi.org/10.1016/j.tvjl.2009.10.008>
- Sada, A., Tambuwal, F.M., Egwu, G.O., Ahmad, K.H., Umar, B.N., Ibrahim, A.M., Abdullahi, M.S., 2021. Serological survey and isolation of *Mycoplasma mycoides* subspecies *mycoides* from cattle slaughtered at Katsina state central abattoir, Nigeria. *Sokoto J. Vet. Sci.* 19, 129–132. <https://doi.org/10.4314/sokjvs.v19i2.8>
- Sada, A., Tambuwal, F.M., Egwu, G.O., Manga, S.B., Akalusi, Y., Bello, M.B., 2015. Contagious bovine pleuropneumonia (CBPP) vaccination and prevalence (2000-2012) in Katsina state, north-western Nigeria. *Vom J. Vet. Sci.* 10, 33–40.
- Saeed, E.M.A., Osman, S.A., 2018. Clinical and laboratory diagnosis of contagious caprine pleuropneumonia in Qassim region, Saudi Arabia: a comparative study. *Trop. Biomed.* 35, 67–75.
- Sajiki, Y., Konnai, S., Goto, S., Okagawa, T., Ohira, K., Shimakura, H., Maekawa, N., Gondaira, S., Higuchi, H., Tajima, M., Hirano, Y., Kohara, J., Murata, S., Ohashi, K., 2020. The Suppression of Th1 Response by Inducing TGF- β 1 From Regulatory T Cells in Bovine Mycoplasmosis. *Front. Vet. Sci.* 7, 609443. <https://doi.org/10.3389/fvets.2020.609443>
- Sakuma, A., Sugawara, S., Hidaka, H., Nakajo, M., Suda, Y., Shimazu, T., Rose, M.T., Urakawa, M., Zhuang, T., Zhao, G., Watanabe, K., Nochi, T., Kitazawa, H., Katoh, K., Suzuki, K., Aso, H., 2020. IL-12p40 gene expression in lung and hilar lymph nodes of MPS-resistant pigs. *Anim. Sci. J.* 91. <https://doi.org/10.1111/asj.13450>
- Salgado, A., Cheung, A., Schibrowski, M.L., Wawegama, N.K., Mahony, T.J., Stevenson, M.A., Browning, G.F., Barnes, T.S., Firestone, S.M., 2022a. Bayesian latent class analysis to estimate the optimal

- cut-off for the MiIA ELISA for the detection of *Mycoplasma bovis* antibodies in sera, accounting for repeated measures. *Prev. Vet. Med.* 205, 105694. <https://doi.org/10.1016/j.prevetmed.2022.105694>
- Salgado, A., Firestone, S.M., Watt, A., Thilakarathne, D.S., Condello, A.K., Siu, D., Masukagami, Y., Tivendale, K.A., Stevenson, M.A., Mansell, P.D., Browning, G.F., Wawegama, N.K., 2022b. Evaluation of the MiIA ELISA for the diagnosis of herd infection with *Mycoplasma bovis* using bulk tank milk and estimation of the prevalence of *M. bovis* in Australia. *Vet. Microbiol.* 270, 109454. <https://doi.org/10.1016/j.vetmic.2022.109454>
- Salina, A., Timenetsky, J., Barbosa, M.S., Azevedo, C.M., Langoni, H., 2020. Microbiological and molecular detection of *Mycoplasma bovis* in milk samples from bovine clinical mastitis. *Pesqui. Veterinária Bras.* 40, 82–87. <https://doi.org/10.1590/1678-5150-pvb-6259>
- Salogni, C., Capucchio, M.T., Colombino, E., Pozzi, P., Pasquali, P., Alborali, G.L., 2022. Bacterial polyarthritides in post-weaning pigs in a high-density swine breeding area in Italy. *J. Vet. Diagn. Invest.* 34, 709–711. <https://doi.org/10.1177/10406387221090903>
- Salogni, C., Lazzaro, M., Giovannini, S., Vitale, N., Boniotti, M.B., Pozzi, P., Pasquali, P., Alborali, G.L., 2020. Causes of swine polyserositis in a high-density breeding area in Italy. *J. Vet. Diagn. Invest.* 32, 594–597. <https://doi.org/10.1177/1040638720928973>
- Sánchez, A., Contreras, A., Sánchez-Corral, M.L., Martínez-Nista, C., Collado, S., Sáez, J.L., Minguez, O., Fe, C. de la, 2022. Comparison of commercial enzyme-linked immunosorbent assays for diagnosis of contagious agalactia caused by *Mycoplasma agalactiae*. *J. Vet. Res.* 66, 95–101. <https://doi.org/10.2478/jvetres-2022-0010>
- Sanglard, L.P., PigGen Canada, Mote, B.E., Willson, P., Harding, J.C.S., Plastow, G.S., Dekkers, J.C.M., Serão, N.V.L., 2020. Genomic Analysis of IgG Antibody Response to Common Pathogens in Commercial Sows in Health-Challenged Herds. *Front. Genet.* 11, 593804. <https://doi.org/10.3389/fgene.2020.593804>
- Santos, N.J.R., Brito, D.R.B., Abate, H.L., Paixão, S.F., Soares, E.D.S., Vieira, T.S.W.J., Garcia, J.L., Vieira, R.F.C., Vidotto, O., 2018. Hemotropic mycoplasmas infection in water buffaloes (*Bubalus bubalis*) from northeastern Brazil. *Comp. Immunol. Microbiol. Infect. Dis.* 56, 27–29. <https://doi.org/10.1016/j.cimid.2017.12.003>
- Santos, R.T., Gaeta, N.C., Silveira, B.O., Zanette, A., Riet-Correa, B., Fraga e Silva Raimondo, R., 2022. Bacteria associated with infectious keratoconjunctivitis outbreak in confined lambs. *J. Med. Microbiol.* 71. <https://doi.org/10.1099/jmm.0.001534>
- Saraya, T., 2016. The History of *Mycoplasma pneumoniae* Pneumonia. *Front. Microbiol.* 7, 364. <https://doi.org/10.3389/fmicb.2016.00364>
- Sargeant, J.M., Deb, B., Bergevin, M.D., Churchill, K., Dawkins, K., Dunn, J., Hu, D., Moody, C., O'Connor, A.M., O'Sullivan, T.L., Reist, M., Wang, C., Wilhelm, B., Winder, C.B., 2019. Efficacy of bacterial vaccines to prevent respiratory disease in swine: a systematic review and network meta-analysis. *Anim. Health Res. Rev.* 20, 274–290. <https://doi.org/10.1017/S1466252319000173>
- Sasaoka, F., Suzuki, J., Hirata, T.I., Ichijo, T., Furuhashi, K., Harasawa, R., Satoh, H., 2015. Vertical transmission of *Mycoplasma wenyonii* in cattle, supported by analysis of the ribonuclease P RNA gene - short communication. *Acta Vet. Hung.* 63, 271–274.
- Sato, T., Higuchi, H., Yokota, S., Tamura, Y., 2017. *Mycoplasma bovis* isolates from dairy calves in Japan have less susceptibility than a reference strain to all approved macrolides associated with a point mutation (G748A) combined with multiple species-specific nucleotide alterations in 23S rRNA: Macrolide resistance in *Mycoplasma bovis*. *Microbiol. Immunol.* 61, 215–224. <https://doi.org/10.1111/1348-0421.12490>
- Sato, T., Okubo, T., Usui, M., Higuchi, H., Tamura, Y., 2013. Amino Acid Substitutions in GyrA and ParC are Associated with Fluoroquinolone Resistance in *Mycoplasma bovis* Isolates from Japanese Dairy Calves. *J. Vet. Med. Sci.* 75, 1063–1065. <https://doi.org/10.1292/jvms.12-0508>

- Sawicka-Durkalec, A., Kursa, O., Bednarz, Ł., Tomczyk, G., 2021. Occurrence of *Mycoplasma* spp. in wild birds: phylogenetic analysis and potential factors affecting distribution. *Sci. Rep.* 11, 17065. <https://doi.org/10.1038/s41598-021-96577-0>
- Scacchia, M., Tjipura-Zaire, G., Lelli, R., Sacchini, F., Pini, A., 2011. Contagious bovine pleuropneumonia: humoral and pathological events in cattle infected by endotracheal intubation or by exposure to infected animals. *Vet. Ital.* 47, 407–413.
- Scalisi, N., Kuhnert, P., Amado, M.E.V., Overesch, G., Stärk, K.D.C., Ruggli, N., Jores, J., 2022. Seroprevalence of *Mycoplasma hyopneumoniae* in sows fifteen years after implementation of a control programme for enzootic pneumonia in Switzerland. *Vet. Microbiol.* 270, 109455. <https://doi.org/10.1016/j.vetmic.2022.109455>
- Schibrowski, M.L., Barnes, T., Wawegama, N., Vance, M., Markham, P., Mansell, P., Marena, M., Kanci, A., Perez-Casal, J., Browning, G., Gibson, J., Mahony, T., 2018a. The Performance of Three Immune Assays to Assess the Serological Status of Cattle Experimentally Exposed to *Mycoplasma bovis*. *Vet. Sci.* 5, 27. <https://doi.org/10.3390/vetsci5010027>
- Schibrowski, M.L., Gibson, J.S., Hay, K.E., Mahony, T.J., Barnes, T.S., 2018b. *Mycoplasma bovis* and bovine respiratory disease: A risk factor study in Australian feeder cattle. *Prev. Vet. Med.* 157, 152–161. <https://doi.org/10.1016/j.prevetmed.2018.06.005>
- Schieck, E., Lartigue, C., Frey, J., Voza, N., Hegermann, J., Miller, R.A., Valguarnera, E., Muriuki, C., Meens, J., Nene, V., Naessens, J., Weber, J., Lowary, T.L., Vashee, S., Feldman, M.F., Jores, J., 2016. Galactofuranose in *Mycoplasma mycoides* is important for membrane integrity and conceals adhesins but does not contribute to serum resistance. *Mol. Microbiol.* 99, 55–70. <https://doi.org/10.1111/mmi.13213>
- Schieck, E., Liljander, A., Hamsten, C., Gicheru, N., Scacchia, M., Sacchini, F., Heller, M., Schnee, C., Sterner-Kock, A., Hlinak, A., Naessens, J., Poole, J., Persson, A., Jores, J., 2014. High antibody titres against predicted *Mycoplasma* surface proteins do not prevent sequestration in infected lung tissue in the course of experimental contagious bovine pleuropneumonia. *Vet. Microbiol.* 172, 285–293. <https://doi.org/10.1016/j.vetmic.2014.04.018>
- Schnee, C., Schulsse, S., Hotzel, H., Ayling, R.D., Nicholas, R.A.J., Schubert, E., Heller, M., Ehrlich, R., Sachse, K., 2012. A novel rapid DNA microarray assay enables identification of 37 *Mycoplasma* species and highlights multiple *Mycoplasma* infections. *PLOS ONE* 7, e33237. <https://doi.org/10.1371/journal.pone.0033237>
- Schneider, P., Brill, R., Schouten, I., Nissim-Eliraz, E., Lysnyansky, I., Shpigel, N.Y., 2022. Lipoproteins Are Potent Activators of Nuclear Factor Kappa B in Mammary Epithelial Cells and Virulence Factors in *Mycoplasma bovis* Mastitis. *Microorganisms* 10, 2209. <https://doi.org/10.3390/microorganisms10112209>
- Schönecker, L., Schnyder, P., Schüpbach-Regula, G., Meylan, M., Overesch, G., 2020. Prevalence and antimicrobial resistance of opportunistic pathogens associated with bovine respiratory disease isolated from nasopharyngeal swabs of veal calves in Switzerland. *Prev. Vet. Med.* 185, 105182. <https://doi.org/10.1016/j.prevetmed.2020.105182>
- Schott, C., Cai, H., Parker, L., Bateman, K.G., Caswell, J.L., 2014. Hydrogen Peroxide Production and Free Radical-mediated Cell Stress in *Mycoplasma bovis* Pneumonia. *J. Comp. Pathol.* 150, 127–137. <https://doi.org/10.1016/j.jcpa.2013.07.008>
- Schwarz, L., Strauss, A., Loncaric, I., Spargser, J., Auer, A., Rumenapf, T., Ladinig, A., 2020. The Stable Fly (*Stomoxys calcitrans*) as a Possible Vector Transmitting Pathogens in Austrian Pig Farms. *Microorganisms* 8, 1476. <https://doi.org/10.3390/microorganisms8101476>
- Secka, A., Ceesay, A., Bojang, M., Janneh, B., Camara, S., 2015. CBPP T144/T1SR vaccine induced immune response in vaccinated cattle. *Bull. Anim. Health Prod. Afr.* 63, 229–234.
- Selim, A., Megahed, A., Kandeel, S., Alanazi, A.D., Almohammed, H.I., 2021. Determination of Seroprevalence of Contagious Caprine Pleuropneumonia and Associated Risk Factors in Goats and Sheep Using Classification and Regression Tree. *Animals* 11, 1165. <https://doi.org/10.3390/ani11041165>

- Senturk, S., Mecitoglu, Z., Buyukcangaz, E., Ozyigit, O., 2012. Toxic epidermal necrolysis associated with *Mycoplasma bovis* in calves. *Vet. Rec.* 170, 566–566. <https://doi.org/10.1136/vr.100624>
- Séry, A., Sidibé, C.A.K., Cissé, O., Diallo, M., Koné, M., Waret-Szkuta, A., Roger, F., Thiaucourt, F., Niang, M., 2015. Seroprevalence of contagious bovine pleuropneumonia (CBPP) in Mali. *Trop. Anim. Health Prod.* 47, 395–402. <https://doi.org/10.1007/s11250-014-0738-7>
- Settypalli, T.B.K., Lamien, C.E., Spersger, J., Lelenta, M., Wade, A., Gelaye, E., Loitsch, A., Minoungou, G., Thiaucourt, F., Diallo, A., 2016. One-Step Multiplex RT-qPCR Assay for the Detection of Peste des petits ruminants virus, Capripoxvirus, Pasteurella multocida and Mycoplasma capricolum subspecies (ssp.) capripneumoniae. *PLOS ONE* 11, e0153688. <https://doi.org/10.1371/journal.pone.0153688>
- Severo, D.R.T., Werlang, R.A., Mori, A.P., Baldi, K.R.A., Mendes, R.E., Surian, S.R.S., Coldebella, A., Kramer, B., Trevisol, I.M., Gomes, T.M.A., Silva, V.S., 2021. Health profile of free-range wild boar (*Sus scrofa*) subpopulations hunted in Santa Catarina State, Brazil. *Transbound. Emerg. Dis.* 68, 857–869. <https://doi.org/10.1111/tbed.13752>
- Shah, M.K., Saddique, U., Ahmad, S., Iqbal, A., Ali, A., Shahzad, W., Khan, M.S., Khan, H., Hanif-ur-Rahman, Shah, S.S.A., Israr, M., 2017. Molecular characterization of local isolates of Mycoplasma capricolum sub specie Capripneumoniae in goats (Capra hircus) of Khyber Pakhtunkhwa, Pakistan. *Pak. Vet. J.* 37, 90–94.
- Shah, S.S.A., Umer Sadique, Z., Ahoor-ul-Hassan, Ahmad, S., Khan, H., Shah, M.K., Israr, M., Hanif-ur-Rahman, 2017. Clinico-pathological profile and frequency of Mycoplasma mycoides subsp. capri infection in goats in northern zone of Khyber-Pakhtunkhwa, Pakistan. *Vet. Sarajevo* 66, 72–77.
- Shahzad, W., Yaqoob, T., Mukhtar, N., Munir, R., Ahmad, R., Khan, M.S., Hussain, A., 2016. Seroprevalence of Mycoplasma capricolum subsp. capripneumoniae in goats through cELISA in different districts of Punjab, Pakistan. *JAPS J. Anim. Plant Sci.* 26, 931–937.
- Shamsaddini Bafti, M., Pourbakhsh, S.A., Ezatkah, M., Ashtari, A., 2017. Detection of Mycoplasma agalactiae in small ruminants of southeast Iran. *Arch. Razi Inst.* 72, 237–242.
- Sharma, S., Citti, C., Sagné, E., Marendra, M.S., Markham, P.F., Browning, G.F., 2015a. Development and Host Compatibility of Plasmids for Two Important Ruminant Pathogens, Mycoplasma bovis and Mycoplasma agalactiae. *PLOS ONE* 10, e0119000. <https://doi.org/10.1371/journal.pone.0119000>
- Sharma, S., Tivendale, K.A., Markham, P.F., Browning, G.F., 2015b. Disruption of the membrane nuclease gene (MBOVPG45_0215) of Mycoplasma bovis greatly reduces cellular nuclease activity. *J. Bacteriol.* 197, 1549–1558.
- Shen, Q., Sun, S., Xu, G., Fan, X., Jiang, H., Feng, Y., Peng, X., Zhu, L., Qin, Y., Ding, J., 2020. Complete Genome Sequence of Mycoplasma bovis Strain XBY01, Isolated from Henan Province, China. *Microbiol. Resour. Announc.* 9, e00001-20. <https://doi.org/10.1128/MRA.00001-20>
- Shen, Y., Hu, W., Wei, Y., Feng, Z., Yang, Q., 2017. Effects of Mycoplasma hyopneumoniae on porcine nasal cavity dendritic cells. *Vet. Microbiol.* 198, 1–8. <https://doi.org/10.1016/j.vetmic.2016.11.018>
- Shi, F., Zhao, Y., Sun, Y., Chen, C., 2020. Development and application of a colloidal carbon test strip for the detection of antibodies against Mycoplasma bovis. *World J. Microbiol. Biotechnol.* 36, 157. <https://doi.org/10.1007/s11274-020-02930-2>
- Shi, Y., Habibi, P., Haq, A.N.U., Saeed, M., Gulghutay Amjad, N., Khan, I., 2023. Seed-Based System for Cost-Effective Production of Vaccine Against Chronic Respiratory Disease in Chickens. *Mol. Biotechnol.* 65, 570–580. <https://doi.org/10.1007/s12033-022-00554-5>
- Shiferaw, J., Shifara, F., Tefera, M., Feyisa, A., Tamiru, Y., 2022. Seroprevalence and Associated Risk Factors of Mycoplasma gallisepticum Infection in Poultry Farms of Hawasa and Bishoftu, Central Ethiopia. *Vet. Med. Res. Rep.* 13, 101–107. <https://doi.org/10.2147/VMRR.S360669>
- ShiKai, S., Xin, L., Feng, C., DingAi, W., JunPeng, L., JianPing, Q., TingRong, L., 2017a. Epidemiological investigation of Mycoplasma synoviae in native chicken breeds in China. *BMC Vet. Res.* 13.

- ShiKai, S., Xin, L., JunMei, L., ZhongQiang, T., Feng, C., YongChang, C., JianPing, Q., TingRong, L., 2017b. Phylogenetic and pathogenic analysis of *Mycoplasma synoviae* isolated from native chicken breeds in China. *Poult. Sci.* 96, 2057–2063.
- Shil, P.K., Kanci, A., Browning, G.F., Marendra, M.S., Noormohammadi, A.H., Markham, P.F., 2011. GapA+*Mycoplasma gallisepticum* ts-11 has improved vaccine characteristics. *Microbiology* 157, 1740–1749. <https://doi.org/10.1099/mic.0.046789-0>
- Shimazu, T., Borjigin, L., Katayama, Y., Li, M., Satoh, T., Watanabe, K., Kitazawa, H., Roh, S., Aso, H., Katoh, K., Suda, Y., Sakuma, A., Nakajo, M., Suzuki, K., 2013. Immunological characterization of peripheral blood leukocytes using vaccine for mycoplasmal pneumonia of swine (MPS) in swine line selected for resistance to MPS. *Anim. Sci. J.* 84, 683–692. <https://doi.org/10.1111/asj.12058>
- Shirkey, N., Roug, A., Besser, T., Bleich, V.C., Darby, N., Dekelaita, D., Galloway, N.L., Gonzales, B., Hughson, D., Konde, L., Monello, R., Prentice, P.R., Vu, R., Wehausen, J., Munk, B., Powers, J., Epps, C.W., 2021. Previously Unrecognized Exposure of Desert Bighorn Sheep (*Ovis canadensis nelsoni*) to *Mycoplasma ovipneumoniae* in the California Mojave Desert. *J. Wildl. Dis.* 57. <https://doi.org/10.7589/JWD-D-20-00098>
- Shoib, M., 2019. Mycoplasmosis in poultry, a perpetual problem. *J. Microbiol. Biotechnol. Food Sci.* 8, 1271–1275.
- Sibila, M., Guevara, G., Cuadrado, R., Pleguezuelos, P., Pérez, D., Pérez de Rozas, A., Huerta, E., Llorens, A., Valero, O., Pérez, M., López, C., Krejci, R., Segalés, J., 2020. Comparison of *Mycoplasma hyopneumoniae* and porcine circovirus 2 commercial vaccines efficacy when applied separate or combined under experimental conditions. *Porc. Health Manag.* 6, 11. <https://doi.org/10.1186/s40813-020-00148-0>
- Sibila, M., Pieters, M., Molitor, T., Maes, D., Haesebrouck, F., Segalés, J., 2009. Current perspectives on the diagnosis and epidemiology of *Mycoplasma hyopneumoniae* infection. *Vet. J. Lond. Engl.* 1997 181, 221–231. <https://doi.org/10.1016/j.tvjl.2008.02.020>
- Sid, H., Hartmann, S., Petersen, H., Ryll, M., Rautenschlein, S., 2016. *Mycoplasma gallisepticum* modifies the pathogenesis of influenza A virus in the avian tracheal epithelium. *Int. J. Med. Microbiol.* 306, 174–186. <https://doi.org/10.1016/j.ijmm.2016.04.001>
- Siddique, A.B., Rahman, S.U., Ulhaq, M., Naveed, R., 2020. Occurrence, molecular identification and antibiotic resistance profiling of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* from chronic respiratory disease cases in poultry birds and farm environment. *Slov. Vet. Res.* 57. <https://doi.org/10.26873/SVR-598-2020>
- Sidibé, C.A.K., Grosbois, V., Thiaucourt, F., Niang, M., Lesnoff, M., Roger, F., 2012. Performance evaluation of two serological tests for contagious bovine pleuropneumonia (CBPP) detection in an enzootic area using a Bayesian framework. *Trop. Anim. Health Prod.* 44, 1233–1238. <https://doi.org/10.1007/s11250-011-0063-3>
- Silva, A.P.S.P., Storino, G.Y., Ferreyra, F.S.M., Zhang, M., Fano, E., Polson, D., Wang, C., Derscheid, R.J., Zimmerman, J.J., Clavijo, M.J., Arruda, B.L., 2022. Cough associated with the detection of *Mycoplasma hyopneumoniae* DNA in clinical and environmental specimens under controlled conditions. *Porc. Health Manag.* 8, 6. <https://doi.org/10.1186/s40813-022-00249-y>
- Silva, C.B.C., Chagas, W., Santos, R.F., Gomes, L.R., Ganda, M.R., Lima, A.M.C., 2015. Seroprevalence of *Salmonella* and *Mycoplasma* in commercial broilers, backyard chickens, and spent hens in the region of Triângulo Mineiro, State of Minas Gerais, Brazil. *Rev. Bras. Ciênc. Avícola* 17, 57–62. <https://doi.org/10.1590/1516-635x170157-62>
- Silva, G.S., Yeske, P., Morrison, R.B., Linhares, D.C.L., 2019. Benefit-cost analysis to estimate the payback time and the economic value of two *Mycoplasma hyopneumoniae* elimination methods in breeding herds. *Prev. Vet. Med.* 168, 95–102.
- Silva, R.L., Figueira, A.A., Silva, M.M., Dias, T.S., Machado, L.S., Soares, N.M., Nascimento, E.R., Pereira, V.L.A., 2021. Detection of *Mycoplasma Synoviae* and Other Pathogens in Laying Hens with

- Respiratory Signs in the Rearing and Production Phases. *Braz. J. Poult. Sci.* 23, eRBCA-2020-1318. <https://doi.org/10.1590/1806-9061-2020-1318>
- Simbizi, V., Moerane, R., Ramsay, G., Mubamba, C., Abolnik, C., Gummow, B., 2021. A study of rural chicken farmers, diseases and remedies in the Eastern Cape province of South Africa. *Prev. Vet. Med.* 194, 105430. <https://doi.org/10.1016/j.prevetmed.2021.105430>
- Siqueira, F.M., Gerber, A.L., Guedes, R.L.M., Almeida, L.G., Schrank, I.S., Vasconcelos, A.T.R., Zaha, A., 2014. Unravelling the Transcriptome Profile of the Swine Respiratory Tract Mycoplasmas. *PLOS ONE* 9, e110327. <https://doi.org/10.1371/journal.pone.0110327>
- Siqueira, F.M., Morais, G.L. de, Higashi, S., Beier, L.S., Breyer, G.M., Godinho, C.P. de S., Sagot, M.F., Schrank, I.S., Zaha, A., Vasconcelos, A.T.R. de, 2016. Mycoplasma non-coding RNA: identification of small RNAs and targets. *BMC Genomics* 17.
- Soayfane, Z., Houshaymi, B., Nicholas, R.A.J., 2018. *Mycoplasma capricolum* subsp. *capripneumoniae*, the cause of contagious caprine pleuropneumonia, comprises two distinct biochemical groups. *Open Vet. J.* 8, 393. <https://doi.org/10.4314/ovj.v8i4.7>
- Soehnen, M.K., Aydin, A., Lengerich, E.J., Houser, B.A., Fenton, G.D., Lyszczek, H.R., Burns, C.M., Byler, L.I., Hattel, A.L., Wolfgang, D.R., Jayarao, B.M., 2011. Blinded, controlled field trial of two commercially available *Mycoplasma bovis* bacterin vaccines in veal calves. *Vaccine* 29, 5347–5354. <https://doi.org/10.1016/j.vaccine.2011.05.092>
- Soehnen, M.K., Aydin, A., Murthy, K.S., Lengerich, E.J., Hattel, A.L., Houser, B.A., Fenton, G.D., Lyszczek, H.R., Burns, C.M., Townsend, A.M., Brooks, J.W., Wolfgang, D.R., Jayarao, B.M., 2012. Epidemiology of *Mycoplasma bovis* in Pennsylvania veal calves. *J. Dairy Sci.* 95, 247–254. <https://doi.org/10.3168/jds.2011-4309>
- Soladoye, A., Nduka, O., Ayoade, A., Andrew, A., Oluwole, O., 2016. CBPP: Pastoralist Perception Survey on the Problems Associated with T1/44 Vaccine Administration in Abuja, Nigeria. *Alex. J. Vet. Sci.* 51, 78. <https://doi.org/10.5455/ajvs.241549>
- Sonalio, K., Almeida, H.M.S., Mechler-Dreibi, M.L., Storino, G.Y., Haesebrouck, F., Maes, D., de Oliveira, L.G., 2022. Influence of *Mycoplasma hyopneumoniae* natural infection on the respiratory microbiome diversity of finishing pigs. *Vet. Res.* 53, 20. <https://doi.org/10.1186/s13567-022-01038-9>
- Song, Q., Song, W., Zhang, W., He, L., Fang, R., Zhou, Y., Shen, B., Hu, M., Zhao, J., 2018. Identification of erythrocyte membrane proteins interacting with *Mycoplasma suis* GAPDH and OSGEP. *Res. Vet. Sci.* 119, 85–90. <https://doi.org/10.1016/j.rvsc.2018.05.001>
- Sosa, C., Blois, A., Ibáñez, F., Tamiozzo, P., 2019. Genetic diversity of *Mycoplasma hyopneumoniae* in Mendoza province. *Rev. Argent. Microbiol.* 51, 229–233. <https://doi.org/10.1016/j.ram.2018.07.004>
- Souza, U.A., Oberrather, K., Fagundes-Moreira, R., Almeida, B.A. de, Valle, S. de F., Giroto-Soares, A., Soares, J.F., 2019. First molecular detection of *Mycoplasma ovis* (Hemotropic mycoplasmas) from Sheep in Brazil. *Rev. Bras. Parasitol. Veterinária* 28, 360–366. <https://doi.org/10.1590/s1984-29612019022>
- Spaan, R.S., Epps, C.W., Crowhurst, R., Whittaker, D., Cox, M., Duarte, A., 2021. Impact of *Mycoplasma ovipneumoniae* on juvenile bighorn sheep (*Ovis canadensis*) survival in the northern Basin and Range ecosystem. *PeerJ* 9, e10710. <https://doi.org/10.7717/peerj.10710>
- Spergser, J., Macher, K., Kargl, M., Lysnyansky, I., Rosengarten, R., 2013. Emergence, re-emergence, spread and host species crossing of *Mycoplasma bovis* in the Austrian Alps caused by a single endemic strain. *Vet. Microbiol.* 164, 299–306. <https://doi.org/10.1016/j.vetmic.2013.02.007>
- Sponheim, A., Alvarez, J., Fano, E., Schmaling, E., Dee, S., Hanson, D., Wetzell, T., Pieters, M., 2020. Comparison of the sensitivity of laryngeal swabs and deep tracheal catheters for detection of *Mycoplasma hyopneumoniae* in experimentally and naturally infected pigs early and late after infection. *Vet. Microbiol.* 241, 108500. <https://doi.org/10.1016/j.vetmic.2019.108500>
- Sponheim, A., Munoz-Zanzi, C., Fano, E., Polson, D., Pieters, M., 2021. Pooled-sample testing for detection of *Mycoplasma hyopneumoniae* during late experimental infection as a diagnostic

- tool for a herd eradication program. *Prev. Vet. Med.* 189, 105313. <https://doi.org/10.1016/j.prevetmed.2021.105313>
- Ssematimba, A., Jores, J., Mariner, J.C., 2015. Mathematical Modelling of the Transmission Dynamics of Contagious Bovine Pleuropneumonia Reveals Minimal Target Profiles for Improved Vaccines and Diagnostic Assays. *PLOS ONE* 10, e0116730. <https://doi.org/10.1371/journal.pone.0116730>
- Stadler, J., Ade, J., Hermanns, W., Ritzmann, M., Wentzel, S., Hoelzle, K., Hoelzle, L.E., 2021. Clinical, haematological and pathomorphological findings in *Mycoplasma suis* infected pigs. *BMC Vet. Res.* 17, 214. <https://doi.org/10.1186/s12917-021-02919-5>
- Stadler, J., Ade, J., Ritzmann, M., Hoelzle, K., Hoelzle, L.E., 2020. Detection of a novel haemoplasma species in fattening pigs with skin alterations, fever and anaemia. *Vet. Rec.* 187, 66–66. <https://doi.org/10.1136/vr.105721>
- Stadler, J., Jannasch, C., Mack, S.L., Dietz, S., Zöls, S., Ritzmann, M., Hoelzle, K., Hoelzle, L.E., 2014. Clinical and haematological characterisation of *Mycoplasma suis* infections in splenectomised and non-splenectomised pigs. *Vet. Microbiol.* 172, 294–300. <https://doi.org/10.1016/j.vetmic.2014.05.012>
- Stadler, J., Willi, S., Ritzmann, M., Eddicks, M., Ade, J., Hoelzle, K., Hoelzle, L.E., 2019. Detection of *Mycoplasma suis* in pre-suckling piglets indicates a vertical transmission. *BMC Vet. Res.* 15, 252. <https://doi.org/10.1186/s12917-019-2001-y>
- Staley, M., Bonneaud, C., McGraw, K.J., Vleck, C.M., Hill, G.E., 2018a. Detection of *Mycoplasma gallisepticum* in House Finches (*Haemorhous mexicanus*) from Arizona. *Avian Dis.* 62, 14–17. <https://doi.org/10.1637/11610-021317-Reg.1>
- Staley, M., Hill, G.E., Josefson, C.C., Armbruster, J.W., Bonneaud, C., 2018b. Bacterial Pathogen Emergence Requires More than Direct Contact with a Novel Passerine Host. *Infect. Immun.* 86, e00863-17. <https://doi.org/10.1128/IAI.00863-17>
- Sterner-Kock, A., Haider, W., Sacchini, F., Liljander, A., Meens, J., Poole, J., Guschlbauer, M., Heller, M., Naessens, J., Jores, J., 2016. Morphological characterization and immunohistochemical detection of the proinflammatory cytokines IL-1 β , IL-17A, and TNF- α in lung lesions associated with contagious bovine pleuropneumonia. *Trop. Anim. Health Prod.* 48, 569–576. <https://doi.org/10.1007/s11250-016-0994-9>
- Stevanović, O., Jurković, D., Polkinghorne, A., Čeleš, A., Ilić, T., Dimitrijević, S., Nedić, D., Beck, R., 2020. Molecular detection of *Babesia divergens* and *Mycoplasma wenyonii* infection in cattle from Bosnia And Herzegovina. *Parasitol. Res.* 119, 1423–1427. <https://doi.org/10.1007/s00436-020-06630-6>
- Stingelin, G.M., Mechler-Dreibi, M.L., Storino, G.Y., Sonalio, K., Almeida, H.M. de S., Petri, F.A.M., de Oliveira, L.G., 2022. Chemotherapeutic Strategies with Valnemulin, Tilimicosin, and Tulathromycin to Control *Mycoplasma hyopneumoniae* Infection in Pigs. *Antibiotics* 11, 893. <https://doi.org/10.3390/antibiotics11070893>
- Storino, G.Y., Petri, F.A.M., Mechler-Dreibi, M.L., Aguiar, G.A., Toledo, L.T., Arruda, L.P., Malcher, C.S., Martins, T.S., Montassier, H.J., Sant'Anna, O.A., Fantini, M.C.A., de Oliveira, L.G., 2023. Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control *Mycoplasma hyopneumoniae* in Swine Production. *Int. J. Mol. Sci.* 24, 6591. <https://doi.org/10.3390/ijms24076591>
- Strässle, M., Laloli, L., Gultom, M., V'kovski, P., Stoffel, M.H., Crespo Pomar, S., Chanfon Bätzner, A., Ebert, N., Labroussaa, F., Dijkman, R., Jores, J., Thiel, V., 2021. Establishment of caprine airway epithelial cells grown in an air-liquid interface system to study caprine respiratory viruses and bacteria. *Vet. Microbiol.* 257, 109067. <https://doi.org/10.1016/j.vetmic.2021.109067>
- Stroebe, C., Alexander, T., Workentine, M.L., Timsit, E., 2018. Effects of transportation to and commingling at an auction market on nasopharyngeal and tracheal bacterial communities of recently weaned beef cattle. *Vet. Microbiol.* 223, 126–133. <https://doi.org/10.1016/j.vetmic.2018.08.007>

- Subbaiyan, A., Thomas, P., Sankar, M., Rana, R., Chaudhuri, P., 2021. Multilocus sequence typing of pathogenic *Mycoplasma mycoides* subsp. *capri* reveals the predominance of a novel clonal complex among isolates from goats in India. *Arch. Microbiol.* 203, 1149–1157. <https://doi.org/10.1007/s00203-020-02100-w>
- Subramaniam, S., Bergonier, D., Poumarat, F., Capaul, S., Schlatter, Y., Nicolet, J., Frey, J., 1998. Species identification of *Mycoplasma bovis* and *Mycoplasma agalactiae* based on the *uvrC* genes by PCR. *Mol. Cell. Probes* 12, 161–169. <https://doi.org/10.1006/mcpr.1998.0160>
- Suh, J., Oh, T., Chae, C., 2022. An evaluation of intradermal all-in-one vaccine based on an inactivated recombinant *Mycoplasma hyopneumoniae* strain expressing porcine circovirus type 2 (PCV2) capsid protein against Korean stains of PCV2d and *M. hyopneumoniae* challenge. *Comp. Immunol. Microbiol. Infect. Dis.* 90–91, 101911. <https://doi.org/10.1016/j.cimid.2022.101911>
- Sui, C., Cui, H., Ji, J., Xu, X., Kan, Y., Yao, L., Bi, Y., Zhang, X., Xie, Q., 2022. Epidemiological investigations and locally determined genotype diversity of *Mycoplasma synoviae* in Central China from 2017 to 2019. *Poult. Sci.* 101, 101522. <https://doi.org/10.1016/j.psj.2021.101522>
- Suleiman, A., Bello, M., Dzikwi, A.A., Talba, A.M., Grema, H.A., Geidam, Y.A., 2015a. Serological prevalence of contagious bovine pleuropneumonia in agro-pastoral areas of Nigeria. *Trop. Anim. Health Prod.* 47, 1033–1042. <https://doi.org/10.1007/s11250-015-0824-5>
- Suleiman, A., Jackson, E., Rushton, J., 2018. Perceptions, circumstances and motivators affecting the implementation of contagious bovine pleuropneumonia control programmes in Nigerian Fulani pastoral herds. *Prev. Vet. Med.* 149, 67–74. <https://doi.org/10.1016/j.prevetmed.2017.10.011>
- Suleiman, A., Jackson, E.L., Rushton, J., 2015b. Challenges of pastoral cattle production in a sub-humid zone of Nigeria. *Trop. Anim. Health Prod.* 47, 1177–1185. <https://doi.org/10.1007/s11250-015-0845-0>
- Suleman, M., Cyprian, F.S., Jimbo, S., Maina, T., Prysliak, T., Windeyer, C., Perez-Casal, J., 2018. *Mycoplasma bovis*-Induced Inhibition of Bovine Peripheral Blood Mononuclear Cell Proliferation Is Ameliorated after Blocking the Immune-Inhibitory Programmed Death 1 Receptor. *Infect. Immun.* 86, e00921-17. <https://doi.org/10.1128/IAI.00921-17>
- Suleman, M., Prysliak, T., Clarke, K., Burrage, P., Windeyer, C., Perez-Casal, J., 2016a. *Mycoplasma bovis* isolates recovered from cattle and bison (*Bison bison*) show differential in vitro effects on PBMC proliferation, alveolar macrophage apoptosis and invasion of epithelial and immune cells. *Vet. Microbiol.* 186, 28–36. <https://doi.org/10.1016/j.vetmic.2016.02.016>
- Suleman, M., Prysliak, T., Windeyer, C., Perez-Casal, J., 2016b. In vitro antimicrobial susceptibility of *Mycoplasma bovis* clinical isolates recovered from bison (*Bison bison*). *Can. J. Microbiol.* 62, 272–278. <https://doi.org/10.1139/cjm-2015-0763>
- Sulyok, K.M., Bekő, K., Kreizinger, Z., Wehmann, E., Jerzsele, Á., Rónai, Z., Turcsányi, I., Makrai, L., Szeredi, L., Jánosi, S., Nagy, S.Á., Gyuranecz, M., 2018. Development of molecular methods for the rapid detection of antibiotic susceptibility of *Mycoplasma bovis*. *Vet. Microbiol.* 213, 47–57. <https://doi.org/10.1016/j.vetmic.2017.11.026>
- Sulyok, K.M., Kreizinger, Z., Fekete, L., Hrivnák, V., Magyar, T., Jánosi, S., Schweitzer, N., Turcsányi, I., Makrai, L., Erdélyi, K., Gyuranecz, M., 2014a. Antibiotic susceptibility profiles of *Mycoplasma bovis* strains isolated from cattle in Hungary, Central Europe. *BMC Vet. Res.* 10.
- Sulyok, K.M., Kreizinger, Z., Fekete, L., Jánosi, S., Schweitzer, N., Turcsányi, I., Makrai, L., Erdélyi, K., Gyuranecz, M., 2014b. Phylogeny of *Mycoplasma bovis* isolates from Hungary based on multi locus sequence typing and multiple-locus variable-number tandem repeat analysis. *BMC Vet. Res.* 10.
- Sulyok, K.M., Kreizinger, Z., Wehmann, E., Lysnyansky, I., Bányai, K., Marton, S., Jerzsele, Á., Rónai, Z., Turcsányi, I., Makrai, L., Jánosi, S., Nagy, S.Á., Gyuranecz, M., 2017. Mutations associated with decreased susceptibility to seven antimicrobial families in field and laboratory-derived *Mycoplasma bovis* strains. *Antimicrob. Agents Chemother.* 61.

- Sumith, K.S., Umesh, C.G., Ravishankar, C., Manju, K.M., Ajithkumar, S., 2021. Evaluation of therapeutic efficacy of oxytetracycline against caprine respiratory mycoplasmosis using clinical score card method. *J. Vet. Anim. Sci.* 52. <https://doi.org/10.51966/jvas.2021.52.4.331-334>
- Sun, P., Luo, H., Zhang, X., Xu, J., Guo, Y., He, S., 2018. Whole-Genome Sequence of *Mycoplasma bovis* Strain Ningxia-1. *Genome Announc.* 6, e01367-17. <https://doi.org/10.1128/genomeA.01367-17>
- Sun, Q., Wei, X., Chen, W., Zhong, Q., Yan, Z., Zhou, Q., Cao, Y., Chen, F., 2022. Characterization and Evaluation of a Novel Conserved Membrane Antigen P35 of *Mycoplasma synoviae*. *Front. Vet. Sci.* 9, 836110. <https://doi.org/10.3389/fvets.2022.836110>
- Sun, Y., Wang, Y., Zhao, Y., Zou, M., Peng, X., 2021. Exosomal miR-181a-5p reduce *Mycoplasma gallisepticum* (HS strain) infection in chicken by targeting PPM1B and activating the TLR2-mediated MyD88/NF- κ B signaling pathway. *Mol. Immunol.* 140, 144–157. <https://doi.org/10.1016/j.molimm.2021.09.005>
- Sun, Y., Wang, Y., Zou, M., Wang, T., Wang, L., Peng, X., 2022. Lnc90386 Sponges miR-33-5p to Mediate *Mycoplasma gallisepticum*-Induced Inflammation and Apoptosis in Chickens via the JNK Pathway. *Front. Immunol.* 13, 887602. <https://doi.org/10.3389/fimmu.2022.887602>
- Sun, Z., Fu, P., Wei, K., Zhang, H., Zhang, Y., Xu, J., Jiang, F., Liu, X., Xu, W., Wu, W., 2014. Identification of Novel Immunogenic Proteins from *Mycoplasma bovis* and Establishment of an Indirect ELISA Based on Recombinant E1 Beta Subunit of the Pyruvate Dehydrogenase Complex. *PLOS ONE* 9, e88328. <https://doi.org/10.1371/journal.pone.0088328>
- Sunaga, F., Tsuchiaka, S., Kishimoto, M., Aoki, H., Kakinoki, M., Kure, K., Okumura, H., Okumura, M., Okumura, A., Nagai, M., Omatsu, T., Mizutani, T., 2020. Development of a one-run real-time PCR detection system for pathogens associated with porcine respiratory diseases. *J. Vet. Med. Sci.* 82, 217–223.
- Suwanruengsri, M., Uemura, R., Izzati, U.Z., Kanda, T., Fuke, N., Yasuda, M., Hirai, T., Yamaguchi, R., 2021. *Mycoplasma bovis* May Travel Along the Eustachian Tube to Cause Meningitis in Japanese Black Cattle. *J. Comp. Pathol.* 188, 13–20. <https://doi.org/10.1016/j.jcpa.2021.08.001>
- Suwanruengsri, M., Uemura, R., Kanda, T., Fuke, N., Nueangphuet, P., Pornthummawat, A., Yasuda, M., Hirai, T., Yamaguchi, R., 2022. Production of granulomas in *Mycoplasma bovis* infection associated with meningitis-meningoencephalitis, endocarditis, and pneumonia in cattle. *J. Vet. Diagn. Invest.* 34, 68–76. <https://doi.org/10.1177/10406387211053254>
- SuYeon, K., HongGu, J., 2015. Evaluation of adjuvant effects of fucoidan for improving vaccine efficacy. *J. Vet. Sci.* 16, 145–150.
- Szacawa, E., Niemczuk, K., Dudek, K., Bednarek, D., Rosales, R., Ayling, R., 2015. *Mycoplasma bovis* infections and co-infections with other *Mycoplasma* spp. with different clinical manifestations in affected cattle herds in eastern region of Poland. *Bull. Vet. Inst. Puławy* 59, 331–337.
- Szacawa, E., Szymańska-Czerwińska, M., Niemczuk, K., Dudek, K., Woźniakowski, G., Bednarek, D., 2016. Prevalence of pathogens from Mollicutes class in cattle affected by respiratory diseases and molecular characteristics of *Mycoplasma bovis* field strains. *J. Vet. Res.* 60, 391–397.
- Tadee, P., Chanrittisen, K., Thainoi, N., Thongkamkoon, P., Patchanee, P., 2018. Genetic diversity and global relationships of *Mycoplasma hyopneumoniae* from slaughter age pigs in Chiang Mai and Lamphun provinces, Thailand. *Jpn. J. Vet. Res.* 66, 251–259.
- Taiyari, H., Faiz, N.M., Abu, J., Zakaria, Z., 2021. Antimicrobial minimum inhibitory concentration of *Mycoplasma gallisepticum*: a systematic review. *J. Appl. Poult. Res.* 30, 100160. <https://doi.org/10.1016/j.japr.2021.100160>
- Takeuti, K.L., de Barcellos, D.E.S.N., de Andrade, C.P., de Almeida, L.L., Pieters, M., 2017a. Infection dynamics and genetic variability of *Mycoplasma hyopneumoniae* in self-replacement gilts. *Vet. Microbiol.* 208, 18–24. <https://doi.org/10.1016/j.vetmic.2017.07.007>

- Takeuti, K.L., de Barcellos, D.E.S.N., de Lara, A.C., Kunrath, C.F., Pieters, M., 2017b. Detection of *Mycoplasma hyopneumoniae* in naturally infected gilts over time. *Vet. Microbiol.* 203, 215–220. <https://doi.org/10.1016/j.vetmic.2017.03.025>
- Talenton, V., Baby, V., Gourgues, G., Mouden, C., Claverol, S., Vashee, S., Blanchard, A., Labroussaa, F., Jores, J., Arfi, Y., Sirand-Pugnet, P., Lartigue, C., 2022. Genome Engineering of the Fast-Growing *Mycoplasma feriruminatoris* toward a Live Vaccine Chassis. *ACS Synth. Biol.* 11, 1919–1930. <https://doi.org/10.1021/acssynbio.2c00062>
- Tambi, N.E., Maina, W.O., Ndi, C., 2006. An estimation of the economic impact of contagious bovine pleuropneumonia in Africa. *Rev. Sci. Tech. Int. Off. Epizoot.* 25, 999–1011.
- Tambuwal, F.M., Egwu, G.O., Stipkovits, L., 2017. Serological evidence of emerging *Mycoplasma bovis* infection in Nigerian local cattle. *Vom J. Vet. Sci.* 12, 28–36.
- Tamiozzo, P., Zamora, R., Lucchesi, P.M.A., Estanguet, A., Parada, J., Carranza, A., Camacho, P., Ambrogi, A., 2015. MLVA typing of *Mycoplasma hyopneumoniae* bacterins and field strains. *Vet. Rec. Open* 2.
- Tan, L., Hu, M., Yu, S., Wang, X., Lu, F., Liu, F., Qiu, X., Song, C., Sun, Y., Ding, C., 2015. Characterization of the chaperonin GroEL in *Mycoplasma gallisepticum*. *Arch. Microbiol.* 197, 235–244. <https://doi.org/10.1007/s00203-014-1047-2>
- Tao, Y., Li, G., Zheng, W., Shu, J., Chen, J., Yang, F., Wu, Y., He, Y., 2019. Development of a Combined Genetic Engineering Vaccine for Porcine Circovirus Type 2 and *Mycoplasma Hyopneumoniae* by a Baculovirus Expression System. *Int. J. Mol. Sci.* 20, 4425. <https://doi.org/10.3390/ijms20184425>
- Tardy, F., Aspan, A., Autio, T., Ridley, A., Tricot, A., Colin, A., Pohjanvirta, T., Smid, B., Harders, F., Lindegaard, M., Tølbøll Lauritsen, K., Lyhs, U., Wisselink, H.J., Strube, M.L., 2020. *Mycoplasma bovis* in Nordic European Countries: Emergence and Dominance of a New Clone. *Pathogens* 9, 875. <https://doi.org/10.3390/pathogens9110875>
- Tardy, F., Mick, V., Dordet-Frisoni, E., Marena, M.S., Sirand-Pugnet, P., Blanchard, A., Citti, C., 2015. Integrative Conjugative Elements Are Widespread in Field Isolates of *Mycoplasma* Species Pathogenic for Ruminants. *Appl. Environ. Microbiol.* 81, 1634–1643. <https://doi.org/10.1128/AEM.03723-14>
- Tardy, L., Giraudeau, M., Hill, G.E., McGraw, K.J., Bonneaud, C., 2019. Contrasting evolution of virulence and replication rate in an emerging bacterial pathogen. *Proc. Natl. Acad. Sci.* 116, 16927–16932. <https://doi.org/10.1073/pnas.1901556116>
- Tasker, S., 2022. Hemotropic *Mycoplasma*. *Vet. Clin. North Am. Small Anim. Pract., Vector-Borne Diseases* 52, 1319–1340. <https://doi.org/10.1016/j.cvsm.2022.06.010>
- Tatay-Dualde, J., Prats-van der Ham, M., de la Fe, C., Gómez-Martín, Á., Paterna, A., Corrales, J.C., Contreras, A., Sánchez, A., 2016. Multilocus sequence typing of *Mycoplasma mycoides* subsp. *capri* to assess its genetic variability in a contagious agalactia endemic area. *Vet. Microbiol.* 191, 60–64. <https://doi.org/10.1016/j.vetmic.2016.06.002>
- Tatay-Dualde, J., Prats-van der Ham, M., de la Fe, C., Paterna, A., Sánchez, A., Corrales, J.C., Contreras, A., Gómez-Martín, Á., 2017a. Resistance mechanisms against quinolones in *Mycoplasma capricolum* subsp. *capricolum*. *Vet. J.* 223, 1–4. <https://doi.org/10.1016/j.tvjl.2017.03.007>
- Tatay-Dualde, J., Prats-van der Ham, M., de la Fe, C., Paterna, A., Sánchez, A., Corrales, J.C., Contreras, A., Gómez-Martín, Á., 2017b. Mutations in the quinolone resistance determining region conferring resistance to fluoroquinolones in *Mycoplasma agalactiae*. *Vet. Microbiol.* 207, 63–68. <https://doi.org/10.1016/j.vetmic.2017.06.003>
- Tatay-Dualde, J., Prats-van der Ham, M., de la Fe, C., Paterna, A., Sánchez, A., Corrales, J.C., Contreras, A., Tola, S., Gómez-Martín, Á., 2017c. Antimicrobial susceptibility and multilocus sequence typing of *Mycoplasma capricolum* subsp. *capricolum*. *PLOS ONE* 12, e0174700. <https://doi.org/10.1371/journal.pone.0174700>

- Tatay-Dualde, J., Sánchez, A., Prats-van der Ham, M., Gómez-Martín, A., Paterna, A., Corrales, J.C., de la Fe, C., Contreras, A., Amores, J., 2015. Sensitivity of two methods to detect *Mycoplasma agalactiae* in goat milk. *Ir. Vet. J.* 68, 21. <https://doi.org/10.1186/s13620-015-0049-y>
- Tatsukawa, F., Nohara, R., Taniguchi, T., Goto, A., Misawa, N., Katamoto, H., 2021. Detection of *Mycoplasma wenyonii* and “*Candidatus Mycoplasma haemobos*” from Japanese Black breeding cows in Kyushu and Okinawa region, southern part of Japan. *J. Vet. Med. Sci.* 83, 9–16. <https://doi.org/10.1292/jvms.20-0505>
- Tavares, B.A. da R., Paes, J.A., Zaha, A., Ferreira, H.B., 2022. Reannotation of *Mycoplasma hyopneumoniae* hypothetical proteins revealed novel potential virulence factors. *Microb. Pathog.* 162, 105344. <https://doi.org/10.1016/j.micpath.2021.105344>
- Tawfik, R., Khalil, S., Ellakany, H., Torky, H., Abdellrazeq, G., Abumandour, M., ElShal, N., 2018. Molecular Characterization of *Mycoplasma Synoviae* Isolated From the Respiratory System and Joints of Chickens with Special Reference of *vlhA* Gene. *Alex. J. Vet. Sci.* 59, 57. <https://doi.org/10.5455/ajvs.13882>
- Taylor, D.J., 2013. *Pig Diseases*, 9th ed. 5m Publishing, Sheffield, UK.
- ter Veen, C., de Wit, J.J., Feberwee, A., 2020. Relative contribution of vertical, within-farm and between-farm transmission of *Mycoplasma synoviae* in layer pullet flocks. *Avian Pathol.* 49, 56–61. <https://doi.org/10.1080/03079457.2019.1664725>
- ter Veen, C., Dijkman, R., de Wit, J.J., Gyuranecz, M., Feberwee, A., 2021. Decrease of *Mycoplasma gallisepticum* seroprevalence and introduction of new genotypes in Dutch commercial poultry during the years 2001–2018. *Avian Pathol.* 50, 52–60. <https://doi.org/10.1080/03079457.2020.1832958>
- Teshome, D., Sori, T., Sacchini, F., Wieland, B., 2019. Epidemiological investigations of contagious caprine pleuropneumonia in selected districts of Borana zone, Southern Oromia, Ethiopia. *Trop. Anim. Health Prod.* 51, 703–711. <https://doi.org/10.1007/s11250-018-1744-y>
- Thantrige-Don, N., Lung, O., Furukawa-Stoffer, T., Buchanan, C., Joseph, T., Godson, D.L., Gilleard, J., Alexander, T., Ambagala, A., 2018. A novel multiplex PCR-electronic microarray assay for rapid and simultaneous detection of bovine respiratory and enteric pathogens. *J. Virol. Methods* 261, 51–62. <https://doi.org/10.1016/j.jviromet.2018.08.010>
- Tharwat, M., 2021. Alterations in acid-base balance, blood gases, and hematobiochemical profiles of whole-blood and thoracic fluid in goats with contagious caprine pleuropneumonia. *Vet. World* 14, 1874–1878. <https://doi.org/10.14202/vetworld.2021.1874-1878>
- Thiaucourt, F., Manso-Silvan, L., Salah, W., Barbe, V., Vacherie, B., Jacob, D., Breton, M., Dupuy, V., Lomenech, A.M., Blanchard, A., Sirand-Pugnet, P., 2011. *Mycoplasma mycoides*, from “*mycoides Small Colony*” to “*capri*”. A microevolutionary perspective. *BMC Genomics* 12, 114. <https://doi.org/10.1186/1471-2164-12-114>
- Thiry, J., González-Martín, J.V., Elvira, L., Pagot, E., Voisin, F., Lequeux, G., Weingarten, A., de Haas, V., 2014. Treatment of naturally occurring bovine respiratory disease in juvenile calves with a single administration of a florfenicol plus flunixin meglumine formulation. *Vet. Rec.* 174, 430–430. <https://doi.org/10.1136/vr.102017>
- Thivyanathan, V., Gorenstein, D.G., 2012. Aptamers and the Next Generation of Diagnostic Reagents. *Proteomics Clin. Appl.* 6, 563–573. <https://doi.org/10.1002/prca.201200042>
- Thomas, A., Dizier, I., Linden, A., Mainil, J., Frey, J., Vilei, E.M., 2004. Conservation of the *uvrC* gene sequence in *Mycoplasma bovis* and its use in routine PCR diagnosis. *Vet. J. Lond. Engl.* 1997 168, 100–102. <https://doi.org/10.1016/j.tvj.2003.10.006>
- Thomason, C.A., Mullen, N., Belden, L.K., May, M., Hawley, D.M., 2017. Resident Microbiome Disruption with Antibiotics Enhances Virulence of a Colonizing Pathogen. *Sci. Rep.* 7, 16177. <https://doi.org/10.1038/s41598-017-16393-3>
- Thongmeesee, K., Kamkong, P., Thanee, S., Wattanapansak, S., Kaewthamasorn, M., Tiawsirisup, S., 2022. Molecular detection and genetic analysis of porcine haemoplasmas in commercial pig

- farms from Thailand reveal a putative novel species. *Transbound. Emerg. Dis.* 69. <https://doi.org/10.1111/tbed.14537>
- Tian, W., Zhao, C., Hu, Q., Sun, J., Peng, X., 2016. Roles of Toll-like receptors 2 and 6 in the inflammatory response to *Mycoplasma gallisepticum* infection in DF-1 cells and in chicken embryos. *Dev. Comp. Immunol.* 59, 39–47. <https://doi.org/10.1016/j.dci.2016.01.008>
- Tian, Y., Xu, Z., Wen, Y., Yang, M., Ning, Y., Wang, Z., Ding, H., 2021. Development of an indirect ELISA for detection of anti-*Mycoplasma hyopneumoniae* IgG in naturally infected pathogen-induced convalescent sera. *BMC Vet. Res.* 17, 123. <https://doi.org/10.1186/s12917-021-02828-7>
- Timonen, A.A.E., Autio, T., Pohjanvirta, T., Häkkinen, L., Katholm, J., Petersen, A., Mötus, K., Kalmus, P., 2020. Dynamics of the within-herd prevalence of *Mycoplasma bovis* intramammary infection in endemically infected dairy herds. *Vet. Microbiol.* 242, 108608. <https://doi.org/10.1016/j.vetmic.2020.108608>
- Timonen, A.A.E., Katholm, J., Petersen, A., Mötus, K., Kalmus, P., 2017. Within-herd prevalence of intramammary infection caused by *Mycoplasma bovis* and associations between cow udder health, milk yield, and composition. *J. Dairy Sci.* 100, 6554–6561. <https://doi.org/10.3168/jds.2016-12267>
- Timsit, E., Workentine, M., van der Meer, F., Alexander, T., 2018. Distinct bacterial metacommunities inhabit the upper and lower respiratory tracts of healthy feedlot cattle and those diagnosed with bronchopneumonia. *Vet. Microbiol.* 221, 105–113. <https://doi.org/10.1016/j.vetmic.2018.06.007>
- Tizioto, P.C., Kim, J., Seabury, C.M., Schnabel, R.D., Gershwin, L.J., Van Eenennaam, A.L., Toaff-Rosenstein, R., Neiberghs, H.L., Bovine Respiratory Disease Complex Coordinated Agricultural Project Research Team, Taylor, J.F., 2015. Immunological Response to Single Pathogen Challenge with Agents of the Bovine Respiratory Disease Complex: An RNA-Sequence Analysis of the Bronchial Lymph Node Transcriptome. *PLOS ONE* 10, e0131459. <https://doi.org/10.1371/journal.pone.0131459>
- Tocqueville, V., Ferré, S., Nguyen, N.H.P., Kempf, I., Marois-Créhan, C., 2014. Multilocus sequence typing of *Mycoplasma hyorhinis* strains identified by a real-time TaqMan PCR assay. *J. Clin. Microbiol.* 52, 1664–1671. <https://doi.org/10.1128/JCM.03437-13>
- Todaro, M., Puleio, R., Sabelli, C., Scatassa, M.L., Console, A., Loria, G.R., 2015. Determination of milk production losses in Valle del Belice sheep following experimental infection of *Mycoplasma agalactiae*. *Small Rumin. Res.* 123, 167–172. <https://doi.org/10.1016/j.smallrumres.2014.10.005>
- Toledo, M.A., Leite, A.I., Gonçalves, L.R., Sousa, K.C.M. de, Amaral, R.B. do, Silva, G.C.P. da, Machado, R.Z., André, M.R., 2016. High occurrence of *Mycoplasma suis* infection in swine herds from non-technified farms in Mossoró, state of Rio Grande do Norte, northeastern Brazil. *Braz. J. Vet. Parasitol.* 25, 414–417.
- Tolone, M., Suter, A.M., Borrello, S., Tumino, S., Scatassa, M.L., Portolano, B., Puleio, R., Nicholas, R.A., Loria, G.R., 2019. Effect of *Mycoplasma agalactiae* mastitis on milk production and composition in Valle dell Belice dairy sheep. *Ital. J. Anim. Sci.* 18, 1067–1072. <https://doi.org/10.1080/1828051X.2019.1617044>
- Tong, S., Shi, N., Zheng, K., Yin, Z., Zhang, X., Liu, Y., 2022. Genomic Variant in NK-Lysin Gene Is Associated with T Lymphocyte Subpopulations in Pigs. *Genes* 13, 1985. <https://doi.org/10.3390/genes13111985>
- Tonni, M., Boniotti, M.B., Gasparini, S., Guarneri, F., Formenti, N., Pieters, M., Pasquali, P., Alborali, G.L., 2021. Genomic variability of *Mycoplasma hyopneumoniae* within pig lung lobes. *Porc. Health Manag.* 7, 14. <https://doi.org/10.1186/s40813-021-00195-1>
- Tonni, M., Formenti, N., Boniotti, M.B., Guarneri, F., Scali, F., Romeo, C., Pasquali, P., Pieters, M., Maes, D., Alborali, G.L., 2022. The role of co-infections in *M. hyopneumoniae* outbreaks among heavy fattening pigs: a field study. *Vet. Res.* 53, 41. <https://doi.org/10.1186/s13567-022-01061-w>

- Totté, P., Bonnefois, T., Manso-Silvan, L., 2022. Interactions between *Mycoplasma mycoides mycoides* and bovine macrophages under physiological conditions (preprint). Immunology. <https://doi.org/10.1101/2022.12.06.519279>
- Totté, P., Puech, C., Rodrigues, V., Bertin, C., Manso-Silvan, L., Thiaucourt, F., 2015. Free exopolysaccharide from *Mycoplasma mycoides* subsp. *mycoides* possesses anti-inflammatory properties. Vet. Res. 46.
- Totté, P., Rodrigues, V., Yaya, A., Hamadou, B., Cisse, O., Diallo, M., Niang, M., Thiaucourt, F., Dedieu, L., 2008. Analysis of cellular responses to *Mycoplasma mycoides* subsp. *mycoides* small colony biotype associated with control of contagious bovine pleuropneumonia. Vet. Res. 39, 8. <https://doi.org/10.1051/vetres:2007046>
- Totte, P., Yaya, A., Sery, A., Wesonga, H., Wade, A., Naessens, J., Niang, M., Thiaucourt, F., 2013. Characterization of Anamnestic T-cell Responses Induced by Conventional Vaccines against Contagious Bovine Pleuropneumonia. PLOS ONE 8, e57509. <https://doi.org/10.1371/journal.pone.0057509>
- Touloudi, A., Valiakos, G., Athanasiou, L.V., Birtsas, P., Giannakopoulos, A., Papaspyropoulos, K., Kalaitzis, C., Sokos, C., Tsokana, C.N., Spyrou, V., Petrovska, L., Billinis, C., 2015. A serosurvey for selected pathogens in Greek European wild boar. Vet. Rec. Open 2. <https://doi.org/10.1136/vetreco-2014-000077>
- Trüeb, B., Catelli, E., Luehrs, A., Nathues, H., Kuhnert, P., 2016. Genetic variability and limited clonality of *Mycoplasma hyorhinis* in pig herds. Vet. Microbiol. 191, 9–14. <https://doi.org/10.1016/j.vetmic.2016.05.015>
- Trueeb, B.S., Braun, R.O., Auray, G., Kuhnert, P., Summerfield, A., 2020. Differential innate immune responses induced by *Mycoplasma hyopneumoniae* and *Mycoplasma hyorhinis* in various types of antigen presenting cells. Vet. Microbiol. 240, 108541. <https://doi.org/10.1016/j.vetmic.2019.108541>
- Trueeb, B.S., Gerber, S., Maes, D., Gharib, W.H., Kuhnert, P., 2019. Tn-sequencing of *Mycoplasma hyopneumoniae* and *Mycoplasma hyorhinis* mutant libraries reveals non-essential genes of porcine mycoplasmas differing in pathogenicity. Vet. Res. 50.
- Tseng, C.-W., Chiu, C.-J., Kanci, A., Citti, C., Rosengarten, R., Browning, G.F., Markham, P.F., 2017a. The *oppD* Gene and Putative Peptidase Genes May Be Required for Virulence in *Mycoplasma gallisepticum*. Infect. Immun. 85, e00023-17. <https://doi.org/10.1128/IAI.00023-17>
- Tseng, C.-W., Chiu, C.-J., Kanci, A., Noormohammadi, A.H., Browning, G.F., Markham, P.F., 2017b. Safety and efficacy of a *Mycoplasma gallisepticum oppD* knockout mutant as a vaccine candidate. Vaccine 35, 6248–6253. <https://doi.org/10.1016/j.vaccine.2017.08.073>
- Tumino, S., Tolone, M., Parco, A., Puleio, R., Arcoleo, G., Manno, C., Nicholas, R.A.J., Loria, G.R., 2020. Validation of Loop-Mediated Isothermal Amplification (LAMP) Field Tool for Rapid and Sensitive Diagnosis of Contagious Agalactia in Small Ruminants. Animals 10, 509. <https://doi.org/10.3390/ani10030509>
- Uddin, M.I., Abid, M.H., Islam, M.S., Rakib, T.M., Sen, A.B., Chowdhury, S.M.Z.H., Anwar, M.N., Kamaruddin, K.M., 2016. Molecular identification of *Mycoplasma synoviae* from seroprevalent commercial breeder farms at Chittagong district, Bangladesh. Vet. World 9, 1063–1069.
- Uemoto, Y., Ichinoseki, K., Matsumoto, T., Oka, N., Takamori, H., Kadowaki, H., Kojima-Shibata, C., Suzuki, E., Okamura, T., Aso, H., Kitazawa, H., Satoh, M., Uenishi, H., Suzuki, K., 2021. Genome-wide association studies for production, respiratory disease, and immune-related traits in Landrace pigs. Sci. Rep. 11, 15823. <https://doi.org/10.1038/s41598-021-95339-2>
- Ulloa, F., Soto, J.P., Kruze, J., Mella, A., 2021. *Mycoplasma* isolation in milk samples from dairy herds in Chile. Austral J. Vet. Sci. 53, 109–113.
- Um, H., Yang, S., Oh, T., Cho, H., Park, K.H., Suh, J., Chae, C., 2021a. A field efficacy trial of a trivalent vaccine containing porcine circovirus type 2a and 2b, and *Mycoplasma hyopneumoniae* in three herds. Vet. Med. Sci. 8, 578–590. <https://doi.org/10.1002/vms3.657>

- Um, H., Yang, S., Oh, T., Park, K., Cho, H., Suh, J., Min, K.-D., Chae, C., 2021b. Comparative Evaluation of Growth Performance between Bivalent and Trivalent Vaccines Containing Porcine Circovirus Type 2 (PCV2) and *Mycoplasma hyopneumoniae* in a Herd with Subclinical PCV2d Infection and Enzootic Pneumonia. *Vaccines* 9, 450. <https://doi.org/10.3390/vaccines9050450>
- Ur Rehman, F., Khan, F.A., Saeed, M., Ali, M., Khan, H., Ahmad, F., Ullah, Q., 2022. Clinicopathological and Sero-Molecular Detection of *Mycoplasma capricolum* subsp. *capripneumoniae* in Goats in Southern Areas of Pakistan. *Vet. Med. Int.* 2022, 1–11. <https://doi.org/10.1155/2022/9508810>
- Uriarte, J., Cerdá, R., Stanchi, N., 2015. Chicken erythrocyte invasion capability of a *Mycoplasma synoviae* strain isolated in Argentina. *Analecta Vet.* 35, 21–24.
- Urie, N.J., Highland, M.A., Knowles, D.P., Branan, M.A., Herndon, D.R., Marshall, K.L., 2019. *Mycoplasma ovis* infection in domestic sheep (*Ovis aries*) in the United States: prevalence, distribution, associated risk factors, and associated outcomes. *Prev. Vet. Med.* 171.
- USDA, 2022. Summary of Studies Supporting USDA Product Licensure.
- USDA, 2017. Contagious bovine pleuropneumonia standard operating procedures, Foreign Animal Disease Preparedness & Response Plan. USDA.
- USDA APHIS, 2020. *Mycoplasma ovipneumoniae* [WWW Document]. USDA Anim. Plant Health Insp. Serv. URL https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/sa_animal_disease_information/sheep-goat/movi/mycoplasma-ovipneumoniae
- Ustulin, M., Rossi, E., Vio, D., 2021. A case of pericarditis caused by *Mycoplasma hyorhinis* in a weaned piglet. *Porc. Health Manag.* 7, 32. <https://doi.org/10.1186/s40813-021-00211-4>
- Vähänikkilä, N., Pohjanvirta, T., Haapala, V., Simojoki, H., Soveri, T., Browning, G.F., Pelkonen, S., Wawegama, N.K., Autio, T., 2019. Characterisation of the course of *Mycoplasma bovis* infection in naturally infected dairy herds. *Vet. Microbiol.* 231, 107–115. <https://doi.org/10.1016/j.vetmic.2019.03.007>
- Valeris-Chacin, R., Powledge, S., McAtee, T., Morley, P.S., Richeson, J., 2022. *Mycoplasma bovis* is associated with *Mannheimia haemolytica* during acute bovine respiratory disease in feedlot cattle. *Front. Microbiol.* 13, 946792. <https://doi.org/10.3389/fmicb.2022.946792>
- Valeris-Chacin, R., Sponheim, A., Fano, E., Isaacson, R., Singer, R.S., Nerem, J., Leite, F.L., Pieters, M., 2021. Relationships among Fecal, Air, Oral, and Tracheal Microbial Communities in Pigs in a Respiratory Infection Disease Model. *Microorganisms* 9, 252. <https://doi.org/10.3390/microorganisms9020252>
- van der Merwe, J., Prysliak, T., Perez-Casal, J., 2010. Invasion of Bovine Peripheral Blood Mononuclear Cells and Erythrocytes by *Mycoplasma bovis*. *Infect. Immun.* 78, 4570–4578. <https://doi.org/10.1128/IAI.00707-10>
- Van, E.R., Wrobel, E.R., Wilcoxon, T.E., 2018. Variation in seroprevalence of antibodies against *Mycoplasma gallisepticum* and Avipoxvirus in nine species of birds with differential access to feeders. *Avian Biol. Res.* 11, 7–11.
- van Kuppeveld, F.J., van der Logt, J.T., Angulo, A.F., van Zoest, M.J., Quint, W.G., Niesters, H.G., Galama, J.M., Melchers, W.J., 1992. Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification. *Appl. Environ. Microbiol.* 58, 2606–2615. <https://doi.org/10.1128/aem.58.8.2606-2615.1992>
- Van, N.T.B., Cuong, N.V., Nhung, N.T., Yen, N.T.P., Vy, L., Kiet, B.T., Hoang, N.V., Hien, V.B., Thu, H.T.V., Chansiripornchai, N., Thwaites, G.E., Choisy, M., Carrique-Mas, J., 2021. A seroepidemiological investigation on major viral and bacterial pathogens in small-scale chicken flocks in the Mekong delta region of Vietnam. *Thai J. Vet. Med.* 51, 729–733.
- Van, N.T.B., Yen, N.T.P., Nhung, N.T., Cuong, N.V., Kiet, B.T., Hoang, N.V., Hien, V.B., Chansiripornchai, N., Choisy, M., Ribas, A., Campbell, J., Thwaites, G., Carrique-Mas, J., 2020. Characterization

- of viral, bacterial, and parasitic causes of disease in small-scale chicken flocks in the Mekong Delta of Vietnam. *Poult. Sci.* 99, 783–790. <https://doi.org/10.1016/j.psj.2019.10.033>
- Vangroenweghe, F., Karriker, L., Main, R., Christianson, E., Marsteller, T., Hammen, K., Bates, J., Thomas, P., Ellingson, J., Harmon, K., Abate, S., Crawford, K., 2015a. Assessment of litter prevalence of *Mycoplasma hyopneumoniae* in preweaned piglets utilizing an antemortem tracheobronchial mucus collection technique and a real-time polymerase chain reaction assay. *J. Vet. Diagn. Invest.* 27, 606–610. <https://doi.org/10.1177/1040638715595062>
- Vangroenweghe, F., Labarque, G.G., Piepers, S., Strutzberg-Minder, K., Maes, D., 2015b. *Mycoplasma hyopneumoniae* infections in peri-weaned and post-weaned pigs in Belgium and The Netherlands: Prevalence and associations with climatic conditions. *Vet. J.* 205, 93–97. <https://doi.org/10.1016/j.tvjl.2015.03.028>
- Vangroenweghe, F., Willems, E., Malášek, J., Thas, O., Maes, D., 2018. Use of trachea-bronchial swab qPCR testing to confirm *Mycoplasma hyopneumoniae* seropositivity in an SPF breeding herd. *Porc. Health Manag.* 4, 12. <https://doi.org/10.1186/s40813-018-0088-3>
- Veldhuis, A.M.B., Aalberts, M., Penterman, P., Wever, P., Schaik, G. van, 2022. Bayesian diagnostic test evaluation and true prevalence estimation of *Mycoplasma bovis* in dairy cattle., in: *Proceedings of the Society for Veterinary Epidemiology and Preventive Medicine Annual Meeting, Belfast, Northern Ireland, UK, 23-25 March 2022. Society for Veterinary Epidemiology and Preventive Medicine*, pp. 69–80.
- Vereecke, N., Bokma, J., Haesebrouck, F., Nauwynck, H., Boyen, F., Pardon, B., Theuns, S., 2020. High quality genome assemblies of *Mycoplasma bovis* using a taxon-specific Bonito basecaller for MinION and Flongle long-read nanopore sequencing. *BMC Bioinformatics* 21, 517. <https://doi.org/10.1186/s12859-020-03856-0>
- Verwoolde, M.B., Arts, J., Jansen, C.A., Parmentier, H.K., Lammers, A., 2022. Transgenerational Effects of Maternal Immune Activation on Specific Antibody Responses in Layer Chickens. *Front. Vet. Sci.* 9.
- Virginio, V.G., Bandeira, N.C., Leal, F.M. dos A., Lancellotti, M., Zaha, A., Ferreira, H.B., 2017. Assessment of the adjuvant activity of mesoporous silica nanoparticles in recombinant *Mycoplasma hyopneumoniae* antigen vaccines. *Heliyon* 3, e00225. <https://doi.org/10.1016/j.heliyon.2016.e00225>
- Voltarelli, D.C., de Alcântara, B.K., Lunardi, M., Alfieri, A.F., de Arruda Leme, R., Alfieri, A.A., 2018. A nested-PCR strategy for molecular diagnosis of mollicutes in uncultured biological samples from cows with vulvovaginitis. *Anim. Reprod. Sci.* 188, 137–143. <https://doi.org/10.1016/j.anireprosci.2017.11.018>
- Vudriko, P., Ekiri, A.B., Endacott, I., Williams, S., Gityamwi, N., Byaruhanga, J., Alafiatayo, R., Mijten, E., Tweyongyere, R., Varga, G., Cook, A.J.C., 2021. A Survey of Priority Livestock Diseases and Laboratory Diagnostic Needs of Animal Health Professionals and Farmers in Uganda. *Front. Vet. Sci.* 8, 721800. <https://doi.org/10.3389/fvets.2021.721800>
- Waithanji, E., Kairu-Wanyoike, S.W., Liani, M., 2019a. The Role of Gender and Other Socioeconomic Factors in the Adoption of the Contagious Bovine Pleuropneumonia Vaccine: A Literature Review. *East Afr. Agric. For. J.* 83, 221–238. <https://doi.org/10.1080/00128325.2019.1604195>
- Waithanji, E., Mtimet, N., Muindi, P., 2019b. Contagious Bovine Pleuropneumonia Vaccine Delivery and Adoption by Women and Men in North-Eastern Kenya. *Eur. J. Dev. Res.* 31, 364–387. <https://doi.org/10.1057/s41287-018-0157-0>
- Walsh, D.P., Cassirer, E.F., Bonds, M.D., Brown, D.R., Edwards, W.H., Weiser, G.C., Drew, M.L., Briggs, R.E., Fox, K.A., Miller, M.W., Shanthalingam, S., Srikumaran, S., Besser, T.E., 2016. Concordance in diagnostic testing for respiratory pathogens of bighorn sheep. *Wildl. Soc. Bull.* 40, 634–642. <https://doi.org/10.1002/wsb.721>
- Wanasawaeng, W., Chaichote, S., Chansiripornchai, N., 2015. Development of ELISA and serum plate agglutination for detecting antibodies of *Mycoplasma gallisepticum* using strain of Thai isolate. *Thai J. Vet. Med.* 45, 499–507.

- Wang, Jian, Chen, X., Li, J., Ishfaq, M., 2021a. Gut Microbiota Dysbiosis Aggravates *Mycoplasma gallisepticum* Colonization in the Chicken Lung. *Front. Vet. Sci.* 8, 788811. <https://doi.org/10.3389/fvets.2021.788811>
- Wang, J., Hua, L., Gan, Y., Yuan, T., Li, L., Yu, Y., Xie, Q., Olaniran, A.O., Chiliza, T.E., Shao, G., Feng, Z., Pillay, B., Xiong, Q., 2022a. Virulence and Inoculation Route Influence the Consequences of *Mycoplasma hyorhinis* Infection in Bama Miniature Pigs. *Microbiol. Spectr.* 10, e02493-21. <https://doi.org/10.1128/spectrum.02493-21>
- Wang, Jian, Ishfaq, M., Fan, Q., Chen, C., Li, J., 2020. A respiratory commensal bacterium acts as a risk factor for *Mycoplasma gallisepticum* infection in chickens. *Vet. Immunol. Immunopathol.* 230, 110127. <https://doi.org/10.1016/j.vetimm.2020.110127>
- Wang, Jian, Ishfaq, M., Li, J., 2021b. *Lactobacillus salivarius* ameliorated *Mycoplasma gallisepticum*-induced inflammatory injury and secondary *Escherichia coli* infection in chickens: Involvement of intestinal microbiota. *Vet. Immunol. Immunopathol.* 233, 110192. <https://doi.org/10.1016/j.vetimm.2021.110192>
- Wang, Jia, Li, Y., Pan, L., Li, J., Yu, Y., Liu, B., Zubair, M., Wei, Y., Pillay, B., Olaniran, A.O., Chiliza, T.E., Shao, G., Feng, Z., Xiong, Q., 2021. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) moonlights as an adhesin in *Mycoplasma hyorhinis* adhesion to epithelial cells as well as a plasminogen receptor mediating extracellular matrix degradation. *Vet. Res.* 52, 80. <https://doi.org/10.1186/s13567-021-00952-8>
- Wang, J., Yu, Y., Li, Y., Li, S., Wang, L., Wei, Y., Wu, Y., Pillay, B., Olaniran, A.O., Chiliza, T.E., Shao, G., Feng, Z., Xiong, Q., 2022b. A multifunctional enolase mediates cytoadhesion and interaction with host plasminogen and fibronectin in *Mycoplasma hyorhinis*. *Vet. Res.* 53, 26. <https://doi.org/10.1186/s13567-022-01041-0>
- Wang, Jinfeng, Li, R., Sun, X., Liu, L., Hao, X., Wang, Jianchang, Yuan, W., 2020. Development and validation of the isothermal recombinase polymerase amplification assays for rapid detection of *Mycoplasma ovipneumoniae* in sheep. *BMC Vet. Res.* 16, 172. <https://doi.org/10.1186/s12917-020-02387-3>
- Wang, K., Liu, X., Li, Q., Wan, K., Gao, R., Han, G., Li, C., Xu, M., Jia, B., Shen, X., 2020. MHC-DRB1 exon 2 polymorphism and its association with *mycoplasma ovipneumonia* resistance or susceptibility genotypes in sheep. *J. Genet.* 99, 22. <https://doi.org/10.1007/s12041-020-1175-1>
- Wang, X., Cui, Y., Zhang, Y., Shi, K., Yan, Y., Jian, F., Zhang, L., Wang, R., Ning, C., 2017. Molecular characterization of hemotropic mycoplasmas (*Mycoplasma ovis* and 'Candidatus *Mycoplasma haemovis*') in sheep and goats in China. *BMC Vet. Res.* 13, 142. <https://doi.org/10.1186/s12917-017-1062-z>
- Wang, X., Wang, Y., Huang, H., Bai, F., Shi, X., Ma, C., Gao, Y., Zhang, J., Zhang, W., Hao, Y., 2018. Understanding the metabolism of *Mycoplasma mycoides* subsp. *capri* in vitro by a transcriptomic analysis. *J. Integr. Agric.* 17, 428–435. [https://doi.org/10.1016/S2095-3119\(17\)61747-7](https://doi.org/10.1016/S2095-3119(17)61747-7)
- Wang, Y., 2020. Research Progress on MicroRNAs Involved in the Regulation of Chicken Diseases. *J. Poult. Sci.* 57, 7–17. <https://doi.org/10.2141/jpsa.0190073>
- Wang, Y., Liang, Y., Hu, F., Sun, Y., Zou, M., Luo, R., Peng, X., 2022. Chinese herbal formulae defend against *Mycoplasma gallisepticum* infection. *J. Integr. Agric.* 21, 3026–3036. <https://doi.org/10.1016/j.jia.2022.07.038>
- Wang, Y., Tong, D., Sun, Y., Sun, H., Liu, F., Zou, M., Luo, R., Peng, X., 2021. DF-1 cells prevent MG-HS infection through *gga-miR-24-3p/RAP1B* mediated decreased proliferation and increased apoptosis. *Res. Vet. Sci.* 141, 164–173. <https://doi.org/10.1016/j.rvsc.2021.10.021>
- Wang, Y., Yi, L., Zhang, F., Qiu, X., Tan, L., Yu, S., Cheng, X., Ding, C., 2017. Identification of genes involved in *Mycoplasma gallisepticum* biofilm formation using mini-Tn4001-SGM transposon mutagenesis. *Vet. Microbiol.* 198, 17–22. <https://doi.org/10.1016/j.vetmic.2016.11.021>

- Wawegama, N.K., Browning, G.F., Kanci, A., Marendra, M.S., Markham, P.F., 2014. Development of a Recombinant Protein-Based Enzyme-Linked Immunosorbent Assay for Diagnosis of *Mycoplasma bovis* Infection in Cattle. *Clin. Vaccine Immunol.* 21, 196–202. <https://doi.org/10.1128/CVI.00670-13>
- Wawegama, N.K., Markham, P.F., Kanci, A., Schibrowski, M., Oswin, S., Barnes, T.S., Firestone, S.M., Mahony, T.J., Browning, G.F., 2016. Evaluation of an IgG Enzyme-Linked Immunosorbent Assay as a Serological Assay for Detection of *Mycoplasma bovis* Infection in Feedlot Cattle. *J. Clin. Microbiol.* 54, 1269–1275. <https://doi.org/10.1128/JCM.02492-15>
- Wegner, B., Tenhüdfeld, J., Vogels, J., Beumer, M., Kamphues, J., Hansmann, F., Rieger, H., grosse Beilage, E., Hennig-Pauka, I., 2020. Lameness in fattening pigs – *Mycoplasma hyosynoviae*, osteochondropathy and reduced dietary phosphorus level as three influencing factors: a case report. *Porc. Health Manag.* 6, 41. <https://doi.org/10.1186/s40813-020-00184-w>
- Weitzman, C.L., Thomason, C., Schuler, E.J.A., Leon, A.E., Teemer, S.R., Hawley, D.M., 2020. House finches with high coccidia burdens experience more severe experimental *Mycoplasma gallisepticum* infections. *Parasitol. Res.* 119, 3535–3539. <https://doi.org/10.1007/s00436-020-06814-0>
- Welchman, D., Tasker, J., Poulos, C., Ellis, C., Bradbury, J.M., 2022. Survey of respiratory disease associated with *Mycoplasma gallisepticum* in British gamebirds (2016–2019): In vitro antibiotic sensitivity, pathology and detection of other pathogens. *Vet. Rec.* 191. <https://doi.org/10.1002/vetr.1972>
- Weldearegay, Y., Müller, S., Hänske, J., Schulze, A., Kostka, A., Rüger, N., Hewicker-Trautwein, M., Brehm, R., Valentin-Weigand, P., Kammerer, R., Jores, J., Meens, J., 2019. Host-Pathogen Interactions of *Mycoplasma mycoides* in Caprine and Bovine Precision-Cut Lung Slices (PCLS) Models. *Pathogens* 8, 82. <https://doi.org/10.3390/pathogens8020082>
- Weldearegay, Y.B., Pich, A., Schieck, E., Liljander, A., Gicheru, N., Wesonga, H., Thiaucourt, F., Kiirika, L.M., Valentin-Weigand, P., Jores, J., Meens, J., 2016. Proteomic characterization of pleural effusion, a specific host niche of *Mycoplasma mycoides* subsp. *mycoides* from cattle with contagious bovine pleuropneumonia (CBPP). *J. Proteomics* 131, 93–103. <https://doi.org/10.1016/j.jprot.2015.10.016>
- Wen, Y., Chen, Z., Tian, Y., Yang, M., Dong, Q., Yang, Y., Ding, H., 2022. Incomplete autophagy promotes the proliferation of *Mycoplasma hyopneumoniae* through the JNK and Akt pathways in porcine alveolar macrophages. *Vet. Res.* 53, 62. <https://doi.org/10.1186/s13567-022-01074-5>
- Werdel, T.J., Jenks, J.A., Besser, T.E., Kanta, J.T., Lehman, C.P., Frink, T.J., 2020. Restoration of a bighorn sheep population impeded by *Mycoplasma ovipneumoniae* exposure. *Restor. Ecol.* 28, 387–395. <https://doi.org/10.1111/rec.13084>
- Westberg, J., Persson, A., Holmberg, A., Goesmann, A., Lundeberg, J., Johansson, K.-E., Pettersson, B., Uhlén, M., 2004. The Genome Sequence of *Mycoplasma mycoides* subsp. *mycoides* SC Type Strain PG1T, the Causative Agent of Contagious Bovine Pleuropneumonia (CBPP). *Genome Res.* 14, 221–227. <https://doi.org/10.1101/gr.1673304>
- White, B.J., Anderson, D.E., Renter, D.G., Larson, R.L., Mosier, D.A., Kelly, L.L., Theurer, M.E., Robért, B.D., Walz, M.L., 2012. Clinical, behavioral, and pulmonary changes in calves following inoculation with *Mycoplasma bovis*. *Am. J. Vet. Res.* 73, 490–497. <https://doi.org/10.2460/ajvr.73.4.490>
- Whithear, K.G., 1996. Control of avian mycoplasmoses by vaccination. *Rev. Sci. Tech. Int. Off. Epizoot.* 15, 1527–1553. <https://doi.org/10.20506/rst.15.4.985>
- Wijesurendra, D.S., Kanci, A., Tivendale, K.A., Bacci, B., Noormohammadi, A.H., Browning, G.F., Markham, P.F., 2015. Development of a *Mycoplasma gallisepticum* infection model in turkeys. *Avian Pathol.* 44, 35–42. <https://doi.org/10.1080/03079457.2014.992390>
- Wijesurendra, D.S., Kanci, A., Tivendale, K.A., Devlin, J.M., Wawegama, N.K., Bacci, B., Noormohammadi, A.H., Markham, P.F., Browning, G.F., 2017. Immune responses to

- vaccination and infection with *Mycoplasma gallisepticum* in turkeys. *Avian Pathol.* 46, 464–473. <https://doi.org/10.1080/03079457.2017.1311990>
- Williams, S., Endacott, I., Ekiri, A.B., Kichuki, M., Dineva, M., Galipo, E., Alexeenko, V., Alafiatayo, R., Mijten, E., Varga, G., Cook, A.J.C., 2022. Barriers to vaccine use in small ruminants and poultry in Tanzania. *Onderstepoort J. Vet. Res.* 89, 11. <https://doi.org/10.4102/ojvr.v89i1.2007>
- Wilson, S., Van Brussel, L., Saunders, G., Runnels, P., Taylor, L., Fredrickson, D., Salt, J., 2013. Vaccination of Piglets up to 1 Week of Age with a Single-Dose *Mycoplasma hyopneumoniae* Vaccine Induces Protective Immunity within 2 Weeks against Virulent Challenge in the Presence of Maternally Derived Antibodies. *Clin. Vaccine Immunol.* 20, 720–724. <https://doi.org/10.1128/CVI.00078-13>
- Windsor, P., 2022. Anaemia in Lambs Caused by *Mycoplasma ovis*: Global and Australian Perspectives. *Animals* 12, 1372. <https://doi.org/10.3390/ani12111372>
- Wise, K.S., Calcutt, M.J., Foecking, M.F., Madupu, R., DeBoy, R.T., Röske, K., Hvinden, M.L., Martin, T.R., Durkin, A.S., Glass, J.I., Methé, B.A., 2012. Complete Genome Sequences of *Mycoplasma leachii* Strain PG50^T and the Pathogenic *Mycoplasma mycoides* subsp. *mycoides* Small Colony Biotype Strain Gladysdale. *J. Bacteriol.* 194, 4448–4449. <https://doi.org/10.1128/JB.00761-12>
- Wise, K.S., Calcutt, M.J., Foecking, M.F., Röske, K., Madupu, R., Methé, B.A., 2011. Complete Genome Sequence of *Mycoplasma bovis* Type Strain PG45 (ATCC 25523). *Infect. Immun.* 79, 982–983. <https://doi.org/10.1128/IAI.00726-10>
- Wisselink, H.J., Smid, B., Plater, J., Ridley, A., Andersson, A.-M., Aspán, A., Pohjanvirta, T., Vähänikkilä, N., Larsen, H., Høggberg, J., Colin, A., Tardy, F., 2019. A European interlaboratory trial to evaluate the performance of different PCR methods for *Mycoplasma bovis* diagnosis. *BMC Vet. Res.* 15, 86. <https://doi.org/10.1186/s12917-019-1819-7>
- Witter, R., Melo, A.L.T., Pacheco, T. dos A., Meneguzzi, M., Boas, R.V., Dutra, V., Nakazato, L., Chitarra, C.S., Oliveira, A.C.S. de, Pacheco, R.C., 2017. Prevalence of “Candidatus *Mycoplasma haemobos*” detected by PCR, in dairy cattle from Ji-Paraná in the north region of Brazil. *Ciênc. Rural* 47. <https://doi.org/10.1590/0103-8478cr20160805>
- Witvliet, M., Holtslag, H., Nell, T., Segers, R., Fachinger, V., 2015. Efficacy and safety of a combined Porcine Circovirus and *Mycoplasma hyopneumoniae* vaccine in finishing pigs. *Trials Vaccinol.* 4, 43–49. <https://doi.org/10.1016/j.trivac.2015.04.002>
- WOAH, 2023a. Contagious bovine pleuropneumonia [WWW Document]. World Organ. Anim. Health. URL <https://www.woah.org/en/disease/contagious-bovine-pleuropneumonia/>
- WOAH, 2023b. Contagious Bovine Pleuropneumonia [WWW Document]. GF-TADs Afr. URL <https://rr-africa.woah.org/en/projects/gf-tads-for-africa/contagious-bovine-pleuropneumonia/>
- WOAH, 2023c. Contagious agalactia [WWW Document]. World Organ. Anim. Health. URL <https://www.woah.org/en/disease/contagious-agalactia/>
- WOAH, 2023d. Contagious caprine pleuropneumonia [WWW Document]. World Organ. Anim. Health. URL <https://www.woah.org/en/disease/contagious-caprine-pleuropneumonia/>
- WOAH, 2022a. List of CBPP free members. URL <https://www.woah.org/en/disease/contagious-bovine-pleuropneumonia>
- WOAH, 2022b. Avian mycoplasmosis, in: *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2022*. WOAH, Paris, France.
- WOAH, 2020. Contagious bovine pleuropneumonia, OIE Technical Disease Cards. World Organisation for Animal Health, Paris.
- WOAH, 2018. Contagious bovine pleuropneumonia, in: *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals*. WOAH, Paris, France.
- Wolff, P.L., Blanchong, J.A., Nelson, D.D., Plummer, P.J., McAdoo, C., Cox, M., Besser, T.E., Muñoz-Gutiérrez, J., Anderson, C.A., 2019. Detection of *Mycoplasma ovipneumoniae* in Pneumonic Mountain Goat (*Oreamnos americanus*) Kids. *J. Wildl. Dis.* 55, 206. <https://doi.org/10.7589/2018-02-052>

- Wood, M.E., Fox, K.A., Jennings-Gaines, J., Killion, H.J., Amundson, S., Miller, M.W., Edwards, W.H., 2017. How Respiratory Pathogens Contribute to Lamb Mortality in a Poorly Performing Bighorn Sheep (*Ovis canadensis*) Herd. *J. Wildl. Dis.* 53, 126. <https://doi.org/10.7589/2016-05-097>
- Woolums, A.R., Berghaus, R.D., Smith, D.R., White, B.J., Engelken, T.J., Irsik, M.B., Matlik, D.K., Jones, A.L., Smith, I.J., 2014. A survey of veterinarians in 6 US states regarding their experience with nursing beef calf respiratory disease. *Bov. Pract.* 48, 26–35.
- Wrobel, E.R., Wilcoxon, T.E., Nuzzo, J.T., Seitz, J., 2016. Seroprevalence of Avian Pox and *Mycoplasma gallisepticum* in Raptors in Central Illinois. *J. Raptor Res.* 50, 289–294. <https://doi.org/10.3356/JRR-15-43.1>
- Wu, C., Zhong, L., Zhang, L., Li, W., Liu, B., Huang, B., Luo, Z., Wu, Y., 2022. Study on the mechanism of *Mycoplasma gallisepticum* infection on chicken tracheal mucosa injury. *Avian Pathol.* 51, 361–373. <https://doi.org/10.1080/03079457.2022.2068997>
- Wu, X., Ma, J., Jia, S., Zhang, Xudong, Zhang, Xinlan, An, Z., Wei, Y., Xing, X., Wen, F., Gao, Y., Bao, S., 2022. High Concentration of FBS Can Save mTOR Down-Regulation Caused by *Mycoplasmas bovis* Infection. *Vet. Sci.* 9, 630. <https://doi.org/10.3390/vetsci9110630>
- Wu, X., Zhang, S., Long, C., An, Z., Xing, X., Wen, F., Bao, S., 2021. *Mycoplasmas bovis* P48 induces apoptosis in EBL cells via an endoplasmic reticulum stress-dependent signaling pathway. *Vet. Microbiol.* 255, 109013. <https://doi.org/10.1016/j.vetmic.2021.109013>
- Wu, Z., Fan, Q., Miao, Y., Tian, E., Ishfaq, M., Li, J., 2020. Baicalin inhibits inflammation caused by coinfection of *Mycoplasma gallisepticum* and *Escherichia coli* involving IL-17 signaling pathway. *Poult. Sci.* 99, 5472–5480. <https://doi.org/10.1016/j.psj.2020.08.070>
- Xi, X., CongMing, W., YaoWen, C., MengJiao, K., XiaoWei, L., ShuangYang, D., JianZhong, S., 2015. Proteomic analysis of tylosin-resistant *Mycoplasma gallisepticum* reveals enzymatic activities associated with resistance. *Sci. Rep.* 5.
- Xia, W., Chen, K., Liu, W., Yin, Y., Yao, Q., Ban, Y., Pu, Y., Zhan, X., Bian, H., Yu, S., Han, K., Yang, L., Wang, H., Fan, Z., 2022. Rapid and visual detection of *Mycoplasma synoviae* by recombinase-aided amplification assay combined with a lateral flow dipstick. *Poult. Sci.* 101, 101860. <https://doi.org/10.1016/j.psj.2022.101860>
- Xie, X., Hao, F., Chen, R., Wang, J., Wei, Y., Liu, J., Wang, H., Zhang, Z., Bai, Y., Shao, G., Xiong, Q., Feng, Z., 2021. Nicotinamide Adenine Dinucleotide-Dependent Flavin Oxidoreductase of *Mycoplasma hyopneumoniae* Functions as a Potential Novel Virulence Factor and Not Only as a Metabolic Enzyme. *Front. Microbiol.* 12, 747421. <https://doi.org/10.3389/fmicb.2021.747421>
- Xin, J., Li, Y., Nicholas, R.A.J., Chen, C., Liu, Y., Zhang, M., Dong, H., 2012. A history of the prevalence and control of contagious bovine pleuropneumonia in China. *Vet. J.* 191, 166–170. <https://doi.org/10.1016/j.tvjl.2011.02.011>
- Xiong, Q., Wang, J., Ji, Y., Ni, B., Zhang, B., Ma, Q., Wei, Y., Xiao, S., Feng, Z., Liu, M., Shao, G., 2016. The functions of the variable lipoprotein family of *Mycoplasma hyorhinis* in adherence to host cells. *Vet. Microbiol.* 186, 82–89. <https://doi.org/10.1016/j.vetmic.2016.01.017>
- Xu, B., Chen, X., Lu, F., Sun, Y., Sun, H., Zhang, J., Shen, L., Pan, Q., Liu, C., Zhang, X., 2021. Comparative Genomics of *Mycoplasma synoviae* and New Targets for Molecular Diagnostics. *Front. Vet. Sci.* 8, 640067. <https://doi.org/10.3389/fvets.2021.640067>
- Xu, B., Liu, R., Ding, M., Zhang, J., Sun, H., Liu, C., Lu, F., Zhao, S., Pan, Q., Zhang, X., 2020a. Interaction of *Mycoplasma synoviae* with chicken synovial sheath cells contributes to macrophage recruitment and inflammation. *Poult. Sci.* 99, 5366–5377. <https://doi.org/10.1016/j.psj.2020.08.003>
- Xu, B., Liu, R., Tao, L., Ding, M., Lu, F., Zhang, J., Sun, H., Liu, C., Pan, Q., Zhao, S., Zhang, X., 2020b. Complete Genome Sequencing of *Mycoplasma synoviae* Strain HN01, Isolated from Chicken in Henan Province, China. *Microbiol. Resour. Announc.* 9, e01480-19. <https://doi.org/10.1128/MRA.01480-19>

- Xu, J., Teng, D., Jiang, F., Zhang, Y., El-Ashram, S.A., Wang, H., Sun, Z., He, J., Shen, J., Wu, W., Li, J., 2015. *Mycoplasma gallisepticum* MGA_0676 is a membrane-associated cytotoxic nuclease with a staphylococcal nuclease region essential for nuclear translocation and apoptosis induction in chicken cells. *Appl. Microbiol. Biotechnol.* 99, 1859–1871. <https://doi.org/10.1007/s00253-014-6185-6>
- Xu, M., Liu, Y., Mayinuer, T., Lin, Y., Wang, Y., Gao, J., Wang, D., Kastelic, J.P., Han, B., 2022. *Mycoplasma bovis* inhibits autophagy in bovine mammary epithelial cells via a PTEN/PI3K-Akt-mTOR-dependent pathway. *Front. Microbiol.* 13, 935547. <https://doi.org/10.3389/fmicb.2022.935547>
- Xue, D., Li, Y., Jiang, Z., Deng, G., Li, M., Liu, X., Wang, Y., 2017. A ROS-dependent and Caspase-3-mediated apoptosis in sheep bronchial epithelial cells in response to *Mycoplasma Ovipneumoniae* infections. *Vet. Immunol. Immunopathol.* 187, 55–63. <https://doi.org/10.1016/j.vetimm.2017.04.004>
- Xue, D., Ma, Y., Li, M., Li, Y., Luo, H., Liu, X., Wang, Y., 2015. *Mycoplasma ovipneumoniae* induces inflammatory response in sheep airway epithelial cells via a MyD88-dependent TLR signaling pathway. *Vet. Immunol. Immunopathol.* 163, 57–66. <https://doi.org/10.1016/j.vetimm.2014.11.008>
- Xue, J., Xu, M.Y., Ma, Z.J., Zhao, J., Jin, N., Zhang, G.Z., 2017. Serological investigation of *Mycoplasma synoviae* infection in China from 2010 to 2015. *Poult. Sci.* 96, 3109–3112. <https://doi.org/10.3382/ps/pex134>
- Yadav, J.P., Batra, K., Singh, Y., Singh, M., 2021. Comparative evaluation of indirect-ELISA and DOT blot assay for serodetection of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* antibodies in poultry. *J. Microbiol. Methods* 189, 106317. <https://doi.org/10.1016/j.mimet.2021.106317>
- Yadav, J.P., Singh, Y., Jindal, N., Mahajan, N.K., 2022a. Rapid and specific detection of *Mycoplasma gallisepticum* and *Mycoplasma synoviae* infection in poultry using single and duplex PCR assays. *J. Microbiol. Methods* 192, 106365. <https://doi.org/10.1016/j.mimet.2021.106365>
- Yadav, J.P., Tomar, P., Singh, Y., Khurana, S.K., 2022b. Insights on *Mycoplasma gallisepticum* and *Mycoplasma synoviae* infection in poultry: a systematic review. *Anim. Biotechnol.* 33, 1711–1720. <https://doi.org/10.1080/10495398.2021.1908316>
- Yair, Y., Borovok, I., Mikula, I., Falk, R., Fox, L.K., Gophna, U., Lysnyansky, I., 2020. Genomics-based epidemiology of bovine *Mycoplasma bovis* strains in Israel. *BMC Genomics* 21, 70. <https://doi.org/10.1186/s12864-020-6460-0>
- Yang, F., Tang, C., Wang, Y., Zhang, H., Yue, H., 2011. Genome Sequence of *Mycoplasma ovipneumoniae* Strain SC01. *J. Bacteriol.* 193, 5018. <https://doi.org/10.1128/JB.05363-11>
- Yang, J., Liu, Y., Lin, C., Yan, R., Li, Z., Chen, Q., Zhang, H., Xu, H., Chen, X., Chen, Y., Guo, A., Hu, C., 2022. Regularity of Toll-Like Receptors in Bovine Mammary Epithelial Cells Induced by *Mycoplasma bovis*. *Front. Vet. Sci.* 9, 846700. <https://doi.org/10.3389/fvets.2022.846700>
- Yang, S., Lee, J., Oh, T., Park, K., Cho, H., Suh, J., Min, K.-D., Ham, HeeJin, Chae, C., 2022. Comparative growth performance of 3 types of combination vaccines containing porcine Circovirus 2 and *Mycoplasma hyopneumoniae* under field conditions. *Can. J. Vet. Res.* 86, 93–101.
- Yang, S., Park, S., Oh, T., Cho, H., Chae, C., 2020. Efficacy comparison of commercial porcine circovirus type 2 (PCV2) and *Mycoplasma hyopneumoniae* monovalent and bivalent vaccines against a dual challenge. *Can. J. Vet. Res.* 84, 272–282.
- Yang, Y., Wang, Y., Zou, M., Deng, G., Peng, X., 2021. gga-miR-142-3p negatively regulates *Mycoplasma gallisepticum* (HS strain)-induced inflammatory cytokine production via the NF- κ B and MAPK signaling by targeting TAB2. *Inflamm. Res.* 70, 1217–1231. <https://doi.org/10.1007/s00011-021-01499-2>
- Yansambou, M.S., Diallo, A.A., Idi, M., Gagara, H., Haido, A.M., Bada Alambedji, R., 2018. Serological Prevalence of Contagious Bovine Pleuropneumonia in Niger in 2017. *Front. Vet. Sci.* 5, 238. <https://doi.org/10.3389/fvets.2018.00238>

- Yatoo, M.I., Parray, O.R., Bashir, S.T., Muheet, Bhat, R.A., Gopalakrishnan, A., Karthik, K., Dhama, K., Singh, S.V., 2019. Contagious caprine pleuropneumonia - a comprehensive review. *Vet. Q.* 39, 1–25.
- Ybañez, A.P., Ybañez, R.H.D., Armonia, R.K.M., Chico, J.K.E., Ferraren, K.J.V., Tapdasan, E.P., Salces, C.B., Maurillo, B.C.A., Galon, E.M.S., Macalanda, A.M.C., Moumouni, P.F.A., XueNan, X., 2019. First molecular detection of *Mycoplasma wenyonii* and the ectoparasite biodiversity in dairy water buffalo and cattle in Bohol, Philippines. *Parasitol. Int.* 70, 77–81.
- Yeske, P., Valeris-Chacin, R., Singer, R.S., Pieters, M., 2020. Survival analysis of two *Mycoplasma hyopneumoniae* eradication methods. *Prev. Vet. Med.* 174, 104811. <https://doi.org/10.1016/j.prevetmed.2019.104811>
- Yin, X., Wang, Y., Sun, Y., Han, Y., Sun, H., Zou, M., Luo, R., Peng, X., 2021. Down-regulated gga-miR-223 inhibits proliferation and induces apoptosis of MG-infected DF-1 cells by targeting FOXO3. *Microb. Pathog.* 155, 104927. <https://doi.org/10.1016/j.micpath.2021.104927>
- YongPeng, G., HongMei, Z., JiaYao, W., Jing, H., Khan, F.A., JingJing, Z., AiZhen, G., Xi, C., 2017. TrmFO, a fibronectin-binding adhesin of *Mycoplasma bovis*. *Int. J. Mol. Sci.* 18.
- Yu, Ying, Chen, Y., Wang, Y., Li, Y., Zhang, L., Xin, J., 2018. TLR2/MyD88/NF- κ B signaling pathway regulates IL-1 β production in DF-1 cells exposed to *Mycoplasma gallisepticum* LAMPs. *Microb. Pathog.* 117, 225–231. <https://doi.org/10.1016/j.micpath.2018.02.037>
- Yu, Yanfei, Liu, M., Hua, L., Qiu, M., Zhang, W., Wei, Y., Gan, Y., Feng, Z., Shao, G., Xiong, Q., 2018a. Fructose-1,6-bisphosphate aldolase encoded by a core gene of *Mycoplasma hyopneumoniae* contributes to host cell adhesion. *Vet. Res.* 49, 114. <https://doi.org/10.1186/s13567-018-0610-2>
- Yu, Yanfei, Wang, H., Wang, J., Feng, Z., Wu, M., Liu, B., Xin, J., Xiong, Q., Liu, M., Shao, G., 2018b. Elongation Factor Thermo Unstable (EF-Tu) Moonlights as an Adhesin on the Surface of *Mycoplasma hyopneumoniae* by Binding to Fibronectin. *Front. Microbiol.* 9, 974. <https://doi.org/10.3389/fmicb.2018.00974>
- Yu, Y., Zhang, L., Chen, Y., Li, Y., Wang, Z., Li, G., Wang, G., Xin, J., 2019. GroEL Protein (Heat Shock Protein 60) of *Mycoplasma gallisepticum* Induces Apoptosis in Host Cells by Interacting with Annexin A2. *Infect. Immun.* 87, e00248-19. <https://doi.org/10.1128/IAI.00248-19>
- Yuan, B., Zou, M., Zhao, Y., Zhang, K., Sun, Y., Peng, X., 2018. Up-Regulation of miR-130b-3p Activates the PTEN/PI3K/AKT/NF- κ B Pathway to Defense against *Mycoplasma gallisepticum* (HS Strain) Infection of Chicken. *Int. J. Mol. Sci.* 19, 2172. <https://doi.org/10.3390/ijms19082172>
- Yuan, L., Rui, W., WenJing, S., ZhiQiang, S., Fan, B., HuaJun, Z., JiuQing, X., 2020. Comparative genomics analysis of *Mycoplasma capricolum* subsp. *capripneumoniae* 87001. *Genomics San Diego* 112, 615–620.
- Yue, W., Liu, Y., Meng, Y., Ma, H., He, J., 2021. Prevalence of porcine respiratory pathogens in slaughterhouses in Shanxi Province, China. *Vet. Med. Sci.* 7, 1339–1346. <https://doi.org/10.1002/vms3.532>
- Yun, J., Mao, L., Li, J., Hao, F., Yang, L., Zhang, W., Sun, M., Liu, M., Wang, S., Li, W., 2022. Molecular characterization and antimicrobial resistance profile of pathogenic *Escherichia coli* from goats with respiratory disease in eastern China. *Microb. Pathog.* 166, 105501. <https://doi.org/10.1016/j.micpath.2022.105501>
- YuZi, W., Ishag, H.Z.A., LiZhong, H., Lei, Z., BeiBei, L., ZhenZhen, Z., HaiYan, W., YanNa, W., ZhiXin, F., Chenia, H.Y., GuoQing, S., QiYan, X., 2019. Establishment and application of a real-time, duplex PCR method for simultaneous detection of *Mycoplasma hyopneumoniae* and *Mycoplasma hyorhinis*. *Kafkas Üniversitesi Vet. Fakültesi Derg.* 25, 405–414.
- Zakeri, A., Pourbakhsh, S.A., 2017. Differential diagnosis between ts-11 vaccine strain and field *Mycoplasma gallisepticum* isolates in clinical samples by PCR-RFLP. *Eur. Poult. Sci.* 81.
- Zarina, M., Zamri-Saad, M., Latiffah, H., Shahrom, M.S., Norlida, O., 2016. Seroprevalence and detection of Contagious Bovine Pleuropneumonia (CBPP) in northeast states of Peninsular Malaysia. *Pertanika J. Trop. Agric. Sci.* 39, 257–265.

- Zbinden, C., Pilo, P., Frey, J., Bruckmaier, R.M., Wellnitz, O., 2015. The immune response of bovine mammary epithelial cells to live or heat-inactivated *Mycoplasma bovis*. *Vet. Microbiol.* 179, 336–340.
- Zerbo, L.H., Dahourou, L.D., Sidi, M., Ouoba, L.B., Ouandaogo, S.H., Bazimo, G., N’paton Sie, B., Traore, K.Z.A., Tapsoba, M., Ouedraogo, A., Yaogo, D., Nebie, N., Guitti, M., Coulibaly, N., Guinguere, I., Savadogo, J., 2021. Seroprevalence and determinants of contagious bovine pleuropneumonia in cattle in Burkina Faso. *Trop. Anim. Health Prod.* 53, 39. <https://doi.org/10.1007/s11250-020-02455-8>
- Zhang, D., Long, Y., Li, M., Gong, J., Li, X., Lin, J., Meng, J., Gao, K., Zhao, R., Jin, T., 2018. Development and evaluation of novel recombinant adenovirus-based vaccine candidates for infectious bronchitis virus and *Mycoplasma gallisepticum* in chickens. *Avian Pathol.* 47, 213–222. <https://doi.org/10.1080/03079457.2017.1403009>
- Zhang, H., Lu, D., Zhang, Y., Zhao, G., Raheem, A., Chen, Y., Chen, X., Hu, C., Chen, H., Yang, L., Guo, A., 2022. Annexin A2 regulates *Mycoplasma bovis* adhesion and invasion to embryo bovine lung cells affecting molecular expression essential to inflammatory response. *Front. Immunol.* 13, 974006. <https://doi.org/10.3389/fimmu.2022.974006>
- Zhang, H., Wang, Yuanyuan, Gao, L., Wang, Yan, Wei, R., 2021. Genotype diversity of *Mycoplasma Hypopneumoniae* in Chinese swine herds based on multilocus sequence typing. *BMC Vet. Res.* 17, 347. <https://doi.org/10.1186/s12917-021-03059-6>
- Zhang, J., Cao, J., Zhu, M., Xu, M., Shi, F., 2019. Loop-mediated isothermal amplification-lateral-flow dipstick (LAMP-LFD) to detect *Mycoplasma ovipneumoniae*. *World J. Microbiol. Biotechnol.* 35, 31. <https://doi.org/10.1007/s11274-019-2601-5>
- Zhang, R., Han, X., Chen, Y., Mustafa, R., Qi, J., Chen, X., Hu, C., Chen, H., Guo, A., 2014. Attenuated *Mycoplasma bovis* strains provide protection against virulent infection in calves. *Vaccine* 32, 3107–3114. <https://doi.org/10.1016/j.vaccine.2013.12.004>
- Zhang, W., Liu, Y., Zhang, Q., Waqas Ali Shah, S., Wu, Z., Wang, J., Ishfaq, M., Li, J., 2020. *Mycoplasma gallisepticum* Infection Impaired the Structural Integrity and Immune Function of Bursa of Fabricius in Chicken: Implication of Oxidative Stress and Apoptosis. *Front. Vet. Sci.* 7, 225. <https://doi.org/10.3389/fvets.2020.00225>
- Zhang, X., Chen, Y., Wei, Z., Ma, S., Guo, M., Chu, D., Zhang, C., Cao, Y., Wu, Y., 2021a. Complete Genome Sequencing of the Attenuated Strain *Mycoplasma synoviae* 5-9. *Microbiol. Resour. Announc.* 10, e00981-21. <https://doi.org/10.1128/MRA.00981-21>
- Zhang, X., Chen, Y., Xie, D., Guo, M., Ma, S., Chen, M., Chu, D., Wu, Y., 2021b. Multi-locus sequence typing analysis of *Mycoplasma synoviae* isolates reveals unique sequence types in China. *Vet. Microbiol.* 259, 109101. <https://doi.org/10.1016/j.vetmic.2021.109101>
- Zhang, X., Guo, M., Xie, D., Chen, Y., Zhang, C., Cao, Y., Wu, Y., 2022. Antibiotic resistance of *Mycoplasma Synoviae* strains isolated in China from 2016 to 2019. *BMC Vet. Res.* 18, 1. <https://doi.org/10.1186/s12917-021-03104-4>
- Zhang, Y., Gan, Y., Bao, H., Wang, R., 2023. Perturbations of gut microbiome and metabolome of pigs infected with *Mycoplasma hyorhinis*. *J. Sci. Food Agric.* <https://doi.org/10.1002/jsfa.12690>
- Zhang, Y., Li, X., Zhao, H., Jiang, F., Wang, Z., Wu, W., 2019. Antibodies Specific to Membrane Proteins Are Effective in Complement-Mediated Killing of *Mycoplasma bovis*. *Infect. Immun.* 87, e00740-19. <https://doi.org/10.1128/IAI.00740-19>
- Zhang, Y., Ma, C., Han, Y., Jin, H., Luo, H., Hao, X., Li, M., 2022. Integrative Analysis of the Nasal Microbiota and Serum Metabolites in Bovines with Respiratory Disease by 16S rRNA Sequencing and Gas Chromatography/Mass Selective Detector-Based Metabolomics. *Int. J. Mol. Sci.* 23, 12028. <https://doi.org/10.3390/ijms231912028>
- Zhang, Y., Zou, Y., Ma, P., Muhammad, H.M., Li, Y., Jiang, P., 2015. Identification of *Mycoplasma suis* MSG1 interaction proteins on porcine erythrocytes. *Arch. Microbiol.* 197, 277–283. <https://doi.org/10.1007/s00203-014-1050-7>

- Zhang, Z., He, M., Jiang, J., Li, X., Li, H., Zhang, W., Chen, S., Du, L., Man, C., Chen, Q., Gao, H., Wang, F., 2022a. First Report and Comparative Genomic Analysis of *Mycoplasma capricolum* subsp. *capricolum* HN-B in Hainan Island, China. *Microorganisms* 10, 2298. <https://doi.org/10.3390/microorganisms10112298>
- Zhang, Z., Jiang, J., He, M., Li, H., Cheng, Y., An, Q., Chen, S., Du, L., Man, C., Chen, Q., Li, L., Wang, F., 2022b. First Report and Comparative Genomic Analysis of a *Mycoplasma mycoides* Subspecies *capri* HN-A in Hainan Island. *Microorganisms* 10, 1908. <https://doi.org/10.3390/microorganisms10101908>
- Zhao, G., Hou, P., Huan, Y., He, C., Wang, H., He, H., 2018. Development of a recombinase polymerase amplification combined with a lateral flow dipstick assay for rapid detection of the *Mycoplasma bovis*. *BMC Vet. Res.* 14, 412. <https://doi.org/10.1186/s12917-018-1703-x>
- Zhao, G., Zhang, H., Chen, X., Zhu, X., Guo, Y., He, C., Anwar Khan, F., Chen, Y., Hu, C., Chen, H., Guo, A., 2017. *Mycoplasma bovis* NADH oxidase functions as both a NADH oxidizing and O₂ reducing enzyme and an adhesin. *Sci. Rep.* 7, 44. <https://doi.org/10.1038/s41598-017-00121-y>
- Zhao, G., Zhu, X., Zhang, H., Chen, Y., Schieck, E., Hu, C., Chen, H., Guo, A., 2021. Novel Secreted Protein of *Mycoplasma bovis* MbovP280 Induces Macrophage Apoptosis Through CRYAB. *Front. Immunol.* 12, 619362. <https://doi.org/10.3389/fimmu.2021.619362>
- Zhao, H., Zhang, Y., Wang, Z., Liu, M., Wang, P., Wu, W., Peng, C., 2021. MBOVPG45_0375 Encodes an IgG-Binding Protein and MBOVPG45_0376 Encodes an IgG-Cleaving Protein in *Mycoplasma bovis*. *Front. Vet. Sci.* 8, 644224. <https://doi.org/10.3389/fvets.2021.644224>
- Zhao, J., Du, Y., Song, Y., Zhou, P., Chu, Y., Wu, J., 2021. Investigation of the prevalence of *Mycoplasma ovipneumoniae* in Southern Xinjiang, China. *J. Vet. Res.* 65, 155–160. <https://doi.org/10.2478/jvetres-2021-0021>
- Zhao, Y., Hou, Y., Zhang, K., Yuan, B., Peng, X., 2017a. Identification of differentially expressed miRNAs through high-throughput sequencing in the chicken lung in response to *Mycoplasma gallisepticum* HS. *Comp. Biochem. Physiol. Part D Genomics Proteomics* 22, 146–156. <https://doi.org/10.1016/j.cbd.2017.04.004>
- Zhao, Y., Ren, Z., Kang, Q., Chen, Y., Wang, X., Tang, X., Zhang, F., Qin, J., 2017b. Development of an antigen specific colloidal gold immunochromatographic assay for detection of antibody to *M. wenyonii* in bovine sera. *J. Microbiol. Methods* 143, 58–62. <https://doi.org/10.1016/j.mimet.2017.10.002>
- Zhao, Y., Zou, M., Sun, Y., Zhang, K., Peng, X., 2019. gga-miR-21 modulates *Mycoplasma gallisepticum* (HS strain)-Induced inflammation via targeting MAP3K1 and activating MAPKs and NF- κ B pathways. *Vet. Microbiol.* 237, 108407. <https://doi.org/10.1016/j.vetmic.2019.108407>
- Zheng, W., Porter, E., Noll, L., Stoy, C., Lu, N., Wang, Y., Liu, X., Purvis, T., Peddireddi, L., Lubbers, B., Hanzlicek, G., Henningson, J., Liu, Z., Bai, J., 2019. A multiplex real-time PCR assay for the detection and differentiation of five bovine pinkeye pathogens. *J. Microbiol. Methods* 160, 87–92. <https://doi.org/10.1016/j.mimet.2019.03.024>
- ZhongYang, L., JianSong, Z., YiJuan, S., YuTing, X., YuFeng, L., JiaRong, X., 2017. Seroprevalence of *Mycoplasma suis* infection in pigs in eastern China as estimated by a blocking enzyme-linked immunosorbent assay. *Can. J. Vet. Res.* 81, 313–317.
- Zhou, J., Ding, Y., He, Y., Chu, Y., Zhao, P., Ma, L., Wang, X., Li, X., Liu, Y., 2014. The Effect of Multiple Evolutionary Selections on Synonymous Codon Usage of Genes in the *Mycoplasma bovis* Genome. *PLOS ONE* 9, e108949. <https://doi.org/10.1371/journal.pone.0108949>
- Zhu, H., Wei, Y., Huang, L., Liu, D., Xie, Y., Xia, D., Bian, H., Feng, L., Liu, C., 2019. Identification of specific B cell linear epitopes of *mycoplasma hyorhinitis* P37 protein using monoclonal antibodies against baculovirus-expressed P37 protein. *BMC Microbiol.* 19, 242. <https://doi.org/10.1186/s12866-019-1614-4>
- Zhu, K., Chen, H., Jin, J., Wang, N., Ma, G., Huang, J., Feng, Y., Xin, J., Zhang, H., Liu, H., 2020. Functional Identification and Structural Analysis of a New Lipoate Protein Ligase in *Mycoplasma*

- hyopneumoniae. *Front. Cell. Infect. Microbiol.* 10, 156. <https://doi.org/10.3389/fcimb.2020.00156>
- Zhu, L., Konsak, B.M., Olaogun, O.M., Agnew-Crompton, R., Kanci, A., Marena, M.S., Browning, G.F., Noormohammadi, Amir.H., 2017. Identification of a new genetic marker in *Mycoplasma synoviae* vaccine strain MS-H and development of a strategy using polymerase chain reaction and high-resolution melting curve analysis for differentiating MS-H from field strains. *Vet. Microbiol.* 210, 49–55. <https://doi.org/10.1016/j.vetmic.2017.08.021>
- Zhu, L., Shahid, M.A., Markham, J., Browning, G.F., Noormohammadi, A.H., Marena, M.S., 2018. Genome analysis of *Mycoplasma synoviae* strain MS-H, the most common *M. synoviae* strain with a worldwide distribution. *BMC Genomics* 19, 117. <https://doi.org/10.1186/s12864-018-4501-8>
- Zhu, M., Cao, S., Zheng, W., Zhai, M., Wang, M., Blair, H.T., Morris, S.T., Zhang, H., Zhao, Z., 2021a. miR-509-5p anti-infection response for mycoplasma pneumonia in sheep by targeting NF-κB pathway. *Vet. Immunol. Immunopathol.* 238, 110275. <https://doi.org/10.1016/j.vetimm.2021.110275>
- Zhu, M., Nan, Y., Zhai, M., Wang, M., Shao, Y., Blair, H.T., Morris, S.T., Kenyon, P.R., Zhao, Z., Zhang, H., 2021b. Comparative profiling of the resistance of different genotypes of mannose-binding lectin to *Mycoplasma pneumoniae* infection in Chinese Merino sheep based on high-throughput sequencing technology. *Vet. Immunol. Immunopathol.* 233, 110183. <https://doi.org/10.1016/j.vetimm.2021.110183>
- Zhu, X., Dong, Y., Baranowski, E., Li, X., Zhao, G., Hao, Z., Zhang, H., Chen, Y., Hu, C., Chen, H., Citti, C., Guo, A., 2020. Mbov_0503 Encodes a Novel Cytoadhesin that Facilitates *Mycoplasma bovis* Interaction with Tight Junctions. *Microorganisms* 8, 164. <https://doi.org/10.3390/microorganisms8020164>
- Zhu, Z., Qu, G., Wang, C., Wang, L., Du, J., Li, Q., Shen, Z., Chen, X., 2022. Development of Immunochromatographic Assay for the Rapid Detection of *Mycoplasma capricolum* subsp. *capripneumoniae* Antibodies. *Front. Microbiol.* 12, 743980. <https://doi.org/10.3389/fmicb.2021.743980>
- Zou, M., Fu, Y., Zhao, Y., Sun, Y., Yin, X., Peng, X., 2022. *Mycoplasma gallisepticum* induced exosomal gga-miR-193a to disturb cell proliferation, apoptosis, and cytokine production by targeting the KRAS/ERK signaling pathway. *Int. Immunopharmacol.* 111, 109090. <https://doi.org/10.1016/j.intimp.2022.109090>
- Zou, M., Yang, L., Niu, L., Zhao, Y., Sun, Y., Fu, Y., Peng, X., 2021. Baicalin ameliorates *Mycoplasma gallisepticum* -induced lung inflammation in chicken by inhibiting TLR6-mediated NF-κB signalling. *Br. Poult. Sci.* 62, 199–210. <https://doi.org/10.1080/00071668.2020.1847251>
- Zou, Y., Mason, M.G., Botella, J.R., 2020. Evaluation and improvement of isothermal amplification methods for point-of-need plant disease diagnostics. *PLOS ONE* 15, e0235216. <https://doi.org/10.1371/journal.pone.0235216>

Appendices

Abbreviations

AHAW	Animal Health and Welfare
AMPV	Avian Metapneumovirus
ARS	Agricultural Research Service
BEI	Binary Ethyleneimine
BMDC	Bone Marrow-derived Dendritic Cell
bp	base pair
BRD	Bovine Respiratory Disease
CBPP	Contagious Bovine Pleuropneumonia
CCPP	Contagious Caprine Pleuropneumonia
cELISA	competitive ELISA
cgMLST	core genome Multilocus Sequence Typing
<i>C. M. haemobos</i>	<i>Candidatus Mycoplasma haemobos</i>
<i>C. M. haemosuis</i>	<i>Candidatus Mycoplasma haemosuis</i>
<i>C. M. haemovis</i>	<i>Candidatus Mycoplasma haemovis</i>
CRISPR	Clustered Regularly Interspaced Short Palindromic Repeats
DC	Dendritic Cell
DEG	Differentially Expressed Gene
DIVA	Differentiating Infected from Vaccinated Animals
DNA	Deoxyribonucleic Acid
dpi	days post-infection/immunisation
EBL	Embryonic Bovine Lung
ECM	Extracellular Matrix
EFSA	European Food Safety Authority
ELISA	Enzyme-Linked Immunosorbent Assay
EU	European Union
FAO	Food and Agriculture Organization of the United Nations
FISH	Fluorescence <i>In Situ</i> Hybridisation
GBP	Great British Pounds
GlpO	l- α -glycerol-3-phosphate oxidase
HRM	High-Resolution Melting

IAV	Influenza A Virus
IFN	Interferon
Ig	Immunoglobulin
IGS	Intergenic Spacer
IHC	Immunohistochemistry
IL	Interleukin
IM	Intramuscular
IZS	Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise
JAK	Janus Kinase
kb	kilobase(pair)
LAMP	Loop-Mediated Isothermal Amplification
Lpp	Lipoprotein
MALDI-TOF MS	Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry
MAMA	Mismatch Amplification Mutation Assay
MAPK	Mitogen-Activated Protein Kinase
MBL	Mannose-Binding Lectin
<i>Mccp</i>	<i>Mycoplasma capricolum</i> subspecies <i>capripneumoniae</i>
MEC	Mammary Epithelial Cells
<i>Mfl</i>	<i>Mycoplasma flocculare</i>
<i>M. gal</i>	<i>Mycoplasma gallisepticum</i>
MHC	Major Histocompatibility Complex
<i>Mhp</i>	<i>Mycoplasma hyopneumoniae</i>
<i>Mhr</i>	<i>Mycoplasma hyorhinitis</i>
<i>Mhs</i>	<i>Mycoplasma hyosynoviae</i>
MIC	Minimum Inhibitory Concentration
miRNA	microRNA
MLST	Multilocus Sequence Typing
MLVA	Multilocus Variable number tandem repeat Analysis
<i>Mmc</i>	<i>Mycoplasma mycoides</i> subspecies <i>capri</i>
<i>Mmm</i>	<i>Mycoplasma mycoides</i> subspecies <i>mycoides</i>
MOI	Multiplicity Of Infection
MPS	Mycoplasmal Pneumonia of Swine
<i>M. syn</i>	<i>Mycoplasma synoviae</i>

MYD88	Myeloid Differentiation Factor 88
NET	Neutrophil Extracellular Trap
NF- κ B	Nuclear Factor- κ B
NK	Natural Killer
NOD	Nucleotide-binding Oligomerization Domain-containing protein
OIE	Office International des Epizooties (now the World Organisation for Animal Health)
PAM	Porcine Alveolar Macrophage
PBMC	Peripheral Blood Mononuclear Cell
PCR	Polymerase Chain Reaction
PCV	Porcine Circovirus
PRRSV	Porcine Reproductive and Respiratory Syndrome Virus
qPCR	quantitative real-time Polymerase Chain Reaction
QRDR	Quinolone Resistance-Determining Region
RNA	Ribonucleic Acid
rRNA	ribosomal Ribonucleic Acid
ROS	Reactive Oxygen Species
RPA	Recombinase Polymerase Amplification
sIAV	swine Influenza A Virus
sIgA	secretory Immunoglobulin A
SNP	Single Nucleotide Polymorphism
SNV	Single Nucleotide Variant
SPLUNC1	Short palate, lung, and nasal epithelium clone 1
ST	Sequence Type
STAR-IDAZ	Strategic Alliance for Research into Infectious Diseases of Animals and Zoonoses
STAT	Signal Transducer and Activator of Transcription
TLR	Toll-Like Receptor
TNF	Tumour Necrosis Factor
TOC	Tracheal Organ Culture
UK	United Kingdom
USA	United States of America
USD	United States Dollars
USDA	United States Department of Agriculture

VNTR

Variable Number Tandem Repeat

WOAH

World Organisation for Animal Health

Details of searches

The literature search terms provided below were used to interrogate the CAB Abstracts database (www.cabdirect.org) on 31st January 2023. The searches were repeated using the PubMed database (which has a shorter lag time between publication and updating) on 8th May 2023, to capture any new literature published during the report-writing period.

Topic	Search terms	Date range
<i>Mycoplasma mycoides</i> subsp. <i>mycoides</i>	CBPP or "Mycoplasma mycoides subsp. mycoides" or "bovine pleuropneumoni*" or (pleuropneumonia and cattle) or "contagious bovine pleuropneumonia"	1/1/2012 – 31/1/23
<i>Mycoplasma bovis</i>	"mycoplasma bovis" and (cattle or bison or buffalo* or bt:bovidae)	1/1/2012 – 31/1/23
Other mycoplasmas affecting cattle	"Mycoplasma alkalescens" OR "Mycoplasma bovigenitalium" OR "Mycoplasma bovirhinis" OR "Mycoplasma bovoculi" OR "Mycoplasma californicum" OR "Mycoplasma canadense" OR "Mycoplasma dispar"	1/1/2015 – 31/1/23
Mycoplasmas affecting small ruminants	("Mycoplasma conjunctivae" OR "Mycoplasma ovipneumoniae" OR "Mycoplasma putrefaciens" OR "Mycoplasma agalactiae" OR "Mycoplasma capricolum" OR "Mycoplasma capricolum subsp. capricolum" OR "Mycoplasma capricolum subsp. capripneumoniae" OR "Mycoplasma mycoides subsp. capri") or (mycoplasm* and (sheep or goats))	1/1/2015 – 31/1/23
Mycoplasmas affecting swine	("Mycoplasma hyopneumoniae" OR "Mycoplasma hyorhinis" OR "Mycoplasma hyosynoviae") or (mycoplasm* and pigs)	1/1/2015 – 31/1/23
Mycoplasmas affecting poultry	("Mycoplasma gallisepticum" OR "Mycoplasma gallopavonis" OR "Mycoplasma meleagridis" OR "Mycoplasma synoviae" OR "Mycoplasma anatis" OR "Mycoplasma iowae") or (mycoplasm* and (fowls or chickens or turkeys or ducks or geese or poultry or quails))	1/1/2015 – 31/1/23

Financial Support

This study was jointly supported by the USDA-ARS and the Secretariat to STAR-IDAZ IRC (SIRCAH2), funded by the European Commission [Horizon Europe Grant Agreement number 101082377] and UK Research and Innovation (UKRI) under the UK Government's Horizon Europe funding guarantee [grant numbers 10055666 and 10058793].

Conflict of Interest Statement

The authors declare no conflict of interest.

Additional Resources

Please see the following websites for additional information and/or resources around the content and aims of this report:

[STAR-IDAZ](#)

[USDA ARS](#)

[PubMLST database](#)

[DISCONTOOLS](#)

[Vet immunology toolkit \(UK\)](#)

[http://www.vetimm.org/ \(USA\)](http://www.vetimm.org/)